<SEC-DOCUMENT>0000914475-20-000036.txt : 20201109
<SEC-HEADER>0000914475-20-000036.hdr.sgml : 20201109
<ACCEPTANCE-DATETIME>20201109160407
ACCESSION NUMBER:		0000914475-20-000036
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		57
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201109
DATE AS OF CHANGE:		20201109

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROCRINE BIOSCIENCES INC
		CENTRAL INDEX KEY:			0000914475
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330525145
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22705
		FILM NUMBER:		201297657

	BUSINESS ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 617-7600

	MAIL ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nbix-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:b79d3e40-aa4b-4356-aa3c-d2eb2732ffa0,g:9f3edc10-8601-4580-b4de-4b1ad44f8b95,d:01dca92a9a894c839fd91f8b5b3beba6--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nbix="http://www.neurocrine.com/20200930" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nbix-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80L2ZyYWc6NTAyMjRhYmQ5MGEwNGE5Mjk0ZGI5MTIzNzA4MGNkYmEvdGFibGU6NzM4OTNhYWQzN2UzNDQ3YmE0MzAwNzM5MmE2ZjBhMjYvdGFibGVyYW5nZTo3Mzg5M2FhZDM3ZTM0NDdiYTQzMDA3MzkyYTZmMGEyNl8yLTEtMS0xLTA_f788bb49-2d89-4ead-a09a-6418cf24b72f">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80L2ZyYWc6NTAyMjRhYmQ5MGEwNGE5Mjk0ZGI5MTIzNzA4MGNkYmEvdGFibGU6NzM4OTNhYWQzN2UzNDQ3YmE0MzAwNzM5MmE2ZjBhMjYvdGFibGVyYW5nZTo3Mzg5M2FhZDM3ZTM0NDdiYTQzMDA3MzkyYTZmMGEyNl8zLTEtMS0xLTA_79bd39fc-ab39-4434-bc20-0ae803de17b2">2020</ix:nonNumeric><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80L2ZyYWc6NTAyMjRhYmQ5MGEwNGE5Mjk0ZGI5MTIzNzA4MGNkYmEvdGFibGU6NzM4OTNhYWQzN2UzNDQ3YmE0MzAwNzM5MmE2ZjBhMjYvdGFibGVyYW5nZTo3Mzg5M2FhZDM3ZTM0NDdiYTQzMDA3MzkyYTZmMGEyNl80LTEtMS0xLTA_66fec70e-8dd5-40cc-9aae-b4c9fcd91c78">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80L2ZyYWc6NTAyMjRhYmQ5MGEwNGE5Mjk0ZGI5MTIzNzA4MGNkYmEvdGFibGU6NzM4OTNhYWQzN2UzNDQ3YmE0MzAwNzM5MmE2ZjBhMjYvdGFibGVyYW5nZTo3Mzg5M2FhZDM3ZTM0NDdiYTQzMDA3MzkyYTZmMGEyNl81LTEtMS0xLTA_459c66c1-4eee-408c-91ba-939cec2acf68">0000914475</ix:nonNumeric><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80L2ZyYWc6NTAyMjRhYmQ5MGEwNGE5Mjk0ZGI5MTIzNzA4MGNkYmEvdGFibGU6NzM4OTNhYWQzN2UzNDQ3YmE0MzAwNzM5MmE2ZjBhMjYvdGFibGVyYW5nZTo3Mzg5M2FhZDM3ZTM0NDdiYTQzMDA3MzkyYTZmMGEyNl82LTEtMS0xLTA_0438e0de-4f06-46b7-9ce9-1f1a620b7fb8">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i43dc46d58e014745aa62c8e09a24d851_D20180101-20181231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzQtMC0xLTEtMA_ea544724-28b1-46be-84e8-aa74a9f36877">us-gaap:AccountingStandardsUpdate201602Member</ix:nonNumeric><ix:nonNumeric contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502" name="nbix:NumberOfConsecutiveBusinessDays" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMTE3Nw_a1999c43-97d5-4934-9864-f07cd2e0e9ca">P5D</ix:nonNumeric><ix:nonNumeric contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502" name="nbix:NumberOfConsecutiveBusinessDays" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMTIyMg_0e6c4b54-2041-4866-8f9f-60a13836b830">P5D</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81NS9mcmFnOmNkZjcyMzc4MDM0YzQ5NzRhYWQ3OGU5NGZjYmYxMWQ3L3RhYmxlOmI0MjZkYWI5YjMxMjQzY2I5YjI0YWZmMDUzZTYxYmE4L3RhYmxlcmFuZ2U6YjQyNmRhYjliMzEyNDNjYjliMjRhZmYwNTNlNjFiYThfMi0xLTEtMS0w_fe353dba-0939-4bbb-92a8-c58f547af2d0">0.0131711</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nbix-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i444e2c86d32342048de12245f7f211f5_I20201104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2eac757373044c73b10d89d2901aca4a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ie9e8ecaa7faf4bd7aefcbbb4825de4ad_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ac9bb3945ab4fa6a54c3854917ec6be_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8b7535c94394a5eb4e42047c2f78f8c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if63b65b04e2b4ba8a6410f5550f0dada_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id237bed344304cdfb92dba0f37b8b2ea_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id28a908f24d443b491ef90114eab031e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07aa10bbd36d4f218b7067892376a3d9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib46c14fbf85f4a67bc18bbc72105f4a4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i911a596594bb42f1ac774b4d2e8002bc_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic68d7f4878b240c2a94c47549bedae1d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5f511a933434ea0834f118c4f341f90_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedcce6b874c74163b624aa2b15ebb12b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e06729230ea4ca7a95cf735dd99be6d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bcde4ddd2f54c21aa4bd738ffd07957_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99a4ab0b6ccf43d6bd7626714d91bae1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bb7f4b1f21943c6863d8cba446f1522_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfb97fb7839e4786b037248a2437f3e4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf98ce15cffa48d490acc123240b6de1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92e0ed27615f42b28fa6f250cf9e5fb5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i993fc948fbfd4c9e818abdde04072290_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c745beb45d74cb091440fb03cecacf2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdf214a2337843e78d1a347256aaaa00_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib77575bdbf4040e39375b79ca78eff52_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2ded9247e98428593f3e2412173375b_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i124193d520854efcb3745edbaed9fea0_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib12e0fe57cf54c4eb690db593d5ab12f_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i268579fde8b349778a731f000224ca07_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec797011e09546cd8f24887ec442c1c5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb42b25d794147b1aed333e2f3166703_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd133a6a9d584e259b82b5bcc97dfc26_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9fc314f633842568fae2c624fd6a730_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic436e3bb1c9b40c5a2c28786df5e2f5e_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i305a4e84d6d84699b8b9301835f9518f_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i730787997d6d4c228ee797868cbe3082_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5eafa440da15427d8d322a26e23e8db7_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i543b37a401f842f297d00c6f44d8c51d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bcc585face2402191cabf07bfd067f5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1679f6518a049a0b79b7b15a1277d4d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icce724fa185b4a2e81da141dd2ca4c69_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie82ca40bd6b7437b85500edd36e2ac78_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6512d4e06fe64b8c8902cb07fd087fe7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i993fa090c95f4e7791e5c5d7159708d5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1e75fea41454043ab426501ad55a6dd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib022af9959ba424787b942770385acd6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i473e921631e44d049f986015d23f8c8e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd3a22690ded4fd58399451eeb2ff477_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a72aa82edb54cb9aa6dd689f379b35e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b9bcef8502e4089bb1a8346e1df9932_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i252046dd1c50470ea1cf51b3a7d8bbda_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a4f65fc8aa34883b840cee701384a7b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1ccdf0b325741f783c0d8b5806ef5e9_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42a7ca788f2e494ea2ff656d2aecaa79_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43dc46d58e014745aa62c8e09a24d851_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3ac91b9e8aa453fa75f654a778253ac_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice72e35fd4be4be0bd6c7d149fff6950_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="subsidiary"><xbrli:measure>nbix:subsidiary</xbrli:measure></xbrli:unit><xbrli:context id="i1bc3cf10ca8443d19bf1d4cf81b112be_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fd2fda8589244c78b0b293642285e18_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id529934387f148b18fa1109106ad5a55_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabd2ce28d6694a2486d931e1479cf385_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05e0789a004a4bb0b0b9943498ed0bde_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:NBI827104Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c7cce679a364cb494b726cf6f83dd4f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:DevelopmentProductCandidatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f38dd2e87214e4e86b4617f5f7a47c9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if408f3cef84a459fb036f2dae9a47b78_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied735b11fcf841da816bf129e0782ef6_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie59f33ba48b64fbf878b1b0bb32cd3bf_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:BIALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43207eb5afba4545a651896bc4052742_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:BIALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic154a10198a440abaa45ffe2168bfe4b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:BIALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e46865cecac4d2e9ae909b186261e3c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ee32bf37a3e4fba90e0c87db9c24cfe_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3af452bac274c8e8d92baa671e21fba_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81d37dbacd1842e99e2686ec8fd6dbba_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66b2b24b15f44827a87d688b20158136_D20150301-20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad9db265321c411f9f43fa242382852e_D20170701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78ce841bcaf4462aa4b7ca2f1059a21d_D20191001-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc967843177445f2a9bb563c19ee7472_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic92441dd53a14a03a31909df31c4a184_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c4ebb0a6f1f49b0a4d3e6a407449d98_D20100601-20100630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-06-01</xbrli:startDate><xbrli:endDate>2010-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45766b13b1314f7181ad53c4c44d2508_D20100701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ea18c769a47425d951bc4f1d6cdec54_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if00ff3fffef04ee986b1a2c2119dfc0b_D20100601-20100630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-06-01</xbrli:startDate><xbrli:endDate>2010-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17e8669ff7be4a52b5af69d877498dc5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20a97471294c419191a3a2888e675b4b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a39b454de5141cea8123d360608a3c6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57f46c4cf6f1473794e3e0ebadd216a7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5839adaf15cb411e85d5303f2631e97d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1afe9cac6b0a42a5b77948695251abfb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11b4128b861b49e2a5858306369cb09d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cf4cd2db9454c90a62e4deb58db04b8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i874e4b9552c648458ec045b9740fcc7c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib471b42e9f1046758a5cc3d418a9adea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if06c15e28fd64cffadb8a9783937f723_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd9a4794daba4b7cad0104baa5442100_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39d07970489d4ae1a26d531d4e995b63_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4eee421ab3034f1daf75320fc8835187_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89d87039af9d4dc6bd52a3bb4c9ebf21_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>nbix:security</xbrli:measure></xbrli:unit><xbrli:context id="ia63ae906e9934f57874ae4728dd57afa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id38c7267b80a405180f7b4356f67da8c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibee55973814540e4871f791d8dc70e46_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib426e74a445c45f1a83118960cccbf06_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie84a00bf79934f488db237577d55db78_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea9d8f3b23ca486497408024718a6b8e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65a6bbf5e65a4158a60237d7a4a04db0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ec61ef3dcdf4b1aacbd98b013a506b7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc97788aa86f4300961cef399f992f04_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c29e9b0363d417bad2a59f28a1c803c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5598a209b61b4400b094160c9896fa48_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29381f8c070e44f0842d377f5116a9e2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i947a42782e644b31b40e973a6c34e453_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee9777017ba44b219d3e743580405ac2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7a75fd9bbac4ee49d0da09da35fb326_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb30e5a8cedc49c8be9971e52ba47b85_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i760c3e1139cd490996ecb9f7296243b7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42324c42b21949c28b491aa55a7bfbbb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18fb70203f184d1491ea807cbc815619_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if469c62de0cd4ef3830eba7c5402aaab_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17b0221281ec4463a4179b1554cbcd76_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0025cac95494cda9e9476a6c30b7005_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2709795600e4b4fa0cab1e10d78bb24_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6458a3c1f27445708ec1f66fe52e22d1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if56d9dc3007d41128722f44d864811d6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9756d3e20b3947848211cd89041634fc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc0623eb842b4201884c1c1da60ba35d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc01e0adf5ed40e9ab710401d911d109_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfd9db69bbe949f189e03e61899a8e08_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97214347d5cd4c00a185bedc120c3fc1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d8647d7d7e94a8097f66d3842b61c42_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i956362b694e94668b36c6160186aa324_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bd0085725324e26a27750e423d72760_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic049401a5b67418d851adeae321ac164_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8225b8bb50704b84b3bf86c3349c534e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id219f8da90c541daad4ba23316ba4c2b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d6d32eba9d04110a989008d1fa4f90e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88f522c740114d6180c33b2389f52046_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2f301c2004b4bcabafe4296fb59ec8e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1156dc5768584b87af9adf9ad1d62009_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iced281cb3fd145e8913b24a5a0bc1e69_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia410bcb0c63a42d99db1e5658b91727a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0864c4bbd4b141eb98515b636f8eb88c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c40b36432b0492eb3eae0f8756d0ae1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f45d9693ffb42a189e35266c2e96545_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69670247a1db4f42b3852d733ac9597d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica74b071cda746a582b3ab295bc26cff_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05df2fa389dd4adfa5053ad89459ac4c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id03b83fda3a5401ea309441030aea98b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18cbac244f574159aedb1993c131e819_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4783baa5d824c89aae723867da90a4b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic92b89ea55554deea11eb52be454b4ee_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59c2ec22479846c8887639d01cec2ac1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38a85a52092b47eba3e6679338c961b6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i314a5ccd83a84b54958bcd28fb8db860_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dea7ef570bb4538b6abd0b0f50563ea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e4a588721b04ed3a8c49e19b0c7d7e2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie87e6dea946b4fee812d375f72857a05_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4257d9e01c5447b8694ff0d39ac4ad4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fd7f2df19284e068ed3299724415484_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95be335e9ca1424784a8b065207d5d2c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8978c466f89f48bd919bee1246ba7dc3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib765b7aaf76a45f5b319d34681ef5aad_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1168865b09414dd1928d3fb6d2fe8156_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b5a1372b6934d52bbc0746277c0a30f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c444f4feaa2474398f957750041cb1d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i233e986aada74f71bd2484e81cfad9fa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9640ba89a44d41bfb7a046a01479976d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd5b76e3383e44738b173add3da702c6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieecb12e2940b487ead1f8d0f74107902_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i258c656656094522924117a0e6348166_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2f58151776d4b13be04977281fa947d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb9d6e37865d45e1b6f401b3e4cdc23d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4745ddf52c234ed591471f3b27a1ab8b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3f9f730b48d44688a63762017a09db2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic06223c92c5f4dd8a253034a82b987b2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic019c50768b247589e3afba7ef8f7b7f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib44d224bf6a0454381c51416f7a36089_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9fb6311be4848ee9588bffda41c01e0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11cff9bc4f0243cb87ef4cff58b89ee3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie25967604f04462d8e53ffad9c71948b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id07323ca55464999892b9d6fb0d0b763_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i685588d754634ef2a7b97a70c6fdabbf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if718bd63b45a4840af81b12174f10513_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b082681e677454181d88e9e537d5fde_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a5d39b84bb845bd89918fb5088efac0_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f09b45aebbe45268c2465fc1d568035_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f9f6865463c43fd9a44068085061fc5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83b13e1b031e48228c7b0620b1ebe113_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6049f25752e8431ba1fbece7b41b3e27_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0b79a1a18384f138069f378bdbe69b4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0548c87128c9494d8cbb70c28471b350_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c084bc0f4cb428bbc964d8727a9a1bb_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cb6cd0e456d4f4bbd214884933a1f9a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72cdfb757c4d4f1daaf47570c8615274_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i0aa63587c87c4b9cab14160d1d2d336a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icac2aad9c7b14b7c897eaed6bd6f1176_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e0a7e787f35452e9cf3c1d60a078e47_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i6cb2fa374db842989cd35f0f03a92fd5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:A12780ElCaminoRealMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b783069862c4a7aa49f88ea6fee4135_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:A12790ElCaminoRealSuite130Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i388a89deda29498bb6086f28660869e9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:A12790ElCaminoRealSuite150Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i873fe30d887a4b389617d2698e039940_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:A12790ElCaminoRealSuite300Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i473d326a3edd493a836fb98886d2085a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:A12777HighBluffDriveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc20284842904d03ab36d24c9fed65c5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:A12790ElCaminoRealSuite200Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id19b886ce9774875bcec5de9e1655ca9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:A12790ElCaminoRealSuite100Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="renewaloption"><xbrli:measure>nbix:renewalOption</xbrli:measure></xbrli:unit><xbrli:context id="i5dc56b70fae344879faba70a7e60b7f8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nbix:A1278012790ElCaminoRealMasterLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i132f21d3f9184d5493988e86fd0dc307_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95cb82a96ba143258e37a17f6ad70802_I20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-02</xbrli:startDate><xbrli:endDate>2017-05-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:context id="i0e4f2c61bb0c4669bf03824d0717d032_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e3872d7a51340d7bd8d1873912c8acb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6a49b9383644b8e949247b3f6dc07c3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4556b63f7bc4fc98ded870e841fc0f1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie07c04ad31ab444aa78ad245a76043b3_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idae84b2bcee5402c8d33bf434a519a5a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7952abe718084d38a17f69cd5d0327b6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic23a449373e942b6a52ed76757c61821_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd783faa158b4dbe92e4b587a15e4e5b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b9ca9a1b5ab47359e53b9d1690424a9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16bcd03519fb4b91b7c49c28141acd41_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic83bc456a2d24aea914f39864a46ea36_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46cad86f1cef4f9796a18fb9899c6bd5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ideea8abfeaaf4691a87a843e06657dea_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb3a8bd5463f49769dbf1087a66ca8c8_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a2aaf5893684e989b254984e9c0e7c2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5e51d3e6c184bf388994f88f70e42b4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5484b1436d094cdaaf477c90a7f1ed3b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cb16bd71c524c9a890f849d3486c0c8_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i01dca92a9a894c839fd91f8b5b3beba6_1"></div><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:29.761%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjA3_2e4b762b-50ec-4035-abb9-1c30849c1085">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:29.761%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGFibGU6M2VlMWM0N2NkYjdiNDRmMjkwMGU5NjRlOGQxMjFjYTkvdGFibGVyYW5nZTozZWUxYzQ3Y2RiN2I0NGYyOTAwZTk2NGU4ZDEyMWNhOV8wLTAtMS0xLTA_203f56db-f447-4115-bda0-72d001805608">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8xMzk_0a978fff-58df-4ffa-ae6a-0cb269147f57">September 30, 2020</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGFibGU6N2MzYTI1MDUyODI3NDliZGJhNzg4ZDY1YjJjODUyZDUvdGFibGVyYW5nZTo3YzNhMjUwNTI4Mjc0OWJkYmE3ODhkNjViMmM4NTJkNV8wLTAtMS0xLTA_1e566193-7364-419b-b20e-0ab68a3dc582">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjAz_95568986-5d29-487e-b397-3fd15ed11261">0-22705</ix:nonNumeric> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:29.761%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjA4_3f20c48b-5cca-40ca-b1b4-d86b9f398358">NEUROCRINE BIOSCIENCES, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:29.761%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjEy_89ae50bb-27d7-4ae0-91fe-7ce2b298af7b">Delaware</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">incorporation or organization)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjEz_5a36d7a8-6b3b-4e70-9137-6d5e5d7f0e77">12780 El Camino Real</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjE0_ae1945cc-1214-4676-9248-d9a891c9d8f8">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjA5_46a8c10a-f881-4a97-bb1a-10ebf984655b">CA</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive office)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjA1_976c0d6b-48cc-4254-ab93-03007396bb98">33-0525145</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Identification No.)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjA2_91ee1840-f59f-424d-9927-c76ded79937f">92130</ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Zip Code)</span></div><div style="margin-top:6pt;text-align:center"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjA0_e46eb5cf-a4a6-48c6-a97d-a5abe10da790"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(858</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjEw_958507cf-d011-4ebc-af59-c71dc85eca54">617-7600</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:29.761%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:11pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.467%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGFibGU6NDZlNWI2MzBlMTRmNDM5YzhkYTRhODZhZGZhN2NhZjQvdGFibGVyYW5nZTo0NmU1YjYzMGUxNGY0MzljOGRhNGE4NmFkZmE3Y2FmNF8xLTAtMS0xLTA_0e6d35db-e73e-4eb3-8dd3-945b1312f93b">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGFibGU6NDZlNWI2MzBlMTRmNDM5YzhkYTRhODZhZGZhN2NhZjQvdGFibGVyYW5nZTo0NmU1YjYzMGUxNGY0MzljOGRhNGE4NmFkZmE3Y2FmNF8xLTItMS0xLTA_5eb1ec9f-5c77-4c5e-87e1-2fdb5f9f5cf8">NBIX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGFibGU6NDZlNWI2MzBlMTRmNDM5YzhkYTRhODZhZGZhN2NhZjQvdGFibGVyYW5nZTo0NmU1YjYzMGUxNGY0MzljOGRhNGE4NmFkZmE3Y2FmNF8xLTQtMS0xLTA_0a19165d-ecc1-45f1-85c0-03d4eeb76d6c">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days:&#160;&#160;<ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjAx_e47163d9-cb25-4bb4-93f1-4b736eeb58ec">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;&#160;No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjEx_007d02e6-1bdd-41e1-b561-4acd66f11064">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;&#160;No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</span></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGFibGU6NDA5ZjYyYjQwZGJiNGFlZjlmMDkzMzE3ZGNhYzdmNDcvdGFibGVyYW5nZTo0MDlmNjJiNDBkYmI0YWVmOWYwOTMzMTdkY2FjN2Y0N18wLTAtMS0xLTA_a75da631-9c70-49cc-8fea-a9d7ab253fde">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGFibGU6NDA5ZjYyYjQwZGJiNGFlZjlmMDkzMzE3ZGNhYzdmNDcvdGFibGVyYW5nZTo0MDlmNjJiNDBkYmI0YWVmOWYwOTMzMTdkY2FjN2Y0N18xLTQtMS0xLTA_c3b746bd-c883-405d-9116-20504aaaee54">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGFibGU6NDA5ZjYyYjQwZGJiNGFlZjlmMDkzMzE3ZGNhYzdmNDcvdGFibGVyYW5nZTo0MDlmNjJiNDBkYmI0YWVmOWYwOTMzMTdkY2FjN2Y0N18yLTEtMS0xLTA_f181b6c3-128c-41c4-8ebe-924e4d070048">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjAy_6c225dbd-096b-4aba-83b9-0d28cfaec100">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;&#160;No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The number of outstanding shares of the registrant&#8217;s common stock, par value $0.001 per share, was  <ix:nonFraction unitRef="shares" contextRef="i444e2c86d32342048de12245f7f211f5_I20201104" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8xNjQ5MjY3NDQzOTAx_78bf4c27-f78b-497d-8765-f60765ef006d">93,429,153</ix:nonFraction> as of November&#160;4, 2020.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i01dca92a9a894c839fd91f8b5b3beba6_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PAGE</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i01dca92a9a894c839fd91f8b5b3beba6_10">Part I. Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i01dca92a9a894c839fd91f8b5b3beba6_10">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01dca92a9a894c839fd91f8b5b3beba6_13">Item&#160;1. Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i01dca92a9a894c839fd91f8b5b3beba6_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0000EE;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Condensed Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i01dca92a9a894c839fd91f8b5b3beba6_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0000EE;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income for the Three and Nine Months Ended September 30, 2020 and 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i01dca92a9a894c839fd91f8b5b3beba6_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0000EE;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three and Nine Months Ended September 30, 2020 and 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i01dca92a9a894c839fd91f8b5b3beba6_22">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0000EE;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2020 and 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i01dca92a9a894c839fd91f8b5b3beba6_25">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01dca92a9a894c839fd91f8b5b3beba6_28">Notes to the Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i01dca92a9a894c839fd91f8b5b3beba6_28">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01dca92a9a894c839fd91f8b5b3beba6_64">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i01dca92a9a894c839fd91f8b5b3beba6_64">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01dca92a9a894c839fd91f8b5b3beba6_67">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i01dca92a9a894c839fd91f8b5b3beba6_67">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01dca92a9a894c839fd91f8b5b3beba6_70">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i01dca92a9a894c839fd91f8b5b3beba6_70">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i01dca92a9a894c839fd91f8b5b3beba6_73">Part II. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i01dca92a9a894c839fd91f8b5b3beba6_73">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01dca92a9a894c839fd91f8b5b3beba6_76">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i01dca92a9a894c839fd91f8b5b3beba6_76">23</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01dca92a9a894c839fd91f8b5b3beba6_79">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i01dca92a9a894c839fd91f8b5b3beba6_79">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i01dca92a9a894c839fd91f8b5b3beba6_82">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i01dca92a9a894c839fd91f8b5b3beba6_82">47</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i01dca92a9a894c839fd91f8b5b3beba6_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Part I. Financial Information</span></div><div id="i01dca92a9a894c839fd91f8b5b3beba6_13"></div><div style="margin-bottom:10pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;1. Financial Statements</span></div><div id="i01dca92a9a894c839fd91f8b5b3beba6_16"></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMy0xLTEtMS0w_1af183c2-4a59-43c9-83de-550ba0b9178e">425.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMy0zLTEtMS0w_4f9fcbef-20f1-42f2-80e9-a289c7700bdf">112.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale, at fair value (amortized cost $<ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfNC0wLTEtMS0wL3RleHRyZWdpb246M2QwOTZhMjU1MjMxNDAyMWFiNmE1MDVkNDkyYWE3ZWRfNzE_541e4713-0238-45b9-95d5-59d3c8975dce">517.3</ix:nonFraction> million at September&#160;30, 2020 and $<ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfNC0wLTEtMS0wL3RleHRyZWdpb246M2QwOTZhMjU1MjMxNDAyMWFiNmE1MDVkNDkyYWE3ZWRfODQ_1d929166-e8ff-4f5a-b501-248bd99ee336">557.3</ix:nonFraction> million at December&#160;31, 2019)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfNC0xLTEtMS0w_8376cbfe-afa5-46f0-a3c4-94afc6ed0534">519.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfNC0zLTEtMS0w_af827454-16bf-4d57-9a6c-258abee0602f">558.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfNS0xLTEtMS0w_1cfbe2fa-0df2-49ad-bd00-c56cc6bf5fa7">156.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfNS0zLTEtMS0w_9dc62bd0-cc6a-48fc-987b-dcb076deb35b">126.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfNi0xLTEtMS0w_0cc36c79-21a1-4e19-9965-0e4fe6ab1c0c">20.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfNi0zLTEtMS0w_14c60074-2d3c-48d6-9c32-f2fb006c8609">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfNy0xLTEtMS0w_9e21f61f-3268-4805-bd37-661699114cd5">34.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfNy0zLTEtMS0w_7f56874a-e9bc-435b-a467-c31b0ca3afc3">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfOC0xLTEtMS0w_1619dcd5-106c-4ee3-b9f7-11d2842cf7e7">1,156.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfOC0zLTEtMS0w_835a6325-2e06-4361-9d6d-4622bc2869ed">831.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale, at fair value (amortized cost $<ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfOS0wLTEtMS0wL3RleHRyZWdpb246ZDY5YWRmYjMzMGQyNDc0ZmI5Yzc4NTcxODBlMzM2MjNfNzE_ffab961f-2c06-4125-8e41-e4c2cc3adb79">180.3</ix:nonFraction> million at September&#160;30, 2020 and $<ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfOS0wLTEtMS0wL3RleHRyZWdpb246ZDY5YWRmYjMzMGQyNDc0ZmI5Yzc4NTcxODBlMzM2MjNfODQ_be1ede80-4df0-407e-a44c-f4ff3438ce20">299.3</ix:nonFraction> million at December&#160;31, 2019)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfOS0xLTEtMS0w_bfaeb1ee-b307-4450-891f-d57da1c32451">181.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfOS0zLTEtMS0w_6578a964-31ed-4b1e-aa8d-fabfe5842f4c">299.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTAtMS0xLTEtMA_6a18f55b-4d18-4667-a533-b929bde41302">71.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTAtMy0xLTEtMA_a7be8c4e-79b5-4dda-b897-72822eb70b52">74.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTEtMS0xLTEtMA_f0b3711b-58fc-4137-bb9a-1585e2a077b0">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTEtMy0xLTEtMA_604fc4a1-e0e1-4a61-b589-7791d16358a4">55.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTItMS0xLTEtMA_3564ea8b-4ee2-406b-920e-b9b619cc17f9">43.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTItMy0xLTEtMA_ee76cb12-84d1-4a4f-927b-643392fffe13">41.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTMtMS0xLTEtMA_e04271d6-7af5-4097-83b3-97b17056fdf5">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTMtMy0xLTEtMA_667d936f-3e2c-46c0-8778-dac7caad7a89">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTQtMS0xLTEtMA_576f8c12-d39e-48b4-9c4d-69381b17d969">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTQtMy0xLTEtMA_d60857b1-4054-43df-bc0d-c9237468cb23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTUtMS0xLTEtMA_7bf28fcb-f543-4ca1-86c2-3b7e0a53810d">1,502.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTUtMy0xLTEtMA_277dd9b3-b329-4cba-a6d4-b483bc7946d6">1,306.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTktMS0xLTEtMA_651e8794-ac90-4af4-b8dd-2208f57fb272">170.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTktMy0xLTEtMA_7e9744f1-f5d3-42eb-9ea9-7c3a3ab44ed7">141.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:ConvertibleDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjAtMS0xLTEtMA_dd5f41e9-5396-4fec-96d3-b8dfade9b52b">425.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:ConvertibleDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjAtMy0xLTEtMA_9e4e6158-a817-4a52-8d7d-232d0a9e5a1e">408.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjEtMS0xLTEtMA_d5cbfd33-b4ad-4884-ba11-e5d554d9094a">15.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjEtMy0xLTEtMA_2051fdf7-da50-45ea-8e7a-9f2becf04ef4">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjItMS0xLTEtMA_7f865c7e-cbe4-405f-82ff-06b7f0773208">611.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjItMy0xLTEtMA_99aae680-5f50-4c1b-91c5-6ec6085f7e81">565.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjQtMS0xLTEtMA_b1e66f2a-bd18-4b1a-a01f-7cdbb25a59f5">83.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjQtMy0xLTEtMA_f1c74d97-5fb2-415d-842d-9ec913d64601">86.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjUtMS0xLTEtMA_0a18d2ae-a607-4a1f-9c9e-1928b11674d4">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjUtMy0xLTEtMA_e9afcfa4-ac8c-4ab3-919c-1f290531540d">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjYtMS0xLTEtMA_7ffb8d5a-f44c-4d89-8a54-5476ca87e0b9">698.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjYtMy0xLTEtMA_59723865-ac5a-4755-8595-248ab687b3dc">669.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmY3NzYzMjc4NzlhYTQzN2RhZDUzYmQ2MTc5YmJmYzdjXzIy_34d791e9-a0a8-4241-9573-adb9254cf497"><ix:nonFraction unitRef="usdPerShare" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmY3NzYzMjc4NzlhYTQzN2RhZDUzYmQ2MTc5YmJmYzdjXzIy_c744558a-eb8f-4cad-8ec3-ceb674687edf">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmY3NzYzMjc4NzlhYTQzN2RhZDUzYmQ2MTc5YmJmYzdjXzM2_ae641ccd-d7b1-4fd9-9bb1-f366ab10f6c0"><ix:nonFraction unitRef="shares" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmY3NzYzMjc4NzlhYTQzN2RhZDUzYmQ2MTc5YmJmYzdjXzM2_c167538a-a5cd-4a6f-b984-8ea7fae0970d">5.0</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmY3NzYzMjc4NzlhYTQzN2RhZDUzYmQ2MTc5YmJmYzdjXzU4_6ee378ab-8a5e-44e6-a0a2-9cc0d7a6622a"><ix:nonFraction unitRef="shares" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmY3NzYzMjc4NzlhYTQzN2RhZDUzYmQ2MTc5YmJmYzdjXzU4_7019c571-d836-44c9-8d2e-61eff455679e"><ix:nonFraction unitRef="shares" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmY3NzYzMjc4NzlhYTQzN2RhZDUzYmQ2MTc5YmJmYzdjXzU4_7519461a-744d-43af-b858-43e059547840"><ix:nonFraction unitRef="shares" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmY3NzYzMjc4NzlhYTQzN2RhZDUzYmQ2MTc5YmJmYzdjXzU4_84afd9c5-0cf6-4228-b161-724fda2a1814">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at September&#160;30, 2020 and December&#160;31, 2019</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjktMS0xLTEtMA_3106bf04-d8bb-44c9-b0af-eb3b1e2babdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjktMy0xLTEtMA_1435b61f-849d-4ce7-8688-e7cfa711c5c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmE0NzM0ZGJhNGYwMTRhZjBhYWNmYTdiYzNiMTYzMjI1XzE5_cb5f776c-77fd-4fed-ac95-79c6fd6cd71a"><ix:nonFraction unitRef="usdPerShare" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmE0NzM0ZGJhNGYwMTRhZjBhYWNmYTdiYzNiMTYzMjI1XzE5_f1f20d53-2c3f-4059-b02e-11622352e457">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmE0NzM0ZGJhNGYwMTRhZjBhYWNmYTdiYzNiMTYzMjI1XzMz_1798bb52-f385-4005-9e10-3e26b0cc9f53"><ix:nonFraction unitRef="shares" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmE0NzM0ZGJhNGYwMTRhZjBhYWNmYTdiYzNiMTYzMjI1XzMz_aa65ae66-d116-400d-9851-2a61af74e228">220.0</ix:nonFraction></ix:nonFraction> shares authorized; issued and outstanding shares were <ix:nonFraction unitRef="shares" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="INF" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmE0NzM0ZGJhNGYwMTRhZjBhYWNmYTdiYzNiMTYzMjI1Xzkw_e5e81a52-2cf2-4b59-9ed4-60ff34b05320"><ix:nonFraction unitRef="shares" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmE0NzM0ZGJhNGYwMTRhZjBhYWNmYTdiYzNiMTYzMjI1Xzkw_e750d545-a1d4-4250-8233-d495779a7088">93.4</ix:nonFraction></ix:nonFraction> at September&#160;30, 2020 and <ix:nonFraction unitRef="shares" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmE0NzM0ZGJhNGYwMTRhZjBhYWNmYTdiYzNiMTYzMjI1XzEwMw_a10232d6-0539-4480-a781-6496f937e8c5"><ix:nonFraction unitRef="shares" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="INF" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmE0NzM0ZGJhNGYwMTRhZjBhYWNmYTdiYzNiMTYzMjI1XzEwMw_e8819df7-1931-4d61-8652-bc36d95c562f">92.3</ix:nonFraction></ix:nonFraction> at December&#160;31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzAtMS0xLTEtMA_d029de17-1ab0-4b38-8359-9b3127d4b1bc">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzAtMy0xLTEtMA_1c5905b0-d772-4389-8bf9-29a9b69e496e">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzEtMS0xLTEtMA_3b9f7b39-6737-426d-9d2c-4793c56161f4">1,874.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzEtMy0xLTEtMA_3cb49a15-407c-4e4c-84d6-a7c93b270efa">1,768.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzItMS0xLTEtMA_071756a0-8e19-461a-a9fa-9adb278a887a">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzItMy0xLTEtMA_cd70b850-cd20-4d88-bc6f-fcd8ae6f58b2">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzMtMS0xLTEtMA_03d5404b-8bc9-4bb7-864b-77c1b343dcb0">1,073.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzMtMy0xLTEtMA_1bc57485-973c-43fd-ad11-fcd482f8527d">1,132.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzQtMS0xLTEtMA_bcb5e2fd-d0b9-4356-8469-e8f04ed71e61">804.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzQtMy0xLTEtMA_23567f36-5b21-4950-b96a-4cbf0008d89e">636.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzUtMS0xLTEtMA_8f027eb3-764b-4e27-9252-971a3104f075">1,502.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzUtMy0xLTEtMA_e8d307cb-00d2-4713-b0c6-6f7e9e39c6d6">1,306.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i01dca92a9a894c839fd91f8b5b3beba6_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND COMPREHENSIVE (LOSS) INCOME</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9e8ecaa7faf4bd7aefcbbb4825de4ad_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMy0xLTEtMS0w_1ad28e93-cdf7-45e7-aa39-db3c9b105f72">254.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac9bb3945ab4fa6a54c3854917ec6be_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMy0zLTEtMS0w_68740537-4eb8-472d-a3b5-6e410fe5396d">198.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8b7535c94394a5eb4e42047c2f78f8c_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMy01LTEtMS0w_24557775-c807-489b-ae94-fd29aa103dea">752.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if63b65b04e2b4ba8a6410f5550f0dada_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMy03LTEtMS0w_c76f2a46-37dd-483e-bcc6-dbfbdd420fa1">515.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id237bed344304cdfb92dba0f37b8b2ea_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNC0xLTEtMS0w_47e18044-ccc9-415d-ba8b-11614e0e2899">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id28a908f24d443b491ef90114eab031e_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNC0zLTEtMS0w_70516504-3afd-47f5-ba77-308990a6933d">24.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07aa10bbd36d4f218b7067892376a3d9_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNC01LTEtMS0w_a23d8d3a-f9a8-4d75-8793-4a36ff1b650a">45.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46c14fbf85f4a67bc18bbc72105f4a4_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNC03LTEtMS0w_bbdbbdb8-c994-4595-9c0c-e26e5f722f41">29.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNS0xLTEtMS0w_4fee7d97-113b-4f78-a943-6c9232124973">258.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNS0zLTEtMS0w_50755aff-6ccc-4014-baae-04a04bca9e94">222.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNS01LTEtMS0w_60d31adb-50ce-4f94-bd27-67ad350231cd">798.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNS03LTEtMS0w_70474a56-c0af-4caa-9fe6-2cfff57a1386">544.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNy0xLTEtMS0w_e5ef48ed-1e27-4a45-b948-76995ffda24d">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNy0zLTEtMS0w_09d5ca15-51a5-4e73-a1a7-655b0527e566">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNy01LTEtMS0w_19d24c85-a9a6-45a8-9862-faf2e4be8db9">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNy03LTEtMS0w_af003321-1d82-4666-9978-e63f5ac56428">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfOC0xLTEtMS0w_ade14888-2365-422f-b1e6-def8994e6952">69.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfOC0zLTEtMS0w_b846cf7b-50ea-4778-87de-31bd0c5eec65">45.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfOC01LTEtMS0w_be2a5a43-f407-419d-898c-d9385df5ac1d">208.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfOC03LTEtMS0w_7c00fd24-0c60-41d8-8323-bcacb1cff849">144.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfOS0xLTEtMS0w_31fff12f-bc47-4ecf-adf1-2324fac1e2fc">118.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfOS0zLTEtMS0w_28905415-f9ad-4b8e-922c-67fbe9f094e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfOS01LTEtMS0w_0d2b5cf6-93cf-4235-9305-551f8c52a50a">164.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfOS03LTEtMS0w_293737dc-44db-4014-b2d7-fc0361b41ef4">118.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTAtMS0xLTEtMA_289d750e-51e5-436b-9df4-18189d5ed39c">112.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTAtMy0xLTEtMA_a6a71782-ec5c-4d6d-ba54-ad3bef7e1364">84.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTAtNS0xLTEtMA_6d81c808-d99a-4333-940d-46de8413ce52">326.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTAtNy0xLTEtMA_a4a9abe7-3918-44fc-b435-0b5d0020ace3">252.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTEtMS0xLTEtMA_febd9ea2-40ae-4494-bbd3-23c5d7e654bd">302.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTEtMy0xLTEtMA_e14dfbd1-0ded-4c99-8712-188b623c60ea">132.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTEtNS0xLTEtMA_221183c0-9d97-44fa-bbe6-935319d9bc4d">706.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTEtNy0xLTEtMA_c0a1c0c7-3f81-489f-a319-0c8788943480">520.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating (loss) income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTItMS0xLTEtMA_acd6279a-1a39-4b21-bbdf-b1e8a6965772">44.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTItMy0xLTEtMA_5bcdb2d5-0cee-403e-b9ef-7021431931b6">90.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTItNS0xLTEtMA_f5adec0a-12f6-4d43-9325-c3c1c2bfe32a">91.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTItNy0xLTEtMA_4bc766f8-06e2-4869-a923-9fb95cb9480c">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTQtMS0xLTEtMA_99c5e494-cee9-4be8-8db6-ec41134bc820">8.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTQtMy0xLTEtMA_f1f6b8eb-a1af-4b77-a9f8-3dc5561396a1">8.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTQtNS0xLTEtMA_e0afd457-03c0-409b-b655-a5bf1db60120">25.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTQtNy0xLTEtMA_b04aef27-007c-45a1-84e6-1f7fe45cc179">23.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTUtMS0xLTEtMA_6b441665-a885-4cad-935e-48bc124937c7">7.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTUtMy0xLTEtMA_0cc38a31-73fe-4175-8c8f-9b2872e6abcd">28.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTUtNS0xLTEtMA_133d2a44-a709-4c02-b37e-a83826b607ac">12.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTUtNy0xLTEtMA_7488421a-a4fc-48e0-8add-3fdf47c91dda">5.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income and other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTYtMS0xLTEtMA_ff0a136f-21c0-426f-9fc5-d75ff26af6e1">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTYtMy0xLTEtMA_ec6d1497-29bf-476c-b901-a4dec39f239e">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTYtNS0xLTEtMA_94a7f7ab-805c-4f70-9cb0-26959c95d23f">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="nbix:InvestmentIncomeAndOtherNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTYtNy0xLTEtMA_d176d808-0446-497b-ae3b-475cca1143b4">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTctMS0xLTEtMA_058d8b80-8d63-452f-922e-f8bb69629ade">12.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTctMy0xLTEtMA_7adcab95-0b8a-4075-89e5-81fd84c7452e">31.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTctNS0xLTEtMA_c7090757-6d41-42ef-88b2-91e3f54dbbe1">26.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTctNy0xLTEtMA_ee2d45a7-4eff-4223-927b-13ee6ad75ba2">15.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) income before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTgtMS0xLTEtMA_a360e027-5c04-4909-8862-635434274684">57.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTgtMy0xLTEtMA_e4c1e72c-37e1-47b2-9b6b-711f839596a9">58.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTgtNS0xLTEtMA_51069def-3c0a-4a0e-8943-0ba34460ebe2">65.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTgtNy0xLTEtMA_dfc66b74-1927-45de-8bd5-9090aa912407">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTktMS0xLTEtMA_48e38ee0-5f4c-415c-b658-4477dc927167">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTktMy0xLTEtMA_90afcbea-2672-464e-8f12-0fa019792f7a">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTktNS0xLTEtMA_37b4f711-75f5-4243-9e89-789f96a2306a">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTktNy0xLTEtMA_8ea07299-3f9d-43bd-8afe-d48302d174e9">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjAtMS0xLTEtMA_be3c6ec1-50e6-4c09-a0ee-227a885eb2b3">57.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjAtMy0xLTEtMA_336c8c0a-d77c-41f4-b519-0a4e34dbd3a9">53.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjAtNS0xLTEtMA_a93e9eab-1d2d-45df-89b6-483524b6a704">59.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjAtNy0xLTEtMA_ae4d60f2-cb45-4c1c-8463-33d18faee9b3">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized (loss) gain on debt securities available-for-sale, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjEtMS0xLTEtMA_9cfe23f6-f597-47c9-b551-a2cbfe75e071">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjEtMy0xLTEtMA_ab0a5e97-2f38-4d3a-9006-8185b3173778">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjEtNS0xLTEtMA_ca2c15f0-ffcd-4f16-ab0c-5a325851b85f">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjEtNy0xLTEtMA_f19ed418-3657-4ff7-ba2b-c8030ea3a800">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjItMS0xLTEtMA_cc601241-608b-4d6a-9b63-bcddb4ecc1d9">59.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjItMy0xLTEtMA_bb4eac60-d5d9-429d-9673-6e80be0820ce">54.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjItNS0xLTEtMA_0124b8f7-0f7f-4405-9981-8694f9c6d27a">61.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjItNy0xLTEtMA_cf94c640-57e0-4b44-8398-658bf1f71f09">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share, basic</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjMtMS0xLTEtMA_de41c906-afe0-41be-84db-424183cfe257">0.62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjMtMy0xLTEtMA_2fb3a5cb-f3d8-492b-957f-2fc06168b376">0.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjMtNS0xLTEtMA_d088c2d0-2fb2-47ea-b995-5e9b151b830a">0.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjMtNy0xLTEtMA_f179da3d-1cab-46db-a121-a5bee29bb277">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share, diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjQtMS0xLTEtMA_83e56332-05ef-49b2-97b4-c498947324f1">0.62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjQtMy0xLTEtMA_abbf3147-5192-479f-bd4f-b15990087e8a">0.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjQtNS0xLTEtMA_d2aa1d5d-07a7-46c2-a311-2e61807bf093">0.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjQtNy0xLTEtMA_69107389-e969-4c9b-8218-4282d48d2f99">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, basic</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjUtMS0xLTEtMA_fb05df00-c50c-4c89-b7ba-6fc162719cd7">93.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjUtMy0xLTEtMA_a0677a32-2257-4bc6-b410-23683ddc65aa">91.9</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjUtNS0xLTEtMA_49e25e16-9ec6-4acb-865c-888937633f73">93.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjUtNy0xLTEtMA_7f889d1a-0c29-443b-adda-325a6a45a41b">91.4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding, diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjYtMS0xLTEtMA_c634e0d7-ee52-45bf-994f-fc2756167763">93.3</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjYtMy0xLTEtMA_2b7e83e5-bb3e-4cca-a56d-841ec98ad6c7">96.1</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjYtNS0xLTEtMA_abf34724-fd66-4121-902c-6c9ee9c20e50">98.0</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjYtNy0xLTEtMA_a7bd88c6-ef57-4cd5-ad31-eb748eee647d">95.2</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i01dca92a9a894c839fd91f8b5b3beba6_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.469%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at June&#160;30, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i911a596594bb42f1ac774b4d2e8002bc_I20200630" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMy0xLTEtMS0w_f470b0cf-cce4-486c-9f1a-c33b8f6c238b">93.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911a596594bb42f1ac774b4d2e8002bc_I20200630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMy0zLTEtMS0w_41bad60a-020f-48da-a6b7-6e7ef415a756">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic68d7f4878b240c2a94c47549bedae1d_I20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMy01LTEtMS0w_96c0a383-2234-4972-b75c-f935873b6109">1,842.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5f511a933434ea0834f118c4f341f90_I20200630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMy03LTEtMS0w_fa48cf20-5423-4f94-8f24-516bde1e9753">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedcce6b874c74163b624aa2b15ebb12b_I20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMy05LTEtMS0w_959bdbe8-b7a6-4627-acd4-2fad06d105af">1,015.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e06729230ea4ca7a95cf735dd99be6d_I20200630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMy0xMS0xLTEtMA_c1cd2d27-17ee-4584-9c81-1d39075fb85f">831.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bcde4ddd2f54c21aa4bd738ffd07957_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfNC05LTEtMS0w_50a28435-3ac5-41e3-97ea-cd974a537a36">57.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfNC0xMS0xLTEtMA_e2ee15f3-7682-4d6d-909e-60164d946380">57.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on debt securities available-for-sale, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99a4ab0b6ccf43d6bd7626714d91bae1_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfNS03LTEtMS0w_ab2e5976-d690-40c8-ad36-6ef1918ca328">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfNS0xMS0xLTEtMA_e3117a46-be02-4d98-802a-ad22498acc25">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb7f4b1f21943c6863d8cba446f1522_D20200701-20200930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfNi01LTEtMS0w_15dca255-2438-4474-81f4-bb075b7dcaec">26.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfNi0xMS0xLTEtMA_61cce060-308b-4dce-9b21-6bebe1393eac">26.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfb97fb7839e4786b037248a2437f3e4_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOC0xLTEtMS0w_dc6b7f56-263d-44dd-9012-7212950bd8e9">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb7f4b1f21943c6863d8cba446f1522_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOC01LTEtMS0w_1bf4886b-ca01-40ae-bf68-8ce21e97eab0">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOC0xMS0xLTEtMA_9bec22f2-109f-41c0-bb48-7943bc1d2a1d">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for employee stock purchase plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfb97fb7839e4786b037248a2437f3e4_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOS0xLTEtMS0yOTIx_949a07b1-bc3a-4bd0-b22d-2d4a2dab4f9a">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb7f4b1f21943c6863d8cba446f1522_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOS01LTEtMS0yODky_ef650389-7295-4bfa-87dc-95d21e07311c">2.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOS0xMS0xLTEtMjk0Mw_087dd8ad-0610-40c7-b82a-cfd5d07ab123">2.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at September&#160;30, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf98ce15cffa48d490acc123240b6de1_I20200930" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOS0xLTEtMS0w_bbd05024-2b8d-4028-b6f2-f7527cda4b2d">93.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf98ce15cffa48d490acc123240b6de1_I20200930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOS0zLTEtMS0w_89229a49-89d6-4084-bdb7-fc99b83c7b60">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92e0ed27615f42b28fa6f250cf9e5fb5_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOS01LTEtMS0w_92e4db9b-3f43-4f3c-8869-5ed070726e9f">1,874.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i993fc948fbfd4c9e818abdde04072290_I20200930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOS03LTEtMS0w_1b286138-8c7e-41ea-91b5-f5e2ad1c9d0c">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c745beb45d74cb091440fb03cecacf2_I20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOS05LTEtMS0w_1b7551cd-4786-45f3-84fd-5466c7bac9ad">1,073.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOS0xMS0xLTEtMA_a8d8b460-ca95-43a2-b94d-44d8bdf11ba4">804.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at June&#160;30, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifdf214a2337843e78d1a347256aaaa00_I20190630" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTEtMS0xLTEtMA_0ea5a073-693d-4a1f-84ba-bb767d2bdc1e">91.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdf214a2337843e78d1a347256aaaa00_I20190630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTEtMy0xLTEtMA_d85fe4cf-d21c-47a3-af23-450e4c438067">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib77575bdbf4040e39375b79ca78eff52_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTEtNS0xLTEtMA_0c813b36-f33d-4986-b807-22e21b195a45">1,703.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ded9247e98428593f3e2412173375b_I20190630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTEtNy0xLTEtMA_32e4a034-2a99-4a65-8b03-b4aff288fbf6">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i124193d520854efcb3745edbaed9fea0_I20190630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTEtOS0xLTEtMA_8f6a3281-c4c2-4a5b-8c4a-792f402a29a4">1,220.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12e0fe57cf54c4eb690db593d5ab12f_I20190630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTEtMTEtMS0xLTA_00d93f29-34f0-43cc-8315-a739a70585fe">483.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i268579fde8b349778a731f000224ca07_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTItOS0xLTEtMA_f18a8bb5-d461-49d1-8685-4498d3c52b54">53.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTItMTEtMS0xLTA_02de269c-9b1b-4e0c-8166-6576a45db3dd">53.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain on debt securities available-for-sale, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec797011e09546cd8f24887ec442c1c5_D20190701-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTMtNy0xLTEtMA_52fea3b0-a53a-472d-ac1e-9e538a5e5bae">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTMtMTEtMS0xLTA_ef7fdceb-e421-4933-bcad-d963bc68cc7d">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb42b25d794147b1aed333e2f3166703_D20190701-20190930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTQtNS0xLTEtMA_d1789b1c-1b1c-4905-87bd-a4aae738ed33">20.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTQtMTEtMS0xLTA_1605d492-52cd-407e-a894-04e63b9caec0">20.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd133a6a9d584e259b82b5bcc97dfc26_D20190701-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTUtMS0xLTEtMA_e5bf62d0-1c5b-4452-9be0-fe3514536979">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb42b25d794147b1aed333e2f3166703_D20190701-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTUtNS0xLTEtMA_02357ccd-21fb-4daa-8752-61a75ba5bc2c">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTUtMTEtMS0xLTA_2017a170-3f68-4db8-bb7d-f3eecca76f13">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for employee stock purchase plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd133a6a9d584e259b82b5bcc97dfc26_D20190701-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTctMS0xLTEtMjkyNA_6e856700-a388-4a24-961b-7cddcba49d1a">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb42b25d794147b1aed333e2f3166703_D20190701-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTctNS0xLTEtMjg5NA_e4d35901-ec88-4d06-bf31-643f629ef05a">2.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTctMTEtMS0xLTI5NDU_77acbcc0-4415-45c0-ac31-f2196f7657fc">2.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at September&#160;30, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9fc314f633842568fae2c624fd6a730_I20190930" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTYtMS0xLTEtMA_85d920f5-253f-4f36-81c3-d982af3fcd64">92.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9fc314f633842568fae2c624fd6a730_I20190930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTYtMy0xLTEtMA_be371dc7-3e8f-4520-b79a-da9b208b8dc7">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic436e3bb1c9b40c5a2c28786df5e2f5e_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTYtNS0xLTEtMA_07a715a9-e51d-4069-bd93-3d1d2f3b7ccd">1,739.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i305a4e84d6d84699b8b9301835f9518f_I20190930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTYtNy0xLTEtMA_8b3e3fc2-6eb4-4275-ad8d-d0566c41308a">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730787997d6d4c228ee797868cbe3082_I20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTYtOS0xLTEtMA_8dd3e9a0-568b-40bd-bfe0-ba7e1e52f4f3">1,166.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eafa440da15427d8d322a26e23e8db7_I20190930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTYtMTEtMS0xLTA_d4c1cebe-3d98-4df4-9719-c65f7fcbac19">574.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i543b37a401f842f297d00c6f44d8c51d_I20191231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTgtMS0xLTEtMA_150637e8-f347-46c1-9c95-cccceb8dc4c8">92.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i543b37a401f842f297d00c6f44d8c51d_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTgtMy0xLTEtMA_03134d55-4b1b-417b-9b79-151f0a28ebb3">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bcc585face2402191cabf07bfd067f5_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTgtNS0xLTEtMA_7a55043a-bff4-4320-9dcb-33613100c03e">1,768.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1679f6518a049a0b79b7b15a1277d4d_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTgtNy0xLTEtMA_f2455506-b1bd-4820-905e-32dd98cc887f">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icce724fa185b4a2e81da141dd2ca4c69_I20191231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTgtOS0xLTEtMA_78c367d1-a067-4ec3-9cec-348de6ffb520">1,132.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTgtMTEtMS0xLTA_66de63c0-425f-46fd-91db-a4f1b2ec9af2">636.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie82ca40bd6b7437b85500edd36e2ac78_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTktOS0xLTEtMA_3480b01d-6df5-4ee7-af9b-a7b2ed05fab9">59.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTktMTEtMS0xLTA_e377c14b-cfe4-4900-afe0-33d906e857e9">59.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain on debt securities available-for-sale, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6512d4e06fe64b8c8902cb07fd087fe7_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjAtNy0xLTEtMA_6088182e-d132-476f-9268-ccb8455189b8">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjAtMTEtMS0xLTA_1e970394-de08-4080-a01a-1ef66f5561ff">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i993fa090c95f4e7791e5c5d7159708d5_D20200101-20200930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjEtNS0xLTEtMA_5b0f675f-c0e6-43ba-92ff-b10a9d746941">79.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjEtMTEtMS0xLTA_3626130e-bbab-4d4f-8bcc-8502d38f6a13">79.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for vested restricted stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1e75fea41454043ab426501ad55a6dd_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjItMS0xLTEtMA_0d2b3d08-c0b1-4acf-b553-5f960c5ac264">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for stock options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1e75fea41454043ab426501ad55a6dd_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjMtMS0xLTEtMA_a02158f8-a3d5-44e1-bd6f-d1292adaba9f">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i993fa090c95f4e7791e5c5d7159708d5_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjMtNS0xLTEtMA_d48b9b32-156c-4751-a6b7-acb28aed95c9">21.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjMtMTEtMS0xLTA_dc3a7933-33e0-42e6-8cee-9ecff7780d5f">21.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1e75fea41454043ab426501ad55a6dd_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjYtMS0xLTEtMjkyNw_ea15360f-d79c-4372-8cf1-ce434fd763d6">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i993fa090c95f4e7791e5c5d7159708d5_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjQtNS0xLTEtMA_6bbae6a1-6b3c-48ea-a6f9-792d14ef8f5c">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjQtMTEtMS0xLTA_53ad6a6d-9dd4-43f0-bcaf-c13f813c85d1">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at September&#160;30, 2020</span></div></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf98ce15cffa48d490acc123240b6de1_I20200930" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjUtMS0xLTEtMA_f04ce6fc-1538-41e0-a926-b3cd71082312">93.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf98ce15cffa48d490acc123240b6de1_I20200930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjUtMy0xLTEtMA_aa584af1-13b3-4450-8743-e1257f901a72">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92e0ed27615f42b28fa6f250cf9e5fb5_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjUtNS0xLTEtMA_9687afc1-0934-48d6-8013-dd9fbf894ea7">1,874.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i993fc948fbfd4c9e818abdde04072290_I20200930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjUtNy0xLTEtMA_679e0aa0-9e9e-41da-a11f-390b19531703">3.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c745beb45d74cb091440fb03cecacf2_I20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjUtOS0xLTEtMA_d2c9e9c4-f232-4542-8e93-ae7f804cb327">1,073.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjUtMTEtMS0xLTA_390eddec-1639-41b5-bf2b-c17ccc801ebd">804.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2018</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib022af9959ba424787b942770385acd6_I20181231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjctMS0xLTEtMA_1f1cbde3-54ac-4abd-b8f3-2ff12bee691a">90.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib022af9959ba424787b942770385acd6_I20181231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjctMy0xLTEtMA_ac7f9d24-f136-4366-90a9-94dfe6dd2ca4">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i473e921631e44d049f986015d23f8c8e_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjctNS0xLTEtMA_8483b4b5-707c-4fdc-ac6c-a336e8cd0000">1,660.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd3a22690ded4fd58399451eeb2ff477_I20181231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjctNy0xLTEtMA_78b7273c-ddce-4ae8-8ef6-bba2200f2f4d">2.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a72aa82edb54cb9aa6dd689f379b35e_I20181231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjctOS0xLTEtMA_c0899782-e058-43fe-ab57-ddb8169e45f7">1,177.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b9bcef8502e4089bb1a8346e1df9932_I20181231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjctMTEtMS0xLTA_a45d2719-8921-4060-9b9a-7f6c04805e57">480.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252046dd1c50470ea1cf51b3a7d8bbda_D20190101-20190930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjgtOS0xLTEtMA_1ba6175b-e9a7-4c59-89e6-208a28a13934">3.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjgtMTEtMS0xLTA_8c10c30d-73ff-47f4-8203-dd63a40f7299">3.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain on debt securities available-for-sale, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a4f65fc8aa34883b840cee701384a7b_D20190101-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjktNy0xLTEtMA_8132733c-3859-4cff-958b-46c6a73a27ad">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjktMTEtMS0xLTA_3414ea5a-9d03-44ef-92d7-4249be6fa1d6">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ccdf0b325741f783c0d8b5806ef5e9_D20190101-20190930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzAtNS0xLTEtMA_7fdb1c5e-7738-4b80-be59-176756f5caa4">54.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzAtMTEtMS0xLTA_c0c75aa4-d634-4b0d-85a6-eba9226f9090">54.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for vested restricted stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42a7ca788f2e494ea2ff656d2aecaa79_D20190101-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzEtMS0xLTEtMA_add40a99-2bab-4df3-a26a-1629eff5ebcc">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for stock options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42a7ca788f2e494ea2ff656d2aecaa79_D20190101-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzItMS0xLTEtMA_be6c22ff-7977-4535-bfe2-1fe822694bea">0.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ccdf0b325741f783c0d8b5806ef5e9_D20190101-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzItNS0xLTEtMA_35a5e3a0-97cc-4a24-9abe-6dd6bfb7abc4">20.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzItMTEtMS0xLTA_d0f619bb-cb4d-47bb-9156-42900bcd67df">20.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42a7ca788f2e494ea2ff656d2aecaa79_D20190101-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzUtMS0xLTEtMjkzMA_5f61e51e-3960-41aa-89c2-0733fc957ea2">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ccdf0b325741f783c0d8b5806ef5e9_D20190101-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzMtNS0xLTEtMA_4ef4b305-488e-4287-8530-9b43b7636f9d">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzMtMTEtMS0xLTA_3eaa40e5-a95f-4e08-b2e0-5a95668b72aa">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzQtMC0xLTEtMA_ea544724-28b1-46be-84e8-aa74a9f36877">Cumulative-effect adjustment to equity due to adoption of ASU 2016-02</span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3ac91b9e8aa453fa75f654a778253ac_I20181231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzQtOS0xLTEtMA_8f0ddfce-4767-4b63-8de1-cf2099e1b513">8.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice72e35fd4be4be0bd6c7d149fff6950_I20181231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzQtMTEtMS0xLTA_65054267-2c36-4f2a-b057-5c292fbf71f6">8.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at September&#160;30, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9fc314f633842568fae2c624fd6a730_I20190930" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzUtMS0xLTEtMA_4d450174-a071-4be6-a3d3-b9de4da1565e">92.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9fc314f633842568fae2c624fd6a730_I20190930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzUtMy0xLTEtMA_d3b96007-1ce4-4448-a3b7-8091189a0b38">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic436e3bb1c9b40c5a2c28786df5e2f5e_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzUtNS0xLTEtMA_65171138-b147-4c3a-b869-ee56a0589e97">1,739.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i305a4e84d6d84699b8b9301835f9518f_I20190930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzUtNy0xLTEtMA_fbb6b82d-4a03-455a-bc21-82771ed0949a">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i730787997d6d4c228ee797868cbe3082_I20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzUtOS0xLTEtMA_e60a9eda-f705-4c74-8409-20113d23cf52">1,166.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eafa440da15427d8d322a26e23e8db7_I20190930" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzUtMTEtMS0xLTA_2c1211b0-536a-472a-a2e3-650f9f2a0e68">574.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i01dca92a9a894c839fd91f8b5b3beba6_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMy0xLTEtMS0w_881b35c1-b3c9-4c87-ace7-25c76318ae93">59.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMy0zLTEtMS0w_3c121be5-c69c-417a-8d4e-b0d8b99cfc2e">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reconciliation of net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfNS0xLTEtMS0w_a3567a0f-db2a-43cf-bcd1-8bfd93efc2bb">79.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfNS0zLTEtMS0w_fb1023b6-5675-4eb8-b8a6-113a2054a093">54.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfNi0xLTEtMS0w_42a3ef99-d978-4662-b316-f62951a25bf4">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfNi0zLTEtMS0w_60fb1f38-1394-41b7-aeee-73f941e04bba">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfNy0xLTEtMS0w_422896eb-9904-4eb2-a6cc-f1d19f423f78">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfNy0zLTEtMS0w_ff81ecc6-76b1-45e7-a2f3-894077515221">14.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfOC0xLTEtMS0w_38153ec7-5e54-436f-99df-e9ea8eac4536">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfOC0zLTEtMS0w_573c4959-d9a2-4f74-b569-34d9c5eac0e5">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of equity security investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfOS0xLTEtMS0w_ed9c3aa9-8697-4d01-b4e8-b68d6b3cdb7e">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfOS0zLTEtMS0w_67a83a70-6876-4e03-a5aa-2a88007f94c7">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTAtMS0xLTEtMA_89c43c9c-2db1-4d16-b092-a3afdd42f076">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTAtMy0xLTEtMA_e573e2b6-b079-4d4a-ba88-eaa5059bc9ea">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTItMS0xLTEtMA_04a790ca-11b4-400f-9101-4ef8b6d18611">30.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTItMy0xLTEtMA_a8d9c5f8-78c3-4b7b-9883-a363ef651b2e">57.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTMtMS0xLTEtMA_03c385a6-0d67-43ea-abde-07dadcb7d31a">3.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTMtMy0xLTEtMA_403a6052-d414-4a0b-bf2a-934d1b8887c8">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTQtMS0xLTEtMA_52f31bf6-3adc-4d66-aa1a-5b0e91f922b7">28.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTQtMy0xLTEtMA_313258ed-6430-481c-ad96-325d06796db7">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTUtMS0xLTEtMA_713942f9-d234-48e1-a713-997d7ac2ddc8">29.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTUtMy0xLTEtMA_7d0124ee-a494-4006-85b7-d89fe615e3ad">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTYtMS0xLTEtMA_b2366b4d-ace9-4770-bade-2d9875b0d775">139.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTYtMy0xLTEtMA_7214909b-10f1-4d61-b65b-3ed5c5fef1b2">49.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTktMS0xLTEtMA_691c25fb-c71b-4257-ab30-ff71ba38a3e5">399.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTktMy0xLTEtMA_e86b6b5c-7910-4a08-9555-e2bcc0a442bb">467.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 0.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales and maturities of debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjAtMS0xLTEtMA_a4948fa5-38eb-45dc-829c-486c4ee72775">557.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjAtMy0xLTEtMA_4f6cbd52-2351-497d-aa36-d62852f7dd33">488.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjEtMS0xLTEtMA_5c05fc2f-5d8a-4e0c-a1cf-7bc82960623e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjEtMy0xLTEtMA_c887a003-3f09-4065-82b5-c4f177c6f9c6">54.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 0.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjItMS0xLTEtMA_9848193b-d901-42ca-8d4f-852a020eb29a">6.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjItMy0xLTEtMA_3d37250c-5337-4720-9a35-4c8be2f8226b">11.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjMtMS0xLTEtMA_a143c2ca-9230-4dd9-852f-68de10314782">151.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjMtMy0xLTEtMA_3c961806-f52c-4748-a8bf-f2237784aea4">44.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 0.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjYtMS0xLTEtMA_4954ac55-da44-47bf-a4eb-968da2299a14">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjYtMy0xLTEtMA_31b66736-3b56-4304-9346-53ac7cff1003">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjctMS0xLTEtMA_fca97caa-1fb3-4f81-8517-c3db0e038181">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjctMy0xLTEtMA_afa28484-c2cb-4e43-8d17-25375ab0d1a3">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjgtMS0xLTEtMA_4281ba1d-d3a3-40fa-8505-06467fa80908">313.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjgtMy0xLTEtMA_18ce82dc-9d08-4719-b680-0b0121c71438">24.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjktMS0xLTEtMA_0a35738c-4f05-4492-bf77-6200faddbf49">115.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b9bcef8502e4089bb1a8346e1df9932_I20181231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjktMy0xLTEtMA_e8defad8-5773-4b01-9ae1-de7e22295c16">147.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMzAtMS0xLTEtMA_eb6b1925-b852-4224-8771-9db0cb5a74c7">428.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eafa440da15427d8d322a26e23e8db7_I20190930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMzAtMy0xLTEtMA_9126252a-c3f7-4eb8-a0f5-628bf3dd13af">171.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental Disclosure:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash capital expenditures</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMzMtMS0xLTEtMA_f7c75301-11f0-483a-95f8-0b60bb0467bf">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMzMtMy0xLTEtMA_f82c1bf8-5161-4b64-8805-eff4c4e8e20b">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMzQtMS0xLTEtMA_8cb8acf4-b974-4d7f-90c7-e519d0cd3120">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMzQtMy0xLTEtMA_2fdaf426-362e-42fa-9f22-e2b220455376">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMzUtMS0xLTEtMA_055e3cb9-6412-41c9-bd8e-2834659d86cc">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMzUtMy0xLTEtMA_4d967af7-c6f7-45dd-ac62-0d5ee541a231">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i01dca92a9a894c839fd91f8b5b3beba6_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEUROCRINE BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i01dca92a9a894c839fd91f8b5b3beba6_31"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zMS9mcmFnOmJmMDkzOGVlMWI5NTQ3ZDc5NDQ3ODJkYmFkYmRmNzk4L3RleHRyZWdpb246YmYwOTM4ZWUxYjk1NDdkNzk0NDc4MmRiYWRiZGY3OThfMTQwNzE_05bf3741-fb23-4211-928d-e4a05632e12e" continuedAt="i886fa7138c684d24b1ce0c54a14ca61f" escape="true">Organization and Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i886fa7138c684d24b1ce0c54a14ca61f" continuedAt="i1e2f056eca6646e58b4439cf235203c9"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="nbix:BusinessDescriptionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zMS9mcmFnOmJmMDkzOGVlMWI5NTQ3ZDc5NDQ3ODJkYmFkYmRmNzk4L3RleHRyZWdpb246YmYwOTM4ZWUxYjk1NDdkNzk0NDc4MmRiYWRiZGY3OThfMTQwNjg_797e92c8-2084-46df-8f22-140c1899348a" escape="true"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences, Inc., or Neurocrine Biosciences, the Company, we, our or us, was incorporated in California in 1992 and reincorporated in Delaware in 1996. Neurocrine Continental, Inc., is a Delaware corporation and a wholly owned subsidiary of Neurocrine Biosciences. We also have <ix:nonFraction unitRef="subsidiary" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="nbix:NumberOfIrishSubsidiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zMS9mcmFnOmJmMDkzOGVlMWI5NTQ3ZDc5NDQ3ODJkYmFkYmRmNzk4L3RleHRyZWdpb246YmYwOTM4ZWUxYjk1NDdkNzk0NDc4MmRiYWRiZGY3OThfMzcy_c8a2f0ed-6ed5-4622-a1cd-f1e330978971">two</ix:nonFraction> wholly owned Irish subsidiaries, Neurocrine Therapeutics, Ltd. and Neurocrine Europe, Ltd., both of which were formed in December 2014 and are inactive. </span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a commercial-stage biopharmaceutical company focused on discovering and developing innovative and life-changing treatments for patients with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. We specialize in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. Currently, we are primarily focused on the commercialization of INGREZZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in the United States, or US, our first US Food and Drug Administration, or FDA, approved product.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zMS9mcmFnOmJmMDkzOGVlMWI5NTQ3ZDc5NDQ3ODJkYmFkYmRmNzk4L3RleHRyZWdpb246YmYwOTM4ZWUxYjk1NDdkNzk0NDc4MmRiYWRiZGY3OThfMjc0ODc3OTE0OTQ0OQ_2b116d9b-614c-44cd-8c19-3c93706e5a2e" escape="true"><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the US, or GAAP, for interim financial information and with the instructions of the Securities and Exchange Commission, or SEC, on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of Neurocrine Biosciences and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2019, included in our Annual Report on Form 10-K, or the 2019 Form 10-K, filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or the full year. The condensed consolidated balance sheet at December&#160;31, 2019, has been derived from the audited financial statements as of that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no significant changes to our significant accounting policies as disclosed in the 2019 Form 10-K, except as set forth below.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:DebtPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zMS9mcmFnOmJmMDkzOGVlMWI5NTQ3ZDc5NDQ3ODJkYmFkYmRmNzk4L3RleHRyZWdpb246YmYwOTM4ZWUxYjk1NDdkNzk0NDc4MmRiYWRiZGY3OThfMTQwNjk_edb06104-7cb7-4e9f-b828-02190e69d4b3" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist of investments in certificates of deposit, corporate debt securities, and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become <ix:nonNumeric contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" format="ixt-sec:durday" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zMS9mcmFnOmJmMDkzOGVlMWI5NTQ3ZDc5NDQ3ODJkYmFkYmRmNzk4L3RleHRyZWdpb246YmYwOTM4ZWUxYjk1NDdkNzk0NDc4MmRiYWRiZGY3OThfNzI2MA_3fb7b0f1-eb34-43fa-9c6b-5c2a0880eabb">90</ix:nonNumeric> days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.</span></div></ix:nonNumeric><div><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zMS9mcmFnOmJmMDkzOGVlMWI5NTQ3ZDc5NDQ3ODJkYmFkYmRmNzk4L3RleHRyZWdpb246YmYwOTM4ZWUxYjk1NDdkNzk0NDc4MmRiYWRiZGY3OThfMTQwNzM_8e4721ef-2ffa-44f0-ba18-fc0f99ee8ca3" continuedAt="i460929a0fcf54a6bb46f03a636ed6e12" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Credit Losses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span></ix:nonNumeric></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1e2f056eca6646e58b4439cf235203c9" continuedAt="i4a21217da65143bc84bef8208a1d4acd"><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i460929a0fcf54a6bb46f03a636ed6e12">Accrued interest receivables on debt securities available-for-sale totaled $<ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zMS9mcmFnOmJmMDkzOGVlMWI5NTQ3ZDc5NDQ3ODJkYmFkYmRmNzk4L3RleHRyZWdpb246YmYwOTM4ZWUxYjk1NDdkNzk0NDc4MmRiYWRiZGY3OThfOTIxNA_ed4ddee7-c30f-4b8f-b24c-d085afdee8ed">3.5</ix:nonFraction> million at September&#160;30, 2020. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. <ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zMS9mcmFnOmJmMDkzOGVlMWI5NTQ3ZDc5NDQ3ODJkYmFkYmRmNzk4L3RleHRyZWdpb246YmYwOTM4ZWUxYjk1NDdkNzk0NDc4MmRiYWRiZGY3OThfOTYzMA_7003046f-559e-459f-9fe4-a9d5fb28b23c">No</ix:nonFraction> accrued interest receivables were written off during the nine months ended September&#160;30, 2020.</ix:continuation></span></div><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zMS9mcmFnOmJmMDkzOGVlMWI5NTQ3ZDc5NDQ3ODJkYmFkYmRmNzk4L3RleHRyZWdpb246YmYwOTM4ZWUxYjk1NDdkNzk0NDc4MmRiYWRiZGY3OThfMTQwNzQ_3d354fcf-4f99-4701-a8f9-3ced1780c8b4" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents, debt securities available-for-sale and equity securities at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources, and analyzing data in certain instances.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities of certain companies that are subject to holding period restrictions longer than one year are classified as Level 3 and carried at fair value using an option pricing valuation model. The most significant assumptions within the option pricing valuation model are the stock price volatility, which is based on the historical volatility of similar companies, and the discount for lack of marketability related to the term of the restrictions.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zMS9mcmFnOmJmMDkzOGVlMWI5NTQ3ZDc5NDQ3ODJkYmFkYmRmNzk4L3RleHRyZWdpb246YmYwOTM4ZWUxYjk1NDdkNzk0NDc4MmRiYWRiZGY3OThfMTQwNzU_ed7a23f4-d23f-4a9d-ad27-4715524692ef" continuedAt="ia58fd282307c4aeb9d99399ac34859a9" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2016-13. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted Accounting Standards Update, or ASU, 2016-13,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using the modified retrospective transition method. For debt securities available-for-sale, the standard requires an investor to determine whether a decline in the fair value below the amortized cost basis of the investment is due to credit-related factors. Credit-related impairment is recognized as an allowance for credit loss on the balance sheet with a corresponding adjustment to earnings. Credit losses are limited to the amount by which the investment&#8217;s amortized cost basis exceeds its fair value and may be subsequently reversed if conditions change. Any impairment that is not credit related is recognized in other comprehensive income or loss, as applicable, net of applicable taxes.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of ASU 2016-13 did not result in a cumulative-effect adjustment to retained earnings. The comparative prior period information continues to be reported under the accounting standards in effect during those periods.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2019-12. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application of Topic 740. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, with early adoption permitted in any interim period for which financial statements have not yet been made available for issuance. We are currently evaluating the effect ASU 2019-12 will have on our condensed consolidated financial statements and related disclosures.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2020-06. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments, and amends existing earnings-per-share, or EPS, guidance by requiring that an entity use the if-converted method when calculating diluted EPS for convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4a21217da65143bc84bef8208a1d4acd"><ix:continuation id="ia58fd282307c4aeb9d99399ac34859a9">years, with early adoption permitted for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We are currently evaluating the effect ASU 2020-06 will have on our condensed consolidated financial statements and related disclosures.</ix:continuation></ix:continuation></span></div><div id="i01dca92a9a894c839fd91f8b5b3beba6_34"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMzg0ODI5MDczNDE4NQ_05c299ae-564c-45b6-9539-7a576f12c574" continuedAt="ic87638ddfe3b41209653d96dbcdc63b8" escape="true">Significant Collaboration and Licensing Agreements</ix:nonNumeric></span></div><ix:continuation id="ic87638ddfe3b41209653d96dbcdc63b8" continuedAt="i06390ec7933d41dca8ecdaf3344430d1"><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In June 2020, we entered into an exclusive license agreement with Takeda, which became effective in July 2020, to develop and commercialize certain compounds in Takeda&#8217;s early to mid-stage psychiatry pipeline. Specifically, Takeda granted us an exclusive license to the following seven assets: (i) NBI-1065844 (TAK-831) for schizophrenia, (ii) NBI-1065845 (TAK-653) for treatment-resistant depression, (iii) NBI-1065846 (TAK-041) for anhedonia (which together with the NBI-1065845 are referred to as the Phase II Ready Assets), and (iv) four non-clinical stage assets, or the Non-Clinical Assets.</span></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NBI-1065844 is deemed a royalty-bearing product under the license agreement pursuant to which we will be responsible for all costs and expenses associated with the development, manufacture, and commercialization of such asset, subject to certain exceptions, and Takeda will be eligible to receive development and commercial milestones and royalties with respect to such asset, or a Royalty-Bearing Product, and Takeda will retain the right to opt-in to a profit sharing arrangement pursuant to which we and Takeda will equally share in the operating profits and losses related to such asset, subject to certain exceptions, in lieu of receiving milestones and royalties, or a Profit-Share Product. Subject to specified conditions, Takeda may elect to exercise such opt-in right for NBI-1065844 before we initiate a Phase III clinical trial. Each of the Phase II Ready Assets is deemed a Profit-Share Product and Takeda will retain the right to opt-out of the profit-sharing arrangement for such asset pursuant to which such asset would become a Royalty-Bearing Product. Takeda may elect to exercise such opt-out rights with respect to a Phase II Ready Asset immediately following the completion of the second Phase II clinical trial for such Phase II Ready Asset. In addition, under certain circumstances related to the development and commercialization activities to be performed by us, Takeda may elect to opt-out of the profit-sharing arrangement for a Profit-Share Product before the initiation of a Phase III clinical trial for such product.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Non-Clinical Assets will be Royalty-Bearing Products pursuant to which we will be responsible for all costs and expenses associated with the development, manufacture, and commercialization of such assets, subject to certain exceptions.</span></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Takeda $<ix:nonFraction unitRef="usd" contextRef="i1bc3cf10ca8443d19bf1d4cf81b112be_I20200731" decimals="-5" format="ixt:numdotdecimal" name="nbix:UpfrontPaymentsMade" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzMyMTgzMw_eea5d7f4-f32e-4ec9-adf4-244efaa8b58a">120.0</ix:nonFraction>&#160;million upfront</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which, including certain transaction related costs, was expensed as IPR&amp;D in the third quarter of 2020</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the agreement, </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda may also be entitled to receive payments of up to $<ix:nonFraction unitRef="usd" contextRef="i0fd2fda8589244c78b0b293642285e18_I20200930" decimals="-8" format="ixt:numdotdecimal" name="nbix:PotentialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzMyMjA3OQ_6c388c09-c6b7-444a-9ea7-804df82fc2da">1.9</ix:nonFraction>&#160;billion upon the achievement of certain development and commercial milestones associated with Royalty-Bearing Products, as well as receive royalties on future net sales of Royalty-Bearing Products. On a country-by-country and product-by-product basis, royalty payments would commence on the first commercial sale of a Royalty-Bearing Product and terminate on the later of (i) the expiration of the last patent covering such Royalty-Bearing Product in such country, (ii) a number of years from the first commercial sale of such Royalty-Bearing Product in such country and (iii) the expiration of regulatory exclusivity for Royalty-Bearing Product in such country.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the license agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which, (i) for any Royalty-Bearing Product, the royalty term has expired in such country; and (ii) for any Profit-Share Product, for so long as we continue to develop, manufacture, or commercialize such licensed product.  We may terminate the license agreement for convenience in its entirety or in one or more (but not all) of the United States, Japan, the European Union, and the United Kingdom, or the Major Markets, on 6 months&#8217; written notice to Takeda (i) with respect to all licensed products prior to the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes, as defined in the agreement, prior to the first commercial sale of the first licensed product in such target class(es) for which first commercial sale occurs. We may terminate the license agreement for convenience in its entirety or in one or more (but not all) of the Major Markets on 12 months&#8217; written notice to Takeda (i) with respect to all licensed products following the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes following the first commercial sale of the first licensed product in such target class(es) for which first commercial sale. Takeda may terminate the license agreement, subject to specified conditions, (i) if we challenge the validity or enforceability of certain Takeda intellectual property rights or (ii) on a target class-by-target class basis, in the event that we do not conduct any material development or commercialization activities with respect to any licensed product within such target class for a specified continuous period. Subject to a cure period, either party may terminate the license agreement in the event of any material breach, solely with respect to the target class of a licensed product to which such material breach relates, or in its entirety in the event of any material breach that relates to all licensed products.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i06390ec7933d41dca8ecdaf3344430d1" continuedAt="i2d85acedcfe54e1a95e84a5f8aaa3b19"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Idorsia.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we entered a collaboration and licensing agreement with Idorsia to license the global rights to NBI-827104, a potent, selective, orally active and brain penetrating T-type calcium channel blocker, in clinical development for the treatment of a rare pediatric epilepsy. The agreement also included a research collaboration to discover and identify additional novel T-type calcium channel blockers as development candidates. </span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the exercise of the option, we paid Idorsia $<ix:nonFraction unitRef="usd" contextRef="id529934387f148b18fa1109106ad5a55_I20200531" decimals="-5" format="ixt:numdotdecimal" name="nbix:UpfrontPaymentsMade" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzMzODQ4OQ_57c7e817-4cd3-436a-a5c9-4428b0f54945">45.0</ix:nonFraction>&#160;million upfront, which was expensed as IPR&amp;D in the second quarter of 2020. Further, as part of the research collaboration, we provided Idorsia with an incremental $<ix:nonFraction unitRef="usd" contextRef="id529934387f148b18fa1109106ad5a55_I20200531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzMzODY0OQ_654ef9ed-f15b-4dfa-8a62-ab4661fc6666">7.2</ix:nonFraction>&#160;million in funding, which was recorded as a prepaid asset to be expensed over the <ix:nonNumeric contextRef="iabd2ce28d6694a2486d931e1479cf385_D20200501-20200531" format="ixt-sec:durwordsen" name="nbix:ResearchCollaborationTerm" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjc0ODc3OTE3NjkxNg_0f460622-10f3-4801-85f2-797fba76c4b5">two-year</ix:nonNumeric> research collaboration term.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the agreement, upon the achievement of certain development and regulatory milestones, Idorsia may be entitled to receive payments of up to $<ix:nonFraction unitRef="usd" contextRef="i05e0789a004a4bb0b0b9943498ed0bde_I20200930" decimals="-5" format="ixt:numdotdecimal" name="nbix:PotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzMzODkyOQ_424265b1-5e6e-4c06-8cd1-02ba33d0219c">365.0</ix:nonFraction>&#160;million with respect to NBI-827104 and up to $<ix:nonFraction unitRef="usd" contextRef="i2c7cce679a364cb494b726cf6f83dd4f_I20200930" decimals="-5" format="ixt:numdotdecimal" name="nbix:PotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzMzODk3MA_1adfd72a-ce16-4243-81fc-e2aa2a3caf33">620.0</ix:nonFraction>&#160;million with respect to the development candidates. In addition, Idorsia may also be entitled to receive payments of up to $<ix:nonFraction unitRef="usd" contextRef="i1f38dd2e87214e4e86b4617f5f7a47c9_I20200930" decimals="-5" format="ixt:numdotdecimal" name="nbix:PotentialCommercialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzMzOTA4OQ_17caf7c7-f2dd-432e-a0b3-f576bdb2fac5">750.0</ix:nonFraction>&#160;million upon the achievement of certain commercial milestones, as well as receive royalties on the net sales of any collaboration product. Further, we will be responsible for all manufacturing, development and commercialization costs of any collaboration product.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the collaboration and licensing agreement, in its entirety or with respect to a particular compound or development candidate, by providing <ix:nonNumeric contextRef="iabd2ce28d6694a2486d931e1479cf385_D20200501-20200531" format="ixt-sec:durday" name="nbix:TerminationNoticePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzMzOTUwNQ_6002b933-8043-4e08-89ff-1e9af146b33e">90</ix:nonNumeric> days&#8217; written notice to Idorsia. Further, in the event a party commits a material breach and fails to cure such material breach within <ix:nonNumeric contextRef="iabd2ce28d6694a2486d931e1479cf385_D20200501-20200531" format="ixt-sec:durday" name="nbix:TerminationNoticePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzMzOTYzOQ_f4a56746-afca-47d1-8710-40503c6239eb">90</ix:nonNumeric> days after receiving written notice thereof, the non-breaching party may terminate the agreement in its entirety immediately upon written notice to the breaching party.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Xenon. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a license and collaboration agreement with Xenon Pharmaceuticals Inc., or Xenon, to identify, research, and develop sodium channel inhibitors, including clinical candidate NBI-921352 and three preclinical candidates, which compounds we will have the exclusive right to further develop and commercialize under the terms and conditions set forth in the agreement.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be solely responsible, at our sole cost and expense, for all development and manufacturing of the compounds and any pharmaceutical product that contains a compound, subject to Xenon&#8217;s right to elect to co-fund the development of one product in a major indication and thus receive a mid-single digit percentage increase in royalties owed on the net sales of such product in the US. If Xenon exercises such option, the parties will share equally all reasonable and documented costs and expenses incurred in connection with the development of such product in the applicable indication, except costs and expenses that are solely related to the development of such product for regulatory approval outside the US.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the term of the license and collaboration agreement will continue on a product-by-product and country-by-country basis until the expiration of the royalty term for such product in such country. Upon the expiration of the royalty term for a particular product and country, the exclusive license granted by Xenon to us with respect to such product and country will become fully paid, royalty free, perpetual, and irrevocable. We may terminate the license and collaboration agreement by providing at least <ix:nonNumeric contextRef="if408f3cef84a459fb036f2dae9a47b78_D20191201-20191231" format="ixt-sec:durday" name="nbix:TerminationNoticePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM0NzA4Mw_33eca6cd-db87-471a-b3ce-80de24d9a86f">90</ix:nonNumeric> days&#8217; written notice, provided that such unilateral termination will not be effective for certain products until we have used commercially reasonable efforts to complete certain specified clinical studies. Either party may terminate the agreement in the event of a material breach in whole or in part, subject to specified conditions.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voyager.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2019, we entered into a collaboration and license agreement with Voyager, a clinical-stage gene therapy company. The agreement is focused on the development and commercialization of four programs using Voyager&#8217;s proprietary gene therapy platform. The four programs consist of the NBIb-1817 program for Parkinson&#8217;s disease, the Friedreich&#8217;s ataxia program and the rights to two undisclosed programs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to development plans agreed to by us and Voyager, unless Voyager exercises its co-development and co-commerci</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alization rights as provided for in the agreement, we will be responsible for all development costs. Further, upon the occurrence of a specified event for each program, we will assume responsibility for the development, manufacturing, and commercialization activit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies of such program.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the collaboration and license agreement with Voyager upon <ix:nonNumeric contextRef="ied735b11fcf841da816bf129e0782ef6_D20190601-20190630" format="ixt-sec:durday" name="nbix:TerminationNoticePeriodBeforeFirstCommercialSale" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM1MzcyOA_eabbfee3-6867-4dfb-8814-6ad1522f7d62">180</ix:nonNumeric> days&#8217; written notice to Voyager prior to the first commercial sale of any collaboration product or upon <ix:nonNumeric contextRef="ied735b11fcf841da816bf129e0782ef6_D20190601-20190630" format="ixt-sec:durwordsen" name="nbix:TerminationNoticePeriodAfterFirstCommercialSale" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM1MzgzMQ_811683b8-8099-4b08-bedf-4dd1bf1301ed">one year</ix:nonNumeric> after the date of notice if such notice is provided after the first commercial sale of any collaboration product. Unless terminated earlier, the agreement will continue in effect until the expiration of the last to expire royalty term with respect to any collaboration product or the last expiration or termination of any exercised co-development and co-commercialization rights by Voyager as provided for in the agreement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIAL &#8211; Portela &amp; Ca, S.A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2017, we entered into an exclusive license agreement with BIAL&#160;&#8211; Portela &amp; Ca, S.A., or BIAL, for the development and commercialization of ONGENTYS for the treatment of human diseases and conditions, including Parkinson&#8217;s disease, in the US and Canada. </span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we received FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients, which was commercialized by our commercial team in late September 2020. FDA approval for ONGENTYS for Parkinson&#8217;s disease triggered a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="ie59f33ba48b64fbf878b1b0bb32cd3bf_I20200430" decimals="-5" format="ixt:numdotdecimal" name="nbix:MilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM1NzY4Nw_253d4ef1-d531-4a28-86cc-ef5653b07ffd">20.0</ix:nonFraction> million, which was expensed </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2d85acedcfe54e1a95e84a5f8aaa3b19" continuedAt="ib6f16337c3b7462f91f6e51714362c55"><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as R&amp;D in the second quarter of 2020. Pursuant to the terms of the agreement, BIAL may also be entitled to receive up to $<ix:nonFraction unitRef="usd" contextRef="i43207eb5afba4545a651896bc4052742_I20200930" decimals="-5" format="ixt:numdotdecimal" name="nbix:PotentialCommercialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM1NzgzMg_3753232a-9b40-4852-84df-41edb3fc4cff">75.0</ix:nonFraction>&#160;million upon the achievement of certain commercial milestones.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we are responsible for the commercialization of ONGENTYS in the US and Canada. Further, we  rely on BIAL for the commercial supply of ONGENTYS. Upon our written request prior to the estimated expiration of the term of a licensed product, the parties shall negotiate a good faith continuation of BIAL&#8217;s supply of such licensed product after the term. After the term, and if BIAL is not supplying a certain licensed product, we shall pay BIAL a trademark royalty based on the net sales of such licensed product.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization of ONGENTYS, we determined certain annual sales forecasts. In the event we fail to meet the minimum sales requirements for a particular year, we would be obligated to pay BIAL an amount equal to the difference between the actual net sales and minimum sales requirements for such year.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-product and country-by-country basis until a generic product in respect of such licensed product under the agreement is sold in a country and sales of such generic product are greater than a specified percentage of total sales of such licensed product in such country.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either party may terminate the agreement if the other party materially breaches the agreement and does not cure the breach within a specified notice period, or upon the other party&#8217;s insolvency. BIAL may terminate the agreement if we fail to use commercially reasonable efforts to submit an NDA for a licensed product by a specified date, in the event we fail to meet the minimum sales requirements for any <ix:nonNumeric contextRef="ic154a10198a440abaa45ffe2168bfe4b_D20200101-20200930" format="ixt-sec:durwordsen" name="nbix:MinimumSalesRequirementPeriodThresholdToTerminateAgreement" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM1OTQ5OQ_d248127f-f1d9-433b-aa15-4ddf74b85143">two years</ix:nonNumeric>, or under certain circumstances involving a change of control of Neurocrine Biosciences. Under certain circumstances where BIAL elects to terminate the agreement in connection with a change of control of Neurocrine Biosciences, BIAL would be obligated to pay us a termination fee. We may terminate the agreement at any time for any reason upon nine months&#8217; written notice to BIAL.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mitsubishi Tanabe Pharma Corporation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2015, we entered into a collaboration and license agreement with Mitsubishi Tanabe Pharma Corporation, or MTPC, for the development and commercialization of INGREZZA for movement disorders in Japan and other select Asian markets. </span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2020, we recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i8e46865cecac4d2e9ae909b186261e3c_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMTE0NDY_d4b46f3e-a89e-4e54-b3c8-2e6d6d2bc86f">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4ee32bf37a3e4fba90e0c87db9c24cfe_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMTY0OTI2NzQ4MjA3NQ_ee48a710-a604-405d-b852-013268f03769">1.8</ix:nonFraction>&#160;million, respectively, in connection with the ongoing KINECT-HD study, a placebo-controlled Phase III study of valbenazine in adult Huntington&#8217;s disease patients with chorea. In accordance with our continuing performance obligations, $<ix:nonFraction unitRef="usd" contextRef="if3af452bac274c8e8d92baa671e21fba_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMTE2NjA_6dfd1d67-2584-4396-ae4d-e9d36c878f55">7.6</ix:nonFraction>&#160;million of the $<ix:nonFraction unitRef="usd" contextRef="i81d37dbacd1842e99e2686ec8fd6dbba_D20150301-20150331" decimals="-5" format="ixt:numdotdecimal" name="nbix:UpfrontPaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMTE2NzA_babb8760-3ff9-4aeb-b720-b7a8f3d964d9">30.0</ix:nonFraction>&#160;million upfront payment received from MTPC in connection with the agreement is being deferred and will be recognized as revenue over the KINECT-HD study period using an input method according to costs incurred to-date relative to estimated total costs associated with the study. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception of the agreement, we have recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i66b2b24b15f44827a87d688b20158136_D20150301-20170630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMTE5OTk_e6a504a0-4490-4cac-b994-9f2d2fa5c552">19.8</ix:nonFraction>&#160;million associated with the delivery of a technology license and existing know-how, $<ix:nonFraction unitRef="usd" contextRef="iad9db265321c411f9f43fa242382852e_D20170701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMTIwNzg_3a75843f-0a44-427e-add7-4337ee147042">15.0</ix:nonFraction>&#160;million associated with the achievement of a certain development milestones, and $<ix:nonFraction unitRef="usd" contextRef="i78ce841bcaf4462aa4b7ca2f1059a21d_D20191001-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMTIxNTQ_a48d5065-0d39-4816-bf10-a17854393536">2.6</ix:nonFraction>&#160;million associated with our performance of the ongoing KINECT-HD study. Pursuant to the terms of the agreement, we may also be entitled to receive payments of up to $<ix:nonFraction unitRef="usd" contextRef="if3af452bac274c8e8d92baa671e21fba_I20200930" decimals="-5" format="ixt:numdotdecimal" name="nbix:PotentialMilestonePaymentReceipts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMTIzMTQ_9de8dec9-686e-4ed5-bbfa-0647930427c8">70.0</ix:nonFraction>&#160;million upon the achievement of certain regulatory and commercial milestones, receive payments for the manufacture of certain pharmaceutical products, as well as receive royalties on the net sales of collaboration products in select territories in Asia.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, MTPC is responsible for all third-party development, marketing, and commercialization costs in Japan and other select Asian markets and we would be entitled to a percentage of sales of INGREZZA in Japan and other select Asian markets for the longer of <ix:nonNumeric contextRef="icc967843177445f2a9bb563c19ee7472_D20150301-20150331" format="ixt-sec:durwordsen" name="nbix:PatentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMTI4NDk_0ceff35c-14af-4daf-a304-931d8e1475c8">ten years</ix:nonNumeric> or the life of the related patent rights. Further, the collaboration effort between the parties to advance INGREZZA towards commercialization in Japan and other select Asian markets is governed by joint steering and development committees with representatives from both parties. There are no performance, cancellation, termination, or refund provisions in the agreement that would have a material financial consequence to us. We do not directly control when event-based payments will be achieved or when royalty payments will begin. MTPC may terminate the agreement at its discretion upon <ix:nonNumeric contextRef="i81d37dbacd1842e99e2686ec8fd6dbba_D20150301-20150331" format="ixt-sec:durday" name="nbix:TerminationNoticePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMTM0NDE_b289260e-72a1-4279-81c9-a94bd7072746">180</ix:nonNumeric> days' written notice to us. In such event, all INGREZZA product rights for Japan and other select Asian markets would revert to us.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2010, we entered into an exclusive worldwide collaboration with AbbVie to develop and commercialize elagolix and all next-generation gonadotropin-releasing factor antagonists for women&#8217;s and men&#8217;s health.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie received approval of ORILISSA for the management of moderate to severe endometriosis pain in women from the FDA in July 2018 and Health Canada in October 2018.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, AbbVie received approval from the FDA for ORIAHNN for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. FDA approval for ORIAHNN for uterine fibroids resulted in the achievement of a $<ix:nonFraction unitRef="usd" contextRef="ic92441dd53a14a03a31909df31c4a184_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM2MjAyNQ_a78767d3-950d-4a6a-8d0a-67d4c363f72e">30.0</ix:nonFraction>&#160;million regulatory milestone, which was recognized as collaboration revenue in the second quarter of 2020. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib6f16337c3b7462f91f6e51714362c55"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception of the agreement, we have recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i3c4ebb0a6f1f49b0a4d3e6a407449d98_D20100601-20100630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM2MjE5Mw_78297ed2-8386-4f40-afe5-804313586bfa">75.0</ix:nonFraction>&#160;million associated with the delivery of a technology license and existing know-how and $<ix:nonFraction unitRef="usd" contextRef="i45766b13b1314f7181ad53c4c44d2508_D20100701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM2MjI3Ng_309bf281-5fad-4630-ace2-1ff784ecee26">165.0</ix:nonFraction>&#160;million associated with the achievement of certain development and regulatory milestones. Pursuant to the terms of the agreement, we may also be entitled to receive additional payments of up to $<ix:nonFraction unitRef="usd" contextRef="i5ea18c769a47425d951bc4f1d6cdec54_I20200930" decimals="-5" format="ixt:numdotdecimal" name="nbix:PotentialMilestonePaymentReceipts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM2MjQ1NQ_4b4629b2-3834-415d-a447-9bfab7bef8a8">366.0</ix:nonFraction>&#160;million upon the achievement of certain development, regulatory and commercial milestones.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, AbbVie is responsible for all third-party development, marketing, and commercialization costs. We will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of <ix:nonNumeric contextRef="if00ff3fffef04ee986b1a2c2119dfc0b_D20100601-20100630" format="ixt-sec:durwordsen" name="nbix:PatentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM2Mjc2Mg_e710029a-8beb-4b8c-bd69-727f47991fc4">ten years</ix:nonNumeric> or the life of the related patent rights. AbbVie may terminate the collaboration at its discretion upon <ix:nonNumeric contextRef="i3c4ebb0a6f1f49b0a4d3e6a407449d98_D20100601-20100630" format="ixt-sec:durday" name="nbix:TerminationNoticePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM2Mjg3MA_bfe3b652-1ec2-4917-95c3-e94830533bfa">180</ix:nonNumeric> days&#8217; written notice to us.</span></div></ix:continuation><div id="i01dca92a9a894c839fd91f8b5b3beba6_37"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RleHRyZWdpb246OTUzMmIxNTM2YzI4NGJhOWIyNzU0ODE4YzBlMWM2OTVfMTU1NQ_1ecebf7d-0deb-4e5f-8ab2-6b804df89636" continuedAt="i2042e899be9047908ffa5ba9e0821114" escape="true">Debt Securities</ix:nonNumeric></span></div><ix:continuation id="i2042e899be9047908ffa5ba9e0821114" continuedAt="iec3f0b2722e94b3ebeca403d1192ab5f"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RleHRyZWdpb246OTUzMmIxNTM2YzI4NGJhOWIyNzU0ODE4YzBlMWM2OTVfMTU1MQ_fd5ff4ed-d0ec-435d-81f4-56b81c05e1f8" escape="true"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss), allowance for credit losses, and fair value of debt securities available-for-sale at September&#160;30, 2020, aggregated by major security type and contractual maturity:</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.833%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gain</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17e8669ff7be4a52b5af69d877498dc5_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMS01LTEtMS0w_715b5c23-1d24-43ab-b96b-a69f6006246f">104.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17e8669ff7be4a52b5af69d877498dc5_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMS03LTEtMS0w_134726c0-afef-4be7-83e7-fcf9471fbf65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17e8669ff7be4a52b5af69d877498dc5_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMS05LTEtMS0w_c4c9854b-d57d-448b-8093-3656f54118a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17e8669ff7be4a52b5af69d877498dc5_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMS0xMS0xLTEtMA_a5c16880-8f32-4b81-bf36-28b91091773b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17e8669ff7be4a52b5af69d877498dc5_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMS0xMy0xLTEtMA_8b645843-3f6b-4510-8423-037d4890d7ca">104.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20a97471294c419191a3a2888e675b4b_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMi01LTEtMS0w_500af600-755a-4dcd-a20a-fe2bedcfbaf2">283.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20a97471294c419191a3a2888e675b4b_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMi03LTEtMS0w_27953443-71cc-41fa-ab8a-54d6fc6d18cf">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20a97471294c419191a3a2888e675b4b_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMi05LTEtMS0w_3a63e7c2-13cb-4d43-af5b-1dfb6a426fab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20a97471294c419191a3a2888e675b4b_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMi0xMS0xLTEtMA_b771aa8f-b0c1-460a-a9c6-9b8cade2b429">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20a97471294c419191a3a2888e675b4b_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMi0xMy0xLTEtMA_6063af9f-b78b-4667-aab9-37028dfb3c46">285.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a39b454de5141cea8123d360608a3c6_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMy01LTEtMS0w_a7ada17a-835a-4775-9a80-3d1ee158209d">128.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a39b454de5141cea8123d360608a3c6_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMy03LTEtMS0w_f31fed84-cf65-47cc-99a4-26935384395a">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a39b454de5141cea8123d360608a3c6_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMy05LTEtMS0w_b53cc60b-9a8d-4a4d-8ecd-82fb8ab3529b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a39b454de5141cea8123d360608a3c6_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMy0xMS0xLTEtMA_2c2e489b-ccb5-4022-9b40-7b80ff207ef6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a39b454de5141cea8123d360608a3c6_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMy0xMy0xLTEtMA_dae8b98d-8651-429e-ac8b-21d0885e788a">129.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f46c4cf6f1473794e3e0ebadd216a7_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNC01LTEtMS0w_7247b66c-eb4e-4e46-8778-eca3d1e0bf86">517.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f46c4cf6f1473794e3e0ebadd216a7_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNC03LTEtMS0w_711bba76-c33a-468c-a1e0-d0da98771a29">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f46c4cf6f1473794e3e0ebadd216a7_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNC05LTEtMS0w_83313ac2-f58b-46c7-b8d8-a91dd90f14ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f46c4cf6f1473794e3e0ebadd216a7_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNC0xMS0xLTEtMA_a15fee8c-0ae0-484e-a436-7b83b540f0e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57f46c4cf6f1473794e3e0ebadd216a7_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNC0xMy0xLTEtMA_bef0601c-e0ef-4aa3-8324-7e5510012b8b">519.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5839adaf15cb411e85d5303f2631e97d_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNi01LTEtMS0w_d4b59a1c-15fc-465d-855d-c46226af1ad9">142.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5839adaf15cb411e85d5303f2631e97d_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNi03LTEtMS0w_f29291bf-8cc9-49a2-9445-79cbf862b2fe">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5839adaf15cb411e85d5303f2631e97d_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNi05LTEtMS0w_c6b143dc-e244-485c-a129-1049e7aa6ee7">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5839adaf15cb411e85d5303f2631e97d_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNi0xMS0xLTEtMA_b9fac117-609b-451e-8a97-7e381aed1ad4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5839adaf15cb411e85d5303f2631e97d_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNi0xMy0xLTEtMA_a620bad9-4b47-42ec-9bb2-f361bac6acdc">143.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1afe9cac6b0a42a5b77948695251abfb_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNy01LTEtMS0w_79e4c48c-2adf-4ebb-afc1-42d4a38b61d5">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1afe9cac6b0a42a5b77948695251abfb_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNy03LTEtMS0w_fb5d8371-5171-48a7-845c-58c6182f36cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1afe9cac6b0a42a5b77948695251abfb_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNy05LTEtMS0w_6a6748bc-3e6a-40e8-8e75-56b73465ab64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1afe9cac6b0a42a5b77948695251abfb_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNy0xMS0xLTEtMA_7d74fe0e-a866-4708-b00c-39da80aeedb4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1afe9cac6b0a42a5b77948695251abfb_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNy0xMy0xLTEtMA_f61f577c-f062-4581-9f60-2136c8679e25">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11b4128b861b49e2a5858306369cb09d_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfOC01LTEtMS0w_52fc9186-32f6-4f4d-aa23-b363c64c7c53">180.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11b4128b861b49e2a5858306369cb09d_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfOC03LTEtMS0w_cac9f77a-dce7-4b43-8e1d-ee0720197df3">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11b4128b861b49e2a5858306369cb09d_I20200930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfOC05LTEtMS0w_49de1dd0-eb2b-4e73-8f34-13ebe7299465">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11b4128b861b49e2a5858306369cb09d_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfOC0xMS0xLTEtMA_6cb100ca-4af7-4ff9-8e4f-5d36b4208e3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11b4128b861b49e2a5858306369cb09d_I20200930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfOC0xMy0xLTEtMA_8b2caffa-6a6a-43a3-8df7-8a43f4660bd3">181.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income, and fair value of debt securities available-for-sale at December&#160;31, 2019, aggregated by major security type and contractual maturity:</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.832%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gain</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cf4cd2db9454c90a62e4deb58db04b8_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMS01LTEtMS0w_90080abc-fa82-4175-9b5b-22dba45140d5">144.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cf4cd2db9454c90a62e4deb58db04b8_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMS03LTEtMS0w_d6029e55-2706-4e0e-8871-29e5b9400d6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cf4cd2db9454c90a62e4deb58db04b8_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMS05LTEtMS0w_73e7e6ae-a655-4a4a-afbc-f2aa841dc046">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cf4cd2db9454c90a62e4deb58db04b8_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMS0xMS0xLTEtMA_28b5111a-f159-4902-b2a5-edac9e6227f0">144.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i874e4b9552c648458ec045b9740fcc7c_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMi01LTEtMS0w_76f5361e-37c7-422f-b4ae-d336463834f6">270.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i874e4b9552c648458ec045b9740fcc7c_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMi03LTEtMS0w_5a4601e4-2616-41a3-b263-b645a86a67e0">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i874e4b9552c648458ec045b9740fcc7c_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMi05LTEtMS0w_f0d5f883-fcd6-4b15-a997-a627f61e0d16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i874e4b9552c648458ec045b9740fcc7c_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMi0xMS0xLTEtMA_74412118-f018-424f-8c5c-0ab1cc71daf6">271.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib471b42e9f1046758a5cc3d418a9adea_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMy01LTEtMS0w_975c7654-90f4-40a6-ae64-b39406f77ccc">142.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib471b42e9f1046758a5cc3d418a9adea_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMy03LTEtMS0w_55e8b3fa-aeb1-4308-9920-f1380562ff2d">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib471b42e9f1046758a5cc3d418a9adea_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMy05LTEtMS0w_ecaa18a2-9cbf-4702-92c6-88b77e8e09be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib471b42e9f1046758a5cc3d418a9adea_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMy0xMS0xLTEtMA_4b42fd2b-1ce5-4f8a-b193-78f809b7a298">142.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06c15e28fd64cffadb8a9783937f723_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNC01LTEtMS0w_45b56736-cdd0-4560-841f-3d3720ad1d67">557.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06c15e28fd64cffadb8a9783937f723_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNC03LTEtMS0w_4bfbe917-980b-4fd3-aba4-b476919a9d2b">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06c15e28fd64cffadb8a9783937f723_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNC05LTEtMS0w_214ea419-ceaa-4c07-85ef-8f46ccba2c21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if06c15e28fd64cffadb8a9783937f723_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNC0xMS0xLTEtMA_5ed37a06-b526-4bb5-bf09-db780cf7b01d">558.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd9a4794daba4b7cad0104baa5442100_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNi01LTEtMS0w_ad30b58e-2957-4622-aa5e-b7e806a9ef9e">250.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd9a4794daba4b7cad0104baa5442100_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNi03LTEtMS0w_2a30b758-cf4c-4105-84d1-8c1b3f6ddb4d">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd9a4794daba4b7cad0104baa5442100_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNi05LTEtMS0w_6cbd8da8-b706-48c3-8b4d-6b45d590b5d7">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd9a4794daba4b7cad0104baa5442100_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNi0xMS0xLTEtMA_121f48c6-d72e-4ad9-bc39-1aa93a8faaf4">250.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39d07970489d4ae1a26d531d4e995b63_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNy01LTEtMS0w_996f9cb6-e9a0-4a9b-8182-6284abadb665">48.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39d07970489d4ae1a26d531d4e995b63_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNy03LTEtMS0w_8c649346-ea46-4edb-9774-be8ca6f5a0a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39d07970489d4ae1a26d531d4e995b63_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNy05LTEtMS0w_95a5e084-9ce0-4da4-9493-e19c2d9a67b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39d07970489d4ae1a26d531d4e995b63_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNy0xMS0xLTEtMA_2fd9c707-ea71-4da0-a435-4a80825e42ce">48.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eee421ab3034f1daf75320fc8835187_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfOC01LTEtMS0w_f642c496-4a30-4980-9c07-b191b635fda8">299.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eee421ab3034f1daf75320fc8835187_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfOC03LTEtMS0w_a1389632-8884-4532-a09e-af55c5f06b74">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4eee421ab3034f1daf75320fc8835187_I20191231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfOC05LTEtMS0w_6541da4e-26bd-45c3-9bdf-31957a283ef6">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eee421ab3034f1daf75320fc8835187_I20191231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfOC0xMS0xLTEtMA_fea48734-983e-4bb3-8932-7d7f85949013">299.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RleHRyZWdpb246OTUzMmIxNTM2YzI4NGJhOWIyNzU0ODE4YzBlMWM2OTVfMTY0OTI2NzQ0MzczMQ_d0b9a769-61f6-4f3c-8e61-5ebabf220568" continuedAt="i5d0a94819e3e4f99a7bbe09e74fe1459" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes debt securities available-for-sale in an unrealized loss position for which an allowance for credit losses has not been recorded at September&#160;30, 2020, aggregated by major security type and length of time in a continuous unrealized loss position:</span></div><div style="margin-bottom:4pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89d87039af9d4dc6bd52a3bb4c9ebf21_I20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjQxNjZmZWQ1MDMzODRhYWE4MjBiYTQ1YTVmYmIzZWVkL3RhYmxlcmFuZ2U6NDE2NmZlZDUwMzM4NGFhYTgyMGJhNDVhNWZiYjNlZWRfMy0xLTEtMS0xNjk_8bbe09c9-abdf-4b1d-9743-2febe11dec0b">39.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89d87039af9d4dc6bd52a3bb4c9ebf21_I20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjQxNjZmZWQ1MDMzODRhYWE4MjBiYTQ1YTVmYmIzZWVkL3RhYmxlcmFuZ2U6NDE2NmZlZDUwMzM4NGFhYTgyMGJhNDVhNWZiYjNlZWRfMy0zLTEtMS0xNzM_cb516565-f0c4-4d06-8da9-0816c5801d25">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89d87039af9d4dc6bd52a3bb4c9ebf21_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjQxNjZmZWQ1MDMzODRhYWE4MjBiYTQ1YTVmYmIzZWVkL3RhYmxlcmFuZ2U6NDE2NmZlZDUwMzM4NGFhYTgyMGJhNDVhNWZiYjNlZWRfMy01LTEtMS0xNzM_40e6fc5b-3141-4620-842c-915868be3d5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89d87039af9d4dc6bd52a3bb4c9ebf21_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjQxNjZmZWQ1MDMzODRhYWE4MjBiYTQ1YTVmYmIzZWVkL3RhYmxlcmFuZ2U6NDE2NmZlZDUwMzM4NGFhYTgyMGJhNDVhNWZiYjNlZWRfMy03LTEtMS0xNzM_9dbc5db1-f43b-4929-ae34-f5ddf2aef386">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89d87039af9d4dc6bd52a3bb4c9ebf21_I20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjQxNjZmZWQ1MDMzODRhYWE4MjBiYTQ1YTVmYmIzZWVkL3RhYmxlcmFuZ2U6NDE2NmZlZDUwMzM4NGFhYTgyMGJhNDVhNWZiYjNlZWRfMy05LTEtMS0xNzM_c6f4cc9a-f6f8-4da3-976f-e7b283440941">39.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89d87039af9d4dc6bd52a3bb4c9ebf21_I20200930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjQxNjZmZWQ1MDMzODRhYWE4MjBiYTQ1YTVmYmIzZWVkL3RhYmxlcmFuZ2U6NDE2NmZlZDUwMzM4NGFhYTgyMGJhNDVhNWZiYjNlZWRfMy0xMS0xLTEtMTcz_2518c997-9243-410e-aae4-88e67dfcc865">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>At September&#160;30, 2020, our security portfolio consisted of <ix:nonFraction unitRef="security" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="INF" name="nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RleHRyZWdpb246OTUzMmIxNTM2YzI4NGJhOWIyNzU0ODE4YzBlMWM2OTVfNzY1_1fb5bf61-7ac3-4a92-9a24-09e0048cc328">143</ix:nonFraction> securities related to investments in debt securities available-for-sale, of which <ix:nonFraction unitRef="security" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RleHRyZWdpb246OTUzMmIxNTM2YzI4NGJhOWIyNzU0ODE4YzBlMWM2OTVfODUw_92304155-5b7a-467e-8480-e65aa3d37a07">14</ix:nonFraction> securities were in an unrealized loss position.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in corporate debt securities in an unrealized loss position at September&#160;30, 2020 are of high credit quality (rated A- or higher). Unrealized losses on these investments were primarily due to changes in interest rates. We do not intend </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iec3f0b2722e94b3ebeca403d1192ab5f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis.</span></div><ix:continuation id="i5d0a94819e3e4f99a7bbe09e74fe1459"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes debt securities available-for-sale in an unrealized loss position at December&#160;31, 2019, aggregated by major security type and length of time in a continuous unrealized loss position:</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63ae906e9934f57874ae4728dd57afa_I20191231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOmFhZTQ5MzdmOWNhZjQ0OTc5NGY2ZGFkNmExOWY3ZGM4L3RhYmxlcmFuZ2U6YWFlNDkzN2Y5Y2FmNDQ5Nzk0ZjZkYWQ2YTE5ZjdkYzhfMi0xLTEtMS0w_5da45b07-3777-4da5-a1e1-563e5052a9c3">186.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63ae906e9934f57874ae4728dd57afa_I20191231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOmFhZTQ5MzdmOWNhZjQ0OTc5NGY2ZGFkNmExOWY3ZGM4L3RhYmxlcmFuZ2U6YWFlNDkzN2Y5Y2FmNDQ5Nzk0ZjZkYWQ2YTE5ZjdkYzhfMi0zLTEtMS0w_27eb338f-0311-4be2-aeb5-89e2a8536a16">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63ae906e9934f57874ae4728dd57afa_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOmFhZTQ5MzdmOWNhZjQ0OTc5NGY2ZGFkNmExOWY3ZGM4L3RhYmxlcmFuZ2U6YWFlNDkzN2Y5Y2FmNDQ5Nzk0ZjZkYWQ2YTE5ZjdkYzhfMi01LTEtMS0w_b8366c26-8f2d-42c4-9da0-88c1aabda0fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63ae906e9934f57874ae4728dd57afa_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOmFhZTQ5MzdmOWNhZjQ0OTc5NGY2ZGFkNmExOWY3ZGM4L3RhYmxlcmFuZ2U6YWFlNDkzN2Y5Y2FmNDQ5Nzk0ZjZkYWQ2YTE5ZjdkYzhfMi03LTEtMS0w_77e48d4f-fa94-45d5-97aa-874699e8f6dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63ae906e9934f57874ae4728dd57afa_I20191231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOmFhZTQ5MzdmOWNhZjQ0OTc5NGY2ZGFkNmExOWY3ZGM4L3RhYmxlcmFuZ2U6YWFlNDkzN2Y5Y2FmNDQ5Nzk0ZjZkYWQ2YTE5ZjdkYzhfMi05LTEtMS0w_2f448367-5d43-45b0-986b-c8d4f610b104">186.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63ae906e9934f57874ae4728dd57afa_I20191231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOmFhZTQ5MzdmOWNhZjQ0OTc5NGY2ZGFkNmExOWY3ZGM4L3RhYmxlcmFuZ2U6YWFlNDkzN2Y5Y2FmNDQ5Nzk0ZjZkYWQ2YTE5ZjdkYzhfMi0xMS0xLTEtMA_a37fc91f-fb83-4100-acb9-6050f98bb506">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div id="i01dca92a9a894c839fd91f8b5b3beba6_40"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RleHRyZWdpb246NjdkZDEyODkyZGI0NDc4ZDkzMTQwMjI2YjJkZjc0YWJfOTI0_f57b3f86-2080-4c1d-9315-e5cbce5edaa8" continuedAt="i076a16d9fdd5446b980ca9dc5ce6c56f" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i076a16d9fdd5446b980ca9dc5ce6c56f" continuedAt="i58977a3f895d4e8d947bfe1b024daec8"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RleHRyZWdpb246NjdkZDEyODkyZGI0NDc4ZDkzMTQwMjI2YjJkZjc0YWJfOTI1_72e3b287-b428-46a4-af05-c21b454e585f" escape="true"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments at September&#160;30, 2020, which were measured at fair value on a recurring basis, consisted of the following:</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id38c7267b80a405180f7b4356f67da8c_I20200930" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMy0xLTEtMS0w_7da5be67-59b5-4c0b-a0f1-09656a75b803">425.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibee55973814540e4871f791d8dc70e46_I20200930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMy0zLTEtMS0w_854562d5-3ea9-4954-a2ba-571949b669e6">425.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib426e74a445c45f1a83118960cccbf06_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMy01LTEtMS0w_51167006-cc41-46c6-9075-1b4ffc992c3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie84a00bf79934f488db237577d55db78_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMy03LTEtMS0w_53b26cad-ccc2-41cd-bf45-2f1e3f844c77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea9d8f3b23ca486497408024718a6b8e_I20200930" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNC0xLTEtMS0w_7ae1aa2e-e5ed-41e9-9dfc-6fad040332b0">425.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65a6bbf5e65a4158a60237d7a4a04db0_I20200930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNC0zLTEtMS0w_6d8a3eaf-b6d2-4841-84c0-f01ed0dd5967">425.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ec61ef3dcdf4b1aacbd98b013a506b7_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNC01LTEtMS0w_492ca6e8-3255-41a8-ae7f-407abbdb0db2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc97788aa86f4300961cef399f992f04_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNC03LTEtMS0w_98b712c7-7072-4093-833e-72989c97b885">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c29e9b0363d417bad2a59f28a1c803c_I20200930" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNi0xLTEtMS0w_8513b146-330c-42f6-a173-1e011712b8c4">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5598a209b61b4400b094160c9896fa48_I20200930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNi0zLTEtMS0w_e1daff7a-e5d3-4e48-822c-1179c523631b">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29381f8c070e44f0842d377f5116a9e2_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNi01LTEtMS0w_ca58b9e5-c735-451e-a259-53615223b4a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i947a42782e644b31b40e973a6c34e453_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNi03LTEtMS0w_890a284d-eefd-4346-8f36-f6d6b6ef6cbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee9777017ba44b219d3e743580405ac2_I20200930" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNy0xLTEtMS0w_915fdde6-3188-4a23-973c-037e58104474">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7a75fd9bbac4ee49d0da09da35fb326_I20200930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNy0zLTEtMS0w_ff7d169d-d469-48f6-9121-20cca47a7843">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb30e5a8cedc49c8be9971e52ba47b85_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNy01LTEtMS0w_5180eefd-d001-4e0b-b43e-10eb7b5d9b86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i760c3e1139cd490996ecb9f7296243b7_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNy03LTEtMS0w_f303aad7-f4ea-47e0-b55b-f7d7f4003dbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42324c42b21949c28b491aa55a7bfbbb_I20200930" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfOS0xLTEtMS0w_067842ab-d3fc-427a-9491-e3eb1718c9b8">104.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18fb70203f184d1491ea807cbc815619_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfOS0zLTEtMS0w_543a7ce7-2c85-4a34-8b7b-3325dea86448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if469c62de0cd4ef3830eba7c5402aaab_I20200930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfOS01LTEtMS0w_0b86600a-d8c1-44a2-8cb7-daa4477fe0e9">104.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17b0221281ec4463a4179b1554cbcd76_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfOS03LTEtMS0w_de6dc16e-9e5d-4b95-970e-64641a055152">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89d87039af9d4dc6bd52a3bb4c9ebf21_I20200930" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTAtMS0xLTEtMA_bccd8ea0-9547-4cbc-a6d2-638d24253663">429.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0025cac95494cda9e9476a6c30b7005_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTAtMy0xLTEtMA_714848b9-cbef-4468-8252-3019dae96b2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2709795600e4b4fa0cab1e10d78bb24_I20200930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTAtNS0xLTEtMA_47607afe-ebd0-4c51-9f7d-e2fbc15b3392">429.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6458a3c1f27445708ec1f66fe52e22d1_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTAtNy0xLTEtMA_d8da29aa-3f8f-4a07-8a89-e245bebf80fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if56d9dc3007d41128722f44d864811d6_I20200930" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTEtMS0xLTEtMA_820d1d05-8748-4724-a4d7-c1178f9c3849">166.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9756d3e20b3947848211cd89041634fc_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTEtMy0xLTEtMA_b64c4531-f354-4450-8ebb-1fe3ca8dad9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0623eb842b4201884c1c1da60ba35d_I20200930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTEtNS0xLTEtMA_0d445272-4e01-464d-9be7-d1a13ba19d9b">166.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc01e0adf5ed40e9ab710401d911d109_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTEtNy0xLTEtMA_0fa723d6-d7af-4c38-83dc-d30beb0574a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd9db69bbe949f189e03e61899a8e08_I20200930" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTItMS0xLTEtMA_181c98f4-2dac-4484-b5bf-325bd58cbe05">700.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97214347d5cd4c00a185bedc120c3fc1_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTItMy0xLTEtMA_6a74e1a0-00e2-4836-aade-9096751eb28d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d8647d7d7e94a8097f66d3842b61c42_I20200930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTItNS0xLTEtMA_96aaef7f-af79-4838-8173-276256bb8780">700.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i956362b694e94668b36c6160186aa324_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTItNy0xLTEtMA_51950928-5b6c-4a6b-b370-894f963765de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bd0085725324e26a27750e423d72760_I20200930" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTQtMS0xLTEtMA_43c5e0b6-c3eb-4576-8099-ff4393095004">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic049401a5b67418d851adeae321ac164_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTQtMy0xLTEtMA_d73426a4-4453-4b1b-a006-6ff702656a7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8225b8bb50704b84b3bf86c3349c534e_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTQtNS0xLTEtMA_9081f0a0-3624-4224-a6b0-6ec8e59860a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id219f8da90c541daad4ba23316ba4c2b_I20200930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTQtNy0xLTEtMA_657930ef-170e-4509-8af9-c8102812a8a2">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d6d32eba9d04110a989008d1fa4f90e_I20200930" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTUtMS0xLTEtMA_201ffefe-5439-4a06-b2fe-b0aff1f590cb">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88f522c740114d6180c33b2389f52046_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTUtMy0xLTEtMA_d1052133-8bb0-4852-8650-e6c4ec09e945">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2f301c2004b4bcabafe4296fb59ec8e_I20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTUtNS0xLTEtMA_21461374-3748-42fe-bf98-fa00b66d166f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1156dc5768584b87af9adf9ad1d62009_I20200930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTUtNy0xLTEtMA_35876894-d1a8-4fe9-8ea7-6ab4d2196560">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total recurring fair value measurements</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTYtMS0xLTEtMA_ad2543ad-ce2a-4109-aec0-438fe00815c5">1,173.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iced281cb3fd145e8913b24a5a0bc1e69_I20200930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTYtMy0xLTEtMA_5c4f6175-7a6d-4c82-9d98-2195b702085e">428.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia410bcb0c63a42d99db1e5658b91727a_I20200930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTYtNS0xLTEtMA_83d62b7a-e4dc-4e07-9f25-58b22f20af80">700.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0864c4bbd4b141eb98515b636f8eb88c_I20200930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTYtNy0xLTEtMA_ccb5d5e9-2988-47a9-b69f-d2f9808b8358">43.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments at December&#160;31, 2019, which were measured at fair value on a recurring basis, consisted of the following:</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c40b36432b0492eb3eae0f8756d0ae1_I20191231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMy0xLTEtMS0w_a74ebe95-5856-4759-aab8-5ce2972ea25e">112.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f45d9693ffb42a189e35266c2e96545_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMy0zLTEtMS0w_f423352c-1323-45e6-adbe-8d2ab675c19f">112.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69670247a1db4f42b3852d733ac9597d_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMy01LTEtMS0w_71501cd0-7228-4926-864a-16182822a74c">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica74b071cda746a582b3ab295bc26cff_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMy03LTEtMS0w_aea28025-93b3-44ef-a231-20b7fb322dbe">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05df2fa389dd4adfa5053ad89459ac4c_I20191231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNC0xLTEtMS0w_7230ab13-2100-44bc-8d51-1eb2ebadce8b">112.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03b83fda3a5401ea309441030aea98b_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNC0zLTEtMS0w_76acf5bc-be27-4bd9-8b8d-5b3670096b31">112.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18cbac244f574159aedb1993c131e819_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNC01LTEtMS0w_fed7738c-aaea-40d5-80de-54e51eca3314">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4783baa5d824c89aae723867da90a4b_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNC03LTEtMS0w_c98b1c88-2e6a-4b51-baeb-26157ad778fd">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92b89ea55554deea11eb52be454b4ee_I20191231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNi0xLTEtMS0w_44df3cff-396a-4ecc-939d-dd1700943c82">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59c2ec22479846c8887639d01cec2ac1_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNi0zLTEtMS0w_40ef2691-9ea3-4fad-9266-ddcb1bfe2a26">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a85a52092b47eba3e6679338c961b6_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNi01LTEtMS0w_cdcef13e-a063-4238-8385-bcce48203d05">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314a5ccd83a84b54958bcd28fb8db860_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNi03LTEtMS0w_53d6edd2-30f6-482a-98a2-0c090ce506ef">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dea7ef570bb4538b6abd0b0f50563ea_I20191231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNy0xLTEtMS0w_20a3620f-6ac4-492f-b433-01e4445d15b2">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4a588721b04ed3a8c49e19b0c7d7e2_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNy0zLTEtMS0w_53a24b8e-2443-4220-9b9c-c22112c33e19">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie87e6dea946b4fee812d375f72857a05_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNy01LTEtMS0w_b87bfd3e-f8f2-4465-a119-ae8f8011949f">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4257d9e01c5447b8694ff0d39ac4ad4_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNy03LTEtMS0w_036c154b-5a46-42b8-868c-b51d8faa3fb1">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fd7f2df19284e068ed3299724415484_I20191231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfOS0xLTEtMS0w_aed25413-b388-4bc3-8bad-0a99e8468e05">144.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95be335e9ca1424784a8b065207d5d2c_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfOS0zLTEtMS0w_4ef24e3b-9226-4acd-9517-87899602e120">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8978c466f89f48bd919bee1246ba7dc3_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfOS01LTEtMS0w_09f8f2f5-f39f-4460-9b20-82dbba1be2ec">144.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib765b7aaf76a45f5b319d34681ef5aad_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfOS03LTEtMS0w_ce2fb678-baf9-4831-9160-115ff0d95420">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63ae906e9934f57874ae4728dd57afa_I20191231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTAtMS0xLTEtMA_fe4ab572-96c3-4e09-8340-2423be159b85">521.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1168865b09414dd1928d3fb6d2fe8156_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTAtMy0xLTEtMA_fdc42936-9e0f-4f96-a1df-dae918cd1527">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b5a1372b6934d52bbc0746277c0a30f_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTAtNS0xLTEtMA_02e2cb63-2ef7-490d-ba17-55c2dd961a33">521.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c444f4feaa2474398f957750041cb1d_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTAtNy0xLTEtMA_d6bdc02b-9c1e-4dfd-a8b1-8829b12f1993">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233e986aada74f71bd2484e81cfad9fa_I20191231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTEtMS0xLTEtMA_1b8a6e88-8b2a-4624-9d33-7cc979e2dcd5">191.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9640ba89a44d41bfb7a046a01479976d_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTEtMy0xLTEtMA_e1e6c54a-6167-4232-8187-54c8da73f79e">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd5b76e3383e44738b173add3da702c6_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTEtNS0xLTEtMA_ae7d0469-6635-4b85-8985-e649484c5572">191.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieecb12e2940b487ead1f8d0f74107902_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTEtNy0xLTEtMA_a992be4f-8a56-479a-b271-3a3c8b19e62a">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i258c656656094522924117a0e6348166_I20191231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTItMS0xLTEtMA_29bfa141-6119-4533-a95b-aa5acf97492c">857.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2f58151776d4b13be04977281fa947d_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTItMy0xLTEtMA_59348fb0-ed53-4372-ad81-b1bf45ea926d">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb9d6e37865d45e1b6f401b3e4cdc23d_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTItNS0xLTEtMA_50e6a687-75c7-4b07-b3e9-56f0a42aeb23">857.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4745ddf52c234ed591471f3b27a1ab8b_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTItNy0xLTEtMA_65afcf19-b2b9-40f5-8de1-1015be3e2e5b">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3f9f730b48d44688a63762017a09db2_I20191231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTQtMS0xLTEtMA_ff825879-bf0a-41c1-8e70-204a061494be">55.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic06223c92c5f4dd8a253034a82b987b2_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTQtMy0xLTEtMA_e392e230-1c81-4803-9e33-08efbe50e379">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic019c50768b247589e3afba7ef8f7b7f_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTQtNS0xLTEtMA_5ce14b2e-3585-46fe-b7b2-22c78fe53417">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib44d224bf6a0454381c51416f7a36089_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTQtNy0xLTEtMA_fd69a26a-6e81-48ca-98ed-4565b2d0500d">55.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9fb6311be4848ee9588bffda41c01e0_I20191231" decimals="-5" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTUtMS0xLTEtMA_4875e688-7a06-4a10-ae7b-1d1609749160">55.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11cff9bc4f0243cb87ef4cff58b89ee3_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTUtMy0xLTEtMA_d9b1105c-4b66-429f-96f4-650e6a47dd2e">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie25967604f04462d8e53ffad9c71948b_I20191231" decimals="-5" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTUtNS0xLTEtMA_4c190d41-ee19-4ae2-bc14-510737920a87">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id07323ca55464999892b9d6fb0d0b763_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTUtNy0xLTEtMA_f99969e8-b024-49ab-b6db-425a7809ffd8">55.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total recurring fair value measurements</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Investments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTYtMS0xLTEtMA_61a05e5c-04b5-46b3-8ba5-fef7d02f95a2">1,029.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i685588d754634ef2a7b97a70c6fdabbf_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTYtMy0xLTEtMA_c77db0f5-27bc-4fe6-8409-1d8892751149">115.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if718bd63b45a4840af81b12174f10513_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTYtNS0xLTEtMA_ed58b5ed-cee3-44ce-86bf-aedd30008a28">857.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b082681e677454181d88e9e537d5fde_I20191231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTYtNy0xLTEtMA_3df24040-7fac-4ca3-9734-3519883040dd">55.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i58977a3f895d4e8d947bfe1b024daec8"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RleHRyZWdpb246NjdkZDEyODkyZGI0NDc4ZDkzMTQwMjI2YjJkZjc0YWJfOTI2_cec62eae-d81d-4ee0-8e1a-9d2e48bb9448" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of equity security investments, which were  measured at fair value on a recurring basis using significant unobservable inputs (Level 3):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a5d39b84bb845bd89918fb5088efac0_I20200630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfMi0xLTEtMS0w_b9a93bcc-aca5-4a74-9f8e-56c1a08519d3">50.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f09b45aebbe45268c2465fc1d568035_I20190630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfMi0zLTEtMS0w_db00cc5f-2105-4b7e-9224-abf2a07fc1d1">77.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f9f6865463c43fd9a44068085061fc5_I20191231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfMi01LTEtMS0w_21b155ac-a953-4b1f-8e67-f088c6c6eb7e">55.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83b13e1b031e48228c7b0620b1ebe113_I20181231" decimals="-5" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfMi03LTEtMS0w_abfed893-8f90-407b-89a6-d9ed0ea3ff01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6049f25752e8431ba1fbece7b41b3e27_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfMy0xLTEtMS0w_3f357123-eab1-46bd-bc27-d39d3fdd2852">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b79a1a18384f138069f378bdbe69b4_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfMy0zLTEtMS0w_629c15a4-9e9e-401c-9cda-e1c6d4a81369">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0548c87128c9494d8cbb70c28471b350_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfMy01LTEtMS0w_84bd5f2a-32b8-4942-abf8-126c15632176">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c084bc0f4cb428bbc964d8727a9a1bb_D20190101-20190930" decimals="-5" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfMy03LTEtMS0w_5861f86a-ebfd-4e8f-9563-b9ee3d485927">54.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss included in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6049f25752e8431ba1fbece7b41b3e27_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfNC0xLTEtMS0w_fdce9c7f-4205-4b15-abea-55b28dc27e7d">7.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0b79a1a18384f138069f378bdbe69b4_D20190701-20190930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfNC0zLTEtMS0w_e5a80d2d-76b7-4112-8f31-afa21e3c3b18">28.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0548c87128c9494d8cbb70c28471b350_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfNC01LTEtMS0w_e3f496ee-5ab1-4ed2-ab47-622bd8e381c2">12.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c084bc0f4cb428bbc964d8727a9a1bb_D20190101-20190930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfNC03LTEtMS0w_da5fad0a-2b11-4f0d-9496-7a88b063f3f3">5.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb6cd0e456d4f4bbd214884933a1f9a_I20200930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfNS0xLTEtMS0w_87c0c8a0-6b74-440f-a3e7-208cde5a159c">43.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72cdfb757c4d4f1daaf47570c8615274_I20190930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfNS0zLTEtMS0w_276fce96-34ba-427d-8fad-46250915931f">48.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cb6cd0e456d4f4bbd214884933a1f9a_I20200930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfNS01LTEtMS0w_5363b20d-498b-4436-8a5a-39f2820a56aa">43.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72cdfb757c4d4f1daaf47570c8615274_I20190930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfNS03LTEtMS0w_0b8a296b-6e03-4d24-a2a0-4913a465bfeb">48.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>At September&#160;30, 2020, the discount for lack of marketability used in the valuation analysis of equity securities ranged from <ix:nonFraction unitRef="number" contextRef="i0aa63587c87c4b9cab14160d1d2d336a_I20200930" decimals="3" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RleHRyZWdpb246NjdkZDEyODkyZGI0NDc4ZDkzMTQwMjI2YjJkZjc0YWJfNTM3_482d95cf-3707-4816-a9ae-e32d219af759">16.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="icac2aad9c7b14b7c897eaed6bd6f1176_I20200930" decimals="3" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RleHRyZWdpb246NjdkZDEyODkyZGI0NDc4ZDkzMTQwMjI2YjJkZjc0YWJfNTQz_94aa4c83-40fb-4389-b320-80254308f41b">31.5</ix:nonFraction>% (weighted average of <ix:nonFraction unitRef="number" contextRef="i9e0a7e787f35452e9cf3c1d60a078e47_I20200930" decimals="3" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RleHRyZWdpb246NjdkZDEyODkyZGI0NDc4ZDkzMTQwMjI2YjJkZjc0YWJfNTY3_5a18ecc4-f4f7-49a9-8f09-551ef1d8c357">26.8</ix:nonFraction>%). The discount for lack of marketability was weighted by the relative fair value of the instruments. A significant increase (decrease) in the discount for lack of marketability in isolation would result in a significantly lower (higher) fair value measurement. Unrealized gains and losses on equity securities are included in other income (expense), net.</span></div></ix:continuation><div id="i01dca92a9a894c839fd91f8b5b3beba6_43"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80My9mcmFnOmExMzgwNmNjMDYwNzQ1NzM5NmY2OTdiMTQyYTAxMjlmL3RleHRyZWdpb246YTEzODA2Y2MwNjA3NDU3Mzk2ZjY5N2IxNDJhMDEyOWZfNjE_cd8b9d34-5f05-4983-a350-1f3552c3124c" continuedAt="i8ae7f9db96af41599d658ed7b49ecb0e" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="i8ae7f9db96af41599d658ed7b49ecb0e"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80My9mcmFnOmExMzgwNmNjMDYwNzQ1NzM5NmY2OTdiMTQyYTAxMjlmL3RleHRyZWdpb246YTEzODA2Y2MwNjA3NDU3Mzk2ZjY5N2IxNDJhMDEyOWZfNjI_8b5c6e65-7a16-4af7-826a-e39602d3fc68" escape="true"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80My9mcmFnOmExMzgwNmNjMDYwNzQ1NzM5NmY2OTdiMTQyYTAxMjlmL3RhYmxlOjcyY2FjYTUzZjQ5NTRmZjg5ODkzZWQyMDI4OTNhNjZmL3RhYmxlcmFuZ2U6NzJjYWNhNTNmNDk1NGZmODk4OTNlZDIwMjg5M2E2NmZfMS0xLTEtMS0w_f8496226-5e96-4aeb-8009-e8ad60802851">14.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80My9mcmFnOmExMzgwNmNjMDYwNzQ1NzM5NmY2OTdiMTQyYTAxMjlmL3RhYmxlOjcyY2FjYTUzZjQ5NTRmZjg5ODkzZWQyMDI4OTNhNjZmL3RhYmxlcmFuZ2U6NzJjYWNhNTNmNDk1NGZmODk4OTNlZDIwMjg5M2E2NmZfMS0zLTEtMS0w_57456823-9b9e-4d5e-801e-74b4d728a42b">14.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80My9mcmFnOmExMzgwNmNjMDYwNzQ1NzM5NmY2OTdiMTQyYTAxMjlmL3RhYmxlOjcyY2FjYTUzZjQ5NTRmZjg5ODkzZWQyMDI4OTNhNjZmL3RhYmxlcmFuZ2U6NzJjYWNhNTNmNDk1NGZmODk4OTNlZDIwMjg5M2E2NmZfMi0xLTEtMS0w_62a9a15e-69ed-418c-a370-7c376e8fb549">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80My9mcmFnOmExMzgwNmNjMDYwNzQ1NzM5NmY2OTdiMTQyYTAxMjlmL3RhYmxlOjcyY2FjYTUzZjQ5NTRmZjg5ODkzZWQyMDI4OTNhNjZmL3RhYmxlcmFuZ2U6NzJjYWNhNTNmNDk1NGZmODk4OTNlZDIwMjg5M2E2NmZfMi0zLTEtMS0w_3588441e-aa84-49a1-8706-1195e83629bc">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80My9mcmFnOmExMzgwNmNjMDYwNzQ1NzM5NmY2OTdiMTQyYTAxMjlmL3RhYmxlOjcyY2FjYTUzZjQ5NTRmZjg5ODkzZWQyMDI4OTNhNjZmL3RhYmxlcmFuZ2U6NzJjYWNhNTNmNDk1NGZmODk4OTNlZDIwMjg5M2E2NmZfMy0xLTEtMS0w_bb16a4e7-87a7-47f5-b24f-d20f073b180b">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80My9mcmFnOmExMzgwNmNjMDYwNzQ1NzM5NmY2OTdiMTQyYTAxMjlmL3RhYmxlOjcyY2FjYTUzZjQ5NTRmZjg5ODkzZWQyMDI4OTNhNjZmL3RhYmxlcmFuZ2U6NzJjYWNhNTNmNDk1NGZmODk4OTNlZDIwMjg5M2E2NmZfMy0zLTEtMS0w_b8568985-d6a0-4794-b864-5d543c325642">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80My9mcmFnOmExMzgwNmNjMDYwNzQ1NzM5NmY2OTdiMTQyYTAxMjlmL3RhYmxlOjcyY2FjYTUzZjQ5NTRmZjg5ODkzZWQyMDI4OTNhNjZmL3RhYmxlcmFuZ2U6NzJjYWNhNTNmNDk1NGZmODk4OTNlZDIwMjg5M2E2NmZfNC0xLTEtMS0w_d22b98c9-88b7-4467-9fd8-5e893eb433c4">20.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80My9mcmFnOmExMzgwNmNjMDYwNzQ1NzM5NmY2OTdiMTQyYTAxMjlmL3RhYmxlOjcyY2FjYTUzZjQ5NTRmZjg5ODkzZWQyMDI4OTNhNjZmL3RhYmxlcmFuZ2U6NzJjYWNhNTNmNDk1NGZmODk4OTNlZDIwMjg5M2E2NmZfNC0zLTEtMS0w_5ea9f7e2-2bcf-45fb-ae0e-1c5b315d0436">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i01dca92a9a894c839fd91f8b5b3beba6_46"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6. Cash, Cash Equivalents and <ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="nbix:RestrictedCashTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80Ni9mcmFnOjg0ZjllOWYxZDk0MjRiOGZiMzcyMmJhYzcwM2MyMTNjL3RleHRyZWdpb246ODRmOWU5ZjFkOTQyNGI4ZmIzNzIyYmFjNzAzYzIxM2NfMjg1_6b7248d0-a23b-40a9-a453-2ac4de7f3fc6" continuedAt="ie327adfefdaa4508936287e79618a662" escape="true">Restricted Cash</ix:nonNumeric></span></div><ix:continuation id="ie327adfefdaa4508936287e79618a662"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80Ni9mcmFnOjg0ZjllOWYxZDk0MjRiOGZiMzcyMmJhYzcwM2MyMTNjL3RleHRyZWdpb246ODRmOWU5ZjFkOTQyNGI4ZmIzNzIyYmFjNzAzYzIxM2NfMjg2_f4bc46b3-20ec-45a3-8f5b-9c99bcfdb250" escape="true"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80Ni9mcmFnOjg0ZjllOWYxZDk0MjRiOGZiMzcyMmJhYzcwM2MyMTNjL3RhYmxlOjNhZDkxZGRhNjYwNzRkZGE5M2UyZjlkNGFjMTJiOWVhL3RhYmxlcmFuZ2U6M2FkOTFkZGE2NjA3NGRkYTkzZTJmOWQ0YWMxMmI5ZWFfMS0xLTEtMS0w_c3a37829-fcc4-4024-a50d-9c51d544bb5e">425.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80Ni9mcmFnOjg0ZjllOWYxZDk0MjRiOGZiMzcyMmJhYzcwM2MyMTNjL3RhYmxlOjNhZDkxZGRhNjYwNzRkZGE5M2UyZjlkNGFjMTJiOWVhL3RhYmxlcmFuZ2U6M2FkOTFkZGE2NjA3NGRkYTkzZTJmOWQ0YWMxMmI5ZWFfMS0zLTEtMS0w_94738c1a-f93b-4448-8954-90b93f64d714">112.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80Ni9mcmFnOjg0ZjllOWYxZDk0MjRiOGZiMzcyMmJhYzcwM2MyMTNjL3RhYmxlOjNhZDkxZGRhNjYwNzRkZGE5M2UyZjlkNGFjMTJiOWVhL3RhYmxlcmFuZ2U6M2FkOTFkZGE2NjA3NGRkYTkzZTJmOWQ0YWMxMmI5ZWFfMi0xLTEtMS0w_e77c19e7-de03-4ca1-890a-e6d9a156ee69">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80Ni9mcmFnOjg0ZjllOWYxZDk0MjRiOGZiMzcyMmJhYzcwM2MyMTNjL3RhYmxlOjNhZDkxZGRhNjYwNzRkZGE5M2UyZjlkNGFjMTJiOWVhL3RhYmxlcmFuZ2U6M2FkOTFkZGE2NjA3NGRkYTkzZTJmOWQ0YWMxMmI5ZWFfMi0zLTEtMS0w_90753e42-6f56-4b88-a3bd-685daae37b49">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80Ni9mcmFnOjg0ZjllOWYxZDk0MjRiOGZiMzcyMmJhYzcwM2MyMTNjL3RhYmxlOjNhZDkxZGRhNjYwNzRkZGE5M2UyZjlkNGFjMTJiOWVhL3RhYmxlcmFuZ2U6M2FkOTFkZGE2NjA3NGRkYTkzZTJmOWQ0YWMxMmI5ZWFfMy0xLTEtMS0w_e7350778-ea4b-4546-9e89-a55ced368e28">428.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80Ni9mcmFnOjg0ZjllOWYxZDk0MjRiOGZiMzcyMmJhYzcwM2MyMTNjL3RhYmxlOjNhZDkxZGRhNjYwNzRkZGE5M2UyZjlkNGFjMTJiOWVhL3RhYmxlcmFuZ2U6M2FkOTFkZGE2NjA3NGRkYTkzZTJmOWQ0YWMxMmI5ZWFfMy0zLTEtMS0w_66353ba3-a165-424a-a3bf-4e7bbece7467">115.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i01dca92a9a894c839fd91f8b5b3beba6_49"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfMTMyOA_1f6bd9bf-0348-4a64-9ecc-35bcb0999a4d" continuedAt="i3bcd4c88606644699c45e16fb0a7605c" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i3bcd4c88606644699c45e16fb0a7605c" continuedAt="ia72f7477c7b34a48917f89d8dd7bd4b6"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfMTMyNg_1885cb42-6457-497c-9b32-ffdccd38bd49" continuedAt="iaf1b0b144e744f129ffaef51d1446d1d" escape="true"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfMTMzOQ_bebefe96-6856-408a-ba9c-4dcb9204d382" continuedAt="ic2d87e6cb148440fb10e2ec235bb3110" escape="true"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.377%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Address</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Square Feet</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commencement Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12780 El Camino Real </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office/Laboratory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="sqft" contextRef="i6cb2fa374db842989cd35f0f03a92fd5_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOjdlZDE4ZWQyNDkyMDQ5NjM5YjBmYzQ3MWJhOGY3ZmM5L3RhYmxlcmFuZ2U6N2VkMThlZDI0OTIwNDk2MzliMGZjNDcxYmE4ZjdmYzlfMS00LTEtMS0w_d069bebe-367f-4ce4-b4dd-1e3ea6f0b007">141,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 7, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 31, 2031</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12790 El Camino Real, Suite 130 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="sqft" contextRef="i6b783069862c4a7aa49f88ea6fee4135_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOjdlZDE4ZWQyNDkyMDQ5NjM5YjBmYzQ3MWJhOGY3ZmM5L3RhYmxlcmFuZ2U6N2VkMThlZDI0OTIwNDk2MzliMGZjNDcxYmE4ZjdmYzlfMi00LTEtMS0w_f2dcdc57-2ccf-4b28-88c8-1235e5daa58e">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 1, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 31, 2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12790 El Camino Real, Suite 150 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="sqft" contextRef="i388a89deda29498bb6086f28660869e9_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOjdlZDE4ZWQyNDkyMDQ5NjM5YjBmYzQ3MWJhOGY3ZmM5L3RhYmxlcmFuZ2U6N2VkMThlZDI0OTIwNDk2MzliMGZjNDcxYmE4ZjdmYzlfMy00LTEtMS0w_ae408b94-29a6-4a87-ad32-bc3b1c4b41fa">8,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 7, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 31, 2031</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12790 El Camino Real, Suite 300 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="sqft" contextRef="i873fe30d887a4b389617d2698e039940_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOjdlZDE4ZWQyNDkyMDQ5NjM5YjBmYzQ3MWJhOGY3ZmM5L3RhYmxlcmFuZ2U6N2VkMThlZDI0OTIwNDk2MzliMGZjNDcxYmE4ZjdmYzlfNC00LTEtMS0w_f7ac24b9-9909-426c-ab73-18a3ad1448ec">28,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 1, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 31, 2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12777 High Bluff Drive</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="sqft" contextRef="i473d326a3edd493a836fb98886d2085a_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOjdlZDE4ZWQyNDkyMDQ5NjM5YjBmYzQ3MWJhOGY3ZmM5L3RhYmxlcmFuZ2U6N2VkMThlZDI0OTIwNDk2MzliMGZjNDcxYmE4ZjdmYzlfNS00LTEtMS0w_a7d32283-e9d1-45f3-aed1-2c7b0a0899dd">45,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 1, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 31, 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12790 El Camino Real, Suite 200 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="sqft" contextRef="idc20284842904d03ab36d24c9fed65c5_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOjdlZDE4ZWQyNDkyMDQ5NjM5YjBmYzQ3MWJhOGY3ZmM5L3RhYmxlcmFuZ2U6N2VkMThlZDI0OTIwNDk2MzliMGZjNDcxYmE4ZjdmYzlfNi00LTEtMS0w_d2d232c2-7fd5-4bac-9f67-e7e1bb0e8890">28,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 31, 2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12790 El Camino Real, Suite 100 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="sqft" contextRef="id19b886ce9774875bcec5de9e1655ca9_I20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOjdlZDE4ZWQyNDkyMDQ5NjM5YjBmYzQ3MWJhOGY3ZmM5L3RhYmxlcmFuZ2U6N2VkMThlZDI0OTIwNDk2MzliMGZjNDcxYmE4ZjdmYzlfNy00LTEtMS0w_8404c6d2-8aad-44d0-b5fe-b3087e77a2a8">17,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 31, 2031</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(1) Under the terms of the 12780/12790 El Camino Real master lease, we have <ix:nonFraction unitRef="renewaloption" contextRef="i5dc56b70fae344879faba70a7e60b7f8_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="nbix:NumberOfRenewalOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfMTY0_88740f02-0960-4440-873e-14260b35f972">two</ix:nonFraction> options to extend the term of the lease for a period of <ix:nonNumeric contextRef="i5dc56b70fae344879faba70a7e60b7f8_I20200930" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfMjIz_139d3e57-0cbc-43e1-a949-9e2426016d02">ten years</ix:nonNumeric> each. We were not reasonably certain to exercise either of these options at lease commencement. As such, neither option was recognized as part of the associated operating lease right-of-use asset or liability.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="iaf1b0b144e744f129ffaef51d1446d1d"><ix:continuation id="ic2d87e6cb148440fb10e2ec235bb3110">Note: In connection with our operating leases, in lieu of cash security deposits, Wells Fargo Bank, N.A., issued letters of credit on our behalf, which are secured by deposits totaling $<ix:nonFraction unitRef="usd" contextRef="i132f21d3f9184d5493988e86fd0dc307_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfNjIx_33f0eb60-edd3-4c07-aaa6-be3c61d65186">3.2</ix:nonFraction>&#160;million.</ix:continuation></ix:continuation> </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia72f7477c7b34a48917f89d8dd7bd4b6"><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating lease cost was $<ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfNjU1_b11a75b6-28ad-4ec4-8f19-e7469a9a160e">7.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfNjYy_e1358b51-3023-4e35-8120-39f25dbc35a3">5.9</ix:nonFraction> million for the nine months ended September&#160;30, 2020 and 2019, respectively. Cash paid for amounts in the measurement of lease liabilities for operating cash flows from operating leases was $<ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfODI3_76cac8d5-68be-4bc4-978e-78a789798c00">6.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfODM0_1b495d70-1e28-466e-9ca0-538c4e82de20">5.5</ix:nonFraction> million for the nine months ended September&#160;30, 2020 and 2019, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases had a weighted average remaining lease term of approximately <ix:nonNumeric contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfOTY4_bf87e45a-c0c6-4fe9-9993-4f80425ef43a">10.5</ix:nonNumeric> years and <ix:nonNumeric contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfOTc1_2402291a-54e5-4e2c-bf05-013c260bd648">11.2</ix:nonNumeric> years at September&#160;30, 2020 and December&#160;31, 2019, respectively, and a weighted average discount rate of <ix:nonFraction unitRef="number" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfMTA0Ng_2d8990d5-bb7c-4bd8-b25c-325630ba2396"><ix:nonFraction unitRef="number" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfMTA0Ng_388a2849-3c08-4682-9ffa-29528014dd68">5.8</ix:nonFraction></ix:nonFraction>% at September&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfMTMyNw_6a94171b-19d5-4836-8688-24d4ca08aa79" escape="true"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfMTMzMg_4f09dcce-2ecf-41aa-99f3-b5ac3fe386d8" escape="true"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximate future minimum lease payments under operating leases were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.953%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2020 (3 months remaining)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOmEzOTVkNGE3NjJlYTQyMTM5Y2ZjMmNiYmRjMGU1ODY4L3RhYmxlcmFuZ2U6YTM5NWQ0YTc2MmVhNDIxMzljZmMyY2JiZGMwZTU4NjhfMS0xLTEtMS0w_1b827ade-aee3-43f7-b069-3f28172fbfa4">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOmEzOTVkNGE3NjJlYTQyMTM5Y2ZjMmNiYmRjMGU1ODY4L3RhYmxlcmFuZ2U6YTM5NWQ0YTc2MmVhNDIxMzljZmMyY2JiZGMwZTU4NjhfMi0xLTEtMS0w_507c6ce5-0dca-42cf-b901-a42e91275abf">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOmEzOTVkNGE3NjJlYTQyMTM5Y2ZjMmNiYmRjMGU1ODY4L3RhYmxlcmFuZ2U6YTM5NWQ0YTc2MmVhNDIxMzljZmMyY2JiZGMwZTU4NjhfMy0xLTEtMS0w_eff05a5a-fbc9-4e05-8245-f0affba31d3e">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOmEzOTVkNGE3NjJlYTQyMTM5Y2ZjMmNiYmRjMGU1ODY4L3RhYmxlcmFuZ2U6YTM5NWQ0YTc2MmVhNDIxMzljZmMyY2JiZGMwZTU4NjhfNC0xLTEtMS0w_5b63d503-b4ab-483f-bcba-304cd5ad1074">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOmEzOTVkNGE3NjJlYTQyMTM5Y2ZjMmNiYmRjMGU1ODY4L3RhYmxlcmFuZ2U6YTM5NWQ0YTc2MmVhNDIxMzljZmMyY2JiZGMwZTU4NjhfNS0xLTEtMS0w_3cdff458-2c16-4039-a187-86f95a3b449b">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="nbix:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOmEzOTVkNGE3NjJlYTQyMTM5Y2ZjMmNiYmRjMGU1ODY4L3RhYmxlcmFuZ2U6YTM5NWQ0YTc2MmVhNDIxMzljZmMyY2JiZGMwZTU4NjhfNi0xLTEtMS0w_65bb29a3-8da2-44e1-96ca-2d9b6c0c6b9a">79.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOmEzOTVkNGE3NjJlYTQyMTM5Y2ZjMmNiYmRjMGU1ODY4L3RhYmxlcmFuZ2U6YTM5NWQ0YTc2MmVhNDIxMzljZmMyY2JiZGMwZTU4NjhfNy0xLTEtMS0w_a93250f7-5a2c-4e3d-a011-d92ab31fa053">126.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOmEzOTVkNGE3NjJlYTQyMTM5Y2ZjMmNiYmRjMGU1ODY4L3RhYmxlcmFuZ2U6YTM5NWQ0YTc2MmVhNDIxMzljZmMyY2JiZGMwZTU4NjhfOC0xLTEtMS0w_fb351fa6-a85e-4e92-bf6f-2254473f4c61">33.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOmEzOTVkNGE3NjJlYTQyMTM5Y2ZjMmNiYmRjMGU1ODY4L3RhYmxlcmFuZ2U6YTM5NWQ0YTc2MmVhNDIxMzljZmMyY2JiZGMwZTU4NjhfOS0xLTEtMS0w_1c63118f-3712-4f9c-a899-9b1ff648a2bc">92.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOmEzOTVkNGE3NjJlYTQyMTM5Y2ZjMmNiYmRjMGU1ODY4L3RhYmxlcmFuZ2U6YTM5NWQ0YTc2MmVhNDIxMzljZmMyY2JiZGMwZTU4NjhfMTAtMS0xLTEtMA_21c09a44-fa23-4ec2-b604-5c4b0c26a35c">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOmEzOTVkNGE3NjJlYTQyMTM5Y2ZjMmNiYmRjMGU1ODY4L3RhYmxlcmFuZ2U6YTM5NWQ0YTc2MmVhNDIxMzljZmMyY2JiZGMwZTU4NjhfMTEtMS0xLTEtMA_a72f8e54-295c-4321-853f-a92d71eac094">83.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note: Amounts presented in the table above exclude $<ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" format="ixt:numdotdecimal" name="nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfMTIyNw_f3535727-66e5-4474-8d7d-0435b5504d4a">28.3</ix:nonFraction> million of non-cancelable future minimum lease payments for operating leases that have not yet commenced.</span></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div id="i01dca92a9a894c839fd91f8b5b3beba6_52"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfOTQ0Mw_44f40785-b041-41c1-ae59-e74b22d46f8a" continuedAt="idf848c6fe68d443a95cb5fc8c218f6a1" escape="true">Convertible Senior Notes</ix:nonNumeric></span></div><ix:continuation id="idf848c6fe68d443a95cb5fc8c218f6a1" continuedAt="i6a9d7ce9fe9a49468aa60a792351297d"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;2, 2017, we completed a private placement of&#160;$<ix:nonFraction unitRef="usd" contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfODU_c56dbf7d-56c2-4a43-b97b-8a997efefecf">517.5</ix:nonFraction> million&#160;in aggregate principal amount of&#160;<ix:nonFraction unitRef="number" contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMTIx_13bcc69b-4ee9-4c7a-b206-989e7dcac434">2.25</ix:nonFraction>%&#160;convertible senior notes due 2024 and entered into an indenture agreement, or the 2024 Indenture, with respect to the 2024 Notes. The 2024 Notes accrue interest at a fixed rate of&#160;<ix:nonFraction unitRef="number" contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMzA0_869f9a64-9d61-47f9-9176-f6784dd95e7e">2.25</ix:nonFraction>%&#160;per year, payable semiannually in arrears on May&#160;15 and November&#160;15 of each year, beginning on November&#160;15, 2017. The 2024 Notes mature on May 15, 2024. The net proceeds from the issuance of the 2024 Notes were approximately $<ix:nonFraction unitRef="usd" contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNTIy_8c833f51-2608-45d7-9887-d99c66a5df6a">502.8</ix:nonFraction> million, after deducting commissions and the offering expenses payable by us.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May&#160;15, 2024, only under the following circumstances:</span></div><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.07pt">during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least&#160;<ix:nonFraction unitRef="d" contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfOTIy_13a4201d-a35c-4647-876a-053ea1cd678c">20</ix:nonFraction>&#160;trading days (whether or not consecutive) during a period of&#160;<ix:nonFraction unitRef="d" contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfOTg2_55dfaf6b-3666-47c8-a02e-20b686ccc5bd">30</ix:nonFraction>&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than&#160;<ix:nonFraction unitRef="number" contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMTEwNw_4fbda302-a077-4b0f-951d-a7a23134d48a">130</ix:nonFraction>%&#160;of the conversion price on each applicable trading day;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.3pt">during the&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMTE3Nw_a1999c43-97d5-4934-9864-f07cd2e0e9ca">five</span> business-day period immediately after any&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMTIyMg_0e6c4b54-2041-4866-8f9f-60a13836b830">five</span>&#160;consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2024 Indenture) per&#160;$<ix:nonFraction unitRef="usd" contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502" decimals="INF" format="ixt:numdotdecimal" name="nbix:PrincipalAmountOnConversionRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMTM0Nw_bfc0c5cd-aff7-4d12-a1c5-620d434c4e23">1,000</ix:nonFraction>&#160;principal amount of the 2024 Notes for each trading day of the measurement period was less than&#160;<ix:nonFraction unitRef="number" contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502" decimals="INF" name="nbix:MinimumPercentageOfTradingPriceToLastReportedSalePrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMTQ0Ng_9b832bbb-be6e-469b-8db2-16547973db4f">98</ix:nonFraction>%&#160;of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;</span></div><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.53pt">upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.07pt">if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after January&#160;15, 2024, until the close of business on the scheduled trading day immediately preceding May&#160;15, 2024, holders may convert their 2024 Notes at any time.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the conditional conversion feature described under (i) above had been triggered as of September 30, 2020, holders of the 2024 Notes may convert the 2024 Notes at any time during the period beginning on October 1, 2020 and ending at the close of business on December 31, 2020. Accordingly, the 2024 Notes have been classified as a current liability as of September 30, 2020. The future conditional convertibility of the 2024 Notes will be monitored at each quarterly reporting date and analyzed dependent upon market prices of our common stock during the prescribed measurement periods.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6a9d7ce9fe9a49468aa60a792351297d" continuedAt="icd1bb450741649e186d6447a2dfe9737"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, holders will receive the principal amount of their 2024 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the&#160;<ix:nonFraction unitRef="d" contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMjc2Nw_665b3dc3-774c-4ba4-be05-252ff84ee992">30</ix:nonFraction>&#160;consecutive trading days during the observation period (as more fully described in the 2024 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of our common stock or a combination of cash and shares of our common stock, at our option.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our intent and policy to settle conversions through combination settlement, which essentially involves repayment of an amount of cash equal to the &#8220;principal portion&#8221; and delivery of the &#8220;share amount&#8221; in excess of the principal portion in shares of common stock or cash. In general, for each $<ix:nonFraction unitRef="usd" contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502" decimals="INF" format="ixt:numdotdecimal" name="nbix:PrincipalAmountOnConversionRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMzM1MA_deabdd2d-2a7e-4e1d-836a-98ba45ba01b9">1,000</ix:nonFraction> in principal, the &#8220;principal portion&#8221; of cash upon settlement is defined as the lesser of $<ix:nonFraction unitRef="usd" contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502" decimals="INF" format="ixt:numdotdecimal" name="nbix:PrincipalAmountOnConversionRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMzQ0Mw_ce18665f-4d39-4105-8418-94d90c85334d">1,000</ix:nonFraction>, and the conversion value during the <ix:nonNumeric contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502" format="ixt-sec:durday" name="nbix:DebtConversionObservationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMzQ4Mw_90121100-4859-4607-9120-b020a4946ca3">25</ix:nonNumeric>-day observation period as described in the 2024 Indenture. The conversion value is the sum of the daily conversion value which is the product of the effective conversion rate divided by <ix:nonNumeric contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502" format="ixt-sec:durday" name="nbix:DebtConversionObservationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMzY3Mg_ef6c3b2b-d171-47ef-95b8-536bed64a19a">25</ix:nonNumeric> days and the daily volume weighted average price, or VWAP, of our common stock. The &#8220;share amount&#8221; is the cumulative &#8220;daily share amount&#8221; during the observation period, which is calculated by dividing the daily VWAP into the difference between the daily conversion value (i.e., conversion rate x daily VWAP) and $<ix:nonFraction unitRef="usd" contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502" decimals="INF" format="ixt:numdotdecimal" name="nbix:PrincipalAmountOnConversionRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMzk4Mg_8233bdbc-8794-46c1-8197-e23711daff10">1,000</ix:nonFraction>. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial conversion rate for the 2024 Notes is&#160;13.1711&#160;shares of common stock per&#160;$<ix:nonFraction unitRef="usd" contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502" decimals="INF" format="ixt:numdotdecimal" name="nbix:PrincipalAmountOnConversionRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNDA3Mg_5d5d73ff-1910-4c30-8e08-31b66de1ebad">1,000</ix:nonFraction>&#160;principal amount, which is equivalent to an initial conversion price of&#160;approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNDE2MQ_0bc3b3ed-b0a7-446d-941c-cf1beba34e05">75.92</ix:nonFraction>&#160;per share of our common stock. At the initial conversion rate, settlement of the 2024 Notes for shares of our common stock would approximate <ix:nonFraction unitRef="shares" contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNDMwNQ_3232ff32-3013-4198-b34c-b61b7904a2e9">6.8</ix:nonFraction> million shares. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2024 Notes represented a premium of approximately&#160;<ix:nonFraction unitRef="number" contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502" decimals="3" name="nbix:DebtInstrumentConvertibleConversionPremium" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNDUyOQ_3c3eef82-1e76-41f5-bef4-dfda469c4275">42.5</ix:nonFraction>%&#160;to the closing sale price of&#160;$<ix:nonFraction unitRef="usdPerShare" contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNDU2MQ_88e128f2-5b95-431f-bf1a-5a996aa1926c">53.28</ix:nonFraction>&#160;per share of our common stock on the Nasdaq Global Select Market on April&#160;26, 2017, the date that we priced the private offering of the 2024 Notes.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2024 Notes will be paid pursuant to the terms of the 2024 Indenture. In the event that all of the 2024 Notes are converted, we would be required to repay the&#160;$<ix:nonFraction unitRef="usd" contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNTA5Ng_6610bdf7-076f-450b-a51b-88602cf7d8c7">517.5</ix:nonFraction>&#160;million&#160;in principal value and any conversion premium in any combination of cash and shares of our common stock, at our option.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not redeem the 2024 Notes prior to May&#160;15, 2021. On or after May&#160;15, 2021, we may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2024 Indenture) of our common stock has been at least&#160;<ix:nonFraction unitRef="number" contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNTQ1OQ_85bded9c-2744-4dea-9fa6-43f407e2920e">130</ix:nonFraction>%&#160;of the conversion price then in effect for at least&#160;<ix:nonFraction unitRef="d" contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNTUxNA_6981e142-7472-498e-96d8-9602d5f48fcb">20</ix:nonFraction>&#160;trading days (whether or not consecutive) during any&#160;<ix:nonFraction unitRef="d" contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNTU3MA_91f6c034-3742-4e70-b2d6-b1def80e1378">30</ix:nonFraction>&#160;consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption. The redemption price will equal the sum of (i)&#160;<ix:nonFraction unitRef="number" contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNTc2MA_8374f0ba-4f5c-4348-9dc4-e267324067da">100</ix:nonFraction>%&#160;of the principal amount of the 2024 Notes being redeemed, plus (ii)&#160;accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. No sinking fund is provided for the 2024 Notes.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we undergo a fundamental change, as defined in the 2024 Indenture, subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to&#160;<ix:nonFraction unitRef="number" contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNjIxNQ_6f112087-986d-4aba-8819-061808e0e5a4">100</ix:nonFraction>%&#160;of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a &#8216;&#8216;make-whole fundamental change&#8217;&#8217; (as defined in the 2024 Indenture) occurs prior to January&#160;15, 2024, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with the make-whole fundamental change.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to separately account for the liability and equity components of the 2024 Notes as they may be settled entirely or partially in cash upon conversion in a manner that reflects our economic interest cost. The liability component of the instrument was valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. The initial carrying value of the liability component of $<ix:nonFraction unitRef="usd" contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502" decimals="-5" format="ixt:numdotdecimal" name="nbix:DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNzM0OA_f0a749ca-746a-4f23-a3c0-2f0e2f6d0b26">368.3</ix:nonFraction> million&#160;was calculated using a&#160;<ix:nonFraction unitRef="number" contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502" decimals="3" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNzM3NA_7faa0455-f030-4ff1-98aa-09d83f54239d">7.5</ix:nonFraction>%&#160;assumed borrowing rate. The equity component of $<ix:nonFraction unitRef="usd" contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNzQyNQ_b9d5db3c-ae74-4b81-ba84-d930d6fe59ca">149.2</ix:nonFraction> million, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2024 Notes and was recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. That equity component is treated as a discount on the liability component of the 2024 Notes, which is amortized over the <ix:nonNumeric contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfOTQ0NQ_2603b84b-2b62-4ec9-9588-f5126f2f218f">seven-year</ix:nonNumeric> term of the 2024 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. At September&#160;30, 2020, the remaining period over which the discount on the liability component will be amortized was approximately <ix:nonNumeric contextRef="i0e4f2c61bb0c4669bf03824d0717d032_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfODA5OA_ed2fef51-f69a-4031-a896-bf613432eab0">3.6</ix:nonNumeric> years.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the total transaction costs of approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfODE2MA_5c17a3a3-4915-4bc5-a81d-4647fb476b95">14.7</ix:nonFraction> million&#160;related to the issuance of the 2024 Notes to the liability and equity components of the 2024 Notes based on their relative values. Transaction costs attributable to the liability </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="icd1bb450741649e186d6447a2dfe9737"><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">component are amortized to interest expense over the&#160;<ix:nonNumeric contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfOTQ0Ng_69a6faa1-4fb6-40d4-8ade-4d96be53c9fe">seven-year</ix:nonNumeric> term of the 2024 Notes, and transaction costs attributable to the equity component are netted with the equity component in stockholders&#8217; equity.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2024 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default,&#160;<ix:nonFraction unitRef="number" contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502" decimals="INF" name="nbix:DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfODg4NQ_7673a49e-dd29-4de8-b738-dc480321df34">100</ix:nonFraction>%&#160;of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.</span></div><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfOTQ0MA_587736fa-f528-4a15-8a09-82ae750ff7f2" escape="true"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes, net of discounts and deferred financing costs, consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RhYmxlOjU1ODA2Mzg4ZDE2NzQ3NGZiMWY5YTk3N2IyZjBjMmFiL3RhYmxlcmFuZ2U6NTU4MDYzODhkMTY3NDc0ZmIxZjlhOTc3YjJmMGMyYWJfMS0xLTEtMS0w_dd88be7c-d298-4d85-9f6c-c8e0a1e42ca8">517.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RhYmxlOjU1ODA2Mzg4ZDE2NzQ3NGZiMWY5YTk3N2IyZjBjMmFiL3RhYmxlcmFuZ2U6NTU4MDYzODhkMTY3NDc0ZmIxZjlhOTc3YjJmMGMyYWJfMS0zLTEtMS0w_587354eb-443c-422b-90d0-7ea96722ce1c">517.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RhYmxlOjU1ODA2Mzg4ZDE2NzQ3NGZiMWY5YTk3N2IyZjBjMmFiL3RhYmxlcmFuZ2U6NTU4MDYzODhkMTY3NDc0ZmIxZjlhOTc3YjJmMGMyYWJfMi0xLTEtMS0w_99098010-f1f7-46e9-a7be-e201d5476688">5.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RhYmxlOjU1ODA2Mzg4ZDE2NzQ3NGZiMWY5YTk3N2IyZjBjMmFiL3RhYmxlcmFuZ2U6NTU4MDYzODhkMTY3NDc0ZmIxZjlhOTc3YjJmMGMyYWJfMi0zLTEtMS0w_cf51ceef-c640-4909-8cb0-19770085239d">6.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt discount, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RhYmxlOjU1ODA2Mzg4ZDE2NzQ3NGZiMWY5YTk3N2IyZjBjMmFiL3RhYmxlcmFuZ2U6NTU4MDYzODhkMTY3NDc0ZmIxZjlhOTc3YjJmMGMyYWJfMy0xLTEtMS0w_fd997c56-a985-4c6b-ac90-31a102bd8e4d">86.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RhYmxlOjU1ODA2Mzg4ZDE2NzQ3NGZiMWY5YTk3N2IyZjBjMmFiL3RhYmxlcmFuZ2U6NTU4MDYzODhkMTY3NDc0ZmIxZjlhOTc3YjJmMGMyYWJfMy0zLTEtMS0w_bedf795f-fb82-4ed5-b5ed-d3933f7b6cad">101.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RhYmxlOjU1ODA2Mzg4ZDE2NzQ3NGZiMWY5YTk3N2IyZjBjMmFiL3RhYmxlcmFuZ2U6NTU4MDYzODhkMTY3NDc0ZmIxZjlhOTc3YjJmMGMyYWJfNC0xLTEtMS0w_ef3ce65d-5d0c-481d-9955-4e6a30e3570e">425.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231" decimals="-5" name="us-gaap:ConvertibleDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RhYmxlOjU1ODA2Mzg4ZDE2NzQ3NGZiMWY5YTk3N2IyZjBjMmFiL3RhYmxlcmFuZ2U6NTU4MDYzODhkMTY3NDc0ZmIxZjlhOTc3YjJmMGMyYWJfNC0zLTEtMS0w_fe290789-dba7-4666-9332-63555817d342">408.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>The 2024 Notes were recorded at the estimated value of a similar non-convertible instrument on the date of issuance and accretes to the face value of the 2024 Notes over their <ix:nonNumeric contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfOTQ0MQ_63ec4c51-56ce-4707-b918-7604c3aa48a9">seven-year</ix:nonNumeric> term. The fair value of the 2024 Notes, which was estimated utilizing market quotations from an over-the-counter trading market (Level 2), was $<ix:nonFraction unitRef="usd" contextRef="i1e3872d7a51340d7bd8d1873912c8acb_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfOTQxOQ_90747f8e-88ea-47c4-9b37-b9b9e28bb94a">713.0</ix:nonFraction> million at September&#160;30, 2020 and $<ix:nonFraction unitRef="usd" contextRef="id6a49b9383644b8e949247b3f6dc07c3_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfOTQzMg_56ca54ef-dc7c-4e64-b1d2-e8b6ee9fdf16">596.8</ix:nonFraction> million at December&#160;31, 2019.</span></div></ix:continuation><div id="i01dca92a9a894c839fd91f8b5b3beba6_58"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RleHRyZWdpb246NTQ0MjUyZmRjZGNmNDAwMTlkZGI2ZDQ0Y2Q5NjUyNzZfMTA2MQ_19ea59ed-3298-4c1f-a849-f28253ac76f4" continuedAt="ie2ff3d8528b341faaeda93896aed1a17" escape="true">Net (Loss) Income Per Share</ix:nonNumeric></span></div><ix:continuation id="ie2ff3d8528b341faaeda93896aed1a17"><ix:nonNumeric contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RleHRyZWdpb246NTQ0MjUyZmRjZGNmNDAwMTlkZGI2ZDQ0Y2Q5NjUyNzZfMTA2Mg_08e80ed3-bb2a-4f13-855f-7db4860a038c" escape="true"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income per share was calculated as follows:</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMi0xLTEtMS0w_b53124b4-fa74-4bfe-b814-fcdc8dc6a445">57.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMi0zLTEtMS0w_6afe0ac2-0eb3-4f49-8599-b15d5928bdda">53.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMi01LTEtMS0w_f5eed12f-9e72-45cf-a716-f1079b0c6bd0">59.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMi03LTEtMS0w_95823a5e-1a99-4706-83e9-be11991506aa">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNC0xLTEtMS0w_2777ae8c-8126-478e-8ce1-8e480bf2ffbf">93.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNC0zLTEtMS0w_c09571ad-839c-4317-9717-b887a0371419">91.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNC01LTEtMS0w_e7778204-9369-4af9-9535-1ce4a51af036">93.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNC03LTEtMS0w_0b3e53d2-88be-4482-870d-5561c2a36e87">91.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4556b63f7bc4fc98ded870e841fc0f1_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNi0xLTEtMS0w_5563a5af-ba20-498c-a4cc-25dc7a34381d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie07c04ad31ab444aa78ad245a76043b3_D20190701-20190930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNi0zLTEtMS0w_3f7a1dee-ee4a-4e28-b18b-a8b2f27937f2">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idae84b2bcee5402c8d33bf434a519a5a_D20200101-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNi01LTEtMS0w_3a1b0d75-c78e-44c6-81c7-9233313e450f">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7952abe718084d38a17f69cd5d0327b6_D20190101-20190930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNi03LTEtMS0w_998a74b9-72a4-407c-bfb9-2e0d64e68ee9">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic23a449373e942b6a52ed76757c61821_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNy0xLTEtMS0w_4875ac47-cdb0-4105-8492-a572d37b89a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd783faa158b4dbe92e4b587a15e4e5b_D20190701-20190930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNy0zLTEtMS0w_c7e4d36a-ca79-4889-8a7c-8101cf211455">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b9ca9a1b5ab47359e53b9d1690424a9_D20200101-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNy01LTEtMS0w_eb8fabd6-edec-48de-b4ee-eb0764ef0d06">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16bcd03519fb4b91b7c49c28141acd41_D20190101-20190930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNy03LTEtMS0w_012bf218-5fa5-413b-9815-832c8485e99a">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic83bc456a2d24aea914f39864a46ea36_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfOC0xLTEtMS0w_ba9bb32d-6d8b-478a-b4df-41c61fce317e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46cad86f1cef4f9796a18fb9899c6bd5_D20190701-20190930" decimals="-5" name="nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfOC0zLTEtMS0w_55b39e62-0512-464e-8f24-f6dbcf35f238">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ideea8abfeaaf4691a87a843e06657dea_D20200101-20200930" decimals="-5" name="nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfOC01LTEtMS0w_f63a4000-5368-4ac7-8d1e-b9a877870d0a">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb3a8bd5463f49769dbf1087a66ca8c8_D20190101-20190930" decimals="-5" name="nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfOC03LTEtMS0w_c59c6675-520b-4a29-b807-614703f8f205">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfOS0xLTEtMS0w_9a591c48-2268-40f2-9e99-5b8f2f379330">93.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfOS0zLTEtMS0w_a9eb2d4b-6204-44e5-b62f-351fdb12eaae">96.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfOS01LTEtMS0w_ffc98b2f-2498-4a4b-b704-2977a62bd95f">98.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfOS03LTEtMS0w_dcc2ce41-2c08-4bf8-ab6f-a22cdca377e8">95.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMTEtMS0xLTEtMA_880913db-c28b-4bea-afac-258d149a0e6a">0.62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMTEtMy0xLTEtMA_7cba7c83-1e76-4681-8c01-3d85f3ffa684">0.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMTEtNS0xLTEtMA_26d39876-1414-4187-8458-d66f7aebb01a">0.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMTEtNy0xLTEtMA_6d017759-802b-4dbd-94e9-c47d1f703fcd">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMTItMS0xLTEtMA_e5bdc458-83b7-4584-80ca-2600fafdbcc3">0.62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMTItMy0xLTEtMA_7720cbd3-5ad0-4470-8aea-b7ec1af4c149">0.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMTItNS0xLTEtMA_9855a723-9d74-4dd8-8dec-68332d1382fc">0.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMTItNy0xLTEtMA_f923f71d-1db9-404e-a5eb-52a319aa621a">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible debt instruments that may be settled entirely or partly in cash (such as the 2024 Notes) may, in certain circumstances where the borrower has the ability and intent to settle in cash, be accounted for under the treasury stock method. We issued the 2024 Notes with a combination settlement feature, which we have the ability and intent to use upon conversion of the 2024 Notes, to settle the principal amount of debt for cash and the excess of the principal portion in shares of our common stock. As a result, of the approximately <ix:nonFraction unitRef="shares" contextRef="i0e4f2c61bb0c4669bf03824d0717d032_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RleHRyZWdpb246NTQ0MjUyZmRjZGNmNDAwMTlkZGI2ZDQ0Y2Q5NjUyNzZfNjM1_e671b605-687b-4704-9a7b-25cf39c37747">6.8</ix:nonFraction> million shares underlying the 2024 Notes, only the shares required to settle the excess of the principal portion are considered under the treasury stock method.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were <ix:nonFraction unitRef="shares" contextRef="i8a2aaf5893684e989b254984e9c0e7c2_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RleHRyZWdpb246NTQ0MjUyZmRjZGNmNDAwMTlkZGI2ZDQ0Y2Q5NjUyNzZfOTEw_6cd30e70-7d66-441f-bc69-e471bc9376fd">10.9</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="if5e51d3e6c184bf388994f88f70e42b4_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RleHRyZWdpb246NTQ0MjUyZmRjZGNmNDAwMTlkZGI2ZDQ0Y2Q5NjUyNzZfOTE3_c5ada473-b4a7-4e88-beeb-921c1550499d">1.8</ix:nonFraction>&#160;million for the three and nine months ended September&#160;30, 2020, respectively, and <ix:nonFraction unitRef="shares" contextRef="i5484b1436d094cdaaf477c90a7f1ed3b_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RleHRyZWdpb246NTQ0MjUyZmRjZGNmNDAwMTlkZGI2ZDQ0Y2Q5NjUyNzZfOTg4_228260f9-f077-4650-a03e-e3fc04ef281d">2.3</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="i4cb16bd71c524c9a890f849d3486c0c8_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RleHRyZWdpb246NTQ0MjUyZmRjZGNmNDAwMTlkZGI2ZDQ0Y2Q5NjUyNzZfOTk1_d1144f27-ab3a-4abd-83e4-c66bdbb50bd0">2.2</ix:nonFraction>&#160;million for the three and nine months ended September&#160;30, 2019, respectively.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i01dca92a9a894c839fd91f8b5b3beba6_64"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations section contains forward-looking statements, which involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in Part II, Item&#160;1A under the caption &#8220;Risk Factors.&#8221; The interim financial statements and this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December&#160;31, 2019 and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, which are contained in our Annual Report on Form 10-K for the year ended December&#160;31, 2019 and our Quarterly Report on Form 10-Q for the six months ended June 30, 2020.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a commercial-stage biopharmaceutical company focused on discovering and developing innovative and life-changing treatments for patients with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. We specialize in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. Currently, we are primarily focused on the commercialization of INGREZZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in the United States, or US, our first US Food and Drug Administration, or FDA, approved product.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2017, we received FDA approval of our first marketed product, INGREZZA, for the treatment of adults with tardive dyskinesia, or TD. Shortly after receiving FDA approval, we began commercializing INGREZZA in the US using a specialty sales force primarily focused on educating physicians who treat patients with TD, including psychiatrists and neurologists.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we received FDA approval for ONGENTYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (opicapone) as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients, which was commercialized by our commercial team in late September 2020.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration partner, AbbVie Inc., or AbbVie, received approval of ORILISSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (elagolix) for the management of moderate to severe endometriosis pain in women from the FDA in July 2018 and Health Canada in October 2018. In May 2020, AbbVie received approval from the FDA for ORIAHNN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (elagolix) for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. We receive royalties at tiered percentage rates on any net sales of ORILISSA and ORIAHNN.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in May 2020, we entered into a collaboration and licensing agreement with Idorsia Pharmaceuticals Ltd, or Idorsia. In connection with the agreement, we paid Idorsia $45.0 million upfront to gain a license to NBI-827104, a potent, selective, orally active and brain penetrating T-type calcium channel blocker, in clinical development for the treatment of a rare pediatric epilepsy. The agreement includes a research collaboration to discover and identify additional novel T-type calcium channel blockers as development candidates.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we entered into an exclusive license agreement with Takeda Pharmaceutical Company Limited, or Takeda, which became effective in July 2020. The agreement is focused on the development and commercialization of certain compounds in Takeda&#8217;s early to mid-stage psychiatry pipeline. In connection with the agreement, we paid Takeda $120.0 million upfront to gain an exclusive license to seven of Takeda&#8217;s pipeline programs, including three clinical-stage assets for schizophrenia, treatment-resistant depression, and anhedonia. The collaboration also includes a cost-sharing arrangement for certain collaboration activities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our late-stage pipeline includes valbenazine for the treatment of chorea in adult patients with Huntington&#8217;s disease, or HD, crinecerfont (NBI-74788) for the treatment of congenital adrenal hyperplasia, or CAH, in adult patients, and NBIb-1817 (VY-AADC) for the treatment of advanced Parkinson&#8217;s disease patients with motor fluctuations that are refractory to medical management. Our product candidate for advanced Parkinson&#8217;s disease is partnered with Voyager Therapeutics, Inc., or Voyager.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our early-stage clinical pipeline includes crinecerfont for the treatment of CAH in pediatric patients, elagolix for the treatment of polycystic ovary syndrome, or PCOS, in women, NBI-1065844 (TAK-831) for the treatment of schizophrenia, NBI-1065845 (TAK-653) for the treatment of treatment-resistant depression, NBI-1065846 (TAK-041) for the treatment of anhedonia in depression, NBI-921352 (XEN901) for the treatment of epilepsy, and NBI-827104 (ACT-709478) for the treatment of a rare pediatric epilepsy. Our product candidate for PCOS is partnered with AbbVie.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Going forward, we expect to augment our product pipeline by acquiring, through license or otherwise, additional drug candidates for research and development, or R&amp;D, and potential commercialization.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global COVID-19 pandemic has dramatically changed the ways in which we live and interact with one another. While we adapt to this new shared reality, our mission remains unchanged: to discover and develop life-changing treatments for people with serious, challenging and under-addressed disorders.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we are unable to reliably estimate the duration or extent of any potential business disruption or financial impact during this time, including any impacts on INGREZZA product sales or R&amp;D expense, we remain committed to (1) prioritizing the safety, health and well-being of patients, their caregivers, healthcare providers and our employees; (2) ensuring patients with TD are well supported and have continued uninterrupted access to INGREZZA, for which we currently do not expect any supply disruption; and (3) advancing ongoing clinical studies. As part of this commitment, we implemented a &#8220;Work from Home Policy&#8221; in early March 2020 for employees not involved in business-critical activities. For employees involved in business-critical activities, we implemented safety measures designed to comply with federal, state and local guidelines.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the impact of COVID-19, we initially paused enrollment of new patients in several of our clinical trials. Beginning in the third quarter of 2020, we began enrolling patients in our HD and CAH studies. To date, we have not experienced any interruption of our supply of drug products needed to support our ongoing clinical studies, but we expect that completion and data readouts for several of our ongoing and planned studies will be delayed.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to believe that existing funds, cash generated from operations, and existing sources of and access to financing are adequate to satisfy our needs for working capital, capital expenditures, debt service requirements and other business development initiatives that we plan to strategically pursue. However, should the COVID-19 pandemic and any associated recession or depression continue for a prolonged period, our results of operations, financial condition, liquidity and cash flows could be materially impacted by lower revenues and profitability and a lower likelihood of effectively and efficiently developing new medicines.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the Three and Nine Months Ended September&#160;30, 2020 and 2019</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues by category.</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">in millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">752.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">515.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">544.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales, Net. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales were $254.1 million and $752.8 million for the three and nine months ended September&#160;30, 2020, respectively, compared with $198.1 million and $515.0 million in the comparable periods last year, reflecting increased INGREZZA net product sales primarily driven by new patient additions. ONGENTYS net product sales were $0.1 million for the three and nine months ended September&#160;30, 2020.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue reflects the achievement of certain development, regulatory and commercial milestones, royalties received on any net sales of ORILISSA and ORIAHNN and license fees earned under our collaboration agreements with AbbVie and Mitsubishi Tanabe Pharma Corporation, or MTPC. Collaboration revenue was $4.4 million and $45.2 million for the three and nine months ended September&#160;30, 2020, respectively, compared with $24.0 million and $29.0 million in the comparable periods last year, primarily reflecting the achievement of a $30.0 million regulatory milestone associated with AbbVie&#8217;s receipt of FDA approval for ORIAHNN for uterine fibroids in May 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales was $2.7 million and $7.2 million for the three and nine months ended September&#160;30, 2020, respectively, compared with $2.2 million and $4.9 million in the comparable periods last year.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We support our drug discovery and development efforts through the commitment of significant resources to discovery, R&amp;D programs and business development opportunities.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs are reflected in the applicable development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same reporting period. For several of our programs, the R&amp;D activities are part of our collaborative and other relationships.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Late stage consists of costs incurred related to product candidates in Phase II registrational studies and onwards. Early stage consists of costs incurred related to product candidates in post-investigational new drug application, or IND, through Phase II non-registrational studies. Research and discovery consists of pre-IND costs. Milestone expenses reflect payments made in connection with our collaborative and other relationships. Payroll and benefits consists of costs incurred for salaries and wages, payroll taxes, benefits and share-based compensation associated with employees involved in ongoing R&amp;D activities. Share-based compensation may fluctuate from period to period based on factors that are not within our control, such as our stock price on the dates share-based grants are issued. Facilities and other consists of indirect costs incurred in support of overall R&amp;D activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses. These costs are not allocated to a specific program or stage.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents R&amp;D expense by category:</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Late stage</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Early stage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and discovery</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payroll and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Facilities and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total R&amp;D expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expense was $69.1 million and $208.3 million for the three and nine months ended September&#160;30, 2020, respectively, compared with $45.3 million and  $144.7 million in the comparable periods last year, primarily reflecting increased investment to support advancing our expanded clinical portfolio and increased personnel expenses on higher headcount.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Idorsia, we recorded a charge of $46.0 million, accounted for as in-process research and development, or IPR&amp;D, in the second quarter of 2020. In the third quarter of 2020, we recorded a charge of $118.5 million, accounted for as IPR&amp;D, in connection with the payment of the upfront fee pursuant to our exclusive license agreement with Takeda. In connection with the payments of the upfront fees pursuant to our collaboration and license agreement with Voyager, we recorded charges of $118.1 million, accounted for as IPR&amp;D, in the first nine months of 2019.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales, General and Administrative. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales, general and administrative, or SG&amp;A, expense was $112.5 million and $326.8 million for the three and nine months ended September&#160;30, 2020, respectively, compared with $84.5 million and $252.8 million in the comparable periods last year, primarily reflecting increased personnel expenses on higher headcount and continued investment in INGREZZA marketing.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Expense, Net </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net, was $12.8 million and $31.7 million for the three months ended September&#160;30, 2020 and 2019, respectively. For the nine months ended September&#160;30, 2020, other expense, net, was $26.2 million, compared with $15.6 million in the comparable period last year. Periodic fluctuations in other expense, net, primarily reflect unrealized gains or losses recognized to adjust our equity investments in Voyager and Xenon Pharmaceuticals Inc. to fair value.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for income taxes was $0.5 million and $5.6 million for the three and nine months ended September&#160;30, 2020, respectively, compared with $4.6 million and $4.9 million in the comparable periods last year. At September&#160;30, 2020 and 2019, we had full valuation allowances against our net deferred tax assets as realization was uncertain. As a result, tax expense for the three and nine months ended September&#160;30, 2020 and 2019, respectively, varies from the statutory tax rate primarily due to changes in our valuation allowances, net of other permanent book/tax differences, tax credits generated and impacts of changes in tax laws.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net (Loss) Income</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred a net loss of  $57.6 million, or $0.62 diluted net loss per share, for the three months ended September&#160;30, 2020, compared with net income of $53.8 million, or $0.56 diluted earnings per share, in the comparable period last year. For the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September&#160;30, 2020, net income was $59.4 million, or $0.61 diluted earnings per share, compared with $3.0 million, or $0.03 diluted earnings per share, in the comparable period last year.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, our cash and cash equivalents and debt securities available-for-sale totaled $1.1&#160;billion compared with $970.2 million at December&#160;31, 2019.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities was $139.6 million for the nine months ended September&#160;30, 2020, compared with $49.5 million in the comparable period last year, primarily reflecting increased INGREZZA net product sales offset partially by increased upfront payments in connection with our collaborations with Idorsia and Takeda.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $151.8 million for the nine months ended September&#160;30, 2020, compared with net cash used in investing activities of $44.9 million in the comparable period last year, reflecting timing differences related to purchases, sales and maturities of debt securities available-for-sale, changes in our portfolio-mix, and an equity investment of $54.7 million in Voyager in March 2019.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $21.6 million for the nine months ended September&#160;30, 2020, compared with $20.0 million in the comparable period last year, reflecting proceeds from issuances of our common stock.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, we issued $517.5 million of 2.25% convertible senior notes due May 15, 2024.</span></div><div style="margin-bottom:4pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:4pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any off-balance sheet arrangements at September&#160;30, 2020 or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes to our critical accounting policies as disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to interest rate risk on our short-term investments. The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest in highly liquid and high-quality government and other debt securities. To minimize our exposure due to adverse shifts in interest rates, we invest in short-term securities and ensure that the maximum average maturity of our investments does not exceed twelve months. If a 1% change in interest rates were to have occurred on September&#160;30, 2020, it would not have had a material effect on the fair value of our investment portfolio as of that date. Due to the short holding period of our investments, we have concluded that we do not have a material financial market risk exposure.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a summary of new accounting pronouncements which may be applicable to us, see Note 1 to the condensed consolidated financial statements included in this report.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements that involve a number of risks and uncertainties. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements can be identified by the use of forward-looking words such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;hopes,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;plan,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;continue,&#8221; &#8220;seeks,&#8221; &#8220;proforma,&#8221; or &#8220;anticipates,&#8221; or other similar words (including their use in the negative), or by discussions of future matters such as the development of new products, technology enhancements, possible changes in legislation and other statements that are not historical. These statements include but are not limited to statements under the captions &#8220;Risk Factors,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; as well as other sections in this report. You should be aware that the occurrence of any of the events discussed under the heading in Part II titled &#8220;Item 1A. Risk Factors&#8221; and elsewhere in this report could substantially harm our business, results of operations and financial condition and that if any of these events occurs, the trading price of our common stock could decline and you could lose all or a part of the value of your shares of our common stock.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cautionary statements made in this report are intended to be applicable to all related forward-looking statements wherever they may appear in this report. We urge you not to place undue reliance on these forward-looking statements, which </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">speak only as of the date of this report. Except as required by law, we assume no obligation to update our forward-looking statements, even if new information becomes available in the future.</span></div><div id="i01dca92a9a894c839fd91f8b5b3beba6_67"></div><div style="margin-bottom:4pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A discussion of our exposure to, and management of, market risk appears in Part I, Item&#160;2 of this Quarterly Report on Form&#160;10-Q&#160;under the heading &#8220;Interest Rate Risk.&#8221;</span></div><div id="i01dca92a9a894c839fd91f8b5b3beba6_70"></div><div style="margin-bottom:4pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports required by the Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the timelines specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by SEC Rule 13a-15(b), we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the quarter covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An evaluation was also performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of any changes to our internal control over financial reporting that occurred during our last fiscal quarter and that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Our evaluation did not identify significant changes in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) that occurred during the quarter ended September&#160;30, 2020, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i01dca92a9a894c839fd91f8b5b3beba6_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Part II. Other Information</span></div><div id="i01dca92a9a894c839fd91f8b5b3beba6_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following information sets forth risk factors that could cause our actual results to differ materially from those contained in forward-looking statements we have made in this Quarterly Report on Form 10-Q and those we may make from time to time. If any of the following risks actually occur, our business, operating results, prospects or financial condition could be harmed. Additional risks not presently known to us, or that we currently deem immaterial, may also affect our business operations. The risk factors set forth below with an asterisk (*) contain changes to the risk factors set forth in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2019.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks and uncertainties related to our business, many of which are beyond our control.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, risks associated with our business include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to successfully commercialize INGREZZA, ONGENTYS, or any of our product candidates if they are approved in the future.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If physicians and patients do not continue to accept INGREZZA or do not accept ONGENTYS or any of our other products, or our sales and marketing efforts are not effective, we may not generate sufficient revenue.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Governmental and third-party payors may impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products that could limit our product revenues and delay sustained profitability.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business could be adversely affected by the effects of health pandemics or epidemics, including the COVID-19 pandemic, in regions where we or third parties on which we rely have significant sales and marketing efforts or manufacturing facilities, concentrations of clinical trial sites or other business operations, or materially affect our operations, and at our clinical trial sites, as well as the business or operations of our manufacturers, CROs or other third parties with whom we conduct business.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because the development of our product candidates is subject to a substantial degree of technological uncertainty, we may not succeed in developing any of our product candidates.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials may be delayed for safety or other reasons, or fail to demonstrate the safety and efficacy of our product candidates, which could prevent or significantly delay their regulatory approval.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Use of our approved products or those of our collaborators, including INGREZZA, ONGENTYS, ORILISSA, and ORIAHNN could be associated with side effects or adverse events.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently have no manufacturing capabilities. If third-party manufacturers of INGREZZA, ONGENTYS or any of our product candidates fail to devote sufficient time and resources to our concerns, or if their performance is substandard, our clinical trials and product introductions may be delayed, and our costs may rise.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently depend on a limited number of third-party suppliers. The loss of these suppliers, or delays or problems in the supply of INGREZZA or ONGENTYS, could materially and adversely affect our ability to successfully commercialize INGREZZA or ONGENTYS.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to retain and recruit qualified scientists or if any of our key senior executives discontinues his or her employment with us, it may delay our development efforts or impact our commercialization of INGREZZA, ONGENTYS or any product candidate approved by the FDA.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We license some of our core technologies and drug candidates from third parties. If we default on any of our obligations under those licenses, or violate the terms of these licenses, we could lose our rights to those technologies and drug candidates or be forced to pay damages.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a history of losses and expect to increase our expenses for the foreseeable future, and we may not be able to sustain profitability.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have recently increased the size of our organization and will need to continue to increase the size of our organization. We may encounter difficulties with managing our growth, which could adversely affect our results of operations.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our customers are concentrated and therefore the loss of a significant customer may harm our business.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we cannot raise additional funding, we may be unable to complete development of our product candidates or establish commercial and manufacturing capabilities in the future.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health care reform measures and other recent legislative initiatives could adversely affect our business.</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to protect our intellectual property, our competitors could develop and market products based on our discoveries, which may reduce demand for our products.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Company</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We may not be able to continue to successfully commercialize INGREZZA, or any of our product candidates if they are approved in the future.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to produce INGREZZA revenues consistent with expectations ultimately depends on our ability to sell our products and secure adequate third-party reimbursement if and when they are approved by the FDA. Our experience in marketing and selling pharmaceutical products began with INGREZZA&#8217;s approval in 2017, when we hired our sales force and established our distribution and reimbursement capabilities, all of which are necessary to successfully commercialize our current and future products. We have continued to invest in our commercial infrastructure and distribution capabilities in the past three years, including our sales force expansion in late 2018. While our team members and consultants have experience marketing and selling pharmaceutical products, we may face difficulties related to managing the rapid growth of our personnel and infrastructure, and there can be no guarantee that we will be able to maintain the personnel, systems, arrangements and capabilities necessary to successfully commercialize INGREZZA, ONGENTYS or any product candidate approved by the FDA in the future. </span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our business has been and may continue to be adversely affected by the effects of health pandemics or epidemics, including the ongoing COVID-19 pandemic. Most hospitals, community mental health facilities, and other healthcare facilities have implemented policies that limit access of our sales representatives, medical affairs personnel, and patients to such facilities. Due to these closures and our work from home decisions, our field force is currently functioning utilizing digital and telephonic engagement tools and tactics, which may be less effective than our ordinary course sales and marketing programs. If we fail to maintain successful marketing, sales and reimbursement capabilities, our product revenues may suffer.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*If physicians and patients do not continue to accept INGREZZA or do not accept ONGENTYS or any of our other products, or our sales and marketing efforts are not effective, we may not generate sufficient revenue.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of INGREZZA, ONGENTYS or any of our other products, if approved for marketing, will depend upon the acceptance of those products as safe and effective by the medical community and patients.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market acceptance of INGREZZA, ONGENTYS or any of our other products could be affected by a number of factors, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of receipt of marketing approvals for indications;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety and efficacy of the products;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing of our products;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of healthcare payor coverage and adequate reimbursement for the products;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public perception regarding any gene therapy products we may develop;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of existing competitor products addressing our target markets or the emergence of equivalent or superior products; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost-effectiveness of the products.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the medical community and patients do not ultimately accept our products as being safe, effective, superior and/or cost-effective, we may not generate sufficient revenue.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Governmental and third-party payors may impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products that could limit our product revenues and delay sustained profitability.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize any products successfully, including INGREZZA and ONGENTYS, will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available. The continuing efforts of government and third-party payors to contain or reduce the costs of health care through various means may reduce our potential revenues. These payors&#8217; efforts could decrease the price that we receive for any products we may develop and sell in the future.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available regardless of whether they are approved by the FDA for that particular use.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities and other third-party payors are developing increasingly sophisticated methods of controlling healthcare costs, such as by limiting coverage and the amount of reimbursement for particular medications. Further, no uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the US. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. In addition, communications from government officials regarding health care costs and pharmaceutical pricing could have a negative impact on our stock price, even if such communications do not ultimately impact coverage or reimbursement decisions for our products.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may also be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. In addition, gene therapy treatments, which we are developing pursuant to our collaboration and license agreement with Voyager, face additional uncertainty related to pricing and reimbursement. As an example, there are a limited number of gene therapy products currently approved for coverage and reimbursement by the Centers for Medicare &amp; Medicaid Services, or CMS.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize INGREZZA, ONGENTYS or any other product candidate for which we obtain marketing approval. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Our business could be adversely affected by the effects of health pandemics or epidemics, including the COVID-19 pandemic, in regions where we or third parties on which we rely have significant sales and marketing efforts or manufacturing facilities, concentrations of clinical trial sites or other business operations, or materially affect our operations, and at our clinical trial sites, as well as the business or operations of our manufacturers, CROs or other third parties with whom we conduct business.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health pandemics or epidemics in regions where we have concentrations of clinical trial sites or other business operations, and could cause significant disruption in the operations of third-party manufacturers and CROs upon whom we rely. As a result of the ongoing COVID-19 pandemic, we may experience disruptions that could severely impact our supply chain, ongoing and future clinical trials and commercialization of INGREZZA and ONGENTYS. For example, COVID-19 has resulted in increased travel restrictions and the shutdown or delay of business activities in various regions, including San Diego, California, where our headquarters are located. In response to state and local restrictions, we implemented work-from-home policies for all employees except certain key essential members involved in business-critical activities.&#160;The effects of the stay at home order and our work-from-home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations due to COVID-19 could negatively impact our business, operating results and financial condition.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarantines, stay at home orders and other state and local restrictions, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases, could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, clinical site initiation and patient enrollment may be delayed due to concerns for patient safety and prioritization of healthcare resources toward the COVID-19 pandemic. Some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients, principal investigators and site staff (who as healthcare providers may have heightened exposure to COVID-19) may be hindered, which would adversely impact our clinical trial operations. For example, due to the impact of the COVID-19 pandemic, we initially paused enrollment of new patients in several of our clinical trials.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since then, we have recently begun enrolling patients again in the Phase III study of valbenazine for chorea in Huntington disease and the Phase IIa pediatric study of crinecerfont in CAH.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, increases in COVID-19 cases or hospitalizations in the future could cause us to again limit or suspend our patient enrollment and screening activities.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, the pandemic is currently resulting in disruption of global financial markets. This disruption, if sustained or recurrent, could make it more difficult for us to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global COVID-19 pandemic continues to rapidly evolve. The ultimate impact of the COVID-19 pandemic or a similar health pandemic or epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. These effects could have a material impact on our operations.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Because the development of our product candidates is subject to a substantial degree of technological uncertainty, we may not succeed in developing any of our product candidates.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are currently in research or clinical development with the exceptions of INGREZZA, which has been approved by the FDA for TD, ONGENTYS, which has been approved by the FDA for Parkinson&#8217;s disease, ORILISSA (partnered with AbbVie), which has been approved by the FDA for the management of moderate to severe endometriosis pain in women, and ORIAHNN (partnered with AbbVie), which has been approved by the FDA for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Only a small number of research and development programs ultimately result in commercially successful drugs. In addition, to date the FDA has granted regulatory approval for only a very limited number of gene therapy products. Potential products that appear to be promising at early stages of development may not reach the market for a number of reasons. These reasons include the possibilities that the potential products may:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be found ineffective or cause harmful side effects during preclinical studies or clinical trials;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fail to receive necessary regulatory approvals on a timely basis or at all;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be precluded from commercialization by proprietary rights of third parties;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be difficult to manufacture on a large scale; or</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be uneconomical to commercialize or fail to achieve market acceptance.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates encounters any of these potential problems, we may never successfully market that product candidate.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Our clinical trials may be delayed or fail to demonstrate the safety and efficacy of our product candidates, which could prevent or significantly delay their regulatory approval.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining regulatory approval for the sale of any of our potential products, we must subject these product candidates to extensive preclinical and clinical testing to demonstrate their safety and efficacy for humans. Clinical trials are expensive, time-consuming and may take years to complete.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the clinical trials of our product candidates, we face the risks that:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or similar foreign regulatory authority may not allow an IND application or foreign equivalent filings required to initiate human clinical studies for our drug candidates or the FDA may require additional preclinical studies as a condition of the initiation of Phase I clinical studies, or additional clinical studies for progression from Phase&#160;I to Phase&#160;II, or Phase&#160;II to Phase&#160;III, or for NDA approval;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product candidate may not prove to be effective or as effective as other competing product candidates;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may discover that a product candidate may cause harmful side effects or results of required toxicology studies may not be acceptable to the FDA;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results may not replicate the results of earlier, smaller trials;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or similar foreign regulatory authorities may require use of new or experimental endpoints that may prove insensitive to treatment effects;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or the FDA or similar foreign regulatory authorities may suspend the trials;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results may not be statistically significant;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient recruitment may be slower than expected;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may not accept the data from any trial or trial site outside of the US;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients may drop out of the trials;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen disruptions or delays may occur, caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory requirements may change.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risks and uncertainties impact all of our clinical programs and any of the clinical, regulatory or operational events described above could change our planned clinical and regulatory activities. For example, due to the impact of the COVID-19 pandemic, we paused enrollment of new patients in several of our clinical trials, and increases in COVID-19 cases or hospitalizations in the future could cause us to further limit or suspend our patient enrollment and screening activities. Additionally, any of these events described above could result in suspension of a program and/or obviate any filings for necessary regulatory approvals.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, late-stage clinical trials are often conducted with patients having the most advanced stages of disease. During the course of treatment, these patients can die or suffer other adverse medical effects for reasons that may not be related to the pharmaceutical agent being tested but which can nevertheless adversely affect clinical trial results. Any failure or substantial delay in completing clinical trials for our product candidates may severely harm our business.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy for fully developing and commercializing ORILISSA and ORIAHNN is dependent upon maintaining our current collaboration agreement with AbbVie. This collaboration agreement provides for significant future payments should certain development, regulatory and commercial milestones be achieved, and royalties on future sales of elagolix. Under this agreement, AbbVie is responsible for, among other things, conducting clinical trials and obtaining required regulatory approvals for elagolix; as well as manufacturing and commercialization of ORILISSA and ORIAHNN.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of our reliance on AbbVie for the commercialization and continued development of ORILISSA and ORIAHNN, there could be substantial impairments if AbbVie:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">does not successfully commercialize ORILISSA for endometriosis or ORIAHNN for uterine fibroids;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">does not conduct its collaborative activities in a timely manner;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">does not devote sufficient time and resources to our partnered programs;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">terminates its agreement with us;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develops, either alone or with others, products that may compete with elagolix;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes our respective allocations of rights to any products or technology developed during our collaboration; or</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">merges with a third party that wants to terminate our agreement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are a party to several other collaboration and license agreements, including our agreements with BIAL, MTPC, Voyager, Xenon, Idorsia and Takeda. These collaborations are subject to risks and uncertainties similar to those described above. In some situations, we may not be able to influence our collaboration partners&#8217; decisions regarding the development and collaboration of our partnered product products and product candidates, and as a result, our collaboration partners may not pursue or prioritize the development and commercialization of those partnered products and product candidates in a manner that is in our best interest. We may also need to enter into other licensing collaborations to assist in the development and commercialization of other product candidates we are developing now or may develop in the future, and any such future collaborations would be subject to similar risks and uncertainties.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These issues and possible disagreements with our current or any future corporate collaborators could lead to delays in the collaborative research, development or commercialization of our product candidates. Furthermore, disagreements with these parties could require or result in litigation or arbitration, which would be time-consuming and expensive. If any of these issues arise, it may delay the development and commercialization of drug candidates and, ultimately, our generation of product revenues.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We may not be able to successfully commercialize ONGENTYS.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we received FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson&#8217;s disease patients, and in September 2020, we launched the commercial sale of ONGENTYS with our existing INGREZZA infrastructure. The successful commercialization of ONGENTYS is subject to many risks, and there are numerous examples of unsuccessful product launches and failures, including by pharmaceutical companies with more experience and resources than us. If we are unable to effectively train our employees and equip them with effective materials, including medical and sales literature to help them inform and educate health care practitioners about the benefits of ONGENTYS and its proper administration, our commercialization of ONGENTYS may not be successful. Even if we are successful in effectively training and equipping our sales force, there are many factors that could cause the commercialization of ONGENTYS to be unsuccessful, including a number of factors that are outside our control. Health care practitioners may not prescribe ONGENTYS and patients may be unwilling to use ONGENTYS if insurance coverage is not provided or reimbursement is inadequate. In addition, our ability to train our employees and effectively communicate with potential prescribers could be adversely affected by the effects of health pandemics or epidemics, including the ongoing COVID-19 pandemic.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Use of our approved products or those of our collaborators, including INGREZZA, ONGENTYS, ORILISSA, and ORIAHNN could be associated with side effects or adverse events.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with most pharmaceutical products, use of our approved products or those of our collaborators, including INGREZZA, ONGENTYS, ORILISSA, and ORIAHNN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could be associated with side effects or adverse events which can vary in severity (from minor adverse reactions to death) and frequency (infrequent or prevalent). Side effects or adverse events associated with the use of our products or those of our collaborators may be observed at any time, including after a product is commercialized, and reports of any such side effects or adverse events may negatively impact demand for our or our collaborators&#8217; products or affect our or our collaborators&#8217; ability to maintain regulatory approval for such products. Side effects or other safety issues associated with the use of our approved products or those of our collaborators could require us or our collaborators to modify or halt commercialization of these products or expose us to product liability lawsuits which will harm our business. We or our collaborators may be required by regulatory agencies to conduct additional studies regarding the safety and efficacy of our products which we have not planned or anticipated. Furthermore, there can be no assurance that we or our collaborators will resolve any issues related to any product related adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Gene therapy treatments, which we are developing pursuant to our collaboration and license agreement with Voyager, may be perceived as unsafe or may result in unforeseen adverse events. Negative public opinion and increased regulatory scrutiny of gene therapy may adversely affect our ability to initiate or continue clinical development or obtain regulatory approvals for gene therapy product candidates or the commercialization of gene therapy products.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gene therapy remains a novel technology, with few gene therapy products approved to date in the US. Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">medical community. As part of our collaboration and license agreement with Voyager, RESTORE-1, a Phase II clinical trial of NBIb-1817, is being conducted. There is no guarantee that this program or other collaboration gene therapy product candidates will not be placed on clinical hold by the FDA, as has been the case for many gene therapy clinical programs. In November 2020, the Drug Safety Monitoring Board reviewed certain patient imaging data, and asked for additional patient data as well as recommended that we discontinue dosing of subjects in the RESTORE-1 clinical trial until these additional data can be reviewed. Based in part on the data, we are preparing an expedited IND safety report. Even if we are able to successfully complete clinical development of a gene therapy product and obtain commercial approval, the success of our collaboration with Voyager will depend upon physicians who specialize in the treatment of genetic diseases targeted by gene therapy product candidates, prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are familiar and for which greater clinical data may be available. More restrictive government regulations, negative public opinion related to gene therapy products, or safety issues identified in our clinical trials may delay or impair the development and commercialization of our gene therapy product candidates or demand for any gene therapy products we develop.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The limited precedent for gene therapy approvals makes it difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for the product candidates we are developing through our collaboration with Voyager.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has limited experience in the review and approval of gene therapy products. The limited precedent for gene therapy approvals makes it difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for the product candidates we are developing through our collaboration with Voyager.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory requirements governing gene therapy products have changed frequently and may continue to change in the future. As a result, the regulatory review process may take longer or cost more than we anticipate, including requirements for additional preclinical studies or clinical trials, and delay or prevent approval and commercialization of our gene therapy product candidates we are developing through our collaboration with Voyager. While the FDA has issued draft guidance for the development of gene therapies and proposed rules that would streamline certain requirements to which gene therapies are currently subject, it remains to be seen as to whether such initiatives will ultimately increase the speed of drug development in gene therapies such as the product candidates we are developing through our collaboration with Voyager.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue, and our business, financial condition, results of operations and prospects would be harmed. If our gene therapy products are approved but fail to achieve market acceptance among physicians, patients, hospitals, third-party payors or others in the medical community, we will not be able to generate significant revenue.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are subject to rapid and intense technological change. We face, and will continue to face, competition in the development and marketing of our products and product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition may also arise from, among other things:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other drug development technologies;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">methods of preventing or reducing the incidence of disease, including vaccines; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new small molecule or other classes of therapeutic agents.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developments by others may render our product candidates or technologies obsolete or noncompetitive.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are commercializing and performing research on or developing products for the treatment of several disorders including endometriosis, TD, uterine fibroids, essential tremor, classic congenital adrenal hyperplasia, pain, Parkinson&#8217;s disease, Friedreich&#8217;s ataxia, and other neurological and endocrine-related diseases and disorders, and there are a number of competitors to our products and product candidates. If one or more of our competitors&#8217; products or programs are successful, the market for our products may be reduced or eliminated.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With respect to INGREZZA for TD, we compete with Teva Pharmaceutical Industries, which received FDA approval for AUSTEDO to treat TD in August 2017, and several clinical development-stage programs targeting TD and related movement disorders. Additionally, there are a number of commercially available medicines used to treat TD off-label, such as Xenazine (tetrabenazine) and generic equivalents, and various antipsychotic medications (e.g., clozapine), anticholinergics, benzodiazepines (off-label), and botulinum toxin.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In endometriosis, ORILISSA and ORIAHNN each compete with several FDA-approved products for the treatment of endometriosis, uterine fibroids, infertility, and central precocious puberty. Additionally, there is also competition </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from surgical intervention, including hysterectomies and ablations. Separate from these options, there are many programs in clinical development which serve as potential future competition. Lastly, there are numerous medicines used to treat the symptoms of disease (vs. endometriosis or uterine fibroids directly) which may also serve as competition: oral contraceptives, NSAIDs and other pain medications including opioids.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With respect to ONGENTYS for Parkinson&#8217;s disease, there are currently two other FDA-approved COMT inhibitors. ONGENTYS competes directly with these two drugs and their generic equivalents. Additionally, there are a number of alternative adjunctive treatment options (FDA-approved and in clinical development) for Parkinson&#8217;s patients which compete with ONGENTYS, including various L-dopa preparations, dopamine agonists, MAO-B inhibitors and others. In terms of potential future competition, there are several programs in late-stage clinical development.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As for CAH, high doses of corticosteroids are the current standard of care to both correct the endogenous cortisol deficiency as well as reduce the excessive ACTH levels. In the US alone, there are more than two dozen companies manufacturing steroid-based products. Additionally, there are several companies developing medicinal treatments for CAH.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our investigational therapies for potential use in epilepsy may in the future compete with numerous approved products and development-stage programs being pursued by several companies.</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our development programs using Voyager&#8217;s proprietary gene therapy platform (NBIb-1817 for Parkinson&#8217;s disease and the Friedreich&#8217;s ataxia program) may in the future compete with development-stage programs being pursued by numerous companies.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared to us, many of our competitors and potential competitors have substantially greater:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">capital resources;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">research and development resources, including personnel and technology;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory experience;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical study and clinical testing experience;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing, marketing and distribution experience; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production facilities.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We currently have no manufacturing capabilities. If third-party manufacturers of INGREZZA, ONGENTYS or any of our product candidates fail to devote sufficient time and resources to our concerns, or if their performance is substandard, our clinical trials and product introductions may be delayed, and our costs may rise.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past utilized, and intend to continue to utilize, third-party manufacturers to produce the drug compounds we use in our clinical trials and for the commercialization of our products. We have limited experience in manufacturing products for commercial purposes and do not currently have any manufacturing facilities. Establishing internal commercial manufacturing capabilities would require significant time and resources, and we may not be able to timely or successfully establish such capabilities. Consequently, we depend on, and will continue to depend on, several contract manufacturers for all production of products for development and commercial purposes, including INGREZZA and ONGENTYS. If we are unable to obtain or retain third-party manufacturers, we will not be able to develop or commercialize our products, including INGREZZA and ONGENTYS. The manufacture of our products for clinical trials and commercial purposes is subject to specific FDA regulations, including current Good Manufacturing Practice regulations. Our third-party manufacturers, including BIAL and its suppliers, might not comply with FDA regulations relating to manufacturing our products for clinical trials and commercial purposes or other regulatory requirements now or in the future. In addition, the manufacture of gene therapy products, which will be necessary under our collaboration and license agreement with Voyager, is technically complex and necessitates substantial expertise and capital investment. Our reliance on contract manufacturers also exposes us to the following risks:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">contract manufacturers may encounter difficulties in achieving volume production, quality control or quality assurance, and also may experience shortages in qualified personnel. As a result, our contract manufacturers might not be able to meet our clinical schedules or adequately manufacture our products in commercial quantities when required;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">switching manufacturers may be difficult because the number of potential manufacturers is limited. It may be difficult or impossible for us to find a replacement manufacturer quickly on acceptable terms, or at all;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to successfully produce, store or distribute our products; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">drug manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the US Drug Enforcement Administration, and other agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current dependence upon third parties for the manufacture of our products may reduce our profit margin, if any, on the sale of INGREZZA, ONGENTYS, or our future products and our ability to develop and deliver products on a timely and competitive basis.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We currently depend on a limited number of third-party suppliers. The loss of these suppliers, or delays or problems in the supply of INGREZZA or ONGENTYS, could materially and adversely affect our ability to successfully commercialize INGREZZA or ONGENTYS.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of process controls required to consistently produce the active pharmaceutical ingredients, or API, and the finished product in sufficient quantities while meeting detailed product specifications on a repeated basis. Manufacturers of pharmaceutical products may encounter difficulties in production, such as difficulties with production costs and yields, process controls, quality control and quality assurance, including testing of stability, impurities and impurity levels and other product specifications by validated test methods, compliance with strictly enforced US, state, and non-US regulations, and disruptions caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic. We depend on a limited number of suppliers for the production of INGREZZA and its API. If our third-party suppliers for INGREZZA encounter these or any other manufacturing, quality or compliance difficulties, we may be unable to meet commercial demand for INGREZZA, which could materially and adversely affect our ability to successfully commercialize INGREZZA. In addition, under the terms of our agreement with BIAL, although we are responsible for the management of all ONGENTYS commercialization activities, we depend on BIAL and its suppliers to supply all drug product for the commercialization of ONGENTYS. BIAL relies on third-party contract manufacturers to produce ONGENTYS. These contract manufacturers may encounter difficulties in achieving volume production, quality control, or quality assurance. As a result, these contract manufacturers may not be able to adequately produce ONGENTYS in commercial quantities when required, which may impact our ability to deliver ONGENTYS on a timely basis.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our suppliers fail or refuse to supply us with INGREZZA or its API for any reason, it would take a significant amount of time and expense to qualify a new supplier. The FDA and similar international regulatory bodies must approve manufacturers of the active and inactive pharmaceutical ingredients and certain packaging materials used in pharmaceutical products. The loss of a supplier could require us to obtain regulatory clearance and to incur validation and other costs associated with the transfer of the API or product manufacturing processes. If there are delays in qualifying new suppliers or facilities or a new supplier is unable to meet FDA or a similar international regulatory body&#8217;s requirements for approval, there could be a shortage of INGREZZA, which could materially and adversely affect our ability to successfully commercialize INGREZZA. If BIAL is unable or refuses to supply us with ONGENTYS drug product for any reason, or does not meet FDA or international regulators&#8217; requirements for approval, we have limited opportunity to qualify a new supplier. This could materially and adversely affect our ability to successfully commercialize ONGENTYS.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The independent clinical investigators and contract research organizations that we rely upon to conduct our clinical trials may not be diligent, careful or timely, and may make mistakes, in the conduct of our trials.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on independent clinical investigators and contract research organizations, or CROs, to conduct our clinical trials under their agreements with us. The investigators are not our employees, and we cannot control the amount or timing of resources that they devote to our programs. If our independent investigators fail to devote sufficient time and resources to our drug development programs, or if their performance is substandard, or not in compliance with Good Clinical Practices, it may delay or prevent the approval of our FDA applications and our introduction of new drugs. The CROs we contract with for execution of our clinical trials play a significant role in the conduct of the trials and the subsequent collection and analysis of data. Failure of the CROs to meet their obligations could adversely affect clinical development of our products. Moreover, these independent investigators and CROs may also have relationships with other commercial entities, some of which may compete with us. If independent investigators and CROs assist our competitors at our expense, it could harm our competitive position.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not and will not have access to all information regarding the products and product candidates we licensed to AbbVie.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not and will not have access to all information regarding elagolix, including potentially material information about commercialization plans, medical information strategies, clinical trial design and execution, safety reports from clinical trials, safety reports, regulatory affairs, process development, manufacturing and other areas known by AbbVie. In addition, we have confidentiality obligations under our agreement with AbbVie. Thus, our ability to keep our shareholders informed about the status of elagolix will be limited by the degree to which AbbVie keeps us informed and allows us to disclose such information to the public. If AbbVie fails to keep us informed about commercialization efforts related to elagolix, or the status of the clinical development or regulatory approval pathway of other product candidates licensed to it, we may make operational and/or investment decisions that we would not have made had we been fully informed, which may materially and adversely affect our business and operations.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We are subject to ongoing obligations and continued regulatory review for INGREZZA. Additionally, our other product candidates, if approved, could be subject to labeling and other post-marketing requirements and restrictions.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory approvals for any of our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase IV clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. For example, with respect to the FDA&#8217;s approval of INGREZZA for TD in April 2017, we are subject to certain post-marketing requirements and commitments. In addition, with respect to INGREZZA, and any product candidate that the FDA or a comparable foreign regulatory authority approves, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current Good Manufacturing Practices for any clinical trials that we conduct post-approval. Failure to comply with these ongoing regulatory requirements, or later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, may result in, among other things:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, changes in the product&#8217;s label, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on clinical trials;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of these events may adversely affect our business, prospects and ability to achieve or sustain profitability on a sustained basis.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*If we are unable to retain and recruit qualified scientists or if any of our key senior executives discontinues his or her employment with us, it may delay our development efforts or impact our commercialization of INGREZZA, ONGENTYS or any product candidate approved by the FDA.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the principal members of our management and scientific staff. The loss of any of these people could impede the achievement of our objectives, including the successful commercialization of INGREZZA, ONGENTYS or any product candidate approved by the FDA. Furthermore, recruiting and retaining qualified scientific personnel to perform research and development work in the future, along with personnel with experience marketing and selling pharmaceutical products, is critical to our success. We may be unable to attract and retain personnel on acceptable terms given the competition among biotechnology, pharmaceutical and health care companies, universities and non-profit research institutions for experienced scientists and individuals with experience marketing and selling pharmaceutical products. We may face particular retention challenges in light of the recent rapid growth in our personnel and infrastructure and the perceived impact of those changes upon our corporate culture. In addition, we rely on a significant number of consultants to assist us in formulating our research and development strategy and our commercialization strategy. Our consultants may have commitments to, or advisory or consulting agreements with, other entities that may limit their availability to us.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*If the market opportunities for our products and product candidates are smaller than we believe they are, our revenues may be adversely affected, and our business may suffer.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the diseases that INGREZZA, ONGENTYS and our other product candidates are being developed to address are in underserved and underdiagnosed populations. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who will seek treatment utilizing our products or product candidates, may not be accurate. If our estimates of the prevalence or number of patients potentially on therapy prove to be inaccurate, the market opportunities for INGREZZA, ONGENTYS and our other product candidates may be smaller than we believe they are, our prospects for generating expected revenue may be adversely affected and our business may suffer.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We license some of our core technologies and drug candidates from third parties. If we default on any of our obligations under those licenses, or violate the terms of these licenses, we could lose our rights to those technologies and drug candidates or be forced to pay damages.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on licenses from third parties for some of our key technologies. These licenses typically subject us to various commercialization, reporting and other obligations. If we fail to comply with these obligations, we could lose important rights. If we were to default on our obligations under any of our licenses, we could lose some or all of our rights to develop, market and sell products covered by these licenses. For example, BIAL may terminate our license agreement, pursuant to which we have rights to commercialize ONGENTYS, if we fail to use commercially reasonable efforts to comply with specified obligations under the license agreement, or if we otherwise breach the license agreement. In addition, several of our collaboration and license agreements allow our licensors to terminate such agreements if we challenge the validity or enforceability of certain intellectual property rights or if we commit a material breach in whole or in part of the agreement and do not cure such breach within the agreed upon cure period. In addition, if we were to violate any of the terms of our licenses, we could become subject to damages. Likewise, if we were to lose our rights under a license to use proprietary research tools, it could adversely affect our existing collaborations or adversely affect our ability to form new collaborations. We also face the risk that our licensors could, for a number of reasons, lose patent protection or lose their rights to the technologies we have licensed, thereby impairing or extinguishing our rights under our licenses with them.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have sold $517.5&#160;million aggregate principal amount of 2.25% convertible senior notes due May 15, 2024, or the 2024 Notes. We may also incur additional indebtedness to meet future financing needs. Our indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increasing our vulnerability to adverse economic and industry conditions;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limiting our ability to obtain additional financing;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring the dedication of a substantial portion of our cash flow from operations to service our indebtedness, which will reduce the amount of cash available for other purposes;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limiting our flexibility to plan for, or react to, changes in our business;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diluting the interests of our existing stockholders as a result of issuing shares of our common stock upon conversion of the 2024 Notes; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due under the 2024 Notes and any additional indebtedness that we may incur. In addition, our cash needs may increase in the future. In addition, any future indebtedness that we may incur may contain financial and other restrictive covenants that limit our ability to operate our business, raise capital or make payments under our other indebtedness. If we fail to comply with these covenants or to make payments under our indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that and our other indebtedness becoming immediately payable in full.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*The conditional conversion feature of the 2024 Notes may adversely affect our financial condition, operating results, or liquidity.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conditional conversion feature of the 2024 Notes was triggered as of September 30, 2020, meaning holders of 2024 Notes are entitled to convert their 2024 Notes at any time during the period beginning on October 1, 2020, and ending at the close of business on December 31, 2020. The conditional conversion feature may also be triggered again in the future. If one or more of the holders of the 2024 Notes elects to convert their notes, unless we satisfy our conversion obligation by </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">delivering only shares of our common stock, we would be required to settle all or a portion of our conversion obligation through the payment of cash, which could adversely affect our liquidity. The conditional convertibility of the 2024 Notes will be monitored at each quarterly reporting date and analyzed dependent upon market prices of our common stock during the prescribed measurement periods.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We have a history of losses and expect to increase our expenses for the foreseeable future, and we may not be able to sustain profitability.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant net losses and negative cash flow from operations. At December 31, 2019, we had an accumulated deficit of $1.1 billion as a result of historical operating losses.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2017, we received FDA approval of INGREZZA for TD. In July 2018, our partner AbbVie received FDA approval for ORILISSA for the management of moderate to severe endometriosis pain in women. In April 2020, we received FDA approval of ONGENTYS for Parkinson&#8217;s disease. In May 2020, our partner AbbVie received FDA approval for ORIAHNN for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. However, we have not yet obtained regulatory approvals for any other product candidates. Even if we continue to succeed in commercializing INGREZZA, or if we successfully commercialize ONGENTYS or are successful in developing and commercializing any of our other product candidates, we may not be able to sustain profitability. We also expect to continue to incur significant operating and capital expenditures as we:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialize INGREZZA for TD;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialize ONGENTYS for Parkinson&#8217;s disease;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approvals for our product candidates;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop, formulate, manufacture and commercialize our product candidates;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-license or acquire new product development opportunities;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">implement additional internal systems and infrastructure; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional clinical, scientific, sales and marketing personnel.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to increase our expenses and other investments in the coming years as we fund our operations, in-licensing or acquisition opportunities, and capital expenditures. While we were profitable for the nine months ended September 30, 2020, we were not profitable for the three months ended September 30, 2020, and our future operating results and profitability may fluctuate from period to period due to the factors described above, and we will need to generate significant revenues to achieve and maintain profitability and positive cash flow on a sustained basis. We may not be able to generate these revenues, and we may never achieve profitability on a sustained basis in the future. Our failure to maintain or increase profitability on a sustained basis could negatively impact the market price of our common stock.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We have recently increased the size of our organization and will need to continue to increase the size of our organization. We may encounter difficulties with managing our growth, which could adversely affect our results of operations.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020, we had approximately 825 full-time employees. Although we have substantially increased the size of our organization, we may need to add additional qualified personnel and resources, especially now that we have a commercial sales force. Our current infrastructure may be inadequate to support our development and commercialization efforts and expected growth. Future growth will impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional employees, and may take time away from running other aspects of our business, including development and commercialization of our product candidates.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to commercialize INGREZZA, ONGENTYS and any other product candidates that receive regulatory approval will depend, in part, on our ability to manage any future growth effectively. In particular, as we commercialize INGREZZA and ONGENTYS, we will need to support the training and ongoing activities of our sales force and will likely need to continue to expand the size of our employee base for managerial, operational, financial and other resources. To that end, we must be able to successfully:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage our development efforts effectively;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">integrate additional management, administrative and manufacturing personnel;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further develop our marketing and sales organization; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain sufficient administrative, accounting and management information systems and controls.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to accomplish these tasks or successfully manage our operations and, accordingly, may not achieve our research, development, and commercialization goals. Our failure to accomplish any of these goals could harm our financial results and prospects.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is commonplace in the biotechnology industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Because our operating results may vary significantly in future periods, our stock price may decline.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly revenues, expenses and operating results have fluctuated in the past and are likely to fluctuate significantly in the future. Our financial results are unpredictable and may fluctuate, for among other reasons, due to seasonality and timing of customer purchases and commercial sales of INGREZZA, impact of the commercial launch of ONGENTYS and ORIAHNN, royalties from out-licensed products, the impact of Medicare Part D coverage, our achievement of product development objectives and milestones, clinical trial enrollment and expenses, research and development expenses and the timing and nature of contract manufacturing, contract research payments and disruptions caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic. A high portion of our costs are predetermined on an annual basis, due in part to our significant research and development costs. Thus, small declines in revenue could disproportionately affect financial results in a quarter. While we were not profitable for the three months ended September&#160;30, 2020, our future operating results and profitability may fluctuate from period to period, and even if we become profitable on a quarterly or annual basis, we may not be able to sustain or increase our profitability. Moreover, as our company and our market capitalization have grown, our financial performance has become increasingly subject to quarterly and annual comparisons with the expectations of securities analysts or investors. The failure of our financial results to meet these expectations, either in a single quarterly or annual period over a sustained period time, could cause our stock price to decline.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flows, financial condition or results of operations.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business and financial condition. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, or the Tax Act, enacted many significant changes to the US tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act repealed or modified in future legislation. For example, the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future US tax expense.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Our ability to use net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net operating loss, or NOL, carryforwards generated in tax years ending on or prior to December 31, 2017, are only permitted to be carried forward for 20 years under applicable US tax law. Under the Tax Cut and Jobs Act, as modified by the CARES Act, our federal NOLs generated in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs in tax years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to the Tax Cut and Jobs Act or the CARES Act. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. We do not believe we have experienced any previous ownership changes, but the determination is complex and there can be no assurance we are correct. Furthermore, we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, our pre-2018 NOL carryforwards may expire prior to being used and our NOL carryforwards generated in tax years beginning after December 31, 2020, will be subject to a percentage limitation and, if we undergo an ownership change (or if we previously underwent such an ownership change), our ability to use all of our pre-change NOLs and other pre-change tax attributes (such as research tax credits) to offset our post-change income or taxes may be limited. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, we may be unable to use all or a material portion of our NOLs and other tax attributes, which could adversely affect our future cash flows.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability from state to state, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*The price of our common stock is volatile.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market prices for securities of biotechnology and pharmaceutical companies historically have been highly volatile, and the market for these securities has from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. The COVID-19 pandemic, for example, has negatively affected the stock market and investor sentiment and has resulted in significant volatility. Furthermore, especially as we and our market capitalization have grown, the price of our common stock has been increasingly affected by quarterly and annual comparisons with the valuations and recommendations of the analysts who cover our business. If our results do not meet these analysts&#8217; forecasts, the expectations of our investors or the financial guidance we provide to investors in any period, which is based on assumptions that may be incorrect or that may change from quarter to quarter, the market price of our common stock could decline. Over the course of the last twelve months, the price of our common stock has ranged from approximately $72 per share to approximately $136 per share. The market price of our common stock may fluctuate in response to many factors, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of INGREZZA and ORILISSA;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impact of the commercial launch of ONGENTYS and ORIAHNN;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the status and cost of our post-marketing commitments for INGREZZA and ONGENTYS;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our clinical trials;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reports of safety issues related to INGREZZA, ONGENTYS, ORILISSA, or ORIAHNN;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning new and existing collaboration agreements;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations or new therapeutic products by us or others;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic and market conditions, including economic and market conditions affecting the biotechnology industry;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in patent or other proprietary rights;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments related to the FDA;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future sales of our common stock by us or our stockholders;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">comments by securities analysts;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our operating results;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential litigation matters;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government regulation;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government and third-party payor coverage and reimbursement;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of any of our product candidates, if approved, to achieve commercial success;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions caused by man-made or natural disasters or public health pandemics or epidemics or other business interruptions, including, for example, the COVID-19 pandemic; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern as to the safety of our drugs.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our customers are concentrated and therefore the loss of a significant customer may harm our business.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into distribution agreements with a limited number of specialty pharmacy providers and a specialty distributor, and all of our product sales are to these customers. Two of these customers represented approximately 86% of our product revenue for the year ended December 31, 2019 and a significant majority of our accounts receivable balance at December 31, 2019. If any of these significant customers becomes subject to bankruptcy, is unable to pay us for our products or is acquired by a company that wants to terminate the relationship with us, or if we otherwise lose any of these significant customers, our revenue, results of operations and cash flows would be adversely affected. Even if we replace the loss of a significant customer, we cannot predict with certainty that such transition would not result in a decline in our revenue, results of operations and cash flows.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*If we cannot raise additional funding, we may be unable to complete development of our product candidates or establish commercial and manufacturing capabilities in the future.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may require additional funding to effectively commercialize INGREZZA or ONGENTYS, to continue our research and product development programs, to conduct preclinical studies and clinical trials, for operating expenses, to pursue regulatory approvals for our product candidates, for the costs involved in filing and prosecuting patent applications and enforcing or defending patent claims, if any, and the cost of product in-licensing and any possible acquisitions. In addition, we may require additional funding to establish manufacturing and marketing capabilities in the future. We believe that our existing capital resources, together with investment income, and future payments due under our strategic alliances, will be sufficient to satisfy our current and projected funding requirements for at least the next twelve months. However, these resources might be insufficient to conduct research and development programs, the cost of product in-taking and possible acquisitions, fully commercialize products and operate the company to the full extent currently planned. If we cannot obtain adequate funds, we may be required to curtail significantly our commercial plans or one or more of our research and development programs or obtain funds through additional arrangements with corporate collaborators or others that may require us to relinquish rights to some of our technologies or product candidates.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the commercial success of INGREZZA, ONGENTYS, ORILISSA, and/or ORIAHNN;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt service obligations on the 2024 Notes;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued scientific progress in our R&amp;D and clinical development programs;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the magnitude and complexity of our research and development programs;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress with preclinical testing and clinical trials;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and costs involved in obtaining regulatory approvals;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in filing and pursuing patent applications, enforcing patent claims, or engaging in interference proceedings or other patent litigation;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the establishment of additional strategic alliances;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments related to any future litigation;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of commercialization activities and arrangements, including manufacturing of our product candidates; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of product in-licensing and any possible acquisitions.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek additional funding through strategic alliances and may seek additional funding through public or private sales of our securities, including equity securities. In addition, during the second quarter of 2017, we issued the 2024 Notes and we have previously financed capital purchases and may continue to pursue opportunities to obtain additional debt financing in the future. Additional equity or debt financing might not be available on reasonable terms, if at all. In addition, disruptions due to the COVID-19 pandemic could make it more difficult for us to access capital. Any additional equity financings will be dilutive to our stockholders and any additional debt financings may involve operating covenants that restrict our business.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with changing regulation of corporate governance and public disclosure may result in additional expenses.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changing laws, regulations and standards relating to corporate governance and public disclosure, including the Dodd-Frank Wall Street Reform and Consumer Protection Act, new SEC regulations and Nasdaq rules, are creating uncertainty for companies such as ours. These laws, regulations and standards are subject to varying interpretations in some cases due to their lack of specificity, and as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies, which could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We are committed to maintaining high standards of corporate governance and public disclosure. As a result, our efforts to comply with evolving laws, regulations and standards have resulted in, and are likely to continue to result in, increased sales, general and administrative expenses and management time related to compliance activities. If we fail to comply with these laws, regulations and standards, our reputation may be harmed, and we might be subject to sanctions or investigation by regulatory authorities, such as the SEC. Any such action could adversely affect our financial results and the market price of our common stock.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Industry</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Health care reform measures and other recent legislative initiatives could adversely affect our business.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The business and financial condition of pharmaceutical and biotechnology companies are affected by the efforts of governmental and third-party payors to contain or reduce the costs of health care. In the US, comprehensive health care reform legislation was enacted by the Federal government and we expect that there will continue to be a number of federal and state proposals to implement government control over the pricing of prescription pharmaceuticals. In addition, increasing emphasis on reducing the cost of health care in the US will continue to put pressure on the rate of adoption and pricing of prescription pharmaceuticals. Moreover, in some foreign jurisdictions, pricing of prescription pharmaceuticals is already subject to government control. Additionally, other federal and state legislation imposes new obligations on manufacturers of pharmaceutical products, among others, related to product tracking and tracing. Among the requirements of this new legislation, manufacturers are required to provide certain information regarding the drug product provided to individuals and entities to which product ownership is transferred, label drug product with a product identifier, and keep certain records regarding distribution of the drug product. Further, under this new legislation, manufacturers will have drug product investigation, quarantine, disposition, notification and purchaser license verification responsibilities related to counterfeit, diverted, stolen, and intentionally adulterated products, as well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution such that they would be reasonably likely to result in serious health consequences or death.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in March 2010, Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, was signed into law, which was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose taxes and fees on the health industry and impose additional health policy reforms. Among the provisions of the ACA of importance to our potential drug candidates are:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual, nondeductible fee on any entity that manufactures, or imports, specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Medicare Part&#160;D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; and</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain legal and political challenges to certain aspects of the ACA. Since January 2017, several executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the ACA have been put into place. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. Legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act includes a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. The Bipartisan Budget Act of 2018, or the BBA, among other things, amended the ACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole&#8221;. In December 2018, CMS published a new final rule permitting further collections and payments to and from certain ACA-qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminates the health insurer tax. On December 14, 2018, a US District Court Judge in Texas ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act. Additionally, on December 18, 2019, the US Court of Appeals for the 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Circuit ruled that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On March 2, 2020, the United States Supreme Court granted the petitions for writs of certiorari to review this case. It is unclear how such litigation and other efforts to repeal and replace the ACA will impact the ACA and our business.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2%&#160;per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and, due to subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2030 unless additional Congressional action is taken. However, the Medicare sequester reductions under the BBA will be suspended from May 1, 2020 through December 31, 2020 due to the COVID-19 pandemic. The American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional changes that may affect our business include the expansion of new programs such as Medicare payment for performance initiatives for physicians under the Medicare Access and CHIP Reauthorization Act of 2015, which ended the use of the statutory formula, also referred to as the Sustainable Growth Rate, for clinician payment and established a quality payment incentive program, also referred to as the Quality Payment Program. This program provides clinicians with two ways to participate, including through the Advanced Alternative Payment Models, or APMs, and the Merit-based Incentive Payment System, or MIPS. In November 2019, CMS issued a final rule finalizing the changes to the Quality Payment Program. At this time, it remains unclear how the introduction of the Quality Payment Program will impact overall physician reimbursement.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the current presidential administration&#8217;s budget proposal for the 2021 fiscal year includes a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the Trump administration sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. Further, the current presidential administration released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. The US Department of Health and Human Services, or HHS, has solicited feedback on certain of these measures and, additionally, has implemented others under its existing authority. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage plans the option to use step therapy for Part B drugs beginning January 1, 2020. This final rule codified CMS&#8217;s policy change that was effective January 1, 2019.  On July 24, 2020, the Trump </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administration announced four executive orders related to prescription drug pricing that attempt to implement several of the administration&#8217;s proposals, including a policy that would tie Medicare Part B drug prices to international drug prices; one that directs HHS to finalize the Canadian drug importation proposed rule previously issued by HHS and makes other changes allowing for personal importation of drugs from Canada; one that directs HHS to finalize the rulemaking process on modifying the anti-kickback law safe harbors for plans, pharmacies, and pharmaceutical benefit managers; and one that reduces costs of insulin and epipens to patients of federally qualified health centers.  While some of these and other measures may require additional authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. In particular, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain sustained profitability or commercialize our drugs.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently unable to predict what additional legislation or regulation, if any, relating to the health care industry may be enacted in the future or what effect recently enacted federal legislation or any such additional legislation or regulation would have on our business. The pendency or approval of such proposals or reforms could result in a decrease in our stock price or limit our ability to raise capital or to enter into collaboration agreements for the further development and commercialization of our programs and products.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any relationships with healthcare professionals, principal investigators, consultants, customers (actual and potential) and third-party payors in connection with our current and future business activities are and will continue to be subject, directly or indirectly, to federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could&#160;face penalties, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations and activities may be directly, or indirectly, subject to various federal and state healthcare laws, including without limitation, fraud and abuse laws, false claims laws, data privacy and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers. These laws may restrict or prohibit a wide range of business activities, including, but not limited to, research, manufacturing, distribution, pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. These laws may impact, among other things, our current activities with principal investigators and research subjects, as well as current and future sales, marketing, patient co-payment assistance and education programs.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such laws include:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal civil and criminal false claims laws, including the federal civil False Claims Act, and civil monetary penalties laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, which imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and its implementing regulations, which also imposes obligations, including mandatory contractual terms, on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses,  as well as their business </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associates and their subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to CMS information related to payments or other transfers of value made to physicians, as defined by such law, and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report such information regarding its relationships with physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and certified nurse midwives during the previous year; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state, local, and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures or drug pricing; state and local laws that require the registration of pharmaceutical sales representatives; state and local &#8220;drug take back&#8221; laws and regulations; and state and foreign laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. While our interactions with healthcare professionals, including our speaker programs and other arrangements, such as our contributions to patient assistance programs, have been structured to comply with these laws and related guidance, it is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws. If our operations or activities are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any sales of our product once commercialized outside the US will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We could face liability if a regulatory authority determines that we are promoting INGREZZA, ONGENTYS or any of our product candidates that receives regulatory approval, for &#8220;off-label&#8221; uses.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company may not promote &#8220;off-label&#8221; uses for its drug products. An off-label use is the use of a product for an indication that is not described in the product&#8217;s FDA-approved label in the US or for uses in other jurisdictions that differ from those approved by the applicable regulatory agencies. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. A company that is found to have promoted off-label use of its product may be subject to significant liability, including civil and criminal sanctions. We intend to comply with the requirements and restrictions of the FDA and other regulatory agencies with respect to our promotion of our products, including INGREZZA and ONGENTYS, but we cannot be sure that the FDA or other regulatory agencies will agree that we have not violated their restrictions. As a result, we may be subject to criminal and civil liability. In addition, our management&#8217;s attention could be diverted to handle any such alleged violations. If the FDA or any other governmental agency initiates an enforcement action against us, or if we are the subject of a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> suit brought by a private plaintiff on behalf of the government, and it is determined that we violated prohibitions relating to the promotion of products for unapproved uses, we could be subject to substantial civil or criminal fines or damage awards and other sanctions such as consent decrees and corporate integrity agreements pursuant to which our activities would be subject to ongoing </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">scrutiny and monitoring to ensure compliance with applicable laws and regulations. Any such fines, awards or other sanctions would have an adverse effect on our revenue, business, financial prospects, and reputation.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect our intellectual property, our competitors could develop and market products based on our discoveries, which may reduce demand for our products.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend on our ability to, among other things:</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain patent protection for our products;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preserve our trade secrets;</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prevent third parties from infringing upon our proprietary rights; and</span></div><div style="margin-bottom:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operate without infringing upon the proprietary rights of others, both in the US and internationally.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the substantial length of time and expense associated with bringing new products through the development and regulatory approval processes in order to reach the marketplace, the pharmaceutical industry places considerable importance on obtaining patent and trade secret protection for new technologies, products and processes. Accordingly, we intend to seek patent protection for our proprietary technology and compounds. However, we face the risk that we may not obtain any of these patents and that the breadth of claims we obtain, if any, may not provide adequate protection of our proprietary technology or compounds.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely upon unpatented trade secrets and improvements, unpatented know-how and continuing technological innovation to develop and maintain our competitive position, which we seek to protect, in part, through confidentiality agreements with our commercial collaborators, employees and consultants. We also have invention or patent assignment agreements with our employees and some, but not all, of our commercial collaborators and consultants. However, if our employees, commercial collaborators or consultants breach these agreements, we may not have adequate remedies for any such breach, and our trade secrets may otherwise become known or independently discovered by our competitors.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we own a number of patents, the issuance of a patent is not conclusive as to its validity or enforceability, and third parties may challenge the validity or enforceability of our patents. We cannot assure you how much protection, if any, will be given to our patents if we attempt to enforce them and they are challenged in court or in other proceedings. It is possible that a competitor may successfully challenge our patents or that challenges will result in limitations of their coverage. Moreover, competitors may infringe our patents or successfully avoid them through design innovation. To prevent infringement or unauthorized use, we may need to file infringement claims, which are expensive and time-consuming. In addition, in an infringement proceeding a court may decide that a patent of ours is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover its technology. Interference proceedings declared by the US Patent and Trademark Office may be necessary to determine the priority of inventions with respect to our patent applications or those of our licensors. Litigation or interference proceedings may fail and, even if successful, may result in substantial costs and be a distraction to management. We cannot assure you that we will be able to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the US.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to obtain or maintain orphan drug designation or other regulatory exclusivity for some of our product candidates, our competitive position would be harmed.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product candidate that receives orphan drug designation can benefit from a streamlined regulatory process as well as potential commercial benefits following approval. Currently, this designation provides market exclusivity in the US and the EU for seven years and ten years, respectively, if a product is the first such product approved for such orphan indication. This market exclusivity does not, however, pertain to indications other than those for which the drug was specifically designated in the approval, nor does it prevent other types of drugs from receiving orphan designations or approvals in these same indications. Further, even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the new drug is clinically superior to the orphan product or a market shortage occurs.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, orphan exclusivity may be reduced to six years if the drug no longer satisfies the original designation criteria or can be lost altogether if the marketing authorization holder consents to a second orphan drug application or cannot supply enough drug, or when a second applicant demonstrates its drug is &#8220;clinically superior&#8221; to the original orphan drug. We may not be successful obtaining orphan drug designations for any indications and, even if we succeed, such orphan drug designations may fail to result in or maintain orphan drug exclusivity upon approval, which would harm our competitive position.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The technologies we use in our research as well as the drug targets we select may infringe the patents or violate the proprietary rights of third&#160;parties.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that third parties will not assert patent or other intellectual property infringement claims against us or our collaborators with respect to technologies used in potential products. If a patent infringement suit were brought against us or our collaborators, we or our collaborators could be forced to stop or delay developing, manufacturing or selling potential products that are claimed to infringe a third party&#8217;s intellectual property unless that party grants us or our collaborators rights to use its intellectual property. In such cases, we could be required to obtain licenses to patents or proprietary rights of others in order to continue to commercialize our products. However, we may not be able to obtain any licenses required under any patents or proprietary rights of third parties on acceptable terms, or at all. Even if our collaborators or we were able to obtain rights to the third party&#8217;s intellectual property, these rights may be non-exclusive, thereby giving our competitors access to the same intellectual property. Ultimately, we may be unable to commercialize some of our potential products or may have to cease some of our business operations as a result of patent infringement claims, which could severely harm our business.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees and independent contractors, such as principal investigators, consultants, commercial partners and vendors, or by employees of our commercial partners could include failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with manufacturing standards we have established, to comply with federal and state healthcare fraud and abuse laws, to report financial information or data accurately, to maintain the confidentiality of our trade secrets or the trade secrets of our commercial partners, or to disclose unauthorized activities to us. In particular, sales, marketing and other business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, kickbacks, self-dealing and other abusive practices. Employee and independent contractor misconduct could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Any action against our employees, independent contractors, principal investigators, consultants, commercial partners or vendors for violations of these laws could result in significant civil, criminal, and administrative penalties, fines, and imprisonment.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*We face potential product liability exposure far in excess of our insurance coverage.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of any of our potential products in clinical trials, and the sale of any approved products, including INGREZZA and ONGENTYS, may expose us to liability claims. These claims might be made directly by consumers, health care providers, pharmaceutical companies or others selling our products. We have product liability insurance coverage for our clinical trials in the amount of $45.0 million per occurrence and $45.0 million in the aggregate. In addition, we have product liability insurance related to the sale of INGREZZA and ONGENTYS in the amount of $45.0&#160;million per occurrence and $45.0&#160;million in the aggregate. However, our insurance may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability from any current or future clinical trials or approved products. A successful product liability claim, or series of claims, brought against us would decrease our cash reserves and could cause our stock price to fall. Furthermore, regardless of the eventual outcome of a product liability claim, any product liability claim against us may decrease demand for our approved products, including INGREZZA and ONGENTYS, damage our reputation, result in regulatory investigations that could require costly recalls or product modifications, cause clinical trial participants to withdrawal, result in costs to defend the related litigation, decrease our revenue, and divert management&#8217;s attention from managing our business.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our activities involve hazardous materials, and we may be liable for any resulting contamination or injuries.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research activities involve the controlled use of hazardous materials. We cannot eliminate the risk of accidental contamination or injury from these materials. If an accident occurs, a court may hold us liable for any resulting damages, which may harm our results of operations and cause us to use a substantial portion of our cash reserves, which would force us to seek additional financing.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">*Cyber security breaches and other disruptions could compromise our information, including the theft of our intellectual property, and could expose us to liability, which would cause our business and reputation to suffer.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business. In the ordinary course of our business, we collect and store confidential and sensitive electronic information on our networks and in our data centers. This information includes, among other things, our intellectual property and proprietary information, the confidential information of our collaborators and licensees, and the personally identifiable </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information of our employees. It is important to our operations and business strategy that this electronic information remains secure and is perceived to be secure. The size and complexity of our information technology systems, and those of third-party vendors with whom we contract, and the volume of data we retain, make such systems potentially vulnerable to breakdown, malicious intrusion, security breaches and other cyber-attacks. Additionally, natural disasters, public health pandemics or epidemics (including, for example, the COVID-19 pandemic), terrorism, war and telecommunication and electrical failures may result in damage to or the interruption or impairment of key business processes, or the loss or corruption of confidential information, including intellectual property, proprietary business information and personal information. Information security risks have significantly increased in recent years in part due to the proliferation of new technologies and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including foreign private parties and state actors. A security breach or privacy violation that leads to disclosure or modification of or prevents access to personally identifiable information or other protected information could harm our reputation, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, require us to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect personal data, resulting in increased costs or loss of revenue. Similarly, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Additionally, theft of our intellectual property or proprietary business information could require substantial expenditures to remedy. If we are unable to prevent such security breaches or privacy violations or implement satisfactory remedial measures, our operations could be disrupted, and we may suffer loss of reputation, financial loss and other regulatory penalties because of lost or misappropriated information. In addition, these breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. Moreover, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information, trade secrets or other intellectual property. As cyber threats continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any information security vulnerabilities. While we have implemented security measures to protect our data security and information technology systems, such measures may not prevent such events. Significant disruptions of our information technology systems or breaches of data security could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. For example, the EU&#8217;s General Data Protection Regulation, or GDPR, imposes strict obligations on the processing of personal data, including personal health data, and the free movement of such data. The GDPR applies to any company established in the EU as well as any company outside the EU that processes personal data in connection with the offering of goods or services to individuals in the EU or the monitoring of their behavior. The GDPR enhances data protection obligations for processors and controllers of personal data, including, for example, obligations relating to: processing health and other sensitive data; obtaining consent of individuals; providing notice to individuals regarding data processing activities; responding to data subject requests; taking certain measures when engaging third-party processors; notifying data subjects and regulators of data breaches; implementing safeguards to protect the security and confidentiality of personal data; and transferring personal data to countries outside the EU, including the US. The GDPR imposes substantial fines for breaches of data protection requirements, which can be up to four percent of global revenue or 20 million euros, whichever is greater, and it also confers a private right of action on data subjects for breaches of data protection requirements. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to change our business practices or lead to government enforcement actions, private litigation or significant penalties against us and could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, California recently enacted legislation that has been dubbed the first &#8220;GDPR-like&#8221; law in the US. Known as the California Consumer Privacy Act, or CCPA, it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA, which went into effect on January 1, 2020, requires covered companies to provide new disclosures to California consumers, and provides such consumers new ways to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Some observers have noted that the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CCPA could mark the beginning of a trend toward more stringent privacy legislation in the US, which could increase our potential liability and adversely affect our business.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="i01dca92a9a894c839fd91f8b5b3beba6_79"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following exhibits are filed as part of, or incorporated by reference into, this report:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459018026844/nbix-ex31_91.htm">Certificate of Incorporation, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 3.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on November 5, 2018</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000091447520000025/nbix-20200828exhibit31.htm">Certificate of Amendment of Bylaws</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K filed on August 28, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/0000898430-96-002108.txt">Form of Common Stock Certificate</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to the Company&#8217;s Registration Statement on Form S-1 (Registration No. 333-03172)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517154199/d390610dex41.htm">Indenture, dated as of May&#160;2, 2017, by and between the Company and U.S. Bank National Association, as Trustee</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 4.1 of the Company&#8217;s Current Report on Form 8-K filed on May 2, 2017</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000119312517154199/d390610dex991.htm">Form of Note representing the Company&#8217;s 2.25% Convertible Notes due 2024</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 99.1 of the Company&#8217;s Current Report on Form 8-K filed on May 2, 2017</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/914475/000156459020003773/nbix-ex44_74.htm">Description of Common Stock of the Company</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reference:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 4.4 of the Company&#8217;s Annual Report on Form 10-K filed on February 7, 2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="nbix-20200930exhibit311.htm">Certification of Chief Executive Officer pursuant to Rules&#160;13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="nbix-20200930exhibit312.htm">Certification of Chief Financial Officer pursuant to Rules&#160;13a-14 and 15d-14 promulgated under the Securities Exchange Act of 1934</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="nbix-20200930exhibit32.htm">Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Instance Document. &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-bottom:4pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">* These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and are not to be incorporated by reference into any filing of Neurocrine Biosciences, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Except as specifically noted above, the Company&#8217;s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K have a Commission File Number of 000-22705.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="i01dca92a9a894c839fd91f8b5b3beba6_82"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.472%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NEUROCRINE BIOSCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: November&#160;9, 2020</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Matthew C. Abernethy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer<br/>(Duly authorized officer and Principal Financial Officer)</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>nbix-20200930exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i7ee68abddaad4364a8737852c398448c_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kevin C. Gorman, Chief Executive Officer of Neurocrine Biosciences, Inc., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Neurocrine Biosciences, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; November&#160;9, 2020</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kevin C. Gorman&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin C. Gorman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>nbix-20200930exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ib5db2283055649399d4d6c35d8efbd18_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Matthew C. Abernethy, Chief Financial Officer of Neurocrine Biosciences, Inc., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of Neurocrine Biosciences, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; November&#160;9, 2020</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Matthew C. Abernethy&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>nbix-20200930exhibit32.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ice4f7ec126e14a10ab0cc69734f6a183_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Neurocrine Biosciences, Inc. (Company) on Form 10-Q for the period ended September&#160;30, 2020 as filed with the Securities and Exchange Commission on the date hereof (Report), I, Kevin C. Gorman, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d), of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">That information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:14pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kevin C. Gorman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin C. Gorman</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Neurocrine Biosciences, Inc. (Company) on Form 10-Q for the period ended September&#160;30, 2020 as filed with the Securities and Exchange Commission on the date hereof (Report), I, Matthew C. Abernethy, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d), of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">That information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Matthew C. Abernethy&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew C. Abernethy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>nbix-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b79d3e40-aa4b-4356-aa3c-d2eb2732ffa0,g:9f3edc10-8601-4580-b4de-4b1ad44f8b95-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nbix="http://www.neurocrine.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.neurocrine.com/20200930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.neurocrine.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements Of Operations And Comprehensive (Loss) Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPolicies" roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesPolicies" roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>2403401 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantCollaborationandLicensingAgreements" roleURI="http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreements">
        <link:definition>2104102 - Disclosure - Significant Collaboration and Licensing Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail" roleURI="http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail">
        <link:definition>2405402 - Disclosure - Significant Collaboration and Licensing Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecurities" roleURI="http://www.neurocrine.com/role/DebtSecurities">
        <link:definition>2106103 - Disclosure - Debt Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesTables" roleURI="http://www.neurocrine.com/role/DebtSecuritiesTables">
        <link:definition>2307301 - Disclosure - Debt Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail" roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail">
        <link:definition>2408403 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesAdditionalInformationDetail" roleURI="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetail">
        <link:definition>2409404 - Disclosure - Debt Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail" roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail">
        <link:definition>2410405 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.neurocrine.com/role/FairValueMeasurements">
        <link:definition>2111104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.neurocrine.com/role/FairValueMeasurementsTables">
        <link:definition>2312302 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail" roleURI="http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail">
        <link:definition>2413406 - Disclosure - Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail" roleURI="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail">
        <link:definition>2414407 - Disclosure - Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetail" roleURI="http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail">
        <link:definition>2415408 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.neurocrine.com/role/Inventories">
        <link:definition>2116105 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.neurocrine.com/role/InventoriesTables">
        <link:definition>2317303 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesSummaryofInventoriesDetail" roleURI="http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail">
        <link:definition>2418409 - Disclosure - Inventories - Summary of Inventories (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCash" roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash">
        <link:definition>2119106 - Disclosure - Cash, Cash Equivalents and Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCashTables" roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables">
        <link:definition>2320304 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail" roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail">
        <link:definition>2421410 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.neurocrine.com/role/Leases">
        <link:definition>2122107 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.neurocrine.com/role/LeasesTables">
        <link:definition>2323305 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDisclosureDetail" roleURI="http://www.neurocrine.com/role/LeasesDisclosureDetail">
        <link:definition>2424411 - Disclosure - Leases - Disclosure (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetail" roleURI="http://www.neurocrine.com/role/LeasesAdditionalInformationDetail">
        <link:definition>2425412 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLiabilityPaymentDueDetail" roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail">
        <link:definition>2426413 - Disclosure - Leases - Liability, Payment, Due (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLiabilityPaymentDueDetail_1" roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail_1">
        <link:definition>2426413 - Disclosure - Leases - Liability, Payment, Due (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotes" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes">
        <link:definition>2127108 - Disclosure - Convertible Senior Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesTables" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables">
        <link:definition>2328306 - Disclosure - Convertible Senior Notes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesAdditionalInformationDetail" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail">
        <link:definition>2429414 - Disclosure - Convertible Senior Notes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail" roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail">
        <link:definition>2430415 - Disclosure - Convertible Senior Notes - Debt Net of Discounts and Deferred Financing Costs (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShare" roleURI="http://www.neurocrine.com/role/NetLossIncomePerShare">
        <link:definition>2131109 - Disclosure - Net (Loss) Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShareTables" roleURI="http://www.neurocrine.com/role/NetLossIncomePerShareTables">
        <link:definition>2332307 - Disclosure - Net (Loss) Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShareScheduleofNetIncomePerShareDetail" roleURI="http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail">
        <link:definition>2433416 - Disclosure - Net (Loss) Income Per Share - Schedule of Net Income Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossIncomePerShareAdditionalInformationDetail" roleURI="http://www.neurocrine.com/role/NetLossIncomePerShareAdditionalInformationDetail">
        <link:definition>2434417 - Disclosure - Net (Loss) Income Per Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="nbix_A12790ElCaminoRealSuite100Member" abstract="true" name="A12790ElCaminoRealSuite100Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_UpfrontPaymentsMade" abstract="false" name="UpfrontPaymentsMade" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_TerminationNoticePeriodAfterFirstCommercialSale" abstract="false" name="TerminationNoticePeriodAfterFirstCommercialSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_UpfrontPaymentsReceived" abstract="false" name="UpfrontPaymentsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_CashAndMoneyMarketFundMember" abstract="true" name="CashAndMoneyMarketFundMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_MilestonePayment" abstract="false" name="MilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_BusinessDescriptionPolicyTextBlock" abstract="false" name="BusinessDescriptionPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbix_MinimumSalesRequirementPeriodThresholdToTerminateAgreement" abstract="false" name="MinimumSalesRequirementPeriodThresholdToTerminateAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_A12777HighBluffDriveMember" abstract="true" name="A12777HighBluffDriveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_PatentTerm" abstract="false" name="PatentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_NBI827104Member" abstract="true" name="NBI827104Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_InvestmentIncomeAndOtherNet" abstract="false" name="InvestmentIncomeAndOtherNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced" abstract="false" name="NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_ResearchCollaborationTerm" abstract="false" name="ResearchCollaborationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_RestrictedCashMember" abstract="true" name="RestrictedCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_NumberOfConsecutiveBusinessDays" abstract="false" name="NumberOfConsecutiveBusinessDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" abstract="false" name="IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="nbix_BIALMember" abstract="true" name="BIALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" abstract="false" name="DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbix_TotalEquitySecuritiesMember" abstract="true" name="TotalEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" abstract="false" name="MinimumPercentageOfTradingPriceToLastReportedSalePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbix_PotentialMilestonePaymentReceipts" abstract="false" name="PotentialMilestonePaymentReceipts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_LongTermInvestmentsMember" abstract="true" name="LongTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_TerminationNoticePeriod" abstract="false" name="TerminationNoticePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_RestrictedCashTextBlock" abstract="false" name="RestrictedCashTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbix_StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember" abstract="true" name="StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_PotentialMilestonePayments" abstract="false" name="PotentialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_MitsubishiTanabePharmaCorporationMember" abstract="true" name="MitsubishiTanabePharmaCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_NumberOfIrishSubsidiaries" abstract="false" name="NumberOfIrishSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbix_VoyagerTherapeuticsMember" abstract="true" name="VoyagerTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_A12780ElCaminoRealMember" abstract="true" name="A12780ElCaminoRealMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_A12790ElCaminoRealSuite150Member" abstract="true" name="A12790ElCaminoRealSuite150Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_A12790ElCaminoRealSuite130Member" abstract="true" name="A12790ElCaminoRealSuite130Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_TerminationNoticePeriodBeforeFirstCommercialSale" abstract="false" name="TerminationNoticePeriodBeforeFirstCommercialSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_NumberOfRenewalOptions" abstract="false" name="NumberOfRenewalOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbix_CollaborationRevenueMember" abstract="true" name="CollaborationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_A12790ElCaminoRealSuite200Member" abstract="true" name="A12790ElCaminoRealSuite200Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember" abstract="true" name="TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_DebtInstrumentConvertibleConversionPremium" abstract="false" name="DebtInstrumentConvertibleConversionPremium" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" abstract="false" name="SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="nbix_A12790ElCaminoRealSuite300Member" abstract="true" name="A12790ElCaminoRealSuite300Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_IdorsiaPharmaceuticalsLtdMember" abstract="true" name="IdorsiaPharmaceuticalsLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_A1278012790ElCaminoRealMasterLeaseMember" abstract="true" name="A1278012790ElCaminoRealMasterLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_DevelopmentProductCandidatesMember" abstract="true" name="DevelopmentProductCandidatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_TakedaPharmaceuticalCompanyLimitedMember" abstract="true" name="TakedaPharmaceuticalCompanyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_A225ConvertibleSeniorNotesMember" abstract="true" name="A225ConvertibleSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" abstract="false" name="DebtSecuritiesAvailableForSalePositionNumberOfPositions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="nbix_XenonPharmaceuticalsIncMember" abstract="true" name="XenonPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="nbix_PrincipalAmountOnConversionRate" abstract="false" name="PrincipalAmountOnConversionRate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent" abstract="false" name="DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_DebtConversionObservationPeriod" abstract="false" name="DebtConversionObservationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="nbix_PotentialCommercialMilestonePayments" abstract="false" name="PotentialCommercialMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="nbix_AbbvieIncMember" abstract="true" name="AbbvieIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>nbix-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b79d3e40-aa4b-4356-aa3c-d2eb2732ffa0,g:9f3edc10-8601-4580-b4de-4b1ad44f8b95-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/CoverPage" xlink:type="simple" xlink:href="nbix-20200930.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nbix-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b0db2965-8523-407f-bd32-0043aa90d529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_882adf5e-41eb-4517-a700-26bc965235f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b0db2965-8523-407f-bd32-0043aa90d529" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_882adf5e-41eb-4517-a700-26bc965235f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_7bc4ee21-723c-4bd0-b273-01c68a42fcde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b0db2965-8523-407f-bd32-0043aa90d529" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_7bc4ee21-723c-4bd0-b273-01c68a42fcde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5e6528f8-7549-40c8-9565-9e0e5f3014b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b0db2965-8523-407f-bd32-0043aa90d529" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5e6528f8-7549-40c8-9565-9e0e5f3014b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0d890136-c860-4709-981a-028270098f33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b0db2965-8523-407f-bd32-0043aa90d529" xlink:to="loc_us-gaap_InventoryNet_0d890136-c860-4709-981a-028270098f33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_bbb6c239-36ce-46e6-9076-77509feafc95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b0db2965-8523-407f-bd32-0043aa90d529" xlink:to="loc_us-gaap_OtherAssetsCurrent_bbb6c239-36ce-46e6-9076-77509feafc95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dda02058-e276-4e3b-9758-6e254544d409" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_643ec2e8-42e7-465f-8746-7262d2d692ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dda02058-e276-4e3b-9758-6e254544d409" xlink:to="loc_us-gaap_PreferredStockValue_643ec2e8-42e7-465f-8746-7262d2d692ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_03eda9ad-4bb0-4499-8251-c2ef2f90b1d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dda02058-e276-4e3b-9758-6e254544d409" xlink:to="loc_us-gaap_CommonStockValue_03eda9ad-4bb0-4499-8251-c2ef2f90b1d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0533b7a4-1707-4b7d-a294-af0f401a1f13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dda02058-e276-4e3b-9758-6e254544d409" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0533b7a4-1707-4b7d-a294-af0f401a1f13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b5ac951d-447b-4f80-8531-7ad984c927b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dda02058-e276-4e3b-9758-6e254544d409" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b5ac951d-447b-4f80-8531-7ad984c927b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7eefb759-ad35-466b-afa3-8e013300a952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dda02058-e276-4e3b-9758-6e254544d409" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7eefb759-ad35-466b-afa3-8e013300a952" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6c280935-b2ae-4315-9550-72de32966db3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_95a36079-ada0-4403-b351-ece01914b8c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6c280935-b2ae-4315-9550-72de32966db3" xlink:to="loc_us-gaap_AssetsCurrent_95a36079-ada0-4403-b351-ece01914b8c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_430a73e2-1039-4a7e-8e7f-0d2c3d5ecfb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6c280935-b2ae-4315-9550-72de32966db3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_430a73e2-1039-4a7e-8e7f-0d2c3d5ecfb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7e439e6c-9598-4a7d-bc5b-4c3814bc1e94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6c280935-b2ae-4315-9550-72de32966db3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7e439e6c-9598-4a7d-bc5b-4c3814bc1e94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_12c6301f-46d6-4bb6-9d09-a7f6739b6545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6c280935-b2ae-4315-9550-72de32966db3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRestricted_12c6301f-46d6-4bb6-9d09-a7f6739b6545" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bd6392e3-1268-4873-b901-206409775a8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6c280935-b2ae-4315-9550-72de32966db3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bd6392e3-1268-4873-b901-206409775a8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_8ac8021b-be25-4b7b-94c5-8a6f0425666f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6c280935-b2ae-4315-9550-72de32966db3" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_8ac8021b-be25-4b7b-94c5-8a6f0425666f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_2eb43d9c-5633-4e6f-8e31-c0a5f0d970e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6c280935-b2ae-4315-9550-72de32966db3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_2eb43d9c-5633-4e6f-8e31-c0a5f0d970e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1e023e97-e018-41d6-900e-d99c225677d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9ebd6397-b8de-4723-a563-38b79599e374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1e023e97-e018-41d6-900e-d99c225677d5" xlink:to="loc_us-gaap_LiabilitiesCurrent_9ebd6397-b8de-4723-a563-38b79599e374" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_88bd81ae-a6f5-45a1-a1b8-9ad91383c62d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1e023e97-e018-41d6-900e-d99c225677d5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_88bd81ae-a6f5-45a1-a1b8-9ad91383c62d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_90cf865c-07ad-43d7-940b-9ed2dc621004" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_1e023e97-e018-41d6-900e-d99c225677d5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_90cf865c-07ad-43d7-940b-9ed2dc621004" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63698ea3-73eb-461e-abf5-6a9d6cc065f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3ac3815d-83f1-4af5-9155-534ce94aa1ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63698ea3-73eb-461e-abf5-6a9d6cc065f8" xlink:to="loc_us-gaap_Liabilities_3ac3815d-83f1-4af5-9155-534ce94aa1ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_82c014c6-dfb2-416d-abcf-d2bcf7ef4db0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63698ea3-73eb-461e-abf5-6a9d6cc065f8" xlink:to="loc_us-gaap_StockholdersEquity_82c014c6-dfb2-416d-abcf-d2bcf7ef4db0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_80569677-d45c-48bb-ac5d-79359ca16967" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9cc2a8fa-bcae-4535-b567-d12157fa7482" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_80569677-d45c-48bb-ac5d-79359ca16967" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9cc2a8fa-bcae-4535-b567-d12157fa7482" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_d8a98e98-db31-4d72-a9fa-040e6e20e414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_80569677-d45c-48bb-ac5d-79359ca16967" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_d8a98e98-db31-4d72-a9fa-040e6e20e414" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_f01d1a3e-be3a-4cd3-8398-227b3de7f732" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_80569677-d45c-48bb-ac5d-79359ca16967" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_f01d1a3e-be3a-4cd3-8398-227b3de7f732" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nbix-20200930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" xlink:type="simple" xlink:href="nbix-20200930.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1b2dcf44-60b9-4546-b6ff-fa43241e37b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c8e43c52-afed-46c7-97a5-ecb80ce349a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1b2dcf44-60b9-4546-b6ff-fa43241e37b8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c8e43c52-afed-46c7-97a5-ecb80ce349a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3dafcafb-bfdb-457f-8c9d-cca5c279fa50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1b2dcf44-60b9-4546-b6ff-fa43241e37b8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3dafcafb-bfdb-457f-8c9d-cca5c279fa50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7938786c-ac2c-4489-aa12-8850eec55d54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_381f5611-b35f-43cf-be24-4a113d05740b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_7938786c-ac2c-4489-aa12-8850eec55d54" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_381f5611-b35f-43cf-be24-4a113d05740b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e0773552-64d5-4ad3-a2d5-5da1571fc202" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_7938786c-ac2c-4489-aa12-8850eec55d54" xlink:to="loc_us-gaap_CostsAndExpenses_e0773552-64d5-4ad3-a2d5-5da1571fc202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b89cd4a1-358a-494d-b938-05e3ad273eaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3e066019-8050-455a-95af-822a4b1eb94a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b89cd4a1-358a-494d-b938-05e3ad273eaf" xlink:to="loc_us-gaap_OperatingIncomeLoss_3e066019-8050-455a-95af-822a4b1eb94a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_938f2848-81f8-4edb-9c7f-3042677a644a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b89cd4a1-358a-494d-b938-05e3ad273eaf" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_938f2848-81f8-4edb-9c7f-3042677a644a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_346734f8-d8c5-4be3-9927-7264c6e116c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0707f766-c06e-42c9-80e4-5b109663660c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_346734f8-d8c5-4be3-9927-7264c6e116c4" xlink:to="loc_us-gaap_InterestExpense_0707f766-c06e-42c9-80e4-5b109663660c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_392a5f1c-dd17-4ec9-8546-ee8a2137ee6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_346734f8-d8c5-4be3-9927-7264c6e116c4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_392a5f1c-dd17-4ec9-8546-ee8a2137ee6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet_326edc5d-374e-456b-b27d-d52b6aad8d06" xlink:href="nbix-20200930.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_346734f8-d8c5-4be3-9927-7264c6e116c4" xlink:to="loc_nbix_InvestmentIncomeAndOtherNet_326edc5d-374e-456b-b27d-d52b6aad8d06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c1fd7ab5-a5d9-453d-9919-93de93735bbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2a377971-a215-47d4-8f86-fe268d45a0d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c1fd7ab5-a5d9-453d-9919-93de93735bbf" xlink:to="loc_us-gaap_NetIncomeLoss_2a377971-a215-47d4-8f86-fe268d45a0d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_75d4e60d-dd1f-4ea5-94b7-f1716a472637" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c1fd7ab5-a5d9-453d-9919-93de93735bbf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_75d4e60d-dd1f-4ea5-94b7-f1716a472637" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a6a2ff2a-53b2-4196-82f9-48e25eeee209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e2a9647c-5d91-4f12-a262-159547b4bdba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a6a2ff2a-53b2-4196-82f9-48e25eeee209" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e2a9647c-5d91-4f12-a262-159547b4bdba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_eefc1cc6-8d19-4a38-834e-c15f0745b940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a6a2ff2a-53b2-4196-82f9-48e25eeee209" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_eefc1cc6-8d19-4a38-834e-c15f0745b940" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_2f3d1edb-55b5-4e2c-8b4f-dd578402144d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a6a2ff2a-53b2-4196-82f9-48e25eeee209" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_2f3d1edb-55b5-4e2c-8b4f-dd578402144d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1dce0650-e1af-4c17-8298-7ad80e2e0f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a6a2ff2a-53b2-4196-82f9-48e25eeee209" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1dce0650-e1af-4c17-8298-7ad80e2e0f1b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nbix-20200930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nbix-20200930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_163b18be-2261-4073-9a35-16348ad57f9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9855796e-4711-463a-a83a-329653b152b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_163b18be-2261-4073-9a35-16348ad57f9b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9855796e-4711-463a-a83a-329653b152b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_40206364-efbf-475e-9139-2259e66e6563" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_163b18be-2261-4073-9a35-16348ad57f9b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_40206364-efbf-475e-9139-2259e66e6563" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c185b650-97e9-4b3d-a061-01202fedbcb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_163b18be-2261-4073-9a35-16348ad57f9b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c185b650-97e9-4b3d-a061-01202fedbcb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d15b47b2-6b36-414f-822c-813e35cfb576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7a272bd0-ea3b-4dec-a4c4-b346893ec068" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d15b47b2-6b36-414f-822c-813e35cfb576" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_7a272bd0-ea3b-4dec-a4c4-b346893ec068" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_e24d39ef-72b8-454c-83af-3801c0b44438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d15b47b2-6b36-414f-822c-813e35cfb576" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_e24d39ef-72b8-454c-83af-3801c0b44438" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_6fd23ef2-3666-4df7-ae55-63c82d0d92b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d15b47b2-6b36-414f-822c-813e35cfb576" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_6fd23ef2-3666-4df7-ae55-63c82d0d92b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_65b49c60-e111-40ee-afbe-4b0371c037d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d15b47b2-6b36-414f-822c-813e35cfb576" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_65b49c60-e111-40ee-afbe-4b0371c037d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2f4e423-a40d-44cd-a492-b6a00ce3de6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ff8ce812-14e2-4767-bfc0-87adf13fd4e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2f4e423-a40d-44cd-a492-b6a00ce3de6b" xlink:to="loc_us-gaap_NetIncomeLoss_ff8ce812-14e2-4767-bfc0-87adf13fd4e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b6a3e2ca-7f82-41ad-906b-fddc8c68110c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2f4e423-a40d-44cd-a492-b6a00ce3de6b" xlink:to="loc_us-gaap_ShareBasedCompensation_b6a3e2ca-7f82-41ad-906b-fddc8c68110c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_27c09c39-17e7-436e-89ee-b3cf11dbf94e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2f4e423-a40d-44cd-a492-b6a00ce3de6b" xlink:to="loc_us-gaap_Depreciation_27c09c39-17e7-436e-89ee-b3cf11dbf94e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_784ac26c-83c1-4200-8825-75e6aabe444e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2f4e423-a40d-44cd-a492-b6a00ce3de6b" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_784ac26c-83c1-4200-8825-75e6aabe444e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_f56d44d8-27bb-4479-ba6e-e4ef6374b1c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2f4e423-a40d-44cd-a492-b6a00ce3de6b" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_f56d44d8-27bb-4479-ba6e-e4ef6374b1c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_aa427ac1-ddc0-4aaa-919a-cff502016d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2f4e423-a40d-44cd-a492-b6a00ce3de6b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_aa427ac1-ddc0-4aaa-919a-cff502016d9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_a51555cb-9162-451a-af5b-853370e35e79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2f4e423-a40d-44cd-a492-b6a00ce3de6b" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_a51555cb-9162-451a-af5b-853370e35e79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_52bd7f34-e6f5-4438-abc2-5ce33ad7f828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2f4e423-a40d-44cd-a492-b6a00ce3de6b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_52bd7f34-e6f5-4438-abc2-5ce33ad7f828" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_026d25c1-a7a2-4f72-ac03-c958d8b9a631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2f4e423-a40d-44cd-a492-b6a00ce3de6b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_026d25c1-a7a2-4f72-ac03-c958d8b9a631" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6989aa64-7e78-49bf-91a8-6288189dad22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2f4e423-a40d-44cd-a492-b6a00ce3de6b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6989aa64-7e78-49bf-91a8-6288189dad22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_1ba0b7a1-7822-4899-aba8-e6a4c63bfb58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2f4e423-a40d-44cd-a492-b6a00ce3de6b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_1ba0b7a1-7822-4899-aba8-e6a4c63bfb58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bf8e0717-bbb8-4877-9a4e-72f0a5e11adb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ebd7142-9f4f-40bb-8e31-082384ccf9bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bf8e0717-bbb8-4877-9a4e-72f0a5e11adb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ebd7142-9f4f-40bb-8e31-082384ccf9bb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="nbix-20200930.xsd#OrganizationandSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nbix-20200930.xsd#OrganizationandSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreements" xlink:type="simple" xlink:href="nbix-20200930.xsd#SignificantCollaborationandLicensingAgreements"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecurities" xlink:type="simple" xlink:href="nbix-20200930.xsd#DebtSecurities"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/DebtSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesTables" xlink:type="simple" xlink:href="nbix-20200930.xsd#DebtSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea8ecca2-c0e7-47e8-ada3-ca68fdfd726a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_eb16667b-3e52-4c8d-9dfd-4a2582fdf083" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea8ecca2-c0e7-47e8-ada3-ca68fdfd726a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_eb16667b-3e52-4c8d-9dfd-4a2582fdf083" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_12bad497-89db-4047-91ba-6a3a9efe58fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea8ecca2-c0e7-47e8-ada3-ca68fdfd726a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_12bad497-89db-4047-91ba-6a3a9efe58fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_8fc49459-7d95-48f3-96a8-fc471ad18f35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea8ecca2-c0e7-47e8-ada3-ca68fdfd726a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_8fc49459-7d95-48f3-96a8-fc471ad18f35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ecab3ae3-993b-42e8-b95e-f8c99b21a927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea8ecca2-c0e7-47e8-ada3-ca68fdfd726a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ecab3ae3-993b-42e8-b95e-f8c99b21a927" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#DebtSecuritiesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_a7eec258-f9ac-4e5a-8b3f-3f15a423da6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_e15034fb-6951-4dbf-989b-c8472746f0aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_a7eec258-f9ac-4e5a-8b3f-3f15a423da6a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_e15034fb-6951-4dbf-989b-c8472746f0aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_c9a0abaf-29a6-4dc9-9ebc-fee8915c87a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_a7eec258-f9ac-4e5a-8b3f-3f15a423da6a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_c9a0abaf-29a6-4dc9-9ebc-fee8915c87a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f43ed6fe-e289-4bea-a57d-ce8d1a9ea65c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_cb06ebdc-cb7e-4ecc-aefd-a2b810ca0507" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f43ed6fe-e289-4bea-a57d-ce8d1a9ea65c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_cb06ebdc-cb7e-4ecc-aefd-a2b810ca0507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_833d8016-42c2-40c5-a1e8-96b327f42940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f43ed6fe-e289-4bea-a57d-ce8d1a9ea65c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_833d8016-42c2-40c5-a1e8-96b327f42940" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="nbix-20200930.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="nbix-20200930.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail" xlink:type="simple" xlink:href="nbix-20200930.xsd#FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/Inventories" xlink:type="simple" xlink:href="nbix-20200930.xsd#Inventories"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/Inventories" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/InventoriesTables" xlink:type="simple" xlink:href="nbix-20200930.xsd#InventoriesTables"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/InventoriesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#InventoriesSummaryofInventoriesDetail"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_db806428-fc0c-4aa3-a456-17f6bcded053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_360d95e6-7808-4004-8bb4-9d0410fb7031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_db806428-fc0c-4aa3-a456-17f6bcded053" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_360d95e6-7808-4004-8bb4-9d0410fb7031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_218959b1-e579-41ee-a81e-0d69fd47ac12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_db806428-fc0c-4aa3-a456-17f6bcded053" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_218959b1-e579-41ee-a81e-0d69fd47ac12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ef324e98-4a8a-40eb-a003-8a8a415a229e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_db806428-fc0c-4aa3-a456-17f6bcded053" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_ef324e98-4a8a-40eb-a003-8a8a415a229e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash" xlink:type="simple" xlink:href="nbix-20200930.xsd#CashCashEquivalentsandRestrictedCash"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables" xlink:type="simple" xlink:href="nbix-20200930.xsd#CashCashEquivalentsandRestrictedCashTables"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_273d1c01-caaa-47f6-9b01-7cc7e02efb27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_22be5397-3e7b-454d-a519-3ef14529ac49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_273d1c01-caaa-47f6-9b01-7cc7e02efb27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_22be5397-3e7b-454d-a519-3ef14529ac49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_ad20e146-1d82-4574-8e07-775700a0102d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_273d1c01-caaa-47f6-9b01-7cc7e02efb27" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_ad20e146-1d82-4574-8e07-775700a0102d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/Leases" xlink:type="simple" xlink:href="nbix-20200930.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesTables" xlink:type="simple" xlink:href="nbix-20200930.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesDisclosureDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#LeasesDisclosureDetail"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/LeasesDisclosureDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#LeasesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/LeasesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#LeasesLiabilityPaymentDueDetail"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6cd3d222-92e8-4170-8748-1526193ba1ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_11d3c302-5d36-45e2-9ee7-e9ba24f1c278" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6cd3d222-92e8-4170-8748-1526193ba1ce" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_11d3c302-5d36-45e2-9ee7-e9ba24f1c278" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0c693d6e-d8c6-4a1c-bda1-e666729a621e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6cd3d222-92e8-4170-8748-1526193ba1ce" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0c693d6e-d8c6-4a1c-bda1-e666729a621e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0a8279d9-6135-4523-86ea-1a3402ee2025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6cd3d222-92e8-4170-8748-1526193ba1ce" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0a8279d9-6135-4523-86ea-1a3402ee2025" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3ee8d669-7ea2-4ca0-8554-b98b51f565b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6cd3d222-92e8-4170-8748-1526193ba1ce" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3ee8d669-7ea2-4ca0-8554-b98b51f565b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5553d72d-d889-40cf-8379-bf770bbd1b5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6cd3d222-92e8-4170-8748-1526193ba1ce" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5553d72d-d889-40cf-8379-bf770bbd1b5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_c0b5660c-ea4b-4933-8172-a5ffd7ba6f4d" xlink:href="nbix-20200930.xsd#nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6cd3d222-92e8-4170-8748-1526193ba1ce" xlink:to="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_c0b5660c-ea4b-4933-8172-a5ffd7ba6f4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_056b5541-b4c0-4dd4-bc66-2df83a0ee616" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0902bbc4-188f-457e-90cf-5157dd9ba5d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_056b5541-b4c0-4dd4-bc66-2df83a0ee616" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_0902bbc4-188f-457e-90cf-5157dd9ba5d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_08f7d550-7ff9-4631-8a97-1d19ba048af4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_056b5541-b4c0-4dd4-bc66-2df83a0ee616" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_08f7d550-7ff9-4631-8a97-1d19ba048af4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail_1" xlink:type="simple" xlink:href="nbix-20200930.xsd#LeasesLiabilityPaymentDueDetail_1"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_43e01cdc-6185-41a2-baf9-e1483239fce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fe228b4a-d2ae-4817-82ae-33ad04f63e7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_43e01cdc-6185-41a2-baf9-e1483239fce0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fe228b4a-d2ae-4817-82ae-33ad04f63e7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_119912d5-b221-408c-b578-b7737162ac74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_43e01cdc-6185-41a2-baf9-e1483239fce0" xlink:to="loc_us-gaap_OperatingLeaseLiability_119912d5-b221-408c-b578-b7737162ac74" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes" xlink:type="simple" xlink:href="nbix-20200930.xsd#ConvertibleSeniorNotes"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables" xlink:type="simple" xlink:href="nbix-20200930.xsd#ConvertibleSeniorNotesTables"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#ConvertibleSeniorNotesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_30ceab64-041e-467d-b7c5-c568c7e575b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_46f04848-621a-443d-943c-7e858879868a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_30ceab64-041e-467d-b7c5-c568c7e575b3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_46f04848-621a-443d-943c-7e858879868a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_3b62538b-9bf6-48b2-8fb7-3f821c7624c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_30ceab64-041e-467d-b7c5-c568c7e575b3" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_3b62538b-9bf6-48b2-8fb7-3f821c7624c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_a62918ef-c4a1-437b-b16b-7f9ead36b66f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_30ceab64-041e-467d-b7c5-c568c7e575b3" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_a62918ef-c4a1-437b-b16b-7f9ead36b66f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetLossIncomePerShare" xlink:type="simple" xlink:href="nbix-20200930.xsd#NetLossIncomePerShare"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/NetLossIncomePerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetLossIncomePerShareTables" xlink:type="simple" xlink:href="nbix-20200930.xsd#NetLossIncomePerShareTables"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/NetLossIncomePerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#NetLossIncomePerShareScheduleofNetIncomePerShareDetail"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a8b541ed-bba3-4564-b08d-9f7ee5f5e1f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_62f866bf-c15b-4ec4-b347-e701e97fb5c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a8b541ed-bba3-4564-b08d-9f7ee5f5e1f2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_62f866bf-c15b-4ec4-b347-e701e97fb5c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4facd533-49f2-4fb2-8fbc-3e35085713d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a8b541ed-bba3-4564-b08d-9f7ee5f5e1f2" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_4facd533-49f2-4fb2-8fbc-3e35085713d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_88203821-0fca-4ee4-b5c2-d78b0c39e0db" xlink:href="nbix-20200930.xsd#nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a8b541ed-bba3-4564-b08d-9f7ee5f5e1f2" xlink:to="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_88203821-0fca-4ee4-b5c2-d78b0c39e0db" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetLossIncomePerShareAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#NetLossIncomePerShareAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.neurocrine.com/role/NetLossIncomePerShareAdditionalInformationDetail" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>nbix-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b79d3e40-aa4b-4356-aa3c-d2eb2732ffa0,g:9f3edc10-8601-4580-b4de-4b1ad44f8b95-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CoverPage" xlink:type="simple" xlink:href="nbix-20200930.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/CoverPage" xlink:type="extended" id="ibba48f57c9a54dd29b4da12f1d309098_CoverPage"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nbix-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i0fd7c3928bf44cb299d6b6fccc486c1a_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nbix-20200930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i7d4e60e7c2424641a72c6b6668555f0d_CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" xlink:type="simple" xlink:href="nbix-20200930.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" xlink:type="extended" id="i7017f5d689a441f79d13d28b1ae6df8e_CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_9d4b59e2-0d65-40d1-81d4-098704afd0f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_RevenuesAbstract_9d4b59e2-0d65-40d1-81d4-098704afd0f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_33ba4188-6050-4313-853b-755d951e7163" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_9d4b59e2-0d65-40d1-81d4-098704afd0f6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_33ba4188-6050-4313-853b-755d951e7163" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1998520c-14c4-4325-ba98-9c2b148f433f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1998520c-14c4-4325-ba98-9c2b148f433f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_14c17962-601e-42e0-a481-b9747c0c849a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1998520c-14c4-4325-ba98-9c2b148f433f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_14c17962-601e-42e0-a481-b9747c0c849a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4df093ad-d3c5-4174-93c4-960dbf657d06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1998520c-14c4-4325-ba98-9c2b148f433f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4df093ad-d3c5-4174-93c4-960dbf657d06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_766d076a-e740-4993-800f-485e4df2c2e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1998520c-14c4-4325-ba98-9c2b148f433f" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_766d076a-e740-4993-800f-485e4df2c2e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_73512a62-ffcb-486a-be98-2a1e266fe081" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1998520c-14c4-4325-ba98-9c2b148f433f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_73512a62-ffcb-486a-be98-2a1e266fe081" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0f9b6aca-75c1-46c4-94a8-3172d443ea4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1998520c-14c4-4325-ba98-9c2b148f433f" xlink:to="loc_us-gaap_CostsAndExpenses_0f9b6aca-75c1-46c4-94a8-3172d443ea4e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d3e7c5fd-8820-43f1-9b06-b11c348c3148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_OperatingIncomeLoss_d3e7c5fd-8820-43f1-9b06-b11c348c3148" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7cdcad13-605c-4370-8a52-2fbd3491893a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7cdcad13-605c-4370-8a52-2fbd3491893a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8ad1a7f0-bb8b-4cac-ab54-f60c2a31d1d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7cdcad13-605c-4370-8a52-2fbd3491893a" xlink:to="loc_us-gaap_InterestExpense_8ad1a7f0-bb8b-4cac-ab54-f60c2a31d1d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e0c00f84-947d-4b6a-8753-e8407bb1d23d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7cdcad13-605c-4370-8a52-2fbd3491893a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e0c00f84-947d-4b6a-8753-e8407bb1d23d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet_cf5ea9f3-539b-4a2c-bc12-2d95e31bc781" xlink:href="nbix-20200930.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7cdcad13-605c-4370-8a52-2fbd3491893a" xlink:to="loc_nbix_InvestmentIncomeAndOtherNet_cf5ea9f3-539b-4a2c-bc12-2d95e31bc781" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b5e78470-23cb-41d7-b14f-6aeda275b57a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7cdcad13-605c-4370-8a52-2fbd3491893a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_b5e78470-23cb-41d7-b14f-6aeda275b57a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ac9116c-fad5-4a24-829e-5552e1ddb8cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ac9116c-fad5-4a24-829e-5552e1ddb8cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3de2c483-f436-42c9-be08-4813127ec4ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3de2c483-f436-42c9-be08-4813127ec4ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ca93e1fb-303e-4830-9f87-c66dd4320f0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_NetIncomeLoss_ca93e1fb-303e-4830-9f87-c66dd4320f0e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5def406c-a291-452d-9bde-bf139020a7fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5def406c-a291-452d-9bde-bf139020a7fd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7f667e18-022b-4596-8f29-58ab927e8691" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_7f667e18-022b-4596-8f29-58ab927e8691" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3997c4e8-3b46-4f7e-9e13-2bb84718b137" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_EarningsPerShareBasic_3997c4e8-3b46-4f7e-9e13-2bb84718b137" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f8d64ee7-232d-453c-9290-1507825572ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f8d64ee7-232d-453c-9290-1507825572ed" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3608871a-346f-4253-81e4-a20736da4ed8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3608871a-346f-4253-81e4-a20736da4ed8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_23c44288-9ebd-4052-97e2-c2cc08c11a23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_23c44288-9ebd-4052-97e2-c2cc08c11a23" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_01606784-23b2-4037-9761-aefe3498c44a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_StatementTable_01606784-23b2-4037-9761-aefe3498c44a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_57a568ce-bc66-400f-8b52-6eaad889f7a2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_01606784-23b2-4037-9761-aefe3498c44a" xlink:to="loc_srt_ProductOrServiceAxis_57a568ce-bc66-400f-8b52-6eaad889f7a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_57a568ce-bc66-400f-8b52-6eaad889f7a2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_57a568ce-bc66-400f-8b52-6eaad889f7a2" xlink:to="loc_srt_ProductsAndServicesDomain_57a568ce-bc66-400f-8b52-6eaad889f7a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a55fb3d9-2cad-4c13-8fb1-db7cde7e472e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_57a568ce-bc66-400f-8b52-6eaad889f7a2" xlink:to="loc_srt_ProductsAndServicesDomain_a55fb3d9-2cad-4c13-8fb1-db7cde7e472e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e40de880-b3c4-4905-8d4d-668d66ceb6af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a55fb3d9-2cad-4c13-8fb1-db7cde7e472e" xlink:to="loc_us-gaap_ProductMember_e40de880-b3c4-4905-8d4d-668d66ceb6af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CollaborationRevenueMember_ae4d0e29-0999-4573-a9ce-fe0f8aea32a2" xlink:href="nbix-20200930.xsd#nbix_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a55fb3d9-2cad-4c13-8fb1-db7cde7e472e" xlink:to="loc_nbix_CollaborationRevenueMember_ae4d0e29-0999-4573-a9ce-fe0f8aea32a2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nbix-20200930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i6991681bb776496cbc3ce93cefc7f9fc_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_c8bc1f20-4e66-4679-9ce0-382080f9727d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_SharesOutstanding_c8bc1f20-4e66-4679-9ce0-382080f9727d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_04d69a8a-b428-4886-b231-1a817ff80742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_StockholdersEquity_04d69a8a-b428-4886-b231-1a817ff80742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_83d6399f-d0a6-44fd-8ae8-f146e71bc127" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_NetIncomeLoss_83d6399f-d0a6-44fd-8ae8-f146e71bc127" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8a81c28d-c6e2-450a-acef-ef4efb88583e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8a81c28d-c6e2-450a-acef-ef4efb88583e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ed4ba2b9-416c-45ea-9700-d609174b57cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ed4ba2b9-416c-45ea-9700-d609174b57cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_9cf5b634-4cc5-4196-8945-134ab0184b87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_9cf5b634-4cc5-4196-8945-134ab0184b87" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8fa5f91b-5b13-42ba-9e53-8d905ddbbe86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8fa5f91b-5b13-42ba-9e53-8d905ddbbe86" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7e1f5d0c-de4c-4514-a627-5009109dd7b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7e1f5d0c-de4c-4514-a627-5009109dd7b8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_307be4c9-5a3c-48ea-bb13-15bbe3593ad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_307be4c9-5a3c-48ea-bb13-15bbe3593ad6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_b66adf67-cf52-44b9-95ba-72d4b71788d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_b66adf67-cf52-44b9-95ba-72d4b71788d1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_5bd1a9e1-d5ab-4ecc-ad39-f71068d2b674" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3c41363e-0130-44f1-8253-b9781cd63a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_493d5c64-8eac-43bd-95a8-e2802dac823c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_493d5c64-8eac-43bd-95a8-e2802dac823c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cff7e972-2eb8-41ae-9885-3be11a614d4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_StatementTable_cff7e972-2eb8-41ae-9885-3be11a614d4e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_dd956f16-6cf9-4d2b-873e-8fae8254e132" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cff7e972-2eb8-41ae-9885-3be11a614d4e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_dd956f16-6cf9-4d2b-873e-8fae8254e132" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dd956f16-6cf9-4d2b-873e-8fae8254e132_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dd956f16-6cf9-4d2b-873e-8fae8254e132" xlink:to="loc_us-gaap_EquityComponentDomain_dd956f16-6cf9-4d2b-873e-8fae8254e132_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c0bcd89c-0157-4903-8e3f-472e08278465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dd956f16-6cf9-4d2b-873e-8fae8254e132" xlink:to="loc_us-gaap_EquityComponentDomain_c0bcd89c-0157-4903-8e3f-472e08278465" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cd870aca-b445-40cc-a2d9-78c8057382e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c0bcd89c-0157-4903-8e3f-472e08278465" xlink:to="loc_us-gaap_CommonStockMember_cd870aca-b445-40cc-a2d9-78c8057382e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3f677a73-2110-4c16-891e-1526fa37be11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c0bcd89c-0157-4903-8e3f-472e08278465" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3f677a73-2110-4c16-891e-1526fa37be11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5ae205c0-51a4-4fc7-b2d6-5cb909c37a61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c0bcd89c-0157-4903-8e3f-472e08278465" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5ae205c0-51a4-4fc7-b2d6-5cb909c37a61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_00c7c9f7-715b-47bd-a477-6b960fc377d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c0bcd89c-0157-4903-8e3f-472e08278465" xlink:to="loc_us-gaap_RetainedEarningsMember_00c7c9f7-715b-47bd-a477-6b960fc377d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e28f2d8e-6bab-402f-8207-0171d1985d38" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cff7e972-2eb8-41ae-9885-3be11a614d4e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e28f2d8e-6bab-402f-8207-0171d1985d38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e28f2d8e-6bab-402f-8207-0171d1985d38_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e28f2d8e-6bab-402f-8207-0171d1985d38" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e28f2d8e-6bab-402f-8207-0171d1985d38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3f4752d8-0ff7-4393-b036-684bd3cda839" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e28f2d8e-6bab-402f-8207-0171d1985d38" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3f4752d8-0ff7-4393-b036-684bd3cda839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_72b65054-8e01-4202-ae3d-1097ad285460" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3f4752d8-0ff7-4393-b036-684bd3cda839" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_72b65054-8e01-4202-ae3d-1097ad285460" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nbix-20200930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="id46d660b58644d9781d3be23effbdbb8_CondensedConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="nbix-20200930.xsd#OrganizationandSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="extended" id="i6fec5f99f4fd42a3a15ca6aa98ea3157_OrganizationandSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nbix-20200930.xsd#OrganizationandSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i7de6edfd975e44adbd473ce854436b0b_OrganizationandSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" id="i1cb7e094e4af4440a61f11ef6ac1a3bc_OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreements" xlink:type="simple" xlink:href="nbix-20200930.xsd#SignificantCollaborationandLicensingAgreements"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreements" xlink:type="extended" id="i29f38f74ac914581bdca16fe9436c8c4_SignificantCollaborationandLicensingAgreements"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail" xlink:type="extended" id="i6b706c71610c487ca0de77d5fc609222_SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsMade_402d0c35-116d-48a4-aa37-7fa1f80af850" xlink:href="nbix-20200930.xsd#nbix_UpfrontPaymentsMade"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_UpfrontPaymentsMade_402d0c35-116d-48a4-aa37-7fa1f80af850" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePayments_84a22bbf-b432-4a37-8ae7-a1a69284f573" xlink:href="nbix-20200930.xsd#nbix_PotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_PotentialMilestonePayments_84a22bbf-b432-4a37-8ae7-a1a69284f573" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_bc219551-ad7c-4d6c-a2d5-22e7bdc181ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_bc219551-ad7c-4d6c-a2d5-22e7bdc181ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ResearchCollaborationTerm_38630f62-55c9-4a84-a721-88a66f324b0e" xlink:href="nbix-20200930.xsd#nbix_ResearchCollaborationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_ResearchCollaborationTerm_38630f62-55c9-4a84-a721-88a66f324b0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialCommercialMilestonePayments_07ae1869-72e2-4d50-819d-6f0cfd227b76" xlink:href="nbix-20200930.xsd#nbix_PotentialCommercialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_PotentialCommercialMilestonePayments_07ae1869-72e2-4d50-819d-6f0cfd227b76" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TerminationNoticePeriod_92921dc6-914a-49ce-a251-5d50f03bb6fd" xlink:href="nbix-20200930.xsd#nbix_TerminationNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_TerminationNoticePeriod_92921dc6-914a-49ce-a251-5d50f03bb6fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TerminationNoticePeriodBeforeFirstCommercialSale_136d24a2-a491-4032-947d-9ad2f4cf8559" xlink:href="nbix-20200930.xsd#nbix_TerminationNoticePeriodBeforeFirstCommercialSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_TerminationNoticePeriodBeforeFirstCommercialSale_136d24a2-a491-4032-947d-9ad2f4cf8559" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TerminationNoticePeriodAfterFirstCommercialSale_9d0e5c80-39c7-4c31-baab-64c31ef47dad" xlink:href="nbix-20200930.xsd#nbix_TerminationNoticePeriodAfterFirstCommercialSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_TerminationNoticePeriodAfterFirstCommercialSale_9d0e5c80-39c7-4c31-baab-64c31ef47dad" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestonePayment_a7360b4f-35d7-4799-bf90-89b99a771325" xlink:href="nbix-20200930.xsd#nbix_MilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_MilestonePayment_a7360b4f-35d7-4799-bf90-89b99a771325" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumSalesRequirementPeriodThresholdToTerminateAgreement_ffd0aaf8-b742-4c86-864b-6b73561158f0" xlink:href="nbix-20200930.xsd#nbix_MinimumSalesRequirementPeriodThresholdToTerminateAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_MinimumSalesRequirementPeriodThresholdToTerminateAgreement_ffd0aaf8-b742-4c86-864b-6b73561158f0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2c315666-d441-4243-968e-fc4b048e85d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2c315666-d441-4243-968e-fc4b048e85d0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_abecdd5d-d7cd-4c91-9846-23b8f90a2b16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_abecdd5d-d7cd-4c91-9846-23b8f90a2b16" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsReceived_8617b491-b5a9-4099-957e-e170e6ba1a6a" xlink:href="nbix-20200930.xsd#nbix_UpfrontPaymentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_UpfrontPaymentsReceived_8617b491-b5a9-4099-957e-e170e6ba1a6a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cdc416db-6d25-458e-8924-796a966a210e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cdc416db-6d25-458e-8924-796a966a210e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePaymentReceipts_c20a89b3-08f5-4aa5-8597-aeabc7be42f4" xlink:href="nbix-20200930.xsd#nbix_PotentialMilestonePaymentReceipts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_PotentialMilestonePaymentReceipts_c20a89b3-08f5-4aa5-8597-aeabc7be42f4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PatentTerm_688d748d-56c3-413b-8f4d-312d56e6a3f1" xlink:href="nbix-20200930.xsd#nbix_PatentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_PatentTerm_688d748d-56c3-413b-8f4d-312d56e6a3f1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e81119b5-a85d-4157-bdc4-8e5d7c1b1f42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e81119b5-a85d-4157-bdc4-8e5d7c1b1f42" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c5e46bf8-3b9a-4dc4-bbc2-eb72fef6578e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e81119b5-a85d-4157-bdc4-8e5d7c1b1f42" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c5e46bf8-3b9a-4dc4-bbc2-eb72fef6578e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c5e46bf8-3b9a-4dc4-bbc2-eb72fef6578e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c5e46bf8-3b9a-4dc4-bbc2-eb72fef6578e" xlink:to="loc_us-gaap_RelatedPartyDomain_c5e46bf8-3b9a-4dc4-bbc2-eb72fef6578e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_31ece9eb-5ab3-41dd-b95c-6f79bf9684a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c5e46bf8-3b9a-4dc4-bbc2-eb72fef6578e" xlink:to="loc_us-gaap_RelatedPartyDomain_31ece9eb-5ab3-41dd-b95c-6f79bf9684a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_b5013b3c-27b7-40eb-92bc-76d806912b5e" xlink:href="nbix-20200930.xsd#nbix_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_31ece9eb-5ab3-41dd-b95c-6f79bf9684a6" xlink:to="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_b5013b3c-27b7-40eb-92bc-76d806912b5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IdorsiaPharmaceuticalsLtdMember_bd3f66fd-5374-4160-8e88-a24b9c518281" xlink:href="nbix-20200930.xsd#nbix_IdorsiaPharmaceuticalsLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_31ece9eb-5ab3-41dd-b95c-6f79bf9684a6" xlink:to="loc_nbix_IdorsiaPharmaceuticalsLtdMember_bd3f66fd-5374-4160-8e88-a24b9c518281" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember_85645ae4-6a98-40ce-a6d9-fbb5ab8a709d" xlink:href="nbix-20200930.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_31ece9eb-5ab3-41dd-b95c-6f79bf9684a6" xlink:to="loc_nbix_XenonPharmaceuticalsIncMember_85645ae4-6a98-40ce-a6d9-fbb5ab8a709d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember_107a9f0e-e632-4099-9fdf-9c1e5c8119c2" xlink:href="nbix-20200930.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_31ece9eb-5ab3-41dd-b95c-6f79bf9684a6" xlink:to="loc_nbix_VoyagerTherapeuticsMember_107a9f0e-e632-4099-9fdf-9c1e5c8119c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BIALMember_81bea410-ff48-4e90-a4bc-0242f366c677" xlink:href="nbix-20200930.xsd#nbix_BIALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_31ece9eb-5ab3-41dd-b95c-6f79bf9684a6" xlink:to="loc_nbix_BIALMember_81bea410-ff48-4e90-a4bc-0242f366c677" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MitsubishiTanabePharmaCorporationMember_46167b35-1129-441c-aaa8-9097267965c1" xlink:href="nbix-20200930.xsd#nbix_MitsubishiTanabePharmaCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_31ece9eb-5ab3-41dd-b95c-6f79bf9684a6" xlink:to="loc_nbix_MitsubishiTanabePharmaCorporationMember_46167b35-1129-441c-aaa8-9097267965c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AbbvieIncMember_c913a34a-9774-4632-a185-a8b344990cc7" xlink:href="nbix-20200930.xsd#nbix_AbbvieIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_31ece9eb-5ab3-41dd-b95c-6f79bf9684a6" xlink:to="loc_nbix_AbbvieIncMember_c913a34a-9774-4632-a185-a8b344990cc7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c42eec6d-8779-4884-a898-8763043babb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e81119b5-a85d-4157-bdc4-8e5d7c1b1f42" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c42eec6d-8779-4884-a898-8763043babb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c42eec6d-8779-4884-a898-8763043babb8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c42eec6d-8779-4884-a898-8763043babb8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c42eec6d-8779-4884-a898-8763043babb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5b2abc66-a51f-432c-88b2-558a9018cadf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c42eec6d-8779-4884-a898-8763043babb8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5b2abc66-a51f-432c-88b2-558a9018cadf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_b27f36d9-b9a0-4602-bffa-ef6d2cd80d26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5b2abc66-a51f-432c-88b2-558a9018cadf" xlink:to="loc_us-gaap_CollaborativeArrangementMember_b27f36d9-b9a0-4602-bffa-ef6d2cd80d26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_affb7cfd-8b31-4811-aba4-69b38fd32534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e81119b5-a85d-4157-bdc4-8e5d7c1b1f42" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_affb7cfd-8b31-4811-aba4-69b38fd32534" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_affb7cfd-8b31-4811-aba4-69b38fd32534_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_affb7cfd-8b31-4811-aba4-69b38fd32534" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_affb7cfd-8b31-4811-aba4-69b38fd32534_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d4671450-fcf2-49fa-b13f-9308c00bab91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_affb7cfd-8b31-4811-aba4-69b38fd32534" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d4671450-fcf2-49fa-b13f-9308c00bab91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_835fce1c-e953-4cca-bacd-7db929e71166" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d4671450-fcf2-49fa-b13f-9308c00bab91" xlink:to="loc_us-gaap_PatentsMember_835fce1c-e953-4cca-bacd-7db929e71166" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e33901b1-5687-4c04-8a37-ad44b73654f1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e81119b5-a85d-4157-bdc4-8e5d7c1b1f42" xlink:to="loc_srt_RangeAxis_e33901b1-5687-4c04-8a37-ad44b73654f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e33901b1-5687-4c04-8a37-ad44b73654f1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e33901b1-5687-4c04-8a37-ad44b73654f1" xlink:to="loc_srt_RangeMember_e33901b1-5687-4c04-8a37-ad44b73654f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f90e24b5-5d9f-4ea3-b1a3-f79d0d9d4cb2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e33901b1-5687-4c04-8a37-ad44b73654f1" xlink:to="loc_srt_RangeMember_f90e24b5-5d9f-4ea3-b1a3-f79d0d9d4cb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_63577649-6dd7-428d-bd56-5b7d7d938f05" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f90e24b5-5d9f-4ea3-b1a3-f79d0d9d4cb2" xlink:to="loc_srt_MinimumMember_63577649-6dd7-428d-bd56-5b7d7d938f05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_45874085-65e8-4734-8e49-e30fe5ca4c97" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e81119b5-a85d-4157-bdc4-8e5d7c1b1f42" xlink:to="loc_srt_ProductOrServiceAxis_45874085-65e8-4734-8e49-e30fe5ca4c97" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_45874085-65e8-4734-8e49-e30fe5ca4c97_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_45874085-65e8-4734-8e49-e30fe5ca4c97" xlink:to="loc_srt_ProductsAndServicesDomain_45874085-65e8-4734-8e49-e30fe5ca4c97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b524c65e-dfa5-4d26-87e9-4f12c12b942a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_45874085-65e8-4734-8e49-e30fe5ca4c97" xlink:to="loc_srt_ProductsAndServicesDomain_b524c65e-dfa5-4d26-87e9-4f12c12b942a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NBI827104Member_5846fc20-91d1-49a2-8103-0b289636d131" xlink:href="nbix-20200930.xsd#nbix_NBI827104Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b524c65e-dfa5-4d26-87e9-4f12c12b942a" xlink:to="loc_nbix_NBI827104Member_5846fc20-91d1-49a2-8103-0b289636d131" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DevelopmentProductCandidatesMember_988a3c21-2912-4a4f-bb52-02b783494d23" xlink:href="nbix-20200930.xsd#nbix_DevelopmentProductCandidatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b524c65e-dfa5-4d26-87e9-4f12c12b942a" xlink:to="loc_nbix_DevelopmentProductCandidatesMember_988a3c21-2912-4a4f-bb52-02b783494d23" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecurities" xlink:type="simple" xlink:href="nbix-20200930.xsd#DebtSecurities"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/DebtSecurities" xlink:type="extended" id="id8e9ec24305046eaa0e0cd4e51b58dde_DebtSecurities"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesTables" xlink:type="simple" xlink:href="nbix-20200930.xsd#DebtSecuritiesTables"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesTables" xlink:type="extended" id="ifb4dca3999e346b68a98db9fdf9a79a2_DebtSecuritiesTables"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail" xlink:type="extended" id="i6574bcd893d14b19bcffb1df21a8c8dc_DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53c1abce-af7b-4085-895c-124222b14eb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_da0610b0-e267-41b7-866b-090d79bbe3ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53c1abce-af7b-4085-895c-124222b14eb7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_da0610b0-e267-41b7-866b-090d79bbe3ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_029d03cd-a5f8-4042-bd1f-0a2b02bdfcfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53c1abce-af7b-4085-895c-124222b14eb7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_029d03cd-a5f8-4042-bd1f-0a2b02bdfcfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_32fe936c-486a-4731-8034-a5322d0d7115" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53c1abce-af7b-4085-895c-124222b14eb7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_32fe936c-486a-4731-8034-a5322d0d7115" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_60fe6ee9-ca38-4354-8f36-79a9b48a00fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53c1abce-af7b-4085-895c-124222b14eb7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_60fe6ee9-ca38-4354-8f36-79a9b48a00fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_60a865fb-56ea-4eae-adff-3ba856443944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53c1abce-af7b-4085-895c-124222b14eb7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_60a865fb-56ea-4eae-adff-3ba856443944" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a3d7861d-4697-457d-be12-bea67cd2d13b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53c1abce-af7b-4085-895c-124222b14eb7" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a3d7861d-4697-457d-be12-bea67cd2d13b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_e35bfe6a-0736-46bc-88ba-db063effe9ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a3d7861d-4697-457d-be12-bea67cd2d13b" xlink:to="loc_us-gaap_InvestmentTypeAxis_e35bfe6a-0736-46bc-88ba-db063effe9ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_e35bfe6a-0736-46bc-88ba-db063effe9ca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_e35bfe6a-0736-46bc-88ba-db063effe9ca" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_e35bfe6a-0736-46bc-88ba-db063effe9ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_9a2284c3-bcbf-424c-9954-e051e9fa8be4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_e35bfe6a-0736-46bc-88ba-db063effe9ca" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_9a2284c3-bcbf-424c-9954-e051e9fa8be4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_efc61663-a4a8-4ba8-836b-7687072b0fde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_9a2284c3-bcbf-424c-9954-e051e9fa8be4" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_efc61663-a4a8-4ba8-836b-7687072b0fde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LongTermInvestmentsMember_5ef71b82-24c6-4b4d-9827-78964e88c851" xlink:href="nbix-20200930.xsd#nbix_LongTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_9a2284c3-bcbf-424c-9954-e051e9fa8be4" xlink:to="loc_nbix_LongTermInvestmentsMember_5ef71b82-24c6-4b4d-9827-78964e88c851" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_7a003c0a-6167-4300-a43d-0db0f153fa5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a3d7861d-4697-457d-be12-bea67cd2d13b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_7a003c0a-6167-4300-a43d-0db0f153fa5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7a003c0a-6167-4300-a43d-0db0f153fa5a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_7a003c0a-6167-4300-a43d-0db0f153fa5a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7a003c0a-6167-4300-a43d-0db0f153fa5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_80145d70-4fd3-41e6-93a1-3145dfbfaab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_7a003c0a-6167-4300-a43d-0db0f153fa5a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_80145d70-4fd3-41e6-93a1-3145dfbfaab4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_ba8dffee-1077-4b7e-b9ad-91d90e36718b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_80145d70-4fd3-41e6-93a1-3145dfbfaab4" xlink:to="loc_us-gaap_CommercialPaperMember_ba8dffee-1077-4b7e-b9ad-91d90e36718b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0372edeb-de7c-4e07-93ec-713ab5a2c56e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a3d7861d-4697-457d-be12-bea67cd2d13b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0372edeb-de7c-4e07-93ec-713ab5a2c56e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0372edeb-de7c-4e07-93ec-713ab5a2c56e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0372edeb-de7c-4e07-93ec-713ab5a2c56e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0372edeb-de7c-4e07-93ec-713ab5a2c56e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cdcd2646-eeca-4f40-88e0-9828420fb253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0372edeb-de7c-4e07-93ec-713ab5a2c56e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cdcd2646-eeca-4f40-88e0-9828420fb253" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_f04b0327-4cba-4129-aed4-319bdb5016a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cdcd2646-eeca-4f40-88e0-9828420fb253" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_f04b0327-4cba-4129-aed4-319bdb5016a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_745269e6-4528-4c51-bed2-2504386f6d62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cdcd2646-eeca-4f40-88e0-9828420fb253" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_745269e6-4528-4c51-bed2-2504386f6d62" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#DebtSecuritiesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetail" xlink:type="extended" id="i6cee474b815845a7a40d74274bb99c4a_DebtSecuritiesAdditionalInformationDetail"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail" xlink:type="extended" id="ie30cd21956024c7ab8b7ad2a293a2102_DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1274750d-37c9-42d6-87d8-797bcc3d70a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_ad4bba87-c980-430d-9e4f-0a490980cbb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1274750d-37c9-42d6-87d8-797bcc3d70a4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_ad4bba87-c980-430d-9e4f-0a490980cbb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_131b833f-0939-4d5a-8754-a5cff157f877" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1274750d-37c9-42d6-87d8-797bcc3d70a4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_131b833f-0939-4d5a-8754-a5cff157f877" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_ae365b43-15c1-4874-832d-9cd6417b40ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1274750d-37c9-42d6-87d8-797bcc3d70a4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_ae365b43-15c1-4874-832d-9cd6417b40ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_6011d14b-3c93-4b0d-ae5b-5fcb4573966f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1274750d-37c9-42d6-87d8-797bcc3d70a4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_6011d14b-3c93-4b0d-ae5b-5fcb4573966f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_e5199932-1635-474a-bb9a-d626048c30b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1274750d-37c9-42d6-87d8-797bcc3d70a4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_e5199932-1635-474a-bb9a-d626048c30b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_812c110b-acaa-433c-89f1-86b1c1dcaf71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1274750d-37c9-42d6-87d8-797bcc3d70a4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_812c110b-acaa-433c-89f1-86b1c1dcaf71" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_3a2528f4-0998-4144-b0ee-274036b55204" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1274750d-37c9-42d6-87d8-797bcc3d70a4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_3a2528f4-0998-4144-b0ee-274036b55204" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b8b573a4-79e2-42ac-b62a-9df7852b5aef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_3a2528f4-0998-4144-b0ee-274036b55204" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b8b573a4-79e2-42ac-b62a-9df7852b5aef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b8b573a4-79e2-42ac-b62a-9df7852b5aef_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b8b573a4-79e2-42ac-b62a-9df7852b5aef" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b8b573a4-79e2-42ac-b62a-9df7852b5aef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5b1702e-92a7-4a4f-a387-e1cf243b9938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b8b573a4-79e2-42ac-b62a-9df7852b5aef" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5b1702e-92a7-4a4f-a387-e1cf243b9938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_fb9c7cb9-fd4d-4750-a8fd-382c5c9db0f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5b1702e-92a7-4a4f-a387-e1cf243b9938" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_fb9c7cb9-fd4d-4750-a8fd-382c5c9db0f4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="nbix-20200930.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurements" xlink:type="extended" id="i1629e7fe09d04c14966fbf66eea06738_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="nbix-20200930.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i003556666397409c834cb0a20b037235_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended" id="ib57e12c382f746b9b11fb9d10d9647cc_FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8162c196-5c53-40d0-9261-06580d633aa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_0d81728b-4862-45a0-a437-75acee0bd82b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8162c196-5c53-40d0-9261-06580d633aa6" xlink:to="loc_us-gaap_Investments_0d81728b-4862-45a0-a437-75acee0bd82b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4b901382-12c8-4950-a430-e08933d6e4d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8162c196-5c53-40d0-9261-06580d633aa6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_4b901382-12c8-4950-a430-e08933d6e4d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1565fbf7-06df-4c96-a294-f59ab15da2ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8162c196-5c53-40d0-9261-06580d633aa6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1565fbf7-06df-4c96-a294-f59ab15da2ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_475f077b-90ea-48c3-ba8a-e8bcd47aecfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1565fbf7-06df-4c96-a294-f59ab15da2ba" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_475f077b-90ea-48c3-ba8a-e8bcd47aecfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_475f077b-90ea-48c3-ba8a-e8bcd47aecfe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_475f077b-90ea-48c3-ba8a-e8bcd47aecfe" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_475f077b-90ea-48c3-ba8a-e8bcd47aecfe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_567c32b3-b334-4f24-bfef-277d7ed0a0a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_475f077b-90ea-48c3-ba8a-e8bcd47aecfe" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_567c32b3-b334-4f24-bfef-277d7ed0a0a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CashAndMoneyMarketFundMember_e9cf1a99-2194-46e9-a789-d61ff6226a72" xlink:href="nbix-20200930.xsd#nbix_CashAndMoneyMarketFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_567c32b3-b334-4f24-bfef-277d7ed0a0a2" xlink:to="loc_nbix_CashAndMoneyMarketFundMember_e9cf1a99-2194-46e9-a789-d61ff6226a72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_23bcced9-a97a-4e46-9cfc-e03a6c8d0569" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_567c32b3-b334-4f24-bfef-277d7ed0a0a2" xlink:to="loc_us-gaap_CashEquivalentsMember_23bcced9-a97a-4e46-9cfc-e03a6c8d0569" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_3a3c5065-a294-4947-b915-c3e1a5aec586" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_567c32b3-b334-4f24-bfef-277d7ed0a0a2" xlink:to="loc_us-gaap_CertificatesOfDepositMember_3a3c5065-a294-4947-b915-c3e1a5aec586" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RestrictedCashMember_cc57da9f-dc5e-4817-bbae-adb9537b4a89" xlink:href="nbix-20200930.xsd#nbix_RestrictedCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_567c32b3-b334-4f24-bfef-277d7ed0a0a2" xlink:to="loc_nbix_RestrictedCashMember_cc57da9f-dc5e-4817-bbae-adb9537b4a89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_065773b0-f693-4a65-9368-2a97eb999a82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_567c32b3-b334-4f24-bfef-277d7ed0a0a2" xlink:to="loc_us-gaap_CommercialPaperMember_065773b0-f693-4a65-9368-2a97eb999a82" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2811cedf-06a8-48e7-b990-4740b3a75222" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1565fbf7-06df-4c96-a294-f59ab15da2ba" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2811cedf-06a8-48e7-b990-4740b3a75222" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2811cedf-06a8-48e7-b990-4740b3a75222_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2811cedf-06a8-48e7-b990-4740b3a75222" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2811cedf-06a8-48e7-b990-4740b3a75222_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b30c03b1-4621-4b02-8f33-52986136fc89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2811cedf-06a8-48e7-b990-4740b3a75222" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b30c03b1-4621-4b02-8f33-52986136fc89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3ebeca28-4cba-4263-909e-fa498d1acfdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b30c03b1-4621-4b02-8f33-52986136fc89" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3ebeca28-4cba-4263-909e-fa498d1acfdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_5c17e716-cbcc-49d6-a6f3-7e458f811a9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b30c03b1-4621-4b02-8f33-52986136fc89" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_5c17e716-cbcc-49d6-a6f3-7e458f811a9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_9b971767-41f6-4534-986f-d234b0c5748c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b30c03b1-4621-4b02-8f33-52986136fc89" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_9b971767-41f6-4534-986f-d234b0c5748c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_a0e74384-e7b6-4bf7-92f4-c9a97f06dc77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b30c03b1-4621-4b02-8f33-52986136fc89" xlink:to="loc_us-gaap_EquitySecuritiesMember_a0e74384-e7b6-4bf7-92f4-c9a97f06dc77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TotalEquitySecuritiesMember_1a527493-3a7f-448b-84c8-cca8f2d4505d" xlink:href="nbix-20200930.xsd#nbix_TotalEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b30c03b1-4621-4b02-8f33-52986136fc89" xlink:to="loc_nbix_TotalEquitySecuritiesMember_1a527493-3a7f-448b-84c8-cca8f2d4505d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d95bed3b-5711-4c78-905e-9bf8e3a9dee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1565fbf7-06df-4c96-a294-f59ab15da2ba" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d95bed3b-5711-4c78-905e-9bf8e3a9dee9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d95bed3b-5711-4c78-905e-9bf8e3a9dee9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d95bed3b-5711-4c78-905e-9bf8e3a9dee9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d95bed3b-5711-4c78-905e-9bf8e3a9dee9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c558837a-8d85-4e48-92fc-9509a15918be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d95bed3b-5711-4c78-905e-9bf8e3a9dee9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c558837a-8d85-4e48-92fc-9509a15918be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2e1d4c7b-46b0-4a50-8af9-da6b98314494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c558837a-8d85-4e48-92fc-9509a15918be" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2e1d4c7b-46b0-4a50-8af9-da6b98314494" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c1f29f31-480b-402b-8da5-a546ddaa8317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c558837a-8d85-4e48-92fc-9509a15918be" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c1f29f31-480b-402b-8da5-a546ddaa8317" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_cc9e9f29-48c4-48fc-8a6c-7dbbd6a461c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c558837a-8d85-4e48-92fc-9509a15918be" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_cc9e9f29-48c4-48fc-8a6c-7dbbd6a461c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_547c9fb7-7642-4987-8a44-29b456258a51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1565fbf7-06df-4c96-a294-f59ab15da2ba" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_547c9fb7-7642-4987-8a44-29b456258a51" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_547c9fb7-7642-4987-8a44-29b456258a51_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_547c9fb7-7642-4987-8a44-29b456258a51" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_547c9fb7-7642-4987-8a44-29b456258a51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9017ec14-6de6-4806-b288-72b0772ae1c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_547c9fb7-7642-4987-8a44-29b456258a51" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9017ec14-6de6-4806-b288-72b0772ae1c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_57397cd4-eab2-4cb7-a66a-9004e5c117c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9017ec14-6de6-4806-b288-72b0772ae1c2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_57397cd4-eab2-4cb7-a66a-9004e5c117c3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail" xlink:type="simple" xlink:href="nbix-20200930.xsd#FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail" xlink:type="extended" id="i3b63a221ed5a40689c5222de54b8e7ed_FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04368f98-b4af-49f5-b820-e478ccb7106f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_30b683e5-6ea1-4092-9b7b-b9d15a6533ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04368f98-b4af-49f5-b820-e478ccb7106f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRestricted_30b683e5-6ea1-4092-9b7b-b9d15a6533ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_f1faba3b-8bc6-42df-ab2b-c4314ce4c5c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04368f98-b4af-49f5-b820-e478ccb7106f" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_f1faba3b-8bc6-42df-ab2b-c4314ce4c5c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_dedab84a-2c52-4086-a46f-3c5ec2700a04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04368f98-b4af-49f5-b820-e478ccb7106f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_dedab84a-2c52-4086-a46f-3c5ec2700a04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_58bc1a8a-aaaa-442d-9fe9-4152ff589b41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9637a207-5d3e-41fa-95c7-c08c4e79bc4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04368f98-b4af-49f5-b820-e478ccb7106f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9637a207-5d3e-41fa-95c7-c08c4e79bc4a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAxis_091d594c-33b1-49ad-a30a-4b8cb72abf66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9637a207-5d3e-41fa-95c7-c08c4e79bc4a" xlink:to="loc_us-gaap_CollateralAxis_091d594c-33b1-49ad-a30a-4b8cb72abf66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain_091d594c-33b1-49ad-a30a-4b8cb72abf66_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CollateralAxis_091d594c-33b1-49ad-a30a-4b8cb72abf66" xlink:to="loc_us-gaap_CollateralDomain_091d594c-33b1-49ad-a30a-4b8cb72abf66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain_1b49dda6-fe7c-4f01-98b5-d2f33189ff49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CollateralAxis_091d594c-33b1-49ad-a30a-4b8cb72abf66" xlink:to="loc_us-gaap_CollateralDomain_1b49dda6-fe7c-4f01-98b5-d2f33189ff49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_6703e8d6-24f5-426a-8ce5-e32627504105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollateralDomain_1b49dda6-fe7c-4f01-98b5-d2f33189ff49" xlink:to="loc_us-gaap_EquitySecuritiesMember_6703e8d6-24f5-426a-8ce5-e32627504105" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_beb636ce-7f4d-4afd-9271-fe37b77f6b3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9637a207-5d3e-41fa-95c7-c08c4e79bc4a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_beb636ce-7f4d-4afd-9271-fe37b77f6b3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_beb636ce-7f4d-4afd-9271-fe37b77f6b3b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_beb636ce-7f4d-4afd-9271-fe37b77f6b3b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_beb636ce-7f4d-4afd-9271-fe37b77f6b3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_316ace04-bc7e-4f5c-9da6-6c77b040e546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_beb636ce-7f4d-4afd-9271-fe37b77f6b3b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_316ace04-bc7e-4f5c-9da6-6c77b040e546" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6427952e-511f-456f-861c-15e06322f5c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_316ace04-bc7e-4f5c-9da6-6c77b040e546" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6427952e-511f-456f-861c-15e06322f5c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e98f08f5-2430-476e-8c5c-a32cee181fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9637a207-5d3e-41fa-95c7-c08c4e79bc4a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e98f08f5-2430-476e-8c5c-a32cee181fb5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e98f08f5-2430-476e-8c5c-a32cee181fb5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e98f08f5-2430-476e-8c5c-a32cee181fb5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e98f08f5-2430-476e-8c5c-a32cee181fb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4d8b91a6-be70-4a93-959e-499bc9295f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e98f08f5-2430-476e-8c5c-a32cee181fb5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4d8b91a6-be70-4a93-959e-499bc9295f1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d71c6cf2-a8e1-48b1-9ea0-760c342d3eb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4d8b91a6-be70-4a93-959e-499bc9295f1b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d71c6cf2-a8e1-48b1-9ea0-760c342d3eb5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended" id="i086f397c4cf644e8ba281bb048b4f330_FairValueMeasurementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ee6933ad-e000-43f9-95b2-1d196f54a7bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_5d512a09-1e15-4541-a72a-bdbdefcfead9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ee6933ad-e000-43f9-95b2-1d196f54a7bd" xlink:to="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_5d512a09-1e15-4541-a72a-bdbdefcfead9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b66bdbac-3bf5-49a2-83f8-8eee2ed672d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ee6933ad-e000-43f9-95b2-1d196f54a7bd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b66bdbac-3bf5-49a2-83f8-8eee2ed672d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_810a1568-cbf1-4c7b-898f-0336ad6e3417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b66bdbac-3bf5-49a2-83f8-8eee2ed672d3" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_810a1568-cbf1-4c7b-898f-0336ad6e3417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_810a1568-cbf1-4c7b-898f-0336ad6e3417_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_810a1568-cbf1-4c7b-898f-0336ad6e3417" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_810a1568-cbf1-4c7b-898f-0336ad6e3417_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_3fd04393-3b34-4013-a3f1-10ab7694c367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_810a1568-cbf1-4c7b-898f-0336ad6e3417" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_3fd04393-3b34-4013-a3f1-10ab7694c367" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_f9758211-f4eb-4c75-a173-a2deb46441d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3fd04393-3b34-4013-a3f1-10ab7694c367" xlink:to="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_f9758211-f4eb-4c75-a173-a2deb46441d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9ef13c53-b3d7-4db1-ace6-bb95aafb31a7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b66bdbac-3bf5-49a2-83f8-8eee2ed672d3" xlink:to="loc_srt_RangeAxis_9ef13c53-b3d7-4db1-ace6-bb95aafb31a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9ef13c53-b3d7-4db1-ace6-bb95aafb31a7_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9ef13c53-b3d7-4db1-ace6-bb95aafb31a7" xlink:to="loc_srt_RangeMember_9ef13c53-b3d7-4db1-ace6-bb95aafb31a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5f5e2f1f-6f94-4ca2-86ed-f71a1bbe1e4e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9ef13c53-b3d7-4db1-ace6-bb95aafb31a7" xlink:to="loc_srt_RangeMember_5f5e2f1f-6f94-4ca2-86ed-f71a1bbe1e4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cd809249-098d-4d1f-adf0-0ed06cc90e7e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5f5e2f1f-6f94-4ca2-86ed-f71a1bbe1e4e" xlink:to="loc_srt_MinimumMember_cd809249-098d-4d1f-adf0-0ed06cc90e7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e3a15cb7-c87d-41fd-ac7d-049e26520ae7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5f5e2f1f-6f94-4ca2-86ed-f71a1bbe1e4e" xlink:to="loc_srt_MaximumMember_e3a15cb7-c87d-41fd-ac7d-049e26520ae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_b87cb46c-ed13-4e8d-a62c-7801cbaf43fa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5f5e2f1f-6f94-4ca2-86ed-f71a1bbe1e4e" xlink:to="loc_srt_WeightedAverageMember_b87cb46c-ed13-4e8d-a62c-7801cbaf43fa" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/Inventories" xlink:type="simple" xlink:href="nbix-20200930.xsd#Inventories"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/Inventories" xlink:type="extended" id="i278053c74a774d3bbe6dcbe72d4a9d7e_Inventories"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/InventoriesTables" xlink:type="simple" xlink:href="nbix-20200930.xsd#InventoriesTables"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/InventoriesTables" xlink:type="extended" id="i2c74f2a044ab4822b5bc42e06538597a_InventoriesTables"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#InventoriesSummaryofInventoriesDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail" xlink:type="extended" id="iff44156afa274cfc95d58d369e0e2fbf_InventoriesSummaryofInventoriesDetail"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash" xlink:type="simple" xlink:href="nbix-20200930.xsd#CashCashEquivalentsandRestrictedCash"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash" xlink:type="extended" id="ib3bcf5dba74e4648a9ffc30fba837e77_CashCashEquivalentsandRestrictedCash"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables" xlink:type="simple" xlink:href="nbix-20200930.xsd#CashCashEquivalentsandRestrictedCashTables"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables" xlink:type="extended" id="i785dba71450a46b1bc7b89bd20512544_CashCashEquivalentsandRestrictedCashTables"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="extended" id="ib4e30575f68e43b0a3e3844061d1f642_CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/Leases" xlink:type="simple" xlink:href="nbix-20200930.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/Leases" xlink:type="extended" id="i2072920d7eb044ea8e0848276a06543e_Leases"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesTables" xlink:type="simple" xlink:href="nbix-20200930.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/LeasesTables" xlink:type="extended" id="ieb8e795c730f45eb8995867149df64f2_LeasesTables"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesDisclosureDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#LeasesDisclosureDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/LeasesDisclosureDetail" xlink:type="extended" id="i9b6aa8d72b5f45839791d682a7164f51_LeasesDisclosureDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_f0547358-901a-4469-b16c-74b593b3be69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_5f242fd4-e03d-4e11-b09c-03280069d6a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f0547358-901a-4469-b16c-74b593b3be69" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_5f242fd4-e03d-4e11-b09c-03280069d6a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfRenewalOptions_9272d06b-2b1b-40b0-a758-555b53d214fe" xlink:href="nbix-20200930.xsd#nbix_NumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f0547358-901a-4469-b16c-74b593b3be69" xlink:to="loc_nbix_NumberOfRenewalOptions_9272d06b-2b1b-40b0-a758-555b53d214fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7f3a1437-7034-4c29-8627-681270111cf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f0547358-901a-4469-b16c-74b593b3be69" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7f3a1437-7034-4c29-8627-681270111cf8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_d00ab94c-0912-4ece-9c4d-7f9fafc05fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f0547358-901a-4469-b16c-74b593b3be69" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_d00ab94c-0912-4ece-9c4d-7f9fafc05fb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_3f885d80-8df0-4204-b4df-f836e7cebd70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f0547358-901a-4469-b16c-74b593b3be69" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_3f885d80-8df0-4204-b4df-f836e7cebd70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_28ec0827-c5c0-4460-be0f-df244969c68b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3f885d80-8df0-4204-b4df-f836e7cebd70" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_28ec0827-c5c0-4460-be0f-df244969c68b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_28ec0827-c5c0-4460-be0f-df244969c68b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_28ec0827-c5c0-4460-be0f-df244969c68b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_28ec0827-c5c0-4460-be0f-df244969c68b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6809f23-51fa-4c9d-b7b7-191b32470097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_28ec0827-c5c0-4460-be0f-df244969c68b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6809f23-51fa-4c9d-b7b7-191b32470097" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A12780ElCaminoRealMember_8ba4b5ff-d5d7-4d5c-b508-425f13ff8b84" xlink:href="nbix-20200930.xsd#nbix_A12780ElCaminoRealMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6809f23-51fa-4c9d-b7b7-191b32470097" xlink:to="loc_nbix_A12780ElCaminoRealMember_8ba4b5ff-d5d7-4d5c-b508-425f13ff8b84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A12790ElCaminoRealSuite130Member_54a2b725-5fa8-45ff-95e8-f81796d4aefb" xlink:href="nbix-20200930.xsd#nbix_A12790ElCaminoRealSuite130Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6809f23-51fa-4c9d-b7b7-191b32470097" xlink:to="loc_nbix_A12790ElCaminoRealSuite130Member_54a2b725-5fa8-45ff-95e8-f81796d4aefb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A12790ElCaminoRealSuite150Member_9d00a2c6-e86a-473c-94c9-a7516d35bb67" xlink:href="nbix-20200930.xsd#nbix_A12790ElCaminoRealSuite150Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6809f23-51fa-4c9d-b7b7-191b32470097" xlink:to="loc_nbix_A12790ElCaminoRealSuite150Member_9d00a2c6-e86a-473c-94c9-a7516d35bb67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A12790ElCaminoRealSuite300Member_64813615-b7b8-4f46-a182-2d3212d17bf0" xlink:href="nbix-20200930.xsd#nbix_A12790ElCaminoRealSuite300Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6809f23-51fa-4c9d-b7b7-191b32470097" xlink:to="loc_nbix_A12790ElCaminoRealSuite300Member_64813615-b7b8-4f46-a182-2d3212d17bf0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A12777HighBluffDriveMember_e23beb61-1959-4306-a8a6-d1d21565562f" xlink:href="nbix-20200930.xsd#nbix_A12777HighBluffDriveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6809f23-51fa-4c9d-b7b7-191b32470097" xlink:to="loc_nbix_A12777HighBluffDriveMember_e23beb61-1959-4306-a8a6-d1d21565562f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A12790ElCaminoRealSuite200Member_a89aedce-a45f-48c2-b92b-e6847b38e36d" xlink:href="nbix-20200930.xsd#nbix_A12790ElCaminoRealSuite200Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6809f23-51fa-4c9d-b7b7-191b32470097" xlink:to="loc_nbix_A12790ElCaminoRealSuite200Member_a89aedce-a45f-48c2-b92b-e6847b38e36d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A12790ElCaminoRealSuite100Member_08a62074-ba34-41c4-9c5e-99523fb3594f" xlink:href="nbix-20200930.xsd#nbix_A12790ElCaminoRealSuite100Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6809f23-51fa-4c9d-b7b7-191b32470097" xlink:to="loc_nbix_A12790ElCaminoRealSuite100Member_08a62074-ba34-41c4-9c5e-99523fb3594f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_4dab0c5f-9e73-464d-a718-07279f05a666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3f885d80-8df0-4204-b4df-f836e7cebd70" xlink:to="loc_us-gaap_LeaseContractualTermAxis_4dab0c5f-9e73-464d-a718-07279f05a666" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_4dab0c5f-9e73-464d-a718-07279f05a666_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_4dab0c5f-9e73-464d-a718-07279f05a666" xlink:to="loc_us-gaap_LeaseContractualTermDomain_4dab0c5f-9e73-464d-a718-07279f05a666_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_01685bad-bdf9-40fa-88a0-aad063b643f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_4dab0c5f-9e73-464d-a718-07279f05a666" xlink:to="loc_us-gaap_LeaseContractualTermDomain_01685bad-bdf9-40fa-88a0-aad063b643f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A1278012790ElCaminoRealMasterLeaseMember_c984ff8a-3ed4-4114-b710-b20f4debaa9b" xlink:href="nbix-20200930.xsd#nbix_A1278012790ElCaminoRealMasterLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_01685bad-bdf9-40fa-88a0-aad063b643f2" xlink:to="loc_nbix_A1278012790ElCaminoRealMasterLeaseMember_c984ff8a-3ed4-4114-b710-b20f4debaa9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_61999c2a-4e11-42c7-87fd-2ac2de2324c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3f885d80-8df0-4204-b4df-f836e7cebd70" xlink:to="loc_us-gaap_CreditFacilityAxis_61999c2a-4e11-42c7-87fd-2ac2de2324c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_61999c2a-4e11-42c7-87fd-2ac2de2324c7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_61999c2a-4e11-42c7-87fd-2ac2de2324c7" xlink:to="loc_us-gaap_CreditFacilityDomain_61999c2a-4e11-42c7-87fd-2ac2de2324c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_dc4d1ece-5a72-407b-8a60-0dc41edb24c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_61999c2a-4e11-42c7-87fd-2ac2de2324c7" xlink:to="loc_us-gaap_CreditFacilityDomain_dc4d1ece-5a72-407b-8a60-0dc41edb24c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_314481ec-a658-464d-ba35-49b3d9696be1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_dc4d1ece-5a72-407b-8a60-0dc41edb24c3" xlink:to="loc_us-gaap_LetterOfCreditMember_314481ec-a658-464d-ba35-49b3d9696be1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#LeasesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/LeasesAdditionalInformationDetail" xlink:type="extended" id="ie070a63bf9584bb89c937cb80568a16f_LeasesAdditionalInformationDetail"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#LeasesLiabilityPaymentDueDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail" xlink:type="extended" id="i89739e0c12fd43e4b401b64f106e5357_LeasesLiabilityPaymentDueDetail"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes" xlink:type="simple" xlink:href="nbix-20200930.xsd#ConvertibleSeniorNotes"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotes" xlink:type="extended" id="i444792841abf4d278157bface71579be_ConvertibleSeniorNotes"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables" xlink:type="simple" xlink:href="nbix-20200930.xsd#ConvertibleSeniorNotesTables"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables" xlink:type="extended" id="icd21327193304ab897a92c93bfd5a953_ConvertibleSeniorNotesTables"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#ConvertibleSeniorNotesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" xlink:type="extended" id="ic8a171de11f04337ac434c01f4daa121_ConvertibleSeniorNotesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1c8f830c-fc42-46af-9133-7a25b83fc5af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1c8f830c-fc42-46af-9133-7a25b83fc5af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_702dc2a0-c174-4d4b-a4f0-1be839a00dca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_702dc2a0-c174-4d4b-a4f0-1be839a00dca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_5746bcc9-d6ce-41d2-87c1-6db6b12664ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_5746bcc9-d6ce-41d2-87c1-6db6b12664ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_de1a68b2-fb80-43bb-acc9-4cdb0ade6cde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_de1a68b2-fb80-43bb-acc9-4cdb0ade6cde" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c5a5efa4-19f7-4fcd-9599-2d00f8bc277e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c5a5efa4-19f7-4fcd-9599-2d00f8bc277e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_d3f0757f-6df4-4720-b6a4-c75c25e5d923" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_d3f0757f-6df4-4720-b6a4-c75c25e5d923" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfConsecutiveBusinessDays_5c48997a-ef56-4955-a2ba-acda1e0148c1" xlink:href="nbix-20200930.xsd#nbix_NumberOfConsecutiveBusinessDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_nbix_NumberOfConsecutiveBusinessDays_5c48997a-ef56-4955-a2ba-acda1e0148c1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrincipalAmountOnConversionRate_38c66728-6bdd-4053-86c0-097b01b6a17b" xlink:href="nbix-20200930.xsd#nbix_PrincipalAmountOnConversionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_nbix_PrincipalAmountOnConversionRate_38c66728-6bdd-4053-86c0-097b01b6a17b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_7b61f2e6-b2dd-4f79-9f6e-064b5f791405" xlink:href="nbix-20200930.xsd#nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_7b61f2e6-b2dd-4f79-9f6e-064b5f791405" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtConversionObservationPeriod_106695a0-aec7-4408-b389-b32ea98d4f3a" xlink:href="nbix-20200930.xsd#nbix_DebtConversionObservationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_nbix_DebtConversionObservationPeriod_106695a0-aec7-4408-b389-b32ea98d4f3a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_ca871332-289f-4904-93ff-07d5f78e49d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_ca871332-289f-4904-93ff-07d5f78e49d3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_ed5f1613-1716-4bf7-9719-27eb9f383941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_ed5f1613-1716-4bf7-9719-27eb9f383941" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_5ea63f1b-a1f2-4854-b361-633aa21c891e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_5ea63f1b-a1f2-4854-b361-633aa21c891e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleConversionPremium_a705a2fb-44b6-49d4-a58f-f7208faae77b" xlink:href="nbix-20200930.xsd#nbix_DebtInstrumentConvertibleConversionPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_nbix_DebtInstrumentConvertibleConversionPremium_a705a2fb-44b6-49d4-a58f-f7208faae77b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_e6347b60-b9e3-4b60-9250-dec856d10067" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_SharePrice_e6347b60-b9e3-4b60-9250-dec856d10067" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_d6c9deba-4461-4345-adf6-03080e7cfc58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_d6c9deba-4461-4345-adf6-03080e7cfc58" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent_2766a445-dcbf-4d08-901c-2b500d03494b" xlink:href="nbix-20200930.xsd#nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent_2766a445-dcbf-4d08-901c-2b500d03494b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_098e488c-79fc-408c-99c2-dee439e22a69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_098e488c-79fc-408c-99c2-dee439e22a69" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_8207d920-2d3e-4e99-a51a-d58474c34d1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_8207d920-2d3e-4e99-a51a-d58474c34d1f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_c5be47da-7b32-40d7-9b2e-4f3c2a76579c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentTerm_c5be47da-7b32-40d7-9b2e-4f3c2a76579c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_1f3df5d3-dea0-4464-a426-1485893f1ed7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_1f3df5d3-dea0-4464-a426-1485893f1ed7" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_b8857761-f8ba-43b2-901c-d3402806729d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_b8857761-f8ba-43b2-901c-d3402806729d" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault_d50d1947-de06-4eda-9723-30a534411d11" xlink:href="nbix-20200930.xsd#nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault_d50d1947-de06-4eda-9723-30a534411d11" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_6ffddcd3-8958-4e38-8a29-9a9b81b7923a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentFairValue_6ffddcd3-8958-4e38-8a29-9a9b81b7923a" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_127e7060-2826-4154-b405-f38f97b4662a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentTable_127e7060-2826-4154-b405-f38f97b4662a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ed2a8d24-5269-4592-8113-4dc4698c253a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_127e7060-2826-4154-b405-f38f97b4662a" xlink:to="loc_us-gaap_DebtInstrumentAxis_ed2a8d24-5269-4592-8113-4dc4698c253a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ed2a8d24-5269-4592-8113-4dc4698c253a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ed2a8d24-5269-4592-8113-4dc4698c253a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ed2a8d24-5269-4592-8113-4dc4698c253a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b7ff5612-90be-40d4-b440-280c3d06f513" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ed2a8d24-5269-4592-8113-4dc4698c253a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b7ff5612-90be-40d4-b440-280c3d06f513" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A225ConvertibleSeniorNotesMember_4a7d0307-6f9c-44d3-a429-b1858718b67b" xlink:href="nbix-20200930.xsd#nbix_A225ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7ff5612-90be-40d4-b440-280c3d06f513" xlink:to="loc_nbix_A225ConvertibleSeniorNotesMember_4a7d0307-6f9c-44d3-a429-b1858718b67b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail" xlink:type="extended" id="i3d05b48b8aeb4833950ee0098cd781cd_ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetLossIncomePerShare" xlink:type="simple" xlink:href="nbix-20200930.xsd#NetLossIncomePerShare"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/NetLossIncomePerShare" xlink:type="extended" id="i22136076aba3403eaee46bbe0a82217b_NetLossIncomePerShare"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetLossIncomePerShareTables" xlink:type="simple" xlink:href="nbix-20200930.xsd#NetLossIncomePerShareTables"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/NetLossIncomePerShareTables" xlink:type="extended" id="ifbf41dadc76845c9ac0719ef6272be45_NetLossIncomePerShareTables"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#NetLossIncomePerShareScheduleofNetIncomePerShareDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail" xlink:type="extended" id="i0f9c98d94b794eae9d62530ec48f2351_NetLossIncomePerShareScheduleofNetIncomePerShareDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_2a9d5086-36dc-4d6b-94fa-2c397b8843f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_101815e7-1e29-4ba3-9595-ba4f07cdd76e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2a9d5086-36dc-4d6b-94fa-2c397b8843f4" xlink:to="loc_us-gaap_NetIncomeLoss_101815e7-1e29-4ba3-9595-ba4f07cdd76e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c70eb35c-6de3-4501-80d7-097bce77ce6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2a9d5086-36dc-4d6b-94fa-2c397b8843f4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c70eb35c-6de3-4501-80d7-097bce77ce6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_32e6135c-249e-4779-8792-604960c197b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c70eb35c-6de3-4501-80d7-097bce77ce6c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_32e6135c-249e-4779-8792-604960c197b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_52879397-b8e6-41de-9e9f-15d779b664c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2a9d5086-36dc-4d6b-94fa-2c397b8843f4" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_52879397-b8e6-41de-9e9f-15d779b664c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_77bbd2a0-90b2-4838-bf06-880805477b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_52879397-b8e6-41de-9e9f-15d779b664c7" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_77bbd2a0-90b2-4838-bf06-880805477b4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_15d8d1ca-1c96-451a-9e9c-c2ef189978e2" xlink:href="nbix-20200930.xsd#nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_52879397-b8e6-41de-9e9f-15d779b664c7" xlink:to="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_15d8d1ca-1c96-451a-9e9c-c2ef189978e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8e385244-a6f2-4ab8-9e94-0754bc73e383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_52879397-b8e6-41de-9e9f-15d779b664c7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8e385244-a6f2-4ab8-9e94-0754bc73e383" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3eebf941-eb6f-4c6a-8f83-e83345ce90c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2a9d5086-36dc-4d6b-94fa-2c397b8843f4" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3eebf941-eb6f-4c6a-8f83-e83345ce90c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c7072b94-6acd-4d72-a1eb-e657074ab807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3eebf941-eb6f-4c6a-8f83-e83345ce90c8" xlink:to="loc_us-gaap_EarningsPerShareBasic_c7072b94-6acd-4d72-a1eb-e657074ab807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_92d246da-c9eb-42fc-b568-79d1758588e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3eebf941-eb6f-4c6a-8f83-e83345ce90c8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_92d246da-c9eb-42fc-b568-79d1758588e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ee38d009-609a-443e-8393-f60ad6dd8c84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2a9d5086-36dc-4d6b-94fa-2c397b8843f4" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ee38d009-609a-443e-8393-f60ad6dd8c84" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1c59c6a9-b075-44cc-8889-04bc1b2bb624" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ee38d009-609a-443e-8393-f60ad6dd8c84" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1c59c6a9-b075-44cc-8889-04bc1b2bb624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1c59c6a9-b075-44cc-8889-04bc1b2bb624_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1c59c6a9-b075-44cc-8889-04bc1b2bb624" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1c59c6a9-b075-44cc-8889-04bc1b2bb624_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2d376bc4-de83-4cb0-a6bf-17349f5903aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1c59c6a9-b075-44cc-8889-04bc1b2bb624" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2d376bc4-de83-4cb0-a6bf-17349f5903aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a4fe8959-7775-4655-ab96-ab3cbbbea038" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2d376bc4-de83-4cb0-a6bf-17349f5903aa" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a4fe8959-7775-4655-ab96-ab3cbbbea038" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_3f824dda-bd4a-4a54-afa4-e4a37c0ef77d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2d376bc4-de83-4cb0-a6bf-17349f5903aa" xlink:to="loc_us-gaap_RestrictedStockMember_3f824dda-bd4a-4a54-afa4-e4a37c0ef77d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a009442e-eef9-41b4-9bcc-08f8a908d4f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ee38d009-609a-443e-8393-f60ad6dd8c84" xlink:to="loc_us-gaap_DebtInstrumentAxis_a009442e-eef9-41b4-9bcc-08f8a908d4f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a009442e-eef9-41b4-9bcc-08f8a908d4f9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a009442e-eef9-41b4-9bcc-08f8a908d4f9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a009442e-eef9-41b4-9bcc-08f8a908d4f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e28a8f04-0bbe-4bd8-b86f-de4e2ac2af48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a009442e-eef9-41b4-9bcc-08f8a908d4f9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e28a8f04-0bbe-4bd8-b86f-de4e2ac2af48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember_a1bcea82-8993-4087-bf76-b25e30bcdb94" xlink:href="nbix-20200930.xsd#nbix_TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e28a8f04-0bbe-4bd8-b86f-de4e2ac2af48" xlink:to="loc_nbix_TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember_a1bcea82-8993-4087-bf76-b25e30bcdb94" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetLossIncomePerShareAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#NetLossIncomePerShareAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.neurocrine.com/role/NetLossIncomePerShareAdditionalInformationDetail" xlink:type="extended" id="if604fc9cf86846daa358618df746837c_NetLossIncomePerShareAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_a964e7cf-125c-416e-856e-9945ae546017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_92d5f5c8-ba49-480d-8639-38ab66003728" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_a964e7cf-125c-416e-856e-9945ae546017" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_92d5f5c8-ba49-480d-8639-38ab66003728" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_494700ec-ca66-457a-b653-ea1ff6752937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_a964e7cf-125c-416e-856e-9945ae546017" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_494700ec-ca66-457a-b653-ea1ff6752937" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_c95ce9e5-a356-42ba-a2b4-ded4ca286736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_a964e7cf-125c-416e-856e-9945ae546017" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_c95ce9e5-a356-42ba-a2b4-ded4ca286736" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ff58f5d7-7a3d-47db-aa5c-1303f8dc3e14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_c95ce9e5-a356-42ba-a2b4-ded4ca286736" xlink:to="loc_us-gaap_DebtInstrumentAxis_ff58f5d7-7a3d-47db-aa5c-1303f8dc3e14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ff58f5d7-7a3d-47db-aa5c-1303f8dc3e14_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ff58f5d7-7a3d-47db-aa5c-1303f8dc3e14" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ff58f5d7-7a3d-47db-aa5c-1303f8dc3e14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cabe5a9f-85ad-431c-8cb7-30b854a88b25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ff58f5d7-7a3d-47db-aa5c-1303f8dc3e14" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cabe5a9f-85ad-431c-8cb7-30b854a88b25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A225ConvertibleSeniorNotesMember_e64baa22-8cc6-4a6e-aa76-e41912712b4e" xlink:href="nbix-20200930.xsd#nbix_A225ConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cabe5a9f-85ad-431c-8cb7-30b854a88b25" xlink:to="loc_nbix_A225ConvertibleSeniorNotesMember_e64baa22-8cc6-4a6e-aa76-e41912712b4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_640ef63d-271e-4dcd-9591-5b84924915bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_c95ce9e5-a356-42ba-a2b4-ded4ca286736" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_640ef63d-271e-4dcd-9591-5b84924915bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_640ef63d-271e-4dcd-9591-5b84924915bc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_640ef63d-271e-4dcd-9591-5b84924915bc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_640ef63d-271e-4dcd-9591-5b84924915bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bb3ea319-b3c1-4022-ba2d-63e5a05de782" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_640ef63d-271e-4dcd-9591-5b84924915bc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bb3ea319-b3c1-4022-ba2d-63e5a05de782" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember_fa70e235-004c-4547-9c68-6db24c4a0ea2" xlink:href="nbix-20200930.xsd#nbix_StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bb3ea319-b3c1-4022-ba2d-63e5a05de782" xlink:to="loc_nbix_StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember_fa70e235-004c-4547-9c68-6db24c4a0ea2" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>nbix-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b79d3e40-aa4b-4356-aa3c-d2eb2732ffa0,g:9f3edc10-8601-4580-b4de-4b1ad44f8b95-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_5b36c5f8-030e-4ffa-a5a0-e2caa7ecf12b_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Square feet</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_2486c418-88d1-43ea-9287-ed512dc116cc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_d248a46b-294c-43c2-8bc9-95b3a3523a1a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NBI827104Member_301a247d-3910-43a4-89f8-3319ad8f03cd_terseLabel_en-US" xlink:label="lab_nbix_NBI827104Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NBI-827104</link:label>
    <link:label id="lab_nbix_NBI827104Member_label_en-US" xlink:label="lab_nbix_NBI827104Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NBI-827104 [Member]</link:label>
    <link:label id="lab_nbix_NBI827104Member_documentation_en-US" xlink:label="lab_nbix_NBI827104Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NBI-827104</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NBI827104Member" xlink:href="nbix-20200930.xsd#nbix_NBI827104Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NBI827104Member" xlink:to="lab_nbix_NBI827104Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_82029c00-00a7-4125-ac0b-67729e0251fa_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_201bd6a6-0397-4d01-8342-8d13c65f5849_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_8b601001-a643-4a66-8182-9455d82f3d69_terseLabel_en-US" xlink:label="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_label_en-US" xlink:label="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Reconciliation Of Cash Cash Equivalents And Restricted Cash [Table Text Block]</link:label>
    <link:label id="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_documentation_en-US" xlink:label="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of reconciliation of cash cash equivalents and restricted cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:href="nbix-20200930.xsd#nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:to="lab_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_e2db6d8b-6369-4fdb-8b74-ae9ba1425fa7_verboseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_c004edf8-7e87-4075-8435-d68dcdbd11d2_totalLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_67ecad7f-02e6-4331-9b17-94fb00865619_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_42cbbb22-e007-4f5f-bcaf-2f4d6be8c7a0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_f31aaf28-cf6f-4136-a884-506165af59ca_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_ec045a78-41fd-4324-8c50-1afffa52079d_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_74912e63-af3e-4f39-9201-ef2608d5a279_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_3a7aa72a-d0c1-434f-a910-1a7894e06ab7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_913d346c-a122-41ad-bee5-c35493dc8d39_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_6ab6b4fc-f9fa-4821-8445-451fafca361c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_b6d72a87-d6a9-4ec3-8dc5-a09d198d4df2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_4e1eebe7-9400-495b-b250-48958907b24a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_2cfa54bf-0eb0-4b56-a85e-97c990714df0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_8cd084b6-87ea-4981-873b-3d6a9938b507_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_ae6f5dbe-fa0f-47e4-9d5c-7c936b0d5f1c_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_2bcfec6b-66dc-4f90-a5a4-d0a8670f12dc_terseLabel_en-US" xlink:label="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum percentage of common stock price trigger</link:label>
    <link:label id="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_label_en-US" xlink:label="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Percentage Of Trading Price To Last Reported Sale Price</link:label>
    <link:label id="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_documentation_en-US" xlink:label="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The minimum percentage of the product of the common stock trading price multiplied by the conversion rate during the measurement period as compared to the principal note amount that triggers a conversion option on the notes, if it falls below this percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:href="nbix-20200930.xsd#nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:to="lab_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0b66587c-72dd-4fa6-9378-7113b0acd3be_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_745b07dd-e138-4d59-9fb9-8080db757ce7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction cost related to issuance of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_efb6c1b6-cd33-40dc-9d3b-6f8ac2b69085_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equity securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_8ca789df-7d8b-4dea-aa4d-5666010eef85_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_UpfrontPaymentsMade_90bf140a-3749-4b1a-96bd-eeab17809271_terseLabel_en-US" xlink:label="lab_nbix_UpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments made</link:label>
    <link:label id="lab_nbix_UpfrontPaymentsMade_label_en-US" xlink:label="lab_nbix_UpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payments Made</link:label>
    <link:label id="lab_nbix_UpfrontPaymentsMade_documentation_en-US" xlink:label="lab_nbix_UpfrontPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments made under a collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsMade" xlink:href="nbix-20200930.xsd#nbix_UpfrontPaymentsMade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_UpfrontPaymentsMade" xlink:to="lab_nbix_UpfrontPaymentsMade" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_e2b698e2-cea5-4c97-8af6-a593e7e06c5f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_d786f6cf-834b-4d83-adb8-c27b47c2e889_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_575d7ed2-6155-40d8-8c3d-f3e949a04a58_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_1537f4e6-68f7-47c8-b69e-9c8395d871f1_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtCurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent" xlink:to="lab_us-gaap_ConvertibleDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_InvestmentIncomeAndOtherNet_a185c7d8-6ffe-4feb-a8f0-582decb18ff4_terseLabel_en-US" xlink:label="lab_nbix_InvestmentIncomeAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income and other, net</link:label>
    <link:label id="lab_nbix_InvestmentIncomeAndOtherNet_label_en-US" xlink:label="lab_nbix_InvestmentIncomeAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income And Other Net</link:label>
    <link:label id="lab_nbix_InvestmentIncomeAndOtherNet_documentation_en-US" xlink:label="lab_nbix_InvestmentIncomeAndOtherNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income and other net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet" xlink:href="nbix-20200930.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_InvestmentIncomeAndOtherNet" xlink:to="lab_nbix_InvestmentIncomeAndOtherNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_97c64714-3a3d-42d8-b5b9-8ef0f71cb3a7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_1e171122-cf5f-4bcf-bd39-605298eb3b2e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6bb2ab6e-6d75-4fa7-b9cf-33dfa0df6dfa_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_9c392ce4-dcfd-474b-8e52-e47832f64b61_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5e20982a-9cb0-48a9-87ef-d6119c4f26fa_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_1210ff5a-e951-4f1b-8e6e-8f598869cc66_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_c8a31332-c4d4-44ac-9463-fbef5c33c624_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_700225da-5ff6-440b-8cc4-098009848149_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating (loss) income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7f2e952b-6631-4443-9ebc-b4172786e802_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative-effect adjustment to equity due to adoption of ASU 2016-02</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_234bd02d-357d-478c-99ec-369f8ca7de76_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_A12790ElCaminoRealSuite150Member_79a82385-dbe5-4186-8b85-700bb702f039_terseLabel_en-US" xlink:label="lab_nbix_A12790ElCaminoRealSuite150Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12790 El Camino Real, Suite 150</link:label>
    <link:label id="lab_nbix_A12790ElCaminoRealSuite150Member_label_en-US" xlink:label="lab_nbix_A12790ElCaminoRealSuite150Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12790 El Camino Real Suite 150 [Member]</link:label>
    <link:label id="lab_nbix_A12790ElCaminoRealSuite150Member_documentation_en-US" xlink:label="lab_nbix_A12790ElCaminoRealSuite150Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12790 El Camino Real Suite 150. Office facility held for productive use.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A12790ElCaminoRealSuite150Member" xlink:href="nbix-20200930.xsd#nbix_A12790ElCaminoRealSuite150Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_A12790ElCaminoRealSuite150Member" xlink:to="lab_nbix_A12790ElCaminoRealSuite150Member" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_A12790ElCaminoRealSuite130Member_6fe81986-5f4b-4225-a574-a4a521ddae54_terseLabel_en-US" xlink:label="lab_nbix_A12790ElCaminoRealSuite130Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12790 El Camino Real, Suite 130</link:label>
    <link:label id="lab_nbix_A12790ElCaminoRealSuite130Member_label_en-US" xlink:label="lab_nbix_A12790ElCaminoRealSuite130Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12790 El Camino Real Suite 130 [Member]</link:label>
    <link:label id="lab_nbix_A12790ElCaminoRealSuite130Member_documentation_en-US" xlink:label="lab_nbix_A12790ElCaminoRealSuite130Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12790 El Camino Real Suite 130. Office facility held for productive use.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A12790ElCaminoRealSuite130Member" xlink:href="nbix-20200930.xsd#nbix_A12790ElCaminoRealSuite130Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_A12790ElCaminoRealSuite130Member" xlink:to="lab_nbix_A12790ElCaminoRealSuite130Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_739e176f-ff4a-4f0c-b2b0-b8f29235acc7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_af653799-48f6-4369-a9bf-c5e6ab26c1bf_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_5d091d66-2706-47ff-950c-b8bb9dd9359a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_90e3364a-a830-4796-950e-4f258fcc5636_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_8dd968c8-32ab-413f-8810-3e4bfb9eb9a7_terseLabel_en-US" xlink:label="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 Notes (in shares)</link:label>
    <link:label id="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_label_en-US" xlink:label="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable To Dilutive Effect Of Conversion Of Debt Securities</link:label>
    <link:label id="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_documentation_en-US" xlink:label="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:href="nbix-20200930.xsd#nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:to="lab_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_2342a333-afc7-409c-a1bb-ac87f208f265_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_d200527d-d59f-4af9-8ac3-56ee1109f502_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale, at fair value (amortized cost $180.3 million at September&#160;30, 2020 and $299.3 million at December&#160;31, 2019)</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_9d13954e-7461-4fab-8d06-4f36ad2faa41_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_4715dd8d-2cad-49ff-92b0-2c6960b529d3_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_a82532be-a53e-4fc5-8aa7-555e5b0ab10e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_CollaborationRevenueMember_433e596f-f8fe-4198-aac0-ca778f70ff62_terseLabel_en-US" xlink:label="lab_nbix_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_nbix_CollaborationRevenueMember_label_en-US" xlink:label="lab_nbix_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue [Member]</link:label>
    <link:label id="lab_nbix_CollaborationRevenueMember_documentation_en-US" xlink:label="lab_nbix_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CollaborationRevenueMember" xlink:href="nbix-20200930.xsd#nbix_CollaborationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_CollaborationRevenueMember" xlink:to="lab_nbix_CollaborationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_16b25548-dfc9-413d-9966-8a31603658c5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_6abf3343-a0e2-46eb-9188-cbcbb6af73fb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_196f2aad-ea80-4fc6-a4a8-591cda335661_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6727b637-660c-44fc-aeef-71115fc3d350_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_2a99302a-d8d7-473f-a0a3-dab006568378_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities&#8211;biotechnology industry</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_e08cc5fa-2338-447f-b017-295041234801_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_b2c71160-f6bb-41cd-9dde-32f3ae3366f5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_084cb1f6-0d7e-4708-b9a0-647ca9132be1_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_8ef3b61a-743f-4cf7-9474-02aece88213b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7fe873cc-70c7-41e1-a31a-c6860e0a2aca_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_be3957f5-b8f9-4837-a1f5-365cfad3127f_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold common stock trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_74c0a339-794f-4c00-a9ba-c89ed75012bf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_BusinessDescriptionPolicyTextBlock_bae7d73f-125f-4979-9569-42f99665cee9_terseLabel_en-US" xlink:label="lab_nbix_BusinessDescriptionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_nbix_BusinessDescriptionPolicyTextBlock_label_en-US" xlink:label="lab_nbix_BusinessDescriptionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description [Policy Text Block]</link:label>
    <link:label id="lab_nbix_BusinessDescriptionPolicyTextBlock_documentation_en-US" xlink:label="lab_nbix_BusinessDescriptionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BusinessDescriptionPolicyTextBlock" xlink:href="nbix-20200930.xsd#nbix_BusinessDescriptionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_BusinessDescriptionPolicyTextBlock" xlink:to="lab_nbix_BusinessDescriptionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_9021d416-d5c6-4cea-8fc4-fdbf9b34b17b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_TerminationNoticePeriod_24634331-1256-4f73-ad67-63604fd790ea_terseLabel_en-US" xlink:label="lab_nbix_TerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration termination notice period</link:label>
    <link:label id="lab_nbix_TerminationNoticePeriod_label_en-US" xlink:label="lab_nbix_TerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Notice Period</link:label>
    <link:label id="lab_nbix_TerminationNoticePeriod_documentation_en-US" xlink:label="lab_nbix_TerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of time required for third party collaborator to give written notice prior to terminating the collaborative agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TerminationNoticePeriod" xlink:href="nbix-20200930.xsd#nbix_TerminationNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_TerminationNoticePeriod" xlink:to="lab_nbix_TerminationNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bd41b3eb-9812-4155-8a60-e955224e1614_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0ab483ea-7866-4cfa-ba38-7da22a3c0789_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b36d4e4d-c00e-40b5-8a3c-1f8d081a8f6a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_CashAndMoneyMarketFundMember_96a73e70-d904-4efd-9edf-872d247b435c_terseLabel_en-US" xlink:label="lab_nbix_CashAndMoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and money market funds</link:label>
    <link:label id="lab_nbix_CashAndMoneyMarketFundMember_label_en-US" xlink:label="lab_nbix_CashAndMoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Money Market Fund [Member]</link:label>
    <link:label id="lab_nbix_CashAndMoneyMarketFundMember_documentation_en-US" xlink:label="lab_nbix_CashAndMoneyMarketFundMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency on hand as well as demand deposits with banks or financial institutions, and funds that invest in short-term money-market instruments, for example, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CashAndMoneyMarketFundMember" xlink:href="nbix-20200930.xsd#nbix_CashAndMoneyMarketFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_CashAndMoneyMarketFundMember" xlink:to="lab_nbix_CashAndMoneyMarketFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_3b960fe7-d923-403d-8997-6b9467818784_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_3919f8cb-92d8-4078-9277-7b1f9a5f686d_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_94fb1891-39f3-4b8e-8fc3-c4a524721610_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding at September&#160;30, 2020 and December&#160;31, 2019</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput_6e91f60c-14ca-432b-a938-391c3abcfa24_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities measurement input</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:to="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_e98c9070-3263-44e7-b4d1-acb00dc067be_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4255edb0-a52e-4588-80c0-dbf9583fc178_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PrincipalAmountOnConversionRate_26e9eb3c-ab18-4ec8-b3b0-d9025cfa1754_terseLabel_en-US" xlink:label="lab_nbix_PrincipalAmountOnConversionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount on conversion rate</link:label>
    <link:label id="lab_nbix_PrincipalAmountOnConversionRate_label_en-US" xlink:label="lab_nbix_PrincipalAmountOnConversionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount On Conversion Rate</link:label>
    <link:label id="lab_nbix_PrincipalAmountOnConversionRate_documentation_en-US" xlink:label="lab_nbix_PrincipalAmountOnConversionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount on conversion rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrincipalAmountOnConversionRate" xlink:href="nbix-20200930.xsd#nbix_PrincipalAmountOnConversionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PrincipalAmountOnConversionRate" xlink:to="lab_nbix_PrincipalAmountOnConversionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_995d3525-e132-49bd-93f1-fee03c98602c_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_3aba2bc3-f58b-4b47-8a89-94038fc82486_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_fdf0edee-541d-43b9-9182-1488f8ccb7af_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Longer, Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7dd94599-d0b0-43fb-b625-304e3a7c4506_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_eefeecdd-e9d6-4fdd-8c59-8c17e8f0916a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_e46a9186-b20f-4a3c-b014-eabb58e561ff_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_A12790ElCaminoRealSuite300Member_15e203fe-fca2-4f80-a369-6eff71116954_terseLabel_en-US" xlink:label="lab_nbix_A12790ElCaminoRealSuite300Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12790 El Camino Real, Suite 300</link:label>
    <link:label id="lab_nbix_A12790ElCaminoRealSuite300Member_label_en-US" xlink:label="lab_nbix_A12790ElCaminoRealSuite300Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12790 El Camino Real Suite 300 [Member]</link:label>
    <link:label id="lab_nbix_A12790ElCaminoRealSuite300Member_documentation_en-US" xlink:label="lab_nbix_A12790ElCaminoRealSuite300Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12790 El Camino Real Suite 300. Office facility held for productive use.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A12790ElCaminoRealSuite300Member" xlink:href="nbix-20200930.xsd#nbix_A12790ElCaminoRealSuite300Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_A12790ElCaminoRealSuite300Member" xlink:to="lab_nbix_A12790ElCaminoRealSuite300Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_fde718b4-9d52-4741-8f37-45874c4244fe_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_87f6bb82-b3c5-4643-a557-e52f3339c942_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_ffe996a7-26ac-4380-abff-cec4337b1346_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0fc0fd38-84bd-41f9-9d8b-42a2db0bc00d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_25cd61b3-958f-454c-a29f-06f9ca5267e2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_ea2b6678-1ec3-49d4-8eca-8d441632099a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_10fb9e49-d4d7-453c-8e35-1e51fe1f77c8_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NumberOfRenewalOptions_2028472f-4d3b-44e0-8867-7ca38e172323_terseLabel_en-US" xlink:label="lab_nbix_NumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of renewal options</link:label>
    <link:label id="lab_nbix_NumberOfRenewalOptions_label_en-US" xlink:label="lab_nbix_NumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Renewal Options</link:label>
    <link:label id="lab_nbix_NumberOfRenewalOptions_documentation_en-US" xlink:label="lab_nbix_NumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of renewal options under the terms of the lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfRenewalOptions" xlink:href="nbix-20200930.xsd#nbix_NumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NumberOfRenewalOptions" xlink:to="lab_nbix_NumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_ce883fb0-2339-47f4-8e5a-7b397f3bdc54_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_959db792-ed6b-4bdd-bdb8-dae9cb8f4618_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0cdbc4f3-cd4b-4ede-95f1-2dbb0ddb9819_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2fe166ec-90e4-4afc-8228-365c994b28c9_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contract with customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_15b30c86-ea40-4847-82a0-c8b07d583ff4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_4386a36f-b316-4e2e-90ad-688ede070ec6_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market price of common stock (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_4bf93b0b-14c7-4a75-a7b2-b7467345b775_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets on recurring basis</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRestricted_da161778-6539-4aa5-a2f7-334f0d144ad6_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRestricted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRestricted_acfceb6d-5970-477a-a5a4-19b7db6daf45_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRestricted" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRestricted_c09e1588-9541-4675-a3d4-d1c127a2b05e_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRestricted" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRestricted_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRestricted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Restricted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRestricted" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRestricted" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault_6ae83d39-5e08-4e0e-b0f4-4f709e9ca3c6_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument events of default percentage of principal and accrued and unpaid interest due and payable upon default</link:label>
    <link:label id="lab_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault_label_en-US" xlink:label="lab_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Events Of Default Percentage Of Principal And Accrued And Unpaid Interest Due And Payable Upon Default</link:label>
    <link:label id="lab_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument events of default percentage of principal and accrued and unpaid interest due and payable upon default.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" xlink:href="nbix-20200930.xsd#nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" xlink:to="lab_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_10394086-88b3-4069-933f-94bedd9469af_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_3b63bd48-b2f9-4c60-baa1-1f4aaf4a1618_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes convertible in to shares</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_35b7113a-6b20-447e-867a-05d6e815daab_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_df1ddd01-b6de-4313-8623-ad11a7b8892b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_60ee7fe0-b19c-4163-8a50-59d39501fe50_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_234f7094-2249-4f8b-9d65-85b41e1fcfca_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes conversion price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_336a1d6a-2e65-49a7-b8e0-0c093668c972_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_63e91135-7e60-4a48-a8f9-a61887ea3279_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_30e758a7-6af3-4f6f-933d-d6a9680283b8_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt discount, net</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_9ac75ea5-27d4-477d-8a6c-bb1c97cb36ca_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_64c43999-7556-4a50-adb4-3072e89ba65e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income per share, basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_92a71f63-db72-41a5-971e-895dda476462_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_56752a6b-ffa2-4bab-8b4b-5dcdd8c61fe8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_0107aa7f-4bfc-44b5-939d-8e7a7e846b2f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_2bbcb73a-6f4f-4a79-8abc-caba1f8858ce_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_fa463cb4-ddb0-4c6b-b2b2-93cc28db8623_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_5496b633-969a-4d01-9c69-06ca174f125b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_60cc5ed2-3190-4e3b-b8e4-c795f5dad4f1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_b03d199f-f240-4170-beaf-2b764ca6145a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralDomain_2a147546-7261-4c19-a1cd-a2c7d4dc512e_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral</link:label>
    <link:label id="lab_us-gaap_CollateralDomain_label_en-US" xlink:label="lab_us-gaap_CollateralDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Held [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralDomain" xlink:to="lab_us-gaap_CollateralDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_e7a30055-e6f3-4dff-a57d-cff9601d4c82_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_dd498ded-bed9-499a-8853-0246de1491f0_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_TerminationNoticePeriodAfterFirstCommercialSale_30ec13ae-bd3a-4c86-b430-130fc5b0d4c0_terseLabel_en-US" xlink:label="lab_nbix_TerminationNoticePeriodAfterFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination notice period, after date of notice</link:label>
    <link:label id="lab_nbix_TerminationNoticePeriodAfterFirstCommercialSale_label_en-US" xlink:label="lab_nbix_TerminationNoticePeriodAfterFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Notice Period After First Commercial Sale</link:label>
    <link:label id="lab_nbix_TerminationNoticePeriodAfterFirstCommercialSale_documentation_en-US" xlink:label="lab_nbix_TerminationNoticePeriodAfterFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Notice Period After First Commercial Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TerminationNoticePeriodAfterFirstCommercialSale" xlink:href="nbix-20200930.xsd#nbix_TerminationNoticePeriodAfterFirstCommercialSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_TerminationNoticePeriodAfterFirstCommercialSale" xlink:to="lab_nbix_TerminationNoticePeriodAfterFirstCommercialSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_1db8f201-eae1-457d-bb9d-92277ad6eb1e_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_b776ac9e-99eb-4343-bff7-3d115f19a0b4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_7562f5b2-c9a0-4cb5-b3cc-24c6b2c69b3d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_18cddab4-3b33-4c05-acbf-bbdfe68586e5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NumberOfIrishSubsidiaries_29d29c40-3653-4bb0-833f-7f41c7d8d368_terseLabel_en-US" xlink:label="lab_nbix_NumberOfIrishSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of wholly owned Irish subsidiaries</link:label>
    <link:label id="lab_nbix_NumberOfIrishSubsidiaries_label_en-US" xlink:label="lab_nbix_NumberOfIrishSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Irish Subsidiaries</link:label>
    <link:label id="lab_nbix_NumberOfIrishSubsidiaries_documentation_en-US" xlink:label="lab_nbix_NumberOfIrishSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Irish Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfIrishSubsidiaries" xlink:href="nbix-20200930.xsd#nbix_NumberOfIrishSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NumberOfIrishSubsidiaries" xlink:to="lab_nbix_NumberOfIrishSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_d067f54f-8554-4f64-937e-1736b8b55947_totalLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_A225ConvertibleSeniorNotesMember_80b78890-2bfa-438b-ba5d-438547d3c7e8_terseLabel_en-US" xlink:label="lab_nbix_A225ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Convertible Senior Notes due 2024</link:label>
    <link:label id="lab_nbix_A225ConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_nbix_A225ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_nbix_A225ConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_nbix_A225ConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Convertible Senior Notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A225ConvertibleSeniorNotesMember" xlink:href="nbix-20200930.xsd#nbix_A225ConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_A225ConvertibleSeniorNotesMember" xlink:to="lab_nbix_A225ConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_1ab8974b-d796-4bd4-83d4-628b25573d6b_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_56bd929f-4a7c-422a-8e7f-363802413bef_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_ec40b94a-5df7-4411-b6f4-bbb96b0f537d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_a95cc067-f7f4-4a17-b550-fbfa46e17df0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 220.0 shares authorized; issued and outstanding shares were 93.4 at September&#160;30, 2020 and 92.3 at December&#160;31, 2019</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_4921d535-1f14-47ec-ab47-95716fbbb39f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_7f8d27dd-6257-4240-976e-7c3f3fb0d477_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_d62687f4-2e1b-4204-9b82-6a7afe368381_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_0db520f9-9e46-4cdf-8d14-cdafa3855037_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_9148736a-b0c1-48d3-972a-06683f5a4064_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_A12780ElCaminoRealMember_5e508f25-62cb-4d95-b836-7edde9ae1013_terseLabel_en-US" xlink:label="lab_nbix_A12780ElCaminoRealMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12780 El Camino Real</link:label>
    <link:label id="lab_nbix_A12780ElCaminoRealMember_label_en-US" xlink:label="lab_nbix_A12780ElCaminoRealMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12780 El Camino Real [Member]</link:label>
    <link:label id="lab_nbix_A12780ElCaminoRealMember_documentation_en-US" xlink:label="lab_nbix_A12780ElCaminoRealMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12780 El Camino Real. Office and laboratory facilities held for productive use.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A12780ElCaminoRealMember" xlink:href="nbix-20200930.xsd#nbix_A12780ElCaminoRealMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_A12780ElCaminoRealMember" xlink:to="lab_nbix_A12780ElCaminoRealMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_6044af78-b417-4d48-b500-0ccabf4f2015_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_037ddcda-28dc-4b77-8f51-ddacad49642f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_c07b0c5b-e9db-4e05-bb07-7c5ff7edf33a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_fef90768-e435-48ab-b6d5-413aa20e3128_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior note assumed borrowing rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_MilestonePayment_fc671bca-5521-4ef6-90a1-ce4e261f4895_terseLabel_en-US" xlink:label="lab_nbix_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_nbix_MilestonePayment_label_en-US" xlink:label="lab_nbix_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment</link:label>
    <link:label id="lab_nbix_MilestonePayment_documentation_en-US" xlink:label="lab_nbix_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments made for milestones under a collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestonePayment" xlink:href="nbix-20200930.xsd#nbix_MilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_MilestonePayment" xlink:to="lab_nbix_MilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_bec9cbf1-92dc-4fed-a97e-6dc39c33be2c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_cbf7bc63-5566-4402-bdf0-d8a2c048f49f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_95d6fc73-ded9-407e-8ecc-2e4799762f0e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and maturities of debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_cc979697-200e-42ad-888d-9218840b6b59_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f82e67cd-b58e-4750-ab53-4cefaa47ec96_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_fd4923e7-892f-403f-b3bc-cdd6ea130448_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_a8418074-3efe-40a9-8c09-fea0d00a29b8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for vested restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_cac11467-85b2-460a-bf1f-6747216493f0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_352a8586-f4d2-48cb-aaca-34683bdb5698_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a5b7c4a-002d-4ad5-9eed-829dc2fc37cd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_824b12e4-6fa8-435d-807e-4bbd85d712b2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_a91a0406-ca8f-46ca-9d7e-a0cdab718fcc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_ad10cb33-259c-48b5-b5a9-7add998604e1_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Collaboration and Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b7f8f9e4-bd75-4004-8534-17551826694e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_18d1b9f5-9b6f-4579-8cc9-1792ef04cf84_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f5185d7b-1758-46dd-a31c-648e735b0dee_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_MitsubishiTanabePharmaCorporationMember_2c72e1a2-a182-450f-a897-96eb77a5bba6_terseLabel_en-US" xlink:label="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe</link:label>
    <link:label id="lab_nbix_MitsubishiTanabePharmaCorporationMember_label_en-US" xlink:label="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation [Member]</link:label>
    <link:label id="lab_nbix_MitsubishiTanabePharmaCorporationMember_documentation_en-US" xlink:label="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to the Mitsubishi Tanabe Pharma Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MitsubishiTanabePharmaCorporationMember" xlink:href="nbix-20200930.xsd#nbix_MitsubishiTanabePharmaCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_MitsubishiTanabePharmaCorporationMember" xlink:to="lab_nbix_MitsubishiTanabePharmaCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_19a41baf-1f88-48b8-bfc3-2a147a6e0c6c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f9e2e231-b7ec-4e47-8d0f-c22937c542a8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b56ee88d-48fd-4cd8-84b6-052c4b17ac43_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_dc418b2d-055a-4227-816a-39b74e9abc02_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PotentialMilestonePayments_f8559b26-9f74-4fe1-9d52-c0ede12c0ddc_terseLabel_en-US" xlink:label="lab_nbix_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments</link:label>
    <link:label id="lab_nbix_PotentialMilestonePayments_label_en-US" xlink:label="lab_nbix_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payments</link:label>
    <link:label id="lab_nbix_PotentialMilestonePayments_documentation_en-US" xlink:label="lab_nbix_PotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of potential milestone payments to be paid under a license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePayments" xlink:href="nbix-20200930.xsd#nbix_PotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PotentialMilestonePayments" xlink:to="lab_nbix_PotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_5408511a-7622-49cb-b9fb-9fdad82344a3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PatentTerm_306f413d-f0a7-4f3d-b4a4-ca3025b8a4ec_terseLabel_en-US" xlink:label="lab_nbix_PatentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent term</link:label>
    <link:label id="lab_nbix_PatentTerm_label_en-US" xlink:label="lab_nbix_PatentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent term</link:label>
    <link:label id="lab_nbix_PatentTerm_documentation_en-US" xlink:label="lab_nbix_PatentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PatentTerm" xlink:href="nbix-20200930.xsd#nbix_PatentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PatentTerm" xlink:to="lab_nbix_PatentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_a32f84e7-a247-4c7b-af96-2559fa875e14_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_8aaf60ce-a918-45da-8f5b-18d36d90ec77_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_6860f0d5-afe9-4eac-bd1f-37a30df89a14_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes redemption rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NumberOfConsecutiveBusinessDays_e440c1b0-7a4d-4282-b051-c5eeb5e5e132_terseLabel_en-US" xlink:label="lab_nbix_NumberOfConsecutiveBusinessDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consecutive business days</link:label>
    <link:label id="lab_nbix_NumberOfConsecutiveBusinessDays_label_en-US" xlink:label="lab_nbix_NumberOfConsecutiveBusinessDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Consecutive Business Days</link:label>
    <link:label id="lab_nbix_NumberOfConsecutiveBusinessDays_documentation_en-US" xlink:label="lab_nbix_NumberOfConsecutiveBusinessDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Consecutive Business Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfConsecutiveBusinessDays" xlink:href="nbix-20200930.xsd#nbix_NumberOfConsecutiveBusinessDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NumberOfConsecutiveBusinessDays" xlink:to="lab_nbix_NumberOfConsecutiveBusinessDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_38e42f21-20a7-4488-8aa6-e52d9ef6e2cb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d1929dbc-893c-4b0c-8b45-719319caab7c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale, at fair value (amortized cost $517.3 million at September&#160;30, 2020 and $557.3 million at December&#160;31, 2019)</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_2f182810-2029-48ce-ba6d-b19b9832cef5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_04ce7db1-b4fd-4ced-b819-1cb5ea075042_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d24414de-a320-4146-9f47-b1483f740e68_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_8d986caf-e838-4b93-b0d3-eb06cfe90c83_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d03cae82-0cde-4970-a7cd-a97b573a9deb_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_56c8ba7d-2a60-42fc-b5b5-e64c8645021b_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0423b7f2-cf3c-4ec6-bd36-8b3b56c5c862_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_880c7444-180a-488d-bdf1-bfd881f2f580_terseLabel_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of debt securities available for sale</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_label_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Available For Sale Position Number Of Positions</link:label>
    <link:label id="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_documentation_en-US" xlink:label="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available for sale position number of positions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:href="nbix-20200930.xsd#nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:to="lab_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_0cb72831-316c-4452-907e-5c9978f52588_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 Months or Longer, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_33962ac7-d4d0-4ca4-b1db-c1dc7edfb6d8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtConversionObservationPeriod_ded404de-ade9-4bb3-aa18-34df36a6291f_terseLabel_en-US" xlink:label="lab_nbix_DebtConversionObservationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion observation period</link:label>
    <link:label id="lab_nbix_DebtConversionObservationPeriod_label_en-US" xlink:label="lab_nbix_DebtConversionObservationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Observation Period</link:label>
    <link:label id="lab_nbix_DebtConversionObservationPeriod_documentation_en-US" xlink:label="lab_nbix_DebtConversionObservationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The duration of time during which the weighted-average share price is used to calculate the excess conversion value due upon conversion of a convertible note, in the format of PnYnMnD.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtConversionObservationPeriod" xlink:href="nbix-20200930.xsd#nbix_DebtConversionObservationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtConversionObservationPeriod" xlink:to="lab_nbix_DebtConversionObservationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bd8b5804-347b-4ad7-a3fb-e19cf132de20_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_236a504c-15a9-49f9-b1b9-8cc711045eb7_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1ad7d79a-ff28-4a4c-9766-f4f222deaaa9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_e4f7743d-ef76-4443-9b4c-975a8c493e8b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_cc3772d8-5236-48a9-aa2d-559f05a6c843_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_A12790ElCaminoRealSuite100Member_f87d782f-c240-41c0-a472-82d18e32b1c6_terseLabel_en-US" xlink:label="lab_nbix_A12790ElCaminoRealSuite100Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12790 El Camino Real, Suite 100</link:label>
    <link:label id="lab_nbix_A12790ElCaminoRealSuite100Member_label_en-US" xlink:label="lab_nbix_A12790ElCaminoRealSuite100Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12790 El Camino Real Suite 100 [Member]</link:label>
    <link:label id="lab_nbix_A12790ElCaminoRealSuite100Member_documentation_en-US" xlink:label="lab_nbix_A12790ElCaminoRealSuite100Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12790 El Camino Real Suite 100. Office facility held for productive use.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A12790ElCaminoRealSuite100Member" xlink:href="nbix-20200930.xsd#nbix_A12790ElCaminoRealSuite100Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_A12790ElCaminoRealSuite100Member" xlink:to="lab_nbix_A12790ElCaminoRealSuite100Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7fc243e0-2c07-4197-b16d-3ac6cc67ad02_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_fe8e0034-e16a-4982-9bd5-cdd2c996f2ee_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5c25e5fe-f9bf-48f4-893c-1cc87ac64bed_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_d51a5419-1d63-4d52-b080-e8651b6189a3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivables write-off</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e5cc47bb-e76e-411f-b0ee-dc5bc1a601d4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_1486a323-9848-4841-b76a-25d39157db25_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_434d200e-1f12-4b2c-a0d8-454c631094fd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_UpfrontPaymentsReceived_399697ad-0bbe-4b07-aa2c-cd50f8d201b8_terseLabel_en-US" xlink:label="lab_nbix_UpfrontPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments received</link:label>
    <link:label id="lab_nbix_UpfrontPaymentsReceived_label_en-US" xlink:label="lab_nbix_UpfrontPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payments Received</link:label>
    <link:label id="lab_nbix_UpfrontPaymentsReceived_documentation_en-US" xlink:label="lab_nbix_UpfrontPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments received under a collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsReceived" xlink:href="nbix-20200930.xsd#nbix_UpfrontPaymentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_UpfrontPaymentsReceived" xlink:to="lab_nbix_UpfrontPaymentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_ab093604-4bd3-416b-ae71-d187728cb931_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract_fb57dd45-36de-4728-9678-19908f2fb30f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_58000533-37e7-4a58-a620-201bd8ee4821_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8e51684b-c3f3-4235-ba10-f74e8970e48d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_5816ba10-63ec-4c42-b5d3-5481daf3506f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9d6b7c84-62e4-403b-86df-aa61c94f7bd7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on debt securities available-for-sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_cf05f29d-0971-4993-9508-80807d103186_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bdf268b3-6fd6-4ab9-9349-818548450002_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f03340ff-b381-434b-b2e7-2397ab62cda0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7998d0fc-3307-4067-9a6a-e8a0f589bfc5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_63a226ec-8b66-4edb-b522-86b28fe6ba7a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_34d58607-8bba-49c5-b08d-fe91814f2c3b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_aea5cd01-3df1-489b-94b6-76786834a311_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8a3851ee-ffe8-40a3-9b8d-e40aa1cf0ead_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_8b8fa3fd-7d48-4f9b-8f39-78407e428f18_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_1bdb4445-39de-4f0e-bb85-f637477d5d2a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4a434c34-fe52-4f85-afc0-b70ef5e0c839_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c7e4d12a-9ba4-493e-86a7-2ddb453e0ab2_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income - basic and diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_579eb20e-80b2-4137-9ebf-d42f75b59104_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Description of Operating Lease</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_BIALMember_0b8d5607-5109-4bb5-a646-b332870930d8_terseLabel_en-US" xlink:label="lab_nbix_BIALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B I A L</link:label>
    <link:label id="lab_nbix_BIALMember_label_en-US" xlink:label="lab_nbix_BIALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B I A L [Member]</link:label>
    <link:label id="lab_nbix_BIALMember_documentation_en-US" xlink:label="lab_nbix_BIALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to BIAL, an entity with which Neurocrine has a license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BIALMember" xlink:href="nbix-20200930.xsd#nbix_BIALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_BIALMember" xlink:to="lab_nbix_BIALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ab3454dd-7a25-472a-b096-bb24e3185d34_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_ad1655f5-bad0-443b-b531-b77244adf794_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_297dc2cf-01be-4b6e-8ef6-2d4da73c4a9b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior note carrying value of the equity component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8a5f6f9c-be68-497f-9957-1a1b6c59e775_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1c647ba8-700a-4ef0-bc1f-b4e5ccb204c1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year ending December 31, 2020 (3 months remaining)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_LongTermInvestmentsMember_081f3674-caf9-4b07-bf3c-95e24384b805_terseLabel_en-US" xlink:label="lab_nbix_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_nbix_LongTermInvestmentsMember_label_en-US" xlink:label="lab_nbix_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Investments [Member]</link:label>
    <link:label id="lab_nbix_LongTermInvestmentsMember_documentation_en-US" xlink:label="lab_nbix_LongTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments which are intended be sold or mature more than one year from the balance sheet date or operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LongTermInvestmentsMember" xlink:href="nbix-20200930.xsd#nbix_LongTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_LongTermInvestmentsMember" xlink:to="lab_nbix_LongTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_f89d49fb-8e63-4c13-8e47-8fc19d872ff7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_c7abc29d-8f9e-45d1-99d1-9e6d31a2b2af_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_d956c8a7-761e-40d9-bcfd-8cb6f89488b6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_52f4b2e0-b640-4177-aa64-60175ea98e56_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage of common stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_3ec035c9-3440-4191-a83e-6c2d8e4c0d86_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2e98ac22-d4e7-4392-b93b-95d9661f12a1_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ca0618a4-aaa7-4de2-bcf2-af608cd10460_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_16b61317-3e2d-457e-84c5-c831b73338a2_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_1f8ac0ba-bfe6-4d06-84db-b114f09c3e45_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_f5f3e5ea-1d92-48e2-bb98-7cd31d8f03a0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7edbef7f-d06e-4006-99fd-4f585ca3c618_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_323a8a0e-0698-4dcc-b7ef-bee0ee5db233_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued to settle notes at initial conversion rate (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0ee92c7d-2678-4ecb-adcf-5e1d834ba46e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on debt securities available-for-sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fd8de61e-f659-4f73-9a01-1fc1e927f975_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_a7f3564c-52be-4446-8609-56592dd10eaf_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount for Lack of Marketability</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount for Lack of Marketability [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:to="lab_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4cbf63fb-5d9f-45fc-ac7c-5e2b1207dd81_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_5987ca99-7d73-4927-9a6c-bf4c72bb2e3d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5fcfaa16-dd3c-4f4d-801b-82468fe45dab_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_f167bd67-a6ef-4407-9f00-882a57b3accb_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_RestrictedCashTextBlock_a4c02561-8e14-426e-a6fc-c252a2885745_terseLabel_en-US" xlink:label="lab_nbix_RestrictedCashTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_nbix_RestrictedCashTextBlock_label_en-US" xlink:label="lab_nbix_RestrictedCashTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RestrictedCashTextBlock" xlink:href="nbix-20200930.xsd#nbix_RestrictedCashTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_RestrictedCashTextBlock" xlink:to="lab_nbix_RestrictedCashTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_5178ac09-5095-47cd-8668-3d62079108e7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_dc980371-7ebd-4f35-9209-ae80448daa98_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_9e4d67c8-2f12-48b0-9aeb-70238e32b90f_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_cef73de7-bf18-4ae1-80ba-052f3452e62f_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of equity security investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_337fcb4c-173d-464e-bf37-987a16bf6883_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss included in earnings</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_34ceacce-4773-458a-a7ea-b6a9ba3c0d0c_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_3652ae14-cf3d-4271-9bd4-5bf236860ffb_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_f9312b2d-542d-489c-bca9-39da99daa352_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_92744274-bd41-496c-a9f5-c33398bd4363_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_5fc26925-b5fc-4de2-9fd0-19da65239f8d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosure:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1634c4c9-de1a-49b9-806a-594015a7e740_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_93b159e1-fe79-48e7-a6b7-6501f66de5b6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accreted interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c99324d7-5be8-4443-8fe7-488649cf9bd7_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f37fcc2f-23d4-4148-8e32-c194905c500a_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_bfd2ab50-2fa8-4645-a9ee-e827e8881cb4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_0b263b8b-7e05-4175-a73c-4a53f57bdf2b_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember_02e9de94-65c9-4898-a76c-e8d61e302523_terseLabel_en-US" xlink:label="lab_nbix_TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 Notes</link:label>
    <link:label id="lab_nbix_TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember_label_en-US" xlink:label="lab_nbix_TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Point Two Five Percent Senior Convertible Notes Due Two Thousand Twenty Four [Member]</link:label>
    <link:label id="lab_nbix_TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember_documentation_en-US" xlink:label="lab_nbix_TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two point two five percent senior convertible notes due two thousand twenty four.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember" xlink:href="nbix-20200930.xsd#nbix_TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember" xlink:to="lab_nbix_TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_62a27ae9-daa5-4e45-a526-fa37af1b59da_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_19c30b34-9507-4391-b3fc-33aa83addc8c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_bc1a9d36-2630-4dba-bc68-c307b3124d47_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_e5b8d094-e0eb-46d4-8b75-e1b801eaa985_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_A12777HighBluffDriveMember_e498733f-389b-4c0c-aa43-d7ae711a75e1_terseLabel_en-US" xlink:label="lab_nbix_A12777HighBluffDriveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12777 High Bluff Drive</link:label>
    <link:label id="lab_nbix_A12777HighBluffDriveMember_label_en-US" xlink:label="lab_nbix_A12777HighBluffDriveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12777 High Bluff Drive [Member]</link:label>
    <link:label id="lab_nbix_A12777HighBluffDriveMember_documentation_en-US" xlink:label="lab_nbix_A12777HighBluffDriveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12777 High Bluff Drive. Office facility held for productive use.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A12777HighBluffDriveMember" xlink:href="nbix-20200930.xsd#nbix_A12777HighBluffDriveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_A12777HighBluffDriveMember" xlink:to="lab_nbix_A12777HighBluffDriveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_99ddeae5-49bd-4222-abd3-8b4dd5ccc373_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_212f1b04-0a7b-45c1-a330-5e93b2d7fe1d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_4d8cb8f4-e2a3-4bfd-a44c-72a8347306c5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_fd85db01-afb2-42a5-9f3e-dcb5bb5ac896_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Than 12 Months, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_46ac548e-5386-4f43-9af2-6f32586729ab_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_75fbbe3d-3e4d-427d-8fb9-5fa80af43bbf_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_31266bea-b297-4a59-98fe-35c97c84faa6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_70160a9f-6156-463d-b92a-216a58e1042e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0bebef0a-a54d-4993-ab45-d3a89afb7353_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_751767de-d2bf-4fe9-9305-02c338a49989_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less Than 12 Months, Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_f6ea01f8-5329-4020-9587-d2df162c7804_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember_c6c1a40e-47ba-41c8-9b88-4f2e803866e3_terseLabel_en-US" xlink:label="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda</link:label>
    <link:label id="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember_label_en-US" xlink:label="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited [Member]</link:label>
    <link:label id="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember_documentation_en-US" xlink:label="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:href="nbix-20200930.xsd#nbix_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="lab_nbix_TakedaPharmaceuticalCompanyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_4a90269a-d4d3-4e0d-8a8a-037b633ec7a3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_VoyagerTherapeuticsMember_dd9d6da2-ff3f-488f-96af-44e9738a22d5_terseLabel_en-US" xlink:label="lab_nbix_VoyagerTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voyager</link:label>
    <link:label id="lab_nbix_VoyagerTherapeuticsMember_label_en-US" xlink:label="lab_nbix_VoyagerTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voyager Therapeutics [Member]</link:label>
    <link:label id="lab_nbix_VoyagerTherapeuticsMember_documentation_en-US" xlink:label="lab_nbix_VoyagerTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voyager therapeutics.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember" xlink:href="nbix-20200930.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_VoyagerTherapeuticsMember" xlink:to="lab_nbix_VoyagerTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_94552830-aeb0-419f-ab4f-b6601c2b46b2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5a4f8bcd-77ce-4d24-b427-3c8755ac48b2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for stock option exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_f8b35b07-6645-4c10-82ae-1fcade90f721_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivables</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fd02a333-f2c2-443e-9af4-df1b17059c03_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff_c6347fb7-4f8f-42b4-b0e4-9322ab401c67_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivables write-off threshold period</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accrued Interest, Threshold Period, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_f4d1bff9-9ddf-4156-ba7f-8388d873be21_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_c70fbc45-0c5d-4652-aae7-30716a755ac0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d2235f0f-3496-4010-9401-d72e6cd7bb36_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_bab5a47b-bbec-4f9c-9c9b-284f08bc0c9d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_dc4f85c2-0e1f-4c18-8548-dcb1a81cf691_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b421ded8-231a-4443-aa56-83eee796a884_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_c2f1766e-c326-4c8a-967f-c4d3687ea939_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, current</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_58573548-4466-4aa1-9193-9d91688e7531_terseLabel_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_label_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due After Year Four</link:label>
    <link:label id="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_documentation_en-US" xlink:label="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:href="nbix-20200930.xsd#nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1fef7814-d460-4bcb-805b-fecf429e5691_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0936b888-1401-46e5-8b8a-e9af3a4db9af_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b79f6092-c689-4cad-af02-96e681c17847_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_8cbcc9f0-61c4-4771-a978-c746af2aec34_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="lab_us-gaap_ShortTermDebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_TerminationNoticePeriodBeforeFirstCommercialSale_9be785b0-0393-4253-8c0c-92772326023a_terseLabel_en-US" xlink:label="lab_nbix_TerminationNoticePeriodBeforeFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination notice period, before first commercial sale</link:label>
    <link:label id="lab_nbix_TerminationNoticePeriodBeforeFirstCommercialSale_label_en-US" xlink:label="lab_nbix_TerminationNoticePeriodBeforeFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Notice Period Before First Commercial Sale</link:label>
    <link:label id="lab_nbix_TerminationNoticePeriodBeforeFirstCommercialSale_documentation_en-US" xlink:label="lab_nbix_TerminationNoticePeriodBeforeFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Notice Period Before First Commercial Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TerminationNoticePeriodBeforeFirstCommercialSale" xlink:href="nbix-20200930.xsd#nbix_TerminationNoticePeriodBeforeFirstCommercialSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_TerminationNoticePeriodBeforeFirstCommercialSale" xlink:to="lab_nbix_TerminationNoticePeriodBeforeFirstCommercialSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_dbb9499e-532e-4eb6-9a5b-ffb28806d558_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_59bb98bb-23d0-42c4-9859-9b031c763a04_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of debt securities available for sale in unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_26f925cf-5f2c-4c31-90e5-8d02713c1ba8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_241f6c7d-71a0-4ffc-86a7-377bc329bf2e_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_40c9dced-bcab-4146-b54f-de4cccd9c13c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_TotalEquitySecuritiesMember_9c1d1a46-4028-4613-b981-60ea853fb2a0_terseLabel_en-US" xlink:label="lab_nbix_TotalEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity securities</link:label>
    <link:label id="lab_nbix_TotalEquitySecuritiesMember_label_en-US" xlink:label="lab_nbix_TotalEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Equity Securities [Member]</link:label>
    <link:label id="lab_nbix_TotalEquitySecuritiesMember_documentation_en-US" xlink:label="lab_nbix_TotalEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TotalEquitySecuritiesMember" xlink:href="nbix-20200930.xsd#nbix_TotalEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_TotalEquitySecuritiesMember" xlink:to="lab_nbix_TotalEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_199f48e3-1765-43f0-8b42-ed799d576ea8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, noncurrent</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_819b6584-cd48-4091-bab9-6c67bb5021bf_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_3dba491a-d4bb-451f-8c31-36cc66ed7792_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_42ed7c19-2733-4702-b46a-e5da34df57ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_7f9d76c5-c444-4c65-a536-695dc8de722a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_db855f3f-a08b-41fa-ac66-367fb684ae64_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bf2cd944-33b6-4a2e-afc8-c9b167e0b6c5_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_989ba47d-78bf-463a-ac15-8c0358ce308b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ef129283-789f-4a63-8f95-3d772f041659_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_6ef2a9bf-5127-489a-be92-9a1bde8bf500_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_2157f9dc-2b8b-4246-94be-6f35ce26b9dc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income per share, diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_d5c4493c-d604-420c-b93b-165acf6dbf57_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent_7c005a0e-61cd-4cf2-9935-ca992d882672_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior note carrying value of the liability component</link:label>
    <link:label id="lab_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent_label_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Initial Carrying Amount Of Liability Component</link:label>
    <link:label id="lab_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The carrying amount of the liability component of a convertible note.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent" xlink:href="nbix-20200930.xsd#nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent" xlink:to="lab_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6b646ab8-6bb3-4915-a7ec-31000534b8f8_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_IdorsiaPharmaceuticalsLtdMember_568d9437-4101-49a0-8bb5-d0ccbacf946f_terseLabel_en-US" xlink:label="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia</link:label>
    <link:label id="lab_nbix_IdorsiaPharmaceuticalsLtdMember_label_en-US" xlink:label="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia Pharmaceuticals Ltd [Member]</link:label>
    <link:label id="lab_nbix_IdorsiaPharmaceuticalsLtdMember_documentation_en-US" xlink:label="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia Pharmaceuticals Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:href="nbix-20200930.xsd#nbix_IdorsiaPharmaceuticalsLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:to="lab_nbix_IdorsiaPharmaceuticalsLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_803cd0b4-7aa6-4d2d-b5e2-4679714e41f6_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_845ec8e0-a55d-4eaa-94be-af7e00219b8e_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DevelopmentProductCandidatesMember_ba499f34-bd5e-461e-ac13-0df704e39185_terseLabel_en-US" xlink:label="lab_nbix_DevelopmentProductCandidatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Product Candidates</link:label>
    <link:label id="lab_nbix_DevelopmentProductCandidatesMember_label_en-US" xlink:label="lab_nbix_DevelopmentProductCandidatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Product Candidates [Member]</link:label>
    <link:label id="lab_nbix_DevelopmentProductCandidatesMember_documentation_en-US" xlink:label="lab_nbix_DevelopmentProductCandidatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Product Candidates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DevelopmentProductCandidatesMember" xlink:href="nbix-20200930.xsd#nbix_DevelopmentProductCandidatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DevelopmentProductCandidatesMember" xlink:to="lab_nbix_DevelopmentProductCandidatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_52246a3e-e9af-4275-abd1-e458d42b470c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_A12790ElCaminoRealSuite200Member_74ca9462-bd9c-4c0d-8142-a26b46f149d2_terseLabel_en-US" xlink:label="lab_nbix_A12790ElCaminoRealSuite200Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12790 El Camino Real, Suite 200</link:label>
    <link:label id="lab_nbix_A12790ElCaminoRealSuite200Member_label_en-US" xlink:label="lab_nbix_A12790ElCaminoRealSuite200Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12790 El Camino Real Suite 200 [Member]</link:label>
    <link:label id="lab_nbix_A12790ElCaminoRealSuite200Member_documentation_en-US" xlink:label="lab_nbix_A12790ElCaminoRealSuite200Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12790 El Camino Real Suite 200. Office facility held for productive use.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A12790ElCaminoRealSuite200Member" xlink:href="nbix-20200930.xsd#nbix_A12790ElCaminoRealSuite200Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_A12790ElCaminoRealSuite200Member" xlink:to="lab_nbix_A12790ElCaminoRealSuite200Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_9213e382-248b-4c9a-a372-585f6af665c3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Notes Net of Discount and Deferred Financing Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_bc9e519b-8066-4974-a638-a41239d2e437_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_4fcd29d6-cc0e-4bb1-b518-4d5df36afadf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_RestrictedCashMember_391881ae-b64b-489f-826c-61beee42f74d_terseLabel_en-US" xlink:label="lab_nbix_RestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total restricted cash</link:label>
    <link:label id="lab_nbix_RestrictedCashMember_label_en-US" xlink:label="lab_nbix_RestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash [Member]</link:label>
    <link:label id="lab_nbix_RestrictedCashMember_documentation_en-US" xlink:label="lab_nbix_RestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RestrictedCashMember" xlink:href="nbix-20200930.xsd#nbix_RestrictedCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_RestrictedCashMember" xlink:to="lab_nbix_RestrictedCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember_55c4864d-7428-4f8b-a02a-e9fbb8229c75_terseLabel_en-US" xlink:label="lab_nbix_StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Restricted Stock Units And Convertible Senior Notes</link:label>
    <link:label id="lab_nbix_StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember_label_en-US" xlink:label="lab_nbix_StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Restricted Stock Units And Convertible Senior Notes [Member]</link:label>
    <link:label id="lab_nbix_StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember_documentation_en-US" xlink:label="lab_nbix_StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Restricted Stock Units And Convertible Senior Notes [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember" xlink:href="nbix-20200930.xsd#nbix_StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember" xlink:to="lab_nbix_StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_a9dd96b5-c024-46cd-97e1-f56ec148892a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ddc2c425-c8b1-454d-8c83-112a698cda15_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_82c411ce-d4bf-4413-bd3c-9d30c258e666_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_bdb83d68-d27b-4f4c-8f9f-148a50322cec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold consecutive common stock trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_25590ebf-45e9-4c18-84ab-2ba077c22c90_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_e93d2d7c-4e21-4f59-a04f-e6ed18e88705_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3b0c2785-f76c-453c-957c-560b9d166078_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_76bd8233-25e0-455c-a97b-26ef0abe8533_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities of government-sponsored entities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralAxis_c9902a78-6a21-4681-be76-8ce80e71061b_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral</link:label>
    <link:label id="lab_us-gaap_CollateralAxis_label_en-US" xlink:label="lab_us-gaap_CollateralAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Held [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAxis" xlink:to="lab_us-gaap_CollateralAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_1975e672-bfec-48a4-ae07-7b5f511ad514_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental funding provided</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PotentialMilestonePaymentReceipts_b883013c-9691-4bb8-8000-28a2d1488b5f_terseLabel_en-US" xlink:label="lab_nbix_PotentialMilestonePaymentReceipts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payment receipts</link:label>
    <link:label id="lab_nbix_PotentialMilestonePaymentReceipts_label_en-US" xlink:label="lab_nbix_PotentialMilestonePaymentReceipts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Milestone Payment Receipts</link:label>
    <link:label id="lab_nbix_PotentialMilestonePaymentReceipts_documentation_en-US" xlink:label="lab_nbix_PotentialMilestonePaymentReceipts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential later stage milestone payments and royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePaymentReceipts" xlink:href="nbix-20200930.xsd#nbix_PotentialMilestonePaymentReceipts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PotentialMilestonePaymentReceipts" xlink:to="lab_nbix_PotentialMilestonePaymentReceipts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c3daed98-e6bc-4162-b0b2-53ac164d6e62_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ac170268-3485-4969-9d27-b5cb8789e7ee_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_5bf349a9-6d88-4ef0-bce6-979d628dc903_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_PotentialCommercialMilestonePayments_2a265e26-f979-4b17-a1ad-a07edd57cc2c_terseLabel_en-US" xlink:label="lab_nbix_PotentialCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential commercial milestone payments</link:label>
    <link:label id="lab_nbix_PotentialCommercialMilestonePayments_label_en-US" xlink:label="lab_nbix_PotentialCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Commercial Milestone Payments</link:label>
    <link:label id="lab_nbix_PotentialCommercialMilestonePayments_documentation_en-US" xlink:label="lab_nbix_PotentialCommercialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential payments for commercial milestones under a collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialCommercialMilestonePayments" xlink:href="nbix-20200930.xsd#nbix_PotentialCommercialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_PotentialCommercialMilestonePayments" xlink:to="lab_nbix_PotentialCommercialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_ba546b39-86ce-4a4c-9f0f-1205e58c3ede_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts_4615ee8e-87da-4698-8a9f-780f67030605_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Losses, Policy for Uncollectible Amounts [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" xlink:to="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_d3088459-3ed4-49e3-bccb-40286efe7e72_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_d1bc4d04-0509-4190-a8a0-6abec6b12f33_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_A1278012790ElCaminoRealMasterLeaseMember_83842d41-be8f-4bcf-981b-6211075c6897_terseLabel_en-US" xlink:label="lab_nbix_A1278012790ElCaminoRealMasterLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12780/12790 El Camino Real Master Lease [Member]</link:label>
    <link:label id="lab_nbix_A1278012790ElCaminoRealMasterLeaseMember_label_en-US" xlink:label="lab_nbix_A1278012790ElCaminoRealMasterLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12780/12790 El Camino Real Master Lease [Member]</link:label>
    <link:label id="lab_nbix_A1278012790ElCaminoRealMasterLeaseMember_documentation_en-US" xlink:label="lab_nbix_A1278012790ElCaminoRealMasterLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12780/12790 El Camino Real Master Lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A1278012790ElCaminoRealMasterLeaseMember" xlink:href="nbix-20200930.xsd#nbix_A1278012790ElCaminoRealMasterLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_A1278012790ElCaminoRealMasterLeaseMember" xlink:to="lab_nbix_A1278012790ElCaminoRealMasterLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_271e29de-702c-4e34-9057-d0875f585d71_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_MinimumSalesRequirementPeriodThresholdToTerminateAgreement_150677a2-66b7-43e3-9bf7-0e4ea0e6f4a8_terseLabel_en-US" xlink:label="lab_nbix_MinimumSalesRequirementPeriodThresholdToTerminateAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum sales requirement period</link:label>
    <link:label id="lab_nbix_MinimumSalesRequirementPeriodThresholdToTerminateAgreement_label_en-US" xlink:label="lab_nbix_MinimumSalesRequirementPeriodThresholdToTerminateAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Sales Requirement Period, Threshold To Terminate Agreement</link:label>
    <link:label id="lab_nbix_MinimumSalesRequirementPeriodThresholdToTerminateAgreement_documentation_en-US" xlink:label="lab_nbix_MinimumSalesRequirementPeriodThresholdToTerminateAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Sales Requirement Period, Threshold To Terminate Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumSalesRequirementPeriodThresholdToTerminateAgreement" xlink:href="nbix-20200930.xsd#nbix_MinimumSalesRequirementPeriodThresholdToTerminateAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_MinimumSalesRequirementPeriodThresholdToTerminateAgreement" xlink:to="lab_nbix_MinimumSalesRequirementPeriodThresholdToTerminateAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_389e10e1-557e-4a1e-a2e8-cf807fbaf3c0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_XenonPharmaceuticalsIncMember_5c7eed49-acc1-410b-9a58-fa06fcba482d_terseLabel_en-US" xlink:label="lab_nbix_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon</link:label>
    <link:label id="lab_nbix_XenonPharmaceuticalsIncMember_label_en-US" xlink:label="lab_nbix_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon Pharmaceuticals Inc [Member]</link:label>
    <link:label id="lab_nbix_XenonPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_nbix_XenonPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xenon Pharmaceuticals Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember" xlink:href="nbix-20200930.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_XenonPharmaceuticalsIncMember" xlink:to="lab_nbix_XenonPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_af2cb92f-6254-4d4c-b179-ee0953fc3003_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_9b998281-5d0b-4868-99cb-3de59e809aff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_133ce60f-20e9-41ce-a713-d7606102ea8f_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f77c688c-5551-4a1a-9d8d-4a716cb828ff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_d0cc19d7-c612-4d5a-9319-7a5d1d8690a3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_ResearchCollaborationTerm_248ad0d0-117e-49c1-97fe-87c0f00bad8e_terseLabel_en-US" xlink:label="lab_nbix_ResearchCollaborationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research collaboration term</link:label>
    <link:label id="lab_nbix_ResearchCollaborationTerm_label_en-US" xlink:label="lab_nbix_ResearchCollaborationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration Term</link:label>
    <link:label id="lab_nbix_ResearchCollaborationTerm_documentation_en-US" xlink:label="lab_nbix_ResearchCollaborationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ResearchCollaborationTerm" xlink:href="nbix-20200930.xsd#nbix_ResearchCollaborationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_ResearchCollaborationTerm" xlink:to="lab_nbix_ResearchCollaborationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_c76d8973-4a0a-448f-8fa9-b1436faa3c91_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_ca8e4e82-8b1b-4c15-96d4-840a912b3259_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e8abe75b-1b13-4bb3-a7b1-8e59035e3398_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_233a704c-9043-4079-b702-251136034805_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_1181c931-3c4d-4bb1-a237-658ab5976999_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_DebtInstrumentConvertibleConversionPremium_517792c1-96a4-4772-b84f-dbd222f070ea_terseLabel_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior note premium</link:label>
    <link:label id="lab_nbix_DebtInstrumentConvertibleConversionPremium_label_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Convertible Conversion Premium</link:label>
    <link:label id="lab_nbix_DebtInstrumentConvertibleConversionPremium_documentation_en-US" xlink:label="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of excess of the price paid for the convertible note over the closing stock price on the closing date of the convertible note.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleConversionPremium" xlink:href="nbix-20200930.xsd#nbix_DebtInstrumentConvertibleConversionPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_DebtInstrumentConvertibleConversionPremium" xlink:to="lab_nbix_DebtInstrumentConvertibleConversionPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_55f71ebc-eb62-4816-b76b-a056ed7cc02d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (Loss) Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_98e14d25-a171-4917-9d18-3c63067b85e2_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_9442c746-26cf-4b43-9a18-2f0ad0ca9a39_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_38091deb-9b36-4a4b-9530-dff2ccc75bcf_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_210efd90-54bf-40c5-aa54-7a2504dc5786_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_809ffea8-9e69-4e09-b60d-57f662ea172f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_eaa91cc0-864d-4c79-824d-aa91e8fa9b2a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_AbbvieIncMember_28a49eb9-dc22-4f59-9132-204fe97cf6ca_terseLabel_en-US" xlink:label="lab_nbix_AbbvieIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AbbVie</link:label>
    <link:label id="lab_nbix_AbbvieIncMember_label_en-US" xlink:label="lab_nbix_AbbvieIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abbvie Inc [Member]</link:label>
    <link:label id="lab_nbix_AbbvieIncMember_documentation_en-US" xlink:label="lab_nbix_AbbvieIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to AbbVie Inc., an entity with which Neurocrine has a collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AbbvieIncMember" xlink:href="nbix-20200930.xsd#nbix_AbbvieIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_AbbvieIncMember" xlink:to="lab_nbix_AbbvieIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced_626d31f0-ac3a-469a-9a1b-7ad342eeb7af_terseLabel_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable future minimum lease payments for operating leases that have not yet commenced</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced_label_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced</link:label>
    <link:label id="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced_documentation_en-US" xlink:label="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cancelable future minimum lease payments for operating leases not yet commenced.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced" xlink:href="nbix-20200930.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced" xlink:to="lab_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_78875239-8a1b-4916-a908-5e162b6a2650_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted and Issued Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5f72f6a0-a2a5-4511-a2cb-a43aede2fde0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_234a4e36-0202-4350-b6b1-de846593eff3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_4edc940d-7dbe-46b0-8e61-33a26987258f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount on liability component, remaining amortization period</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>nbix-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b79d3e40-aa4b-4356-aa3c-d2eb2732ffa0,g:9f3edc10-8601-4580-b4de-4b1ad44f8b95-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/role/CoverPage" xlink:type="simple" xlink:href="nbix-20200930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a90b58a5-912d-49fd-bb0d-d5110ab9019f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_DocumentType_a90b58a5-912d-49fd-bb0d-d5110ab9019f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_b9f0c020-af70-4a6f-8add-a099ba339e1f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_DocumentQuarterlyReport_b9f0c020-af70-4a6f-8add-a099ba339e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_920b9c58-b1ab-42fb-85ad-9c92194a17ac" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_DocumentPeriodEndDate_920b9c58-b1ab-42fb-85ad-9c92194a17ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_b2d9a344-21d6-44d4-8f34-553b71940ee0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_DocumentTransitionReport_b2d9a344-21d6-44d4-8f34-553b71940ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b42d2aa6-8db5-4d9e-a5ad-909aad9550f7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_EntityFileNumber_b42d2aa6-8db5-4d9e-a5ad-909aad9550f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_24846c9c-53ed-4cb8-bea2-e133dd438af5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_EntityRegistrantName_24846c9c-53ed-4cb8-bea2-e133dd438af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7d1059fe-ad6c-4896-94de-30cac74a7dcc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7d1059fe-ad6c-4896-94de-30cac74a7dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a3a56488-c374-4f99-9265-1f6eaca6adfb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_EntityTaxIdentificationNumber_a3a56488-c374-4f99-9265-1f6eaca6adfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_22eb320a-5a19-4cf4-9eb5-cd6a4c0b536c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_EntityAddressAddressLine1_22eb320a-5a19-4cf4-9eb5-cd6a4c0b536c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_baced62f-7ee9-44c2-8003-7adc0ef6ab9a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_EntityAddressCityOrTown_baced62f-7ee9-44c2-8003-7adc0ef6ab9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c5aaa29e-571d-4ead-ad19-d1c1e71aedae" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_EntityAddressStateOrProvince_c5aaa29e-571d-4ead-ad19-d1c1e71aedae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4d7d4bbc-1ee9-4916-80c3-dac0e6dcd915" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_EntityAddressPostalZipCode_4d7d4bbc-1ee9-4916-80c3-dac0e6dcd915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_77e21ffd-588e-4ea7-85c3-fc17f0b1da4f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_CityAreaCode_77e21ffd-588e-4ea7-85c3-fc17f0b1da4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_bae73e92-7c6f-460e-9d1b-e43ca3df77c0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_LocalPhoneNumber_bae73e92-7c6f-460e-9d1b-e43ca3df77c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ab82c256-e544-4da9-a46c-0289bbfe3f37" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_Security12bTitle_ab82c256-e544-4da9-a46c-0289bbfe3f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2d48705d-b2ca-4a78-bc05-22882e2aa165" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_TradingSymbol_2d48705d-b2ca-4a78-bc05-22882e2aa165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_24e5687c-f114-4ebf-9313-e7a2cf41a5fd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_SecurityExchangeName_24e5687c-f114-4ebf-9313-e7a2cf41a5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_2c98371d-9623-4405-be21-bc7f1124a1a9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_EntityCurrentReportingStatus_2c98371d-9623-4405-be21-bc7f1124a1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_524db94b-6214-4c2c-ac11-5406f78bbc90" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_EntityInteractiveDataCurrent_524db94b-6214-4c2c-ac11-5406f78bbc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_fe4f99d7-a7e6-4240-a0fb-8b6f43596377" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_EntityFilerCategory_fe4f99d7-a7e6-4240-a0fb-8b6f43596377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_4ce14c5f-4c43-4e01-919e-8bb21ab13b47" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_EntitySmallBusiness_4ce14c5f-4c43-4e01-919e-8bb21ab13b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f317aad5-179a-4788-8888-ce848d0ada4b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_EntityEmergingGrowthCompany_f317aad5-179a-4788-8888-ce848d0ada4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_863c7c2c-b556-41b7-80d1-473f84275ea5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_EntityShellCompany_863c7c2c-b556-41b7-80d1-473f84275ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e535c87d-ebf6-486a-9d27-70a30c38ba46" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e535c87d-ebf6-486a-9d27-70a30c38ba46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_977178cf-d9c8-46b2-9025-554a8f2f5d95" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_AmendmentFlag_977178cf-d9c8-46b2-9025-554a8f2f5d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_9f609e86-285d-4086-9fc8-eb6a4b4ecf15" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_DocumentFiscalYearFocus_9f609e86-285d-4086-9fc8-eb6a4b4ecf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0af9a298-571d-48e8-98f7-8680a26db133" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0af9a298-571d-48e8-98f7-8680a26db133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0b07f0e4-3b74-4066-acd8-5b1449d7d198" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_EntityCentralIndexKey_0b07f0e4-3b74-4066-acd8-5b1449d7d198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_122a55a7-74d8-4cfc-ab53-e157adc06563" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cafa9be5-5101-4797-a462-af296b2a7513" xlink:to="loc_dei_CurrentFiscalYearEndDate_122a55a7-74d8-4cfc-ab53-e157adc06563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="nbix-20200930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_aabdaeab-f042-458c-bae9-07fd1ff09414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_8926ffd5-80e0-4bfc-bac0-4ff5d6808522" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_aabdaeab-f042-458c-bae9-07fd1ff09414" xlink:to="loc_us-gaap_AssetsAbstract_8926ffd5-80e0-4bfc-bac0-4ff5d6808522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_542c8ebc-f234-48e0-b34b-f057671f2edb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8926ffd5-80e0-4bfc-bac0-4ff5d6808522" xlink:to="loc_us-gaap_AssetsCurrentAbstract_542c8ebc-f234-48e0-b34b-f057671f2edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2957d6de-5fa2-4b81-8dbc-ae25dfb7b522" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_542c8ebc-f234-48e0-b34b-f057671f2edb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2957d6de-5fa2-4b81-8dbc-ae25dfb7b522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1c4decdd-48f1-4522-884a-5b0228396afe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_542c8ebc-f234-48e0-b34b-f057671f2edb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1c4decdd-48f1-4522-884a-5b0228396afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c776d7b7-8c04-4d67-ba88-f70dbec76de0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_542c8ebc-f234-48e0-b34b-f057671f2edb" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c776d7b7-8c04-4d67-ba88-f70dbec76de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9770853a-a13b-40b7-a0d1-eb18672314c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_542c8ebc-f234-48e0-b34b-f057671f2edb" xlink:to="loc_us-gaap_InventoryNet_9770853a-a13b-40b7-a0d1-eb18672314c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_5fc89979-d0d6-4216-bfbe-bbfa61d471ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_542c8ebc-f234-48e0-b34b-f057671f2edb" xlink:to="loc_us-gaap_OtherAssetsCurrent_5fc89979-d0d6-4216-bfbe-bbfa61d471ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_40974f1e-bdf0-4d81-a0c3-af973fb266c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_542c8ebc-f234-48e0-b34b-f057671f2edb" xlink:to="loc_us-gaap_AssetsCurrent_40974f1e-bdf0-4d81-a0c3-af973fb266c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_2b8479e4-86c9-4241-be06-90924f689fbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8926ffd5-80e0-4bfc-bac0-4ff5d6808522" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_2b8479e4-86c9-4241-be06-90924f689fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d4c6ee2c-541b-4c64-ba49-46a832ae0763" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8926ffd5-80e0-4bfc-bac0-4ff5d6808522" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d4c6ee2c-541b-4c64-ba49-46a832ae0763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_5a383349-a2e2-4495-abda-ef33868e093a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8926ffd5-80e0-4bfc-bac0-4ff5d6808522" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRestricted_5a383349-a2e2-4495-abda-ef33868e093a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1a94fdcb-cdfc-46e6-bc77-a17644511698" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8926ffd5-80e0-4bfc-bac0-4ff5d6808522" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1a94fdcb-cdfc-46e6-bc77-a17644511698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_a3eee20d-3fe8-4251-8f61-7c50c2758ef7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8926ffd5-80e0-4bfc-bac0-4ff5d6808522" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_a3eee20d-3fe8-4251-8f61-7c50c2758ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e8f0fe6f-d00e-4b79-b20b-d20c6220c1f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8926ffd5-80e0-4bfc-bac0-4ff5d6808522" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e8f0fe6f-d00e-4b79-b20b-d20c6220c1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1bc07987-9d7c-4c49-8c75-4aae46bb2f2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8926ffd5-80e0-4bfc-bac0-4ff5d6808522" xlink:to="loc_us-gaap_Assets_1bc07987-9d7c-4c49-8c75-4aae46bb2f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8a74cffd-0c31-42f1-aa6c-bf5d5132cf0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_aabdaeab-f042-458c-bae9-07fd1ff09414" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8a74cffd-0c31-42f1-aa6c-bf5d5132cf0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_17b6d631-c756-446d-8ee5-9d1a60754a8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8a74cffd-0c31-42f1-aa6c-bf5d5132cf0a" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_17b6d631-c756-446d-8ee5-9d1a60754a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c743ce74-7ab2-49c2-9425-5e69a5cc97af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17b6d631-c756-446d-8ee5-9d1a60754a8b" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c743ce74-7ab2-49c2-9425-5e69a5cc97af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_67c44300-514e-47ab-a4c2-7550a4cec9aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17b6d631-c756-446d-8ee5-9d1a60754a8b" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_67c44300-514e-47ab-a4c2-7550a4cec9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ada61718-b270-47a6-9f5c-f6324786e1ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17b6d631-c756-446d-8ee5-9d1a60754a8b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ada61718-b270-47a6-9f5c-f6324786e1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a6e422f7-1a2c-480a-b6df-7ff7f01d3a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17b6d631-c756-446d-8ee5-9d1a60754a8b" xlink:to="loc_us-gaap_LiabilitiesCurrent_a6e422f7-1a2c-480a-b6df-7ff7f01d3a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fdbaabb9-d39e-4279-a58c-20a80cf073e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8a74cffd-0c31-42f1-aa6c-bf5d5132cf0a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fdbaabb9-d39e-4279-a58c-20a80cf073e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_91dea15a-0cd6-4fb2-bb52-4c5393e053da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8a74cffd-0c31-42f1-aa6c-bf5d5132cf0a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_91dea15a-0cd6-4fb2-bb52-4c5393e053da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_672ba07e-b035-445d-b7c4-b4b8c6257151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8a74cffd-0c31-42f1-aa6c-bf5d5132cf0a" xlink:to="loc_us-gaap_Liabilities_672ba07e-b035-445d-b7c4-b4b8c6257151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1fcba9f6-3b30-4300-86cb-c4b420ece6c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8a74cffd-0c31-42f1-aa6c-bf5d5132cf0a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1fcba9f6-3b30-4300-86cb-c4b420ece6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_eb8ab4f9-baad-4626-9c3a-b1148f8986b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1fcba9f6-3b30-4300-86cb-c4b420ece6c6" xlink:to="loc_us-gaap_PreferredStockValue_eb8ab4f9-baad-4626-9c3a-b1148f8986b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_799049e0-3b6b-4ec5-9d84-990b1bb55672" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1fcba9f6-3b30-4300-86cb-c4b420ece6c6" xlink:to="loc_us-gaap_CommonStockValue_799049e0-3b6b-4ec5-9d84-990b1bb55672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_94870e04-c4c7-4dfb-9108-ea4f1fcc9723" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1fcba9f6-3b30-4300-86cb-c4b420ece6c6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_94870e04-c4c7-4dfb-9108-ea4f1fcc9723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1b03f9d4-ee36-49c8-9bc9-7c8ca8445fcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1fcba9f6-3b30-4300-86cb-c4b420ece6c6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1b03f9d4-ee36-49c8-9bc9-7c8ca8445fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c60d0481-5632-4d43-ba0e-4077f1080d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1fcba9f6-3b30-4300-86cb-c4b420ece6c6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c60d0481-5632-4d43-ba0e-4077f1080d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6de71819-c7d5-4b67-b154-fbb331f2b745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1fcba9f6-3b30-4300-86cb-c4b420ece6c6" xlink:to="loc_us-gaap_StockholdersEquity_6de71819-c7d5-4b67-b154-fbb331f2b745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e25bae64-49b5-4f33-9dc4-c2fae6dfc206" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8a74cffd-0c31-42f1-aa6c-bf5d5132cf0a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e25bae64-49b5-4f33-9dc4-c2fae6dfc206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="nbix-20200930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5db0d701-299e-43a3-bc74-2249785eeed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_5e8e4936-38ce-446a-96f6-913f1f72f626" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5db0d701-299e-43a3-bc74-2249785eeed4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_5e8e4936-38ce-446a-96f6-913f1f72f626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_9e6add98-bd07-4440-8589-5caf6855dc60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5db0d701-299e-43a3-bc74-2249785eeed4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_9e6add98-bd07-4440-8589-5caf6855dc60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9d6a3c7f-c677-4e04-9cb1-da0d02dd1909" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5db0d701-299e-43a3-bc74-2249785eeed4" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9d6a3c7f-c677-4e04-9cb1-da0d02dd1909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_001b3d3f-ebd0-4059-9986-4637a5e936ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5db0d701-299e-43a3-bc74-2249785eeed4" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_001b3d3f-ebd0-4059-9986-4637a5e936ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_08b5bbf8-18cf-4544-8180-8668431cc172" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5db0d701-299e-43a3-bc74-2249785eeed4" xlink:to="loc_us-gaap_PreferredStockSharesIssued_08b5bbf8-18cf-4544-8180-8668431cc172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_651743e0-a4fd-46a3-aa75-548748d178d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5db0d701-299e-43a3-bc74-2249785eeed4" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_651743e0-a4fd-46a3-aa75-548748d178d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_874d7fb7-b739-49fe-8113-5f9c933d8a06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5db0d701-299e-43a3-bc74-2249785eeed4" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_874d7fb7-b739-49fe-8113-5f9c933d8a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1c245d70-875e-4645-af79-1b01084ecc53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5db0d701-299e-43a3-bc74-2249785eeed4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1c245d70-875e-4645-af79-1b01084ecc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a3192e4e-7401-4f7a-959e-0fda394445f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5db0d701-299e-43a3-bc74-2249785eeed4" xlink:to="loc_us-gaap_CommonStockSharesIssued_a3192e4e-7401-4f7a-959e-0fda394445f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_44573e92-b0f6-4b22-841d-b5bf081dca53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5db0d701-299e-43a3-bc74-2249785eeed4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_44573e92-b0f6-4b22-841d-b5bf081dca53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" xlink:type="simple" xlink:href="nbix-20200930.xsd#CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_0f27f35b-c7fe-43fb-92df-744f482ad4b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_01606784-23b2-4037-9761-aefe3498c44a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0f27f35b-c7fe-43fb-92df-744f482ad4b7" xlink:to="loc_us-gaap_StatementTable_01606784-23b2-4037-9761-aefe3498c44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_57a568ce-bc66-400f-8b52-6eaad889f7a2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_01606784-23b2-4037-9761-aefe3498c44a" xlink:to="loc_srt_ProductOrServiceAxis_57a568ce-bc66-400f-8b52-6eaad889f7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a55fb3d9-2cad-4c13-8fb1-db7cde7e472e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_57a568ce-bc66-400f-8b52-6eaad889f7a2" xlink:to="loc_srt_ProductsAndServicesDomain_a55fb3d9-2cad-4c13-8fb1-db7cde7e472e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e40de880-b3c4-4905-8d4d-668d66ceb6af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a55fb3d9-2cad-4c13-8fb1-db7cde7e472e" xlink:to="loc_us-gaap_ProductMember_e40de880-b3c4-4905-8d4d-668d66ceb6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CollaborationRevenueMember_ae4d0e29-0999-4573-a9ce-fe0f8aea32a2" xlink:href="nbix-20200930.xsd#nbix_CollaborationRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a55fb3d9-2cad-4c13-8fb1-db7cde7e472e" xlink:to="loc_nbix_CollaborationRevenueMember_ae4d0e29-0999-4573-a9ce-fe0f8aea32a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_01606784-23b2-4037-9761-aefe3498c44a" xlink:to="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_9d4b59e2-0d65-40d1-81d4-098704afd0f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_RevenuesAbstract_9d4b59e2-0d65-40d1-81d4-098704afd0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_33ba4188-6050-4313-853b-755d951e7163" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_9d4b59e2-0d65-40d1-81d4-098704afd0f6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_33ba4188-6050-4313-853b-755d951e7163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1998520c-14c4-4325-ba98-9c2b148f433f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1998520c-14c4-4325-ba98-9c2b148f433f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_14c17962-601e-42e0-a481-b9747c0c849a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1998520c-14c4-4325-ba98-9c2b148f433f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_14c17962-601e-42e0-a481-b9747c0c849a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4df093ad-d3c5-4174-93c4-960dbf657d06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1998520c-14c4-4325-ba98-9c2b148f433f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_4df093ad-d3c5-4174-93c4-960dbf657d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_766d076a-e740-4993-800f-485e4df2c2e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1998520c-14c4-4325-ba98-9c2b148f433f" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_766d076a-e740-4993-800f-485e4df2c2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_73512a62-ffcb-486a-be98-2a1e266fe081" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1998520c-14c4-4325-ba98-9c2b148f433f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_73512a62-ffcb-486a-be98-2a1e266fe081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0f9b6aca-75c1-46c4-94a8-3172d443ea4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1998520c-14c4-4325-ba98-9c2b148f433f" xlink:to="loc_us-gaap_CostsAndExpenses_0f9b6aca-75c1-46c4-94a8-3172d443ea4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d3e7c5fd-8820-43f1-9b06-b11c348c3148" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_OperatingIncomeLoss_d3e7c5fd-8820-43f1-9b06-b11c348c3148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7cdcad13-605c-4370-8a52-2fbd3491893a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7cdcad13-605c-4370-8a52-2fbd3491893a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8ad1a7f0-bb8b-4cac-ab54-f60c2a31d1d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7cdcad13-605c-4370-8a52-2fbd3491893a" xlink:to="loc_us-gaap_InterestExpense_8ad1a7f0-bb8b-4cac-ab54-f60c2a31d1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e0c00f84-947d-4b6a-8753-e8407bb1d23d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7cdcad13-605c-4370-8a52-2fbd3491893a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e0c00f84-947d-4b6a-8753-e8407bb1d23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_InvestmentIncomeAndOtherNet_cf5ea9f3-539b-4a2c-bc12-2d95e31bc781" xlink:href="nbix-20200930.xsd#nbix_InvestmentIncomeAndOtherNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7cdcad13-605c-4370-8a52-2fbd3491893a" xlink:to="loc_nbix_InvestmentIncomeAndOtherNet_cf5ea9f3-539b-4a2c-bc12-2d95e31bc781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b5e78470-23cb-41d7-b14f-6aeda275b57a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7cdcad13-605c-4370-8a52-2fbd3491893a" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_b5e78470-23cb-41d7-b14f-6aeda275b57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ac9116c-fad5-4a24-829e-5552e1ddb8cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ac9116c-fad5-4a24-829e-5552e1ddb8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3de2c483-f436-42c9-be08-4813127ec4ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3de2c483-f436-42c9-be08-4813127ec4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ca93e1fb-303e-4830-9f87-c66dd4320f0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_NetIncomeLoss_ca93e1fb-303e-4830-9f87-c66dd4320f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5def406c-a291-452d-9bde-bf139020a7fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5def406c-a291-452d-9bde-bf139020a7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7f667e18-022b-4596-8f29-58ab927e8691" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_7f667e18-022b-4596-8f29-58ab927e8691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3997c4e8-3b46-4f7e-9e13-2bb84718b137" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_EarningsPerShareBasic_3997c4e8-3b46-4f7e-9e13-2bb84718b137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f8d64ee7-232d-453c-9290-1507825572ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f8d64ee7-232d-453c-9290-1507825572ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3608871a-346f-4253-81e4-a20736da4ed8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3608871a-346f-4253-81e4-a20736da4ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_23c44288-9ebd-4052-97e2-c2cc08c11a23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6099ff57-b9f6-40a3-aa99-ed202f0c76ab" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_23c44288-9ebd-4052-97e2-c2cc08c11a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="nbix-20200930.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_679c245c-4735-4eb7-aed6-5174b4b7f49e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cff7e972-2eb8-41ae-9885-3be11a614d4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_679c245c-4735-4eb7-aed6-5174b4b7f49e" xlink:to="loc_us-gaap_StatementTable_cff7e972-2eb8-41ae-9885-3be11a614d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_dd956f16-6cf9-4d2b-873e-8fae8254e132" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cff7e972-2eb8-41ae-9885-3be11a614d4e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_dd956f16-6cf9-4d2b-873e-8fae8254e132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c0bcd89c-0157-4903-8e3f-472e08278465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dd956f16-6cf9-4d2b-873e-8fae8254e132" xlink:to="loc_us-gaap_EquityComponentDomain_c0bcd89c-0157-4903-8e3f-472e08278465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cd870aca-b445-40cc-a2d9-78c8057382e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c0bcd89c-0157-4903-8e3f-472e08278465" xlink:to="loc_us-gaap_CommonStockMember_cd870aca-b445-40cc-a2d9-78c8057382e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3f677a73-2110-4c16-891e-1526fa37be11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c0bcd89c-0157-4903-8e3f-472e08278465" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3f677a73-2110-4c16-891e-1526fa37be11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5ae205c0-51a4-4fc7-b2d6-5cb909c37a61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c0bcd89c-0157-4903-8e3f-472e08278465" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5ae205c0-51a4-4fc7-b2d6-5cb909c37a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_00c7c9f7-715b-47bd-a477-6b960fc377d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c0bcd89c-0157-4903-8e3f-472e08278465" xlink:to="loc_us-gaap_RetainedEarningsMember_00c7c9f7-715b-47bd-a477-6b960fc377d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e28f2d8e-6bab-402f-8207-0171d1985d38" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cff7e972-2eb8-41ae-9885-3be11a614d4e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e28f2d8e-6bab-402f-8207-0171d1985d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3f4752d8-0ff7-4393-b036-684bd3cda839" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e28f2d8e-6bab-402f-8207-0171d1985d38" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3f4752d8-0ff7-4393-b036-684bd3cda839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_72b65054-8e01-4202-ae3d-1097ad285460" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3f4752d8-0ff7-4393-b036-684bd3cda839" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_72b65054-8e01-4202-ae3d-1097ad285460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cff7e972-2eb8-41ae-9885-3be11a614d4e" xlink:to="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_c8bc1f20-4e66-4679-9ce0-382080f9727d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_SharesOutstanding_c8bc1f20-4e66-4679-9ce0-382080f9727d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_04d69a8a-b428-4886-b231-1a817ff80742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_StockholdersEquity_04d69a8a-b428-4886-b231-1a817ff80742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_83d6399f-d0a6-44fd-8ae8-f146e71bc127" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_NetIncomeLoss_83d6399f-d0a6-44fd-8ae8-f146e71bc127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8a81c28d-c6e2-450a-acef-ef4efb88583e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8a81c28d-c6e2-450a-acef-ef4efb88583e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ed4ba2b9-416c-45ea-9700-d609174b57cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ed4ba2b9-416c-45ea-9700-d609174b57cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_9cf5b634-4cc5-4196-8945-134ab0184b87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_9cf5b634-4cc5-4196-8945-134ab0184b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8fa5f91b-5b13-42ba-9e53-8d905ddbbe86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8fa5f91b-5b13-42ba-9e53-8d905ddbbe86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7e1f5d0c-de4c-4514-a627-5009109dd7b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_7e1f5d0c-de4c-4514-a627-5009109dd7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_307be4c9-5a3c-48ea-bb13-15bbe3593ad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_307be4c9-5a3c-48ea-bb13-15bbe3593ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_b66adf67-cf52-44b9-95ba-72d4b71788d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_b66adf67-cf52-44b9-95ba-72d4b71788d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_5bd1a9e1-d5ab-4ecc-ad39-f71068d2b674" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_SharesOutstanding_5bd1a9e1-d5ab-4ecc-ad39-f71068d2b674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3c41363e-0130-44f1-8253-b9781cd63a52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_StockholdersEquity_3c41363e-0130-44f1-8253-b9781cd63a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_493d5c64-8eac-43bd-95a8-e2802dac823c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9e58a0e-897f-4869-be4e-7379edb225bb" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_493d5c64-8eac-43bd-95a8-e2802dac823c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="nbix-20200930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_04bee606-0dd3-4c00-a7ad-99ee5268d6e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_32fc7a49-e7a3-4db2-924b-2540072c48f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_04bee606-0dd3-4c00-a7ad-99ee5268d6e6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_32fc7a49-e7a3-4db2-924b-2540072c48f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c441ce48-ed04-4979-ae41-082baa0d7817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_32fc7a49-e7a3-4db2-924b-2540072c48f3" xlink:to="loc_us-gaap_NetIncomeLoss_c441ce48-ed04-4979-ae41-082baa0d7817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4b4aaa41-d3ef-439b-977f-195d05d2acef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_32fc7a49-e7a3-4db2-924b-2540072c48f3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4b4aaa41-d3ef-439b-977f-195d05d2acef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_dbac8f04-da48-4cf1-a9d7-3889034fbb7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4b4aaa41-d3ef-439b-977f-195d05d2acef" xlink:to="loc_us-gaap_ShareBasedCompensation_dbac8f04-da48-4cf1-a9d7-3889034fbb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_9f1f168a-de34-4e4b-8d0e-fe54bdda5b23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4b4aaa41-d3ef-439b-977f-195d05d2acef" xlink:to="loc_us-gaap_Depreciation_9f1f168a-de34-4e4b-8d0e-fe54bdda5b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_5c22d565-402f-4973-b009-0c36eed4a35f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4b4aaa41-d3ef-439b-977f-195d05d2acef" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_5c22d565-402f-4973-b009-0c36eed4a35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_976d6290-c2cb-402d-a9c7-525fa781b7e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4b4aaa41-d3ef-439b-977f-195d05d2acef" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_976d6290-c2cb-402d-a9c7-525fa781b7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_9c89b24f-6b48-426c-b4b4-6dda1b3aece1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4b4aaa41-d3ef-439b-977f-195d05d2acef" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_9c89b24f-6b48-426c-b4b4-6dda1b3aece1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_30b4ce49-ab36-4f12-b420-86f136fd29ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4b4aaa41-d3ef-439b-977f-195d05d2acef" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_30b4ce49-ab36-4f12-b420-86f136fd29ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_901f593d-02cc-4360-9bc3-02351cad8032" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_32fc7a49-e7a3-4db2-924b-2540072c48f3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_901f593d-02cc-4360-9bc3-02351cad8032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c557fba9-5a55-43d6-bfb4-245d865960b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_901f593d-02cc-4360-9bc3-02351cad8032" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c557fba9-5a55-43d6-bfb4-245d865960b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_01233075-ab81-4e8c-9293-2e0fda89069b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_901f593d-02cc-4360-9bc3-02351cad8032" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_01233075-ab81-4e8c-9293-2e0fda89069b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bf3d6f3a-5524-4a3a-a1f1-4b23e93a4850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_901f593d-02cc-4360-9bc3-02351cad8032" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bf3d6f3a-5524-4a3a-a1f1-4b23e93a4850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_fd3fa378-f0e2-4773-8e4a-ea5fb9d89662" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_901f593d-02cc-4360-9bc3-02351cad8032" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_fd3fa378-f0e2-4773-8e4a-ea5fb9d89662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72872d79-7785-46e9-ac99-7912169dc488" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_32fc7a49-e7a3-4db2-924b-2540072c48f3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72872d79-7785-46e9-ac99-7912169dc488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_95ab5c1d-2c08-4496-8e90-db1856b3c106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_04bee606-0dd3-4c00-a7ad-99ee5268d6e6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_95ab5c1d-2c08-4496-8e90-db1856b3c106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_3da50232-e9b7-4835-ae26-cd3b60b388b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_95ab5c1d-2c08-4496-8e90-db1856b3c106" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_3da50232-e9b7-4835-ae26-cd3b60b388b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_0af0176e-6aa9-4644-9e47-a267cdaccb4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_95ab5c1d-2c08-4496-8e90-db1856b3c106" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_0af0176e-6aa9-4644-9e47-a267cdaccb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_4879e83e-f267-41e2-a373-f25ffc4dfba9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_95ab5c1d-2c08-4496-8e90-db1856b3c106" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_4879e83e-f267-41e2-a373-f25ffc4dfba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_be9f3470-f81a-4a61-b642-1f7e68084db2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_95ab5c1d-2c08-4496-8e90-db1856b3c106" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_be9f3470-f81a-4a61-b642-1f7e68084db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3e7ff7d9-249c-43fa-ba88-8c7686b5a85a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_95ab5c1d-2c08-4496-8e90-db1856b3c106" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3e7ff7d9-249c-43fa-ba88-8c7686b5a85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d35c8457-5241-469b-8d5f-fc82b4833186" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_04bee606-0dd3-4c00-a7ad-99ee5268d6e6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d35c8457-5241-469b-8d5f-fc82b4833186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_116a7a70-dc92-4661-83ae-b8b18c6090ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d35c8457-5241-469b-8d5f-fc82b4833186" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_116a7a70-dc92-4661-83ae-b8b18c6090ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d61eb0a5-cffd-4ff7-954a-97cf9520d099" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d35c8457-5241-469b-8d5f-fc82b4833186" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d61eb0a5-cffd-4ff7-954a-97cf9520d099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d56421f3-72b6-4823-a1f4-ba83a2b1b1dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_04bee606-0dd3-4c00-a7ad-99ee5268d6e6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d56421f3-72b6-4823-a1f4-ba83a2b1b1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fcffff40-16eb-4471-a87d-4043a0b530ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_04bee606-0dd3-4c00-a7ad-99ee5268d6e6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fcffff40-16eb-4471-a87d-4043a0b530ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fc16c421-7efe-4b18-8a8d-c2a0f07a94cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_04bee606-0dd3-4c00-a7ad-99ee5268d6e6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fc16c421-7efe-4b18-8a8d-c2a0f07a94cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_82b0c9b6-ac71-43ac-b597-94ada0cd69ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_04bee606-0dd3-4c00-a7ad-99ee5268d6e6" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_82b0c9b6-ac71-43ac-b597-94ada0cd69ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8d37aa3f-294c-4bd6-9066-d427195fbd2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_82b0c9b6-ac71-43ac-b597-94ada0cd69ca" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8d37aa3f-294c-4bd6-9066-d427195fbd2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_5c209195-7e52-415f-b324-4dc5528c3bde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_82b0c9b6-ac71-43ac-b597-94ada0cd69ca" xlink:to="loc_us-gaap_InterestPaidNet_5c209195-7e52-415f-b324-4dc5528c3bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_1a287d12-e381-4112-a401-1d00a40c629e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_82b0c9b6-ac71-43ac-b597-94ada0cd69ca" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_1a287d12-e381-4112-a401-1d00a40c629e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="nbix-20200930.xsd#OrganizationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_216c3a09-25ae-469c-8c19-bbbe5db5eef0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_ed56c821-5061-4bb5-a297-f5ced3f8ef85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_216c3a09-25ae-469c-8c19-bbbe5db5eef0" xlink:to="loc_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock_ed56c821-5061-4bb5-a297-f5ced3f8ef85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="nbix-20200930.xsd#OrganizationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9ccde987-f505-4701-beee-f4f68dc9cfb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BusinessDescriptionPolicyTextBlock_f4d6df3c-6deb-4a31-8fec-51c6d41be500" xlink:href="nbix-20200930.xsd#nbix_BusinessDescriptionPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ccde987-f505-4701-beee-f4f68dc9cfb7" xlink:to="loc_nbix_BusinessDescriptionPolicyTextBlock_f4d6df3c-6deb-4a31-8fec-51c6d41be500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_dca7eaee-2e35-4f00-816e-b25c4dbb1115" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ccde987-f505-4701-beee-f4f68dc9cfb7" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_dca7eaee-2e35-4f00-816e-b25c4dbb1115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_4564efcc-20c4-49f5-a3c9-531d0a0adde6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ccde987-f505-4701-beee-f4f68dc9cfb7" xlink:to="loc_us-gaap_DebtPolicyTextBlock_4564efcc-20c4-49f5-a3c9-531d0a0adde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts_1235c33b-fd41-4900-9fd8-5ce65b3974b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ccde987-f505-4701-beee-f4f68dc9cfb7" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts_1235c33b-fd41-4900-9fd8-5ce65b3974b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2fad42f3-c580-413c-aadb-1dc6a46a96be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ccde987-f505-4701-beee-f4f68dc9cfb7" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2fad42f3-c580-413c-aadb-1dc6a46a96be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7ce73191-5f9f-4a0a-b4a6-fe690ffd8f22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9ccde987-f505-4701-beee-f4f68dc9cfb7" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7ce73191-5f9f-4a0a-b4a6-fe690ffd8f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0253b700-3552-43a3-8241-25a42f4cd8b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfIrishSubsidiaries_cf1ace32-f556-4f23-b8d8-23a610c97da8" xlink:href="nbix-20200930.xsd#nbix_NumberOfIrishSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0253b700-3552-43a3-8241-25a42f4cd8b2" xlink:to="loc_nbix_NumberOfIrishSubsidiaries_cf1ace32-f556-4f23-b8d8-23a610c97da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff_a9b7a619-5190-4389-a219-3830cf382b78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0253b700-3552-43a3-8241-25a42f4cd8b2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff_a9b7a619-5190-4389-a219-3830cf382b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_82a2aaf6-c3f5-4183-a12a-82832bf6243c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0253b700-3552-43a3-8241-25a42f4cd8b2" xlink:to="loc_us-gaap_InterestReceivableCurrent_82a2aaf6-c3f5-4183-a12a-82832bf6243c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_bdc806b0-c432-41a2-a145-7f652a496710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0253b700-3552-43a3-8241-25a42f4cd8b2" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff_bdc806b0-c432-41a2-a145-7f652a496710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreements" xlink:type="simple" xlink:href="nbix-20200930.xsd#SignificantCollaborationandLicensingAgreements"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_d9f434cc-1f97-435b-8bb4-34be9e61b0d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_8408ee37-aa3c-469c-988e-2e60d66d7879" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_d9f434cc-1f97-435b-8bb4-34be9e61b0d9" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_8408ee37-aa3c-469c-988e-2e60d66d7879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_37e2e1e5-5ad5-45c7-8776-866335c1c9cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e81119b5-a85d-4157-bdc4-8e5d7c1b1f42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_37e2e1e5-5ad5-45c7-8776-866335c1c9cd" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e81119b5-a85d-4157-bdc4-8e5d7c1b1f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c5e46bf8-3b9a-4dc4-bbc2-eb72fef6578e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e81119b5-a85d-4157-bdc4-8e5d7c1b1f42" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c5e46bf8-3b9a-4dc4-bbc2-eb72fef6578e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_31ece9eb-5ab3-41dd-b95c-6f79bf9684a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c5e46bf8-3b9a-4dc4-bbc2-eb72fef6578e" xlink:to="loc_us-gaap_RelatedPartyDomain_31ece9eb-5ab3-41dd-b95c-6f79bf9684a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_b5013b3c-27b7-40eb-92bc-76d806912b5e" xlink:href="nbix-20200930.xsd#nbix_TakedaPharmaceuticalCompanyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_31ece9eb-5ab3-41dd-b95c-6f79bf9684a6" xlink:to="loc_nbix_TakedaPharmaceuticalCompanyLimitedMember_b5013b3c-27b7-40eb-92bc-76d806912b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IdorsiaPharmaceuticalsLtdMember_bd3f66fd-5374-4160-8e88-a24b9c518281" xlink:href="nbix-20200930.xsd#nbix_IdorsiaPharmaceuticalsLtdMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_31ece9eb-5ab3-41dd-b95c-6f79bf9684a6" xlink:to="loc_nbix_IdorsiaPharmaceuticalsLtdMember_bd3f66fd-5374-4160-8e88-a24b9c518281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_XenonPharmaceuticalsIncMember_85645ae4-6a98-40ce-a6d9-fbb5ab8a709d" xlink:href="nbix-20200930.xsd#nbix_XenonPharmaceuticalsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_31ece9eb-5ab3-41dd-b95c-6f79bf9684a6" xlink:to="loc_nbix_XenonPharmaceuticalsIncMember_85645ae4-6a98-40ce-a6d9-fbb5ab8a709d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_VoyagerTherapeuticsMember_107a9f0e-e632-4099-9fdf-9c1e5c8119c2" xlink:href="nbix-20200930.xsd#nbix_VoyagerTherapeuticsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_31ece9eb-5ab3-41dd-b95c-6f79bf9684a6" xlink:to="loc_nbix_VoyagerTherapeuticsMember_107a9f0e-e632-4099-9fdf-9c1e5c8119c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_BIALMember_81bea410-ff48-4e90-a4bc-0242f366c677" xlink:href="nbix-20200930.xsd#nbix_BIALMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_31ece9eb-5ab3-41dd-b95c-6f79bf9684a6" xlink:to="loc_nbix_BIALMember_81bea410-ff48-4e90-a4bc-0242f366c677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MitsubishiTanabePharmaCorporationMember_46167b35-1129-441c-aaa8-9097267965c1" xlink:href="nbix-20200930.xsd#nbix_MitsubishiTanabePharmaCorporationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_31ece9eb-5ab3-41dd-b95c-6f79bf9684a6" xlink:to="loc_nbix_MitsubishiTanabePharmaCorporationMember_46167b35-1129-441c-aaa8-9097267965c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_AbbvieIncMember_c913a34a-9774-4632-a185-a8b344990cc7" xlink:href="nbix-20200930.xsd#nbix_AbbvieIncMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_31ece9eb-5ab3-41dd-b95c-6f79bf9684a6" xlink:to="loc_nbix_AbbvieIncMember_c913a34a-9774-4632-a185-a8b344990cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c42eec6d-8779-4884-a898-8763043babb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e81119b5-a85d-4157-bdc4-8e5d7c1b1f42" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c42eec6d-8779-4884-a898-8763043babb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5b2abc66-a51f-432c-88b2-558a9018cadf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c42eec6d-8779-4884-a898-8763043babb8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5b2abc66-a51f-432c-88b2-558a9018cadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_b27f36d9-b9a0-4602-bffa-ef6d2cd80d26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5b2abc66-a51f-432c-88b2-558a9018cadf" xlink:to="loc_us-gaap_CollaborativeArrangementMember_b27f36d9-b9a0-4602-bffa-ef6d2cd80d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_affb7cfd-8b31-4811-aba4-69b38fd32534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e81119b5-a85d-4157-bdc4-8e5d7c1b1f42" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_affb7cfd-8b31-4811-aba4-69b38fd32534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d4671450-fcf2-49fa-b13f-9308c00bab91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_affb7cfd-8b31-4811-aba4-69b38fd32534" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d4671450-fcf2-49fa-b13f-9308c00bab91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_835fce1c-e953-4cca-bacd-7db929e71166" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d4671450-fcf2-49fa-b13f-9308c00bab91" xlink:to="loc_us-gaap_PatentsMember_835fce1c-e953-4cca-bacd-7db929e71166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e33901b1-5687-4c04-8a37-ad44b73654f1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e81119b5-a85d-4157-bdc4-8e5d7c1b1f42" xlink:to="loc_srt_RangeAxis_e33901b1-5687-4c04-8a37-ad44b73654f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f90e24b5-5d9f-4ea3-b1a3-f79d0d9d4cb2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e33901b1-5687-4c04-8a37-ad44b73654f1" xlink:to="loc_srt_RangeMember_f90e24b5-5d9f-4ea3-b1a3-f79d0d9d4cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_63577649-6dd7-428d-bd56-5b7d7d938f05" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f90e24b5-5d9f-4ea3-b1a3-f79d0d9d4cb2" xlink:to="loc_srt_MinimumMember_63577649-6dd7-428d-bd56-5b7d7d938f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_45874085-65e8-4734-8e49-e30fe5ca4c97" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e81119b5-a85d-4157-bdc4-8e5d7c1b1f42" xlink:to="loc_srt_ProductOrServiceAxis_45874085-65e8-4734-8e49-e30fe5ca4c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b524c65e-dfa5-4d26-87e9-4f12c12b942a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_45874085-65e8-4734-8e49-e30fe5ca4c97" xlink:to="loc_srt_ProductsAndServicesDomain_b524c65e-dfa5-4d26-87e9-4f12c12b942a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NBI827104Member_5846fc20-91d1-49a2-8103-0b289636d131" xlink:href="nbix-20200930.xsd#nbix_NBI827104Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b524c65e-dfa5-4d26-87e9-4f12c12b942a" xlink:to="loc_nbix_NBI827104Member_5846fc20-91d1-49a2-8103-0b289636d131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DevelopmentProductCandidatesMember_988a3c21-2912-4a4f-bb52-02b783494d23" xlink:href="nbix-20200930.xsd#nbix_DevelopmentProductCandidatesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b524c65e-dfa5-4d26-87e9-4f12c12b942a" xlink:to="loc_nbix_DevelopmentProductCandidatesMember_988a3c21-2912-4a4f-bb52-02b783494d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e81119b5-a85d-4157-bdc4-8e5d7c1b1f42" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsMade_402d0c35-116d-48a4-aa37-7fa1f80af850" xlink:href="nbix-20200930.xsd#nbix_UpfrontPaymentsMade"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_UpfrontPaymentsMade_402d0c35-116d-48a4-aa37-7fa1f80af850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePayments_84a22bbf-b432-4a37-8ae7-a1a69284f573" xlink:href="nbix-20200930.xsd#nbix_PotentialMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_PotentialMilestonePayments_84a22bbf-b432-4a37-8ae7-a1a69284f573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_bc219551-ad7c-4d6c-a2d5-22e7bdc181ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_bc219551-ad7c-4d6c-a2d5-22e7bdc181ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_ResearchCollaborationTerm_38630f62-55c9-4a84-a721-88a66f324b0e" xlink:href="nbix-20200930.xsd#nbix_ResearchCollaborationTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_ResearchCollaborationTerm_38630f62-55c9-4a84-a721-88a66f324b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialCommercialMilestonePayments_07ae1869-72e2-4d50-819d-6f0cfd227b76" xlink:href="nbix-20200930.xsd#nbix_PotentialCommercialMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_PotentialCommercialMilestonePayments_07ae1869-72e2-4d50-819d-6f0cfd227b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TerminationNoticePeriod_92921dc6-914a-49ce-a251-5d50f03bb6fd" xlink:href="nbix-20200930.xsd#nbix_TerminationNoticePeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_TerminationNoticePeriod_92921dc6-914a-49ce-a251-5d50f03bb6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TerminationNoticePeriodBeforeFirstCommercialSale_136d24a2-a491-4032-947d-9ad2f4cf8559" xlink:href="nbix-20200930.xsd#nbix_TerminationNoticePeriodBeforeFirstCommercialSale"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_TerminationNoticePeriodBeforeFirstCommercialSale_136d24a2-a491-4032-947d-9ad2f4cf8559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TerminationNoticePeriodAfterFirstCommercialSale_9d0e5c80-39c7-4c31-baab-64c31ef47dad" xlink:href="nbix-20200930.xsd#nbix_TerminationNoticePeriodAfterFirstCommercialSale"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_TerminationNoticePeriodAfterFirstCommercialSale_9d0e5c80-39c7-4c31-baab-64c31ef47dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MilestonePayment_a7360b4f-35d7-4799-bf90-89b99a771325" xlink:href="nbix-20200930.xsd#nbix_MilestonePayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_MilestonePayment_a7360b4f-35d7-4799-bf90-89b99a771325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumSalesRequirementPeriodThresholdToTerminateAgreement_ffd0aaf8-b742-4c86-864b-6b73561158f0" xlink:href="nbix-20200930.xsd#nbix_MinimumSalesRequirementPeriodThresholdToTerminateAgreement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_MinimumSalesRequirementPeriodThresholdToTerminateAgreement_ffd0aaf8-b742-4c86-864b-6b73561158f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2c315666-d441-4243-968e-fc4b048e85d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_2c315666-d441-4243-968e-fc4b048e85d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_abecdd5d-d7cd-4c91-9846-23b8f90a2b16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_abecdd5d-d7cd-4c91-9846-23b8f90a2b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_UpfrontPaymentsReceived_8617b491-b5a9-4099-957e-e170e6ba1a6a" xlink:href="nbix-20200930.xsd#nbix_UpfrontPaymentsReceived"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_UpfrontPaymentsReceived_8617b491-b5a9-4099-957e-e170e6ba1a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cdc416db-6d25-458e-8924-796a966a210e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cdc416db-6d25-458e-8924-796a966a210e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PotentialMilestonePaymentReceipts_c20a89b3-08f5-4aa5-8597-aeabc7be42f4" xlink:href="nbix-20200930.xsd#nbix_PotentialMilestonePaymentReceipts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_PotentialMilestonePaymentReceipts_c20a89b3-08f5-4aa5-8597-aeabc7be42f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PatentTerm_688d748d-56c3-413b-8f4d-312d56e6a3f1" xlink:href="nbix-20200930.xsd#nbix_PatentTerm"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9b9b4696-fcab-4e11-aeaf-254ddb2d520e" xlink:to="loc_nbix_PatentTerm_688d748d-56c3-413b-8f4d-312d56e6a3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecurities" xlink:type="simple" xlink:href="nbix-20200930.xsd#DebtSecurities"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2d50707c-a84e-4893-87ec-e1ce3f232136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0c6f12d0-4e38-47a9-8bd3-a913456273f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2d50707c-a84e-4893-87ec-e1ce3f232136" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0c6f12d0-4e38-47a9-8bd3-a913456273f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesTables" xlink:type="simple" xlink:href="nbix-20200930.xsd#DebtSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_12643a92-8dd5-4311-9289-65dc93797017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_5b9102e7-8e7a-4b9a-892d-f61bd977fd81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_12643a92-8dd5-4311-9289-65dc93797017" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_5b9102e7-8e7a-4b9a-892d-f61bd977fd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_bb988561-856c-4d45-a2b7-99d893146a57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_12643a92-8dd5-4311-9289-65dc93797017" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_bb988561-856c-4d45-a2b7-99d893146a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fdbd3ab7-ddca-4c6b-8e8e-496cd8405a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a3d7861d-4697-457d-be12-bea67cd2d13b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fdbd3ab7-ddca-4c6b-8e8e-496cd8405a5e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a3d7861d-4697-457d-be12-bea67cd2d13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_e35bfe6a-0736-46bc-88ba-db063effe9ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a3d7861d-4697-457d-be12-bea67cd2d13b" xlink:to="loc_us-gaap_InvestmentTypeAxis_e35bfe6a-0736-46bc-88ba-db063effe9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_9a2284c3-bcbf-424c-9954-e051e9fa8be4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_e35bfe6a-0736-46bc-88ba-db063effe9ca" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_9a2284c3-bcbf-424c-9954-e051e9fa8be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_efc61663-a4a8-4ba8-836b-7687072b0fde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_9a2284c3-bcbf-424c-9954-e051e9fa8be4" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_efc61663-a4a8-4ba8-836b-7687072b0fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LongTermInvestmentsMember_5ef71b82-24c6-4b4d-9827-78964e88c851" xlink:href="nbix-20200930.xsd#nbix_LongTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_9a2284c3-bcbf-424c-9954-e051e9fa8be4" xlink:to="loc_nbix_LongTermInvestmentsMember_5ef71b82-24c6-4b4d-9827-78964e88c851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_7a003c0a-6167-4300-a43d-0db0f153fa5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a3d7861d-4697-457d-be12-bea67cd2d13b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_7a003c0a-6167-4300-a43d-0db0f153fa5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_80145d70-4fd3-41e6-93a1-3145dfbfaab4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_7a003c0a-6167-4300-a43d-0db0f153fa5a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_80145d70-4fd3-41e6-93a1-3145dfbfaab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_ba8dffee-1077-4b7e-b9ad-91d90e36718b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_80145d70-4fd3-41e6-93a1-3145dfbfaab4" xlink:to="loc_us-gaap_CommercialPaperMember_ba8dffee-1077-4b7e-b9ad-91d90e36718b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0372edeb-de7c-4e07-93ec-713ab5a2c56e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a3d7861d-4697-457d-be12-bea67cd2d13b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0372edeb-de7c-4e07-93ec-713ab5a2c56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cdcd2646-eeca-4f40-88e0-9828420fb253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0372edeb-de7c-4e07-93ec-713ab5a2c56e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cdcd2646-eeca-4f40-88e0-9828420fb253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_f04b0327-4cba-4129-aed4-319bdb5016a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cdcd2646-eeca-4f40-88e0-9828420fb253" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_f04b0327-4cba-4129-aed4-319bdb5016a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_745269e6-4528-4c51-bed2-2504386f6d62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cdcd2646-eeca-4f40-88e0-9828420fb253" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_745269e6-4528-4c51-bed2-2504386f6d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53c1abce-af7b-4085-895c-124222b14eb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a3d7861d-4697-457d-be12-bea67cd2d13b" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53c1abce-af7b-4085-895c-124222b14eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_da0610b0-e267-41b7-866b-090d79bbe3ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53c1abce-af7b-4085-895c-124222b14eb7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_da0610b0-e267-41b7-866b-090d79bbe3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_029d03cd-a5f8-4042-bd1f-0a2b02bdfcfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53c1abce-af7b-4085-895c-124222b14eb7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_029d03cd-a5f8-4042-bd1f-0a2b02bdfcfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_32fe936c-486a-4731-8034-a5322d0d7115" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53c1abce-af7b-4085-895c-124222b14eb7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_32fe936c-486a-4731-8034-a5322d0d7115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_60fe6ee9-ca38-4354-8f36-79a9b48a00fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53c1abce-af7b-4085-895c-124222b14eb7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_60fe6ee9-ca38-4354-8f36-79a9b48a00fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_60a865fb-56ea-4eae-adff-3ba856443944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_53c1abce-af7b-4085-895c-124222b14eb7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_60a865fb-56ea-4eae-adff-3ba856443944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#DebtSecuritiesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_061f602f-9086-4cbe-a66d-31161d134f7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_71706f04-835a-48e0-83b4-4bb4789a1301" xlink:href="nbix-20200930.xsd#nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_061f602f-9086-4cbe-a66d-31161d134f7e" xlink:to="loc_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions_71706f04-835a-48e0-83b4-4bb4789a1301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_d7a08392-0c33-479e-94bd-809a61132a2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_061f602f-9086-4cbe-a66d-31161d134f7e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_d7a08392-0c33-479e-94bd-809a61132a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_62b37f81-ae36-4548-aac1-a9274124555e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_3a2528f4-0998-4144-b0ee-274036b55204" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_62b37f81-ae36-4548-aac1-a9274124555e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_3a2528f4-0998-4144-b0ee-274036b55204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b8b573a4-79e2-42ac-b62a-9df7852b5aef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_3a2528f4-0998-4144-b0ee-274036b55204" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b8b573a4-79e2-42ac-b62a-9df7852b5aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5b1702e-92a7-4a4f-a387-e1cf243b9938" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b8b573a4-79e2-42ac-b62a-9df7852b5aef" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5b1702e-92a7-4a4f-a387-e1cf243b9938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_fb9c7cb9-fd4d-4750-a8fd-382c5c9db0f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b5b1702e-92a7-4a4f-a387-e1cf243b9938" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_fb9c7cb9-fd4d-4750-a8fd-382c5c9db0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1274750d-37c9-42d6-87d8-797bcc3d70a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_3a2528f4-0998-4144-b0ee-274036b55204" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1274750d-37c9-42d6-87d8-797bcc3d70a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_ad4bba87-c980-430d-9e4f-0a490980cbb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1274750d-37c9-42d6-87d8-797bcc3d70a4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_ad4bba87-c980-430d-9e4f-0a490980cbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_131b833f-0939-4d5a-8754-a5cff157f877" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1274750d-37c9-42d6-87d8-797bcc3d70a4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_131b833f-0939-4d5a-8754-a5cff157f877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_ae365b43-15c1-4874-832d-9cd6417b40ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1274750d-37c9-42d6-87d8-797bcc3d70a4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_ae365b43-15c1-4874-832d-9cd6417b40ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_6011d14b-3c93-4b0d-ae5b-5fcb4573966f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1274750d-37c9-42d6-87d8-797bcc3d70a4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_6011d14b-3c93-4b0d-ae5b-5fcb4573966f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_e5199932-1635-474a-bb9a-d626048c30b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1274750d-37c9-42d6-87d8-797bcc3d70a4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_e5199932-1635-474a-bb9a-d626048c30b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_812c110b-acaa-433c-89f1-86b1c1dcaf71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1274750d-37c9-42d6-87d8-797bcc3d70a4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_812c110b-acaa-433c-89f1-86b1c1dcaf71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="nbix-20200930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_43a69bdc-74fb-4b81-b90b-f0e3636d7cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_55574421-652f-429e-93e0-5478e83e43e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_43a69bdc-74fb-4b81-b90b-f0e3636d7cd6" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_55574421-652f-429e-93e0-5478e83e43e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="nbix-20200930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c6c2fcb3-3fcd-4292-99e5-aed5152d8e08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_5b20962d-d874-4781-903d-4c46c104c925" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c6c2fcb3-3fcd-4292-99e5-aed5152d8e08" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_5b20962d-d874-4781-903d-4c46c104c925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7bd7984c-85df-4b81-a040-2130286acfe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c6c2fcb3-3fcd-4292-99e5-aed5152d8e08" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7bd7984c-85df-4b81-a040-2130286acfe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_89eb50af-53ca-4774-939c-70df6e68a3d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1565fbf7-06df-4c96-a294-f59ab15da2ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_89eb50af-53ca-4774-939c-70df6e68a3d2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1565fbf7-06df-4c96-a294-f59ab15da2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_475f077b-90ea-48c3-ba8a-e8bcd47aecfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1565fbf7-06df-4c96-a294-f59ab15da2ba" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_475f077b-90ea-48c3-ba8a-e8bcd47aecfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_567c32b3-b334-4f24-bfef-277d7ed0a0a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_475f077b-90ea-48c3-ba8a-e8bcd47aecfe" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_567c32b3-b334-4f24-bfef-277d7ed0a0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_CashAndMoneyMarketFundMember_e9cf1a99-2194-46e9-a789-d61ff6226a72" xlink:href="nbix-20200930.xsd#nbix_CashAndMoneyMarketFundMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_567c32b3-b334-4f24-bfef-277d7ed0a0a2" xlink:to="loc_nbix_CashAndMoneyMarketFundMember_e9cf1a99-2194-46e9-a789-d61ff6226a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_23bcced9-a97a-4e46-9cfc-e03a6c8d0569" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_567c32b3-b334-4f24-bfef-277d7ed0a0a2" xlink:to="loc_us-gaap_CashEquivalentsMember_23bcced9-a97a-4e46-9cfc-e03a6c8d0569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_3a3c5065-a294-4947-b915-c3e1a5aec586" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_567c32b3-b334-4f24-bfef-277d7ed0a0a2" xlink:to="loc_us-gaap_CertificatesOfDepositMember_3a3c5065-a294-4947-b915-c3e1a5aec586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RestrictedCashMember_cc57da9f-dc5e-4817-bbae-adb9537b4a89" xlink:href="nbix-20200930.xsd#nbix_RestrictedCashMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_567c32b3-b334-4f24-bfef-277d7ed0a0a2" xlink:to="loc_nbix_RestrictedCashMember_cc57da9f-dc5e-4817-bbae-adb9537b4a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_065773b0-f693-4a65-9368-2a97eb999a82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_567c32b3-b334-4f24-bfef-277d7ed0a0a2" xlink:to="loc_us-gaap_CommercialPaperMember_065773b0-f693-4a65-9368-2a97eb999a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2811cedf-06a8-48e7-b990-4740b3a75222" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1565fbf7-06df-4c96-a294-f59ab15da2ba" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2811cedf-06a8-48e7-b990-4740b3a75222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b30c03b1-4621-4b02-8f33-52986136fc89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2811cedf-06a8-48e7-b990-4740b3a75222" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b30c03b1-4621-4b02-8f33-52986136fc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3ebeca28-4cba-4263-909e-fa498d1acfdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b30c03b1-4621-4b02-8f33-52986136fc89" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3ebeca28-4cba-4263-909e-fa498d1acfdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_5c17e716-cbcc-49d6-a6f3-7e458f811a9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b30c03b1-4621-4b02-8f33-52986136fc89" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_5c17e716-cbcc-49d6-a6f3-7e458f811a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_9b971767-41f6-4534-986f-d234b0c5748c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b30c03b1-4621-4b02-8f33-52986136fc89" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_9b971767-41f6-4534-986f-d234b0c5748c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_a0e74384-e7b6-4bf7-92f4-c9a97f06dc77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b30c03b1-4621-4b02-8f33-52986136fc89" xlink:to="loc_us-gaap_EquitySecuritiesMember_a0e74384-e7b6-4bf7-92f4-c9a97f06dc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TotalEquitySecuritiesMember_1a527493-3a7f-448b-84c8-cca8f2d4505d" xlink:href="nbix-20200930.xsd#nbix_TotalEquitySecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b30c03b1-4621-4b02-8f33-52986136fc89" xlink:to="loc_nbix_TotalEquitySecuritiesMember_1a527493-3a7f-448b-84c8-cca8f2d4505d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d95bed3b-5711-4c78-905e-9bf8e3a9dee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1565fbf7-06df-4c96-a294-f59ab15da2ba" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d95bed3b-5711-4c78-905e-9bf8e3a9dee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c558837a-8d85-4e48-92fc-9509a15918be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d95bed3b-5711-4c78-905e-9bf8e3a9dee9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c558837a-8d85-4e48-92fc-9509a15918be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2e1d4c7b-46b0-4a50-8af9-da6b98314494" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c558837a-8d85-4e48-92fc-9509a15918be" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2e1d4c7b-46b0-4a50-8af9-da6b98314494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c1f29f31-480b-402b-8da5-a546ddaa8317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c558837a-8d85-4e48-92fc-9509a15918be" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c1f29f31-480b-402b-8da5-a546ddaa8317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_cc9e9f29-48c4-48fc-8a6c-7dbbd6a461c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c558837a-8d85-4e48-92fc-9509a15918be" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_cc9e9f29-48c4-48fc-8a6c-7dbbd6a461c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_547c9fb7-7642-4987-8a44-29b456258a51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1565fbf7-06df-4c96-a294-f59ab15da2ba" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_547c9fb7-7642-4987-8a44-29b456258a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9017ec14-6de6-4806-b288-72b0772ae1c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_547c9fb7-7642-4987-8a44-29b456258a51" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9017ec14-6de6-4806-b288-72b0772ae1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_57397cd4-eab2-4cb7-a66a-9004e5c117c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9017ec14-6de6-4806-b288-72b0772ae1c2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_57397cd4-eab2-4cb7-a66a-9004e5c117c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8162c196-5c53-40d0-9261-06580d633aa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1565fbf7-06df-4c96-a294-f59ab15da2ba" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8162c196-5c53-40d0-9261-06580d633aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_0d81728b-4862-45a0-a437-75acee0bd82b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8162c196-5c53-40d0-9261-06580d633aa6" xlink:to="loc_us-gaap_Investments_0d81728b-4862-45a0-a437-75acee0bd82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4b901382-12c8-4950-a430-e08933d6e4d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8162c196-5c53-40d0-9261-06580d633aa6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_4b901382-12c8-4950-a430-e08933d6e4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail" xlink:type="simple" xlink:href="nbix-20200930.xsd#FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d82d8b65-c29d-4b01-aad3-fe5727c7de78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9637a207-5d3e-41fa-95c7-c08c4e79bc4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d82d8b65-c29d-4b01-aad3-fe5727c7de78" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9637a207-5d3e-41fa-95c7-c08c4e79bc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAxis_091d594c-33b1-49ad-a30a-4b8cb72abf66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9637a207-5d3e-41fa-95c7-c08c4e79bc4a" xlink:to="loc_us-gaap_CollateralAxis_091d594c-33b1-49ad-a30a-4b8cb72abf66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralDomain_1b49dda6-fe7c-4f01-98b5-d2f33189ff49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollateralDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollateralAxis_091d594c-33b1-49ad-a30a-4b8cb72abf66" xlink:to="loc_us-gaap_CollateralDomain_1b49dda6-fe7c-4f01-98b5-d2f33189ff49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_6703e8d6-24f5-426a-8ce5-e32627504105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollateralDomain_1b49dda6-fe7c-4f01-98b5-d2f33189ff49" xlink:to="loc_us-gaap_EquitySecuritiesMember_6703e8d6-24f5-426a-8ce5-e32627504105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_beb636ce-7f4d-4afd-9271-fe37b77f6b3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9637a207-5d3e-41fa-95c7-c08c4e79bc4a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_beb636ce-7f4d-4afd-9271-fe37b77f6b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_316ace04-bc7e-4f5c-9da6-6c77b040e546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_beb636ce-7f4d-4afd-9271-fe37b77f6b3b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_316ace04-bc7e-4f5c-9da6-6c77b040e546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6427952e-511f-456f-861c-15e06322f5c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_316ace04-bc7e-4f5c-9da6-6c77b040e546" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6427952e-511f-456f-861c-15e06322f5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e98f08f5-2430-476e-8c5c-a32cee181fb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9637a207-5d3e-41fa-95c7-c08c4e79bc4a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e98f08f5-2430-476e-8c5c-a32cee181fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4d8b91a6-be70-4a93-959e-499bc9295f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_e98f08f5-2430-476e-8c5c-a32cee181fb5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4d8b91a6-be70-4a93-959e-499bc9295f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d71c6cf2-a8e1-48b1-9ea0-760c342d3eb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4d8b91a6-be70-4a93-959e-499bc9295f1b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d71c6cf2-a8e1-48b1-9ea0-760c342d3eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04368f98-b4af-49f5-b820-e478ccb7106f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9637a207-5d3e-41fa-95c7-c08c4e79bc4a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04368f98-b4af-49f5-b820-e478ccb7106f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_30b683e5-6ea1-4092-9b7b-b9d15a6533ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04368f98-b4af-49f5-b820-e478ccb7106f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRestricted_30b683e5-6ea1-4092-9b7b-b9d15a6533ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_f1faba3b-8bc6-42df-ab2b-c4314ce4c5c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04368f98-b4af-49f5-b820-e478ccb7106f" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_f1faba3b-8bc6-42df-ab2b-c4314ce4c5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_dedab84a-2c52-4086-a46f-3c5ec2700a04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04368f98-b4af-49f5-b820-e478ccb7106f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_dedab84a-2c52-4086-a46f-3c5ec2700a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRestricted_58bc1a8a-aaaa-442d-9fe9-4152ff589b41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiRestricted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_04368f98-b4af-49f5-b820-e478ccb7106f" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRestricted_58bc1a8a-aaaa-442d-9fe9-4152ff589b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d2aff522-4397-4f8d-aa06-a0c413e6686a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b66bdbac-3bf5-49a2-83f8-8eee2ed672d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d2aff522-4397-4f8d-aa06-a0c413e6686a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b66bdbac-3bf5-49a2-83f8-8eee2ed672d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_810a1568-cbf1-4c7b-898f-0336ad6e3417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b66bdbac-3bf5-49a2-83f8-8eee2ed672d3" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_810a1568-cbf1-4c7b-898f-0336ad6e3417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_3fd04393-3b34-4013-a3f1-10ab7694c367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_810a1568-cbf1-4c7b-898f-0336ad6e3417" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_3fd04393-3b34-4013-a3f1-10ab7694c367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_f9758211-f4eb-4c75-a173-a2deb46441d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3fd04393-3b34-4013-a3f1-10ab7694c367" xlink:to="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_f9758211-f4eb-4c75-a173-a2deb46441d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9ef13c53-b3d7-4db1-ace6-bb95aafb31a7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b66bdbac-3bf5-49a2-83f8-8eee2ed672d3" xlink:to="loc_srt_RangeAxis_9ef13c53-b3d7-4db1-ace6-bb95aafb31a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5f5e2f1f-6f94-4ca2-86ed-f71a1bbe1e4e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9ef13c53-b3d7-4db1-ace6-bb95aafb31a7" xlink:to="loc_srt_RangeMember_5f5e2f1f-6f94-4ca2-86ed-f71a1bbe1e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cd809249-098d-4d1f-adf0-0ed06cc90e7e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5f5e2f1f-6f94-4ca2-86ed-f71a1bbe1e4e" xlink:to="loc_srt_MinimumMember_cd809249-098d-4d1f-adf0-0ed06cc90e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e3a15cb7-c87d-41fd-ac7d-049e26520ae7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5f5e2f1f-6f94-4ca2-86ed-f71a1bbe1e4e" xlink:to="loc_srt_MaximumMember_e3a15cb7-c87d-41fd-ac7d-049e26520ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_b87cb46c-ed13-4e8d-a62c-7801cbaf43fa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5f5e2f1f-6f94-4ca2-86ed-f71a1bbe1e4e" xlink:to="loc_srt_WeightedAverageMember_b87cb46c-ed13-4e8d-a62c-7801cbaf43fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ee6933ad-e000-43f9-95b2-1d196f54a7bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b66bdbac-3bf5-49a2-83f8-8eee2ed672d3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ee6933ad-e000-43f9-95b2-1d196f54a7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_5d512a09-1e15-4541-a72a-bdbdefcfead9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ee6933ad-e000-43f9-95b2-1d196f54a7bd" xlink:to="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_5d512a09-1e15-4541-a72a-bdbdefcfead9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/Inventories" xlink:type="simple" xlink:href="nbix-20200930.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b0367864-a5a5-4ee1-a5b3-c95ec70391d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_843cfa84-610f-4427-9240-68d33c91b99c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b0367864-a5a5-4ee1-a5b3-c95ec70391d8" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_843cfa84-610f-4427-9240-68d33c91b99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/InventoriesTables" xlink:type="simple" xlink:href="nbix-20200930.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_327630dd-cabc-40b1-b726-14bba7d71795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1bbdff9b-c3a0-47f7-ad39-2b0776d25e8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_327630dd-cabc-40b1-b726-14bba7d71795" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1bbdff9b-c3a0-47f7-ad39-2b0776d25e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#InventoriesSummaryofInventoriesDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_7f49abe9-f96e-45fd-9ad3-5a0627ecd67c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_40a70353-5301-4cd6-a8b8-39c72abf1a66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7f49abe9-f96e-45fd-9ad3-5a0627ecd67c" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_40a70353-5301-4cd6-a8b8-39c72abf1a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_d020ca57-ca8b-4f71-ba37-d482a5c1780a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7f49abe9-f96e-45fd-9ad3-5a0627ecd67c" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_d020ca57-ca8b-4f71-ba37-d482a5c1780a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_3bbf9568-cf60-4642-8eda-880719a00952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7f49abe9-f96e-45fd-9ad3-5a0627ecd67c" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_3bbf9568-cf60-4642-8eda-880719a00952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_052a722c-a146-4ad5-8c16-42361a8a0793" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7f49abe9-f96e-45fd-9ad3-5a0627ecd67c" xlink:to="loc_us-gaap_InventoryNet_052a722c-a146-4ad5-8c16-42361a8a0793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash" xlink:type="simple" xlink:href="nbix-20200930.xsd#CashCashEquivalentsandRestrictedCash"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_9e6c3f2b-cb9d-4b0b-937f-2f0599f1eaa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_RestrictedCashTextBlock_df38c124-456f-41c5-b160-42d857488be8" xlink:href="nbix-20200930.xsd#nbix_RestrictedCashTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_9e6c3f2b-cb9d-4b0b-937f-2f0599f1eaa4" xlink:to="loc_nbix_RestrictedCashTextBlock_df38c124-456f-41c5-b160-42d857488be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables" xlink:type="simple" xlink:href="nbix-20200930.xsd#CashCashEquivalentsandRestrictedCashTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_c2ec61f4-26c2-41e1-93ca-4553e51aa45e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_32e5a462-fa06-44f9-951b-a5ef7b5fdc9d" xlink:href="nbix-20200930.xsd#nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_c2ec61f4-26c2-41e1-93ca-4553e51aa45e" xlink:to="loc_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_32e5a462-fa06-44f9-951b-a5ef7b5fdc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_db7fd5d1-89c6-417e-a045-156e9b3e45f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cc7c7b32-1524-4733-a0ff-a5226d2c061d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_db7fd5d1-89c6-417e-a045-156e9b3e45f4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cc7c7b32-1524-4733-a0ff-a5226d2c061d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_0c3938f4-8fed-4dd4-90a2-f0a966b24b6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_db7fd5d1-89c6-417e-a045-156e9b3e45f4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_0c3938f4-8fed-4dd4-90a2-f0a966b24b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_fab1bdda-374b-4f28-8113-313e7b5c7150" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_db7fd5d1-89c6-417e-a045-156e9b3e45f4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_fab1bdda-374b-4f28-8113-313e7b5c7150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/Leases" xlink:type="simple" xlink:href="nbix-20200930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5504f475-b6a4-4a2b-ad6d-48ca8f3ddb05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_45a7c3ce-a994-4617-87a1-d10dd484cf9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5504f475-b6a4-4a2b-ad6d-48ca8f3ddb05" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_45a7c3ce-a994-4617-87a1-d10dd484cf9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesTables" xlink:type="simple" xlink:href="nbix-20200930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ef3feb34-1fe7-432e-ab2f-883e249963f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_12050906-5665-4642-a537-4c3745cc4f43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef3feb34-1fe7-432e-ab2f-883e249963f1" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_12050906-5665-4642-a537-4c3745cc4f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7885624f-9bfd-4700-8fdf-44ad1d423a18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ef3feb34-1fe7-432e-ab2f-883e249963f1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7885624f-9bfd-4700-8fdf-44ad1d423a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesDisclosureDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#LeasesDisclosureDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesDisclosureDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_62307676-e4c8-4037-9996-887425f8a3ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_3f885d80-8df0-4204-b4df-f836e7cebd70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_62307676-e4c8-4037-9996-887425f8a3ce" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_3f885d80-8df0-4204-b4df-f836e7cebd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_28ec0827-c5c0-4460-be0f-df244969c68b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3f885d80-8df0-4204-b4df-f836e7cebd70" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_28ec0827-c5c0-4460-be0f-df244969c68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6809f23-51fa-4c9d-b7b7-191b32470097" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_28ec0827-c5c0-4460-be0f-df244969c68b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6809f23-51fa-4c9d-b7b7-191b32470097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A12780ElCaminoRealMember_8ba4b5ff-d5d7-4d5c-b508-425f13ff8b84" xlink:href="nbix-20200930.xsd#nbix_A12780ElCaminoRealMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6809f23-51fa-4c9d-b7b7-191b32470097" xlink:to="loc_nbix_A12780ElCaminoRealMember_8ba4b5ff-d5d7-4d5c-b508-425f13ff8b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A12790ElCaminoRealSuite130Member_54a2b725-5fa8-45ff-95e8-f81796d4aefb" xlink:href="nbix-20200930.xsd#nbix_A12790ElCaminoRealSuite130Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6809f23-51fa-4c9d-b7b7-191b32470097" xlink:to="loc_nbix_A12790ElCaminoRealSuite130Member_54a2b725-5fa8-45ff-95e8-f81796d4aefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A12790ElCaminoRealSuite150Member_9d00a2c6-e86a-473c-94c9-a7516d35bb67" xlink:href="nbix-20200930.xsd#nbix_A12790ElCaminoRealSuite150Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6809f23-51fa-4c9d-b7b7-191b32470097" xlink:to="loc_nbix_A12790ElCaminoRealSuite150Member_9d00a2c6-e86a-473c-94c9-a7516d35bb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A12790ElCaminoRealSuite300Member_64813615-b7b8-4f46-a182-2d3212d17bf0" xlink:href="nbix-20200930.xsd#nbix_A12790ElCaminoRealSuite300Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6809f23-51fa-4c9d-b7b7-191b32470097" xlink:to="loc_nbix_A12790ElCaminoRealSuite300Member_64813615-b7b8-4f46-a182-2d3212d17bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A12777HighBluffDriveMember_e23beb61-1959-4306-a8a6-d1d21565562f" xlink:href="nbix-20200930.xsd#nbix_A12777HighBluffDriveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6809f23-51fa-4c9d-b7b7-191b32470097" xlink:to="loc_nbix_A12777HighBluffDriveMember_e23beb61-1959-4306-a8a6-d1d21565562f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A12790ElCaminoRealSuite200Member_a89aedce-a45f-48c2-b92b-e6847b38e36d" xlink:href="nbix-20200930.xsd#nbix_A12790ElCaminoRealSuite200Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6809f23-51fa-4c9d-b7b7-191b32470097" xlink:to="loc_nbix_A12790ElCaminoRealSuite200Member_a89aedce-a45f-48c2-b92b-e6847b38e36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A12790ElCaminoRealSuite100Member_08a62074-ba34-41c4-9c5e-99523fb3594f" xlink:href="nbix-20200930.xsd#nbix_A12790ElCaminoRealSuite100Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b6809f23-51fa-4c9d-b7b7-191b32470097" xlink:to="loc_nbix_A12790ElCaminoRealSuite100Member_08a62074-ba34-41c4-9c5e-99523fb3594f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_4dab0c5f-9e73-464d-a718-07279f05a666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3f885d80-8df0-4204-b4df-f836e7cebd70" xlink:to="loc_us-gaap_LeaseContractualTermAxis_4dab0c5f-9e73-464d-a718-07279f05a666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_01685bad-bdf9-40fa-88a0-aad063b643f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_4dab0c5f-9e73-464d-a718-07279f05a666" xlink:to="loc_us-gaap_LeaseContractualTermDomain_01685bad-bdf9-40fa-88a0-aad063b643f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A1278012790ElCaminoRealMasterLeaseMember_c984ff8a-3ed4-4114-b710-b20f4debaa9b" xlink:href="nbix-20200930.xsd#nbix_A1278012790ElCaminoRealMasterLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_01685bad-bdf9-40fa-88a0-aad063b643f2" xlink:to="loc_nbix_A1278012790ElCaminoRealMasterLeaseMember_c984ff8a-3ed4-4114-b710-b20f4debaa9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_61999c2a-4e11-42c7-87fd-2ac2de2324c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3f885d80-8df0-4204-b4df-f836e7cebd70" xlink:to="loc_us-gaap_CreditFacilityAxis_61999c2a-4e11-42c7-87fd-2ac2de2324c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_dc4d1ece-5a72-407b-8a60-0dc41edb24c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_61999c2a-4e11-42c7-87fd-2ac2de2324c7" xlink:to="loc_us-gaap_CreditFacilityDomain_dc4d1ece-5a72-407b-8a60-0dc41edb24c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_314481ec-a658-464d-ba35-49b3d9696be1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_dc4d1ece-5a72-407b-8a60-0dc41edb24c3" xlink:to="loc_us-gaap_LetterOfCreditMember_314481ec-a658-464d-ba35-49b3d9696be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_f0547358-901a-4469-b16c-74b593b3be69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3f885d80-8df0-4204-b4df-f836e7cebd70" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_f0547358-901a-4469-b16c-74b593b3be69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_5f242fd4-e03d-4e11-b09c-03280069d6a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f0547358-901a-4469-b16c-74b593b3be69" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_5f242fd4-e03d-4e11-b09c-03280069d6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfRenewalOptions_9272d06b-2b1b-40b0-a758-555b53d214fe" xlink:href="nbix-20200930.xsd#nbix_NumberOfRenewalOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f0547358-901a-4469-b16c-74b593b3be69" xlink:to="loc_nbix_NumberOfRenewalOptions_9272d06b-2b1b-40b0-a758-555b53d214fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7f3a1437-7034-4c29-8627-681270111cf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f0547358-901a-4469-b16c-74b593b3be69" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7f3a1437-7034-4c29-8627-681270111cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_d00ab94c-0912-4ece-9c4d-7f9fafc05fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f0547358-901a-4469-b16c-74b593b3be69" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_d00ab94c-0912-4ece-9c4d-7f9fafc05fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#LeasesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4d2a5537-f847-4d71-b2bb-49f0122d38f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_2b298c61-8258-427c-9366-b8cbdb4350bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4d2a5537-f847-4d71-b2bb-49f0122d38f7" xlink:to="loc_us-gaap_OperatingLeaseCost_2b298c61-8258-427c-9366-b8cbdb4350bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_383ef274-5d46-4a6e-b8c0-558d879c6d7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4d2a5537-f847-4d71-b2bb-49f0122d38f7" xlink:to="loc_us-gaap_OperatingLeasePayments_383ef274-5d46-4a6e-b8c0-558d879c6d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_672abe49-983a-4f0d-bf5a-7b4399314159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4d2a5537-f847-4d71-b2bb-49f0122d38f7" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_672abe49-983a-4f0d-bf5a-7b4399314159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1b65ca44-9cd0-4f80-9326-828148180ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4d2a5537-f847-4d71-b2bb-49f0122d38f7" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1b65ca44-9cd0-4f80-9326-828148180ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#LeasesLiabilityPaymentDueDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_673785ff-e98c-4f4a-bfb2-761d95539970" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_eedc6e3c-202d-42ab-af70-c6d645c2e5c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_673785ff-e98c-4f4a-bfb2-761d95539970" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_eedc6e3c-202d-42ab-af70-c6d645c2e5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ea9164fb-9f59-4d11-98b4-31f922d67ead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_673785ff-e98c-4f4a-bfb2-761d95539970" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ea9164fb-9f59-4d11-98b4-31f922d67ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4ab0f52d-11d9-41ed-8305-60cfcf4815d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_673785ff-e98c-4f4a-bfb2-761d95539970" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4ab0f52d-11d9-41ed-8305-60cfcf4815d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_85ff1bef-6ef1-411b-86e2-a035975151a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_673785ff-e98c-4f4a-bfb2-761d95539970" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_85ff1bef-6ef1-411b-86e2-a035975151a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_afc75cf5-8764-48a1-853c-61b18f9c211f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_673785ff-e98c-4f4a-bfb2-761d95539970" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_afc75cf5-8764-48a1-853c-61b18f9c211f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_42467217-c5ee-42f2-9d13-0228a94ffa12" xlink:href="nbix-20200930.xsd#nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_673785ff-e98c-4f4a-bfb2-761d95539970" xlink:to="loc_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_42467217-c5ee-42f2-9d13-0228a94ffa12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_060e8e11-e265-496b-8548-be739e399860" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_673785ff-e98c-4f4a-bfb2-761d95539970" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_060e8e11-e265-496b-8548-be739e399860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_45de33e5-5a1f-45b6-b270-6689479e858f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_673785ff-e98c-4f4a-bfb2-761d95539970" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_45de33e5-5a1f-45b6-b270-6689479e858f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6b2b9d37-67d4-4114-a803-c838aea81807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_673785ff-e98c-4f4a-bfb2-761d95539970" xlink:to="loc_us-gaap_OperatingLeaseLiability_6b2b9d37-67d4-4114-a803-c838aea81807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ebc9a02c-997a-4f5c-a6e1-3be1bebcf026" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_673785ff-e98c-4f4a-bfb2-761d95539970" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ebc9a02c-997a-4f5c-a6e1-3be1bebcf026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_626ee958-f523-4690-9ae2-1122f65324c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_673785ff-e98c-4f4a-bfb2-761d95539970" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_626ee958-f523-4690-9ae2-1122f65324c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced_4eaf2638-5652-4c45-a726-7a13af8e3e3b" xlink:href="nbix-20200930.xsd#nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_673785ff-e98c-4f4a-bfb2-761d95539970" xlink:to="loc_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced_4eaf2638-5652-4c45-a726-7a13af8e3e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail_1" xlink:type="simple" xlink:href="nbix-20200930.xsd#LeasesLiabilityPaymentDueDetail_1"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotes" xlink:type="simple" xlink:href="nbix-20200930.xsd#ConvertibleSeniorNotes"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c778c7b4-7da0-496a-9739-96742bd27303" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4928be26-374a-4137-aba1-7cd1b271e7d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c778c7b4-7da0-496a-9739-96742bd27303" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_4928be26-374a-4137-aba1-7cd1b271e7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables" xlink:type="simple" xlink:href="nbix-20200930.xsd#ConvertibleSeniorNotesTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_269ed8b4-c06a-4163-8efd-c05eea038593" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_409b9905-318b-4df7-9247-c11e0674ef68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_269ed8b4-c06a-4163-8efd-c05eea038593" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_409b9905-318b-4df7-9247-c11e0674ef68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#ConvertibleSeniorNotesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f66b4ca2-25e5-41cd-a7ab-8e8ffcb7a311" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_127e7060-2826-4154-b405-f38f97b4662a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f66b4ca2-25e5-41cd-a7ab-8e8ffcb7a311" xlink:to="loc_us-gaap_DebtInstrumentTable_127e7060-2826-4154-b405-f38f97b4662a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ed2a8d24-5269-4592-8113-4dc4698c253a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_127e7060-2826-4154-b405-f38f97b4662a" xlink:to="loc_us-gaap_DebtInstrumentAxis_ed2a8d24-5269-4592-8113-4dc4698c253a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b7ff5612-90be-40d4-b440-280c3d06f513" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ed2a8d24-5269-4592-8113-4dc4698c253a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b7ff5612-90be-40d4-b440-280c3d06f513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A225ConvertibleSeniorNotesMember_4a7d0307-6f9c-44d3-a429-b1858718b67b" xlink:href="nbix-20200930.xsd#nbix_A225ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b7ff5612-90be-40d4-b440-280c3d06f513" xlink:to="loc_nbix_A225ConvertibleSeniorNotesMember_4a7d0307-6f9c-44d3-a429-b1858718b67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_127e7060-2826-4154-b405-f38f97b4662a" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1c8f830c-fc42-46af-9133-7a25b83fc5af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1c8f830c-fc42-46af-9133-7a25b83fc5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_702dc2a0-c174-4d4b-a4f0-1be839a00dca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_702dc2a0-c174-4d4b-a4f0-1be839a00dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_5746bcc9-d6ce-41d2-87c1-6db6b12664ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_5746bcc9-d6ce-41d2-87c1-6db6b12664ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_de1a68b2-fb80-43bb-acc9-4cdb0ade6cde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_de1a68b2-fb80-43bb-acc9-4cdb0ade6cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c5a5efa4-19f7-4fcd-9599-2d00f8bc277e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c5a5efa4-19f7-4fcd-9599-2d00f8bc277e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_d3f0757f-6df4-4720-b6a4-c75c25e5d923" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_d3f0757f-6df4-4720-b6a4-c75c25e5d923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_NumberOfConsecutiveBusinessDays_5c48997a-ef56-4955-a2ba-acda1e0148c1" xlink:href="nbix-20200930.xsd#nbix_NumberOfConsecutiveBusinessDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_nbix_NumberOfConsecutiveBusinessDays_5c48997a-ef56-4955-a2ba-acda1e0148c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_PrincipalAmountOnConversionRate_38c66728-6bdd-4053-86c0-097b01b6a17b" xlink:href="nbix-20200930.xsd#nbix_PrincipalAmountOnConversionRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_nbix_PrincipalAmountOnConversionRate_38c66728-6bdd-4053-86c0-097b01b6a17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_7b61f2e6-b2dd-4f79-9f6e-064b5f791405" xlink:href="nbix-20200930.xsd#nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice_7b61f2e6-b2dd-4f79-9f6e-064b5f791405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtConversionObservationPeriod_106695a0-aec7-4408-b389-b32ea98d4f3a" xlink:href="nbix-20200930.xsd#nbix_DebtConversionObservationPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_nbix_DebtConversionObservationPeriod_106695a0-aec7-4408-b389-b32ea98d4f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_ca871332-289f-4904-93ff-07d5f78e49d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_ca871332-289f-4904-93ff-07d5f78e49d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_ed5f1613-1716-4bf7-9719-27eb9f383941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_ed5f1613-1716-4bf7-9719-27eb9f383941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_5ea63f1b-a1f2-4854-b361-633aa21c891e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_5ea63f1b-a1f2-4854-b361-633aa21c891e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleConversionPremium_a705a2fb-44b6-49d4-a58f-f7208faae77b" xlink:href="nbix-20200930.xsd#nbix_DebtInstrumentConvertibleConversionPremium"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_nbix_DebtInstrumentConvertibleConversionPremium_a705a2fb-44b6-49d4-a58f-f7208faae77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_e6347b60-b9e3-4b60-9250-dec856d10067" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_SharePrice_e6347b60-b9e3-4b60-9250-dec856d10067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_d6c9deba-4461-4345-adf6-03080e7cfc58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_d6c9deba-4461-4345-adf6-03080e7cfc58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent_2766a445-dcbf-4d08-901c-2b500d03494b" xlink:href="nbix-20200930.xsd#nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent_2766a445-dcbf-4d08-901c-2b500d03494b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_098e488c-79fc-408c-99c2-dee439e22a69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_098e488c-79fc-408c-99c2-dee439e22a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_8207d920-2d3e-4e99-a51a-d58474c34d1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_8207d920-2d3e-4e99-a51a-d58474c34d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_c5be47da-7b32-40d7-9b2e-4f3c2a76579c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentTerm_c5be47da-7b32-40d7-9b2e-4f3c2a76579c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_1f3df5d3-dea0-4464-a426-1485893f1ed7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_1f3df5d3-dea0-4464-a426-1485893f1ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_b8857761-f8ba-43b2-901c-d3402806729d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_b8857761-f8ba-43b2-901c-d3402806729d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault_d50d1947-de06-4eda-9723-30a534411d11" xlink:href="nbix-20200930.xsd#nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault_d50d1947-de06-4eda-9723-30a534411d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_6ffddcd3-8958-4e38-8a29-9a9b81b7923a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ee4dca45-421b-4fc7-b7c8-4cd93f3a8583" xlink:to="loc_us-gaap_DebtInstrumentFairValue_6ffddcd3-8958-4e38-8a29-9a9b81b7923a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_be7ec6c5-86e6-48e5-b659-6facea15bf53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_0d1fe4dd-c834-4da8-9eb8-c7e8ad8050fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_be7ec6c5-86e6-48e5-b659-6facea15bf53" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_0d1fe4dd-c834-4da8-9eb8-c7e8ad8050fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_96675d03-b420-4d03-a12c-3e5df02ed97a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_be7ec6c5-86e6-48e5-b659-6facea15bf53" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_96675d03-b420-4d03-a12c-3e5df02ed97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_61df5048-fe13-4ead-b144-4dc9981b8420" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_be7ec6c5-86e6-48e5-b659-6facea15bf53" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_61df5048-fe13-4ead-b144-4dc9981b8420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_cb802cff-52d8-4392-b327-a11d4ecde551" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_be7ec6c5-86e6-48e5-b659-6facea15bf53" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_cb802cff-52d8-4392-b327-a11d4ecde551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetLossIncomePerShare" xlink:type="simple" xlink:href="nbix-20200930.xsd#NetLossIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/NetLossIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f78b0b7d-4f9e-4b52-9cb2-afd9e85fe3ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_f0b190e2-7038-45b9-aab3-928a350bca99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f78b0b7d-4f9e-4b52-9cb2-afd9e85fe3ef" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_f0b190e2-7038-45b9-aab3-928a350bca99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetLossIncomePerShareTables" xlink:type="simple" xlink:href="nbix-20200930.xsd#NetLossIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/NetLossIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e675b316-3bad-4207-b196-1cbbc060470a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_870a96e4-eaec-4417-9287-cc2b6485fc04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e675b316-3bad-4207-b196-1cbbc060470a" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_870a96e4-eaec-4417-9287-cc2b6485fc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#NetLossIncomePerShareScheduleofNetIncomePerShareDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c2f0a636-e67d-4aec-b40d-74caf4ab42d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ee38d009-609a-443e-8393-f60ad6dd8c84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c2f0a636-e67d-4aec-b40d-74caf4ab42d5" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ee38d009-609a-443e-8393-f60ad6dd8c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1c59c6a9-b075-44cc-8889-04bc1b2bb624" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ee38d009-609a-443e-8393-f60ad6dd8c84" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1c59c6a9-b075-44cc-8889-04bc1b2bb624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2d376bc4-de83-4cb0-a6bf-17349f5903aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1c59c6a9-b075-44cc-8889-04bc1b2bb624" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2d376bc4-de83-4cb0-a6bf-17349f5903aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a4fe8959-7775-4655-ab96-ab3cbbbea038" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2d376bc4-de83-4cb0-a6bf-17349f5903aa" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a4fe8959-7775-4655-ab96-ab3cbbbea038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_3f824dda-bd4a-4a54-afa4-e4a37c0ef77d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2d376bc4-de83-4cb0-a6bf-17349f5903aa" xlink:to="loc_us-gaap_RestrictedStockMember_3f824dda-bd4a-4a54-afa4-e4a37c0ef77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a009442e-eef9-41b4-9bcc-08f8a908d4f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ee38d009-609a-443e-8393-f60ad6dd8c84" xlink:to="loc_us-gaap_DebtInstrumentAxis_a009442e-eef9-41b4-9bcc-08f8a908d4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e28a8f04-0bbe-4bd8-b86f-de4e2ac2af48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a009442e-eef9-41b4-9bcc-08f8a908d4f9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e28a8f04-0bbe-4bd8-b86f-de4e2ac2af48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember_a1bcea82-8993-4087-bf76-b25e30bcdb94" xlink:href="nbix-20200930.xsd#nbix_TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e28a8f04-0bbe-4bd8-b86f-de4e2ac2af48" xlink:to="loc_nbix_TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember_a1bcea82-8993-4087-bf76-b25e30bcdb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_2a9d5086-36dc-4d6b-94fa-2c397b8843f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_ee38d009-609a-443e-8393-f60ad6dd8c84" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_2a9d5086-36dc-4d6b-94fa-2c397b8843f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_101815e7-1e29-4ba3-9595-ba4f07cdd76e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2a9d5086-36dc-4d6b-94fa-2c397b8843f4" xlink:to="loc_us-gaap_NetIncomeLoss_101815e7-1e29-4ba3-9595-ba4f07cdd76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c70eb35c-6de3-4501-80d7-097bce77ce6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2a9d5086-36dc-4d6b-94fa-2c397b8843f4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c70eb35c-6de3-4501-80d7-097bce77ce6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_32e6135c-249e-4779-8792-604960c197b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_c70eb35c-6de3-4501-80d7-097bce77ce6c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_32e6135c-249e-4779-8792-604960c197b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_52879397-b8e6-41de-9e9f-15d779b664c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2a9d5086-36dc-4d6b-94fa-2c397b8843f4" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_52879397-b8e6-41de-9e9f-15d779b664c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_77bbd2a0-90b2-4838-bf06-880805477b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_52879397-b8e6-41de-9e9f-15d779b664c7" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_77bbd2a0-90b2-4838-bf06-880805477b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_15d8d1ca-1c96-451a-9e9c-c2ef189978e2" xlink:href="nbix-20200930.xsd#nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_52879397-b8e6-41de-9e9f-15d779b664c7" xlink:to="loc_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities_15d8d1ca-1c96-451a-9e9c-c2ef189978e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8e385244-a6f2-4ab8-9e94-0754bc73e383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_52879397-b8e6-41de-9e9f-15d779b664c7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8e385244-a6f2-4ab8-9e94-0754bc73e383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3eebf941-eb6f-4c6a-8f83-e83345ce90c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_2a9d5086-36dc-4d6b-94fa-2c397b8843f4" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3eebf941-eb6f-4c6a-8f83-e83345ce90c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c7072b94-6acd-4d72-a1eb-e657074ab807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3eebf941-eb6f-4c6a-8f83-e83345ce90c8" xlink:to="loc_us-gaap_EarningsPerShareBasic_c7072b94-6acd-4d72-a1eb-e657074ab807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_92d246da-c9eb-42fc-b568-79d1758588e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_3eebf941-eb6f-4c6a-8f83-e83345ce90c8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_92d246da-c9eb-42fc-b568-79d1758588e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.neurocrine.com/role/NetLossIncomePerShareAdditionalInformationDetail" xlink:type="simple" xlink:href="nbix-20200930.xsd#NetLossIncomePerShareAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.neurocrine.com/role/NetLossIncomePerShareAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ecb080ae-b488-4ff3-b685-85a456b6c002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_c95ce9e5-a356-42ba-a2b4-ded4ca286736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ecb080ae-b488-4ff3-b685-85a456b6c002" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_c95ce9e5-a356-42ba-a2b4-ded4ca286736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ff58f5d7-7a3d-47db-aa5c-1303f8dc3e14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_c95ce9e5-a356-42ba-a2b4-ded4ca286736" xlink:to="loc_us-gaap_DebtInstrumentAxis_ff58f5d7-7a3d-47db-aa5c-1303f8dc3e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_cabe5a9f-85ad-431c-8cb7-30b854a88b25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ff58f5d7-7a3d-47db-aa5c-1303f8dc3e14" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_cabe5a9f-85ad-431c-8cb7-30b854a88b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_A225ConvertibleSeniorNotesMember_e64baa22-8cc6-4a6e-aa76-e41912712b4e" xlink:href="nbix-20200930.xsd#nbix_A225ConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_cabe5a9f-85ad-431c-8cb7-30b854a88b25" xlink:to="loc_nbix_A225ConvertibleSeniorNotesMember_e64baa22-8cc6-4a6e-aa76-e41912712b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_640ef63d-271e-4dcd-9591-5b84924915bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_c95ce9e5-a356-42ba-a2b4-ded4ca286736" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_640ef63d-271e-4dcd-9591-5b84924915bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bb3ea319-b3c1-4022-ba2d-63e5a05de782" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_640ef63d-271e-4dcd-9591-5b84924915bc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bb3ea319-b3c1-4022-ba2d-63e5a05de782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_nbix_StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember_fa70e235-004c-4547-9c68-6db24c4a0ea2" xlink:href="nbix-20200930.xsd#nbix_StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bb3ea319-b3c1-4022-ba2d-63e5a05de782" xlink:to="loc_nbix_StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember_fa70e235-004c-4547-9c68-6db24c4a0ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_a964e7cf-125c-416e-856e-9945ae546017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_c95ce9e5-a356-42ba-a2b4-ded4ca286736" xlink:to="loc_us-gaap_ShortTermDebtLineItems_a964e7cf-125c-416e-856e-9945ae546017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_92d5f5c8-ba49-480d-8639-38ab66003728" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_a964e7cf-125c-416e-856e-9945ae546017" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_92d5f5c8-ba49-480d-8639-38ab66003728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_494700ec-ca66-457a-b653-ea1ff6752937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_a964e7cf-125c-416e-856e-9945ae546017" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_494700ec-ca66-457a-b653-ea1ff6752937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>nbix-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nbix="http://www.neurocrine.com/20200930"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nbix-20200930.xsd" xlink:type="simple"/>
    <context id="i855097c18a2c429892d9974c37a69a36_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i444e2c86d32342048de12245f7f211f5_I20201104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2020-11-04</instant>
        </period>
    </context>
    <context id="ia560b50de8b4433b9f89b2a27688c2f6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2eac757373044c73b10d89d2901aca4a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie9e8ecaa7faf4bd7aefcbbb4825de4ad_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3ac9bb3945ab4fa6a54c3854917ec6be_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib8b7535c94394a5eb4e42047c2f78f8c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if63b65b04e2b4ba8a6410f5550f0dada_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id237bed344304cdfb92dba0f37b8b2ea_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id28a908f24d443b491ef90114eab031e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i07aa10bbd36d4f218b7067892376a3d9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib46c14fbf85f4a67bc18bbc72105f4a4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i911a596594bb42f1ac774b4d2e8002bc_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic68d7f4878b240c2a94c47549bedae1d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia5f511a933434ea0834f118c4f341f90_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iedcce6b874c74163b624aa2b15ebb12b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5e06729230ea4ca7a95cf735dd99be6d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4bcde4ddd2f54c21aa4bd738ffd07957_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i99a4ab0b6ccf43d6bd7626714d91bae1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2bb7f4b1f21943c6863d8cba446f1522_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icfb97fb7839e4786b037248a2437f3e4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icf98ce15cffa48d490acc123240b6de1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i92e0ed27615f42b28fa6f250cf9e5fb5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i993fc948fbfd4c9e818abdde04072290_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0c745beb45d74cb091440fb03cecacf2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifdf214a2337843e78d1a347256aaaa00_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ib77575bdbf4040e39375b79ca78eff52_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ic2ded9247e98428593f3e2412173375b_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i124193d520854efcb3745edbaed9fea0_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ib12e0fe57cf54c4eb690db593d5ab12f_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i268579fde8b349778a731f000224ca07_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iec797011e09546cd8f24887ec442c1c5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icb42b25d794147b1aed333e2f3166703_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idd133a6a9d584e259b82b5bcc97dfc26_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie9fc314f633842568fae2c624fd6a730_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ic436e3bb1c9b40c5a2c28786df5e2f5e_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i305a4e84d6d84699b8b9301835f9518f_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i730787997d6d4c228ee797868cbe3082_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i5eafa440da15427d8d322a26e23e8db7_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i543b37a401f842f297d00c6f44d8c51d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1bcc585face2402191cabf07bfd067f5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia1679f6518a049a0b79b7b15a1277d4d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icce724fa185b4a2e81da141dd2ca4c69_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie82ca40bd6b7437b85500edd36e2ac78_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6512d4e06fe64b8c8902cb07fd087fe7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i993fa090c95f4e7791e5c5d7159708d5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if1e75fea41454043ab426501ad55a6dd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib022af9959ba424787b942770385acd6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i473e921631e44d049f986015d23f8c8e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibd3a22690ded4fd58399451eeb2ff477_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8a72aa82edb54cb9aa6dd689f379b35e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7b9bcef8502e4089bb1a8346e1df9932_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i252046dd1c50470ea1cf51b3a7d8bbda_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1a4f65fc8aa34883b840cee701384a7b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id1ccdf0b325741f783c0d8b5806ef5e9_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i42a7ca788f2e494ea2ff656d2aecaa79_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i43dc46d58e014745aa62c8e09a24d851_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib3ac91b9e8aa453fa75f654a778253ac_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ice72e35fd4be4be0bd6c7d149fff6950_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1bc3cf10ca8443d19bf1d4cf81b112be_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i0fd2fda8589244c78b0b293642285e18_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id529934387f148b18fa1109106ad5a55_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="iabd2ce28d6694a2486d931e1479cf385_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i05e0789a004a4bb0b0b9943498ed0bde_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:NBI827104Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2c7cce679a364cb494b726cf6f83dd4f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">nbix:DevelopmentProductCandidatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1f38dd2e87214e4e86b4617f5f7a47c9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:IdorsiaPharmaceuticalsLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if408f3cef84a459fb036f2dae9a47b78_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:XenonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ied735b11fcf841da816bf129e0782ef6_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:VoyagerTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ie59f33ba48b64fbf878b1b0bb32cd3bf_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:BIALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i43207eb5afba4545a651896bc4052742_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:BIALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic154a10198a440abaa45ffe2168bfe4b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:BIALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8e46865cecac4d2e9ae909b186261e3c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4ee32bf37a3e4fba90e0c87db9c24cfe_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if3af452bac274c8e8d92baa671e21fba_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i81d37dbacd1842e99e2686ec8fd6dbba_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="i66b2b24b15f44827a87d688b20158136_D20150301-20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="iad9db265321c411f9f43fa242382852e_D20170701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i78ce841bcaf4462aa4b7ca2f1059a21d_D20191001-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icc967843177445f2a9bb563c19ee7472_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="ic92441dd53a14a03a31909df31c4a184_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3c4ebb0a6f1f49b0a4d3e6a407449d98_D20100601-20100630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-06-01</startDate>
            <endDate>2010-06-30</endDate>
        </period>
    </context>
    <context id="i45766b13b1314f7181ad53c4c44d2508_D20100701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5ea18c769a47425d951bc4f1d6cdec54_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if00ff3fffef04ee986b1a2c2119dfc0b_D20100601-20100630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nbix:AbbvieIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-06-01</startDate>
            <endDate>2010-06-30</endDate>
        </period>
    </context>
    <context id="i17e8669ff7be4a52b5af69d877498dc5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i20a97471294c419191a3a2888e675b4b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5a39b454de5141cea8123d360608a3c6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i57f46c4cf6f1473794e3e0ebadd216a7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5839adaf15cb411e85d5303f2631e97d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1afe9cac6b0a42a5b77948695251abfb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i11b4128b861b49e2a5858306369cb09d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4cf4cd2db9454c90a62e4deb58db04b8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i874e4b9552c648458ec045b9740fcc7c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib471b42e9f1046758a5cc3d418a9adea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if06c15e28fd64cffadb8a9783937f723_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idd9a4794daba4b7cad0104baa5442100_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i39d07970489d4ae1a26d531d4e995b63_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4eee421ab3034f1daf75320fc8835187_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nbix:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i89d87039af9d4dc6bd52a3bb4c9ebf21_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia63ae906e9934f57874ae4728dd57afa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id38c7267b80a405180f7b4356f67da8c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibee55973814540e4871f791d8dc70e46_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib426e74a445c45f1a83118960cccbf06_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie84a00bf79934f488db237577d55db78_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iea9d8f3b23ca486497408024718a6b8e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i65a6bbf5e65a4158a60237d7a4a04db0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1ec61ef3dcdf4b1aacbd98b013a506b7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibc97788aa86f4300961cef399f992f04_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6c29e9b0363d417bad2a59f28a1c803c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5598a209b61b4400b094160c9896fa48_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i29381f8c070e44f0842d377f5116a9e2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i947a42782e644b31b40e973a6c34e453_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iee9777017ba44b219d3e743580405ac2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib7a75fd9bbac4ee49d0da09da35fb326_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="icb30e5a8cedc49c8be9971e52ba47b85_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i760c3e1139cd490996ecb9f7296243b7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i42324c42b21949c28b491aa55a7bfbbb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i18fb70203f184d1491ea807cbc815619_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if469c62de0cd4ef3830eba7c5402aaab_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i17b0221281ec4463a4179b1554cbcd76_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia0025cac95494cda9e9476a6c30b7005_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib2709795600e4b4fa0cab1e10d78bb24_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6458a3c1f27445708ec1f66fe52e22d1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if56d9dc3007d41128722f44d864811d6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9756d3e20b3947848211cd89041634fc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="idc0623eb842b4201884c1c1da60ba35d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifc01e0adf5ed40e9ab710401d911d109_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="idfd9db69bbe949f189e03e61899a8e08_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i97214347d5cd4c00a185bedc120c3fc1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8d8647d7d7e94a8097f66d3842b61c42_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i956362b694e94668b36c6160186aa324_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3bd0085725324e26a27750e423d72760_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic049401a5b67418d851adeae321ac164_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8225b8bb50704b84b3bf86c3349c534e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id219f8da90c541daad4ba23316ba4c2b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1d6d32eba9d04110a989008d1fa4f90e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i88f522c740114d6180c33b2389f52046_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id2f301c2004b4bcabafe4296fb59ec8e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1156dc5768584b87af9adf9ad1d62009_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iced281cb3fd145e8913b24a5a0bc1e69_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia410bcb0c63a42d99db1e5658b91727a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0864c4bbd4b141eb98515b636f8eb88c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8c40b36432b0492eb3eae0f8756d0ae1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4f45d9693ffb42a189e35266c2e96545_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i69670247a1db4f42b3852d733ac9597d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ica74b071cda746a582b3ab295bc26cff_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:CashAndMoneyMarketFundMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i05df2fa389dd4adfa5053ad89459ac4c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id03b83fda3a5401ea309441030aea98b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i18cbac244f574159aedb1993c131e819_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic4783baa5d824c89aae723867da90a4b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic92b89ea55554deea11eb52be454b4ee_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i59c2ec22479846c8887639d01cec2ac1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i38a85a52092b47eba3e6679338c961b6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i314a5ccd83a84b54958bcd28fb8db860_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4dea7ef570bb4538b6abd0b0f50563ea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2e4a588721b04ed3a8c49e19b0c7d7e2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie87e6dea946b4fee812d375f72857a05_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib4257d9e01c5447b8694ff0d39ac4ad4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">nbix:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9fd7f2df19284e068ed3299724415484_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i95be335e9ca1424784a8b065207d5d2c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8978c466f89f48bd919bee1246ba7dc3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib765b7aaf76a45f5b319d34681ef5aad_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1168865b09414dd1928d3fb6d2fe8156_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0b5a1372b6934d52bbc0746277c0a30f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4c444f4feaa2474398f957750041cb1d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i233e986aada74f71bd2484e81cfad9fa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9640ba89a44d41bfb7a046a01479976d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idd5b76e3383e44738b173add3da702c6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ieecb12e2940b487ead1f8d0f74107902_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i258c656656094522924117a0e6348166_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia2f58151776d4b13be04977281fa947d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifb9d6e37865d45e1b6f401b3e4cdc23d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4745ddf52c234ed591471f3b27a1ab8b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib3f9f730b48d44688a63762017a09db2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic06223c92c5f4dd8a253034a82b987b2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic019c50768b247589e3afba7ef8f7b7f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib44d224bf6a0454381c51416f7a36089_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie9fb6311be4848ee9588bffda41c01e0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i11cff9bc4f0243cb87ef4cff58b89ee3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie25967604f04462d8e53ffad9c71948b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id07323ca55464999892b9d6fb0d0b763_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">nbix:TotalEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i685588d754634ef2a7b97a70c6fdabbf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if718bd63b45a4840af81b12174f10513_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4b082681e677454181d88e9e537d5fde_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3a5d39b84bb845bd89918fb5088efac0_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6f09b45aebbe45268c2465fc1d568035_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i3f9f6865463c43fd9a44068085061fc5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i83b13e1b031e48228c7b0620b1ebe113_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6049f25752e8431ba1fbece7b41b3e27_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie0b79a1a18384f138069f378bdbe69b4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0548c87128c9494d8cbb70c28471b350_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1c084bc0f4cb428bbc964d8727a9a1bb_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0cb6cd0e456d4f4bbd214884933a1f9a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i72cdfb757c4d4f1daaf47570c8615274_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i0aa63587c87c4b9cab14160d1d2d336a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="icac2aad9c7b14b7c897eaed6bd6f1176_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9e0a7e787f35452e9cf3c1d60a078e47_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6cb2fa374db842989cd35f0f03a92fd5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:A12780ElCaminoRealMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6b783069862c4a7aa49f88ea6fee4135_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:A12790ElCaminoRealSuite130Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i388a89deda29498bb6086f28660869e9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:A12790ElCaminoRealSuite150Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i873fe30d887a4b389617d2698e039940_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:A12790ElCaminoRealSuite300Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i473d326a3edd493a836fb98886d2085a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:A12777HighBluffDriveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="idc20284842904d03ab36d24c9fed65c5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:A12790ElCaminoRealSuite200Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id19b886ce9774875bcec5de9e1655ca9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nbix:A12790ElCaminoRealSuite100Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5dc56b70fae344879faba70a7e60b7f8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">nbix:A1278012790ElCaminoRealMasterLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i132f21d3f9184d5493988e86fd0dc307_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i95cb82a96ba143258e37a17f6ad70802_I20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-02</instant>
        </period>
    </context>
    <context id="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-02</endDate>
        </period>
    </context>
    <context id="i0e4f2c61bb0c4669bf03824d0717d032_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1e3872d7a51340d7bd8d1873912c8acb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id6a49b9383644b8e949247b3f6dc07c3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:A225ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie4556b63f7bc4fc98ded870e841fc0f1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie07c04ad31ab444aa78ad245a76043b3_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idae84b2bcee5402c8d33bf434a519a5a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7952abe718084d38a17f69cd5d0327b6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic23a449373e942b6a52ed76757c61821_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idd783faa158b4dbe92e4b587a15e4e5b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2b9ca9a1b5ab47359e53b9d1690424a9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i16bcd03519fb4b91b7c49c28141acd41_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic83bc456a2d24aea914f39864a46ea36_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i46cad86f1cef4f9796a18fb9899c6bd5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ideea8abfeaaf4691a87a843e06657dea_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icb3a8bd5463f49769dbf1087a66ca8c8_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">nbix:TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8a2aaf5893684e989b254984e9c0e7c2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if5e51d3e6c184bf388994f88f70e42b4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5484b1436d094cdaaf477c90a7f1ed3b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4cb16bd71c524c9a890f849d3486c0c8_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">nbix:StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="subsidiary">
        <measure>nbix:subsidiary</measure>
    </unit>
    <unit id="security">
        <measure>nbix:security</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="renewaloption">
        <measure>nbix:renewalOption</measure>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80L2ZyYWc6NTAyMjRhYmQ5MGEwNGE5Mjk0ZGI5MTIzNzA4MGNkYmEvdGFibGU6NzM4OTNhYWQzN2UzNDQ3YmE0MzAwNzM5MmE2ZjBhMjYvdGFibGVyYW5nZTo3Mzg5M2FhZDM3ZTM0NDdiYTQzMDA3MzkyYTZmMGEyNl8yLTEtMS0xLTA_f788bb49-2d89-4ead-a09a-6418cf24b72f">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80L2ZyYWc6NTAyMjRhYmQ5MGEwNGE5Mjk0ZGI5MTIzNzA4MGNkYmEvdGFibGU6NzM4OTNhYWQzN2UzNDQ3YmE0MzAwNzM5MmE2ZjBhMjYvdGFibGVyYW5nZTo3Mzg5M2FhZDM3ZTM0NDdiYTQzMDA3MzkyYTZmMGEyNl8zLTEtMS0xLTA_79bd39fc-ab39-4434-bc20-0ae803de17b2">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80L2ZyYWc6NTAyMjRhYmQ5MGEwNGE5Mjk0ZGI5MTIzNzA4MGNkYmEvdGFibGU6NzM4OTNhYWQzN2UzNDQ3YmE0MzAwNzM5MmE2ZjBhMjYvdGFibGVyYW5nZTo3Mzg5M2FhZDM3ZTM0NDdiYTQzMDA3MzkyYTZmMGEyNl80LTEtMS0xLTA_66fec70e-8dd5-40cc-9aae-b4c9fcd91c78">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80L2ZyYWc6NTAyMjRhYmQ5MGEwNGE5Mjk0ZGI5MTIzNzA4MGNkYmEvdGFibGU6NzM4OTNhYWQzN2UzNDQ3YmE0MzAwNzM5MmE2ZjBhMjYvdGFibGVyYW5nZTo3Mzg5M2FhZDM3ZTM0NDdiYTQzMDA3MzkyYTZmMGEyNl81LTEtMS0xLTA_459c66c1-4eee-408c-91ba-939cec2acf68">0000914475</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80L2ZyYWc6NTAyMjRhYmQ5MGEwNGE5Mjk0ZGI5MTIzNzA4MGNkYmEvdGFibGU6NzM4OTNhYWQzN2UzNDQ3YmE0MzAwNzM5MmE2ZjBhMjYvdGFibGVyYW5nZTo3Mzg5M2FhZDM3ZTM0NDdiYTQzMDA3MzkyYTZmMGEyNl82LTEtMS0xLTA_0438e0de-4f06-46b7-9ce9-1f1a620b7fb8">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i43dc46d58e014745aa62c8e09a24d851_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzQtMC0xLTEtMA_ea544724-28b1-46be-84e8-aa74a9f36877">us-gaap:AccountingStandardsUpdate201602Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <nbix:NumberOfConsecutiveBusinessDays
      contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMTE3Nw_a1999c43-97d5-4934-9864-f07cd2e0e9ca">P5D</nbix:NumberOfConsecutiveBusinessDays>
    <nbix:NumberOfConsecutiveBusinessDays
      contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMTIyMg_0e6c4b54-2041-4866-8f9f-60a13836b830">P5D</nbix:NumberOfConsecutiveBusinessDays>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81NS9mcmFnOmNkZjcyMzc4MDM0YzQ5NzRhYWQ3OGU5NGZjYmYxMWQ3L3RhYmxlOmI0MjZkYWI5YjMxMjQzY2I5YjI0YWZmMDUzZTYxYmE4L3RhYmxlcmFuZ2U6YjQyNmRhYjliMzEyNDNjYjliMjRhZmYwNTNlNjFiYThfMi0xLTEtMS0w_fe353dba-0939-4bbb-92a8-c58f547af2d0"
      unitRef="number">0.0131711</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <dei:DocumentType
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjA3_2e4b762b-50ec-4035-abb9-1c30849c1085">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGFibGU6M2VlMWM0N2NkYjdiNDRmMjkwMGU5NjRlOGQxMjFjYTkvdGFibGVyYW5nZTozZWUxYzQ3Y2RiN2I0NGYyOTAwZTk2NGU4ZDEyMWNhOV8wLTAtMS0xLTA_203f56db-f447-4115-bda0-72d001805608">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8xMzk_0a978fff-58df-4ffa-ae6a-0cb269147f57">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGFibGU6N2MzYTI1MDUyODI3NDliZGJhNzg4ZDY1YjJjODUyZDUvdGFibGVyYW5nZTo3YzNhMjUwNTI4Mjc0OWJkYmE3ODhkNjViMmM4NTJkNV8wLTAtMS0xLTA_1e566193-7364-419b-b20e-0ab68a3dc582">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjAz_95568986-5d29-487e-b397-3fd15ed11261">0-22705</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjA4_3f20c48b-5cca-40ca-b1b4-d86b9f398358">NEUROCRINE BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjEy_89ae50bb-27d7-4ae0-91fe-7ce2b298af7b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjEz_5a36d7a8-6b3b-4e70-9137-6d5e5d7f0e77">12780 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjE0_ae1945cc-1214-4676-9248-d9a891c9d8f8">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjA5_46a8c10a-f881-4a97-bb1a-10ebf984655b">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityTaxIdentificationNumber
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjA1_976c0d6b-48cc-4254-ab93-03007396bb98">33-0525145</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressPostalZipCode
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjA2_91ee1840-f59f-424d-9927-c76ded79937f">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjA0_e46eb5cf-a4a6-48c6-a97d-a5abe10da790">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjEw_958507cf-d011-4ebc-af59-c71dc85eca54">617-7600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGFibGU6NDZlNWI2MzBlMTRmNDM5YzhkYTRhODZhZGZhN2NhZjQvdGFibGVyYW5nZTo0NmU1YjYzMGUxNGY0MzljOGRhNGE4NmFkZmE3Y2FmNF8xLTAtMS0xLTA_0e6d35db-e73e-4eb3-8dd3-945b1312f93b">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGFibGU6NDZlNWI2MzBlMTRmNDM5YzhkYTRhODZhZGZhN2NhZjQvdGFibGVyYW5nZTo0NmU1YjYzMGUxNGY0MzljOGRhNGE4NmFkZmE3Y2FmNF8xLTItMS0xLTA_5eb1ec9f-5c77-4c5e-87e1-2fdb5f9f5cf8">NBIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGFibGU6NDZlNWI2MzBlMTRmNDM5YzhkYTRhODZhZGZhN2NhZjQvdGFibGVyYW5nZTo0NmU1YjYzMGUxNGY0MzljOGRhNGE4NmFkZmE3Y2FmNF8xLTQtMS0xLTA_0a19165d-ecc1-45f1-85c0-03d4eeb76d6c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjAx_e47163d9-cb25-4bb4-93f1-4b736eeb58ec">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjEx_007d02e6-1bdd-41e1-b561-4acd66f11064">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGFibGU6NDA5ZjYyYjQwZGJiNGFlZjlmMDkzMzE3ZGNhYzdmNDcvdGFibGVyYW5nZTo0MDlmNjJiNDBkYmI0YWVmOWYwOTMzMTdkY2FjN2Y0N18wLTAtMS0xLTA_a75da631-9c70-49cc-8fea-a9d7ab253fde">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGFibGU6NDA5ZjYyYjQwZGJiNGFlZjlmMDkzMzE3ZGNhYzdmNDcvdGFibGVyYW5nZTo0MDlmNjJiNDBkYmI0YWVmOWYwOTMzMTdkY2FjN2Y0N18xLTQtMS0xLTA_c3b746bd-c883-405d-9116-20504aaaee54">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGFibGU6NDA5ZjYyYjQwZGJiNGFlZjlmMDkzMzE3ZGNhYzdmNDcvdGFibGVyYW5nZTo0MDlmNjJiNDBkYmI0YWVmOWYwOTMzMTdkY2FjN2Y0N18yLTEtMS0xLTA_f181b6c3-128c-41c4-8ebe-924e4d070048">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8yMjAy_6c225dbd-096b-4aba-83b9-0d28cfaec100">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i444e2c86d32342048de12245f7f211f5_I20201104"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xL2ZyYWc6ODg5MzIzYTU2NTExNGYzMzlkZWQwMGQ0MWQ3ZTJmOWEvdGV4dHJlZ2lvbjo4ODkzMjNhNTY1MTE0ZjMzOWRlZDAwZDQxZDdlMmY5YV8xNjQ5MjY3NDQzOTAx_78bf4c27-f78b-497d-8765-f60765ef006d"
      unitRef="shares">93429153</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMy0xLTEtMS0w_1af183c2-4a59-43c9-83de-550ba0b9178e"
      unitRef="usd">425300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMy0zLTEtMS0w_4f9fcbef-20f1-42f2-80e9-a289c7700bdf"
      unitRef="usd">112300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfNC0wLTEtMS0wL3RleHRyZWdpb246M2QwOTZhMjU1MjMxNDAyMWFiNmE1MDVkNDkyYWE3ZWRfNzE_541e4713-0238-45b9-95d5-59d3c8975dce"
      unitRef="usd">517300000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfNC0wLTEtMS0wL3RleHRyZWdpb246M2QwOTZhMjU1MjMxNDAyMWFiNmE1MDVkNDkyYWE3ZWRfODQ_1d929166-e8ff-4f5a-b501-248bd99ee336"
      unitRef="usd">557300000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfNC0xLTEtMS0w_8376cbfe-afa5-46f0-a3c4-94afc6ed0534"
      unitRef="usd">519400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfNC0zLTEtMS0w_af827454-16bf-4d57-9a6c-258abee0602f"
      unitRef="usd">558200000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfNS0xLTEtMS0w_1cfbe2fa-0df2-49ad-bd00-c56cc6bf5fa7"
      unitRef="usd">156900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfNS0zLTEtMS0w_9dc62bd0-cc6a-48fc-987b-dcb076deb35b"
      unitRef="usd">126600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfNi0xLTEtMS0w_0cc36c79-21a1-4e19-9965-0e4fe6ab1c0c"
      unitRef="usd">20600000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfNi0zLTEtMS0w_14c60074-2d3c-48d6-9c32-f2fb006c8609"
      unitRef="usd">17300000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfNy0xLTEtMS0w_9e21f61f-3268-4805-bd37-661699114cd5"
      unitRef="usd">34700000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfNy0zLTEtMS0w_7f56874a-e9bc-435b-a467-c31b0ca3afc3"
      unitRef="usd">16600000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfOC0xLTEtMS0w_1619dcd5-106c-4ee3-b9f7-11d2842cf7e7"
      unitRef="usd">1156900000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfOC0zLTEtMS0w_835a6325-2e06-4361-9d6d-4622bc2869ed"
      unitRef="usd">831000000.0</us-gaap:AssetsCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfOS0wLTEtMS0wL3RleHRyZWdpb246ZDY5YWRmYjMzMGQyNDc0ZmI5Yzc4NTcxODBlMzM2MjNfNzE_ffab961f-2c06-4125-8e41-e4c2cc3adb79"
      unitRef="usd">180300000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfOS0wLTEtMS0wL3RleHRyZWdpb246ZDY5YWRmYjMzMGQyNDc0ZmI5Yzc4NTcxODBlMzM2MjNfODQ_be1ede80-4df0-407e-a44c-f4ff3438ce20"
      unitRef="usd">299300000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfOS0xLTEtMS0w_bfaeb1ee-b307-4450-891f-d57da1c32451"
      unitRef="usd">181400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfOS0zLTEtMS0w_6578a964-31ed-4b1e-aa8d-fabfe5842f4c"
      unitRef="usd">299700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTAtMS0xLTEtMA_6a18f55b-4d18-4667-a533-b929bde41302"
      unitRef="usd">71000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTAtMy0xLTEtMA_a7be8c4e-79b5-4dda-b897-72822eb70b52"
      unitRef="usd">74300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTEtMS0xLTEtMA_f0b3711b-58fc-4137-bb9a-1585e2a077b0"
      unitRef="usd">43700000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTEtMy0xLTEtMA_604fc4a1-e0e1-4a61-b589-7791d16358a4"
      unitRef="usd">55900000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTItMS0xLTEtMA_3564ea8b-4ee2-406b-920e-b9b619cc17f9"
      unitRef="usd">43000000.0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTItMy0xLTEtMA_ee76cb12-84d1-4a4f-927b-643392fffe13"
      unitRef="usd">41900000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTMtMS0xLTEtMA_e04271d6-7af5-4097-83b3-97b17056fdf5"
      unitRef="usd">3200000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTMtMy0xLTEtMA_667d936f-3e2c-46c0-8778-dac7caad7a89"
      unitRef="usd">3200000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTQtMS0xLTEtMA_576f8c12-d39e-48b4-9c4d-69381b17d969"
      unitRef="usd">3400000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTQtMy0xLTEtMA_d60857b1-4054-43df-bc0d-c9237468cb23"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTUtMS0xLTEtMA_7bf28fcb-f543-4ca1-86c2-3b7e0a53810d"
      unitRef="usd">1502600000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTUtMy0xLTEtMA_277dd9b3-b329-4cba-a6d4-b483bc7946d6"
      unitRef="usd">1306000000.0</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTktMS0xLTEtMA_651e8794-ac90-4af4-b8dd-2208f57fb272"
      unitRef="usd">170500000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMTktMy0xLTEtMA_7e9744f1-f5d3-42eb-9ea9-7c3a3ab44ed7"
      unitRef="usd">141300000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjAtMS0xLTEtMA_dd5f41e9-5396-4fec-96d3-b8dfade9b52b"
      unitRef="usd">425000000.0</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjAtMy0xLTEtMA_9e4e6158-a817-4a52-8d7d-232d0a9e5a1e"
      unitRef="usd">408800000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjEtMS0xLTEtMA_d5cbfd33-b4ad-4884-ba11-e5d554d9094a"
      unitRef="usd">15500000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjEtMy0xLTEtMA_2051fdf7-da50-45ea-8e7a-9f2becf04ef4"
      unitRef="usd">15200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjItMS0xLTEtMA_7f865c7e-cbe4-405f-82ff-06b7f0773208"
      unitRef="usd">611000000.0</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjItMy0xLTEtMA_99aae680-5f50-4c1b-91c5-6ec6085f7e81"
      unitRef="usd">565300000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjQtMS0xLTEtMA_b1e66f2a-bd18-4b1a-a01f-7cdbb25a59f5"
      unitRef="usd">83000000.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjQtMy0xLTEtMA_f1c74d97-5fb2-415d-842d-9ec913d64601"
      unitRef="usd">86700000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjUtMS0xLTEtMA_0a18d2ae-a607-4a1f-9c9e-1928b11674d4"
      unitRef="usd">4300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjUtMy0xLTEtMA_e9afcfa4-ac8c-4ab3-919c-1f290531540d"
      unitRef="usd">17100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjYtMS0xLTEtMA_7ffb8d5a-f44c-4d89-8a54-5476ca87e0b9"
      unitRef="usd">698300000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjYtMy0xLTEtMA_59723865-ac5a-4755-8595-248ab687b3dc"
      unitRef="usd">669100000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmY3NzYzMjc4NzlhYTQzN2RhZDUzYmQ2MTc5YmJmYzdjXzIy_34d791e9-a0a8-4241-9573-adb9254cf497"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmY3NzYzMjc4NzlhYTQzN2RhZDUzYmQ2MTc5YmJmYzdjXzIy_c744558a-eb8f-4cad-8ec3-ceb674687edf"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmY3NzYzMjc4NzlhYTQzN2RhZDUzYmQ2MTc5YmJmYzdjXzM2_ae641ccd-d7b1-4fd9-9bb1-f366ab10f6c0"
      unitRef="shares">5000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmY3NzYzMjc4NzlhYTQzN2RhZDUzYmQ2MTc5YmJmYzdjXzM2_c167538a-a5cd-4a6f-b984-8ea7fae0970d"
      unitRef="shares">5000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmY3NzYzMjc4NzlhYTQzN2RhZDUzYmQ2MTc5YmJmYzdjXzU4_6ee378ab-8a5e-44e6-a0a2-9cc0d7a6622a"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmY3NzYzMjc4NzlhYTQzN2RhZDUzYmQ2MTc5YmJmYzdjXzU4_7019c571-d836-44c9-8d2e-61eff455679e"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmY3NzYzMjc4NzlhYTQzN2RhZDUzYmQ2MTc5YmJmYzdjXzU4_7519461a-744d-43af-b858-43e059547840"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjktMC0xLTEtMC90ZXh0cmVnaW9uOmY3NzYzMjc4NzlhYTQzN2RhZDUzYmQ2MTc5YmJmYzdjXzU4_84afd9c5-0cf6-4228-b161-724fda2a1814"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjktMS0xLTEtMA_3106bf04-d8bb-44c9-b0af-eb3b1e2babdc"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMjktMy0xLTEtMA_1435b61f-849d-4ce7-8688-e7cfa711c5c2"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmE0NzM0ZGJhNGYwMTRhZjBhYWNmYTdiYzNiMTYzMjI1XzE5_cb5f776c-77fd-4fed-ac95-79c6fd6cd71a"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmE0NzM0ZGJhNGYwMTRhZjBhYWNmYTdiYzNiMTYzMjI1XzE5_f1f20d53-2c3f-4059-b02e-11622352e457"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmE0NzM0ZGJhNGYwMTRhZjBhYWNmYTdiYzNiMTYzMjI1XzMz_1798bb52-f385-4005-9e10-3e26b0cc9f53"
      unitRef="shares">220000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmE0NzM0ZGJhNGYwMTRhZjBhYWNmYTdiYzNiMTYzMjI1XzMz_aa65ae66-d116-400d-9851-2a61af74e228"
      unitRef="shares">220000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmE0NzM0ZGJhNGYwMTRhZjBhYWNmYTdiYzNiMTYzMjI1Xzkw_e5e81a52-2cf2-4b59-9ed4-60ff34b05320"
      unitRef="shares">93400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmE0NzM0ZGJhNGYwMTRhZjBhYWNmYTdiYzNiMTYzMjI1Xzkw_e750d545-a1d4-4250-8233-d495779a7088"
      unitRef="shares">93400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmE0NzM0ZGJhNGYwMTRhZjBhYWNmYTdiYzNiMTYzMjI1XzEwMw_a10232d6-0539-4480-a781-6496f937e8c5"
      unitRef="shares">92300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmE0NzM0ZGJhNGYwMTRhZjBhYWNmYTdiYzNiMTYzMjI1XzEwMw_e8819df7-1931-4d61-8652-bc36d95c562f"
      unitRef="shares">92300000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzAtMS0xLTEtMA_d029de17-1ab0-4b38-8359-9b3127d4b1bc"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzAtMy0xLTEtMA_1c5905b0-d772-4389-8bf9-29a9b69e496e"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzEtMS0xLTEtMA_3b9f7b39-6737-426d-9d2c-4793c56161f4"
      unitRef="usd">1874300000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzEtMy0xLTEtMA_3cb49a15-407c-4e4c-84d6-a7c93b270efa"
      unitRef="usd">1768100000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzItMS0xLTEtMA_071756a0-8e19-461a-a9fa-9adb278a887a"
      unitRef="usd">3200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzItMy0xLTEtMA_cd70b850-cd20-4d88-bc6f-fcd8ae6f58b2"
      unitRef="usd">1400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzMtMS0xLTEtMA_03d5404b-8bc9-4bb7-864b-77c1b343dcb0"
      unitRef="usd">-1073300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzMtMy0xLTEtMA_1bc57485-973c-43fd-ad11-fcd482f8527d"
      unitRef="usd">-1132700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzQtMS0xLTEtMA_bcb5e2fd-d0b9-4356-8469-e8f04ed71e61"
      unitRef="usd">804300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzQtMy0xLTEtMA_23567f36-5b21-4950-b96a-4cbf0008d89e"
      unitRef="usd">636900000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzUtMS0xLTEtMA_8f027eb3-764b-4e27-9252-971a3104f075"
      unitRef="usd">1502600000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xNi9mcmFnOmVhNzNjZTQ4ODUwYjRjZjg4ODcxMDFmOTg0MDZlNTQ1L3RhYmxlOjEyM2EyZTg1MzMxODQzYWVhY2FmOWRkOTVmYTk2MWFhL3RhYmxlcmFuZ2U6MTIzYTJlODUzMzE4NDNhZWFjYWY5ZGQ5NWZhOTYxYWFfMzUtMy0xLTEtMA_e8d307cb-00d2-4713-b0c6-6f7e9e39c6d6"
      unitRef="usd">1306000000.0</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9e8ecaa7faf4bd7aefcbbb4825de4ad_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMy0xLTEtMS0w_1ad28e93-cdf7-45e7-aa39-db3c9b105f72"
      unitRef="usd">254100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ac9bb3945ab4fa6a54c3854917ec6be_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMy0zLTEtMS0w_68740537-4eb8-472d-a3b5-6e410fe5396d"
      unitRef="usd">198100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8b7535c94394a5eb4e42047c2f78f8c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMy01LTEtMS0w_24557775-c807-489b-ae94-fd29aa103dea"
      unitRef="usd">752800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if63b65b04e2b4ba8a6410f5550f0dada_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMy03LTEtMS0w_c76f2a46-37dd-483e-bcc6-dbfbdd420fa1"
      unitRef="usd">515000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id237bed344304cdfb92dba0f37b8b2ea_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNC0xLTEtMS0w_47e18044-ccc9-415d-ba8b-11614e0e2899"
      unitRef="usd">4400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id28a908f24d443b491ef90114eab031e_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNC0zLTEtMS0w_70516504-3afd-47f5-ba77-308990a6933d"
      unitRef="usd">24000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07aa10bbd36d4f218b7067892376a3d9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNC01LTEtMS0w_a23d8d3a-f9a8-4d75-8793-4a36ff1b650a"
      unitRef="usd">45200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib46c14fbf85f4a67bc18bbc72105f4a4_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNC03LTEtMS0w_bbdbbdb8-c994-4595-9c0c-e26e5f722f41"
      unitRef="usd">29000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNS0xLTEtMS0w_4fee7d97-113b-4f78-a943-6c9232124973"
      unitRef="usd">258500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNS0zLTEtMS0w_50755aff-6ccc-4014-baae-04a04bca9e94"
      unitRef="usd">222100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNS01LTEtMS0w_60d31adb-50ce-4f94-bd27-67ad350231cd"
      unitRef="usd">798000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNS03LTEtMS0w_70474a56-c0af-4caa-9fe6-2cfff57a1386"
      unitRef="usd">544000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNy0xLTEtMS0w_e5ef48ed-1e27-4a45-b948-76995ffda24d"
      unitRef="usd">2700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNy0zLTEtMS0w_09d5ca15-51a5-4e73-a1a7-655b0527e566"
      unitRef="usd">2200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNy01LTEtMS0w_19d24c85-a9a6-45a8-9862-faf2e4be8db9"
      unitRef="usd">7200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfNy03LTEtMS0w_af003321-1d82-4666-9978-e63f5ac56428"
      unitRef="usd">4900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfOC0xLTEtMS0w_ade14888-2365-422f-b1e6-def8994e6952"
      unitRef="usd">69100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfOC0zLTEtMS0w_b846cf7b-50ea-4778-87de-31bd0c5eec65"
      unitRef="usd">45300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfOC01LTEtMS0w_be2a5a43-f407-419d-898c-d9385df5ac1d"
      unitRef="usd">208300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfOC03LTEtMS0w_7c00fd24-0c60-41d8-8323-bcacb1cff849"
      unitRef="usd">144700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfOS0xLTEtMS0w_31fff12f-bc47-4ecf-adf1-2324fac1e2fc"
      unitRef="usd">118500000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfOS0zLTEtMS0w_28905415-f9ad-4b8e-922c-67fbe9f094e8"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfOS01LTEtMS0w_0d2b5cf6-93cf-4235-9305-551f8c52a50a"
      unitRef="usd">164500000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfOS03LTEtMS0w_293737dc-44db-4014-b2d7-fc0361b41ef4"
      unitRef="usd">118100000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTAtMS0xLTEtMA_289d750e-51e5-436b-9df4-18189d5ed39c"
      unitRef="usd">112500000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTAtMy0xLTEtMA_a6a71782-ec5c-4d6d-ba54-ad3bef7e1364"
      unitRef="usd">84500000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTAtNS0xLTEtMA_6d81c808-d99a-4333-940d-46de8413ce52"
      unitRef="usd">326800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTAtNy0xLTEtMA_a4a9abe7-3918-44fc-b435-0b5d0020ace3"
      unitRef="usd">252800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTEtMS0xLTEtMA_febd9ea2-40ae-4494-bbd3-23c5d7e654bd"
      unitRef="usd">302800000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTEtMy0xLTEtMA_e14dfbd1-0ded-4c99-8712-188b623c60ea"
      unitRef="usd">132000000.0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTEtNS0xLTEtMA_221183c0-9d97-44fa-bbe6-935319d9bc4d"
      unitRef="usd">706800000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTEtNy0xLTEtMA_c0a1c0c7-3f81-489f-a319-0c8788943480"
      unitRef="usd">520500000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTItMS0xLTEtMA_acd6279a-1a39-4b21-bbdf-b1e8a6965772"
      unitRef="usd">-44300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTItMy0xLTEtMA_5bcdb2d5-0cee-403e-b9ef-7021431931b6"
      unitRef="usd">90100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTItNS0xLTEtMA_f5adec0a-12f6-4d43-9325-c3c1c2bfe32a"
      unitRef="usd">91200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTItNy0xLTEtMA_4bc766f8-06e2-4869-a923-9fb95cb9480c"
      unitRef="usd">23500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTQtMS0xLTEtMA_99c5e494-cee9-4be8-8db6-ec41134bc820"
      unitRef="usd">8500000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTQtMy0xLTEtMA_f1f6b8eb-a1af-4b77-a9f8-3dc5561396a1"
      unitRef="usd">8000000.0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTQtNS0xLTEtMA_e0afd457-03c0-409b-b655-a5bf1db60120"
      unitRef="usd">25000000.0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTQtNy0xLTEtMA_b04aef27-007c-45a1-84e6-1f7fe45cc179"
      unitRef="usd">23800000</us-gaap:InterestExpense>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTUtMS0xLTEtMA_6b441665-a885-4cad-935e-48bc124937c7"
      unitRef="usd">-7000000.0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTUtMy0xLTEtMA_0cc38a31-73fe-4175-8c8f-9b2872e6abcd"
      unitRef="usd">-28500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTUtNS0xLTEtMA_133d2a44-a709-4c02-b37e-a83826b607ac"
      unitRef="usd">-12200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTUtNy0xLTEtMA_7488421a-a4fc-48e0-8add-3fdf47c91dda"
      unitRef="usd">-5800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <nbix:InvestmentIncomeAndOtherNet
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTYtMS0xLTEtMA_ff0a136f-21c0-426f-9fc5-d75ff26af6e1"
      unitRef="usd">2700000</nbix:InvestmentIncomeAndOtherNet>
    <nbix:InvestmentIncomeAndOtherNet
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTYtMy0xLTEtMA_ec6d1497-29bf-476c-b901-a4dec39f239e"
      unitRef="usd">4800000</nbix:InvestmentIncomeAndOtherNet>
    <nbix:InvestmentIncomeAndOtherNet
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTYtNS0xLTEtMA_94a7f7ab-805c-4f70-9cb0-26959c95d23f"
      unitRef="usd">11000000.0</nbix:InvestmentIncomeAndOtherNet>
    <nbix:InvestmentIncomeAndOtherNet
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTYtNy0xLTEtMA_d176d808-0446-497b-ae3b-475cca1143b4"
      unitRef="usd">14000000.0</nbix:InvestmentIncomeAndOtherNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTctMS0xLTEtMA_058d8b80-8d63-452f-922e-f8bb69629ade"
      unitRef="usd">-12800000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTctMy0xLTEtMA_7adcab95-0b8a-4075-89e5-81fd84c7452e"
      unitRef="usd">-31700000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTctNS0xLTEtMA_c7090757-6d41-42ef-88b2-91e3f54dbbe1"
      unitRef="usd">-26200000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTctNy0xLTEtMA_ee2d45a7-4eff-4223-927b-13ee6ad75ba2"
      unitRef="usd">-15600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTgtMS0xLTEtMA_a360e027-5c04-4909-8862-635434274684"
      unitRef="usd">-57100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTgtMy0xLTEtMA_e4c1e72c-37e1-47b2-9b6b-711f839596a9"
      unitRef="usd">58400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTgtNS0xLTEtMA_51069def-3c0a-4a0e-8943-0ba34460ebe2"
      unitRef="usd">65000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTgtNy0xLTEtMA_dfc66b74-1927-45de-8bd5-9090aa912407"
      unitRef="usd">7900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTktMS0xLTEtMA_48e38ee0-5f4c-415c-b658-4477dc927167"
      unitRef="usd">500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTktMy0xLTEtMA_90afcbea-2672-464e-8f12-0fa019792f7a"
      unitRef="usd">4600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTktNS0xLTEtMA_37b4f711-75f5-4243-9e89-789f96a2306a"
      unitRef="usd">5600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMTktNy0xLTEtMA_8ea07299-3f9d-43bd-8afe-d48302d174e9"
      unitRef="usd">4900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjAtMS0xLTEtMA_be3c6ec1-50e6-4c09-a0ee-227a885eb2b3"
      unitRef="usd">-57600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjAtMy0xLTEtMA_336c8c0a-d77c-41f4-b519-0a4e34dbd3a9"
      unitRef="usd">53800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjAtNS0xLTEtMA_a93e9eab-1d2d-45df-89b6-483524b6a704"
      unitRef="usd">59400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjAtNy0xLTEtMA_ae4d60f2-cb45-4c1c-8463-33d18faee9b3"
      unitRef="usd">3000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjEtMS0xLTEtMA_9cfe23f6-f597-47c9-b551-a2cbfe75e071"
      unitRef="usd">-1400000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjEtMy0xLTEtMA_ab0a5e97-2f38-4d3a-9006-8185b3173778"
      unitRef="usd">1000000.0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjEtNS0xLTEtMA_ca2c15f0-ffcd-4f16-ab0c-5a325851b85f"
      unitRef="usd">1800000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjEtNy0xLTEtMA_f19ed418-3657-4ff7-ba2b-c8030ea3a800"
      unitRef="usd">3600000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjItMS0xLTEtMA_cc601241-608b-4d6a-9b63-bcddb4ecc1d9"
      unitRef="usd">-59000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjItMy0xLTEtMA_bb4eac60-d5d9-429d-9673-6e80be0820ce"
      unitRef="usd">54800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjItNS0xLTEtMA_0124b8f7-0f7f-4405-9981-8694f9c6d27a"
      unitRef="usd">61200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjItNy0xLTEtMA_cf94c640-57e0-4b44-8398-658bf1f71f09"
      unitRef="usd">6600000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjMtMS0xLTEtMA_de41c906-afe0-41be-84db-424183cfe257"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjMtMy0xLTEtMA_2fb3a5cb-f3d8-492b-957f-2fc06168b376"
      unitRef="usdPerShare">0.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjMtNS0xLTEtMA_d088c2d0-2fb2-47ea-b995-5e9b151b830a"
      unitRef="usdPerShare">0.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjMtNy0xLTEtMA_f179da3d-1cab-46db-a121-a5bee29bb277"
      unitRef="usdPerShare">0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjQtMS0xLTEtMA_83e56332-05ef-49b2-97b4-c498947324f1"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjQtMy0xLTEtMA_abbf3147-5192-479f-bd4f-b15990087e8a"
      unitRef="usdPerShare">0.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjQtNS0xLTEtMA_d2aa1d5d-07a7-46c2-a311-2e61807bf093"
      unitRef="usdPerShare">0.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjQtNy0xLTEtMA_69107389-e969-4c9b-8218-4282d48d2f99"
      unitRef="usdPerShare">0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjUtMS0xLTEtMA_fb05df00-c50c-4c89-b7ba-6fc162719cd7"
      unitRef="shares">93300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjUtMy0xLTEtMA_a0677a32-2257-4bc6-b410-23683ddc65aa"
      unitRef="shares">91900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjUtNS0xLTEtMA_49e25e16-9ec6-4acb-865c-888937633f73"
      unitRef="shares">93000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjUtNy0xLTEtMA_7f889d1a-0c29-443b-adda-325a6a45a41b"
      unitRef="shares">91400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjYtMS0xLTEtMA_c634e0d7-ee52-45bf-994f-fc2756167763"
      unitRef="shares">93300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjYtMy0xLTEtMA_2b7e83e5-bb3e-4cca-a56d-841ec98ad6c7"
      unitRef="shares">96100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjYtNS0xLTEtMA_abf34724-fd66-4121-902c-6c9ee9c20e50"
      unitRef="shares">98000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8xOS9mcmFnOmY1MzFlNGY0ODBkMTRmNDk5OWY0ZTAwYWIxZTExY2NmL3RhYmxlOjBmMGIzNWMxNWExNzQ0OTA4OWMxNDg0YWY4N2RmYjgyL3RhYmxlcmFuZ2U6MGYwYjM1YzE1YTE3NDQ5MDg5YzE0ODRhZjg3ZGZiODJfMjYtNy0xLTEtMA_a7bd88c6-ef57-4cd5-ad31-eb748eee647d"
      unitRef="shares">95200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="i911a596594bb42f1ac774b4d2e8002bc_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMy0xLTEtMS0w_f470b0cf-cce4-486c-9f1a-c33b8f6c238b"
      unitRef="shares">93200000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i911a596594bb42f1ac774b4d2e8002bc_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMy0zLTEtMS0w_41bad60a-020f-48da-a6b7-6e7ef415a756"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic68d7f4878b240c2a94c47549bedae1d_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMy01LTEtMS0w_96c0a383-2234-4972-b75c-f935873b6109"
      unitRef="usd">1842200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia5f511a933434ea0834f118c4f341f90_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMy03LTEtMS0w_fa48cf20-5423-4f94-8f24-516bde1e9753"
      unitRef="usd">4600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iedcce6b874c74163b624aa2b15ebb12b_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMy05LTEtMS0w_959bdbe8-b7a6-4627-acd4-2fad06d105af"
      unitRef="usd">-1015700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e06729230ea4ca7a95cf735dd99be6d_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMy0xMS0xLTEtMA_c1cd2d27-17ee-4584-9c81-1d39075fb85f"
      unitRef="usd">831200000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i4bcde4ddd2f54c21aa4bd738ffd07957_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfNC05LTEtMS0w_50a28435-3ac5-41e3-97ea-cd974a537a36"
      unitRef="usd">-57600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfNC0xMS0xLTEtMA_e2ee15f3-7682-4d6d-909e-60164d946380"
      unitRef="usd">-57600000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i99a4ab0b6ccf43d6bd7626714d91bae1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfNS03LTEtMS0w_ab2e5976-d690-40c8-ad36-6ef1918ca328"
      unitRef="usd">-1400000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfNS0xMS0xLTEtMA_e3117a46-be02-4d98-802a-ad22498acc25"
      unitRef="usd">-1400000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2bb7f4b1f21943c6863d8cba446f1522_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfNi01LTEtMS0w_15dca255-2438-4474-81f4-bb075b7dcaec"
      unitRef="usd">26700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfNi0xMS0xLTEtMA_61cce060-308b-4dce-9b21-6bebe1393eac"
      unitRef="usd">26700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="icfb97fb7839e4786b037248a2437f3e4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOC0xLTEtMS0w_dc6b7f56-263d-44dd-9012-7212950bd8e9"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2bb7f4b1f21943c6863d8cba446f1522_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOC01LTEtMS0w_1bf4886b-ca01-40ae-bf68-8ce21e97eab0"
      unitRef="usd">2500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOC0xMS0xLTEtMA_9bec22f2-109f-41c0-bb48-7943bc1d2a1d"
      unitRef="usd">2500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="icfb97fb7839e4786b037248a2437f3e4_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOS0xLTEtMS0yOTIx_949a07b1-bc3a-4bd0-b22d-2d4a2dab4f9a"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i2bb7f4b1f21943c6863d8cba446f1522_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOS01LTEtMS0yODky_ef650389-7295-4bfa-87dc-95d21e07311c"
      unitRef="usd">2900000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOS0xMS0xLTEtMjk0Mw_087dd8ad-0610-40c7-b82a-cfd5d07ab123"
      unitRef="usd">2900000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:SharesOutstanding
      contextRef="icf98ce15cffa48d490acc123240b6de1_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOS0xLTEtMS0w_bbd05024-2b8d-4028-b6f2-f7527cda4b2d"
      unitRef="shares">93400000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="icf98ce15cffa48d490acc123240b6de1_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOS0zLTEtMS0w_89229a49-89d6-4084-bdb7-fc99b83c7b60"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i92e0ed27615f42b28fa6f250cf9e5fb5_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOS01LTEtMS0w_92e4db9b-3f43-4f3c-8869-5ed070726e9f"
      unitRef="usd">1874300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i993fc948fbfd4c9e818abdde04072290_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOS03LTEtMS0w_1b286138-8c7e-41ea-91b5-f5e2ad1c9d0c"
      unitRef="usd">3200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0c745beb45d74cb091440fb03cecacf2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOS05LTEtMS0w_1b7551cd-4786-45f3-84fd-5466c7bac9ad"
      unitRef="usd">-1073300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfOS0xMS0xLTEtMA_a8d8b460-ca95-43a2-b94d-44d8bdf11ba4"
      unitRef="usd">804300000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ifdf214a2337843e78d1a347256aaaa00_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTEtMS0xLTEtMA_0ea5a073-693d-4a1f-84ba-bb767d2bdc1e"
      unitRef="shares">91500000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifdf214a2337843e78d1a347256aaaa00_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTEtMy0xLTEtMA_d85fe4cf-d21c-47a3-af23-450e4c438067"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib77575bdbf4040e39375b79ca78eff52_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTEtNS0xLTEtMA_0c813b36-f33d-4986-b807-22e21b195a45"
      unitRef="usd">1703500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic2ded9247e98428593f3e2412173375b_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTEtNy0xLTEtMA_32e4a034-2a99-4a65-8b03-b4aff288fbf6"
      unitRef="usd">600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i124193d520854efcb3745edbaed9fea0_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTEtOS0xLTEtMA_8f6a3281-c4c2-4a5b-8c4a-792f402a29a4"
      unitRef="usd">-1220500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib12e0fe57cf54c4eb690db593d5ab12f_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTEtMTEtMS0xLTA_00d93f29-34f0-43cc-8315-a739a70585fe"
      unitRef="usd">483700000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i268579fde8b349778a731f000224ca07_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTItOS0xLTEtMA_f18a8bb5-d461-49d1-8685-4498d3c52b54"
      unitRef="usd">53800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTItMTEtMS0xLTA_02de269c-9b1b-4e0c-8166-6576a45db3dd"
      unitRef="usd">53800000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="iec797011e09546cd8f24887ec442c1c5_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTMtNy0xLTEtMA_52fea3b0-a53a-472d-ac1e-9e538a5e5bae"
      unitRef="usd">1000000.0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTMtMTEtMS0xLTA_ef7fdceb-e421-4933-bcad-d963bc68cc7d"
      unitRef="usd">1000000.0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icb42b25d794147b1aed333e2f3166703_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTQtNS0xLTEtMA_d1789b1c-1b1c-4905-87bd-a4aae738ed33"
      unitRef="usd">20300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTQtMTEtMS0xLTA_1605d492-52cd-407e-a894-04e63b9caec0"
      unitRef="usd">20300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="idd133a6a9d584e259b82b5bcc97dfc26_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTUtMS0xLTEtMA_e5bf62d0-1c5b-4452-9be0-fe3514536979"
      unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icb42b25d794147b1aed333e2f3166703_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTUtNS0xLTEtMA_02357ccd-21fb-4daa-8752-61a75ba5bc2c"
      unitRef="usd">13100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTUtMTEtMS0xLTA_2017a170-3f68-4db8-bb7d-f3eecca76f13"
      unitRef="usd">13100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="idd133a6a9d584e259b82b5bcc97dfc26_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTctMS0xLTEtMjkyNA_6e856700-a388-4a24-961b-7cddcba49d1a"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="icb42b25d794147b1aed333e2f3166703_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTctNS0xLTEtMjg5NA_e4d35901-ec88-4d06-bf31-643f629ef05a"
      unitRef="usd">2600000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTctMTEtMS0xLTI5NDU_77acbcc0-4415-45c0-ac31-f2196f7657fc"
      unitRef="usd">2600000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:SharesOutstanding
      contextRef="ie9fc314f633842568fae2c624fd6a730_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTYtMS0xLTEtMA_85d920f5-253f-4f36-81c3-d982af3fcd64"
      unitRef="shares">92100000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie9fc314f633842568fae2c624fd6a730_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTYtMy0xLTEtMA_be371dc7-3e8f-4520-b79a-da9b208b8dc7"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic436e3bb1c9b40c5a2c28786df5e2f5e_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTYtNS0xLTEtMA_07a715a9-e51d-4069-bd93-3d1d2f3b7ccd"
      unitRef="usd">1739500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i305a4e84d6d84699b8b9301835f9518f_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTYtNy0xLTEtMA_8b3e3fc2-6eb4-4275-ad8d-d0566c41308a"
      unitRef="usd">1600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i730787997d6d4c228ee797868cbe3082_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTYtOS0xLTEtMA_8dd3e9a0-568b-40bd-bfe0-ba7e1e52f4f3"
      unitRef="usd">-1166700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5eafa440da15427d8d322a26e23e8db7_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTYtMTEtMS0xLTA_d4c1cebe-3d98-4df4-9719-c65f7fcbac19"
      unitRef="usd">574500000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i543b37a401f842f297d00c6f44d8c51d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTgtMS0xLTEtMA_150637e8-f347-46c1-9c95-cccceb8dc4c8"
      unitRef="shares">92300000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i543b37a401f842f297d00c6f44d8c51d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTgtMy0xLTEtMA_03134d55-4b1b-417b-9b79-151f0a28ebb3"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1bcc585face2402191cabf07bfd067f5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTgtNS0xLTEtMA_7a55043a-bff4-4320-9dcb-33613100c03e"
      unitRef="usd">1768100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia1679f6518a049a0b79b7b15a1277d4d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTgtNy0xLTEtMA_f2455506-b1bd-4820-905e-32dd98cc887f"
      unitRef="usd">1400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icce724fa185b4a2e81da141dd2ca4c69_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTgtOS0xLTEtMA_78c367d1-a067-4ec3-9cec-348de6ffb520"
      unitRef="usd">-1132700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTgtMTEtMS0xLTA_66de63c0-425f-46fd-91db-a4f1b2ec9af2"
      unitRef="usd">636900000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ie82ca40bd6b7437b85500edd36e2ac78_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTktOS0xLTEtMA_3480b01d-6df5-4ee7-af9b-a7b2ed05fab9"
      unitRef="usd">59400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMTktMTEtMS0xLTA_e377c14b-cfe4-4900-afe0-33d906e857e9"
      unitRef="usd">59400000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6512d4e06fe64b8c8902cb07fd087fe7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjAtNy0xLTEtMA_6088182e-d132-476f-9268-ccb8455189b8"
      unitRef="usd">1800000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjAtMTEtMS0xLTA_1e970394-de08-4080-a01a-1ef66f5561ff"
      unitRef="usd">1800000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i993fa090c95f4e7791e5c5d7159708d5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjEtNS0xLTEtMA_5b0f675f-c0e6-43ba-92ff-b10a9d746941"
      unitRef="usd">79000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjEtMTEtMS0xLTA_3626130e-bbab-4d4f-8bcc-8502d38f6a13"
      unitRef="usd">79000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="if1e75fea41454043ab426501ad55a6dd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjItMS0xLTEtMA_0d2b3d08-c0b1-4acf-b553-5f960c5ac264"
      unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if1e75fea41454043ab426501ad55a6dd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjMtMS0xLTEtMA_a02158f8-a3d5-44e1-bd6f-d1292adaba9f"
      unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i993fa090c95f4e7791e5c5d7159708d5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjMtNS0xLTEtMA_d48b9b32-156c-4751-a6b7-acb28aed95c9"
      unitRef="usd">21600000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjMtMTEtMS0xLTA_dc3a7933-33e0-42e6-8cee-9ecff7780d5f"
      unitRef="usd">21600000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="if1e75fea41454043ab426501ad55a6dd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjYtMS0xLTEtMjkyNw_ea15360f-d79c-4372-8cf1-ce434fd763d6"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i993fa090c95f4e7791e5c5d7159708d5_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjQtNS0xLTEtMA_6bbae6a1-6b3c-48ea-a6f9-792d14ef8f5c"
      unitRef="usd">5600000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjQtMTEtMS0xLTA_53ad6a6d-9dd4-43f0-bcaf-c13f813c85d1"
      unitRef="usd">5600000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:SharesOutstanding
      contextRef="icf98ce15cffa48d490acc123240b6de1_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjUtMS0xLTEtMA_f04ce6fc-1538-41e0-a926-b3cd71082312"
      unitRef="shares">93400000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="icf98ce15cffa48d490acc123240b6de1_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjUtMy0xLTEtMA_aa584af1-13b3-4450-8743-e1257f901a72"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i92e0ed27615f42b28fa6f250cf9e5fb5_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjUtNS0xLTEtMA_9687afc1-0934-48d6-8013-dd9fbf894ea7"
      unitRef="usd">1874300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i993fc948fbfd4c9e818abdde04072290_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjUtNy0xLTEtMA_679e0aa0-9e9e-41da-a11f-390b19531703"
      unitRef="usd">3200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0c745beb45d74cb091440fb03cecacf2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjUtOS0xLTEtMA_d2c9e9c4-f232-4542-8e93-ae7f804cb327"
      unitRef="usd">-1073300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjUtMTEtMS0xLTA_390eddec-1639-41b5-bf2b-c17ccc801ebd"
      unitRef="usd">804300000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ib022af9959ba424787b942770385acd6_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjctMS0xLTEtMA_1f1cbde3-54ac-4abd-b8f3-2ff12bee691a"
      unitRef="shares">90800000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib022af9959ba424787b942770385acd6_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjctMy0xLTEtMA_ac7f9d24-f136-4366-90a9-94dfe6dd2ca4"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i473e921631e44d049f986015d23f8c8e_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjctNS0xLTEtMA_8483b4b5-707c-4fdc-ac6c-a336e8cd0000"
      unitRef="usd">1660400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibd3a22690ded4fd58399451eeb2ff477_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjctNy0xLTEtMA_78b7273c-ddce-4ae8-8ef6-bba2200f2f4d"
      unitRef="usd">-2000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8a72aa82edb54cb9aa6dd689f379b35e_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjctOS0xLTEtMA_c0899782-e058-43fe-ab57-ddb8169e45f7"
      unitRef="usd">-1177700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7b9bcef8502e4089bb1a8346e1df9932_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjctMTEtMS0xLTA_a45d2719-8921-4060-9b9a-7f6c04805e57"
      unitRef="usd">480800000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i252046dd1c50470ea1cf51b3a7d8bbda_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjgtOS0xLTEtMA_1ba6175b-e9a7-4c59-89e6-208a28a13934"
      unitRef="usd">3000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjgtMTEtMS0xLTA_8c10c30d-73ff-47f4-8203-dd63a40f7299"
      unitRef="usd">3000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1a4f65fc8aa34883b840cee701384a7b_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjktNy0xLTEtMA_8132733c-3859-4cff-958b-46c6a73a27ad"
      unitRef="usd">3600000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMjktMTEtMS0xLTA_3414ea5a-9d03-44ef-92d7-4249be6fa1d6"
      unitRef="usd">3600000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id1ccdf0b325741f783c0d8b5806ef5e9_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzAtNS0xLTEtMA_7fdb1c5e-7738-4b80-be59-176756f5caa4"
      unitRef="usd">54000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzAtMTEtMS0xLTA_c0c75aa4-d634-4b0d-85a6-eba9226f9090"
      unitRef="usd">54000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i42a7ca788f2e494ea2ff656d2aecaa79_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzEtMS0xLTEtMA_add40a99-2bab-4df3-a26a-1629eff5ebcc"
      unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i42a7ca788f2e494ea2ff656d2aecaa79_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzItMS0xLTEtMA_be6c22ff-7977-4535-bfe2-1fe822694bea"
      unitRef="shares">800000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id1ccdf0b325741f783c0d8b5806ef5e9_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzItNS0xLTEtMA_35a5e3a0-97cc-4a24-9abe-6dd6bfb7abc4"
      unitRef="usd">20000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzItMTEtMS0xLTA_d0f619bb-cb4d-47bb-9156-42900bcd67df"
      unitRef="usd">20000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i42a7ca788f2e494ea2ff656d2aecaa79_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzUtMS0xLTEtMjkzMA_5f61e51e-3960-41aa-89c2-0733fc957ea2"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id1ccdf0b325741f783c0d8b5806ef5e9_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzMtNS0xLTEtMA_4ef4b305-488e-4287-8530-9b43b7636f9d"
      unitRef="usd">5100000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzMtMTEtMS0xLTA_3eaa40e5-a95f-4e08-b2e0-5a95668b72aa"
      unitRef="usd">5100000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockholdersEquity
      contextRef="ib3ac91b9e8aa453fa75f654a778253ac_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzQtOS0xLTEtMA_8f0ddfce-4767-4b63-8de1-cf2099e1b513"
      unitRef="usd">8000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ice72e35fd4be4be0bd6c7d149fff6950_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzQtMTEtMS0xLTA_65054267-2c36-4f2a-b057-5c292fbf71f6"
      unitRef="usd">8000000.0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ie9fc314f633842568fae2c624fd6a730_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzUtMS0xLTEtMA_4d450174-a071-4be6-a3d3-b9de4da1565e"
      unitRef="shares">92100000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ie9fc314f633842568fae2c624fd6a730_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzUtMy0xLTEtMA_d3b96007-1ce4-4448-a3b7-8091189a0b38"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic436e3bb1c9b40c5a2c28786df5e2f5e_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzUtNS0xLTEtMA_65171138-b147-4c3a-b869-ee56a0589e97"
      unitRef="usd">1739500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i305a4e84d6d84699b8b9301835f9518f_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzUtNy0xLTEtMA_fbb6b82d-4a03-455a-bc21-82771ed0949a"
      unitRef="usd">1600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i730787997d6d4c228ee797868cbe3082_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzUtOS0xLTEtMA_e60a9eda-f705-4c74-8409-20113d23cf52"
      unitRef="usd">-1166700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5eafa440da15427d8d322a26e23e8db7_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yMi9mcmFnOjUzODkzYzE0MTI1NTRhYjI5NTQ1ODU2Njc3NGE1NmU3L3RhYmxlOjM1ZjhmZjliNGQwMzQ2ZmQ5MDVmZTRhNjY1N2RmNDlmL3RhYmxlcmFuZ2U6MzVmOGZmOWI0ZDAzNDZmZDkwNWZlNGE2NjU3ZGY0OWZfMzUtMTEtMS0xLTA_2c1211b0-536a-472a-a2e3-650f9f2a0e68"
      unitRef="usd">574500000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMy0xLTEtMS0w_881b35c1-b3c9-4c87-ace7-25c76318ae93"
      unitRef="usd">59400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMy0zLTEtMS0w_3c121be5-c69c-417a-8d4e-b0d8b99cfc2e"
      unitRef="usd">3000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfNS0xLTEtMS0w_a3567a0f-db2a-43cf-bcd1-8bfd93efc2bb"
      unitRef="usd">79000000.0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfNS0zLTEtMS0w_fb1023b6-5675-4eb8-b8a6-113a2054a093"
      unitRef="usd">54000000.0</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfNi0xLTEtMS0w_42a3ef99-d978-4662-b316-f62951a25bf4"
      unitRef="usd">6400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfNi0zLTEtMS0w_60fb1f38-1394-41b7-aeee-73f941e04bba"
      unitRef="usd">5400000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfNy0xLTEtMS0w_422896eb-9904-4eb2-a6cc-f1d19f423f78"
      unitRef="usd">15200000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfNy0zLTEtMS0w_ff81ecc6-76b1-45e7-a2f3-894077515221"
      unitRef="usd">14100000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfOC0xLTEtMS0w_38153ec7-5e54-436f-99df-e9ea8eac4536"
      unitRef="usd">1000000.0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfOC0zLTEtMS0w_573c4959-d9a2-4f74-b569-34d9c5eac0e5"
      unitRef="usd">1000000.0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfOS0xLTEtMS0w_ed9c3aa9-8697-4d01-b4e8-b68d6b3cdb7e"
      unitRef="usd">-12200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfOS0zLTEtMS0w_67a83a70-6876-4e03-a5aa-2a88007f94c7"
      unitRef="usd">-5800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTAtMS0xLTEtMA_89c43c9c-2db1-4d16-b092-a3afdd42f076"
      unitRef="usd">1700000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTAtMy0xLTEtMA_e573e2b6-b079-4d4a-ba88-eaa5059bc9ea"
      unitRef="usd">-700000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTItMS0xLTEtMA_04a790ca-11b4-400f-9101-4ef8b6d18611"
      unitRef="usd">30300000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTItMy0xLTEtMA_a8d9c5f8-78c3-4b7b-9883-a363ef651b2e"
      unitRef="usd">57900000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTMtMS0xLTEtMA_03c385a6-0d67-43ea-abde-07dadcb7d31a"
      unitRef="usd">3400000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTMtMy0xLTEtMA_403a6052-d414-4a0b-bf2a-934d1b8887c8"
      unitRef="usd">-100000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTQtMS0xLTEtMA_52f31bf6-3adc-4d66-aa1a-5b0e91f922b7"
      unitRef="usd">28100000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTQtMy0xLTEtMA_313258ed-6430-481c-ad96-325d06796db7"
      unitRef="usd">12300000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTUtMS0xLTEtMA_713942f9-d234-48e1-a713-997d7ac2ddc8"
      unitRef="usd">29700000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTUtMy0xLTEtMA_7d0124ee-a494-4006-85b7-d89fe615e3ad"
      unitRef="usd">-12400000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTYtMS0xLTEtMA_b2366b4d-ace9-4770-bade-2d9875b0d775"
      unitRef="usd">139600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTYtMy0xLTEtMA_7214909b-10f1-4d61-b65b-3ed5c5fef1b2"
      unitRef="usd">49500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTktMS0xLTEtMA_691c25fb-c71b-4257-ab30-ff71ba38a3e5"
      unitRef="usd">399200000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMTktMy0xLTEtMA_e86b6b5c-7910-4a08-9555-e2bcc0a442bb"
      unitRef="usd">467100000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjAtMS0xLTEtMA_a4948fa5-38eb-45dc-829c-486c4ee72775"
      unitRef="usd">557400000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjAtMy0xLTEtMA_4f6cbd52-2351-497d-aa36-d62852f7dd33"
      unitRef="usd">488800000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjEtMS0xLTEtMA_5c05fc2f-5d8a-4e0c-a1cf-7bc82960623e"
      unitRef="usd">0</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjEtMy0xLTEtMA_c887a003-3f09-4065-82b5-c4f177c6f9c6"
      unitRef="usd">54700000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjItMS0xLTEtMA_9848193b-d901-42ca-8d4f-852a020eb29a"
      unitRef="usd">6400000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjItMy0xLTEtMA_3d37250c-5337-4720-9a35-4c8be2f8226b"
      unitRef="usd">11900000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjMtMS0xLTEtMA_a143c2ca-9230-4dd9-852f-68de10314782"
      unitRef="usd">151800000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjMtMy0xLTEtMA_3c961806-f52c-4748-a8bf-f2237784aea4"
      unitRef="usd">-44900000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjYtMS0xLTEtMA_4954ac55-da44-47bf-a4eb-968da2299a14"
      unitRef="usd">21600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjYtMy0xLTEtMA_31b66736-3b56-4304-9346-53ac7cff1003"
      unitRef="usd">20000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjctMS0xLTEtMA_fca97caa-1fb3-4f81-8517-c3db0e038181"
      unitRef="usd">21600000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjctMy0xLTEtMA_afa28484-c2cb-4e43-8d17-25375ab0d1a3"
      unitRef="usd">20000000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjgtMS0xLTEtMA_4281ba1d-d3a3-40fa-8505-06467fa80908"
      unitRef="usd">313000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjgtMy0xLTEtMA_18ce82dc-9d08-4719-b680-0b0121c71438"
      unitRef="usd">24600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjktMS0xLTEtMA_0a35738c-4f05-4492-bf77-6200faddbf49"
      unitRef="usd">115500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7b9bcef8502e4089bb1a8346e1df9932_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMjktMy0xLTEtMA_e8defad8-5773-4b01-9ae1-de7e22295c16"
      unitRef="usd">147200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMzAtMS0xLTEtMA_eb6b1925-b852-4224-8771-9db0cb5a74c7"
      unitRef="usd">428500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5eafa440da15427d8d322a26e23e8db7_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMzAtMy0xLTEtMA_9126252a-c3f7-4eb8-a0f5-628bf3dd13af"
      unitRef="usd">171800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMzMtMS0xLTEtMA_f7c75301-11f0-483a-95f8-0b60bb0467bf"
      unitRef="usd">1100000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMzMtMy0xLTEtMA_f82c1bf8-5161-4b64-8805-eff4c4e8e20b"
      unitRef="usd">100000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:InterestPaidNet
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMzQtMS0xLTEtMA_8cb8acf4-b974-4d7f-90c7-e519d0cd3120"
      unitRef="usd">5800000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMzQtMy0xLTEtMA_2fdaf426-362e-42fa-9f22-e2b220455376"
      unitRef="usd">5800000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMzUtMS0xLTEtMA_055e3cb9-6412-41c9-bd8e-2834659d86cc"
      unitRef="usd">400000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8yNS9mcmFnOjYwYjBkNzUyMzg1YzQzNTZiMjZjODEyYmNiYmQ4NWE2L3RhYmxlOmFkYTc0YWVlOTA5YTQ2MWRiMmI1OTYzMjdhMGZkNmE1L3RhYmxlcmFuZ2U6YWRhNzRhZWU5MDlhNDYxZGIyYjU5NjMyN2EwZmQ2YTVfMzUtMy0xLTEtMA_4d967af7-c6f7-45dd-ac62-0d5ee541a231"
      unitRef="usd">500000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zMS9mcmFnOmJmMDkzOGVlMWI5NTQ3ZDc5NDQ3ODJkYmFkYmRmNzk4L3RleHRyZWdpb246YmYwOTM4ZWUxYjk1NDdkNzk0NDc4MmRiYWRiZGY3OThfMTQwNzE_05bf3741-fb23-4211-928d-e4a05632e12e">Organization and Significant Accounting Policies&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Neurocrine Biosciences, Inc., or Neurocrine Biosciences, the Company, we, our or us, was incorporated in California in 1992 and reincorporated in Delaware in 1996. Neurocrine Continental, Inc., is a Delaware corporation and a wholly owned subsidiary of Neurocrine Biosciences. We also have two wholly owned Irish subsidiaries, Neurocrine Therapeutics, Ltd. and Neurocrine Europe, Ltd., both of which were formed in December 2014 and are inactive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a commercial-stage biopharmaceutical company focused on discovering and developing innovative and life-changing treatments for patients with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. We specialize in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. Currently, we are primarily focused on the commercialization of INGREZZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (valbenazine) in the United States, or US, our first US Food and Drug Administration, or FDA, approved product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the US, or GAAP, for interim financial information and with the instructions of the Securities and Exchange Commission, or SEC, on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of Neurocrine Biosciences and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2019, included in our Annual Report on Form 10-K, or the 2019 Form 10-K, filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or the full year. The condensed consolidated balance sheet at December&#160;31, 2019, has been derived from the audited financial statements as of that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no significant changes to our significant accounting policies as disclosed in the 2019 Form 10-K, except as set forth below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities consist of investments in certificates of deposit, corporate debt securities, and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become 90 days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Allowance for Credit Losses. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest receivables on debt securities available-for-sale totaled $3.5 million at September&#160;30, 2020. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during the nine months ended September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record cash equivalents, debt securities available-for-sale and equity securities at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources, and analyzing data in certain instances.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in equity securities of certain companies that are subject to holding period restrictions longer than one year are classified as Level 3 and carried at fair value using an option pricing valuation model. The most significant assumptions within the option pricing valuation model are the stock price volatility, which is based on the historical volatility of similar companies, and the discount for lack of marketability related to the term of the restrictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU 2016-13. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2020, we adopted Accounting Standards Update, or ASU, 2016-13,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;using the modified retrospective transition method. For debt securities available-for-sale, the standard requires an investor to determine whether a decline in the fair value below the amortized cost basis of the investment is due to credit-related factors. Credit-related impairment is recognized as an allowance for credit loss on the balance sheet with a corresponding adjustment to earnings. Credit losses are limited to the amount by which the investment&#x2019;s amortized cost basis exceeds its fair value and may be subsequently reversed if conditions change. Any impairment that is not credit related is recognized in other comprehensive income or loss, as applicable, net of applicable taxes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The adoption of ASU 2016-13 did not result in a cumulative-effect adjustment to retained earnings. The comparative prior period information continues to be reported under the accounting standards in effect during those periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU 2019-12. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application of Topic 740. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, with early adoption permitted in any interim period for which financial statements have not yet been made available for issuance. We are currently evaluating the effect ASU 2019-12 will have on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU 2020-06. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments, and amends existing earnings-per-share, or EPS, guidance by requiring that an entity use the if-converted method when calculating diluted EPS for convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal &lt;/span&gt;&lt;/div&gt;years, with early adoption permitted for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We are currently evaluating the effect ASU 2020-06 will have on our condensed consolidated financial statements and related disclosures.</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
    <nbix:BusinessDescriptionPolicyTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zMS9mcmFnOmJmMDkzOGVlMWI5NTQ3ZDc5NDQ3ODJkYmFkYmRmNzk4L3RleHRyZWdpb246YmYwOTM4ZWUxYjk1NDdkNzk0NDc4MmRiYWRiZGY3OThfMTQwNjg_797e92c8-2084-46df-8f22-140c1899348a">&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Neurocrine Biosciences, Inc., or Neurocrine Biosciences, the Company, we, our or us, was incorporated in California in 1992 and reincorporated in Delaware in 1996. Neurocrine Continental, Inc., is a Delaware corporation and a wholly owned subsidiary of Neurocrine Biosciences. We also have two wholly owned Irish subsidiaries, Neurocrine Therapeutics, Ltd. and Neurocrine Europe, Ltd., both of which were formed in December 2014 and are inactive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a commercial-stage biopharmaceutical company focused on discovering and developing innovative and life-changing treatments for patients with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. We specialize in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. Currently, we are primarily focused on the commercialization of INGREZZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (valbenazine) in the United States, or US, our first US Food and Drug Administration, or FDA, approved product.&lt;/span&gt;&lt;/div&gt;</nbix:BusinessDescriptionPolicyTextBlock>
    <nbix:NumberOfIrishSubsidiaries
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zMS9mcmFnOmJmMDkzOGVlMWI5NTQ3ZDc5NDQ3ODJkYmFkYmRmNzk4L3RleHRyZWdpb246YmYwOTM4ZWUxYjk1NDdkNzk0NDc4MmRiYWRiZGY3OThfMzcy_c8a2f0ed-6ed5-4622-a1cd-f1e330978971"
      unitRef="subsidiary">2</nbix:NumberOfIrishSubsidiaries>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zMS9mcmFnOmJmMDkzOGVlMWI5NTQ3ZDc5NDQ3ODJkYmFkYmRmNzk4L3RleHRyZWdpb246YmYwOTM4ZWUxYjk1NDdkNzk0NDc4MmRiYWRiZGY3OThfMjc0ODc3OTE0OTQ0OQ_2b116d9b-614c-44cd-8c19-3c93706e5a2e">&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the US, or GAAP, for interim financial information and with the instructions of the Securities and Exchange Commission, or SEC, on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of Neurocrine Biosciences and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2019, included in our Annual Report on Form 10-K, or the 2019 Form 10-K, filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or the full year. The condensed consolidated balance sheet at December&#160;31, 2019, has been derived from the audited financial statements as of that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no significant changes to our significant accounting policies as disclosed in the 2019 Form 10-K, except as set forth below.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zMS9mcmFnOmJmMDkzOGVlMWI5NTQ3ZDc5NDQ3ODJkYmFkYmRmNzk4L3RleHRyZWdpb246YmYwOTM4ZWUxYjk1NDdkNzk0NDc4MmRiYWRiZGY3OThfMTQwNjk_edb06104-7cb7-4e9f-b828-02190e69d4b3">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities consist of investments in certificates of deposit, corporate debt securities, and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become 90 days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zMS9mcmFnOmJmMDkzOGVlMWI5NTQ3ZDc5NDQ3ODJkYmFkYmRmNzk4L3RleHRyZWdpb246YmYwOTM4ZWUxYjk1NDdkNzk0NDc4MmRiYWRiZGY3OThfNzI2MA_3fb7b0f1-eb34-43fa-9c6b-5c2a0880eabb">P90D</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff>
    <us-gaap:FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zMS9mcmFnOmJmMDkzOGVlMWI5NTQ3ZDc5NDQ3ODJkYmFkYmRmNzk4L3RleHRyZWdpb246YmYwOTM4ZWUxYjk1NDdkNzk0NDc4MmRiYWRiZGY3OThfMTQwNzM_8e4721ef-2ffa-44f0-ba18-fc0f99ee8ca3">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Allowance for Credit Losses. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.&lt;/span&gt;Accrued interest receivables on debt securities available-for-sale totaled $3.5 million at September&#160;30, 2020. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during the nine months ended September&#160;30, 2020.</us-gaap:FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts>
    <us-gaap:InterestReceivableCurrent
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zMS9mcmFnOmJmMDkzOGVlMWI5NTQ3ZDc5NDQ3ODJkYmFkYmRmNzk4L3RleHRyZWdpb246YmYwOTM4ZWUxYjk1NDdkNzk0NDc4MmRiYWRiZGY3OThfOTIxNA_ed4ddee7-c30f-4b8f-b24c-d085afdee8ed"
      unitRef="usd">3500000</us-gaap:InterestReceivableCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zMS9mcmFnOmJmMDkzOGVlMWI5NTQ3ZDc5NDQ3ODJkYmFkYmRmNzk4L3RleHRyZWdpb246YmYwOTM4ZWUxYjk1NDdkNzk0NDc4MmRiYWRiZGY3OThfOTYzMA_7003046f-559e-459f-9fe4-a9d5fb28b23c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestWriteoff>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zMS9mcmFnOmJmMDkzOGVlMWI5NTQ3ZDc5NDQ3ODJkYmFkYmRmNzk4L3RleHRyZWdpb246YmYwOTM4ZWUxYjk1NDdkNzk0NDc4MmRiYWRiZGY3OThfMTQwNzQ_3d354fcf-4f99-4701-a8f9-3ced1780c8b4">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record cash equivalents, debt securities available-for-sale and equity securities at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources, and analyzing data in certain instances.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in equity securities of certain companies that are subject to holding period restrictions longer than one year are classified as Level 3 and carried at fair value using an option pricing valuation model. The most significant assumptions within the option pricing valuation model are the stock price volatility, which is based on the historical volatility of similar companies, and the discount for lack of marketability related to the term of the restrictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zMS9mcmFnOmJmMDkzOGVlMWI5NTQ3ZDc5NDQ3ODJkYmFkYmRmNzk4L3RleHRyZWdpb246YmYwOTM4ZWUxYjk1NDdkNzk0NDc4MmRiYWRiZGY3OThfMTQwNzU_ed7a23f4-d23f-4a9d-ad27-4715524692ef">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU 2016-13. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2020, we adopted Accounting Standards Update, or ASU, 2016-13,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;using the modified retrospective transition method. For debt securities available-for-sale, the standard requires an investor to determine whether a decline in the fair value below the amortized cost basis of the investment is due to credit-related factors. Credit-related impairment is recognized as an allowance for credit loss on the balance sheet with a corresponding adjustment to earnings. Credit losses are limited to the amount by which the investment&#x2019;s amortized cost basis exceeds its fair value and may be subsequently reversed if conditions change. Any impairment that is not credit related is recognized in other comprehensive income or loss, as applicable, net of applicable taxes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The adoption of ASU 2016-13 did not result in a cumulative-effect adjustment to retained earnings. The comparative prior period information continues to be reported under the accounting standards in effect during those periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU 2019-12. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application of Topic 740. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, with early adoption permitted in any interim period for which financial statements have not yet been made available for issuance. We are currently evaluating the effect ASU 2019-12 will have on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU 2020-06. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments, and amends existing earnings-per-share, or EPS, guidance by requiring that an entity use the if-converted method when calculating diluted EPS for convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal &lt;/span&gt;&lt;/div&gt;years, with early adoption permitted for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We are currently evaluating the effect ASU 2020-06 will have on our condensed consolidated financial statements and related disclosures.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMzg0ODI5MDczNDE4NQ_05c299ae-564c-45b6-9539-7a576f12c574">Significant Collaboration and Licensing Agreements&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In June 2020, we entered into an exclusive license agreement with Takeda, which became effective in July 2020, to develop and commercialize certain compounds in Takeda&#x2019;s early to mid-stage psychiatry pipeline. Specifically, Takeda granted us an exclusive license to the following seven assets: (i) NBI-1065844 (TAK-831) for schizophrenia, (ii) NBI-1065845 (TAK-653) for treatment-resistant depression, (iii) NBI-1065846 (TAK-041) for anhedonia (which together with the NBI-1065845 are referred to as the Phase II Ready Assets), and (iv) four non-clinical stage assets, or the Non-Clinical Assets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NBI-1065844 is deemed a royalty-bearing product under the license agreement pursuant to which we will be responsible for all costs and expenses associated with the development, manufacture, and commercialization of such asset, subject to certain exceptions, and Takeda will be eligible to receive development and commercial milestones and royalties with respect to such asset, or a Royalty-Bearing Product, and Takeda will retain the right to opt-in to a profit sharing arrangement pursuant to which we and Takeda will equally share in the operating profits and losses related to such asset, subject to certain exceptions, in lieu of receiving milestones and royalties, or a Profit-Share Product. Subject to specified conditions, Takeda may elect to exercise such opt-in right for NBI-1065844 before we initiate a Phase III clinical trial. Each of the Phase II Ready Assets is deemed a Profit-Share Product and Takeda will retain the right to opt-out of the profit-sharing arrangement for such asset pursuant to which such asset would become a Royalty-Bearing Product. Takeda may elect to exercise such opt-out rights with respect to a Phase II Ready Asset immediately following the completion of the second Phase II clinical trial for such Phase II Ready Asset. In addition, under certain circumstances related to the development and commercialization activities to be performed by us, Takeda may elect to opt-out of the profit-sharing arrangement for a Profit-Share Product before the initiation of a Phase III clinical trial for such product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of the Non-Clinical Assets will be Royalty-Bearing Products pursuant to which we will be responsible for all costs and expenses associated with the development, manufacture, and commercialization of such assets, subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the agreement, we paid Takeda $120.0&#160;million upfront&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which, including certain transaction related costs, was expensed as IPR&amp;amp;D in the third quarter of 2020&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the agreement, &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Takeda may also be entitled to receive payments of up to $1.9&#160;billion upon the achievement of certain development and commercial milestones associated with Royalty-Bearing Products, as well as receive royalties on future net sales of Royalty-Bearing Products. On a country-by-country and product-by-product basis, royalty payments would commence on the first commercial sale of a Royalty-Bearing Product and terminate on the later of (i) the expiration of the last patent covering such Royalty-Bearing Product in such country, (ii) a number of years from the first commercial sale of such Royalty-Bearing Product in such country and (iii) the expiration of regulatory exclusivity for Royalty-Bearing Product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the license agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which, (i) for any Royalty-Bearing Product, the royalty term has expired in such country; and (ii) for any Profit-Share Product, for so long as we continue to develop, manufacture, or commercialize such licensed product.  We may terminate the license agreement for convenience in its entirety or in one or more (but not all) of the United States, Japan, the European Union, and the United Kingdom, or the Major Markets, on 6 months&#x2019; written notice to Takeda (i) with respect to all licensed products prior to the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes, as defined in the agreement, prior to the first commercial sale of the first licensed product in such target class(es) for which first commercial sale occurs. We may terminate the license agreement for convenience in its entirety or in one or more (but not all) of the Major Markets on 12 months&#x2019; written notice to Takeda (i) with respect to all licensed products following the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes following the first commercial sale of the first licensed product in such target class(es) for which first commercial sale. Takeda may terminate the license agreement, subject to specified conditions, (i) if we challenge the validity or enforceability of certain Takeda intellectual property rights or (ii) on a target class-by-target class basis, in the event that we do not conduct any material development or commercialization activities with respect to any licensed product within such target class for a specified continuous period. Subject to a cure period, either party may terminate the license agreement in the event of any material breach, solely with respect to the target class of a licensed product to which such material breach relates, or in its entirety in the event of any material breach that relates to all licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Idorsia.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, we entered a collaboration and licensing agreement with Idorsia to license the global rights to NBI-827104, a potent, selective, orally active and brain penetrating T-type calcium channel blocker, in clinical development for the treatment of a rare pediatric epilepsy. The agreement also included a research collaboration to discover and identify additional novel T-type calcium channel blockers as development candidates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the exercise of the option, we paid Idorsia $45.0&#160;million upfront, which was expensed as IPR&amp;amp;D in the second quarter of 2020. Further, as part of the research collaboration, we provided Idorsia with an incremental $7.2&#160;million in funding, which was recorded as a prepaid asset to be expensed over the two-year research collaboration term.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the agreement, upon the achievement of certain development and regulatory milestones, Idorsia may be entitled to receive payments of up to $365.0&#160;million with respect to NBI-827104 and up to $620.0&#160;million with respect to the development candidates. In addition, Idorsia may also be entitled to receive payments of up to $750.0&#160;million upon the achievement of certain commercial milestones, as well as receive royalties on the net sales of any collaboration product. Further, we will be responsible for all manufacturing, development and commercialization costs of any collaboration product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may terminate the collaboration and licensing agreement, in its entirety or with respect to a particular compound or development candidate, by providing 90 days&#x2019; written notice to Idorsia. Further, in the event a party commits a material breach and fails to cure such material breach within 90 days after receiving written notice thereof, the non-breaching party may terminate the agreement in its entirety immediately upon written notice to the breaching party.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Xenon. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, we entered into a license and collaboration agreement with Xenon Pharmaceuticals Inc., or Xenon, to identify, research, and develop sodium channel inhibitors, including clinical candidate NBI-921352 and three preclinical candidates, which compounds we will have the exclusive right to further develop and commercialize under the terms and conditions set forth in the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We will be solely responsible, at our sole cost and expense, for all development and manufacturing of the compounds and any pharmaceutical product that contains a compound, subject to Xenon&#x2019;s right to elect to co-fund the development of one product in a major indication and thus receive a mid-single digit percentage increase in royalties owed on the net sales of such product in the US. If Xenon exercises such option, the parties will share equally all reasonable and documented costs and expenses incurred in connection with the development of such product in the applicable indication, except costs and expenses that are solely related to the development of such product for regulatory approval outside the US.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the term of the license and collaboration agreement will continue on a product-by-product and country-by-country basis until the expiration of the royalty term for such product in such country. Upon the expiration of the royalty term for a particular product and country, the exclusive license granted by Xenon to us with respect to such product and country will become fully paid, royalty free, perpetual, and irrevocable. We may terminate the license and collaboration agreement by providing at least 90 days&#x2019; written notice, provided that such unilateral termination will not be effective for certain products until we have used commercially reasonable efforts to complete certain specified clinical studies. Either party may terminate the agreement in the event of a material breach in whole or in part, subject to specified conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Voyager.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2019, we entered into a collaboration and license agreement with Voyager, a clinical-stage gene therapy company. The agreement is focused on the development and commercialization of four programs using Voyager&#x2019;s proprietary gene therapy platform. The four programs consist of the NBIb-1817 program for Parkinson&#x2019;s disease, the Friedreich&#x2019;s ataxia program and the rights to two undisclosed programs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to development plans agreed to by us and Voyager, unless Voyager exercises its co-development and co-commerci&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;alization rights as provided for in the agreement, we will be responsible for all development costs. Further, upon the occurrence of a specified event for each program, we will assume responsibility for the development, manufacturing, and commercialization activit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ies of such program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may terminate the collaboration and license agreement with Voyager upon 180 days&#x2019; written notice to Voyager prior to the first commercial sale of any collaboration product or upon one year after the date of notice if such notice is provided after the first commercial sale of any collaboration product. Unless terminated earlier, the agreement will continue in effect until the expiration of the last to expire royalty term with respect to any collaboration product or the last expiration or termination of any exercised co-development and co-commercialization rights by Voyager as provided for in the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BIAL &#x2013; Portela &amp;amp; Ca, S.A.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2017, we entered into an exclusive license agreement with BIAL&#160;&#x2013; Portela &amp;amp; Ca, S.A., or BIAL, for the development and commercialization of ONGENTYS for the treatment of human diseases and conditions, including Parkinson&#x2019;s disease, in the US and Canada. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, we received FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients, which was commercialized by our commercial team in late September 2020. FDA approval for ONGENTYS for Parkinson&#x2019;s disease triggered a milestone payment of $20.0 million, which was expensed &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as R&amp;amp;D in the second quarter of 2020. Pursuant to the terms of the agreement, BIAL may also be entitled to receive up to $75.0&#160;million upon the achievement of certain commercial milestones.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, we are responsible for the commercialization of ONGENTYS in the US and Canada. Further, we  rely on BIAL for the commercial supply of ONGENTYS. Upon our written request prior to the estimated expiration of the term of a licensed product, the parties shall negotiate a good faith continuation of BIAL&#x2019;s supply of such licensed product after the term. After the term, and if BIAL is not supplying a certain licensed product, we shall pay BIAL a trademark royalty based on the net sales of such licensed product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon commercialization of ONGENTYS, we determined certain annual sales forecasts. In the event we fail to meet the minimum sales requirements for a particular year, we would be obligated to pay BIAL an amount equal to the difference between the actual net sales and minimum sales requirements for such year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement will continue on a licensed product-by-product and country-by-country basis until a generic product in respect of such licensed product under the agreement is sold in a country and sales of such generic product are greater than a specified percentage of total sales of such licensed product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Either party may terminate the agreement if the other party materially breaches the agreement and does not cure the breach within a specified notice period, or upon the other party&#x2019;s insolvency. BIAL may terminate the agreement if we fail to use commercially reasonable efforts to submit an NDA for a licensed product by a specified date, in the event we fail to meet the minimum sales requirements for any two years, or under certain circumstances involving a change of control of Neurocrine Biosciences. Under certain circumstances where BIAL elects to terminate the agreement in connection with a change of control of Neurocrine Biosciences, BIAL would be obligated to pay us a termination fee. We may terminate the agreement at any time for any reason upon nine months&#x2019; written notice to BIAL.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mitsubishi Tanabe Pharma Corporation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2015, we entered into a collaboration and license agreement with Mitsubishi Tanabe Pharma Corporation, or MTPC, for the development and commercialization of INGREZZA for movement disorders in Japan and other select Asian markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September&#160;30, 2020, we recognized revenue of $0.5&#160;million and $1.8&#160;million, respectively, in connection with the ongoing KINECT-HD study, a placebo-controlled Phase III study of valbenazine in adult Huntington&#x2019;s disease patients with chorea. In accordance with our continuing performance obligations, $7.6&#160;million of the $30.0&#160;million upfront payment received from MTPC in connection with the agreement is being deferred and will be recognized as revenue over the KINECT-HD study period using an input method according to costs incurred to-date relative to estimated total costs associated with the study. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since inception of the agreement, we have recognized revenue of $19.8&#160;million associated with the delivery of a technology license and existing know-how, $15.0&#160;million associated with the achievement of a certain development milestones, and $2.6&#160;million associated with our performance of the ongoing KINECT-HD study. Pursuant to the terms of the agreement, we may also be entitled to receive payments of up to $70.0&#160;million upon the achievement of certain regulatory and commercial milestones, receive payments for the manufacture of certain pharmaceutical products, as well as receive royalties on the net sales of collaboration products in select territories in Asia.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, MTPC is responsible for all third-party development, marketing, and commercialization costs in Japan and other select Asian markets and we would be entitled to a percentage of sales of INGREZZA in Japan and other select Asian markets for the longer of ten years or the life of the related patent rights. Further, the collaboration effort between the parties to advance INGREZZA towards commercialization in Japan and other select Asian markets is governed by joint steering and development committees with representatives from both parties. There are no performance, cancellation, termination, or refund provisions in the agreement that would have a material financial consequence to us. We do not directly control when event-based payments will be achieved or when royalty payments will begin. MTPC may terminate the agreement at its discretion upon 180 days' written notice to us. In such event, all INGREZZA product rights for Japan and other select Asian markets would revert to us.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AbbVie. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2010, we entered into an exclusive worldwide collaboration with AbbVie to develop and commercialize elagolix and all next-generation gonadotropin-releasing factor antagonists for women&#x2019;s and men&#x2019;s health.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AbbVie received approval of ORILISSA for the management of moderate to severe endometriosis pain in women from the FDA in July 2018 and Health Canada in October 2018.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, AbbVie received approval from the FDA for ORIAHNN for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. FDA approval for ORIAHNN for uterine fibroids resulted in the achievement of a $30.0&#160;million regulatory milestone, which was recognized as collaboration revenue in the second quarter of 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since inception of the agreement, we have recognized revenue of $75.0&#160;million associated with the delivery of a technology license and existing know-how and $165.0&#160;million associated with the achievement of certain development and regulatory milestones. Pursuant to the terms of the agreement, we may also be entitled to receive additional payments of up to $366.0&#160;million upon the achievement of certain development, regulatory and commercial milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, AbbVie is responsible for all third-party development, marketing, and commercialization costs. We will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights. AbbVie may terminate the collaboration at its discretion upon 180 days&#x2019; written notice to us.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <nbix:UpfrontPaymentsMade
      contextRef="i1bc3cf10ca8443d19bf1d4cf81b112be_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzMyMTgzMw_eea5d7f4-f32e-4ec9-adf4-244efaa8b58a"
      unitRef="usd">120000000.0</nbix:UpfrontPaymentsMade>
    <nbix:PotentialMilestonePayments
      contextRef="i0fd2fda8589244c78b0b293642285e18_I20200930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzMyMjA3OQ_6c388c09-c6b7-444a-9ea7-804df82fc2da"
      unitRef="usd">1900000000</nbix:PotentialMilestonePayments>
    <nbix:UpfrontPaymentsMade
      contextRef="id529934387f148b18fa1109106ad5a55_I20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzMzODQ4OQ_57c7e817-4cd3-436a-a5c9-4428b0f54945"
      unitRef="usd">45000000.0</nbix:UpfrontPaymentsMade>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="id529934387f148b18fa1109106ad5a55_I20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzMzODY0OQ_654ef9ed-f15b-4dfa-8a62-ab4661fc6666"
      unitRef="usd">7200000</us-gaap:PrepaidExpenseAndOtherAssets>
    <nbix:ResearchCollaborationTerm
      contextRef="iabd2ce28d6694a2486d931e1479cf385_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjc0ODc3OTE3NjkxNg_0f460622-10f3-4801-85f2-797fba76c4b5">P2Y</nbix:ResearchCollaborationTerm>
    <nbix:PotentialMilestonePayments
      contextRef="i05e0789a004a4bb0b0b9943498ed0bde_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzMzODkyOQ_424265b1-5e6e-4c06-8cd1-02ba33d0219c"
      unitRef="usd">365000000.0</nbix:PotentialMilestonePayments>
    <nbix:PotentialMilestonePayments
      contextRef="i2c7cce679a364cb494b726cf6f83dd4f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzMzODk3MA_1adfd72a-ce16-4243-81fc-e2aa2a3caf33"
      unitRef="usd">620000000.0</nbix:PotentialMilestonePayments>
    <nbix:PotentialCommercialMilestonePayments
      contextRef="i1f38dd2e87214e4e86b4617f5f7a47c9_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzMzOTA4OQ_17caf7c7-f2dd-432e-a0b3-f576bdb2fac5"
      unitRef="usd">750000000.0</nbix:PotentialCommercialMilestonePayments>
    <nbix:TerminationNoticePeriod
      contextRef="iabd2ce28d6694a2486d931e1479cf385_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzMzOTUwNQ_6002b933-8043-4e08-89ff-1e9af146b33e">P90D</nbix:TerminationNoticePeriod>
    <nbix:TerminationNoticePeriod
      contextRef="iabd2ce28d6694a2486d931e1479cf385_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzMzOTYzOQ_f4a56746-afca-47d1-8710-40503c6239eb">P90D</nbix:TerminationNoticePeriod>
    <nbix:TerminationNoticePeriod
      contextRef="if408f3cef84a459fb036f2dae9a47b78_D20191201-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM0NzA4Mw_33eca6cd-db87-471a-b3ce-80de24d9a86f">P90D</nbix:TerminationNoticePeriod>
    <nbix:TerminationNoticePeriodBeforeFirstCommercialSale
      contextRef="ied735b11fcf841da816bf129e0782ef6_D20190601-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM1MzcyOA_eabbfee3-6867-4dfb-8814-6ad1522f7d62">P180D</nbix:TerminationNoticePeriodBeforeFirstCommercialSale>
    <nbix:TerminationNoticePeriodAfterFirstCommercialSale
      contextRef="ied735b11fcf841da816bf129e0782ef6_D20190601-20190630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM1MzgzMQ_811683b8-8099-4b08-bedf-4dd1bf1301ed">P1Y</nbix:TerminationNoticePeriodAfterFirstCommercialSale>
    <nbix:MilestonePayment
      contextRef="ie59f33ba48b64fbf878b1b0bb32cd3bf_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM1NzY4Nw_253d4ef1-d531-4a28-86cc-ef5653b07ffd"
      unitRef="usd">20000000.0</nbix:MilestonePayment>
    <nbix:PotentialCommercialMilestonePayments
      contextRef="i43207eb5afba4545a651896bc4052742_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM1NzgzMg_3753232a-9b40-4852-84df-41edb3fc4cff"
      unitRef="usd">75000000.0</nbix:PotentialCommercialMilestonePayments>
    <nbix:MinimumSalesRequirementPeriodThresholdToTerminateAgreement
      contextRef="ic154a10198a440abaa45ffe2168bfe4b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM1OTQ5OQ_d248127f-f1d9-433b-aa15-4ddf74b85143">P2Y</nbix:MinimumSalesRequirementPeriodThresholdToTerminateAgreement>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i8e46865cecac4d2e9ae909b186261e3c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMTE0NDY_d4b46f3e-a89e-4e54-b3c8-2e6d6d2bc86f"
      unitRef="usd">500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i4ee32bf37a3e4fba90e0c87db9c24cfe_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMTY0OTI2NzQ4MjA3NQ_ee48a710-a604-405d-b852-013268f03769"
      unitRef="usd">1800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="if3af452bac274c8e8d92baa671e21fba_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMTE2NjA_6dfd1d67-2584-4396-ae4d-e9d36c878f55"
      unitRef="usd">7600000</us-gaap:ContractWithCustomerLiability>
    <nbix:UpfrontPaymentsReceived
      contextRef="i81d37dbacd1842e99e2686ec8fd6dbba_D20150301-20150331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMTE2NzA_babb8760-3ff9-4aeb-b720-b7a8f3d964d9"
      unitRef="usd">30000000.0</nbix:UpfrontPaymentsReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66b2b24b15f44827a87d688b20158136_D20150301-20170630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMTE5OTk_e6a504a0-4490-4cac-b994-9f2d2fa5c552"
      unitRef="usd">19800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad9db265321c411f9f43fa242382852e_D20170701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMTIwNzg_3a75843f-0a44-427e-add7-4337ee147042"
      unitRef="usd">15000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i78ce841bcaf4462aa4b7ca2f1059a21d_D20191001-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMTIxNTQ_a48d5065-0d39-4816-bf10-a17854393536"
      unitRef="usd">2600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <nbix:PotentialMilestonePaymentReceipts
      contextRef="if3af452bac274c8e8d92baa671e21fba_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMTIzMTQ_9de8dec9-686e-4ed5-bbfa-0647930427c8"
      unitRef="usd">70000000.0</nbix:PotentialMilestonePaymentReceipts>
    <nbix:PatentTerm
      contextRef="icc967843177445f2a9bb563c19ee7472_D20150301-20150331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMTI4NDk_0ceff35c-14af-4daf-a304-931d8e1475c8">P10Y</nbix:PatentTerm>
    <nbix:TerminationNoticePeriod
      contextRef="i81d37dbacd1842e99e2686ec8fd6dbba_D20150301-20150331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMTM0NDE_b289260e-72a1-4279-81c9-a94bd7072746">P180D</nbix:TerminationNoticePeriod>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic92441dd53a14a03a31909df31c4a184_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM2MjAyNQ_a78767d3-950d-4a6a-8d0a-67d4c363f72e"
      unitRef="usd">30000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c4ebb0a6f1f49b0a4d3e6a407449d98_D20100601-20100630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM2MjE5Mw_78297ed2-8386-4f40-afe5-804313586bfa"
      unitRef="usd">75000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45766b13b1314f7181ad53c4c44d2508_D20100701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM2MjI3Ng_309bf281-5fad-4630-ace2-1ff784ecee26"
      unitRef="usd">165000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <nbix:PotentialMilestonePaymentReceipts
      contextRef="i5ea18c769a47425d951bc4f1d6cdec54_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM2MjQ1NQ_4b4629b2-3834-415d-a447-9bfab7bef8a8"
      unitRef="usd">366000000.0</nbix:PotentialMilestonePaymentReceipts>
    <nbix:PatentTerm
      contextRef="if00ff3fffef04ee986b1a2c2119dfc0b_D20100601-20100630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM2Mjc2Mg_e710029a-8beb-4b8c-bd69-727f47991fc4">P10Y</nbix:PatentTerm>
    <nbix:TerminationNoticePeriod
      contextRef="i3c4ebb0a6f1f49b0a4d3e6a407449d98_D20100601-20100630"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNC9mcmFnOjg2YzI0Zjc1NDMxNTRmNzY5MzA4YTIzOTQyMTU5M2MzL3RleHRyZWdpb246ODZjMjRmNzU0MzE1NGY3NjkzMDhhMjM5NDIxNTkzYzNfMjE5OTAyMzM2Mjg3MA_bfe3b652-1ec2-4917-95c3-e94830533bfa">P180D</nbix:TerminationNoticePeriod>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RleHRyZWdpb246OTUzMmIxNTM2YzI4NGJhOWIyNzU0ODE4YzBlMWM2OTVfMTU1NQ_1ecebf7d-0deb-4e5f-8ab2-6b804df89636">Debt Securities&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss), allowance for credit losses, and fair value of debt securities available-for-sale at September&#160;30, 2020, aggregated by major security type and contractual maturity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;129.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;517.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;519.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;180.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;181.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income, and fair value of debt securities available-for-sale at December&#160;31, 2019, aggregated by major security type and contractual maturity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;557.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;558.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes debt securities available-for-sale in an unrealized loss position for which an allowance for credit losses has not been recorded at September&#160;30, 2020, aggregated by major security type and length of time in a continuous unrealized loss position:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;At September&#160;30, 2020, our security portfolio consisted of 143 securities related to investments in debt securities available-for-sale, of which 14 securities were in an unrealized loss position.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investments in corporate debt securities in an unrealized loss position at September&#160;30, 2020 are of high credit quality (rated A- or higher). Unrealized losses on these investments were primarily due to changes in interest rates. We do not intend &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes debt securities available-for-sale in an unrealized loss position at December&#160;31, 2019, aggregated by major security type and length of time in a continuous unrealized loss position:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RleHRyZWdpb246OTUzMmIxNTM2YzI4NGJhOWIyNzU0ODE4YzBlMWM2OTVfMTU1MQ_fd5ff4ed-d0ec-435d-81f4-56b81c05e1f8">&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss), allowance for credit losses, and fair value of debt securities available-for-sale at September&#160;30, 2020, aggregated by major security type and contractual maturity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;283.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;129.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;517.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;519.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;180.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;181.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income, and fair value of debt securities available-for-sale at December&#160;31, 2019, aggregated by major security type and contractual maturity:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.453%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.655%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;557.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;558.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i17e8669ff7be4a52b5af69d877498dc5_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMS01LTEtMS0w_715b5c23-1d24-43ab-b96b-a69f6006246f"
      unitRef="usd">104800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i17e8669ff7be4a52b5af69d877498dc5_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMS03LTEtMS0w_134726c0-afef-4be7-83e7-fcf9471fbf65"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i17e8669ff7be4a52b5af69d877498dc5_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMS05LTEtMS0w_c4c9854b-d57d-448b-8093-3656f54118a7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i17e8669ff7be4a52b5af69d877498dc5_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMS0xMS0xLTEtMA_a5c16880-8f32-4b81-bf36-28b91091773b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i17e8669ff7be4a52b5af69d877498dc5_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMS0xMy0xLTEtMA_8b645843-3f6b-4510-8423-037d4890d7ca"
      unitRef="usd">104800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i20a97471294c419191a3a2888e675b4b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMi01LTEtMS0w_500af600-755a-4dcd-a20a-fe2bedcfbaf2"
      unitRef="usd">283600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i20a97471294c419191a3a2888e675b4b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMi03LTEtMS0w_27953443-71cc-41fa-ab8a-54d6fc6d18cf"
      unitRef="usd">1700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i20a97471294c419191a3a2888e675b4b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMi05LTEtMS0w_3a63e7c2-13cb-4d43-af5b-1dfb6a426fab"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i20a97471294c419191a3a2888e675b4b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMi0xMS0xLTEtMA_b771aa8f-b0c1-460a-a9c6-9b8cade2b429"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i20a97471294c419191a3a2888e675b4b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMi0xMy0xLTEtMA_6063af9f-b78b-4667-aab9-37028dfb3c46"
      unitRef="usd">285300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5a39b454de5141cea8123d360608a3c6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMy01LTEtMS0w_a7ada17a-835a-4775-9a80-3d1ee158209d"
      unitRef="usd">128900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5a39b454de5141cea8123d360608a3c6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMy03LTEtMS0w_f31fed84-cf65-47cc-99a4-26935384395a"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5a39b454de5141cea8123d360608a3c6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMy05LTEtMS0w_b53cc60b-9a8d-4a4d-8ecd-82fb8ab3529b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i5a39b454de5141cea8123d360608a3c6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMy0xMS0xLTEtMA_2c2e489b-ccb5-4022-9b40-7b80ff207ef6"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5a39b454de5141cea8123d360608a3c6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfMy0xMy0xLTEtMA_dae8b98d-8651-429e-ac8b-21d0885e788a"
      unitRef="usd">129300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i57f46c4cf6f1473794e3e0ebadd216a7_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNC01LTEtMS0w_7247b66c-eb4e-4e46-8778-eca3d1e0bf86"
      unitRef="usd">517300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i57f46c4cf6f1473794e3e0ebadd216a7_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNC03LTEtMS0w_711bba76-c33a-468c-a1e0-d0da98771a29"
      unitRef="usd">2100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i57f46c4cf6f1473794e3e0ebadd216a7_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNC05LTEtMS0w_83313ac2-f58b-46c7-b8d8-a91dd90f14ed"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i57f46c4cf6f1473794e3e0ebadd216a7_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNC0xMS0xLTEtMA_a15fee8c-0ae0-484e-a436-7b83b540f0e9"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i57f46c4cf6f1473794e3e0ebadd216a7_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNC0xMy0xLTEtMA_bef0601c-e0ef-4aa3-8324-7e5510012b8b"
      unitRef="usd">519400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5839adaf15cb411e85d5303f2631e97d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNi01LTEtMS0w_d4b59a1c-15fc-465d-855d-c46226af1ad9"
      unitRef="usd">142800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5839adaf15cb411e85d5303f2631e97d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNi03LTEtMS0w_f29291bf-8cc9-49a2-9445-79cbf862b2fe"
      unitRef="usd">1200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5839adaf15cb411e85d5303f2631e97d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNi05LTEtMS0w_c6b143dc-e244-485c-a129-1049e7aa6ee7"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i5839adaf15cb411e85d5303f2631e97d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNi0xMS0xLTEtMA_b9fac117-609b-451e-8a97-7e381aed1ad4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5839adaf15cb411e85d5303f2631e97d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNi0xMy0xLTEtMA_a620bad9-4b47-42ec-9bb2-f361bac6acdc"
      unitRef="usd">143900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1afe9cac6b0a42a5b77948695251abfb_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNy01LTEtMS0w_79e4c48c-2adf-4ebb-afc1-42d4a38b61d5"
      unitRef="usd">37500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1afe9cac6b0a42a5b77948695251abfb_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNy03LTEtMS0w_fb5d8371-5171-48a7-845c-58c6182f36cc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1afe9cac6b0a42a5b77948695251abfb_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNy05LTEtMS0w_6a6748bc-3e6a-40e8-8e75-56b73465ab64"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i1afe9cac6b0a42a5b77948695251abfb_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNy0xMS0xLTEtMA_7d74fe0e-a866-4708-b00c-39da80aeedb4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1afe9cac6b0a42a5b77948695251abfb_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfNy0xMy0xLTEtMA_f61f577c-f062-4581-9f60-2136c8679e25"
      unitRef="usd">37500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i11b4128b861b49e2a5858306369cb09d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfOC01LTEtMS0w_52fc9186-32f6-4f4d-aa23-b363c64c7c53"
      unitRef="usd">180300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i11b4128b861b49e2a5858306369cb09d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfOC03LTEtMS0w_cac9f77a-dce7-4b43-8e1d-ee0720197df3"
      unitRef="usd">1200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i11b4128b861b49e2a5858306369cb09d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfOC05LTEtMS0w_49de1dd0-eb2b-4e73-8f34-13ebe7299465"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i11b4128b861b49e2a5858306369cb09d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfOC0xMS0xLTEtMA_6cb100ca-4af7-4ff9-8e4f-5d36b4208e3c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i11b4128b861b49e2a5858306369cb09d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjlmY2NiZTlmYWEzMTQwMTk5ZjQ3MTAxYTE5MGYxMTZmL3RhYmxlcmFuZ2U6OWZjY2JlOWZhYTMxNDAxOTlmNDcxMDFhMTkwZjExNmZfOC0xMy0xLTEtMA_8b2caffa-6a6a-43a3-8df7-8a43f4660bd3"
      unitRef="usd">181400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4cf4cd2db9454c90a62e4deb58db04b8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMS01LTEtMS0w_90080abc-fa82-4175-9b5b-22dba45140d5"
      unitRef="usd">144500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4cf4cd2db9454c90a62e4deb58db04b8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMS03LTEtMS0w_d6029e55-2706-4e0e-8871-29e5b9400d6c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4cf4cd2db9454c90a62e4deb58db04b8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMS05LTEtMS0w_73e7e6ae-a655-4a4a-afbc-f2aa841dc046"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4cf4cd2db9454c90a62e4deb58db04b8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMS0xMS0xLTEtMA_28b5111a-f159-4902-b2a5-edac9e6227f0"
      unitRef="usd">144500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i874e4b9552c648458ec045b9740fcc7c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMi01LTEtMS0w_76f5361e-37c7-422f-b4ae-d336463834f6"
      unitRef="usd">270500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i874e4b9552c648458ec045b9740fcc7c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMi03LTEtMS0w_5a4601e4-2616-41a3-b263-b645a86a67e0"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i874e4b9552c648458ec045b9740fcc7c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMi05LTEtMS0w_f0d5f883-fcd6-4b15-a997-a627f61e0d16"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i874e4b9552c648458ec045b9740fcc7c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMi0xMS0xLTEtMA_74412118-f018-424f-8c5c-0ab1cc71daf6"
      unitRef="usd">271000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib471b42e9f1046758a5cc3d418a9adea_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMy01LTEtMS0w_975c7654-90f4-40a6-ae64-b39406f77ccc"
      unitRef="usd">142300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib471b42e9f1046758a5cc3d418a9adea_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMy03LTEtMS0w_55e8b3fa-aeb1-4308-9920-f1380562ff2d"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib471b42e9f1046758a5cc3d418a9adea_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMy05LTEtMS0w_ecaa18a2-9cbf-4702-92c6-88b77e8e09be"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib471b42e9f1046758a5cc3d418a9adea_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfMy0xMS0xLTEtMA_4b42fd2b-1ce5-4f8a-b193-78f809b7a298"
      unitRef="usd">142700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if06c15e28fd64cffadb8a9783937f723_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNC01LTEtMS0w_45b56736-cdd0-4560-841f-3d3720ad1d67"
      unitRef="usd">557300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if06c15e28fd64cffadb8a9783937f723_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNC03LTEtMS0w_4bfbe917-980b-4fd3-aba4-b476919a9d2b"
      unitRef="usd">900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if06c15e28fd64cffadb8a9783937f723_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNC05LTEtMS0w_214ea419-ceaa-4c07-85ef-8f46ccba2c21"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if06c15e28fd64cffadb8a9783937f723_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNC0xMS0xLTEtMA_5ed37a06-b526-4bb5-bf09-db780cf7b01d"
      unitRef="usd">558200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="idd9a4794daba4b7cad0104baa5442100_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNi01LTEtMS0w_ad30b58e-2957-4622-aa5e-b7e806a9ef9e"
      unitRef="usd">250500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idd9a4794daba4b7cad0104baa5442100_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNi03LTEtMS0w_2a30b758-cf4c-4105-84d1-8c1b3f6ddb4d"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idd9a4794daba4b7cad0104baa5442100_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNi05LTEtMS0w_6cbd8da8-b706-48c3-8b4d-6b45d590b5d7"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idd9a4794daba4b7cad0104baa5442100_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNi0xMS0xLTEtMA_121f48c6-d72e-4ad9-bc39-1aa93a8faaf4"
      unitRef="usd">250900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i39d07970489d4ae1a26d531d4e995b63_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNy01LTEtMS0w_996f9cb6-e9a0-4a9b-8182-6284abadb665"
      unitRef="usd">48800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i39d07970489d4ae1a26d531d4e995b63_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNy03LTEtMS0w_8c649346-ea46-4edb-9774-be8ca6f5a0a5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i39d07970489d4ae1a26d531d4e995b63_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNy05LTEtMS0w_95a5e084-9ce0-4da4-9493-e19c2d9a67b5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i39d07970489d4ae1a26d531d4e995b63_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfNy0xMS0xLTEtMA_2fd9c707-ea71-4da0-a435-4a80825e42ce"
      unitRef="usd">48800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4eee421ab3034f1daf75320fc8835187_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfOC01LTEtMS0w_f642c496-4a30-4980-9c07-b191b635fda8"
      unitRef="usd">299300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4eee421ab3034f1daf75320fc8835187_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfOC03LTEtMS0w_a1389632-8884-4532-a09e-af55c5f06b74"
      unitRef="usd">500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4eee421ab3034f1daf75320fc8835187_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfOC05LTEtMS0w_6541da4e-26bd-45c3-9bdf-31957a283ef6"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4eee421ab3034f1daf75320fc8835187_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjkwZWYzNDUxMzYxNjRlODE5ODExZGZjN2IzNDhhMWM3L3RhYmxlcmFuZ2U6OTBlZjM0NTEzNjE2NGU4MTk4MTFkZmM3YjM0OGExYzdfOC0xMS0xLTEtMA_fea48734-983e-4bb3-8932-7d7f85949013"
      unitRef="usd">299700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RleHRyZWdpb246OTUzMmIxNTM2YzI4NGJhOWIyNzU0ODE4YzBlMWM2OTVfMTY0OTI2NzQ0MzczMQ_d0b9a769-61f6-4f3c-8e61-5ebabf220568">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes debt securities available-for-sale in an unrealized loss position for which an allowance for credit losses has not been recorded at September&#160;30, 2020, aggregated by major security type and length of time in a continuous unrealized loss position:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate Debt Securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes debt securities available-for-sale in an unrealized loss position at December&#160;31, 2019, aggregated by major security type and length of time in a continuous unrealized loss position:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less Than 12 Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 Months or Longer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i89d87039af9d4dc6bd52a3bb4c9ebf21_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjQxNjZmZWQ1MDMzODRhYWE4MjBiYTQ1YTVmYmIzZWVkL3RhYmxlcmFuZ2U6NDE2NmZlZDUwMzM4NGFhYTgyMGJhNDVhNWZiYjNlZWRfMy0xLTEtMS0xNjk_8bbe09c9-abdf-4b1d-9743-2febe11dec0b"
      unitRef="usd">39800000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i89d87039af9d4dc6bd52a3bb4c9ebf21_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjQxNjZmZWQ1MDMzODRhYWE4MjBiYTQ1YTVmYmIzZWVkL3RhYmxlcmFuZ2U6NDE2NmZlZDUwMzM4NGFhYTgyMGJhNDVhNWZiYjNlZWRfMy0zLTEtMS0xNzM_cb516565-f0c4-4d06-8da9-0816c5801d25"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i89d87039af9d4dc6bd52a3bb4c9ebf21_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjQxNjZmZWQ1MDMzODRhYWE4MjBiYTQ1YTVmYmIzZWVkL3RhYmxlcmFuZ2U6NDE2NmZlZDUwMzM4NGFhYTgyMGJhNDVhNWZiYjNlZWRfMy01LTEtMS0xNzM_40e6fc5b-3141-4620-842c-915868be3d5a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i89d87039af9d4dc6bd52a3bb4c9ebf21_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjQxNjZmZWQ1MDMzODRhYWE4MjBiYTQ1YTVmYmIzZWVkL3RhYmxlcmFuZ2U6NDE2NmZlZDUwMzM4NGFhYTgyMGJhNDVhNWZiYjNlZWRfMy03LTEtMS0xNzM_9dbc5db1-f43b-4929-ae34-f5ddf2aef386"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i89d87039af9d4dc6bd52a3bb4c9ebf21_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjQxNjZmZWQ1MDMzODRhYWE4MjBiYTQ1YTVmYmIzZWVkL3RhYmxlcmFuZ2U6NDE2NmZlZDUwMzM4NGFhYTgyMGJhNDVhNWZiYjNlZWRfMy05LTEtMS0xNzM_c6f4cc9a-f6f8-4da3-976f-e7b283440941"
      unitRef="usd">39800000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i89d87039af9d4dc6bd52a3bb4c9ebf21_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOjQxNjZmZWQ1MDMzODRhYWE4MjBiYTQ1YTVmYmIzZWVkL3RhYmxlcmFuZ2U6NDE2NmZlZDUwMzM4NGFhYTgyMGJhNDVhNWZiYjNlZWRfMy0xMS0xLTEtMTcz_2518c997-9243-410e-aae4-88e67dfcc865"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RleHRyZWdpb246OTUzMmIxNTM2YzI4NGJhOWIyNzU0ODE4YzBlMWM2OTVfNzY1_1fb5bf61-7ac3-4a92-9a24-09e0048cc328"
      unitRef="security">143</nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RleHRyZWdpb246OTUzMmIxNTM2YzI4NGJhOWIyNzU0ODE4YzBlMWM2OTVfODUw_92304155-5b7a-467e-8480-e65aa3d37a07"
      unitRef="security">14</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ia63ae906e9934f57874ae4728dd57afa_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOmFhZTQ5MzdmOWNhZjQ0OTc5NGY2ZGFkNmExOWY3ZGM4L3RhYmxlcmFuZ2U6YWFlNDkzN2Y5Y2FmNDQ5Nzk0ZjZkYWQ2YTE5ZjdkYzhfMi0xLTEtMS0w_5da45b07-3777-4da5-a1e1-563e5052a9c3"
      unitRef="usd">186100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ia63ae906e9934f57874ae4728dd57afa_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOmFhZTQ5MzdmOWNhZjQ0OTc5NGY2ZGFkNmExOWY3ZGM4L3RhYmxlcmFuZ2U6YWFlNDkzN2Y5Y2FmNDQ5Nzk0ZjZkYWQ2YTE5ZjdkYzhfMi0zLTEtMS0w_27eb338f-0311-4be2-aeb5-89e2a8536a16"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ia63ae906e9934f57874ae4728dd57afa_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOmFhZTQ5MzdmOWNhZjQ0OTc5NGY2ZGFkNmExOWY3ZGM4L3RhYmxlcmFuZ2U6YWFlNDkzN2Y5Y2FmNDQ5Nzk0ZjZkYWQ2YTE5ZjdkYzhfMi01LTEtMS0w_b8366c26-8f2d-42c4-9da0-88c1aabda0fb"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ia63ae906e9934f57874ae4728dd57afa_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOmFhZTQ5MzdmOWNhZjQ0OTc5NGY2ZGFkNmExOWY3ZGM4L3RhYmxlcmFuZ2U6YWFlNDkzN2Y5Y2FmNDQ5Nzk0ZjZkYWQ2YTE5ZjdkYzhfMi03LTEtMS0w_77e48d4f-fa94-45d5-97aa-874699e8f6dd"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ia63ae906e9934f57874ae4728dd57afa_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOmFhZTQ5MzdmOWNhZjQ0OTc5NGY2ZGFkNmExOWY3ZGM4L3RhYmxlcmFuZ2U6YWFlNDkzN2Y5Y2FmNDQ5Nzk0ZjZkYWQ2YTE5ZjdkYzhfMi05LTEtMS0w_2f448367-5d43-45b0-986b-c8d4f610b104"
      unitRef="usd">186100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ia63ae906e9934f57874ae4728dd57afa_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl8zNy9mcmFnOjk1MzJiMTUzNmMyODRiYTliMjc1NDgxOGMwZTFjNjk1L3RhYmxlOmFhZTQ5MzdmOWNhZjQ0OTc5NGY2ZGFkNmExOWY3ZGM4L3RhYmxlcmFuZ2U6YWFlNDkzN2Y5Y2FmNDQ5Nzk0ZjZkYWQ2YTE5ZjdkYzhfMi0xMS0xLTEtMA_a37fc91f-fb83-4100-acb9-6050f98bb506"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RleHRyZWdpb246NjdkZDEyODkyZGI0NDc4ZDkzMTQwMjI2YjJkZjc0YWJfOTI0_f57b3f86-2080-4c1d-9315-e5cbce5edaa8">Fair Value Measurements&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments at September&#160;30, 2020, which were measured at fair value on a recurring basis, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&#x2013;biotechnology industry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total recurring fair value measurements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,173.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;428.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments at December&#160;31, 2019, which were measured at fair value on a recurring basis, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;521.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;521.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;857.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;857.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&#x2013;biotechnology industry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total recurring fair value measurements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,029.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;857.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of equity security investments, which were  measured at fair value on a recurring basis using significant unobservable inputs (Level 3):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized loss included in earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;At September&#160;30, 2020, the discount for lack of marketability used in the valuation analysis of equity securities ranged from 16.0% to 31.5% (weighted average of 26.8%). The discount for lack of marketability was weighted by the relative fair value of the instruments. A significant increase (decrease) in the discount for lack of marketability in isolation would result in a significantly lower (higher) fair value measurement. Unrealized gains and losses on equity securities are included in other income (expense), net.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RleHRyZWdpb246NjdkZDEyODkyZGI0NDc4ZDkzMTQwMjI2YjJkZjc0YWJfOTI1_72e3b287-b428-46a4-af05-c21b454e585f">&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments at September&#160;30, 2020, which were measured at fair value on a recurring basis, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&#x2013;biotechnology industry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total recurring fair value measurements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,173.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;428.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments at December&#160;31, 2019, which were measured at fair value on a recurring basis, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;521.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;521.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities of government-sponsored entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;857.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;857.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&#x2013;biotechnology industry&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total recurring fair value measurements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,029.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;857.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:Investments
      contextRef="id38c7267b80a405180f7b4356f67da8c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMy0xLTEtMS0w_7da5be67-59b5-4c0b-a0f1-09656a75b803"
      unitRef="usd">425300000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibee55973814540e4871f791d8dc70e46_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMy0zLTEtMS0w_854562d5-3ea9-4954-a2ba-571949b669e6"
      unitRef="usd">425300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib426e74a445c45f1a83118960cccbf06_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMy01LTEtMS0w_51167006-cc41-46c6-9075-1b4ffc992c3f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie84a00bf79934f488db237577d55db78_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMy03LTEtMS0w_53b26cad-ccc2-41cd-bf45-2f1e3f844c77"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="iea9d8f3b23ca486497408024718a6b8e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNC0xLTEtMS0w_7ae1aa2e-e5ed-41e9-9dfc-6fad040332b0"
      unitRef="usd">425300000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i65a6bbf5e65a4158a60237d7a4a04db0_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNC0zLTEtMS0w_6d8a3eaf-b6d2-4841-84c0-f01ed0dd5967"
      unitRef="usd">425300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1ec61ef3dcdf4b1aacbd98b013a506b7_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNC01LTEtMS0w_492ca6e8-3255-41a8-ae7f-407abbdb0db2"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibc97788aa86f4300961cef399f992f04_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNC03LTEtMS0w_98b712c7-7072-4093-833e-72989c97b885"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i6c29e9b0363d417bad2a59f28a1c803c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNi0xLTEtMS0w_8513b146-330c-42f6-a173-1e011712b8c4"
      unitRef="usd">3200000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5598a209b61b4400b094160c9896fa48_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNi0zLTEtMS0w_e1daff7a-e5d3-4e48-822c-1179c523631b"
      unitRef="usd">3200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i29381f8c070e44f0842d377f5116a9e2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNi01LTEtMS0w_ca58b9e5-c735-451e-a259-53615223b4a9"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i947a42782e644b31b40e973a6c34e453_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNi03LTEtMS0w_890a284d-eefd-4346-8f36-f6d6b6ef6cbb"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="iee9777017ba44b219d3e743580405ac2_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNy0xLTEtMS0w_915fdde6-3188-4a23-973c-037e58104474"
      unitRef="usd">3200000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib7a75fd9bbac4ee49d0da09da35fb326_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNy0zLTEtMS0w_ff7d169d-d469-48f6-9121-20cca47a7843"
      unitRef="usd">3200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icb30e5a8cedc49c8be9971e52ba47b85_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNy01LTEtMS0w_5180eefd-d001-4e0b-b43e-10eb7b5d9b86"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i760c3e1139cd490996ecb9f7296243b7_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfNy03LTEtMS0w_f303aad7-f4ea-47e0-b55b-f7d7f4003dbe"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i42324c42b21949c28b491aa55a7bfbbb_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfOS0xLTEtMS0w_067842ab-d3fc-427a-9491-e3eb1718c9b8"
      unitRef="usd">104800000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i18fb70203f184d1491ea807cbc815619_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfOS0zLTEtMS0w_543a7ce7-2c85-4a34-8b7b-3325dea86448"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if469c62de0cd4ef3830eba7c5402aaab_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfOS01LTEtMS0w_0b86600a-d8c1-44a2-8cb7-daa4477fe0e9"
      unitRef="usd">104800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i17b0221281ec4463a4179b1554cbcd76_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfOS03LTEtMS0w_de6dc16e-9e5d-4b95-970e-64641a055152"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i89d87039af9d4dc6bd52a3bb4c9ebf21_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTAtMS0xLTEtMA_bccd8ea0-9547-4cbc-a6d2-638d24253663"
      unitRef="usd">429200000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia0025cac95494cda9e9476a6c30b7005_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTAtMy0xLTEtMA_714848b9-cbef-4468-8252-3019dae96b2c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib2709795600e4b4fa0cab1e10d78bb24_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTAtNS0xLTEtMA_47607afe-ebd0-4c51-9f7d-e2fbc15b3392"
      unitRef="usd">429200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6458a3c1f27445708ec1f66fe52e22d1_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTAtNy0xLTEtMA_d8da29aa-3f8f-4a07-8a89-e245bebf80fe"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="if56d9dc3007d41128722f44d864811d6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTEtMS0xLTEtMA_820d1d05-8748-4724-a4d7-c1178f9c3849"
      unitRef="usd">166800000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9756d3e20b3947848211cd89041634fc_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTEtMy0xLTEtMA_b64c4531-f354-4450-8ebb-1fe3ca8dad9d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idc0623eb842b4201884c1c1da60ba35d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTEtNS0xLTEtMA_0d445272-4e01-464d-9be7-d1a13ba19d9b"
      unitRef="usd">166800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifc01e0adf5ed40e9ab710401d911d109_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTEtNy0xLTEtMA_0fa723d6-d7af-4c38-83dc-d30beb0574a7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="idfd9db69bbe949f189e03e61899a8e08_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTItMS0xLTEtMA_181c98f4-2dac-4484-b5bf-325bd58cbe05"
      unitRef="usd">700800000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i97214347d5cd4c00a185bedc120c3fc1_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTItMy0xLTEtMA_6a74e1a0-00e2-4836-aade-9096751eb28d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8d8647d7d7e94a8097f66d3842b61c42_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTItNS0xLTEtMA_96aaef7f-af79-4838-8173-276256bb8780"
      unitRef="usd">700800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i956362b694e94668b36c6160186aa324_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTItNy0xLTEtMA_51950928-5b6c-4a6b-b370-894f963765de"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i3bd0085725324e26a27750e423d72760_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTQtMS0xLTEtMA_43c5e0b6-c3eb-4576-8099-ff4393095004"
      unitRef="usd">43700000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic049401a5b67418d851adeae321ac164_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTQtMy0xLTEtMA_d73426a4-4453-4b1b-a006-6ff702656a7a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8225b8bb50704b84b3bf86c3349c534e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTQtNS0xLTEtMA_9081f0a0-3624-4224-a6b0-6ec8e59860a2"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id219f8da90c541daad4ba23316ba4c2b_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTQtNy0xLTEtMA_657930ef-170e-4509-8af9-c8102812a8a2"
      unitRef="usd">43700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i1d6d32eba9d04110a989008d1fa4f90e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTUtMS0xLTEtMA_201ffefe-5439-4a06-b2fe-b0aff1f590cb"
      unitRef="usd">43700000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i88f522c740114d6180c33b2389f52046_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTUtMy0xLTEtMA_d1052133-8bb0-4852-8650-e6c4ec09e945"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id2f301c2004b4bcabafe4296fb59ec8e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTUtNS0xLTEtMA_21461374-3748-42fe-bf98-fa00b66d166f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1156dc5768584b87af9adf9ad1d62009_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTUtNy0xLTEtMA_35876894-d1a8-4fe9-8ea7-6ab4d2196560"
      unitRef="usd">43700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTYtMS0xLTEtMA_ad2543ad-ce2a-4109-aec0-438fe00815c5"
      unitRef="usd">1173000000.0</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iced281cb3fd145e8913b24a5a0bc1e69_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTYtMy0xLTEtMA_5c4f6175-7a6d-4c82-9d98-2195b702085e"
      unitRef="usd">428500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia410bcb0c63a42d99db1e5658b91727a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTYtNS0xLTEtMA_83d62b7a-e4dc-4e07-9f25-58b22f20af80"
      unitRef="usd">700800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0864c4bbd4b141eb98515b636f8eb88c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmQyN2ZjMGE1YzFiYTQyZGE5Y2UwZTY0NTliMjk0NDQ4L3RhYmxlcmFuZ2U6ZDI3ZmMwYTVjMWJhNDJkYTljZTBlNjQ1OWIyOTQ0NDhfMTYtNy0xLTEtMA_ccb5d5e9-2988-47a9-b69f-d2f9808b8358"
      unitRef="usd">43700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i8c40b36432b0492eb3eae0f8756d0ae1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMy0xLTEtMS0w_a74ebe95-5856-4759-aab8-5ce2972ea25e"
      unitRef="usd">112300000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4f45d9693ffb42a189e35266c2e96545_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMy0zLTEtMS0w_f423352c-1323-45e6-adbe-8d2ab675c19f"
      unitRef="usd">112300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i69670247a1db4f42b3852d733ac9597d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMy01LTEtMS0w_71501cd0-7228-4926-864a-16182822a74c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ica74b071cda746a582b3ab295bc26cff_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMy03LTEtMS0w_aea28025-93b3-44ef-a231-20b7fb322dbe"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i05df2fa389dd4adfa5053ad89459ac4c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNC0xLTEtMS0w_7230ab13-2100-44bc-8d51-1eb2ebadce8b"
      unitRef="usd">112300000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id03b83fda3a5401ea309441030aea98b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNC0zLTEtMS0w_76acf5bc-be27-4bd9-8b8d-5b3670096b31"
      unitRef="usd">112300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i18cbac244f574159aedb1993c131e819_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNC01LTEtMS0w_fed7738c-aaea-40d5-80de-54e51eca3314"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic4783baa5d824c89aae723867da90a4b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNC03LTEtMS0w_c98b1c88-2e6a-4b51-baeb-26157ad778fd"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ic92b89ea55554deea11eb52be454b4ee_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNi0xLTEtMS0w_44df3cff-396a-4ecc-939d-dd1700943c82"
      unitRef="usd">3200000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i59c2ec22479846c8887639d01cec2ac1_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNi0zLTEtMS0w_40ef2691-9ea3-4fad-9266-ddcb1bfe2a26"
      unitRef="usd">3200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i38a85a52092b47eba3e6679338c961b6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNi01LTEtMS0w_cdcef13e-a063-4238-8385-bcce48203d05"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i314a5ccd83a84b54958bcd28fb8db860_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNi03LTEtMS0w_53d6edd2-30f6-482a-98a2-0c090ce506ef"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i4dea7ef570bb4538b6abd0b0f50563ea_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNy0xLTEtMS0w_20a3620f-6ac4-492f-b433-01e4445d15b2"
      unitRef="usd">3200000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2e4a588721b04ed3a8c49e19b0c7d7e2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNy0zLTEtMS0w_53a24b8e-2443-4220-9b9c-c22112c33e19"
      unitRef="usd">3200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie87e6dea946b4fee812d375f72857a05_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNy01LTEtMS0w_b87bfd3e-f8f2-4465-a119-ae8f8011949f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib4257d9e01c5447b8694ff0d39ac4ad4_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfNy03LTEtMS0w_036c154b-5a46-42b8-868c-b51d8faa3fb1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i9fd7f2df19284e068ed3299724415484_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfOS0xLTEtMS0w_aed25413-b388-4bc3-8bad-0a99e8468e05"
      unitRef="usd">144500000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i95be335e9ca1424784a8b065207d5d2c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfOS0zLTEtMS0w_4ef24e3b-9226-4acd-9517-87899602e120"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8978c466f89f48bd919bee1246ba7dc3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfOS01LTEtMS0w_09f8f2f5-f39f-4460-9b20-82dbba1be2ec"
      unitRef="usd">144500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib765b7aaf76a45f5b319d34681ef5aad_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfOS03LTEtMS0w_ce2fb678-baf9-4831-9160-115ff0d95420"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ia63ae906e9934f57874ae4728dd57afa_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTAtMS0xLTEtMA_fe4ab572-96c3-4e09-8340-2423be159b85"
      unitRef="usd">521900000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1168865b09414dd1928d3fb6d2fe8156_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTAtMy0xLTEtMA_fdc42936-9e0f-4f96-a1df-dae918cd1527"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0b5a1372b6934d52bbc0746277c0a30f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTAtNS0xLTEtMA_02e2cb63-2ef7-490d-ba17-55c2dd961a33"
      unitRef="usd">521900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4c444f4feaa2474398f957750041cb1d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTAtNy0xLTEtMA_d6bdc02b-9c1e-4dfd-a8b1-8829b12f1993"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i233e986aada74f71bd2484e81cfad9fa_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTEtMS0xLTEtMA_1b8a6e88-8b2a-4624-9d33-7cc979e2dcd5"
      unitRef="usd">191500000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9640ba89a44d41bfb7a046a01479976d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTEtMy0xLTEtMA_e1e6c54a-6167-4232-8187-54c8da73f79e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idd5b76e3383e44738b173add3da702c6_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTEtNS0xLTEtMA_ae7d0469-6635-4b85-8985-e649484c5572"
      unitRef="usd">191500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ieecb12e2940b487ead1f8d0f74107902_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTEtNy0xLTEtMA_a992be4f-8a56-479a-b271-3a3c8b19e62a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i258c656656094522924117a0e6348166_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTItMS0xLTEtMA_29bfa141-6119-4533-a95b-aa5acf97492c"
      unitRef="usd">857900000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia2f58151776d4b13be04977281fa947d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTItMy0xLTEtMA_59348fb0-ed53-4372-ad81-b1bf45ea926d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifb9d6e37865d45e1b6f401b3e4cdc23d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTItNS0xLTEtMA_50e6a687-75c7-4b07-b3e9-56f0a42aeb23"
      unitRef="usd">857900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4745ddf52c234ed591471f3b27a1ab8b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTItNy0xLTEtMA_65afcf19-b2b9-40f5-8de1-1015be3e2e5b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ib3f9f730b48d44688a63762017a09db2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTQtMS0xLTEtMA_ff825879-bf0a-41c1-8e70-204a061494be"
      unitRef="usd">55900000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic06223c92c5f4dd8a253034a82b987b2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTQtMy0xLTEtMA_e392e230-1c81-4803-9e33-08efbe50e379"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic019c50768b247589e3afba7ef8f7b7f_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTQtNS0xLTEtMA_5ce14b2e-3585-46fe-b7b2-22c78fe53417"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib44d224bf6a0454381c51416f7a36089_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTQtNy0xLTEtMA_fd69a26a-6e81-48ca-98ed-4565b2d0500d"
      unitRef="usd">55900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="ie9fb6311be4848ee9588bffda41c01e0_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTUtMS0xLTEtMA_4875e688-7a06-4a10-ae7b-1d1609749160"
      unitRef="usd">55900000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i11cff9bc4f0243cb87ef4cff58b89ee3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTUtMy0xLTEtMA_d9b1105c-4b66-429f-96f4-650e6a47dd2e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie25967604f04462d8e53ffad9c71948b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTUtNS0xLTEtMA_4c190d41-ee19-4ae2-bc14-510737920a87"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id07323ca55464999892b9d6fb0d0b763_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTUtNy0xLTEtMA_f99969e8-b024-49ab-b6db-425a7809ffd8"
      unitRef="usd">55900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:Investments
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTYtMS0xLTEtMA_61a05e5c-04b5-46b3-8ba5-fef7d02f95a2"
      unitRef="usd">1029300000</us-gaap:Investments>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i685588d754634ef2a7b97a70c6fdabbf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTYtMy0xLTEtMA_c77db0f5-27bc-4fe6-8409-1d8892751149"
      unitRef="usd">115500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if718bd63b45a4840af81b12174f10513_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTYtNS0xLTEtMA_ed58b5ed-cee3-44ce-86bf-aedd30008a28"
      unitRef="usd">857900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4b082681e677454181d88e9e537d5fde_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOmJmNDk0YzdhZjU2YTQ0ZTE5ZmRjOWI5Y2NhZWY3Zjk2L3RhYmxlcmFuZ2U6YmY0OTRjN2FmNTZhNDRlMTlmZGM5YjljY2FlZjdmOTZfMTYtNy0xLTEtMA_3df24040-7fac-4ca3-9734-3519883040dd"
      unitRef="usd">55900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RleHRyZWdpb246NjdkZDEyODkyZGI0NDc4ZDkzMTQwMjI2YjJkZjc0YWJfOTI2_cec62eae-d81d-4ee0-8e1a-9d2e48bb9448">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of equity security investments, which were  measured at fair value on a recurring basis using significant unobservable inputs (Level 3):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized loss included in earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i3a5d39b84bb845bd89918fb5088efac0_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfMi0xLTEtMS0w_b9a93bcc-aca5-4a74-9f8e-56c1a08519d3"
      unitRef="usd">50700000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i6f09b45aebbe45268c2465fc1d568035_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfMi0zLTEtMS0w_db00cc5f-2105-4b7e-9224-abf2a07fc1d1"
      unitRef="usd">77400000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i3f9f6865463c43fd9a44068085061fc5_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfMi01LTEtMS0w_21b155ac-a953-4b1f-8e67-f088c6c6eb7e"
      unitRef="usd">55900000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i83b13e1b031e48228c7b0620b1ebe113_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfMi03LTEtMS0w_abfed893-8f90-407b-89a6-d9ed0ea3ff01"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i6049f25752e8431ba1fbece7b41b3e27_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfMy0xLTEtMS0w_3f357123-eab1-46bd-bc27-d39d3fdd2852"
      unitRef="usd">0</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="ie0b79a1a18384f138069f378bdbe69b4_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfMy0zLTEtMS0w_629c15a4-9e9e-401c-9cda-e1c6d4a81369"
      unitRef="usd">0</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i0548c87128c9494d8cbb70c28471b350_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfMy01LTEtMS0w_84bd5f2a-32b8-4942-abf8-126c15632176"
      unitRef="usd">0</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i1c084bc0f4cb428bbc964d8727a9a1bb_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfMy03LTEtMS0w_5861f86a-ebfd-4e8f-9563-b9ee3d485927"
      unitRef="usd">54700000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i6049f25752e8431ba1fbece7b41b3e27_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfNC0xLTEtMS0w_fdce9c7f-4205-4b15-abea-55b28dc27e7d"
      unitRef="usd">-7000000.0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ie0b79a1a18384f138069f378bdbe69b4_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfNC0zLTEtMS0w_e5a80d2d-76b7-4112-8f31-afa21e3c3b18"
      unitRef="usd">-28500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i0548c87128c9494d8cbb70c28471b350_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfNC01LTEtMS0w_e3f496ee-5ab1-4ed2-ab47-622bd8e381c2"
      unitRef="usd">-12200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i1c084bc0f4cb428bbc964d8727a9a1bb_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfNC03LTEtMS0w_da5fad0a-2b11-4f0d-9496-7a88b063f3f3"
      unitRef="usd">-5800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i0cb6cd0e456d4f4bbd214884933a1f9a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfNS0xLTEtMS0w_87c0c8a0-6b74-440f-a3e7-208cde5a159c"
      unitRef="usd">43700000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i72cdfb757c4d4f1daaf47570c8615274_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfNS0zLTEtMS0w_276fce96-34ba-427d-8fad-46250915931f"
      unitRef="usd">48900000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i0cb6cd0e456d4f4bbd214884933a1f9a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfNS01LTEtMS0w_5363b20d-498b-4436-8a5a-39f2820a56aa"
      unitRef="usd">43700000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiRestricted
      contextRef="i72cdfb757c4d4f1daaf47570c8615274_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RhYmxlOjM4OTc4MmVkMmFlMDRhYmY4YzRmNzczODZiYjhiODQ4L3RhYmxlcmFuZ2U6Mzg5NzgyZWQyYWUwNGFiZjhjNGY3NzM4NmJiOGI4NDhfNS03LTEtMS0w_0b8a296b-6e03-4d24-a2a0-4913a465bfeb"
      unitRef="usd">48900000</us-gaap:EquitySecuritiesFvNiRestricted>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="i0aa63587c87c4b9cab14160d1d2d336a_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RleHRyZWdpb246NjdkZDEyODkyZGI0NDc4ZDkzMTQwMjI2YjJkZjc0YWJfNTM3_482d95cf-3707-4816-a9ae-e32d219af759"
      unitRef="number">0.160</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="icac2aad9c7b14b7c897eaed6bd6f1176_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RleHRyZWdpb246NjdkZDEyODkyZGI0NDc4ZDkzMTQwMjI2YjJkZjc0YWJfNTQz_94aa4c83-40fb-4389-b320-80254308f41b"
      unitRef="number">0.315</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="i9e0a7e787f35452e9cf3c1d60a078e47_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80MC9mcmFnOjY3ZGQxMjg5MmRiNDQ3OGQ5MzE0MDIyNmIyZGY3NGFiL3RleHRyZWdpb246NjdkZDEyODkyZGI0NDc4ZDkzMTQwMjI2YjJkZjc0YWJfNTY3_5a18ecc4-f4f7-49a9-8f09-551ef1d8c357"
      unitRef="number">0.268</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80My9mcmFnOmExMzgwNmNjMDYwNzQ1NzM5NmY2OTdiMTQyYTAxMjlmL3RleHRyZWdpb246YTEzODA2Y2MwNjA3NDU3Mzk2ZjY5N2IxNDJhMDEyOWZfNjE_cd8b9d34-5f05-4983-a350-1f3552c3124c">Inventories&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80My9mcmFnOmExMzgwNmNjMDYwNzQ1NzM5NmY2OTdiMTQyYTAxMjlmL3RleHRyZWdpb246YTEzODA2Y2MwNjA3NDU3Mzk2ZjY5N2IxNDJhMDEyOWZfNjI_8b5c6e65-7a16-4af7-826a-e39602d3fc68">&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80My9mcmFnOmExMzgwNmNjMDYwNzQ1NzM5NmY2OTdiMTQyYTAxMjlmL3RhYmxlOjcyY2FjYTUzZjQ5NTRmZjg5ODkzZWQyMDI4OTNhNjZmL3RhYmxlcmFuZ2U6NzJjYWNhNTNmNDk1NGZmODk4OTNlZDIwMjg5M2E2NmZfMS0xLTEtMS0w_f8496226-5e96-4aeb-8009-e8ad60802851"
      unitRef="usd">14800000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80My9mcmFnOmExMzgwNmNjMDYwNzQ1NzM5NmY2OTdiMTQyYTAxMjlmL3RhYmxlOjcyY2FjYTUzZjQ5NTRmZjg5ODkzZWQyMDI4OTNhNjZmL3RhYmxlcmFuZ2U6NzJjYWNhNTNmNDk1NGZmODk4OTNlZDIwMjg5M2E2NmZfMS0zLTEtMS0w_57456823-9b9e-4d5e-801e-74b4d728a42b"
      unitRef="usd">14100000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80My9mcmFnOmExMzgwNmNjMDYwNzQ1NzM5NmY2OTdiMTQyYTAxMjlmL3RhYmxlOjcyY2FjYTUzZjQ5NTRmZjg5ODkzZWQyMDI4OTNhNjZmL3RhYmxlcmFuZ2U6NzJjYWNhNTNmNDk1NGZmODk4OTNlZDIwMjg5M2E2NmZfMi0xLTEtMS0w_62a9a15e-69ed-418c-a370-7c376e8fb549"
      unitRef="usd">1000000.0</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80My9mcmFnOmExMzgwNmNjMDYwNzQ1NzM5NmY2OTdiMTQyYTAxMjlmL3RhYmxlOjcyY2FjYTUzZjQ5NTRmZjg5ODkzZWQyMDI4OTNhNjZmL3RhYmxlcmFuZ2U6NzJjYWNhNTNmNDk1NGZmODk4OTNlZDIwMjg5M2E2NmZfMi0zLTEtMS0w_3588441e-aa84-49a1-8706-1195e83629bc"
      unitRef="usd">1500000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80My9mcmFnOmExMzgwNmNjMDYwNzQ1NzM5NmY2OTdiMTQyYTAxMjlmL3RhYmxlOjcyY2FjYTUzZjQ5NTRmZjg5ODkzZWQyMDI4OTNhNjZmL3RhYmxlcmFuZ2U6NzJjYWNhNTNmNDk1NGZmODk4OTNlZDIwMjg5M2E2NmZfMy0xLTEtMS0w_bb16a4e7-87a7-47f5-b24f-d20f073b180b"
      unitRef="usd">4800000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80My9mcmFnOmExMzgwNmNjMDYwNzQ1NzM5NmY2OTdiMTQyYTAxMjlmL3RhYmxlOjcyY2FjYTUzZjQ5NTRmZjg5ODkzZWQyMDI4OTNhNjZmL3RhYmxlcmFuZ2U6NzJjYWNhNTNmNDk1NGZmODk4OTNlZDIwMjg5M2E2NmZfMy0zLTEtMS0w_b8568985-d6a0-4794-b864-5d543c325642"
      unitRef="usd">1700000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80My9mcmFnOmExMzgwNmNjMDYwNzQ1NzM5NmY2OTdiMTQyYTAxMjlmL3RhYmxlOjcyY2FjYTUzZjQ5NTRmZjg5ODkzZWQyMDI4OTNhNjZmL3RhYmxlcmFuZ2U6NzJjYWNhNTNmNDk1NGZmODk4OTNlZDIwMjg5M2E2NmZfNC0xLTEtMS0w_d22b98c9-88b7-4467-9fd8-5e893eb433c4"
      unitRef="usd">20600000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80My9mcmFnOmExMzgwNmNjMDYwNzQ1NzM5NmY2OTdiMTQyYTAxMjlmL3RhYmxlOjcyY2FjYTUzZjQ5NTRmZjg5ODkzZWQyMDI4OTNhNjZmL3RhYmxlcmFuZ2U6NzJjYWNhNTNmNDk1NGZmODk4OTNlZDIwMjg5M2E2NmZfNC0zLTEtMS0w_5ea9f7e2-2bcf-45fb-ae0e-1c5b315d0436"
      unitRef="usd">17300000</us-gaap:InventoryNet>
    <nbix:RestrictedCashTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80Ni9mcmFnOjg0ZjllOWYxZDk0MjRiOGZiMzcyMmJhYzcwM2MyMTNjL3RleHRyZWdpb246ODRmOWU5ZjFkOTQyNGI4ZmIzNzIyYmFjNzAzYzIxM2NfMjg1_6b7248d0-a23b-40a9-a453-2ac4de7f3fc6">Restricted Cash&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;428.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbix:RestrictedCashTextBlock>
    <nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80Ni9mcmFnOjg0ZjllOWYxZDk0MjRiOGZiMzcyMmJhYzcwM2MyMTNjL3RleHRyZWdpb246ODRmOWU5ZjFkOTQyNGI4ZmIzNzIyYmFjNzAzYzIxM2NfMjg2_f4bc46b3-20ec-45a3-8f5b-9c99bcfdb250">&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;428.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80Ni9mcmFnOjg0ZjllOWYxZDk0MjRiOGZiMzcyMmJhYzcwM2MyMTNjL3RhYmxlOjNhZDkxZGRhNjYwNzRkZGE5M2UyZjlkNGFjMTJiOWVhL3RhYmxlcmFuZ2U6M2FkOTFkZGE2NjA3NGRkYTkzZTJmOWQ0YWMxMmI5ZWFfMS0xLTEtMS0w_c3a37829-fcc4-4024-a50d-9c51d544bb5e"
      unitRef="usd">425300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80Ni9mcmFnOjg0ZjllOWYxZDk0MjRiOGZiMzcyMmJhYzcwM2MyMTNjL3RhYmxlOjNhZDkxZGRhNjYwNzRkZGE5M2UyZjlkNGFjMTJiOWVhL3RhYmxlcmFuZ2U6M2FkOTFkZGE2NjA3NGRkYTkzZTJmOWQ0YWMxMmI5ZWFfMS0zLTEtMS0w_94738c1a-f93b-4448-8954-90b93f64d714"
      unitRef="usd">112300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80Ni9mcmFnOjg0ZjllOWYxZDk0MjRiOGZiMzcyMmJhYzcwM2MyMTNjL3RhYmxlOjNhZDkxZGRhNjYwNzRkZGE5M2UyZjlkNGFjMTJiOWVhL3RhYmxlcmFuZ2U6M2FkOTFkZGE2NjA3NGRkYTkzZTJmOWQ0YWMxMmI5ZWFfMi0xLTEtMS0w_e77c19e7-de03-4ca1-890a-e6d9a156ee69"
      unitRef="usd">3200000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80Ni9mcmFnOjg0ZjllOWYxZDk0MjRiOGZiMzcyMmJhYzcwM2MyMTNjL3RhYmxlOjNhZDkxZGRhNjYwNzRkZGE5M2UyZjlkNGFjMTJiOWVhL3RhYmxlcmFuZ2U6M2FkOTFkZGE2NjA3NGRkYTkzZTJmOWQ0YWMxMmI5ZWFfMi0zLTEtMS0w_90753e42-6f56-4b88-a3bd-685daae37b49"
      unitRef="usd">3200000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80Ni9mcmFnOjg0ZjllOWYxZDk0MjRiOGZiMzcyMmJhYzcwM2MyMTNjL3RhYmxlOjNhZDkxZGRhNjYwNzRkZGE5M2UyZjlkNGFjMTJiOWVhL3RhYmxlcmFuZ2U6M2FkOTFkZGE2NjA3NGRkYTkzZTJmOWQ0YWMxMmI5ZWFfMy0xLTEtMS0w_e7350778-ea4b-4546-9e89-a55ced368e28"
      unitRef="usd">428500000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80Ni9mcmFnOjg0ZjllOWYxZDk0MjRiOGZiMzcyMmJhYzcwM2MyMTNjL3RhYmxlOjNhZDkxZGRhNjYwNzRkZGE5M2UyZjlkNGFjMTJiOWVhL3RhYmxlcmFuZ2U6M2FkOTFkZGE2NjA3NGRkYTkzZTJmOWQ0YWMxMmI5ZWFfMy0zLTEtMS0w_66353ba3-a165-424a-a3bf-4e7bbece7467"
      unitRef="usd">115500000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfMTMyOA_1f6bd9bf-0348-4a64-9ecc-35bcb0999a4d">Leases&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Address&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Square Feet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commencement Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12780 El Camino Real &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office/Laboratory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 7, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 31, 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12790 El Camino Real, Suite 130 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 31, 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12790 El Camino Real, Suite 150 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 7, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 31, 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12790 El Camino Real, Suite 300 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 31, 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12777 High Bluff Drive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 1, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 31, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12790 El Camino Real, Suite 200 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 31, 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12790 El Camino Real, Suite 100 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 31, 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) Under the terms of the 12780/12790 El Camino Real master lease, we have two options to extend the term of the lease for a period of ten years each. We were not reasonably certain to exercise either of these options at lease commencement. As such, neither option was recognized as part of the associated operating lease right-of-use asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note: In connection with our operating leases, in lieu of cash security deposits, Wells Fargo Bank, N.A., issued letters of credit on our behalf, which are secured by deposits totaling $3.2&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operating lease cost was $7.4 million and $5.9 million for the nine months ended September&#160;30, 2020 and 2019, respectively. Cash paid for amounts in the measurement of lease liabilities for operating cash flows from operating leases was $6.4 million and $5.5 million for the nine months ended September&#160;30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operating leases had a weighted average remaining lease term of approximately 10.5 years and 11.2 years at September&#160;30, 2020 and December&#160;31, 2019, respectively, and a weighted average discount rate of 5.8% at September&#160;30, 2020 and December&#160;31, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximate future minimum lease payments under operating leases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2020 (3 months remaining)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accreted interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note: Amounts presented in the table above exclude $28.3 million of non-cancelable future minimum lease payments for operating leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfMTMyNg_1885cb42-6457-497c-9b32-ffdccd38bd49">&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Address&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Square Feet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commencement Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12780 El Camino Real &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office/Laboratory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 7, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 31, 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12790 El Camino Real, Suite 130 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 31, 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12790 El Camino Real, Suite 150 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 7, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 31, 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12790 El Camino Real, Suite 300 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 31, 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12777 High Bluff Drive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 1, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 31, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12790 El Camino Real, Suite 200 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 31, 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12790 El Camino Real, Suite 100 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 31, 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) Under the terms of the 12780/12790 El Camino Real master lease, we have two options to extend the term of the lease for a period of ten years each. We were not reasonably certain to exercise either of these options at lease commencement. As such, neither option was recognized as part of the associated operating lease right-of-use asset or liability.&lt;/span&gt;&lt;/div&gt;Note: In connection with our operating leases, in lieu of cash security deposits, Wells Fargo Bank, N.A., issued letters of credit on our behalf, which are secured by deposits totaling $3.2&#160;million.</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfMTMzOQ_bebefe96-6856-408a-ba9c-4dcb9204d382">&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Address&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Square Feet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commencement Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12780 El Camino Real &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office/Laboratory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 7, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 31, 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12790 El Camino Real, Suite 130 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 31, 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12790 El Camino Real, Suite 150 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 7, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 31, 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12790 El Camino Real, Suite 300 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 31, 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12777 High Bluff Drive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 1, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 31, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12790 El Camino Real, Suite 200 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 31, 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12790 El Camino Real, Suite 100 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Office&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 31, 2031&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) Under the terms of the 12780/12790 El Camino Real master lease, we have two options to extend the term of the lease for a period of ten years each. We were not reasonably certain to exercise either of these options at lease commencement. As such, neither option was recognized as part of the associated operating lease right-of-use asset or liability.&lt;/span&gt;&lt;/div&gt;Note: In connection with our operating leases, in lieu of cash security deposits, Wells Fargo Bank, N.A., issued letters of credit on our behalf, which are secured by deposits totaling $3.2&#160;million.</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i6cb2fa374db842989cd35f0f03a92fd5_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOjdlZDE4ZWQyNDkyMDQ5NjM5YjBmYzQ3MWJhOGY3ZmM5L3RhYmxlcmFuZ2U6N2VkMThlZDI0OTIwNDk2MzliMGZjNDcxYmE4ZjdmYzlfMS00LTEtMS0w_d069bebe-367f-4ce4-b4dd-1e3ea6f0b007"
      unitRef="sqft">141000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i6b783069862c4a7aa49f88ea6fee4135_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOjdlZDE4ZWQyNDkyMDQ5NjM5YjBmYzQ3MWJhOGY3ZmM5L3RhYmxlcmFuZ2U6N2VkMThlZDI0OTIwNDk2MzliMGZjNDcxYmE4ZjdmYzlfMi00LTEtMS0w_f2dcdc57-2ccf-4b28-88c8-1235e5daa58e"
      unitRef="sqft">2000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i388a89deda29498bb6086f28660869e9_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOjdlZDE4ZWQyNDkyMDQ5NjM5YjBmYzQ3MWJhOGY3ZmM5L3RhYmxlcmFuZ2U6N2VkMThlZDI0OTIwNDk2MzliMGZjNDcxYmE4ZjdmYzlfMy00LTEtMS0w_ae408b94-29a6-4a87-ad32-bc3b1c4b41fa"
      unitRef="sqft">8000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i873fe30d887a4b389617d2698e039940_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOjdlZDE4ZWQyNDkyMDQ5NjM5YjBmYzQ3MWJhOGY3ZmM5L3RhYmxlcmFuZ2U6N2VkMThlZDI0OTIwNDk2MzliMGZjNDcxYmE4ZjdmYzlfNC00LTEtMS0w_f7ac24b9-9909-426c-ab73-18a3ad1448ec"
      unitRef="sqft">28000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i473d326a3edd493a836fb98886d2085a_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOjdlZDE4ZWQyNDkyMDQ5NjM5YjBmYzQ3MWJhOGY3ZmM5L3RhYmxlcmFuZ2U6N2VkMThlZDI0OTIwNDk2MzliMGZjNDcxYmE4ZjdmYzlfNS00LTEtMS0w_a7d32283-e9d1-45f3-aed1-2c7b0a0899dd"
      unitRef="sqft">45000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="idc20284842904d03ab36d24c9fed65c5_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOjdlZDE4ZWQyNDkyMDQ5NjM5YjBmYzQ3MWJhOGY3ZmM5L3RhYmxlcmFuZ2U6N2VkMThlZDI0OTIwNDk2MzliMGZjNDcxYmE4ZjdmYzlfNi00LTEtMS0w_d2d232c2-7fd5-4bac-9f67-e7e1bb0e8890"
      unitRef="sqft">28000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="id19b886ce9774875bcec5de9e1655ca9_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOjdlZDE4ZWQyNDkyMDQ5NjM5YjBmYzQ3MWJhOGY3ZmM5L3RhYmxlcmFuZ2U6N2VkMThlZDI0OTIwNDk2MzliMGZjNDcxYmE4ZjdmYzlfNy00LTEtMS0w_8404c6d2-8aad-44d0-b5fe-b3087e77a2a8"
      unitRef="sqft">17000</us-gaap:AreaOfRealEstateProperty>
    <nbix:NumberOfRenewalOptions
      contextRef="i5dc56b70fae344879faba70a7e60b7f8_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfMTY0_88740f02-0960-4440-873e-14260b35f972"
      unitRef="renewaloption">2</nbix:NumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i5dc56b70fae344879faba70a7e60b7f8_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfMjIz_139d3e57-0cbc-43e1-a949-9e2426016d02">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i132f21d3f9184d5493988e86fd0dc307_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfNjIx_33f0eb60-edd3-4c07-aaa6-be3c61d65186"
      unitRef="usd">3200000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:OperatingLeaseCost
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfNjU1_b11a75b6-28ad-4ec4-8f19-e7469a9a160e"
      unitRef="usd">7400000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfNjYy_e1358b51-3023-4e35-8120-39f25dbc35a3"
      unitRef="usd">5900000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfODI3_76cac8d5-68be-4bc4-978e-78a789798c00"
      unitRef="usd">6400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfODM0_1b495d70-1e28-466e-9ca0-538c4e82de20"
      unitRef="usd">5500000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfOTY4_bf87e45a-c0c6-4fe9-9993-4f80425ef43a">P10Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfOTc1_2402291a-54e5-4e2c-bf05-013c260bd648">P11Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfMTA0Ng_2d8990d5-bb7c-4bd8-b25c-325630ba2396"
      unitRef="number">0.058</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfMTA0Ng_388a2849-3c08-4682-9ffa-29528014dd68"
      unitRef="number">0.058</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfMTMyNw_6a94171b-19d5-4836-8688-24d4ca08aa79">&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximate future minimum lease payments under operating leases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2020 (3 months remaining)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accreted interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note: Amounts presented in the table above exclude $28.3 million of non-cancelable future minimum lease payments for operating leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfMTMzMg_4f09dcce-2ecf-41aa-99f3-b5ac3fe386d8">&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximate future minimum lease payments under operating leases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2020 (3 months remaining)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accreted interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Noncurrent operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt;______________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note: Amounts presented in the table above exclude $28.3 million of non-cancelable future minimum lease payments for operating leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOmEzOTVkNGE3NjJlYTQyMTM5Y2ZjMmNiYmRjMGU1ODY4L3RhYmxlcmFuZ2U6YTM5NWQ0YTc2MmVhNDIxMzljZmMyY2JiZGMwZTU4NjhfMS0xLTEtMS0w_1b827ade-aee3-43f7-b069-3f28172fbfa4"
      unitRef="usd">2100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOmEzOTVkNGE3NjJlYTQyMTM5Y2ZjMmNiYmRjMGU1ODY4L3RhYmxlcmFuZ2U6YTM5NWQ0YTc2MmVhNDIxMzljZmMyY2JiZGMwZTU4NjhfMi0xLTEtMS0w_507c6ce5-0dca-42cf-b901-a42e91275abf"
      unitRef="usd">10600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOmEzOTVkNGE3NjJlYTQyMTM5Y2ZjMmNiYmRjMGU1ODY4L3RhYmxlcmFuZ2U6YTM5NWQ0YTc2MmVhNDIxMzljZmMyY2JiZGMwZTU4NjhfMy0xLTEtMS0w_eff05a5a-fbc9-4e05-8245-f0affba31d3e"
      unitRef="usd">10900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOmEzOTVkNGE3NjJlYTQyMTM5Y2ZjMmNiYmRjMGU1ODY4L3RhYmxlcmFuZ2U6YTM5NWQ0YTc2MmVhNDIxMzljZmMyY2JiZGMwZTU4NjhfNC0xLTEtMS0w_5b63d503-b4ab-483f-bcba-304cd5ad1074"
      unitRef="usd">11200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOmEzOTVkNGE3NjJlYTQyMTM5Y2ZjMmNiYmRjMGU1ODY4L3RhYmxlcmFuZ2U6YTM5NWQ0YTc2MmVhNDIxMzljZmMyY2JiZGMwZTU4NjhfNS0xLTEtMS0w_3cdff458-2c16-4039-a187-86f95a3b449b"
      unitRef="usd">11600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <nbix:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOmEzOTVkNGE3NjJlYTQyMTM5Y2ZjMmNiYmRjMGU1ODY4L3RhYmxlcmFuZ2U6YTM5NWQ0YTc2MmVhNDIxMzljZmMyY2JiZGMwZTU4NjhfNi0xLTEtMS0w_65bb29a3-8da2-44e1-96ca-2d9b6c0c6b9a"
      unitRef="usd">79700000</nbix:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOmEzOTVkNGE3NjJlYTQyMTM5Y2ZjMmNiYmRjMGU1ODY4L3RhYmxlcmFuZ2U6YTM5NWQ0YTc2MmVhNDIxMzljZmMyY2JiZGMwZTU4NjhfNy0xLTEtMS0w_a93250f7-5a2c-4e3d-a011-d92ab31fa053"
      unitRef="usd">126100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOmEzOTVkNGE3NjJlYTQyMTM5Y2ZjMmNiYmRjMGU1ODY4L3RhYmxlcmFuZ2U6YTM5NWQ0YTc2MmVhNDIxMzljZmMyY2JiZGMwZTU4NjhfOC0xLTEtMS0w_fb351fa6-a85e-4e92-bf6f-2254473f4c61"
      unitRef="usd">33400000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOmEzOTVkNGE3NjJlYTQyMTM5Y2ZjMmNiYmRjMGU1ODY4L3RhYmxlcmFuZ2U6YTM5NWQ0YTc2MmVhNDIxMzljZmMyY2JiZGMwZTU4NjhfOS0xLTEtMS0w_1c63118f-3712-4f9c-a899-9b1ff648a2bc"
      unitRef="usd">92700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOmEzOTVkNGE3NjJlYTQyMTM5Y2ZjMmNiYmRjMGU1ODY4L3RhYmxlcmFuZ2U6YTM5NWQ0YTc2MmVhNDIxMzljZmMyY2JiZGMwZTU4NjhfMTAtMS0xLTEtMA_21c09a44-fa23-4ec2-b604-5c4b0c26a35c"
      unitRef="usd">9700000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RhYmxlOmEzOTVkNGE3NjJlYTQyMTM5Y2ZjMmNiYmRjMGU1ODY4L3RhYmxlcmFuZ2U6YTM5NWQ0YTc2MmVhNDIxMzljZmMyY2JiZGMwZTU4NjhfMTEtMS0xLTEtMA_a72f8e54-295c-4321-853f-a92d71eac094"
      unitRef="usd">83000000.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl80OS9mcmFnOjMwODE2N2Y3ZmE5MTQzZTU4N2VjYjM1MGI3YWUyODViL3RleHRyZWdpb246MzA4MTY3ZjdmYTkxNDNlNTg3ZWNiMzUwYjdhZTI4NWJfMTIyNw_f3535727-66e5-4474-8d7d-0435b5504d4a"
      unitRef="usd">28300000</nbix:NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfOTQ0Mw_44f40785-b041-41c1-ae59-e74b22d46f8a">Convertible Senior Notes&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;2, 2017, we completed a private placement of&#160;$517.5 million&#160;in aggregate principal amount of&#160;2.25%&#160;convertible senior notes due 2024 and entered into an indenture agreement, or the 2024 Indenture, with respect to the 2024 Notes. The 2024 Notes accrue interest at a fixed rate of&#160;2.25%&#160;per year, payable semiannually in arrears on May&#160;15 and November&#160;15 of each year, beginning on November&#160;15, 2017. The 2024 Notes mature on May 15, 2024. The net proceeds from the issuance of the 2024 Notes were approximately $502.8 million, after deducting commissions and the offering expenses payable by us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May&#160;15, 2024, only under the following circumstances:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.07pt"&gt;during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least&#160;20&#160;trading days (whether or not consecutive) during a period of&#160;30&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than&#160;130%&#160;of the conversion price on each applicable trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.3pt"&gt;during the&#160;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMTE3Nw_a1999c43-97d5-4934-9864-f07cd2e0e9ca"&gt;five&lt;/span&gt; business-day period immediately after any&#160;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMTIyMg_0e6c4b54-2041-4866-8f9f-60a13836b830"&gt;five&lt;/span&gt;&#160;consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2024 Indenture) per&#160;$1,000&#160;principal amount of the 2024 Notes for each trading day of the measurement period was less than&#160;98%&#160;of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(iii)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.53pt"&gt;upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt;padding-left:22.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(iv)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.07pt"&gt;if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after January&#160;15, 2024, until the close of business on the scheduled trading day immediately preceding May&#160;15, 2024, holders may convert their 2024 Notes at any time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the conditional conversion feature described under (i) above had been triggered as of September 30, 2020, holders of the 2024 Notes may convert the 2024 Notes at any time during the period beginning on October 1, 2020 and ending at the close of business on December 31, 2020. Accordingly, the 2024 Notes have been classified as a current liability as of September 30, 2020. The future conditional convertibility of the 2024 Notes will be monitored at each quarterly reporting date and analyzed dependent upon market prices of our common stock during the prescribed measurement periods.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, holders will receive the principal amount of their 2024 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the&#160;30&#160;consecutive trading days during the observation period (as more fully described in the 2024 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of our common stock or a combination of cash and shares of our common stock, at our option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is our intent and policy to settle conversions through combination settlement, which essentially involves repayment of an amount of cash equal to the &#x201c;principal portion&#x201d; and delivery of the &#x201c;share amount&#x201d; in excess of the principal portion in shares of common stock or cash. In general, for each $1,000 in principal, the &#x201c;principal portion&#x201d; of cash upon settlement is defined as the lesser of $1,000, and the conversion value during the 25-day observation period as described in the 2024 Indenture. The conversion value is the sum of the daily conversion value which is the product of the effective conversion rate divided by 25 days and the daily volume weighted average price, or VWAP, of our common stock. The &#x201c;share amount&#x201d; is the cumulative &#x201c;daily share amount&#x201d; during the observation period, which is calculated by dividing the daily VWAP into the difference between the daily conversion value (i.e., conversion rate x daily VWAP) and $1,000. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial conversion rate for the 2024 Notes is&#160;13.1711&#160;shares of common stock per&#160;$1,000&#160;principal amount, which is equivalent to an initial conversion price of&#160;approximately $75.92&#160;per share of our common stock. At the initial conversion rate, settlement of the 2024 Notes for shares of our common stock would approximate 6.8 million shares. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2024 Notes represented a premium of approximately&#160;42.5%&#160;to the closing sale price of&#160;$53.28&#160;per share of our common stock on the Nasdaq Global Select Market on April&#160;26, 2017, the date that we priced the private offering of the 2024 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2024 Notes will be paid pursuant to the terms of the 2024 Indenture. In the event that all of the 2024 Notes are converted, we would be required to repay the&#160;$517.5&#160;million&#160;in principal value and any conversion premium in any combination of cash and shares of our common stock, at our option.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may not redeem the 2024 Notes prior to May&#160;15, 2021. On or after May&#160;15, 2021, we may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2024 Indenture) of our common stock has been at least&#160;130%&#160;of the conversion price then in effect for at least&#160;20&#160;trading days (whether or not consecutive) during any&#160;30&#160;consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption. The redemption price will equal the sum of (i)&#160;100%&#160;of the principal amount of the 2024 Notes being redeemed, plus (ii)&#160;accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. No sinking fund is provided for the 2024 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If we undergo a fundamental change, as defined in the 2024 Indenture, subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to&#160;100%&#160;of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a &#x2018;&#x2018;make-whole fundamental change&#x2019;&#x2019; (as defined in the 2024 Indenture) occurs prior to January&#160;15, 2024, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with the make-whole fundamental change.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to separately account for the liability and equity components of the 2024 Notes as they may be settled entirely or partially in cash upon conversion in a manner that reflects our economic interest cost. The liability component of the instrument was valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. The initial carrying value of the liability component of $368.3 million&#160;was calculated using a&#160;7.5%&#160;assumed borrowing rate. The equity component of $149.2 million, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2024 Notes and was recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. That equity component is treated as a discount on the liability component of the 2024 Notes, which is amortized over the seven-year term of the 2024 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. At September&#160;30, 2020, the remaining period over which the discount on the liability component will be amortized was approximately 3.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the total transaction costs of approximately&#160;$14.7 million&#160;related to the issuance of the 2024 Notes to the liability and equity components of the 2024 Notes based on their relative values. Transaction costs attributable to the liability &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;component are amortized to interest expense over the&#160;seven-year term of the 2024 Notes, and transaction costs attributable to the equity component are netted with the equity component in stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2024 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default,&#160;100%&#160;of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes, net of discounts and deferred financing costs, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;517.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;517.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt discount, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(86.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(101.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;408.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;The 2024 Notes were recorded at the estimated value of a similar non-convertible instrument on the date of issuance and accretes to the face value of the 2024 Notes over their seven-year term. The fair value of the 2024 Notes, which was estimated utilizing market quotations from an over-the-counter trading market (Level 2), was $713.0 million at September&#160;30, 2020 and $596.8 million at December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfODU_c56dbf7d-56c2-4a43-b97b-8a997efefecf"
      unitRef="usd">517500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMTIx_13bcc69b-4ee9-4c7a-b206-989e7dcac434"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMzA0_869f9a64-9d61-47f9-9176-f6784dd95e7e"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNTIy_8c833f51-2608-45d7-9887-d99c66a5df6a"
      unitRef="usd">502800000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfOTIy_13a4201d-a35c-4647-876a-053ea1cd678c"
      unitRef="d">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfOTg2_55dfaf6b-3666-47c8-a02e-20b686ccc5bd"
      unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMTEwNw_4fbda302-a077-4b0f-951d-a7a23134d48a"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <nbix:PrincipalAmountOnConversionRate
      contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMTM0Nw_bfc0c5cd-aff7-4d12-a1c5-620d434c4e23"
      unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <nbix:MinimumPercentageOfTradingPriceToLastReportedSalePrice
      contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMTQ0Ng_9b832bbb-be6e-469b-8db2-16547973db4f"
      unitRef="number">0.98</nbix:MinimumPercentageOfTradingPriceToLastReportedSalePrice>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMjc2Nw_665b3dc3-774c-4ba4-be05-252ff84ee992"
      unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <nbix:PrincipalAmountOnConversionRate
      contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMzM1MA_deabdd2d-2a7e-4e1d-836a-98ba45ba01b9"
      unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <nbix:PrincipalAmountOnConversionRate
      contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMzQ0Mw_ce18665f-4d39-4105-8418-94d90c85334d"
      unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <nbix:DebtConversionObservationPeriod
      contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMzQ4Mw_90121100-4859-4607-9120-b020a4946ca3">P25D</nbix:DebtConversionObservationPeriod>
    <nbix:DebtConversionObservationPeriod
      contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMzY3Mg_ef6c3b2b-d171-47ef-95b8-536bed64a19a">P25D</nbix:DebtConversionObservationPeriod>
    <nbix:PrincipalAmountOnConversionRate
      contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMzk4Mg_8233bdbc-8794-46c1-8197-e23711daff10"
      unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <nbix:PrincipalAmountOnConversionRate
      contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNDA3Mg_5d5d73ff-1910-4c30-8e08-31b66de1ebad"
      unitRef="usd">1000</nbix:PrincipalAmountOnConversionRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNDE2MQ_0bc3b3ed-b0a7-446d-941c-cf1beba34e05"
      unitRef="usdPerShare">75.92</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNDMwNQ_3232ff32-3013-4198-b34c-b61b7904a2e9"
      unitRef="shares">6800000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <nbix:DebtInstrumentConvertibleConversionPremium
      contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNDUyOQ_3c3eef82-1e76-41f5-bef4-dfda469c4275"
      unitRef="number">0.425</nbix:DebtInstrumentConvertibleConversionPremium>
    <us-gaap:SharePrice
      contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNDU2MQ_88e128f2-5b95-431f-bf1a-5a996aa1926c"
      unitRef="usdPerShare">53.28</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNTA5Ng_6610bdf7-076f-450b-a51b-88602cf7d8c7"
      unitRef="usd">517500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNTQ1OQ_85bded9c-2744-4dea-9fa6-43f407e2920e"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNTUxNA_6981e142-7472-498e-96d8-9602d5f48fcb"
      unitRef="d">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNTU3MA_91f6c034-3742-4e70-b2d6-b1def80e1378"
      unitRef="d">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNTc2MA_8374f0ba-4f5c-4348-9dc4-e267324067da"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNjIxNQ_6f112087-986d-4aba-8819-061808e0e5a4"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <nbix:DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent
      contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNzM0OA_f0a749ca-746a-4f23-a3c0-2f0e2f6d0b26"
      unitRef="usd">368300000</nbix:DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNzM3NA_7faa0455-f030-4ff1-98aa-09d83f54239d"
      unitRef="number">0.075</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfNzQyNQ_b9d5db3c-ae74-4b81-ba84-d930d6fe59ca"
      unitRef="usd">149200000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentTerm
      contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfOTQ0NQ_2603b84b-2b62-4ec9-9588-f5126f2f218f">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i0e4f2c61bb0c4669bf03824d0717d032_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfODA5OA_ed2fef51-f69a-4031-a896-bf613432eab0">P3Y7M6D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i95cb82a96ba143258e37a17f6ad70802_I20170502"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfODE2MA_5c17a3a3-4915-4bc5-a81d-4647fb476b95"
      unitRef="usd">14700000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentTerm
      contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfOTQ0Ng_69a6faa1-4fb6-40d4-8ade-4d96be53c9fe">P7Y</us-gaap:DebtInstrumentTerm>
    <nbix:DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault
      contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfODg4NQ_7673a49e-dd29-4de8-b738-dc480321df34"
      unitRef="number">1</nbix:DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfOTQ0MA_587736fa-f528-4a15-8a09-82ae750ff7f2">&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes, net of discounts and deferred financing costs, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;517.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;517.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt discount, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(86.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(101.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;408.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RhYmxlOjU1ODA2Mzg4ZDE2NzQ3NGZiMWY5YTk3N2IyZjBjMmFiL3RhYmxlcmFuZ2U6NTU4MDYzODhkMTY3NDc0ZmIxZjlhOTc3YjJmMGMyYWJfMS0xLTEtMS0w_dd88be7c-d298-4d85-9f6c-c8e0a1e42ca8"
      unitRef="usd">517500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RhYmxlOjU1ODA2Mzg4ZDE2NzQ3NGZiMWY5YTk3N2IyZjBjMmFiL3RhYmxlcmFuZ2U6NTU4MDYzODhkMTY3NDc0ZmIxZjlhOTc3YjJmMGMyYWJfMS0zLTEtMS0w_587354eb-443c-422b-90d0-7ea96722ce1c"
      unitRef="usd">517500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RhYmxlOjU1ODA2Mzg4ZDE2NzQ3NGZiMWY5YTk3N2IyZjBjMmFiL3RhYmxlcmFuZ2U6NTU4MDYzODhkMTY3NDc0ZmIxZjlhOTc3YjJmMGMyYWJfMi0xLTEtMS0w_99098010-f1f7-46e9-a7be-e201d5476688"
      unitRef="usd">5900000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RhYmxlOjU1ODA2Mzg4ZDE2NzQ3NGZiMWY5YTk3N2IyZjBjMmFiL3RhYmxlcmFuZ2U6NTU4MDYzODhkMTY3NDc0ZmIxZjlhOTc3YjJmMGMyYWJfMi0zLTEtMS0w_cf51ceef-c640-4909-8cb0-19770085239d"
      unitRef="usd">6900000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RhYmxlOjU1ODA2Mzg4ZDE2NzQ3NGZiMWY5YTk3N2IyZjBjMmFiL3RhYmxlcmFuZ2U6NTU4MDYzODhkMTY3NDc0ZmIxZjlhOTc3YjJmMGMyYWJfMy0xLTEtMS0w_fd997c56-a985-4c6b-ac90-31a102bd8e4d"
      unitRef="usd">86600000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RhYmxlOjU1ODA2Mzg4ZDE2NzQ3NGZiMWY5YTk3N2IyZjBjMmFiL3RhYmxlcmFuZ2U6NTU4MDYzODhkMTY3NDc0ZmIxZjlhOTc3YjJmMGMyYWJfMy0zLTEtMS0w_bedf795f-fb82-4ed5-b5ed-d3933f7b6cad"
      unitRef="usd">101800000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="ia560b50de8b4433b9f89b2a27688c2f6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RhYmxlOjU1ODA2Mzg4ZDE2NzQ3NGZiMWY5YTk3N2IyZjBjMmFiL3RhYmxlcmFuZ2U6NTU4MDYzODhkMTY3NDc0ZmIxZjlhOTc3YjJmMGMyYWJfNC0xLTEtMS0w_ef3ce65d-5d0c-481d-9955-4e6a30e3570e"
      unitRef="usd">425000000.0</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="i2eac757373044c73b10d89d2901aca4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RhYmxlOjU1ODA2Mzg4ZDE2NzQ3NGZiMWY5YTk3N2IyZjBjMmFiL3RhYmxlcmFuZ2U6NTU4MDYzODhkMTY3NDc0ZmIxZjlhOTc3YjJmMGMyYWJfNC0zLTEtMS0w_fe290789-dba7-4666-9332-63555817d342"
      unitRef="usd">408800000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:DebtInstrumentTerm
      contextRef="ie31aa602d4624c8f918fb28143d4d6e4_D20170502-20170502"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfOTQ0MQ_63ec4c51-56ce-4707-b918-7604c3aa48a9">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i1e3872d7a51340d7bd8d1873912c8acb_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfOTQxOQ_90747f8e-88ea-47c4-9b37-b9b9e28bb94a"
      unitRef="usd">713000000.0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="id6a49b9383644b8e949247b3f6dc07c3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfOTQzMg_56ca54ef-dc7c-4e64-b1d2-e8b6ee9fdf16"
      unitRef="usd">596800000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RleHRyZWdpb246NTQ0MjUyZmRjZGNmNDAwMTlkZGI2ZDQ0Y2Q5NjUyNzZfMTA2MQ_19ea59ed-3298-4c1f-a849-f28253ac76f4">Net (Loss) Income Per Share&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net (loss) income per share was calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(57.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Convertible debt instruments that may be settled entirely or partly in cash (such as the 2024 Notes) may, in certain circumstances where the borrower has the ability and intent to settle in cash, be accounted for under the treasury stock method. We issued the 2024 Notes with a combination settlement feature, which we have the ability and intent to use upon conversion of the 2024 Notes, to settle the principal amount of debt for cash and the excess of the principal portion in shares of our common stock. As a result, of the approximately 6.8 million shares underlying the 2024 Notes, only the shares required to settle the excess of the principal portion are considered under the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were 10.9&#160;million and 1.8&#160;million for the three and nine months ended September&#160;30, 2020, respectively, and 2.3&#160;million and 2.2&#160;million for the three and nine months ended September&#160;30, 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RleHRyZWdpb246NTQ0MjUyZmRjZGNmNDAwMTlkZGI2ZDQ0Y2Q5NjUyNzZfMTA2Mg_08e80ed3-bb2a-4f13-855f-7db4860a038c">&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net (loss) income per share was calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;(in millions, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(57.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (loss) income per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMi0xLTEtMS0w_b53124b4-fa74-4bfe-b814-fcdc8dc6a445"
      unitRef="usd">-57600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMi0zLTEtMS0w_6afe0ac2-0eb3-4f49-8599-b15d5928bdda"
      unitRef="usd">53800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMi01LTEtMS0w_f5eed12f-9e72-45cf-a716-f1079b0c6bd0"
      unitRef="usd">59400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMi03LTEtMS0w_95823a5e-1a99-4706-83e9-be11991506aa"
      unitRef="usd">3000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNC0xLTEtMS0w_2777ae8c-8126-478e-8ce1-8e480bf2ffbf"
      unitRef="shares">93300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNC0zLTEtMS0w_c09571ad-839c-4317-9717-b887a0371419"
      unitRef="shares">91900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNC01LTEtMS0w_e7778204-9369-4af9-9535-1ce4a51af036"
      unitRef="shares">93000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNC03LTEtMS0w_0b3e53d2-88be-4482-870d-5561c2a36e87"
      unitRef="shares">91400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ie4556b63f7bc4fc98ded870e841fc0f1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNi0xLTEtMS0w_5563a5af-ba20-498c-a4cc-25dc7a34381d"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ie07c04ad31ab444aa78ad245a76043b3_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNi0zLTEtMS0w_3f7a1dee-ee4a-4e28-b18b-a8b2f27937f2"
      unitRef="shares">2500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="idae84b2bcee5402c8d33bf434a519a5a_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNi01LTEtMS0w_3a1b0d75-c78e-44c6-81c7-9233313e450f"
      unitRef="shares">2500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i7952abe718084d38a17f69cd5d0327b6_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNi03LTEtMS0w_998a74b9-72a4-407c-bfb9-2e0d64e68ee9"
      unitRef="shares">2600000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ic23a449373e942b6a52ed76757c61821_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNy0xLTEtMS0w_4875ac47-cdb0-4105-8492-a572d37b89a0"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="idd783faa158b4dbe92e4b587a15e4e5b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNy0zLTEtMS0w_c7e4d36a-ca79-4889-8a7c-8101cf211455"
      unitRef="shares">500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i2b9ca9a1b5ab47359e53b9d1690424a9_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNy01LTEtMS0w_eb8fabd6-edec-48de-b4ee-eb0764ef0d06"
      unitRef="shares">500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i16bcd03519fb4b91b7c49c28141acd41_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfNy03LTEtMS0w_012bf218-5fa5-413b-9815-832c8485e99a"
      unitRef="shares">400000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities
      contextRef="ic83bc456a2d24aea914f39864a46ea36_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfOC0xLTEtMS0w_ba9bb32d-6d8b-478a-b4df-41c61fce317e"
      unitRef="shares">0</nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities>
    <nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities
      contextRef="i46cad86f1cef4f9796a18fb9899c6bd5_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfOC0zLTEtMS0w_55b39e62-0512-464e-8f24-f6dbcf35f238"
      unitRef="shares">1300000</nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities>
    <nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities
      contextRef="ideea8abfeaaf4691a87a843e06657dea_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfOC01LTEtMS0w_f63a4000-5368-4ac7-8d1e-b9a877870d0a"
      unitRef="shares">2000000.0</nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities>
    <nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities
      contextRef="icb3a8bd5463f49769dbf1087a66ca8c8_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfOC03LTEtMS0w_c59c6675-520b-4a29-b807-614703f8f205"
      unitRef="shares">800000</nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfOS0xLTEtMS0w_9a591c48-2268-40f2-9e99-5b8f2f379330"
      unitRef="shares">93300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfOS0zLTEtMS0w_a9eb2d4b-6204-44e5-b62f-351fdb12eaae"
      unitRef="shares">96100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfOS01LTEtMS0w_ffc98b2f-2498-4a4b-b704-2977a62bd95f"
      unitRef="shares">98000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfOS03LTEtMS0w_dcc2ce41-2c08-4bf8-ab6f-a22cdca377e8"
      unitRef="shares">95200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMTEtMS0xLTEtMA_880913db-c28b-4bea-afac-258d149a0e6a"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMTEtMy0xLTEtMA_7cba7c83-1e76-4681-8c01-3d85f3ffa684"
      unitRef="usdPerShare">0.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMTEtNS0xLTEtMA_26d39876-1414-4187-8458-d66f7aebb01a"
      unitRef="usdPerShare">0.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMTEtNy0xLTEtMA_6d017759-802b-4dbd-94e9-c47d1f703fcd"
      unitRef="usdPerShare">0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMTItMS0xLTEtMA_e5bdc458-83b7-4584-80ca-2600fafdbcc3"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5e4434ff11df4df198525373f44d9b33_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMTItMy0xLTEtMA_7720cbd3-5ad0-4470-8aea-b7ec1af4c149"
      unitRef="usdPerShare">0.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i855097c18a2c429892d9974c37a69a36_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMTItNS0xLTEtMA_9855a723-9d74-4dd8-8dec-68332d1382fc"
      unitRef="usdPerShare">0.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i01de6f56e9084fa0b902600982ee2775_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RhYmxlOjIwMjExMzRiZDMzZDQ1NDVhMDQ0MDVmMzc1NGZjZTBkL3RhYmxlcmFuZ2U6MjAyMTEzNGJkMzNkNDU0NWEwNDQwNWYzNzU0ZmNlMGRfMTItNy0xLTEtMA_f923f71d-1db9-404e-a5eb-52a319aa621a"
      unitRef="usdPerShare">0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i0e4f2c61bb0c4669bf03824d0717d032_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RleHRyZWdpb246NTQ0MjUyZmRjZGNmNDAwMTlkZGI2ZDQ0Y2Q5NjUyNzZfNjM1_e671b605-687b-4704-9a7b-25cf39c37747"
      unitRef="shares">6800000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8a2aaf5893684e989b254984e9c0e7c2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RleHRyZWdpb246NTQ0MjUyZmRjZGNmNDAwMTlkZGI2ZDQ0Y2Q5NjUyNzZfOTEw_6cd30e70-7d66-441f-bc69-e471bc9376fd"
      unitRef="shares">10900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if5e51d3e6c184bf388994f88f70e42b4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RleHRyZWdpb246NTQ0MjUyZmRjZGNmNDAwMTlkZGI2ZDQ0Y2Q5NjUyNzZfOTE3_c5ada473-b4a7-4e88-beeb-921c1550499d"
      unitRef="shares">1800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5484b1436d094cdaaf477c90a7f1ed3b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RleHRyZWdpb246NTQ0MjUyZmRjZGNmNDAwMTlkZGI2ZDQ0Y2Q5NjUyNzZfOTg4_228260f9-f077-4650-a03e-e3fc04ef281d"
      unitRef="shares">2300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4cb16bd71c524c9a890f849d3486c0c8_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81OC9mcmFnOjU0NDI1MmZkY2RjZjQwMDE5ZGRiNmQ0NGNkOTY1Mjc2L3RleHRyZWdpb246NTQ0MjUyZmRjZGNmNDAwMTlkZGI2ZDQ0Y2Q5NjUyNzZfOTk1_d1144f27-ab3a-4abd-83e4-c66bdbb50bd0"
      unitRef="shares">2200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626798978760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Nov. 04, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-22705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROCRINE BIOSCIENCES, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0525145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12780 El Camino Real<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">617-7600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NBIX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,429,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000914475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626881602520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 425.3<span></span>
</td>
<td class="nump">$ 112.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt securities available-for-sale, at fair value (amortized cost $517.3 million at September&#160;30, 2020 and $557.3 million at December&#160;31, 2019)</a></td>
<td class="nump">519.4<span></span>
</td>
<td class="nump">558.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">156.9<span></span>
</td>
<td class="nump">126.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">20.6<span></span>
</td>
<td class="nump">17.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">34.7<span></span>
</td>
<td class="nump">16.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,156.9<span></span>
</td>
<td class="nump">831.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Debt securities available-for-sale, at fair value (amortized cost $180.3 million at September&#160;30, 2020 and $299.3 million at December&#160;31, 2019)</a></td>
<td class="nump">181.4<span></span>
</td>
<td class="nump">299.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">71.0<span></span>
</td>
<td class="nump">74.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRestricted', window );">Equity securities</a></td>
<td class="nump">43.7<span></span>
</td>
<td class="nump">55.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">43.0<span></span>
</td>
<td class="nump">41.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">3.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,502.6<span></span>
</td>
<td class="nump">1,306.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">170.5<span></span>
</td>
<td class="nump">141.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible senior notes</a></td>
<td class="nump">425.0<span></span>
</td>
<td class="nump">408.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">15.5<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">611.0<span></span>
</td>
<td class="nump">565.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">83.0<span></span>
</td>
<td class="nump">86.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">17.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">698.3<span></span>
</td>
<td class="nump">669.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding at September&#160;30, 2020 and December&#160;31, 2019</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 220.0 shares authorized; issued and outstanding shares were 93.4 at September&#160;30, 2020 and 92.3 at December&#160;31, 2019</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,874.3<span></span>
</td>
<td class="nump">1,768.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,073.3)<span></span>
</td>
<td class="num">(1,132.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">804.3<span></span>
</td>
<td class="nump">636.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,502.6<span></span>
</td>
<td class="nump">$ 1,306.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRestricted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109249958&amp;loc=SL6224234-111729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRestricted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626881863144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized cost, current</a></td>
<td class="nump">$ 517.3<span></span>
</td>
<td class="nump">$ 557.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized cost, noncurrent</a></td>
<td class="nump">$ 180.3<span></span>
</td>
<td class="nump">$ 299.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">220,000,000.0<span></span>
</td>
<td class="nump">220,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">93,400,000<span></span>
</td>
<td class="nump">92,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">93,400,000<span></span>
</td>
<td class="nump">92,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626800397160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements Of Operations And Comprehensive (Loss) Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 258.5<span></span>
</td>
<td class="nump">$ 222.1<span></span>
</td>
<td class="nump">$ 798.0<span></span>
</td>
<td class="nump">$ 544.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">69.1<span></span>
</td>
<td class="nump">45.3<span></span>
</td>
<td class="nump">208.3<span></span>
</td>
<td class="nump">144.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="nump">118.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">164.5<span></span>
</td>
<td class="nump">118.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">112.5<span></span>
</td>
<td class="nump">84.5<span></span>
</td>
<td class="nump">326.8<span></span>
</td>
<td class="nump">252.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">302.8<span></span>
</td>
<td class="nump">132.0<span></span>
</td>
<td class="nump">706.8<span></span>
</td>
<td class="nump">520.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating (loss) income</a></td>
<td class="num">(44.3)<span></span>
</td>
<td class="nump">90.1<span></span>
</td>
<td class="nump">91.2<span></span>
</td>
<td class="nump">23.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(8.5)<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
<td class="num">(25.0)<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized loss on equity securities</a></td>
<td class="num">(7.0)<span></span>
</td>
<td class="num">(28.5)<span></span>
</td>
<td class="num">(12.2)<span></span>
</td>
<td class="num">(5.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_InvestmentIncomeAndOtherNet', window );">Investment income and other, net</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(12.8)<span></span>
</td>
<td class="num">(31.7)<span></span>
</td>
<td class="num">(26.2)<span></span>
</td>
<td class="num">(15.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before provision for income taxes</a></td>
<td class="num">(57.1)<span></span>
</td>
<td class="nump">58.4<span></span>
</td>
<td class="nump">65.0<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(57.6)<span></span>
</td>
<td class="nump">53.8<span></span>
</td>
<td class="nump">59.4<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized (loss) gain on debt securities available-for-sale, net of tax</a></td>
<td class="num">(1.4)<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">$ (59.0)<span></span>
</td>
<td class="nump">$ 54.8<span></span>
</td>
<td class="nump">$ 61.2<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) income per share, basic (in USD per share)</a></td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="nump">$ 0.59<span></span>
</td>
<td class="nump">$ 0.64<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) income per share, diluted (in USD per share)</a></td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="nump">$ 0.61<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">93.3<span></span>
</td>
<td class="nump">91.9<span></span>
</td>
<td class="nump">93.0<span></span>
</td>
<td class="nump">91.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">93.3<span></span>
</td>
<td class="nump">96.1<span></span>
</td>
<td class="nump">98.0<span></span>
</td>
<td class="nump">95.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 254.1<span></span>
</td>
<td class="nump">$ 198.1<span></span>
</td>
<td class="nump">$ 752.8<span></span>
</td>
<td class="nump">$ 515.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=nbix_CollaborationRevenueMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="nump">$ 24.0<span></span>
</td>
<td class="nump">$ 45.2<span></span>
</td>
<td class="nump">$ 29.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_InvestmentIncomeAndOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment income and other net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_InvestmentIncomeAndOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nbix_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nbix_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626800305960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative-effect adjustment to equity due to adoption of ASU 2016-02</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative-effect adjustment to equity due to adoption of ASU 2016-02</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 480.8<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 1,660.4<span></span>
</td>
<td class="num">$ (2.0)<span></span>
</td>
<td class="num">$ (1,177.7)<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on debt securities available-for-sale, net of tax</a></td>
<td class="nump">3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">54.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock for vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for stock option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for stock options</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock for employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock for employee stock purchase plan</a></td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2019</a></td>
<td class="nump">574.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,739.5<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="num">(1,166.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Jun. 30, 2019</a></td>
<td class="nump">483.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,703.5<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(1,220.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">53.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on debt securities available-for-sale, net of tax</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">20.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for stock option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for stock options</a></td>
<td class="nump">13.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock for employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock for employee stock purchase plan</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2019</a></td>
<td class="nump">574.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,739.5<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="num">(1,166.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">636.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,768.1<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="num">(1,132.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">59.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on debt securities available-for-sale, net of tax</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">79.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock for vested restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for stock option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for stock options</a></td>
<td class="nump">21.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock for employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock for employee stock purchase plan</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2020</a></td>
<td class="nump">804.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,874.3<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="num">(1,073.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Jun. 30, 2020</a></td>
<td class="nump">831.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">1,842.2<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="num">(1,015.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="num">(57.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on debt securities available-for-sale, net of tax</a></td>
<td class="num">(1.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">26.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for stock option exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for stock options</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock for employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock for employee stock purchase plan</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Sep. 30, 2020</a></td>
<td class="nump">$ 804.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 1,874.3<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="num">$ (1,073.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626800704872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 59.4<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Reconciliation of net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">79.0<span></span>
</td>
<td class="nump">54.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">6.4<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">14.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Change in fair value of equity security investments</a></td>
<td class="nump">12.2<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(30.3)<span></span>
</td>
<td class="num">(57.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(3.4)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">28.1<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other assets and liabilities, net</a></td>
<td class="num">(29.7)<span></span>
</td>
<td class="nump">12.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">139.6<span></span>
</td>
<td class="nump">49.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of debt securities available-for-sale</a></td>
<td class="num">(399.2)<span></span>
</td>
<td class="num">(467.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of debt securities available-for-sale</a></td>
<td class="nump">557.4<span></span>
</td>
<td class="nump">488.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchases of equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(54.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(6.4)<span></span>
</td>
<td class="num">(11.9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">151.8<span></span>
</td>
<td class="num">(44.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock</a></td>
<td class="nump">21.6<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">21.6<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash, cash equivalents and restricted cash</a></td>
<td class="nump">313.0<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">115.5<span></span>
</td>
<td class="nump">147.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">428.5<span></span>
</td>
<td class="nump">171.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Non-cash capital expenditures</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">5.8<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626798337768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Significant Accounting Policies</a></td>
<td class="text">Organization and Significant Accounting Policies<div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences, Inc., or Neurocrine Biosciences, the Company, we, our or us, was incorporated in California in 1992 and reincorporated in Delaware in 1996. Neurocrine Continental, Inc., is a Delaware corporation and a wholly owned subsidiary of Neurocrine Biosciences. We also have two wholly owned Irish subsidiaries, Neurocrine Therapeutics, Ltd. and Neurocrine Europe, Ltd., both of which were formed in December 2014 and are inactive. </span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a commercial-stage biopharmaceutical company focused on discovering and developing innovative and life-changing treatments for patients with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. We specialize in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. Currently, we are primarily focused on the commercialization of INGREZZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in the United States, or US, our first US Food and Drug Administration, or FDA, approved product.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the US, or GAAP, for interim financial information and with the instructions of the Securities and Exchange Commission, or SEC, on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of Neurocrine Biosciences and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2019, included in our Annual Report on Form 10-K, or the 2019 Form 10-K, filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or the full year. The condensed consolidated balance sheet at December&#160;31, 2019, has been derived from the audited financial statements as of that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no significant changes to our significant accounting policies as disclosed in the 2019 Form 10-K, except as set forth below.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist of investments in certificates of deposit, corporate debt securities, and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become 90 days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Credit Losses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivables on debt securities available-for-sale totaled $3.5 million at September&#160;30, 2020. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during the nine months ended September&#160;30, 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents, debt securities available-for-sale and equity securities at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources, and analyzing data in certain instances.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities of certain companies that are subject to holding period restrictions longer than one year are classified as Level 3 and carried at fair value using an option pricing valuation model. The most significant assumptions within the option pricing valuation model are the stock price volatility, which is based on the historical volatility of similar companies, and the discount for lack of marketability related to the term of the restrictions.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2016-13. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted Accounting Standards Update, or ASU, 2016-13,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using the modified retrospective transition method. For debt securities available-for-sale, the standard requires an investor to determine whether a decline in the fair value below the amortized cost basis of the investment is due to credit-related factors. Credit-related impairment is recognized as an allowance for credit loss on the balance sheet with a corresponding adjustment to earnings. Credit losses are limited to the amount by which the investment&#8217;s amortized cost basis exceeds its fair value and may be subsequently reversed if conditions change. Any impairment that is not credit related is recognized in other comprehensive income or loss, as applicable, net of applicable taxes.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of ASU 2016-13 did not result in a cumulative-effect adjustment to retained earnings. The comparative prior period information continues to be reported under the accounting standards in effect during those periods.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2019-12. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application of Topic 740. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, with early adoption permitted in any interim period for which financial statements have not yet been made available for issuance. We are currently evaluating the effect ASU 2019-12 will have on our condensed consolidated financial statements and related disclosures.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2020-06. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments, and amends existing earnings-per-share, or EPS, guidance by requiring that an entity use the if-converted method when calculating diluted EPS for convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal </span></div>years, with early adoption permitted for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We are currently evaluating the effect ASU 2020-06 will have on our condensed consolidated financial statements and related disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and accounting policies concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626798540664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Collaboration and Licensing Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Significant Collaboration and Licensing Agreements</a></td>
<td class="text">Significant Collaboration and Licensing Agreements<div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In June 2020, we entered into an exclusive license agreement with Takeda, which became effective in July 2020, to develop and commercialize certain compounds in Takeda&#8217;s early to mid-stage psychiatry pipeline. Specifically, Takeda granted us an exclusive license to the following seven assets: (i) NBI-1065844 (TAK-831) for schizophrenia, (ii) NBI-1065845 (TAK-653) for treatment-resistant depression, (iii) NBI-1065846 (TAK-041) for anhedonia (which together with the NBI-1065845 are referred to as the Phase II Ready Assets), and (iv) four non-clinical stage assets, or the Non-Clinical Assets.</span></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NBI-1065844 is deemed a royalty-bearing product under the license agreement pursuant to which we will be responsible for all costs and expenses associated with the development, manufacture, and commercialization of such asset, subject to certain exceptions, and Takeda will be eligible to receive development and commercial milestones and royalties with respect to such asset, or a Royalty-Bearing Product, and Takeda will retain the right to opt-in to a profit sharing arrangement pursuant to which we and Takeda will equally share in the operating profits and losses related to such asset, subject to certain exceptions, in lieu of receiving milestones and royalties, or a Profit-Share Product. Subject to specified conditions, Takeda may elect to exercise such opt-in right for NBI-1065844 before we initiate a Phase III clinical trial. Each of the Phase II Ready Assets is deemed a Profit-Share Product and Takeda will retain the right to opt-out of the profit-sharing arrangement for such asset pursuant to which such asset would become a Royalty-Bearing Product. Takeda may elect to exercise such opt-out rights with respect to a Phase II Ready Asset immediately following the completion of the second Phase II clinical trial for such Phase II Ready Asset. In addition, under certain circumstances related to the development and commercialization activities to be performed by us, Takeda may elect to opt-out of the profit-sharing arrangement for a Profit-Share Product before the initiation of a Phase III clinical trial for such product.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Non-Clinical Assets will be Royalty-Bearing Products pursuant to which we will be responsible for all costs and expenses associated with the development, manufacture, and commercialization of such assets, subject to certain exceptions.</span></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the agreement, we paid Takeda $120.0&#160;million upfront</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which, including certain transaction related costs, was expensed as IPR&amp;D in the third quarter of 2020</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the agreement, </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda may also be entitled to receive payments of up to $1.9&#160;billion upon the achievement of certain development and commercial milestones associated with Royalty-Bearing Products, as well as receive royalties on future net sales of Royalty-Bearing Products. On a country-by-country and product-by-product basis, royalty payments would commence on the first commercial sale of a Royalty-Bearing Product and terminate on the later of (i) the expiration of the last patent covering such Royalty-Bearing Product in such country, (ii) a number of years from the first commercial sale of such Royalty-Bearing Product in such country and (iii) the expiration of regulatory exclusivity for Royalty-Bearing Product in such country.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the license agreement will continue on a licensed product-by-licensed product and country-by-country basis until the date on which, (i) for any Royalty-Bearing Product, the royalty term has expired in such country; and (ii) for any Profit-Share Product, for so long as we continue to develop, manufacture, or commercialize such licensed product.  We may terminate the license agreement for convenience in its entirety or in one or more (but not all) of the United States, Japan, the European Union, and the United Kingdom, or the Major Markets, on 6 months&#8217; written notice to Takeda (i) with respect to all licensed products prior to the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes, as defined in the agreement, prior to the first commercial sale of the first licensed product in such target class(es) for which first commercial sale occurs. We may terminate the license agreement for convenience in its entirety or in one or more (but not all) of the Major Markets on 12 months&#8217; written notice to Takeda (i) with respect to all licensed products following the first commercial sale of the first licensed product for which first commercial sale occurs, or (ii) with respect to all licensed products in one or more given target classes following the first commercial sale of the first licensed product in such target class(es) for which first commercial sale. Takeda may terminate the license agreement, subject to specified conditions, (i) if we challenge the validity or enforceability of certain Takeda intellectual property rights or (ii) on a target class-by-target class basis, in the event that we do not conduct any material development or commercialization activities with respect to any licensed product within such target class for a specified continuous period. Subject to a cure period, either party may terminate the license agreement in the event of any material breach, solely with respect to the target class of a licensed product to which such material breach relates, or in its entirety in the event of any material breach that relates to all licensed products.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Idorsia.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we entered a collaboration and licensing agreement with Idorsia to license the global rights to NBI-827104, a potent, selective, orally active and brain penetrating T-type calcium channel blocker, in clinical development for the treatment of a rare pediatric epilepsy. The agreement also included a research collaboration to discover and identify additional novel T-type calcium channel blockers as development candidates. </span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the exercise of the option, we paid Idorsia $45.0&#160;million upfront, which was expensed as IPR&amp;D in the second quarter of 2020. Further, as part of the research collaboration, we provided Idorsia with an incremental $7.2&#160;million in funding, which was recorded as a prepaid asset to be expensed over the two-year research collaboration term.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the agreement, upon the achievement of certain development and regulatory milestones, Idorsia may be entitled to receive payments of up to $365.0&#160;million with respect to NBI-827104 and up to $620.0&#160;million with respect to the development candidates. In addition, Idorsia may also be entitled to receive payments of up to $750.0&#160;million upon the achievement of certain commercial milestones, as well as receive royalties on the net sales of any collaboration product. Further, we will be responsible for all manufacturing, development and commercialization costs of any collaboration product.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the collaboration and licensing agreement, in its entirety or with respect to a particular compound or development candidate, by providing 90 days&#8217; written notice to Idorsia. Further, in the event a party commits a material breach and fails to cure such material breach within 90 days after receiving written notice thereof, the non-breaching party may terminate the agreement in its entirety immediately upon written notice to the breaching party.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Xenon. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a license and collaboration agreement with Xenon Pharmaceuticals Inc., or Xenon, to identify, research, and develop sodium channel inhibitors, including clinical candidate NBI-921352 and three preclinical candidates, which compounds we will have the exclusive right to further develop and commercialize under the terms and conditions set forth in the agreement.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be solely responsible, at our sole cost and expense, for all development and manufacturing of the compounds and any pharmaceutical product that contains a compound, subject to Xenon&#8217;s right to elect to co-fund the development of one product in a major indication and thus receive a mid-single digit percentage increase in royalties owed on the net sales of such product in the US. If Xenon exercises such option, the parties will share equally all reasonable and documented costs and expenses incurred in connection with the development of such product in the applicable indication, except costs and expenses that are solely related to the development of such product for regulatory approval outside the US.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the term of the license and collaboration agreement will continue on a product-by-product and country-by-country basis until the expiration of the royalty term for such product in such country. Upon the expiration of the royalty term for a particular product and country, the exclusive license granted by Xenon to us with respect to such product and country will become fully paid, royalty free, perpetual, and irrevocable. We may terminate the license and collaboration agreement by providing at least 90 days&#8217; written notice, provided that such unilateral termination will not be effective for certain products until we have used commercially reasonable efforts to complete certain specified clinical studies. Either party may terminate the agreement in the event of a material breach in whole or in part, subject to specified conditions.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voyager.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2019, we entered into a collaboration and license agreement with Voyager, a clinical-stage gene therapy company. The agreement is focused on the development and commercialization of four programs using Voyager&#8217;s proprietary gene therapy platform. The four programs consist of the NBIb-1817 program for Parkinson&#8217;s disease, the Friedreich&#8217;s ataxia program and the rights to two undisclosed programs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to development plans agreed to by us and Voyager, unless Voyager exercises its co-development and co-commerci</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alization rights as provided for in the agreement, we will be responsible for all development costs. Further, upon the occurrence of a specified event for each program, we will assume responsibility for the development, manufacturing, and commercialization activit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies of such program.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the collaboration and license agreement with Voyager upon 180 days&#8217; written notice to Voyager prior to the first commercial sale of any collaboration product or upon one year after the date of notice if such notice is provided after the first commercial sale of any collaboration product. Unless terminated earlier, the agreement will continue in effect until the expiration of the last to expire royalty term with respect to any collaboration product or the last expiration or termination of any exercised co-development and co-commercialization rights by Voyager as provided for in the agreement.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BIAL &#8211; Portela &amp; Ca, S.A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2017, we entered into an exclusive license agreement with BIAL&#160;&#8211; Portela &amp; Ca, S.A., or BIAL, for the development and commercialization of ONGENTYS for the treatment of human diseases and conditions, including Parkinson&#8217;s disease, in the US and Canada. </span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we received FDA approval for ONGENTYS as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors in adult Parkinson's disease patients, which was commercialized by our commercial team in late September 2020. FDA approval for ONGENTYS for Parkinson&#8217;s disease triggered a milestone payment of $20.0 million, which was expensed </span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as R&amp;D in the second quarter of 2020. Pursuant to the terms of the agreement, BIAL may also be entitled to receive up to $75.0&#160;million upon the achievement of certain commercial milestones.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, we are responsible for the commercialization of ONGENTYS in the US and Canada. Further, we  rely on BIAL for the commercial supply of ONGENTYS. Upon our written request prior to the estimated expiration of the term of a licensed product, the parties shall negotiate a good faith continuation of BIAL&#8217;s supply of such licensed product after the term. After the term, and if BIAL is not supplying a certain licensed product, we shall pay BIAL a trademark royalty based on the net sales of such licensed product.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization of ONGENTYS, we determined certain annual sales forecasts. In the event we fail to meet the minimum sales requirements for a particular year, we would be obligated to pay BIAL an amount equal to the difference between the actual net sales and minimum sales requirements for such year.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement will continue on a licensed product-by-product and country-by-country basis until a generic product in respect of such licensed product under the agreement is sold in a country and sales of such generic product are greater than a specified percentage of total sales of such licensed product in such country.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either party may terminate the agreement if the other party materially breaches the agreement and does not cure the breach within a specified notice period, or upon the other party&#8217;s insolvency. BIAL may terminate the agreement if we fail to use commercially reasonable efforts to submit an NDA for a licensed product by a specified date, in the event we fail to meet the minimum sales requirements for any two years, or under certain circumstances involving a change of control of Neurocrine Biosciences. Under certain circumstances where BIAL elects to terminate the agreement in connection with a change of control of Neurocrine Biosciences, BIAL would be obligated to pay us a termination fee. We may terminate the agreement at any time for any reason upon nine months&#8217; written notice to BIAL.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mitsubishi Tanabe Pharma Corporation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2015, we entered into a collaboration and license agreement with Mitsubishi Tanabe Pharma Corporation, or MTPC, for the development and commercialization of INGREZZA for movement disorders in Japan and other select Asian markets. </span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September&#160;30, 2020, we recognized revenue of $0.5&#160;million and $1.8&#160;million, respectively, in connection with the ongoing KINECT-HD study, a placebo-controlled Phase III study of valbenazine in adult Huntington&#8217;s disease patients with chorea. In accordance with our continuing performance obligations, $7.6&#160;million of the $30.0&#160;million upfront payment received from MTPC in connection with the agreement is being deferred and will be recognized as revenue over the KINECT-HD study period using an input method according to costs incurred to-date relative to estimated total costs associated with the study. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception of the agreement, we have recognized revenue of $19.8&#160;million associated with the delivery of a technology license and existing know-how, $15.0&#160;million associated with the achievement of a certain development milestones, and $2.6&#160;million associated with our performance of the ongoing KINECT-HD study. Pursuant to the terms of the agreement, we may also be entitled to receive payments of up to $70.0&#160;million upon the achievement of certain regulatory and commercial milestones, receive payments for the manufacture of certain pharmaceutical products, as well as receive royalties on the net sales of collaboration products in select territories in Asia.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, MTPC is responsible for all third-party development, marketing, and commercialization costs in Japan and other select Asian markets and we would be entitled to a percentage of sales of INGREZZA in Japan and other select Asian markets for the longer of ten years or the life of the related patent rights. Further, the collaboration effort between the parties to advance INGREZZA towards commercialization in Japan and other select Asian markets is governed by joint steering and development committees with representatives from both parties. There are no performance, cancellation, termination, or refund provisions in the agreement that would have a material financial consequence to us. We do not directly control when event-based payments will be achieved or when royalty payments will begin. MTPC may terminate the agreement at its discretion upon 180 days' written notice to us. In such event, all INGREZZA product rights for Japan and other select Asian markets would revert to us.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AbbVie. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2010, we entered into an exclusive worldwide collaboration with AbbVie to develop and commercialize elagolix and all next-generation gonadotropin-releasing factor antagonists for women&#8217;s and men&#8217;s health.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie received approval of ORILISSA for the management of moderate to severe endometriosis pain in women from the FDA in July 2018 and Health Canada in October 2018.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, AbbVie received approval from the FDA for ORIAHNN for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. FDA approval for ORIAHNN for uterine fibroids resulted in the achievement of a $30.0&#160;million regulatory milestone, which was recognized as collaboration revenue in the second quarter of 2020. </span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception of the agreement, we have recognized revenue of $75.0&#160;million associated with the delivery of a technology license and existing know-how and $165.0&#160;million associated with the achievement of certain development and regulatory milestones. Pursuant to the terms of the agreement, we may also be entitled to receive additional payments of up to $366.0&#160;million upon the achievement of certain development, regulatory and commercial milestones.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, AbbVie is responsible for all third-party development, marketing, and commercialization costs. We will be entitled to a percentage of worldwide sales of GnRH Compounds for the longer of ten years or the life of the related patent rights. AbbVie may terminate the collaboration at its discretion upon 180 days&#8217; written notice to us.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626796637128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Debt Securities</a></td>
<td class="text">Debt Securities<div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss), allowance for credit losses, and fair value of debt securities available-for-sale at September&#160;30, 2020, aggregated by major security type and contractual maturity:</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.833%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">519.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income, and fair value of debt securities available-for-sale at December&#160;31, 2019, aggregated by major security type and contractual maturity:</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.832%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">557.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">558.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes debt securities available-for-sale in an unrealized loss position for which an allowance for credit losses has not been recorded at September&#160;30, 2020, aggregated by major security type and length of time in a continuous unrealized loss position:</span></div><div style="margin-bottom:4pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>At September&#160;30, 2020, our security portfolio consisted of 143 securities related to investments in debt securities available-for-sale, of which 14 securities were in an unrealized loss position.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in corporate debt securities in an unrealized loss position at September&#160;30, 2020 are of high credit quality (rated A- or higher). Unrealized losses on these investments were primarily due to changes in interest rates. We do not intend </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to sell these investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost basis.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes debt securities available-for-sale in an unrealized loss position at December&#160;31, 2019, aggregated by major security type and length of time in a continuous unrealized loss position:</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626798179528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments at September&#160;30, 2020, which were measured at fair value on a recurring basis, consisted of the following:</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total recurring fair value measurements</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,173.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments at December&#160;31, 2019, which were measured at fair value on a recurring basis, consisted of the following:</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total recurring fair value measurements</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,029.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of equity security investments, which were  measured at fair value on a recurring basis using significant unobservable inputs (Level 3):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss included in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>At September&#160;30, 2020, the discount for lack of marketability used in the valuation analysis of equity securities ranged from 16.0% to 31.5% (weighted average of 26.8%). The discount for lack of marketability was weighted by the relative fair value of the instruments. A significant increase (decrease) in the discount for lack of marketability in isolation would result in a significantly lower (higher) fair value measurement. Unrealized gains and losses on equity securities are included in other income (expense), net.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626798140392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626798695480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Restricted Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_RestrictedCashTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">Restricted Cash<div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_RestrictedCashTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_RestrictedCashTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626798089992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Address</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Square Feet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commencement Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12780 El Camino Real </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office/Laboratory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 7, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 31, 2031</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12790 El Camino Real, Suite 130 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 1, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 31, 2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12790 El Camino Real, Suite 150 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 7, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 31, 2031</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12790 El Camino Real, Suite 300 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 1, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 31, 2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12777 High Bluff Drive</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 1, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 31, 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12790 El Camino Real, Suite 200 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 31, 2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12790 El Camino Real, Suite 100 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 31, 2031</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(1) Under the terms of the 12780/12790 El Camino Real master lease, we have two options to extend the term of the lease for a period of ten years each. We were not reasonably certain to exercise either of these options at lease commencement. As such, neither option was recognized as part of the associated operating lease right-of-use asset or liability.</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note: In connection with our operating leases, in lieu of cash security deposits, Wells Fargo Bank, N.A., issued letters of credit on our behalf, which are secured by deposits totaling $3.2&#160;million. </span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating lease cost was $7.4 million and $5.9 million for the nine months ended September&#160;30, 2020 and 2019, respectively. Cash paid for amounts in the measurement of lease liabilities for operating cash flows from operating leases was $6.4 million and $5.5 million for the nine months ended September&#160;30, 2020 and 2019, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating leases had a weighted average remaining lease term of approximately 10.5 years and 11.2 years at September&#160;30, 2020 and December&#160;31, 2019, respectively, and a weighted average discount rate of 5.8% at September&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximate future minimum lease payments under operating leases were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2020 (3 months remaining)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note: Amounts presented in the table above exclude $28.3 million of non-cancelable future minimum lease payments for operating leases that have not yet commenced.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626798695480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Senior Notes</a></td>
<td class="text">Convertible Senior Notes<div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;2, 2017, we completed a private placement of&#160;$517.5 million&#160;in aggregate principal amount of&#160;2.25%&#160;convertible senior notes due 2024 and entered into an indenture agreement, or the 2024 Indenture, with respect to the 2024 Notes. The 2024 Notes accrue interest at a fixed rate of&#160;2.25%&#160;per year, payable semiannually in arrears on May&#160;15 and November&#160;15 of each year, beginning on November&#160;15, 2017. The 2024 Notes mature on May 15, 2024. The net proceeds from the issuance of the 2024 Notes were approximately $502.8 million, after deducting commissions and the offering expenses payable by us.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may convert the 2024 Notes at any time prior to the close of business on the business day immediately preceding May&#160;15, 2024, only under the following circumstances:</span></div><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.07pt">during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least&#160;20&#160;trading days (whether or not consecutive) during a period of&#160;30&#160;consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than&#160;130%&#160;of the conversion price on each applicable trading day;</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.3pt">during the&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMTE3Nw_a1999c43-97d5-4934-9864-f07cd2e0e9ca">five</span> business-day period immediately after any&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAxZGNhOTJhOWE4OTRjODM5ZmQ5MWY4YjViM2JlYmE2L3NlYzowMWRjYTkyYTlhODk0YzgzOWZkOTFmOGI1YjNiZWJhNl81Mi9mcmFnOjYxNGIwM2JlYjFkYTQ3NjY5ZWM5MDNlN2E0MWMyNTgzL3RleHRyZWdpb246NjE0YjAzYmViMWRhNDc2NjllYzkwM2U3YTQxYzI1ODNfMTIyMg_0e6c4b54-2041-4866-8f9f-60a13836b830">five</span>&#160;consecutive trading-day period (the measurement period) in which the trading price (as defined in the 2024 Indenture) per&#160;$1,000&#160;principal amount of the 2024 Notes for each trading day of the measurement period was less than&#160;98%&#160;of the product of the last reported sale price of our common stock and the conversion rate on each such trading day;</span></div><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.53pt">upon the occurrence of specified corporate events, including a merger or a sale of all or substantially all of our assets; or</span></div><div style="margin-bottom:4pt;margin-top:4pt;padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.07pt">if we call the 2024 Notes for redemption, until the close of business on the business day immediately preceding the redemption date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after January&#160;15, 2024, until the close of business on the scheduled trading day immediately preceding May&#160;15, 2024, holders may convert their 2024 Notes at any time.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the conditional conversion feature described under (i) above had been triggered as of September 30, 2020, holders of the 2024 Notes may convert the 2024 Notes at any time during the period beginning on October 1, 2020 and ending at the close of business on December 31, 2020. Accordingly, the 2024 Notes have been classified as a current liability as of September 30, 2020. The future conditional convertibility of the 2024 Notes will be monitored at each quarterly reporting date and analyzed dependent upon market prices of our common stock during the prescribed measurement periods.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, holders will receive the principal amount of their 2024 Notes and any excess conversion value, calculated based on the per share volume-weighted average price for each of the&#160;30&#160;consecutive trading days during the observation period (as more fully described in the 2024 Indenture). For both the principal and excess conversion value, holders may receive cash, shares of our common stock or a combination of cash and shares of our common stock, at our option.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our intent and policy to settle conversions through combination settlement, which essentially involves repayment of an amount of cash equal to the &#8220;principal portion&#8221; and delivery of the &#8220;share amount&#8221; in excess of the principal portion in shares of common stock or cash. In general, for each $1,000 in principal, the &#8220;principal portion&#8221; of cash upon settlement is defined as the lesser of $1,000, and the conversion value during the 25-day observation period as described in the 2024 Indenture. The conversion value is the sum of the daily conversion value which is the product of the effective conversion rate divided by 25 days and the daily volume weighted average price, or VWAP, of our common stock. The &#8220;share amount&#8221; is the cumulative &#8220;daily share amount&#8221; during the observation period, which is calculated by dividing the daily VWAP into the difference between the daily conversion value (i.e., conversion rate x daily VWAP) and $1,000. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial conversion rate for the 2024 Notes is&#160;13.1711&#160;shares of common stock per&#160;$1,000&#160;principal amount, which is equivalent to an initial conversion price of&#160;approximately $75.92&#160;per share of our common stock. At the initial conversion rate, settlement of the 2024 Notes for shares of our common stock would approximate 6.8 million shares. The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. The initial conversion price of the 2024 Notes represented a premium of approximately&#160;42.5%&#160;to the closing sale price of&#160;$53.28&#160;per share of our common stock on the Nasdaq Global Select Market on April&#160;26, 2017, the date that we priced the private offering of the 2024 Notes.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of conversion, holders would forgo all future interest payments, any unpaid accrued interest and the possibility of further stock price appreciation. Upon the receipt of conversion requests, the settlement of the 2024 Notes will be paid pursuant to the terms of the 2024 Indenture. In the event that all of the 2024 Notes are converted, we would be required to repay the&#160;$517.5&#160;million&#160;in principal value and any conversion premium in any combination of cash and shares of our common stock, at our option.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not redeem the 2024 Notes prior to May&#160;15, 2021. On or after May&#160;15, 2021, we may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2024 Indenture) of our common stock has been at least&#160;130%&#160;of the conversion price then in effect for at least&#160;20&#160;trading days (whether or not consecutive) during any&#160;30&#160;consecutive trading-day period ending on, and including, the trading day immediately before the date which we provide notice of redemption. The redemption price will equal the sum of (i)&#160;100%&#160;of the principal amount of the 2024 Notes being redeemed, plus (ii)&#160;accrued and unpaid interest, including additional interest, if any, to, but excluding, the redemption date. No sinking fund is provided for the 2024 Notes.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we undergo a fundamental change, as defined in the 2024 Indenture, subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to&#160;100%&#160;of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In addition, if a &#8216;&#8216;make-whole fundamental change&#8217;&#8217; (as defined in the 2024 Indenture) occurs prior to January&#160;15, 2024, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with the make-whole fundamental change.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to separately account for the liability and equity components of the 2024 Notes as they may be settled entirely or partially in cash upon conversion in a manner that reflects our economic interest cost. The liability component of the instrument was valued in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. The initial carrying value of the liability component of $368.3 million&#160;was calculated using a&#160;7.5%&#160;assumed borrowing rate. The equity component of $149.2 million, representing the conversion option, was determined by deducting the fair value of the liability component from the par value of the 2024 Notes and was recorded in additional paid-in capital on the consolidated balance sheet at the issuance date. That equity component is treated as a discount on the liability component of the 2024 Notes, which is amortized over the seven-year term of the 2024 Notes using the effective interest rate method. The equity component is not re-measured as long as it continues to meet the conditions for equity classification. At September&#160;30, 2020, the remaining period over which the discount on the liability component will be amortized was approximately 3.6 years.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the total transaction costs of approximately&#160;$14.7 million&#160;related to the issuance of the 2024 Notes to the liability and equity components of the 2024 Notes based on their relative values. Transaction costs attributable to the liability </span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">component are amortized to interest expense over the&#160;seven-year term of the 2024 Notes, and transaction costs attributable to the equity component are netted with the equity component in stockholders&#8217; equity.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes do not contain any financial or operating covenants or any restrictions on the payment of dividends, the issuance of other indebtedness or the issuance or repurchase of securities by us. The 2024 Indenture contains customary events of default with respect to the 2024 Notes, including that upon certain events of default,&#160;100%&#160;of the principal and accrued and unpaid interest on the 2024 Notes will automatically become due and payable.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes, net of discounts and deferred financing costs, consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt discount, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(86.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>The 2024 Notes were recorded at the estimated value of a similar non-convertible instrument on the date of issuance and accretes to the face value of the 2024 Notes over their seven-year term. The fair value of the 2024 Notes, which was estimated utilizing market quotations from an over-the-counter trading market (Level 2), was $713.0 million at September&#160;30, 2020 and $596.8 million at December&#160;31, 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626893696456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net (Loss) Income Per Share</a></td>
<td class="text">Net (Loss) Income Per Share<div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income per share was calculated as follows:</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Convertible debt instruments that may be settled entirely or partly in cash (such as the 2024 Notes) may, in certain circumstances where the borrower has the ability and intent to settle in cash, be accounted for under the treasury stock method. We issued the 2024 Notes with a combination settlement feature, which we have the ability and intent to use upon conversion of the 2024 Notes, to settle the principal amount of debt for cash and the excess of the principal portion in shares of our common stock. As a result, of the approximately 6.8 million shares underlying the 2024 Notes, only the shares required to settle the excess of the principal portion are considered under the treasury stock method.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were 10.9&#160;million and 1.8&#160;million for the three and nine months ended September&#160;30, 2020, respectively, and 2.3&#160;million and 2.2&#160;million for the three and nine months ended September&#160;30, 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626794732808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_BusinessDescriptionPolicyTextBlock', window );">Description of Business</a></td>
<td class="text"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurocrine Biosciences, Inc., or Neurocrine Biosciences, the Company, we, our or us, was incorporated in California in 1992 and reincorporated in Delaware in 1996. Neurocrine Continental, Inc., is a Delaware corporation and a wholly owned subsidiary of Neurocrine Biosciences. We also have two wholly owned Irish subsidiaries, Neurocrine Therapeutics, Ltd. and Neurocrine Europe, Ltd., both of which were formed in December 2014 and are inactive. </span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a commercial-stage biopharmaceutical company focused on discovering and developing innovative and life-changing treatments for patients with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. We specialize in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. Currently, we are primarily focused on the commercialization of INGREZZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (valbenazine) in the United States, or US, our first US Food and Drug Administration, or FDA, approved product.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the US, or GAAP, for interim financial information and with the instructions of the Securities and Exchange Commission, or SEC, on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. The accompanying unaudited condensed consolidated financial statements include the accounts of Neurocrine Biosciences and our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2019, included in our Annual Report on Form 10-K, or the 2019 Form 10-K, filed with the SEC. The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or the full year. The condensed consolidated balance sheet at December&#160;31, 2019, has been derived from the audited financial statements as of that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no significant changes to our significant accounting policies as disclosed in the 2019 Form 10-K, except as set forth below.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Securities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist of investments in certificates of deposit, corporate debt securities, and securities of government-sponsored entities. We classify debt securities as available-for-sale. Debt securities available-for-sale are recorded at fair value, with unrealized gains and losses included in other comprehensive income or loss, net of tax. We exclude accrued interest from both the fair value and amortized cost basis of debt securities. A debt security is placed on nonaccrual status at the time any principal or interest payments become 90 days delinquent. Interest accrued but not received for a debt security placed on nonaccrual status is reversed against interest income.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income includes amortization of purchase premium or discount. Premiums and discounts on debt securities are amortized using the effective interest rate method. Gains and losses on sales of debt securities are recorded on the trade date in investment income and other, net, and determined using the specific identification method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts', window );">Allowance for Credit Losses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Credit Losses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For debt securities available-for-sale in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span>Accrued interest receivables on debt securities available-for-sale totaled $3.5 million at September&#160;30, 2020. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is excluded from both the fair value and amortized cost basis of the debt security. Uncollectible accrued interest receivables associated with an impaired debt security are reversed against interest income upon identification of the impairment. No accrued interest receivables were written off during the nine months ended September&#160;30, 2020.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents, debt securities available-for-sale and equity securities at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels:</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources, and analyzing data in certain instances.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in equity securities of certain companies that are subject to holding period restrictions longer than one year are classified as Level 3 and carried at fair value using an option pricing valuation model. The most significant assumptions within the option pricing valuation model are the stock price volatility, which is based on the historical volatility of similar companies, and the discount for lack of marketability related to the term of the restrictions.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to their short-term maturities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Issued Accounting Pronouncements</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2016-13. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2020, we adopted Accounting Standards Update, or ASU, 2016-13,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using the modified retrospective transition method. For debt securities available-for-sale, the standard requires an investor to determine whether a decline in the fair value below the amortized cost basis of the investment is due to credit-related factors. Credit-related impairment is recognized as an allowance for credit loss on the balance sheet with a corresponding adjustment to earnings. Credit losses are limited to the amount by which the investment&#8217;s amortized cost basis exceeds its fair value and may be subsequently reversed if conditions change. Any impairment that is not credit related is recognized in other comprehensive income or loss, as applicable, net of applicable taxes.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of ASU 2016-13 did not result in a cumulative-effect adjustment to retained earnings. The comparative prior period information continues to be reported under the accounting standards in effect during those periods.</span></div><div style="margin-bottom:4pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2019-12. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application of Topic 740. ASU 2019-12 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years, with early adoption permitted in any interim period for which financial statements have not yet been made available for issuance. We are currently evaluating the effect ASU 2019-12 will have on our condensed consolidated financial statements and related disclosures.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2020-06. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments, and amends existing earnings-per-share, or EPS, guidance by requiring that an entity use the if-converted method when calculating diluted EPS for convertible instruments. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal </span></div>years, with early adoption permitted for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We are currently evaluating the effect ASU 2020-06 will have on our condensed consolidated financial statements and related disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_BusinessDescriptionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Description</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_BusinessDescriptionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for charging off uncollectible financing receivables, including, but not limited to, factors and methodologies used in estimating the allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (a,b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626796695752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale</a></td>
<td class="text"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income (loss), allowance for credit losses, and fair value of debt securities available-for-sale at September&#160;30, 2020, aggregated by major security type and contractual maturity:</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.833%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Allowance for Credit Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">519.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amortized cost, unrealized gain and loss recognized in accumulated other comprehensive income, and fair value of debt securities available-for-sale at December&#160;31, 2019, aggregated by major security type and contractual maturity:</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.453%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.655%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.832%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">557.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">558.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 to 2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes debt securities available-for-sale in an unrealized loss position for which an allowance for credit losses has not been recorded at September&#160;30, 2020, aggregated by major security type and length of time in a continuous unrealized loss position:</span></div><div style="margin-bottom:4pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Debt Securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes debt securities available-for-sale in an unrealized loss position at December&#160;31, 2019, aggregated by major security type and length of time in a continuous unrealized loss position:</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.358%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less Than 12 Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 Months or Longer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626796631112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Investments Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments at September&#160;30, 2020, which were measured at fair value on a recurring basis, consisted of the following:</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total recurring fair value measurements</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,173.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments at December&#160;31, 2019, which were measured at fair value on a recurring basis, consisted of the following:</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">521.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities of government-sponsored entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities&#8211;biotechnology industry</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total recurring fair value measurements</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,029.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3)</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of equity security investments, which were  measured at fair value on a recurring basis using significant unobservable inputs (Level 3):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss included in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626905614904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626798354888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Restricted Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Restricted Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock', window );">Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of reconciliation of cash cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626798312344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Description of Operating Lease</a></td>
<td class="text"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Address</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Square Feet</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commencement Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12780 El Camino Real </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office/Laboratory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 7, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 31, 2031</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12790 El Camino Real, Suite 130 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 1, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 31, 2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12790 El Camino Real, Suite 150 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 7, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 31, 2031</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12790 El Camino Real, Suite 300 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 1, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 31, 2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12777 High Bluff Drive</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 1, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 31, 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12790 El Camino Real, Suite 200 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 31, 2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12790 El Camino Real, Suite 100 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 31, 2031</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(1) Under the terms of the 12780/12790 El Camino Real master lease, we have two options to extend the term of the lease for a period of ten years each. We were not reasonably certain to exercise either of these options at lease commencement. As such, neither option was recognized as part of the associated operating lease right-of-use asset or liability.</span></div>Note: In connection with our operating leases, in lieu of cash security deposits, Wells Fargo Bank, N.A., issued letters of credit on our behalf, which are secured by deposits totaling $3.2&#160;million.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximate future minimum lease payments under operating leases were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2020 (3 months remaining)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year ending December 31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accreted interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">______________</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note: Amounts presented in the table above exclude $28.3 million of non-cancelable future minimum lease payments for operating leases that have not yet commenced.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626796435352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Summary of Notes Net of Discount and Deferred Financing Costs</a></td>
<td class="text"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes, net of discounts and deferred financing costs, consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">517.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt discount, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(86.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying amount</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626892593816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Income (Loss) Per Share</a></td>
<td class="text"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income per share was calculated as follows:</span></div><div style="margin-bottom:15pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024 Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626794085992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>subsidiary</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_NumberOfIrishSubsidiaries', window );">Number of wholly owned Irish subsidiaries | subsidiary</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff', window );">Accrued interest receivables write-off threshold period</a></td>
<td class="text">90 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest receivables</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff', window );">Accrued interest receivables write-off</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NumberOfIrishSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Irish Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NumberOfIrishSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period when accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), is considered uncollectible and written off, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3C<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL120267859-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of writeoff of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized by reversing interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3D<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL120267862-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626802141704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Collaboration and Licensing Agreements - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
<th class="th" colspan="1">28 Months Ended</th>
<th class="th" colspan="1">123 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2010</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 258.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 222.1<span></span>
</td>
<td class="nump">$ 798.0<span></span>
</td>
<td class="nump">$ 544.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_UpfrontPaymentsMade', window );">Upfront payments made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_IdorsiaPharmaceuticalsLtdMember', window );">Idorsia | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_UpfrontPaymentsMade', window );">Upfront payments made</a></td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Incremental funding provided</a></td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_ResearchCollaborationTerm', window );">Research collaboration term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialCommercialMilestonePayments', window );">Potential commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_TerminationNoticePeriod', window );">Collaboration termination notice period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_IdorsiaPharmaceuticalsLtdMember', window );">Idorsia | Collaborative Arrangement | NBI-827104</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_IdorsiaPharmaceuticalsLtdMember', window );">Idorsia | Collaborative Arrangement | Development Product Candidates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">620.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">620.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">620.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">620.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_XenonPharmaceuticalsIncMember', window );">Xenon | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_TerminationNoticePeriod', window );">Collaboration termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_VoyagerTherapeuticsMember', window );">Voyager | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_TerminationNoticePeriodBeforeFirstCommercialSale', window );">Termination notice period, before first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_TerminationNoticePeriodAfterFirstCommercialSale', window );">Termination notice period, after date of notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_BIALMember', window );">B I A L | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialCommercialMilestonePayments', window );">Potential commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_MinimumSalesRequirementPeriodThresholdToTerminateAgreement', window );">Minimum sales requirement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_TerminationNoticePeriod', window );">Collaboration termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Deferred revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue, balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_UpfrontPaymentsReceived', window );">Upfront payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="nump">$ 19.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePaymentReceipts', window );">Potential milestone payment receipts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe | Collaborative Arrangement | Patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PatentTerm', window );">Patent term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_AbbvieIncMember', window );">AbbVie | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_TerminationNoticePeriod', window );">Collaboration termination notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PotentialMilestonePaymentReceipts', window );">Potential milestone payment receipts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_AbbvieIncMember', window );">AbbVie | Collaborative Arrangement | Patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PatentTerm', window );">Patent term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments made for milestones under a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_MinimumSalesRequirementPeriodThresholdToTerminateAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum Sales Requirement Period, Threshold To Terminate Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_MinimumSalesRequirementPeriodThresholdToTerminateAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PatentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PatentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PotentialCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential payments for commercial milestones under a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PotentialCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PotentialMilestonePaymentReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential later stage milestone payments and royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PotentialMilestonePaymentReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of potential milestone payments to be paid under a license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_ResearchCollaborationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research Collaboration Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_ResearchCollaborationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_TerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of time required for third party collaborator to give written notice prior to terminating the collaborative agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_TerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_TerminationNoticePeriodAfterFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Termination Notice Period After First Commercial Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_TerminationNoticePeriodAfterFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_TerminationNoticePeriodBeforeFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Termination Notice Period Before First Commercial Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_TerminationNoticePeriodBeforeFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_UpfrontPaymentsMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payments made under a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_UpfrontPaymentsMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_UpfrontPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payments received under a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_UpfrontPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_IdorsiaPharmaceuticalsLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_IdorsiaPharmaceuticalsLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nbix_NBI827104Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nbix_NBI827104Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=nbix_DevelopmentProductCandidatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=nbix_DevelopmentProductCandidatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_XenonPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_XenonPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_VoyagerTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_VoyagerTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_BIALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_BIALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_MitsubishiTanabePharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_MitsubishiTanabePharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_AbbvieIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nbix_AbbvieIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626886112968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 517.3<span></span>
</td>
<td class="nump">$ 557.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">519.4<span></span>
</td>
<td class="nump">558.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">283.6<span></span>
</td>
<td class="nump">270.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">285.3<span></span>
</td>
<td class="nump">271.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments | Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">128.9<span></span>
</td>
<td class="nump">142.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">129.3<span></span>
</td>
<td class="nump">142.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">104.8<span></span>
</td>
<td class="nump">144.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">104.8<span></span>
</td>
<td class="nump">144.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=nbix_LongTermInvestmentsMember', window );">Long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">180.3<span></span>
</td>
<td class="nump">299.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">181.4<span></span>
</td>
<td class="nump">299.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=nbix_LongTermInvestmentsMember', window );">Long-term investments | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">142.8<span></span>
</td>
<td class="nump">250.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">143.9<span></span>
</td>
<td class="nump">250.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=nbix_LongTermInvestmentsMember', window );">Long-term investments | Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">37.5<span></span>
</td>
<td class="nump">48.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for Credit Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 37.5<span></span>
</td>
<td class="nump">$ 48.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=nbix_LongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=nbix_LongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626798328536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Securities - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>security</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions', window );">Number of debt securities available for sale</a></td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of debt securities available for sale in unrealized loss position</a></td>
<td class="nump">14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt securities available for sale position number of positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626798761720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Detail) - Corporate debt securities - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less Than 12 Months, Fair Value</a></td>
<td class="nump">$ 39.8<span></span>
</td>
<td class="nump">$ 186.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less Than 12 Months, Unrealized Loss</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 Months or Longer, Fair Value</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 Months or Longer, Unrealized Loss</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total Fair Value</a></td>
<td class="nump">39.8<span></span>
</td>
<td class="nump">186.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total Unrealized Loss</a></td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626881621608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">$ 1,173.0<span></span>
</td>
<td class="nump">$ 1,029.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">428.5<span></span>
</td>
<td class="nump">115.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">700.8<span></span>
</td>
<td class="nump">857.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">43.7<span></span>
</td>
<td class="nump">55.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">429.2<span></span>
</td>
<td class="nump">521.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">429.2<span></span>
</td>
<td class="nump">521.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">166.8<span></span>
</td>
<td class="nump">191.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">166.8<span></span>
</td>
<td class="nump">191.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Securities of government-sponsored entities | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Total debt securities available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">700.8<span></span>
</td>
<td class="nump">857.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Total debt securities available-for-sale | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Total debt securities available-for-sale | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">700.8<span></span>
</td>
<td class="nump">857.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Total debt securities available-for-sale | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities&#8211;biotechnology industry</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">43.7<span></span>
</td>
<td class="nump">55.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities&#8211;biotechnology industry | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities&#8211;biotechnology industry | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities&#8211;biotechnology industry | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">43.7<span></span>
</td>
<td class="nump">55.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=nbix_TotalEquitySecuritiesMember', window );">Total equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">43.7<span></span>
</td>
<td class="nump">55.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=nbix_TotalEquitySecuritiesMember', window );">Total equity securities | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=nbix_TotalEquitySecuritiesMember', window );">Total equity securities | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=nbix_TotalEquitySecuritiesMember', window );">Total equity securities | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">43.7<span></span>
</td>
<td class="nump">55.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember', window );">Cash and money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">425.3<span></span>
</td>
<td class="nump">112.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember', window );">Cash and money market funds | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">425.3<span></span>
</td>
<td class="nump">112.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember', window );">Cash and money market funds | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember', window );">Cash and money market funds | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Total cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">425.3<span></span>
</td>
<td class="nump">112.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Total cash and cash equivalents | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">425.3<span></span>
</td>
<td class="nump">112.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Total cash and cash equivalents | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Total cash and cash equivalents | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_RestrictedCashMember', window );">Total restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_RestrictedCashMember', window );">Total restricted cash | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_RestrictedCashMember', window );">Total restricted cash | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=nbix_RestrictedCashMember', window );">Total restricted cash | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Fair Value</a></td>
<td class="nump">104.8<span></span>
</td>
<td class="nump">144.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 2 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">104.8<span></span>
</td>
<td class="nump">144.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets on recurring basis</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=nbix_TotalEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=nbix_TotalEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=nbix_CashAndMoneyMarketFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=nbix_RestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=nbix_RestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626799530088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRestricted', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 54.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized loss included in earnings</a></td>
<td class="num">$ (7.0)<span></span>
</td>
<td class="num">$ (28.5)<span></span>
</td>
<td class="num">(12.2)<span></span>
</td>
<td class="num">(5.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRestricted', window );">Balance at end of period</a></td>
<td class="nump">43.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities | Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRestricted', window );">Balance at beginning of period</a></td>
<td class="nump">50.7<span></span>
</td>
<td class="nump">77.4<span></span>
</td>
<td class="nump">55.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchases</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">54.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized loss included in earnings</a></td>
<td class="num">(7.0)<span></span>
</td>
<td class="num">(28.5)<span></span>
</td>
<td class="num">(12.2)<span></span>
</td>
<td class="num">(5.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRestricted', window );">Balance at end of period</a></td>
<td class="nump">$ 43.7<span></span>
</td>
<td class="nump">$ 48.9<span></span>
</td>
<td class="nump">$ 43.7<span></span>
</td>
<td class="nump">$ 48.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRestricted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109249958&amp;loc=SL6224234-111729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRestricted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626800525560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - Discount for Lack of Marketability<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Equity securities measurement input</a></td>
<td class="nump">0.160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Equity securities measurement input</a></td>
<td class="nump">0.315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Equity securities measurement input</a></td>
<td class="nump">0.268<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626794021752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Summary of Inventories (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 14.8<span></span>
</td>
<td class="nump">$ 14.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 20.6<span></span>
</td>
<td class="nump">$ 17.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626794022312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Restricted Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 425.3<span></span>
</td>
<td class="nump">$ 112.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 428.5<span></span>
</td>
<td class="nump">$ 115.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626799430504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Disclosure (Detail)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>renewalOption</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash | $</a></td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash | $</a></td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=nbix_A1278012790ElCaminoRealMasterLeaseMember', window );">12780/12790 El Camino Real Master Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_NumberOfRenewalOptions', window );">Number of renewal options | renewalOption</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_A12780ElCaminoRealMember', window );">12780 El Camino Real</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square feet</a></td>
<td class="nump">141,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_A12790ElCaminoRealSuite130Member', window );">12790 El Camino Real, Suite 130</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square feet</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_A12790ElCaminoRealSuite150Member', window );">12790 El Camino Real, Suite 150</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square feet</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_A12790ElCaminoRealSuite300Member', window );">12790 El Camino Real, Suite 300</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square feet</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_A12777HighBluffDriveMember', window );">12777 High Bluff Drive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square feet</a></td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_A12790ElCaminoRealSuite200Member', window );">12790 El Camino Real, Suite 200</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square feet</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_A12790ElCaminoRealSuite100Member', window );">12790 El Camino Real, Suite 100</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square feet</a></td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of renewal options under the terms of the lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=nbix_A1278012790ElCaminoRealMasterLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=nbix_A1278012790ElCaminoRealMasterLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_A12780ElCaminoRealMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_A12780ElCaminoRealMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_A12790ElCaminoRealSuite130Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_A12790ElCaminoRealSuite130Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_A12790ElCaminoRealSuite150Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_A12790ElCaminoRealSuite150Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_A12790ElCaminoRealSuite300Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_A12790ElCaminoRealSuite300Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_A12777HighBluffDriveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_A12777HighBluffDriveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_A12790ElCaminoRealSuite200Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_A12790ElCaminoRealSuite200Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_A12790ElCaminoRealSuite100Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nbix_A12790ElCaminoRealSuite100Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626793975992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Cost</a></td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Payments</a></td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">10 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">5.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626800637288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Liability, Payment, Due (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Year ending December 31, 2020 (3 months remaining)</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Year ending December 31, 2021</a></td>
<td class="nump">10.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Year ending December 31, 2022</a></td>
<td class="nump">10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Year ending December 31, 2023</a></td>
<td class="nump">11.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Year ending December 31, 2024</a></td>
<td class="nump">11.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">79.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">126.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less accreted interest</a></td>
<td class="nump">33.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">92.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current operating lease liabilities</a></td>
<td class="nump">9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">83.0<span></span>
</td>
<td class="nump">$ 86.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced', window );">Non-cancelable future minimum lease payments for operating leases that have not yet commenced</a></td>
<td class="nump">$ 28.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Due After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cancelable future minimum lease payments for operating leases not yet commenced.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626886107736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes - Additional Information (Detail)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 02, 2017 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 517,500,000<span></span>
</td>
<td class="nump">$ 517,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember', window );">2.25% Convertible Senior Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 517,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate percentage</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance</a></td>
<td class="nump">$ 502,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold common stock trading days | d</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive common stock trading days | d</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of common stock price trigger</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_NumberOfConsecutiveBusinessDays', window );">Number of consecutive business days</a></td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_PrincipalAmountOnConversionRate', window );">Principal amount on conversion rate</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice', window );">Minimum percentage of common stock price trigger</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_DebtConversionObservationPeriod', window );">Conversion observation period</a></td>
<td class="text">25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Convertible senior notes convertible in to shares</a></td>
<td class="nump">0.0131711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Convertible senior notes conversion price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 75.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued to settle notes at initial conversion rate (in shares) | shares</a></td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_DebtInstrumentConvertibleConversionPremium', window );">Convertible senior note premium</a></td>
<td class="nump">42.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Market price of common stock (in USD per share) | $ / shares</a></td>
<td class="nump">$ 53.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Convertible senior notes redemption rate</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent', window );">Convertible senior note carrying value of the liability component</a></td>
<td class="nump">$ 368,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Convertible senior note assumed borrowing rate</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Convertible senior note carrying value of the equity component</a></td>
<td class="nump">$ 149,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Convertible senior notes term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Discount on liability component, remaining amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Transaction cost related to issuance of convertible senior notes</a></td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault', window );">Debt instrument events of default percentage of principal and accrued and unpaid interest due and payable upon default</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Convertible senior notes fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 713,000,000.0<span></span>
</td>
<td class="nump">$ 596,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtConversionObservationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The duration of time during which the weighted-average share price is used to calculate the excess conversion value due upon conversion of a convertible note, in the format of PnYnMnD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtConversionObservationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentConvertibleConversionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of excess of the price paid for the convertible note over the closing stock price on the closing date of the convertible note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentConvertibleConversionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the liability component of a convertible note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument events of default percentage of principal and accrued and unpaid interest due and payable upon default.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum percentage of the product of the common stock trading price multiplied by the conversion rate during the measurement period as compared to the principal note amount that triggers a conversion option on the notes, if it falls below this percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_NumberOfConsecutiveBusinessDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Consecutive Business Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_NumberOfConsecutiveBusinessDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_PrincipalAmountOnConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Principal amount on conversion rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_PrincipalAmountOnConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626796588632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Senior Notes - Debt Net of Discounts and Deferred Financing Costs (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal</a></td>
<td class="nump">$ 517.5<span></span>
</td>
<td class="nump">$ 517.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
<td class="num">(5.9)<span></span>
</td>
<td class="num">(6.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Debt discount, net</a></td>
<td class="num">(86.6)<span></span>
</td>
<td class="num">(101.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Net carrying amount</a></td>
<td class="nump">$ 425.0<span></span>
</td>
<td class="nump">$ 408.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28567-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626800568792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share - Schedule of Net Income Per Share (Detail) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income - basic and diluted</a></td>
<td class="num">$ (57.6)<span></span>
</td>
<td class="nump">$ 53.8<span></span>
</td>
<td class="nump">$ 59.4<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">93.3<span></span>
</td>
<td class="nump">91.9<span></span>
</td>
<td class="nump">93.0<span></span>
</td>
<td class="nump">91.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">93.3<span></span>
</td>
<td class="nump">96.1<span></span>
</td>
<td class="nump">98.0<span></span>
</td>
<td class="nump">95.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net (loss) income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in USD per share)</a></td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="nump">$ 0.59<span></span>
</td>
<td class="nump">$ 0.64<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in USD per share)</a></td>
<td class="num">$ (0.62)<span></span>
</td>
<td class="nump">$ 0.56<span></span>
</td>
<td class="nump">$ 0.61<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities', window );">2024 Notes (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nbix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nbix_TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nbix_TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626800809704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net (Loss) Income Per Share - Additional Information (Detail) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 02, 2017</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nbix_StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember', window );">Stock Options Restricted Stock Units And Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember', window );">2.25% Convertible Senior Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued to settle notes at initial conversion rate (in shares)</a></td>
<td class="nump">6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nbix_StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=nbix_StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=nbix_A225ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140626798366472">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
<td class="text">us-gaap:AccountingStandardsUpdate201602Member<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>52
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M#SXU==C2.YQHN<EWQ192:QGGAVO! Z', W!_*:4^G9@7%!NKP_\ 4$L#!!0
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MLL=('9;D.K)S_1@A@O0[<&_6GG!6&_7IJ&0[?@7;7_6T!IMNTSNT")9 QZ\
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M'M*+,.0+T@<2+4D!L,+DH$C>8WQDSD@&^%P:CF.S'J0:O)H0F['@1L0Q:TT
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MB^,7SPNY4#>J^KVXMO#I.%!)]4KEI3:YL&K^T]'E](>73_!^NN$/K=9E]+=
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M56XD]&E<;0J('9DENEYA#$$/!?IG)OFB+/ER:#EC-YV[LAQFJ[P^5I*_X!3
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M#THISTZGC\].70L,XF':W;ZU]&FZV;3UT;64M\J5+;_1&C8;YNQ'.S:#F]U
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MEJH51$$H$?@^S(Y!P/8!#[+YSL4FUJGBFH'UP8DH\[QVM9*V"B%E$!2ZBAL
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M,!6LRBO-GI6C%/L.'Z%@$_$.FM]ZILNE%I^@ L^4VY@0KXPM?#/@CAG@+BL
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MRV<(,O"82O';(]%!!#?#QM,A<#7LN^'KSFA9S'[N19$9L/-2TWZ#Y>%!;N+
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M*K.B/R'!@1O@#7!];DSE/R"#\"-:+_X%4$L#!!0    ( (* :5%@0/1R^00
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M*!X#^8481$/_CH/H04YL,<;ZW5PBX;2(O3_+U/NQ3T\4Q'CNA4&TWTY,OX>
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M[[)9Y0<)'["+89)^@CS-TP-\D[&Z2>";_*.Z5[B2KE#&;2S"CXNU(\OC\/-
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M%AJJ7;FB*<WS-6-YTA4HH#6)&8^2 JLNJOE47NZIP4T)Q&D.^>B&YS!T"6O
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MAH,]77[ID;Y@-8KOB!XLRHS=1@6\:];O^21?@__QU7!\-QX?BP]*S#$*=BM
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M1-NLU$=7V<*:H![D7P]?'$4P0&2.BK38:UGL]);%SM7/KHGKH-XVI2FG\X_
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M-6SL'-,V5'D@>'&VD\)3FB\*R-:_,$N7- T[YP:&C6&OL\/2E\I8YBH%162
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M;&=14%$F%3>D3?AF5[=2*O9D:NV_&*Z-M'K@%L'X:V(*6FJ[&![VE3Y!\IC
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MFB4@MM;H'*V%-$KH=PS70@GJM@(JK0L+'I%&I_"H'9?D_R[S@&)$)Y[N-)K
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MG4[L:U)=<^LF1M:^H:32V/;DAZ7]'Z!R!G8_E])L)DY@^,/,?@)02P,$%
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M-3=&2I4S_ QT^!X@#6D5#EVHT9=DV4W@<%@!OU3#;W>>@&NU\*LFWUEJW:R
M7[>W7A7[C1K^0+9[>.6M^]#:>B5\TMIZY:V[?9WS'U]G??HZZ[/76;]KGW>K
MJ@E?Y_Q]DW6GJ^JX3VKX:,OJK.?Z7T\Y1X_TZ37Z,CSS2,"(,>RM(VZ)."=[
M/.<;P@#?8 _D07]/A4XPX<0-_E%X9*0>&9%'1HU'G\DC\78$K)CO@J68=DPL
MC@47\TW"PH15-6NLM!\I#5?[C^?(''3%6'C,-E6%%$)=F)>ZC:4&&2EK.,C+
M?"S+F(:1RN0B-]/(367D7_!W8F/P"]0F17%[^ZF1_I$DW$H]LI1A?]V*5 M[
M6_P<+VI<;).JQK)*MQR&/5!URP>I[8'2]KW/A4DJ%D\N=8BH+A'8WH^J*HNU
MF5D7AII6*)\V0M-!.9B2T+Q!*!?R, UYJ QY8OLLH(>6&=3D8E8[DD*#F04V
M_"VE-D[T9.^\85;?=XBD=:2^\]Z211&+<EOM/#M<RV^9_TBK%X/C1%UV6EE=
M5..%'/A0;YBO <%L*:9I;HO!"7,KG5!K0^!9: M4V9&#'ZHGOVS&I>^*,;]L
MWY>)YFS/66:Q+]L(3=L(S1N$\O'+\0_5\_^BE!#JQ;\]GXO=']@21OWJ4E%K
M'FK QL_*+$G^@/W7S@]Q[6X\^6. +*@9*J.2(J!U+,-$4@?\O=P!R[R@]\UB
MC;80FK81FC<(Y8.6Y %?S1[BVJ58PSG^-CJZ9[Z]$RNX"Y$I:F-.5&6()+V@
M8Z$7).D%J>GEI161J,NFJ(^*4ZN-T+2-T+Q!*!^T9#6D9K6_B"<FU&&K"219
M"QW+/@5)OD)JOCI\7E\T:&Z>UTBR"E+/_F_^,UZ+.W)@AB0OH&/96"!)&TB]
MM?A2EY/W8$%6/A.[3,H"GEUO!-BI6A%>-EB"@^:4269!:F91N(U7HLY .$:!
MOTHN5KJKM@"C99O*6<D(2,T(8S !(S ]L+YT.?#U8QGXNASX>MN!_^(5JUX>
MQE9Q,:"7=R%%F6D+/7.U3#YV.?=U]=R?%<.L>IB5Z,A&4,<X>N:1E7K/,:,>
M=7=NU*H!8.3'CL;[JOJ!>]N@LGD;HTM:T-7#>T9YL%O08$/!%^SA!3FT->2(
MU\UC:0U)![IZFW X.5XU:&XQ:G7)$+IZ;E^2%6&,V**,XL>.C"S]M4?_K7[%
ME6BS,O6L%1\RWB9"V7T[[ Z*?5O6A+K]FM:0S*&KYWHQ',%SV,%>)4?<)+JR
M+E@9%Y)@6@A-VPC-&X3R$4OZT=7T4WJD(Q)(1$575]:P-([TFG%D2&(RM/_A
M@?4LT9I[N%>HI+M$)E=)PTPIY3V6M&4<O$^);]^VFK.,"AXI;E=:R$Q;R,S5
M,OG )6<939SU@M$LKMUC'M74+Y!PCNK]AN0OXUCV,D;FI4O#L[<HTKJG@%<-
M:*@U\J<AV<Q0;UA&B\4W>BAI&I*@C&/9KQB2C0PU&QU.FM<-FEN0IB%9QE"S
MS&$3[]HHO\XH+E4_5,CHI=%0\8*E[LF6(8G$4!/)P4.Q@E/Z119M(S1M(S1O
M$,J_>)0<9JHYK+GG7C@-34E&)CR2/C0E3YAJGE!/P^L&M&H:]C*?AXDV64??
M? :BB78>C]^1IV?3[TI'T==UA?-C>'(-*\[?P)-)U?E;>/(Q_II4FHT_;IUA
MMJ9> !RR$BYH74LT%HN_%XT/N+^-/EI;^%ST=O1S0[!-6"@@KJ]\T3K)06@@
M_6KW_#]02P,$%     @ @H!I450?/W&6!0  [!X  !D   !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&ULO9E=C]HX%(;_BH5ZT4I#B#\"H6*0IHS:K3251D73
MO5CMA0<,1$UBUC%,=[4_?IW@B1/B.*%=<3-#R#G'KV._3P[)[(6+[]F.,0E^
M)'&:W0YV4N[?CT;9:L<2FGE\SU)U9L-%0J4Z%-M1MA>,KHND)!XAWQ^/$AJE
M@_FL^.Y1S&?\(.,H98\"9(<DH>+O#RSF+[<#.'C]XFNTW<G\B]%\MJ=;MF3R
M:?\HU-&HK+*.$I9F$4^!8)O;P1U\OPC\/*&(^!:QEZSR&>13>>;\>W[P>7T[
M\'-%+&8KF9>@ZM^1+5@<YY64CK]TT4$Y9IY8_?Q:_6,Q>3699YJQ!8]_C]9R
M=SL(!V#--O00RZ_\Y3>F)Q3D]58\SHJ_X$7'^@.P.F22)SI9*4BB]/2?_M 7
MHI( 24L"T@FH;P+6";B8Z$E9,:U[*NE\)O@+$'FTJI9_**Y-D:UF$Z7Y,BZE
M4&<CE2?G]^Q9@B5;'40D(Y:!(;A+N)#1/VP-%CR3-^"3X%D&GE*U2>+BZT]J
M<V2 IFOPH,ZP[ ;<Q6HWT'3%@-I78"'8.I+Z9!'WD48"?*/Q@0&^ >=#WAUI
M%-/GF W5P@R7-&;@[3V3ZLMW2L[3\AZ\??,.O %1"KY$<:P6/YN-I)I[/H/1
M2L_SPVF>J&6>2[;W /9O /*1;TE?N-/OV4JEPSP=3NOI(W7%R\N.RLN.BGJD
M3<Y.7>2A9")1TSJR3"IGR,Q1&)>%<5$8]UO/F\K556LSS/*K^\>#2@*?)4NR
M/QU#DG)(XIQ+?</8EN:4/R[R<ZX<YP&<>'@V.E97P!(55*-JXH)27. 4=[9O
M;>I.!2:5<9$'S[0U8WQO:E<V+I6-^RK+K6)3=BH05$<]T^6*J*F:E*HF[L5L
MM[)-X:3O^&$Y?N@<WZ#"-ES86(8 3CUR=E$L44'H(;NP:2EL^A..!?^J32_V
M7%#)U-U#>2\KO>>P%O0-GOUK^1E6[@GP%QVM"]1,$V)O?+82MK")[P7VI8"&
MGM"-SQZNUA6J0T-O<JZO&=2NSB 8XE]UMJ[@LK8SI*[,D!IVH/HR=^MJ?208
M'D,WD-T&AQ88AT'C5J'#@MJ^@BW2#)"AF\BM%J\T*ZI_V?(C$VE^;ICM53/"
MU64$ZJC3](;!<'(UTQOP0C=Y>YB^"5:(PLI]4"^.)8R@MALY- "&;@+W,?W4
MXN?SVT-'4+V?,Z!&_J^:7E=PF=X94E=F:(XZ:'Z9Z76U/A(JW:Z;UV[3(PNJ
MT;1A>EN8VE>3%G$&U\B-:\>=/4F86$4T!GNZ9\+5]QL$(W(M;R,#7>2&;K>W
M41.\T"=>>+X&EC!"VFZ9R* 7]6Z&V[R-NKMA9TA=F6$Q<C?$?7SMZH*ULMZ-
M,C+ 1AW OM#786\)!LG(C>0.7S=!:]U3EK#V/84-D;&;R \\W5[T$]L0%<-K
M>1@;AF(W0[L]C"V #/T&1RUA:#IMNS_CRI.'WFUOFX=UA7I3CL[U-8-:FW)L
MN(O=K6\/'^L*U8&'?N-10%=479]!-.Y ]&5NQLT.N,7-V$ 8NR'L=K-.KN\N
MV.BN+&'Y[FJY2V/#8>SFL-7-/_GS&QO&XO!J3C=4Q6ZJ]G"Z#9FH059+& I:
MO40,64GO7K?-Z;J"V^F6H'9UAL[$W>_V<#II/I>P.+TKJJ[/@)QT@/PRI^MJ
M/9Q.#*J)&]5NIQ,+I0EN_,ZSA.6[J^6Q**D\3G:3NLWI_\^O<&*(3(*K/4HW
M#"9N!O=XF-X$+)Y47*,7IQE%P@H@ZO(,A4GO;KC5^=W=L#.DKLR0FKB[X3ZN
M=W7 6EGO)ID8G),.G%_H]VE?"8$!=N &MMOO.GGLWE&6*,N.&E5>1>;O@;]0
ML<U?%\9LH])\;Z+F)4ZO5D\'DN^+MY//7$J>%!]WC*Z9R /4^0WG\O4@?^%9
MON">_P=02P,$%     @ @H!I49L",J,? @  K 0  !D   !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&ULK51+C],P$/XK5DX@+9LTZ;)HE49JMR!Z %5; 0?$
MP4DFC;6.G;4GS2Z_GK&3AH):3EP2/^9[S(SMM-?FT=8 R)X;J>PBJ!';NS"T
M10T-M]>Z!44[E38-1YJ:?6A; [STH$:&<12]#1LN5)"E?FUKLE1W*(6"K6&V
M:QIN7E8@=;\(9L%QX4'L:W0+89:V? \[P"_MUM LG%A*T8"R0BMFH%H$R]G=
M:N[B?<!7 ;T]&3.72:[UHYMLRD40.4,@H4#'P.EW@'N0TA&1C:>1,Y@D'?!T
M?&3_X'.G7')NX5[+;Z+$>A&\"U@)%>\D/NC^(XSYW#B^0DOKOZP?8F^3@!6=
M1=V,8'+0"#7\^?-8AQ- '%\ Q",@]KX'(>]RS9%GJ=$],RZ:V-S I^K19$XH
MUY0=&MH5A,-L#3FR'12=$2C LC=L69;"%8Q+ME%#UUWY7JT!N9"OTQ!)UH'#
M8I18#1+Q!8D=M-<LB:Y8',61':1>_J0)R?5D/9ZLQYXWN<"[40>P2 <$[17S
M>7!5LO=/'=&?IO1]F5LTU/X?_Q!-)M'$B\XOB'[NFAP,TQ6UGA3M;QE^H/+P
M7 *CHC'+)9PKU<!^X]G=A3EDLWF2AH<SEN:3I?E_L\2$8IVBVRO%3RB9U-:R
M5EO?\'-VYV?L_N4V/#E\[AY_XF8OE&42*@)%U[>$-L/=&":H6W\><XUTNOVP
MIN<$C N@_4IK/$[<$9\>J.P74$L#!!0    ( (* :5'1%7S@R0(  #\(   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;)6676_:,!2&_XH5]:*5"OG@
MLQ4@M:!NE:B$2MM=3+LP<"!6'3NS#73[]3MVTBP4&N@-L>/S'C_GM6/3VTKU
MJF, 0]X2+G3?BXU)KWU?SV-(J*[+% 2.+*5*J,&N6ODZ54 73I1P/PJ"MI]0
M)KQ!S[V;J$%/K@UG B:*Z'624/7G%KC<]KW0>W_QR%:QL2_\02^E*YB">4XG
M"GM^D67!$A":24$4+/O>37@][-IX%_#"8*M+;6(KF4GY:COWB[X76"#@,#<V
M \7'!H; N4V$&+_SG%XQI166V^_9[USM6,N,:AA*_H,M3-SWNAY9P)*NN7F4
MV^^0U].R^>:2:_=+MGELX)'Y6AN9Y&(D2)C(GO0M]Z$D")N?"*)<$)TJ:.2"
MABLT(W-EC:BA@YZ26Z)L-&:S#>>-4V,U3-A5G!J%HPQU9C""F2%3F*\5,PPT
MJ9%O2FI-G@7N"<[^PH*,L8\C5"S('66*O%"^!G*SH8S3&8<:VEF;4@[D7FQ
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M^0[2 /!\+83^,,P(Z?X8Z5]02P,$%     @ @H!I49<DV;AD @  -@8  !D
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M5V@8*/@%YESEI5 ;B?!JCIKQ\C6< :_AFI>E :[&L3;Y;%2<-]J7.VW:H;W
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M2#, WV\%KJ6^,0=UIY/<Y7]02P,$%     @ @H!I4<90LL*3 @  A 8  !D
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MK5=__0F_79-:E<W1GW7_2>:?4$L! A0#%     @ @H!I40=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" ""@&E1: AI_^X    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " ""@&E1F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( (* :5%;
M:R^D0 4  &05   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " ""@&E1OQ- H_H%   V&   &
M    @(&##0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M@H!I4=9KZ%4B P  'PL  !@              ("!LQ,  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    ( (* :5%#&Q7$P 8  -$=   8
M          " @0L7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    " ""@&E1D[C5!7$'   #*@  &               @($!'@  >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ @H!I47QNL4<"!@  #Q@
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M965T,3 N>&UL4$L! A0#%     @ @H!I4>.OA/I= @  & 4  !D
M     ("!T5P  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (* :5$N /VVZA   #\P   9              "
M@9]Z  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ @H!I
M445Y*'RY!   =0\  !D              ("!P(L  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    " ""@&E1S"%7 <\$  #O#@  &0
M        @(&PD   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   ( (* :5'-<7C1:@(  " %   9              " @;:5  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ @H!I48O"$8O' @  ;P8
M !D              ("!5Y@  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    " ""@&E18DF&$I,$  ">"P  &0              @(%5FP
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( (* :5$BSGX&
MHP(  )<%   9              " @1^@  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ @H!I49ES?1(7 P  I 8  !D
M ("!^:(  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " ""
M@&E1I +]ZY4"  !M!@  &0              @(%'I@  >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( (* :5'/0;. 9 <  ,$K   9
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M970R.2YX;6Q02P$"% ,4    " ""@&E1V,WO_OP#   D#@  &0
M    @('CQ   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M (* :5$)U7D4@P(  (D'   9              " @1;)  !X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ @H!I43<5=3AH @  /08  !D
M             ("!T,L  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    " ""@&E1ER39N&0"   V!@  &0              @(%OS@  >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( (* :5%':&"RM ,
M (T0   9              " @0K1  !X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ @H!I46HX<V>X @  O <  !D              ("!
M]=0  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " ""@&E1
M!:#'2SP#  "3"@  &0              @('DUP  >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    ( (* :5&Y,.=I@P4  -45   9
M      " @5?;  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ @H!I4<90LL*3 @  A 8  !D              ("!$>$  'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " ""@&E1E>GB0D<$   F$0
M&0              @(';XP  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    ( (* :5&]%/1FTP(  $,(   9              " @5GH  !X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ @H!I46H,Q+/@
M 0  5 0  !D              ("!8^L  'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    " ""@&E1#7=@^F@"  "$#0  #0
M@ %Z[0  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( (* :5&7BKL<P    !,"
M   +              "  0WP  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( (*
M:5&8!]\7W ,  +H;   /              "  ?;P  !X;"]W;W)K8F]O:RYX
M;6Q02P$"% ,4    " ""@&E1*5V(H),!  #B&   &@              @ '_
M]   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " ""@&E1
MB(RI-Z4!   O&0  $P              @ '*]@  6T-O;G1E;G1?5'EP97-=
:+GAM;%!+!08     ,0 Q $X-  "@^      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>230</ContextCount>
  <ElementCount>295</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>53</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements Of Operations And Comprehensive (Loss) Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome</Role>
      <ShortName>Condensed Consolidated Statements Of Operations And Comprehensive (Loss) Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Significant Collaboration and Licensing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreements</Role>
      <ShortName>Significant Collaboration and Licensing Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Debt Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecurities</Role>
      <ShortName>Debt Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2116105 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Cash, Cash Equivalents and Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash</Role>
      <ShortName>Cash, Cash Equivalents and Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2127108 - Disclosure - Convertible Senior Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotes</Role>
      <ShortName>Convertible Senior Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2131109 - Disclosure - Net (Loss) Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/NetLossIncomePerShare</Role>
      <ShortName>Net (Loss) Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Debt Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesTables</Role>
      <ShortName>Debt Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/DebtSecurities</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/FairValueMeasurements</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/Inventories</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables</Role>
      <ShortName>Cash, Cash Equivalents and Restricted Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2323305 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/Leases</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2328306 - Disclosure - Convertible Senior Notes (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotesTables</Role>
      <ShortName>Convertible Senior Notes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/ConvertibleSeniorNotes</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2332307 - Disclosure - Net (Loss) Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/NetLossIncomePerShareTables</Role>
      <ShortName>Net (Loss) Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/NetLossIncomePerShare</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Organization and Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Significant Collaboration and Licensing Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail</Role>
      <ShortName>Significant Collaboration and Licensing Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail</Role>
      <ShortName>Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Debt Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Debt Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail</Role>
      <ShortName>Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail</Role>
      <ShortName>Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Inventories - Summary of Inventories (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail</Role>
      <ShortName>Inventories - Summary of Inventories (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail</Role>
      <ShortName>Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Leases - Disclosure (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesDisclosureDetail</Role>
      <ShortName>Leases - Disclosure (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Leases - Liability, Payment, Due (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail</Role>
      <ShortName>Leases - Liability, Payment, Due (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Convertible Senior Notes - Additional Information (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail</Role>
      <ShortName>Convertible Senior Notes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Convertible Senior Notes - Debt Net of Discounts and Deferred Financing Costs (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail</Role>
      <ShortName>Convertible Senior Notes - Debt Net of Discounts and Deferred Financing Costs (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - Net (Loss) Income Per Share - Schedule of Net Income Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail</Role>
      <ShortName>Net (Loss) Income Per Share - Schedule of Net Income Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/NetLossIncomePerShareTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Net (Loss) Income Per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/role/NetLossIncomePerShareAdditionalInformationDetail</Role>
      <ShortName>Net (Loss) Income Per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.neurocrine.com/role/NetLossIncomePerShareTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="nbix-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - nbix-20200930.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - nbix-20200930.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="nbix-20200930.htm">nbix-20200930.htm</File>
    <File>nbix-20200930.xsd</File>
    <File>nbix-20200930_cal.xml</File>
    <File>nbix-20200930_def.xml</File>
    <File>nbix-20200930_lab.xml</File>
    <File>nbix-20200930_pre.xml</File>
    <File>nbix-20200930exhibit311.htm</File>
    <File>nbix-20200930exhibit312.htm</File>
    <File>nbix-20200930exhibit32.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>58
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nbix-20200930.htm": {
   "axisCustom": 0,
   "axisStandard": 19,
   "contextCount": 230,
   "dts": {
    "calculationLink": {
     "local": [
      "nbix-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nbix-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "nbix-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nbix-20200930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nbix-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "nbix-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 368,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 2,
    "http://www.neurocrine.com/20200930": 2,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 9
   },
   "keyCustom": 29,
   "keyStandard": 266,
   "memberCustom": 25,
   "memberStandard": 27,
   "nsprefix": "nbix",
   "nsuri": "http://www.neurocrine.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.neurocrine.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Fair Value Measurements",
     "role": "http://www.neurocrine.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116105 - Disclosure - Inventories",
     "role": "http://www.neurocrine.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:RestrictedCashTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Cash, Cash Equivalents and Restricted Cash",
     "role": "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash",
     "shortName": "Cash, Cash Equivalents and Restricted Cash",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:RestrictedCashTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Leases",
     "role": "http://www.neurocrine.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127108 - Disclosure - Convertible Senior Notes",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotes",
     "shortName": "Convertible Senior Notes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131109 - Disclosure - Net (Loss) Income Per Share",
     "role": "http://www.neurocrine.com/role/NetLossIncomePerShare",
     "shortName": "Net (Loss) Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:BusinessDescriptionPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Significant Accounting Policies (Policies)",
     "role": "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:BusinessDescriptionPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Debt Securities (Tables)",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesTables",
     "shortName": "Debt Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.neurocrine.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Inventories (Tables)",
     "role": "http://www.neurocrine.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ia560b50de8b4433b9f89b2a27688c2f6_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ia560b50de8b4433b9f89b2a27688c2f6_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Cash, Cash Equivalents and Restricted Cash (Tables)",
     "role": "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables",
     "shortName": "Cash, Cash Equivalents and Restricted Cash (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323305 - Disclosure - Leases (Tables)",
     "role": "http://www.neurocrine.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328306 - Disclosure - Convertible Senior Notes (Tables)",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesTables",
     "shortName": "Convertible Senior Notes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332307 - Disclosure - Net (Loss) Income Per Share (Tables)",
     "role": "http://www.neurocrine.com/role/NetLossIncomePerShareTables",
     "shortName": "Net (Loss) Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "nbix:BusinessDescriptionPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbix:NumberOfIrishSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Organization and Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "nbix:BusinessDescriptionPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbix:NumberOfIrishSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "subsidiary",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Significant Collaboration and Licensing Agreements - Additional Information (Detail)",
     "role": "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail",
     "shortName": "Significant Collaboration and Licensing Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i1bc3cf10ca8443d19bf1d4cf81b112be_I20200731",
      "decimals": "-5",
      "lang": "en-US",
      "name": "nbix:UpfrontPaymentsMade",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i57f46c4cf6f1473794e3e0ebadd216a7_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Detail)",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail",
     "shortName": "Debt Securities - Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i57f46c4cf6f1473794e3e0ebadd216a7_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ia560b50de8b4433b9f89b2a27688c2f6_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Debt Securities - Additional Information (Detail)",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetail",
     "shortName": "Debt Securities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ia560b50de8b4433b9f89b2a27688c2f6_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "nbix:DebtSecuritiesAvailableForSalePositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "security",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i89d87039af9d4dc6bd52a3bb4c9ebf21_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Detail)",
     "role": "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail",
     "shortName": "Debt Securities - Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i89d87039af9d4dc6bd52a3bb4c9ebf21_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ia560b50de8b4433b9f89b2a27688c2f6_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Investments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail)",
     "role": "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Investments Measured at Fair Value on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ia560b50de8b4433b9f89b2a27688c2f6_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Investments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ia560b50de8b4433b9f89b2a27688c2f6_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ia560b50de8b4433b9f89b2a27688c2f6_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i2eac757373044c73b10d89d2901aca4a_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiRestricted",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail)",
     "role": "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail",
     "shortName": "Fair Value Measurements - Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Quarterly Basis Using Significant Unobservable Inputs (Level 3) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i3a5d39b84bb845bd89918fb5088efac0_I20200630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiRestricted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i0aa63587c87c4b9cab14160d1d2d336a_I20200930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "role": "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i0aa63587c87c4b9cab14160d1d2d336a_I20200930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ia560b50de8b4433b9f89b2a27688c2f6_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Inventories - Summary of Inventories (Detail)",
     "role": "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail",
     "shortName": "Inventories - Summary of Inventories (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ia560b50de8b4433b9f89b2a27688c2f6_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ia560b50de8b4433b9f89b2a27688c2f6_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)",
     "role": "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail",
     "shortName": "Cash, Cash Equivalents and Restricted Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ia560b50de8b4433b9f89b2a27688c2f6_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "nbix:SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ia560b50de8b4433b9f89b2a27688c2f6_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Leases - Disclosure (Detail)",
     "role": "http://www.neurocrine.com/role/LeasesDisclosureDetail",
     "shortName": "Leases - Disclosure (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i132f21d3f9184d5493988e86fd0dc307_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://www.neurocrine.com/role/LeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ia560b50de8b4433b9f89b2a27688c2f6_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Leases - Liability, Payment, Due (Detail)",
     "role": "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail",
     "shortName": "Leases - Liability, Payment, Due (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ia560b50de8b4433b9f89b2a27688c2f6_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ia560b50de8b4433b9f89b2a27688c2f6_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Convertible Senior Notes - Additional Information (Detail)",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail",
     "shortName": "Convertible Senior Notes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i95cb82a96ba143258e37a17f6ad70802_I20170502",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ia560b50de8b4433b9f89b2a27688c2f6_I20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Convertible Senior Notes - Debt Net of Discounts and Deferred Financing Costs (Detail)",
     "role": "http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail",
     "shortName": "Convertible Senior Notes - Debt Net of Discounts and Deferred Financing Costs (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ia560b50de8b4433b9f89b2a27688c2f6_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - Net (Loss) Income Per Share - Schedule of Net Income Per Share (Detail)",
     "role": "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail",
     "shortName": "Net (Loss) Income Per Share - Schedule of Net Income Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ic83bc456a2d24aea914f39864a46ea36_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "nbix:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements Of Operations And Comprehensive (Loss) Income",
     "role": "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
     "shortName": "Condensed Consolidated Statements Of Operations And Comprehensive (Loss) Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ib4da8ca0bc944c5e86c64c446b665a1e_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i8a2aaf5893684e989b254984e9c0e7c2_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Net (Loss) Income Per Share - Additional Information (Detail)",
     "role": "http://www.neurocrine.com/role/NetLossIncomePerShareAdditionalInformationDetail",
     "shortName": "Net (Loss) Income Per Share - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i8a2aaf5893684e989b254984e9c0e7c2_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ib022af9959ba424787b942770385acd6_I20181231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "ib022af9959ba424787b942770385acd6_I20181231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Significant Accounting Policies",
     "role": "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies",
     "shortName": "Organization and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Significant Collaboration and Licensing Agreements",
     "role": "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreements",
     "shortName": "Significant Collaboration and Licensing Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Debt Securities",
     "role": "http://www.neurocrine.com/role/DebtSecurities",
     "shortName": "Debt Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-20200930.htm",
      "contextRef": "i855097c18a2c429892d9974c37a69a36_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": null,
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - nbix-20200930.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - nbix-20200930.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 53,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nbix_A12777HighBluffDriveMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "12777 High Bluff Drive. Office facility held for productive use.",
        "label": "12777 High Bluff Drive [Member]",
        "terseLabel": "12777 High Bluff Drive"
       }
      }
     },
     "localname": "A12777HighBluffDriveMember",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesDisclosureDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_A1278012790ElCaminoRealMasterLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "12780/12790 El Camino Real Master Lease.",
        "label": "12780/12790 El Camino Real Master Lease [Member]",
        "terseLabel": "12780/12790 El Camino Real Master Lease [Member]"
       }
      }
     },
     "localname": "A1278012790ElCaminoRealMasterLeaseMember",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesDisclosureDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_A12780ElCaminoRealMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "12780 El Camino Real. Office and laboratory facilities held for productive use.",
        "label": "12780 El Camino Real [Member]",
        "terseLabel": "12780 El Camino Real"
       }
      }
     },
     "localname": "A12780ElCaminoRealMember",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesDisclosureDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_A12790ElCaminoRealSuite100Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "12790 El Camino Real Suite 100. Office facility held for productive use.",
        "label": "12790 El Camino Real Suite 100 [Member]",
        "terseLabel": "12790 El Camino Real, Suite 100"
       }
      }
     },
     "localname": "A12790ElCaminoRealSuite100Member",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesDisclosureDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_A12790ElCaminoRealSuite130Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "12790 El Camino Real Suite 130. Office facility held for productive use.",
        "label": "12790 El Camino Real Suite 130 [Member]",
        "terseLabel": "12790 El Camino Real, Suite 130"
       }
      }
     },
     "localname": "A12790ElCaminoRealSuite130Member",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesDisclosureDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_A12790ElCaminoRealSuite150Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "12790 El Camino Real Suite 150. Office facility held for productive use.",
        "label": "12790 El Camino Real Suite 150 [Member]",
        "terseLabel": "12790 El Camino Real, Suite 150"
       }
      }
     },
     "localname": "A12790ElCaminoRealSuite150Member",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesDisclosureDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_A12790ElCaminoRealSuite200Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "12790 El Camino Real Suite 200. Office facility held for productive use.",
        "label": "12790 El Camino Real Suite 200 [Member]",
        "terseLabel": "12790 El Camino Real, Suite 200"
       }
      }
     },
     "localname": "A12790ElCaminoRealSuite200Member",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesDisclosureDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_A12790ElCaminoRealSuite300Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "12790 El Camino Real Suite 300. Office facility held for productive use.",
        "label": "12790 El Camino Real Suite 300 [Member]",
        "terseLabel": "12790 El Camino Real, Suite 300"
       }
      }
     },
     "localname": "A12790ElCaminoRealSuite300Member",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesDisclosureDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_A225ConvertibleSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2.25% Convertible Senior Notes.",
        "label": "2.25% Convertible Senior Notes [Member]",
        "terseLabel": "2.25% Convertible Senior Notes due 2024"
       }
      }
     },
     "localname": "A225ConvertibleSeniorNotesMember",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail",
      "http://www.neurocrine.com/role/NetLossIncomePerShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_AbbvieIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information related to AbbVie Inc., an entity with which Neurocrine has a collaboration agreement.",
        "label": "Abbvie Inc [Member]",
        "terseLabel": "AbbVie"
       }
      }
     },
     "localname": "AbbvieIncMember",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_BIALMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information related to BIAL, an entity with which Neurocrine has a license agreement.",
        "label": "B I A L [Member]",
        "terseLabel": "B I A L"
       }
      }
     },
     "localname": "BIALMember",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_BusinessDescriptionPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Description",
        "label": "Business Description [Policy Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "BusinessDescriptionPolicyTextBlock",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbix_CashAndMoneyMarketFundMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions, and funds that invest in short-term money-market instruments, for example, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Cash And Money Market Fund [Member]",
        "terseLabel": "Cash and money market funds"
       }
      }
     },
     "localname": "CashAndMoneyMarketFundMember",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration revenue.",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_DebtConversionObservationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The duration of time during which the weighted-average share price is used to calculate the excess conversion value due upon conversion of a convertible note, in the format of PnYnMnD.",
        "label": "Debt Conversion Observation Period",
        "terseLabel": "Conversion observation period"
       }
      }
     },
     "localname": "DebtConversionObservationPeriod",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_DebtInstrumentConvertibleConversionPremium": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of excess of the price paid for the convertible note over the closing stock price on the closing date of the convertible note.",
        "label": "Debt Instrument Convertible Conversion Premium",
        "terseLabel": "Convertible senior note premium"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPremium",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nbix_DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying amount of the liability component of a convertible note.",
        "label": "Debt Instrument Convertible Initial Carrying Amount Of Liability Component",
        "terseLabel": "Convertible senior note carrying value of the liability component"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleInitialCarryingAmountOfLiabilityComponent",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument events of default percentage of principal and accrued and unpaid interest due and payable upon default.",
        "label": "Debt Instrument Events Of Default Percentage Of Principal And Accrued And Unpaid Interest Due And Payable Upon Default",
        "terseLabel": "Debt instrument events of default percentage of principal and accrued and unpaid interest due and payable upon default"
       }
      }
     },
     "localname": "DebtInstrumentEventsOfDefaultPercentageOfPrincipalAndAccruedAndUnpaidInterestDueAndPayableUponDefault",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nbix_DebtSecuritiesAvailableForSalePositionNumberOfPositions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities available for sale position number of positions.",
        "label": "Debt Securities Available For Sale Position Number Of Positions",
        "terseLabel": "Number of debt securities available for sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSalePositionNumberOfPositions",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "nbix_DevelopmentProductCandidatesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development Product Candidates",
        "label": "Development Product Candidates [Member]",
        "terseLabel": "Development Product Candidates"
       }
      }
     },
     "localname": "DevelopmentProductCandidatesMember",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_IdorsiaPharmaceuticalsLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Idorsia Pharmaceuticals Ltd",
        "label": "Idorsia Pharmaceuticals Ltd [Member]",
        "terseLabel": "Idorsia"
       }
      }
     },
     "localname": "IdorsiaPharmaceuticalsLtdMember",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the treasury stock method.",
        "label": "Incremental Common Shares Attributable To Dilutive Effect Of Conversion Of Debt Securities",
        "terseLabel": "2024 Notes (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfDebtSecurities",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "nbix_InvestmentIncomeAndOtherNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment income and other net.",
        "label": "Investment Income And Other Net",
        "terseLabel": "Investment income and other, net"
       }
      }
     },
     "localname": "InvestmentIncomeAndOtherNet",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Due After Year Four",
        "label": "Lessee, Operating Lease, Liability, Payments, Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_LongTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments which are intended be sold or mature more than one year from the balance sheet date or operating cycle, if longer.",
        "label": "Long Term Investments [Member]",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestmentsMember",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_MilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments made for milestones under a collaboration agreement.",
        "label": "Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_MinimumPercentageOfTradingPriceToLastReportedSalePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum percentage of the product of the common stock trading price multiplied by the conversion rate during the measurement period as compared to the principal note amount that triggers a conversion option on the notes, if it falls below this percentage.",
        "label": "Minimum Percentage Of Trading Price To Last Reported Sale Price",
        "terseLabel": "Minimum percentage of common stock price trigger"
       }
      }
     },
     "localname": "MinimumPercentageOfTradingPriceToLastReportedSalePrice",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nbix_MinimumSalesRequirementPeriodThresholdToTerminateAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum Sales Requirement Period, Threshold To Terminate Agreement",
        "label": "Minimum Sales Requirement Period, Threshold To Terminate Agreement",
        "terseLabel": "Minimum sales requirement period"
       }
      }
     },
     "localname": "MinimumSalesRequirementPeriodThresholdToTerminateAgreement",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_MitsubishiTanabePharmaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information related to the Mitsubishi Tanabe Pharma Corporation.",
        "label": "Mitsubishi Tanabe Pharma Corporation [Member]",
        "terseLabel": "Mitsubishi Tanabe"
       }
      }
     },
     "localname": "MitsubishiTanabePharmaCorporationMember",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_NBI827104Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "NBI-827104",
        "label": "NBI-827104 [Member]",
        "terseLabel": "NBI-827104"
       }
      }
     },
     "localname": "NBI827104Member",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non cancelable future minimum lease payments for operating leases not yet commenced.",
        "label": "Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced",
        "terseLabel": "Non-cancelable future minimum lease payments for operating leases that have not yet commenced"
       }
      }
     },
     "localname": "NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommenced",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_NumberOfConsecutiveBusinessDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Consecutive Business Days",
        "label": "Number of Consecutive Business Days",
        "terseLabel": "Number of consecutive business days"
       }
      }
     },
     "localname": "NumberOfConsecutiveBusinessDays",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_NumberOfIrishSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Irish Subsidiaries",
        "label": "Number Of Irish Subsidiaries",
        "terseLabel": "Number of wholly owned Irish subsidiaries"
       }
      }
     },
     "localname": "NumberOfIrishSubsidiaries",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "nbix_NumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of renewal options under the terms of the lease.",
        "label": "Number Of Renewal Options",
        "terseLabel": "Number of renewal options"
       }
      }
     },
     "localname": "NumberOfRenewalOptions",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesDisclosureDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "nbix_PatentTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of the patent, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Patent term",
        "terseLabel": "Patent term"
       }
      }
     },
     "localname": "PatentTerm",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_PotentialCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential payments for commercial milestones under a collaboration agreement.",
        "label": "Potential Commercial Milestone Payments",
        "terseLabel": "Potential commercial milestone payments"
       }
      }
     },
     "localname": "PotentialCommercialMilestonePayments",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_PotentialMilestonePaymentReceipts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Potential later stage milestone payments and royalties.",
        "label": "Potential Milestone Payment Receipts",
        "terseLabel": "Potential milestone payment receipts"
       }
      }
     },
     "localname": "PotentialMilestonePaymentReceipts",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_PotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of potential milestone payments to be paid under a license agreement.",
        "label": "Potential Milestone Payments",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "PotentialMilestonePayments",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_PrincipalAmountOnConversionRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Principal amount on conversion rate.",
        "label": "Principal Amount On Conversion Rate",
        "terseLabel": "Principal amount on conversion rate"
       }
      }
     },
     "localname": "PrincipalAmountOnConversionRate",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_ResearchCollaborationTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research Collaboration Term",
        "label": "Research Collaboration Term",
        "terseLabel": "Research collaboration term"
       }
      }
     },
     "localname": "ResearchCollaborationTerm",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_RestrictedCashMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restricted cash.",
        "label": "Restricted Cash [Member]",
        "terseLabel": "Total restricted cash"
       }
      }
     },
     "localname": "RestrictedCashMember",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_RestrictedCashTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restricted Cash [Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCashTextBlock",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbix_StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Options Restricted Stock Units And Convertible Senior Notes [Member].",
        "label": "Stock Options Restricted Stock Units And Convertible Senior Notes [Member]",
        "terseLabel": "Stock Options Restricted Stock Units And Convertible Senior Notes"
       }
      }
     },
     "localname": "StockOptionsRestrictedStockUnitsAndConvertibleSeniorNotesMember",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/NetLossIncomePerShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary of reconciliation of cash cash equivalents and restricted cash.",
        "label": "Summary Of Reconciliation Of Cash Cash Equivalents And Restricted Cash [Table Text Block]",
        "terseLabel": "Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "SummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nbix_TakedaPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Takeda Pharmaceutical Company Limited",
        "label": "Takeda Pharmaceutical Company Limited [Member]",
        "terseLabel": "Takeda"
       }
      }
     },
     "localname": "TakedaPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_TerminationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of time required for third party collaborator to give written notice prior to terminating the collaborative agreement.",
        "label": "Termination Notice Period",
        "terseLabel": "Collaboration termination notice period"
       }
      }
     },
     "localname": "TerminationNoticePeriod",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_TerminationNoticePeriodAfterFirstCommercialSale": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Termination Notice Period After First Commercial Sale",
        "label": "Termination Notice Period After First Commercial Sale",
        "terseLabel": "Termination notice period, after date of notice"
       }
      }
     },
     "localname": "TerminationNoticePeriodAfterFirstCommercialSale",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_TerminationNoticePeriodBeforeFirstCommercialSale": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Termination Notice Period Before First Commercial Sale",
        "label": "Termination Notice Period Before First Commercial Sale",
        "terseLabel": "Termination notice period, before first commercial sale"
       }
      }
     },
     "localname": "TerminationNoticePeriodBeforeFirstCommercialSale",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nbix_TotalEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total equity securities.",
        "label": "Total Equity Securities [Member]",
        "terseLabel": "Total equity securities"
       }
      }
     },
     "localname": "TotalEquitySecuritiesMember",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two point two five percent senior convertible notes due two thousand twenty four.",
        "label": "Two Point Two Five Percent Senior Convertible Notes Due Two Thousand Twenty Four [Member]",
        "terseLabel": "2024 Notes"
       }
      }
     },
     "localname": "TwoPointTwoFivePercentSeniorConvertibleNotesDueTwoThousandTwentyFourMember",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_UpfrontPaymentsMade": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront payments made under a collaboration agreement.",
        "label": "Upfront Payments Made",
        "terseLabel": "Upfront payments made"
       }
      }
     },
     "localname": "UpfrontPaymentsMade",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_UpfrontPaymentsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upfront payments received under a collaboration agreement.",
        "label": "Upfront Payments Received",
        "terseLabel": "Upfront payments received"
       }
      }
     },
     "localname": "UpfrontPaymentsReceived",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nbix_VoyagerTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Voyager therapeutics.",
        "label": "Voyager Therapeutics [Member]",
        "terseLabel": "Voyager"
       }
      }
     },
     "localname": "VoyagerTherapeuticsMember",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nbix_XenonPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Xenon Pharmaceuticals Inc",
        "label": "Xenon Pharmaceuticals Inc [Member]",
        "terseLabel": "Xenon"
       }
      }
     },
     "localname": "XenonPharmaceuticalsIncMember",
     "nsuri": "http://www.neurocrine.com/20200930",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r101",
      "r108",
      "r181",
      "r255",
      "r256",
      "r257",
      "r263",
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative-effect adjustment to equity due to adoption of ASU 2016-02"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r101",
      "r108",
      "r181",
      "r255",
      "r256",
      "r257",
      "r263",
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r101",
      "r108",
      "r181",
      "r255",
      "r256",
      "r257",
      "r263",
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r245",
      "r246",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r351",
      "r403",
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r245",
      "r246",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r351",
      "r403",
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r147",
      "r231",
      "r234",
      "r352",
      "r402",
      "r404"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r147",
      "r231",
      "r234",
      "r352",
      "r402",
      "r404"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r235",
      "r245",
      "r246",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r351",
      "r403",
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r235",
      "r245",
      "r246",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r351",
      "r403",
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r326",
      "r328",
      "r331"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r263",
      "r264",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible List]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r21",
      "r150",
      "r151"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r24",
      "r53",
      "r54",
      "r55",
      "r391",
      "r413",
      "r417"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r52",
      "r55",
      "r56",
      "r98",
      "r99",
      "r100",
      "r274",
      "r408",
      "r409"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r255",
      "r256",
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r247",
      "r248",
      "r259",
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Reconciliation of net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r72",
      "r85",
      "r299"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r67",
      "r85",
      "r301"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetLossIncomePerShareAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetLossIncomePerShareAdditionalInformationDetail",
      "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetLossIncomePerShareAdditionalInformationDetail",
      "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Square feet"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesDisclosureDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r94",
      "r136",
      "r139",
      "r145",
      "r177",
      "r272",
      "r275",
      "r290",
      "r370",
      "r389"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r49",
      "r94",
      "r177",
      "r272",
      "r275",
      "r290"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Fair value of assets on recurring basis"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r160"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r161"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r157",
      "r190"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r154",
      "r158",
      "r190",
      "r374"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r156",
      "r190"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Debt securities available-for-sale, at fair value (amortized cost $517.3 million at September\u00a030, 2020 and $557.3 million at December\u00a031, 2019)"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r156",
      "r190"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Debt securities available-for-sale, at fair value (amortized cost $180.3 million at September\u00a030, 2020 and $299.3 million at December\u00a031, 2019)"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesMember": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Securities [Member]",
        "terseLabel": "Total debt securities available-for-sale"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r97",
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the business description and accounting policies concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization and Significant Accounting Policies"
       }
      }
     },
     "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Non-cash capital expenditures"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r34",
      "r87"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail",
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r81",
      "r87",
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r81",
      "r291"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Total cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r268",
      "r269",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Significant Collaboration and Licensing Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralAxis": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of collateral or no collateral, from lender's perspective.",
        "label": "Collateral Held [Axis]",
        "terseLabel": "Collateral"
       }
      }
     },
     "localname": "CollateralAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Category of collateral or no collateral, from lender's perspective.",
        "label": "Collateral Held [Domain]",
        "terseLabel": "Collateral"
       }
      }
     },
     "localname": "CollateralDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r98",
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 220.0 shares authorized; issued and outstanding shares were 93.4 at September\u00a030, 2020 and 92.3 at December\u00a031, 2019"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r58",
      "r60",
      "r61",
      "r65",
      "r377",
      "r397"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive (loss) income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r228",
      "r229",
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue, balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r233"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Deferred revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Convertible Debt, Current",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "ConvertibleDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r236",
      "r244",
      "r418"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r69",
      "r352"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesDisclosureDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesDisclosureDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r89",
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Shares issued to settle notes at initial conversion rate (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail",
      "http://www.neurocrine.com/role/NetLossIncomePerShareAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Senior Notes"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r17",
      "r18",
      "r371",
      "r372",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail",
      "http://www.neurocrine.com/role/NetLossIncomePerShareAdditionalInformationDetail",
      "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r217"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Convertible senior note carrying value of the equity component"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Convertible senior notes conversion price (in USD per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r43",
      "r222",
      "r223",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Convertible senior notes convertible in to shares"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period",
        "terseLabel": "Discount on liability component, remaining amortization period"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive common stock trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Threshold percentage of common stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "verboseLabel": "Threshold common stock trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r300",
      "r303"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_ConvertibleDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount",
        "verboseLabel": "Principal"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail",
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Convertible senior notes fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r42",
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Convertible senior note assumed borrowing rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail",
      "http://www.neurocrine.com/role/NetLossIncomePerShareAdditionalInformationDetail",
      "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Convertible senior notes redemption rate"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r44",
      "r96",
      "r222",
      "r224",
      "r225",
      "r226",
      "r299",
      "r300",
      "r303",
      "r386"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Convertible senior notes term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r303"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_ConvertibleDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount (premium).",
        "label": "Debt Instrument, Unamortized Discount (Premium), Net",
        "negatedLabel": "Debt discount, net"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r93",
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Debt Securities"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period when accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), is considered uncollectible and written off, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest, Threshold Period, Writeoff",
        "verboseLabel": "Accrued interest receivables write-off threshold period"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestThresholdPeriodWriteoff",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestWriteoff": {
     "auth_ref": [
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of writeoff of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized by reversing interest income.",
        "label": "Debt Securities, Available-for-Sale, Accrued Interest Writeoff",
        "terseLabel": "Accrued interest receivables write-off"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestWriteoff",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r159",
      "r190",
      "r200",
      "r201"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for Credit Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Current",
        "terseLabel": "Amortized cost, current"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Noncurrent",
        "terseLabel": "Amortized cost, noncurrent"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r171",
      "r198",
      "r203"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "12 Months or Longer, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r171",
      "r198"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "12 Months or Longer, Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r171",
      "r198",
      "r203"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Less Than 12 Months, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r171",
      "r198"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Less Than 12 Months, Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r167",
      "r194",
      "r203"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "totalLabel": "Total Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r168",
      "r195"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Total Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": {
     "auth_ref": [
      "r193",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]",
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r166",
      "r197",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Gross Unrealized Losses and Fair Value Available-For-Sale Investments in Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r169",
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of debt securities available for sale in unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Transaction cost related to issuance of convertible senior notes"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r36",
      "r301"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_ConvertibleDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesDebtNetofDiscountsandDeferredFinancingCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r85",
      "r212"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r66",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r114",
      "r116",
      "r121",
      "r122",
      "r123",
      "r127",
      "r128",
      "r378",
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net (loss) income per share, basic (in USD per share)",
        "verboseLabel": "Basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net (loss) income per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r66",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r116",
      "r121",
      "r122",
      "r123",
      "r127",
      "r128",
      "r378",
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net (loss) income per share, diluted (in USD per share)",
        "verboseLabel": "Diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net (Loss) Income Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetLossIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r103",
      "r111",
      "r113",
      "r130",
      "r181",
      "r221",
      "r227",
      "r255",
      "r256",
      "r257",
      "r263",
      "r264",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r408",
      "r409",
      "r410"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNiMeasurementInput": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Measurement Input",
        "terseLabel": "Equity securities measurement input"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRestricted": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of restricted investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Restricted",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRestricted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r176",
      "r399"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedLabel": "Change in fair value of equity security investments",
        "terseLabel": "Unrealized loss on equity securities",
        "verboseLabel": "Unrealized loss included in earnings"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r11",
      "r16",
      "r175",
      "r388",
      "r431",
      "r432",
      "r433"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity securities\u2013biotechnology industry",
        "verboseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r277",
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Investments Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r283",
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Our Investment in Restricted Equity Securities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r278",
      "r323",
      "r324",
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r277",
      "r278",
      "r281",
      "r282",
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r236",
      "r237",
      "r242",
      "r244",
      "r278",
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r236",
      "r237",
      "r242",
      "r244",
      "r278",
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r278",
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r323",
      "r324",
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r284",
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r93",
      "r287",
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r164",
      "r165",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r197",
      "r199",
      "r202",
      "r203",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for charging off uncollectible financing receivables, including, but not limited to, factors and methodologies used in estimating the allowance for credit loss.",
        "label": "Financing Receivable, Allowance for Credit Losses, Policy for Uncollectible Amounts [Policy Text Block]",
        "terseLabel": "Allowance for Credit Losses"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r206",
      "r208",
      "r210",
      "r211",
      "r353",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r206",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r63",
      "r136",
      "r138",
      "r141",
      "r144",
      "r146",
      "r367",
      "r375",
      "r380",
      "r400"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "(Loss) income before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r95",
      "r112",
      "r113",
      "r135",
      "r262",
      "r265",
      "r266",
      "r401"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r123"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r62",
      "r134",
      "r298",
      "r301",
      "r379"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r80",
      "r82",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Accrued interest receivables"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r28",
      "r204"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r47"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r30",
      "r204"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r29",
      "r204"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/InventoriesSummaryofInventoriesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r175",
      "r368",
      "r384",
      "r434"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Debt Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesDisclosureDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesDisclosureDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Description of Operating Lease"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesDisclosureDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesDisclosureDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "Year ending December 31, 2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "Year ending December 31, 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "Year ending December 31, 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "Year ending December 31, 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Year ending December 31, 2020 (3 months remaining)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less accreted interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesDisclosureDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesDisclosureDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r39",
      "r94",
      "r140",
      "r177",
      "r273",
      "r275",
      "r276",
      "r290"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r27",
      "r94",
      "r177",
      "r290",
      "r373",
      "r393"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r41",
      "r94",
      "r177",
      "r273",
      "r275",
      "r276",
      "r290"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using amount by which value of business ownership interest is reduced to reflect lack of ability to convert business interest into cash quickly.",
        "label": "Measurement Input, Discount for Lack of Marketability [Member]",
        "terseLabel": "Discount for Lack of Marketability"
       }
      }
     },
     "localname": "MeasurementInputDiscountForLackOfMarketabilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r81",
      "r83",
      "r86"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r57",
      "r59",
      "r64",
      "r86",
      "r94",
      "r102",
      "r106",
      "r107",
      "r108",
      "r109",
      "r112",
      "r113",
      "r120",
      "r136",
      "r138",
      "r141",
      "r144",
      "r146",
      "r177",
      "r290",
      "r376",
      "r396"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net (loss) income",
        "verboseLabel": "Net (loss) income - basic and diluted"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted and Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r136",
      "r138",
      "r141",
      "r144",
      "r146"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating (loss) income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r309",
      "r315"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Less current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r305"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Noncurrent operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/LeasesLiabilityPaymentDueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r306",
      "r310"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r304"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r312",
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r311",
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r50",
      "r51",
      "r53"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized (loss) gain on debt securities available-for-sale, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r50",
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on debt securities available-for-sale, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r40"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r73",
      "r75",
      "r155"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of debt securities available-for-sale"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireRestrictedInvestments": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.",
        "label": "Payments to Acquire Restricted Investments",
        "negatedLabel": "Purchases of equity securities",
        "verboseLabel": "Purchases"
       }
      }
     },
     "localname": "PaymentsToAcquireRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.neurocrine.com/role/FairValueMeasurementsReconciliationofOurInvestmentinRestrictedEquitySecuritiesMeasuredatFairValueonQuarterlyBasisUsingSignificantUnobservableInputsLevel3Detail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding at September\u00a030, 2020 and December\u00a031, 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Incremental funding provided"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "verboseLabel": "Proceeds from issuance"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r73",
      "r74",
      "r155"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Sales and maturities of debt securities available-for-sale"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r35",
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesDisclosureDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r214",
      "r394"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r12",
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/LeasesDisclosureDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r243",
      "r317",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r243",
      "r317",
      "r319",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r207"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r10",
      "r87",
      "r92",
      "r369",
      "r390"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Restricted Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r6",
      "r14",
      "r87",
      "r92",
      "r435"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalents",
       "weight": 1.0
      },
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CashCashEquivalentsandRestrictedCashSummaryofReconciliationofCashCashEquivalentsandRestrictedCashDetail",
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/LeasesDisclosureDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r227",
      "r258",
      "r392",
      "r412",
      "r417"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r103",
      "r111",
      "r113",
      "r181",
      "r255",
      "r256",
      "r257",
      "r263",
      "r264",
      "r408",
      "r410"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r132",
      "r133",
      "r137",
      "r142",
      "r143",
      "r147",
      "r148",
      "r149",
      "r230",
      "r231",
      "r352"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues",
        "verboseLabel": "Revenue from contract with customer"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Amortized Cost, Gross Unrealized Gains and Losses, Allowance for Credit Losses and Fair Value of Debt Securities Available-For-Sale"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r162",
      "r163",
      "r170",
      "r171",
      "r172",
      "r174",
      "r382",
      "r383"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r44",
      "r96",
      "r222",
      "r224",
      "r225",
      "r226",
      "r299",
      "r300",
      "r303",
      "r386"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Summary of Notes Net of Discount and Deferred Financing Costs"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetLossIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r31",
      "r32",
      "r33"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]",
        "terseLabel": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetLossIncomePerShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "verboseLabel": "Market price of common stock (in USD per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/ConvertibleSeniorNotesAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]",
        "terseLabel": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetLossIncomePerShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r430",
      "r431",
      "r432",
      "r433"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r46",
      "r98",
      "r99",
      "r100",
      "r103",
      "r111",
      "r113",
      "r130",
      "r181",
      "r221",
      "r227",
      "r255",
      "r256",
      "r257",
      "r263",
      "r264",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r408",
      "r409",
      "r410"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r130",
      "r352"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r19",
      "r20",
      "r221",
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock for employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r19",
      "r20",
      "r221",
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock for vested restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r20",
      "r221",
      "r227",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock for stock option exercises (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r19",
      "r20",
      "r221",
      "r227"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock for employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r46",
      "r221",
      "r227"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock for stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r25",
      "r26",
      "r94",
      "r153",
      "r177",
      "r290"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosure:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r164",
      "r165",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail",
      "http://www.neurocrine.com/role/DebtSecuritiesGrossUnrealizedLossesandFairValueAvailableForSaleInvestmentsinUnrealizedLossPositionDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/SignificantCollaborationandLicensingAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r236",
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Securities of government-sponsored entities"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/DebtSecuritiesAmortizedCostGrossUnrealizedGainsandLossesAllowanceforCreditLossesandFairValueofDebtSecuritiesAvailableForSaleDetail",
      "http://www.neurocrine.com/role/FairValueMeasurementsInvestmentsMeasuredatFairValueonRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r115",
      "r123"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)",
        "totalLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r114",
      "r123"
     ],
     "calculation": {
      "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.neurocrine.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://www.neurocrine.com/role/NetLossIncomePerShareScheduleofNetIncomePerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a,b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL6284393-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL120267859-210455"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL120267862-210455"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922890-210455"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28567-108399"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r436": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r437": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r438": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r439": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r441": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>59
<FILENAME>0000914475-20-000036-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000914475-20-000036-xbrl.zip
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M1M<N.'_#GPE.WVAC^T>/[0U'MN<ONO5DV/X>K/!<^N*_FV^W_4'LVN+F53?
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M5 *M,+  XIDU:$"5 (/QAXTT+(QH5D-H9W=H.^]L.VST7MFC]LAV*B(F*Y)
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M!Y9%3=$!  V!>0M>FH41V1.[Y6G))^HL".*"= KR:FPA"(DA8)C"K%>Z HM
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M%.T&TTY+_& BHD6C3<&86AKOB'E>!F1>A(*.%GQ@P1GD:-X0*UE$KN:$#HZ
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M*'>1@%&*:9JL@2J4.Y@O4C976U\\$SN3G E("Y66(H"(U,D$A#HDB3YXQJN
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M^;GW5?$)I-6>$ELDK2FZ=Z,*YZ@M*(DN&0U2"'3OKU;G1]7OZ,DG(L[!R=$
MI=L^LIU&/(F^G%N//Z>V_\&THV=CL7;LR<9DY8,O><)S3<;13T9)3X)$'ZC1
M> $34%AG>$$X(8H;Z9Q!N\7Q!\$$A6_R<54CNQM;VXU)-:W!O.OS=8PV6OWE
MFL_>XM7>]3'*[>RUCYYER+K*/AD:(]5 BB1,0CV&4!C#5.&5##$H8[A*2RN&
M4?[-_)2[8,K,D0JCE!M9S+^D#(^'R\R#5P?1/D\DDD\19'3"I\*"E=FMR (9
M5BBLL"Y2$JPR9$;(T4(_RCCK-\;PF^DSY?,O 7M# 6?0%X\9;[SM>]MY=]#O
M/==!SO6OGXS0@BC4@D HQAC1^<*B:49[3(/7(GHK8&E%4E4H2>XQ97!>C/#E
M$-C_^B_-J/KGL#&*G7B4I3X91_^]@2%(YSBGZ1L6#6+#W\5HU^M>*K_NY?O6
M[W)I]V3D+ YB:!P=#X;'>0AMU&_@&271I>PW]X\<Q.8I2*M^]/+AF)G#Z:BP
M#%(\:#[JCX\)@*G/<F5RF>F[X7GVC2U[5CWRE-RQX;F)C#$ 9S:7L3WJE"/2
MT?J#AN_8X? ><S6O68S%Z(^!+9W.]FG7]3O/NBM:D[D*)3+BB3_(^YDWT,9^
M/6CC+Y>&^-MYJ[>KQYT<T=QUT!--:;^DP1.'=TJ9*S6TDC1X,E=];:_3^KC!
MFF=_=IH[6]T6MFOW[.#S[LX6/G?O8._-WD&+M0[V#M_?G*M.6MT/V Y\QIL/
M^5D$GW6X^6;KH/5F'5K=UY_WNNM\E[WNME[KDZMSU4F4@8O@BJAXS R:%SH$
M7A@0CG+*DN%N/(43X5P6@_F]\3^S6Z:-(SMH?+&=X]N'YJ=B"VH]N),>3,SQ
MV!K72G ')=BX4 (1'8W>I$)XI0KP(A9:1>SG%)Q()@F?AQ5;?V[\=PWUN5G%
ME/WLMW.MSMW!^L0+5W;JZ%-KP_M+EV"IH5*$(GI/"Q")%EIX4A >($:G9) ^
M<YYAL/]IO.GTG>U@4-G!L+*1BR[$T0^5Y)ZK=68 W_&H4"_D$:'8<*<-?Q#]
MYT8W%Y3X>A#+Z5LY9KXR,_4W^H_Q:HP#.RP7.82&[73PC+QZ+D?B_SENYS@<
MPV\7)R?@C2>A^/A2RO.\JO$JJ$E4?B68/\=SCM3SX;P*JA'P*#+P?.K1(/I8
M\G'*&N6JXV'C-[P?:DUC>(PD='C0SQ-ESU<8C0[LZ.9;?+77FUJNUB@OGKS(
M/WYOV%YH_,:NO*U#!<23W&&6/UY4GH]7YJ9,;I:7% [+EI0MM<-1PY!&L*?#
ME]=6LCSV*-:KX\$ FS)>TYA]Y<B.CH>5M Z_-'IP\BF"HI('4WC'1 '.06$X
MZCDXQ27JN- 157PW#F]-F3[YTMA2*R^J-SS),J[;VG )V=:]EY0]1H? [8O
M*FI/LV%!F])MCT9HBDK?,NCW,K?IG#8B\IS3QD:F/-:74V[6[,@V\G*OFY;V
M\AY7,Z!;QW@F$)'MZ%;</^Z,1_ZWBYW&;UFNZI\-QMGRY(S10;M<9G"4EQD\
MMLD=-_C"B,;A/Y:?U$1>Z=7<J1.+^>Q,Y/K))T)4("S*@KH0"J 8#C@A\T0V
M'Z1,E!()M8FLL(FLA"%$TV,;'33BL6&]1T,XL-F:9=,PR&3LN[\V$(W%=P\,
MNVA!\2F#<PJ$)J2+O7":J2?>#:E:]A?[C?U!_^OHX/SH,C+16#8MQ-3NE4O5
MR_F/>522X5O>TL#R,/WG^6D_/>'6YEV<F.GGY.1;VGI^9KM7VOD)MV:N8.>L
M^BJ5ONN@5Q5*L#"$(.73'YU:ENQA@U,_'$9BRXP_0F,?KP_N-@@WPS(T5<O?
ME(2CM /9'N[W!Z??6S:7:=W@U>2$2A*1\TS.JM@[W#W=/7S_=>_-7^W6F]>=
MO<-.MYF)R=DZS^W>/0O=UIK_)I/37.MT6X=XS=J?GW>[&V3WX]]X[]VOFSO-
ML^9.^+S+7A^VV"YIT>N%:*P2P4I."^,5*<!X7^@4;6%-4!8C/YY"7%IY^WWK
M_?B%:>Z;H)QRG:4;3.G11R[G3,%7+P4^=I(3J2^BE.&?]QEYK8X,6]>)WG.3
MXS/2UNTQ-1Y+^((?C[].F._"B7QVA?#&U*/L\S^/A]BP8373Q$]*/:X-(GGN
MT+FZ4'BM>0%$A,)0*E$8@H"U-L8\,_<N-? 6QEBO3P+6L=*.H]9:@1]3@<][
M_$W9UZ_&O5PK\L\4^?3MSOJ%(B>JJ9.>%Y1I7P#U4.CH8EYW'2$010CH:12S
MO(>W?NBI51EZ3C](Q>7I_M]-(+;3]P91RJ$3C.AZ_7+DXW@X3N.A%HX+8'^G
M]&1_4#ZK<YH?_K6-C\[YP1Z^7#]GYKZTAV6$V+,]GXT%TL]<QB:?/!S97K"#
M,&SD.CCM<-O$<_Z;_<?WDG'+<YHIGC^$W#^'/#R(G<Y%MO<WA$:9RAT7TBH'
MQ&[-D5X?@MK%]YBMF&;M5;9S5U;9F?S2Y('33](S)@)2.V+RBG;K;*&Y,P4)
MZ"&2C1Z=_T\]0CTN=3/]-.-QJ9V#B\JL: /ZQZ/2FI=F/6\@.3RW#(-OEZ3Y
M\>S@X7AV\,6TX(MYPGG3S'R/W\OA[O,UD:_+<6:\[KC7'FOO^$%+US4: "+S
M6@;..# D&R%2QD DE1BE27S:R(I,*8$E-&F^C3';\%]+&ZW7US=CP%<+_='D
MA.],#2I?H9S?7.Z7.=R\[  D%<BH\73RO+3]I'6([3[<Y:VU]V>;.ZLGGY1V
M"3Q31<)/!>3UQEI)421)\*^8")%A:<7PW]'T_DX%/U?^<U&OY!*.B*-6_TNY
MF<-8$V&\H</R_)=P?$Z;7E[=L/2H/^:(+P<QSY7Y$K_9PO2R)643R.4EU@W[
MG>/1MY?\;-?3^VZ]JI;.KSD87(8!^[%P@V@_%S8A+E[:SE=[.EQZ<=O^K(K]
MVOZL\U(1Y,<U8:M5W61G]<^WZ[GR_ZM-M':MG=NW/OV9H9A#LT"7)=%3'Z^6
MR]2P&8Q7/]*2@SL.$%PKAS__BPOOM+3PW>J;]>^E0^_A'::Q .4''F3ZX/D1
M"4[I<2P-^?$.#7_8N6E+XV"0B?%_W6$S<@S#WMG!J+&QW'A]D;#9Z(UY,=[U
MCQ?VID.;?NKY^]YQD%_U=I6:4M?>DI9^1&%^[XG?"!,I\7WER&^1U715L-L.
MH1,?W<\_G@$O8?4T;W5SEX0[OU1UK>:=P/U$5O.>;;F'MO&EE8U1[$YFCEXU
MG655UW(U4VTYJV$Y^;0L9Z/\FRXS,2L6/&LK^CAO-6]6]):76U^?B0%]U<?/
MO3S@AI]*-E[.S_S3=M BQ<;V08RCX22I]NT6J>5L^;7H)[_2_"LUCSC+H#98
MOVRPY%0-%H-E51NLVF#-VF!=$J=LJ3:/XOC*86FA\E#J(![@97DMYV]O^\/A
M/QIYMYQNO%@TOH,:%,NS6_B<1K-?KK9<+^<PW&+X:ELW[[;.+*U ;>MJ6[?(
MMJX<4C[H=_"JX63 O+'^G^/VZ+2V;0MLVQA;6A$_MFV/D\%_RCQ]!=7QE1T>
M-%YW^E\OZ]'42K<P2B>65N2B*UV=YIU.FI?EBG[]$;9IU"_MP"WVH\[^5M<>
MH(C5DXR;U4%%=8.*VJ!.QZ#F<DB7XV9LN=&T/;M?&LR+F<)K[:$_'@[SK-_,
MJ%9[MG,Z;)?,[-+.9D,\7I*2S]F*P^/.S;Q1;8 K88 S)*BN+7!M@6L+_!06
M6%VUP'RY\3XOO6N/RBG;I3'%'SKGW[,M[O2'QWEMQZKK'Y]7[VULM8>?:P-;
M#0.+$F>L-K"U@:T-[!,86$6N&EA8SE1U-$ YE<;UW:#O8\CVM+:>E;">69RU
M]:RMY^RMY[-8CJ#X^7*$C>7&9EFIH%Z+4#F;B4)D3[,8H;:9M<U\]HQ37EN,
ML+I<1N>-U]:/^H.:9U;$9LK:9M8VL[:93V4SS56;*9<;ZR<';=>NA^VK8B[S
MO."?S.-YSN9R]DO1:LNYF)93LZ65;>Q9.ZJSF)4QEUEH\,-I3M_4>+J]H-%3
M%H#ZCMROU1GZ2?N>OCS1]POGL6D4K\HE'F9?O>IZ_:3\_E/O4_A9MK'LTY]4
M+;F)B#OV,5^ZTSM?+1H%C] %[$Y=<(<2! _L!OGS;IBG\E\/*F4V+XU_M=E:
M6V]MKZ_EXF7;FV\WUE9W\,N?JV]7\2T:V_]>7[]S/;/RD?/R8K\=]^QQ:(]B
M^,==FU^%>FR*+3,Y_?W#D*UKD ^Z[8^/"8#'::Q:O.IQY0U?MD?X,/_3$2]$
M>+O7P.=T\GS3WQOQQ$<,O2YJV3:"'=E__%JN:_ZJS5U;^50RAKSZZ<GVW)F_
M#KE:/6/2'S<6@?U$!9SUG_<'?8S&BDF3O8\1PXFYT USITY8'0[C%;[Q@_*!
MM[WLK74%R6VE!1_8F[]RC_LW\MZR3^6?^93]]Z/AR0[0#5MBX.6#0'#CK1\D
MH\>^QY34N,S-R1D6(KBC5/,RV#QGS></>?_Q+[9S+:BX[OGO]/JD40$\_\]?
M>L,9C53=[=5NK:M_/ PWBNI;(8D3)$3M #AW)FGCF&5*:NU9DN.B^N/=,2Z+
MZA?BO'#^\;#8M_;H9<;1:B_DO]8O0;0Z>F4'@[Q_S-]Y'X"+^OERQO7S6VW3
M]=W7O<WNWP>ML];AWLY[V%S[\'7W<.MP[W ?/_N3YAI>M[-/FFM[G=;.>_J6
M;QWL=D\ZFX?KITVV?KJWLT^;9\V3S;7W9[L?_S[897C^QRU\WM]=; =K?GQ]
M<'X-/NMXCWV0S9U<J_^O#CXK;],$K;76P=['UX>['W?%WIOWHO5Q#]]Y]V3W
MX^O4/,W;+I7;+WW]1&VBFGM6@!6F .Y-H7F(A1#$6>(,53HNK0 3R]^6VO_^
MZ,)#S-D]4#]-UUV;GH4T/2Q:KX3BBA, K[BC)&@3F"'4>@LVFQYJ*..T-CU/
M;GK.+DP/)).\BZE@)-$"6&*%)M$4EFGC%<8)+J2E%4K97)F>IR;D5Y)=DUL4
M^?R75%RA@.U<5V#TLC#3SR7?33O7HL-P)OKC07O4QKO:+[;=R2FT(O4'Q1 5
MY/>&'362;9_OW/.;[>8-9L]B[L;AJ/$_GX1;_'2_GG/=SR^T??$^J^>O\[H_
MV,:763UO^RML^B1^J0W!/0Q!ZQ7Y>FX(\#Z=^.^MT[V/X<@QD$WV_NOFSMY!
M\_ #;1XV3UIKJZ?XO':KNTZ;:W]_;JUA/WQ<YWL?MU+K;/V3 !I!45X0QG4!
MPIG"B" *80+WVB@1/%(80=5W[,AY^BV#\R(S-5G<>+4PSWW0^7#W4Z-SL=")
M[?M$@V&&2EE$G5(!2=@"31<M&&@7C(F1<XGH%#]#YWF:< +.2:7=?_QD]@2[
MGV/Z+LFM,A6<5A1Z4\4NE>^Z*M;:]B!MNXQ'-5?2NQ0+FZPH0"926.ZA,&"3
MES$0P2$;<[,,OTH*OT_,'C4>O6N*\;FK[;0BN%IM'U5M+V,YFS13(*"@TJ&7
M"T(5QDI?,*&MBY%(PE+V<GJ9S9':/J^,_.IX&^UA8X!4HOTEJ\6M8RT_,D!W
M38Y5V0!-C3=,^GSKHLM;L:;D#[$VVU>3UCZYR)(M2$BL &-#X0(AA1?2>S1
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MOB!L:A5![J8'<[[37&W(GHTA>X(5GK4A>Y@AN^2+3*D0C..%X\R@(7.VL#)
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M YF3!N=%X3PS'K2W0CJCB_%0,*VLUN"TUR"4PV"<#3+% F?CKV\]W!:<N];
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MQ$*Q)Z0VX)3Q0*Y.+$Z6DZF#=]@2TA^M_?4*HGI9L8V&ZNNC>FX6><&QS=*
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MG2:<#[>-3E )7406HE<J:G(F&A65,L$8C:?^0?/PN\1,>_,>?B:RR=OBTLL
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M 6I)@)H?6A2R5%8HR,D4![%6#Q=O)(*)GLA'P4BS BBW+ >Q :I##F(#U+(
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M=6/9^X7?QK)-2DU*]S]*UG3A37L<<V$O'R@*D05PYC,H'AF$H!S88M>$R)-
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M9+!&FNS3VKIN7'O?4-RXMDFI26FUPR)-(RY+(WYQ\I40%2,-Z'4&1<Q!$,1
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M!LC@JW0491=,XLYPOK8NV6/9#173+,3N68@-L3>/V)E-B*XFI[(#ZZ($%6P
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MPDB9JR3AA/ND("+)4M 4=$J,\#3/3>8+DX5FB"L2U?BRS!LSDL7) *.B0+9
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M=YUU;!\]!RCP=\<6)>=N/8WY.=M)KMP0!/_0 #44?<=UAV7C\73=R"UV,X#
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MK)IB51.9B)P8WSPHW0C[E<Q,Y008'J&YZE [,U15'GF24/_[MB94TKQ^(D#
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M>-5Q("">H/%H,':O7N,A=:9',L\ZLXRQN S8E6^<G:$SW">:Y8P!XVKNM#,
MFMS"'<N43OVKU_=,I!_,D;/CKMOS&]]4V47*?-L?8(K_=!\PSK!GRFX9%KJ/
MS[QD8MQY=^!MZKUPEMC$&2(X"-,2+CZ2 C52DZ0.8'">N%9.KHT=(+K=_FG(
M<@@U+H;C8Y@;#%*5[#CN#T;!F(:B*/8S&+BJV.9A+-EC09@<SIBBRY 3-CX>
M1Q$D^GBQ!<; '6%KV6_!D(>=CW["K_X<',;]TQ #$IK,#!SHGV'8.DC7JW*
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MMLA$>PE"4$KS.W-"K4R640MN+;BM(+BUUMK[0#S>J+U#M59Y1@SGBHA,&J(
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MU]6X?4V=!JN3O^^\=KQ>NSNOG7AQR?)N>%#U# CE+Z4!!/+K8G5^6T2*?BH
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M<(HEP^\/><4<S)8BRN$!ZLO.P)75VRRC7E9D.M\CQ!X0=IEP@*L:23F#):!
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M*#>X@9+9^)QZB(>=]1D2UI'2IX!ZWYNL^7H_)N=CY)%PITN7'1:)$<H1:Q
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M"EH]L,_DZO0V*B=>PDV *%KI_BM<D$S%<KJX9D2E71!!87Y..:B$WMK3>GN
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M9.2.!GVPSL4@=*.@/W''GC_I#U/0XWT*_=\7-M@>U2#L<QSA:#-T["Z1S3N
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MB8,Q&S=SD_E)MX[I=DO<TR5^72U&&[%5[URUN&^[O#F,]Z8=[K7E<N6@)SU
M^GXCE(.M\YXV#JXVUDJ_LU:N1_%F2X5CDH=_!T$_](9)Y,8#K%Z*I'!%*A C
M)4@\/Q1].::2R_&ZO7+SR4_[5T+=":#G(X!N(7_N&"L==&+G0<3.RHB=21R)
M21P,74].QJX_#CPWB.$VADDP2H=I*L:!3]T;=P:V[61/)WL>5?;<,6+;R9X'
MD3TGM<DS&"?#, "QX_F>[_I>,'$#?Q2XR7B<3H2,HK[')L\^M9ETLJ>3/=?+
MGCO&C3O9\S"RI[9[QDG?@WL(W: _ '<KB1(W]&7HQOXD\5*L2(L3E#W]^RH
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M6-D!_W<)O\NU3RM)-,%O_VL)TAIT54#B]6<),OW<>05O2 3^^2UXE4S"7G
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M'8DCG/@<[E#BF_[ECVOX[9XC8B('A2TH$/#.G:O#+!OEWC9 .Z(P_JI8M6>
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M)0U6#(<XHV<&E>(8-;05V""Q5!J%@F98A<[QZ;9>L\[=$@,'SH_+$K=!@VG
M?:#Z24H>&R%D'M%XW_H;FG1)3C/.+RHH([YV1DH[_/Z>U!(76O=V>P667"CX
MZ":.#B69.?C%K75%>> <5C3N!@5S3[&L84[L],MR;@M0LY4<FG:ZP)H!:J]W
MJ3!EIHM/\%IX- ]]F)5D1@,B67)SYY<>W:,:8U-D0/RV9GKLJ$:\8RV-ES4N
M2&TF%@[.ZU$;JB0<(SER/1:2<&_UL!%E4EYOZA@#ACJ_$ZL4;,I 2%$-O,W8
MRR55$%64T*(12G6M13W[B54+'K]E]!3D#6)>I(YSV?:,$OY76=YHFZC>'CWA
MU[3YLC7.XT[)9*E'!!+7M%:W[A"K!YEC6[/<:^E]??7GOLDO8JX:\3MJ(OBI
M7G^T.^G"U\3*.@^""IJN:AE/"KFG>$)]4558D%8RPXJQOH*LRF6)_A:?)=OF
MA'F"K)U5&Y5'P66]0/>JW5+BV"$;(:N6S%A?4TI<"9 !N.V9\CNN$6!)(1E8
M'8MH5FJ.%R]*L\I<9(G*[)%)$(N*NP'HHPH83+-?5:-@V'X,UMJ(,C[OV;T&
M/1L>A*M$UDKQ#IS7BJ;)$! \*FOK=A ;?TDR3"P4(Q/IYFQA%E;-H'4/EI6_
M 7ZLQR4S&]YOBHW6%U);NE&S0*E57-:0)XT >.UU]>IEMC0LT%2%HRYKU!,+
M.4OU]'*;N4!\OQI6X(]B!1L 4J$B0:MAQ +\L\L%M41:VRCKEQS4GL!-]E15
M()E#&Z Y-H?XZZ*G1K7%%?>LF.051:;X*M^0=H?W_F]8R4OU8X:S:<H+. 0N
MBWGU9A<@C:<+<%ZQ=5VYT[!;UZWY^J\Y>PCZ,F@N5[6.YKAK+66C;L.JJ&RP
ME7(HUVL%N+ 9;(]&O?9L3FJXY84J%!Z*_$S;"KVL,1'@XLXM_>MB\Y/R=H!^
M+W!QR@C3OOPZ2IGV^K57WU#!&N&EQA-3[3*YW0=O3[UHE8US?U8LJ 22^B]U
M!Z9]YHT@##V8 /:FF_KC]X*:=XU0=@C '0+PWDK?AR+.C:2G>Q;N3A-LB-93
MAQK6;E:52XXC*?.C><';$=MHD!_>-<5L]*4B3S0<2QT-VEK];=2-U=50KZJ1
M$B X4<L](2>' ;CB<] +/?,6JQ%D$W#;E1A(C8#Z 0[=J4T8L_IS&O>*&V3#
MS6JP+P4.C<71UV 9\1YT-*(Z7RX2G$VD,<7PO>;.L";[PC26Z%"V(@Q;@+T'
MTC_*Y%D!"T*<J:+,,]%3I(.'@J.XU1@^#KU,"PJND%$)*X,;J[A#;$&=#F@-
M%K%HKIHNQK9/L5K=177J4K6Z,7%)98*T8( J*3'20?E4C<"*.%<XFYF#[[JU
M)<LOBJGJ)=-GX,;HLE#LSQS& 8\R.FTR%!WG GVX!1?/XQSHLE%9OVFM#"_+
M[G)-2$JMX@M7/4U]S7Z).N?4$)NZ[)VO6$^5YFC*3 "?+9:)K!N;K.Q,3Z=G
M>CH_,Y7Y&<V.4I2NJI=4]+Q)3<SN9+AI9EWK1.L2S'=-,(^^]@3SE<>C%7AK
M\A*+^V;+B$ZT$6T#T=(<)[*^97DNYA7[WRS?>PWQG^4M\\5)N"/"B&+6#>M,
M?<W<.=81>VHV7WGNOW$W'0N:=1EH"XBKY;NN<*RK[NK9]ORHGE%9EI'1$$9*
M=AE:2#?9(.J.U$! *WA@+M$\/,NIC@8U'Y !JM1*HVAJ85VW'RZVV"=-T]H$
MUG/R<M\O#-@XOY* :KC%79U(LX"T-*DL;5K7<1=.$5L*P[9']I^4FC%K$X*'
M<S)8$"I:I+*LCLPQ(T/^=6ML@.)+#:^K4BS\+:L:?8ZE4_#HVO"R4CLV6"].
MMMSLJQTX[TFIZXSGQC9X"EJ2P]$RF1$UH8BQ:B5+:5BQXB6D+_"ZS9IGX%O/
M5$DBC1:F.[866ZGP$2R'1=ITM>[6*T!0#M8P*I9:-@Z^!)LNFU/7,;8C(Q9C
MH?B7[@#8-TV=%Y2WKAIES)Q$4>4ZY"KPO4J,:Q+2'MJ^%H=]JZ_K',L@2P0F
MMDFX=F)LJ-#FP=EC,!M6<6*:',VWTVU>]J6F+/1/Y^B/)#9-P1<QH6NN%AL'
MFT,$6O;\TXY%?,JIB.\S3F_)O&?\10/X%<FS9:X.EL+!ICK@3&3&U_OU' M;
MCH^/8>W+A*S-"S&-9"X^P^LXTGH.FEG@%WY>(I^<+6A4.4EFX]?HYP@0S@D(
MC9+R]>J)8-)C>W:).\+GO#K\^>N]M)^+2TF)&.TP$HG7MHQ.H.AF:"4F6UA)
M#7>>TZI\KZIH#M50Q3C8RW*3Z"8) PN0E-ZR?*V]UUCH!E9SK,] VM('IX49
MNN4Q"Q7A1&4AC-5P-BTB025T/-FX'2.#4]2E)OAK#<A ]I&I&S/%*.JA$56=
M8<[!E 6!,"RU9NMM%H)&<6H !KH_Q&14$..8GU 9>?.=1@-X74R5Y78(!],H
MM$_+L%5U]VB!9Y7UX1YG@W7])&4*U!MJV/*/DB"FT3BO5XMB01$=-P2HJ'43
MPZ])L)9Y;@4EI]E_EEF"!9O-;)<@05813(;IK44,Y))LP]PZ  5YO(DH-H"O
M;QCNK.\-!-_2@EN>S7"0-V;0GP=/J'M?)[8:2YRR#/,L@8.0%'KA"DV=]K].
M=^N"+S)UV@%-.YZ)M(J5=_ >DS-DB5//&.-!V 3.HJH/5G##.+A;40W&D[A>
M%=93<V"-Q,^K-7$/R]-;-Q)Z#;.-(46TK:\.CEE[A7:6P&CFU/BL.NBT.=_3
M++FX"3#E'F=?ON3)<4]50SMMC[]J3+PJ[=D5E ;@:@CR.C41VU>AJT!5C%7'
MZ>MD;*T(&=YE2^7AZ9$]1.F&7_H5!'&6@_=M<**4)5B/87)>H#.>HX?!:SV,
MHC\R^>V-W\&1TUQCEJ#7723<1$/H6A@BPEGWX $"<Q<55J\JD_82?I<WYT#=
M_VI DEP0+@UB'L'E@,,IN4^Q5:J[1 F!5G0&9D*6D D'.LJ%KQ;H^,!W:<$'
MSEO,PP/OS#"*7E=$&%K@V'-- R;H;%5LJ6P+)<=U<@-K*VO4%54GW%"T.#I'
M8_OCEO$\S@BJ*=E4[Z(J9FBU< ^KFY9Q'#B_&@G>S*?#DV&/"G,(T_P9]0W"
M7R3ZT^@!GTFB</L M,0HJ0IP40-,<%6Z?80TME"+<O6C'@^OK#NP,PR0%"VJ
M:?39LZ8Z/(D'[$*DZ0]+ZENI05!0#I).PCI()./& +>$8WW 5G7P"OS.C)VH
MEA70-0@_X.5IO"==+5<CLFV0(Q7/9Z)\V0H11S-3-3B==M?TL#Q&S++$\B+R
MG=9SX1$)[GF9R07='SZR+@;0Q1S=-3WL-36B U;IA1IMADWU3@7"3;X$UNGN
MXD'O8IG7L:'UHCQK)#*8(QG8*>MX5_OOJ!RG5[M:]42'2G]0-8;:EA(-QZN]
M.K36FS6DZF2X\:G]DKTXI=N4+%XS4?NY#,W>%UK\@8=,U T8VWP1/L$I!1EL
MZETSWIDDE]6B#E?87<TVG6-S$4:>*C1C;,NRT::TD R LGZE6;GQ4G&YYTLX
M&FR";->DE5+-W"$ B0W-54A0"PS'$L"P/:*APY&X<YG/N"OSN;I&(,9Z"XZ\
MF_A36^1=);34*&BJ9#.#WSI?^H$1?52?F([87]$DMC(1%?"_<)!?[AR?''$G
M9*RR6?4#++2F-,/L<J5;/!6T.A6.2)9VSIICKAL&-\Q_U*NV^_VM#J1-;C[%
MZ^N9@"IY816OP&]4>GIM*3S\H'[^QJ52L$WEHLAAHJ=Q3>HQ[M?^^9@>V?C-
MVD?X,_CH$]BJ5F>=._7@8(SM=B1-\Q3Y52'(1N!)V&C8\(,N%R/(L_QL@ZSK
M;O$!;U&CJJB9-+HC=?/%7A$T+!JSY"S1]2G#[9VM#/_;A64:5<24.H&@ZJ[[
M@9E6WU,=\&>-)!W[KX@@*$H<U][C) H21Q?RW2\;0_-3C08A=;5?H>?8*&0R
MF2?S(C, /_@MEM%97J&/Q-,)"@NH1[%V=]T/*WXM$VVW2]?E: ROU''F$XC.
MB,J)%PRT0ZGA.F;47<9#8ANK\DM5"FZ7SE>,2$5 (#QI3";=73R"RC+N+@._
M4KV36 AV\#"0J"K>2ZO-%IS6!=F1RL?\_7UW50_/-@H>KBSF>/[Z[#L=\N#G
MO\S5T/>\T8^G.Y?Y7E1'ERJYCJ@'RYV)A$R%7"R6V+@!7Q<5Y8TPG,)([U?W
MPZ_WLYL&G%8O=(\"*3;$S'KA:@<?_L"D8AE^%D >4X@J]-W[E),J$*/HM" <
M45VDFG%K&%;YBNEZ&U*C [Q.C)H/]&R[V ;00$?G@@')#1RIB(H+T]U!)\=!
M]:G(L4B_D8JRS>VZ@>-.G5GWT(_54T,A[[>[)65(QKOWMSB')MP[I:8-*Y%]
MY6W4]97\ZDK%EH4F (UP7407&3?=KDQXG$'BKBJ(VG\&:=2-8@.O2[69Z_@:
MF+@EE$C5$ZSK80T-G8L+#<,SP\9:D5Q@B41B%WMR63'.3RSU9]7P0;PN[??W
M=!97/YKQ+Q5>*\%@LA[1J$QZ,H .!:84"^2B4!-K4-Z2U:9,\>,F$".L%,'&
M:$( YH)1_8%]HO+SL RJ?8 O$D+<VACU5FNE<M: /)%J1#:E0I^R54Z/67TN
M\,7,+P$3M@Z_!<9HIU?(#=< *KB7VXYR?R+ZTV!_FW*/U-;10BJCY'A"8@U.
M@88Q-*?06I&,:R(8A-I!%LB\E(M&Z)&0DIRD8+%'C5)J308?R 28(ZYJN,2U
M1FUP>^NFJ(C9@*&=%JK<G\';]<JMV&=M$!L$N H=?1Z'M[+BU3?8:\H#6 B"
ME<1; Z!-IP-[=1G&]H(A[>2NUZ;@O2 6G,'%M/.'5 B1-%"*K!R=Z1"W9Y?J
M&+U!MB/8ZYYJ1Z=U68]09T6BW&RT+AFY?F=[P2R[EBEAIQ6#;*M>)3TTNT:&
MU/AW[?:?K9!)+5.@@4ZWJ=M%%;(@NAW=-+(4,E91:WX+I;+BXIH:0[]9=J<[
MR_;[FJX%%./"H3,N$&+IU>A^:FX;?V=:;>Q&%^SMI.O%"R-(+CUY5\]A6K]O
MPG9HHG]R?XQJ%MWV284^H(2%Q:=Z]KK&YZ_.V9)3-]4 >+7E3V.3#APT*-0"
M(1DH\48EE0E+V+)8B:E&XE.O8\0]3 )-Q5DQS3X=.+\CQ@'6*U?ULGMJ<WA4
M"@,K4^"Y/07*;3#K\C,&Y"-4J UZEL!#K.HT);TVEKJ3@ZI6]M*&UFOBE6QE
MLDW7O?^DK5L)%7>"U9'QW-=<7X.6-.N;YJ/@MM6DW8BXZ3@TMJS1N;;=A(Y/
M5C)!@OW ;^^*CQXP'F"0HZ] CS772.S1:.>#7VBI1JWFK3ZZ+NKW&%>G[:9L
MT= #6 C3@"DT73PS#%&4W>4\QN6 2"R:0^7P$E14J$904M$1W0"K(U7;[ZBK
M&+YAQ?#D>50,=RRV<X)0C3U!X;:HVM;QLE,^#RK?V-(#TUMF'+:;JO$,=/ID
MG1-LFMU!3DD&*LF4_#%C:W=7]8!7E57S)55MDW%?S765[)2@AC4LA>H=Q<XX
M>SX>6OX:$L2XNP0A6!IOU?8]NQ;'A[U-FL6LX-F%U>:KIKY<BIPOT4A'ACG4
MPG'=&]V#%,6E'C6B-E+4T2I5QGWM0)0&Z'9CQ^JL?C@^_*7GO#G]]56OGIOR
M/S+']Q\G15EE@IY\*C[*1&@4BE:0BX/7!D-G6PI25]M1-!>GL[;R5(3L42$N
M)AAA2XW];L'K6.B869Y.ESQ\>VTTC+(7S33,>M)3/:IJ<X#0?HH.RMG&)_D3
MU\0(U7 ">S#9]B76%?PX[$8R>)I"%UT',=H:8.'C7%OJUC F>3WL[C!_9 :F
M.)(T$@SX!/Y!Z%9FS-2&H*<&\4:RXS%3[>BGJ' $F4Z/WF@W6X:O5!MF!"':
MEIJNJ<.LC41LS^2T"1)X<XSVTHJY:!K6M+J%EG>(7KU4OUD4\R<O#LBJ2D\?
M9M"8*4TJ: L%.]:JALF8DROG!;6)-F/N:N QPM=1Q%L/(./HF.U[;QR6I8:!
M;2"%S6%Q/>!P5BBP[?8.=%*5AW;H_#>7;9OF"8?@)@FS5O6'B3+*U*B*)K@L
M$,>&EE;3\ J2RW3O+AHG#?0#*\P6BD155_/-^*#=7B80<K\&3&*YHN:SJZ^T
M!TWO193U%GF>#1+_JDB<'G6Q#[N]3K\?@H"?.H/^H-^S9K,EE-QL=(:;F52"
MAI")Y!\00=PXH*>H%3CPJDB*N?CWT=M?#U'3 0D7GU93;!?,\O,,Z%D-YA0)
MDOQ6_#,+U)G+7YSW<KZ@01?U8J<"EG NDU;4VS2PFR4;,4(30QO#OD%SEP*1
MQV(>$D=PJ#7&U^8$@GYN$ZQOABQ'$MJ EZKQ;/D2'H(([*J.B$SY96Z]1W.*
MVI("T^>ZA8;5A%@RS<()&EN8FVE /*>W'OW2BF%A9?2R(@FA]-<RUS1M>O-P
MBEDIE JNIY"0D &I-<>MS91S:/KY+"SW>KFZ/H3JARBM!"(.)81"TSZ74_6T
M+*>YL/0.. KJ=[4&>,Y+#)/B#1!>1H2UJWCM$0B<-..\?4VB2#(+FL(\IV(5
MD)%9942I!B3=?K%VC;^YI'H^HCHYZ_[@K-9.S\AE/+*Y-GGY%&"O<6."'Q$/
M%Q@T1O34^)%7KYB[+6V:LJ_!AG!KO(2*BW09-AT+30@^<'[>>O9UEZ>REYOG
MWB@SIB5AM8="=L"]U-R38O^1FBIK#\_6/:0T0'O3Q#UPF=3(V1;\7@LL?BL1
M6U=5CVY5X0X;ZT+ML'S0T6E;)SGMA0+955W^7N<HUT?^48:RJ"Q88,MLL\]E
M?19BC8C9!*2L+Z8%%]EN436#!*DJ<2_.]FJ@4R/0P6%9FUJL45B6CWO<#QQH
MV9'8GA1Y_I:$9U4T7F#QJBX 1I'U@MIE0%E9WT)(3JMX1RS.OV7C !T(T/#P
M+;1AZ(>%@CMG,(EO<8[&E4MIKWRQ93SXE72D!7T1X?P.29,0J>,'#KNA@S!E
M8[674SV,93?K@A0YY]&.:>TH7W.BFV>0@0BE<U(5G.H_C:7KD(R]47O$XQ5?
ML;2,K@O:"JI$>ZBA6]N7HB8+,<21]M2NOID=6;WE<BZKC5NCO11)EE)9_3EH
ML&WA'0OHJ5+-QD5ES:-G4S;39S05E]4R,Z1/U9_K!;,8W-FXK'9)8]2L^ :7
MDR;1;:Y-U,@#S5C;]2!A53V6E!#*R29170,4A !!G,UY!F##_5>%,\#>$7X+
M;U*9.'K>[<9-TJ&@G3Z]X%)W10A6T;05\3>_;G&"JDPUU:H6@HNJ5B4?I75Z
MJPUU!W2M-%C#1DA;NS5*'E&R8K_G?^UJQ?ST^./!%9G3\#!RP<'1!GL>*%7'
M%.LXD=5+UC)KX$Q8$.K&,%R>7D(]5-,B 3!QP:K@:%$#;)HBK>TZ^Y:%;;")
MBM)4F&W&6:=.CFUBDHOZ-D%=;P TVBB4-L-D[TD>I4%-I42%@0'YO,#!IG7B
MKL<4D<)+-P]O-V)?PXSK06SO#YQ?^;JMV7.*H$QN@B1G/!793#E_C9=DFMI8
M#:]1 A7\"_7"&H=3BQ=-;7Q%74',70MB@KTJB'F:0]#!(^6B+W@0,H;1UZV<
MFTK9=Z_?G[Y]]]KU<"B.'K.U-I@M=4Y^.(Y<+_ F/>0,;DLR_5<4)BQ5K&*]
M#2:K3 ^;,>^:*[U.TI$UH )08'4@[Q86\MMY,;4'*]!\<3-Y@40D[BLEM0&"
MO?&VM3Y+"J&<X&R^.KB*SSC">/][-I3>%#E&;O$0?BAPC"#X&)F\E'4INNX9
MS&;B##^&W?\Z]_A1LAEN(\^ICQ-(@%7"74J2[GE"45VVEPB?2JF6I*#$'K9*
M<.#5Y'7,Q;8O$Z>L3971:JV WJS,-+V; ^<'THYJD+">Q<E[43H?W"OX&\?V
M*,Z:T, &A/=35B5[,&O1PFV9 ^JKVJ(SL5]H(ZW4]?)VX%NK4[Y ]:+-O&)S
MA3U%F5L=YN>K"NQ;0?/38<E@X*GDACKM&BE(Z5XPA\U\46>!8-HJ,G8-J?=,
ME(UL<V-IJ40PC[3>XIBV<LC33"YI2!C-ES1W#6?>JP/_UAOH"-B>@^>OZ))(
MCF6"YUXCS?+?S_!;TIX@@]2C%*SIDCH /BFMV=*P\#,,:^8SABLALX?+"/(M
M5IIE[F\T 6AS35<QPR*<+,V8;C=T$%O)/C7F*=NA)4EG]:XQS"QO>TWDU"Z5
M>><^9JQW]!$P4Z3'M2"0IJ1.H34[MC9Q<?H;5D$VD>@3R45 X&<6E\X4NV:R
M!7,DX1-3=_>E,\,8@OX#C<]%1^,:@WHC3..FPH7%.0W>NT9.[(4G=^W@-CUV
M1]^-E0M3PHO%/2LGJS=QRZ2=[I[W[Y[?;0'(8'&+.]TL@"B4PS@0)H**3;2Z
MD=+8&6:B7K. APS0NI**B<E:"M$5O(WTKH$8Q\OFB I=*#<U8R(6+\@$DNQ8
M:6-3;=/I1K-Y>FK(E9+Z&MK>T/N=Y/VM"<L: JK9E+08K+0$#P9,:7@#<NJF
MKMDFBV;2U)-A\!%,TN54*K.!JV0JU/4S)!YCI3;.%>Y8:??64QLSY)2=254S
MVG7G9"N'7]1S) =QB7L55O*%-N2MJ6(Z L,&VAQ+V'1IC;W5+&\OBIZ,+_O:
M6/U(D[!&<3#RD&RA9:YQWHBYN'!0-Y*N<:@A_QH\!.^2S?GU*0<<W5>S4FDP
MO537UPJ#J;*G1@=1J_B)&;(9.]T0+>W90 3U]$M-ZBK4:LK ,""+?LOQ=L9E
M@J[G\2T7UT]74>V[M1O0LPIR--@,X@%@9;/+!<%SL2K*.J%A'+,U+YY<*=O#
MU9Y1?8I6"[0ZOKT@U%N4CA%./Q:PYE2H3$C7"O ! [(;JG!T[X55I-!3LK"1
MT++'Z+$3"S\"+>S#05UKI$59834L$'$W,]Q9GBS1C9+K]=PX<E>%L_E8F]-0
MK4FX>/A\T,J<JK4[_\FZD&TUP35<QPU!&1CR,!9J=&\.?N=BJ=P^RQW4>:M>
M/9;2_BP]_=I3,K5?^W_KKZRC-C7<5)!*)[8),:#K*7_ %A4^Z#7+H^:E#GS_
M@5N$%N=%4G&9-!GG)&-*EN,Z40WV(L9W.,]B9@/7CL(%Z&PT)CI(Q@>^+@3M
MXWG"LV(JP:F75FQ_*JI*:N@HT$\DGAG1[!E(YJ.:_2N,V"KSC3/.A/NR)>9J
M=QV2%XI).<G)X+S(C7*]V _K[<I#^)/-L#8T$.E<66)I,OOE>IIXSD'/.O^O
MK0+MN38BY+I3#CBX*!,VCC4+-[ Z>C1'O(W0T7/ 75"N"3QWA@ [1'1 93$&
M%W*T21V1P'UA>F@%2Y[#WS/1HUG>O:L&C?\(1A9\$1QA\S>Q$)\RE;YA$L_E
MLC06%I7-P*IC7*2K0]8F^D^!![W1=BF\78FL"435'MW N&)'AUN8*8QB<AOF
M29MJNFI(T4;5-IO5UJ3K*\QJJH?!,&!.-3^=J'TX4?LGQB=4"S32A>G5P"M"
M]KB43J-!_51>4"[7MHR/C?^@:W:VM[8<_O[^]/716S,! UZ"WL#A\@SG&P[Z
MF 2F!@;%Q9MR=0J\TU :I\"0O^%A7-?(;#+#3"NE/C6+M#%4MS)+/86^!N8C
M[QHM (>09NTM%&GJPH<DT+F.'OT/R(?/*%E>+$#BP-_XQV]-R4<)$J4>1Z:X
M]P+,=.Q>P5CEO%K%YP6J-_;KV5EY(0_.#E F%9_!.X,']CBP>5[@E0-'8-4[
MO.USD63BLYS3@E^8!7[+[P&F6<+GES,:';1+X5C'9+LRV7'>5CP;4?"DH-H_
MB]DT$P 7N>MEJ!NU7^M%Z]HMRU-9+BB:QI2 M3>EBG47,1'?? F,0"4@&Y@%
M8>G0G[3]^:X&Z:XU2.%>U2#MP/Q/=& 4^:F6Y9F*8"VP'C[G:%]M[YVO$+L?
M=%LQTSD,D.0L2 ^PS5%0#)0>QE4KA4;I;[6+&663Y9OK1UCQ45D^2O\ZOFWZ
MIPV['#B_B&K15#^F;7&;DJ$DQFHVAZW8*-/.BPO8R1H&79OOX>-X#-/5MQ;R
M++&Q6;&UP._@$1PH!\E )8X7J-M/WA\>'U66I8KV;D,W68@3\PS?V^F51S3>
M3+<?:H8KO)":ZNK4V^)20SHTE,VKMV].K6[B@_H=2E'5E&6WW^/3,-Q5:8\D
M*S>9/#>SQL04B#E7^'U6*W2M]M1XCQ>-I:M>YDW,^NV6$S+]E+H.W]+%=;.6
M'1%B8^T7%QNQ5;F:+CO"7U$-@C@KL",6?O7F\*W[@]V<;5B)*P.Q:J%J CJO
M2P_[F+2!8$NG3?#VUMX[CGQ CCQDJ^S5X<\]YQP^BS64'*R*"S"Z,&LJ61Z+
M4G4:*[ -1'Q-L-H3/RLX]0HW@418EFKD.XEY8",D.7H>V$1PM9P$C5?-VD[T
MI/E+G] %1XXY?'7Z,\(&R*DB-RIG9Z"RAL(S11/$Q\5GF5N=[TWD7[4A-Z)B
MSKJ29QMC&[_./,\*["C=QY$773JH#K2CVP>D6\3RSG)0\AH214RM>@B:)&TD
MTI+P);#%>BK!0R5+HCT"Q9*;QK!9=V"X:F:K6\^%X R/1.6M:[33T<0#TX1M
MX)I[65)9N"IJJ75G6<S+3"ZPSJ-9&@$*B> F7I@Z_ZL-%&TS;(^6ZK5\>QWQ
M[4)=AE"?6:)7J-$3.#-BII"(6G%:!?ND.=C^"U7I68CC8,>I NPN(_R S!4+
M*NNIT6*Z_.^#SGA3J:26QK$'LM16_1S,\2+/)2=?ZJ*0[HH>9PQ?743>G?A#
MSBAMU3:K42:FM%ER$T]W&X]3HF)[53U[<!5G>!=E%E&UFGTA72'*0[,(>2IX
MZG WF#/9%ZOP%M6Q=:Q/@6RT/'DP2;C*.E.Y?[O@N/XHC<)--Z 8:<2+[7V#
MNA1ZEPD0<8'@JSDWX_$$O:S492)4/LW @#I^TMO8E6=7.&2(NJ:NU50>F,EN
MNG"<"]RI+@>\DKVX\^MJ:NA:E3,T%]7"66*:SX#]4 5OHJ!;3&VN^DSOBMLV
M.#,*EIBP2<&%*)9Y0MT0*B*P[>"WSTIJ5?E2'3'M8G,_69->&WE0JS$77+IY
M86IC"AX(TZ1])-/FPRSV=EX#+473K,*Z6,XLY<)&I[R";U2S@ ;_L6OKUTE<
M54MOA#Q5^# ,:%2W,$N]-*XR:++L*Z!GW675X_Y/-3)O2UVV]?<ZM$(IGT6+
M!*@M:FIZ-9J0L_SG[0VNYD8VH:!Q!ERCN&Z$RE0=>52NN6!4C"VDNK7;02-$
M_[_VOK6YC>3(]J\@?.T->P/DD)0T(XWV.H)#:6QY9R2MJ%G?>[]L-( "V5:C
M&^X'*?C7W\J3F559W0V2T@PE: 8.>U<2@'[4(RL?)\_ID0V[9/G=X?'> L,4
M[CB J2^'S6';!J-':(JV;[]4@)A)VI?C0VFN^"]5M9C\F"S"UZ"-G#O[T\,)
MI7!N&*QX9>*"#TR>)"Q9Y/C&BBR,2"JMUEKCZ3TBPVV$=3+=&Q\]. 'ON4V>
M6^B_>QV#"4%E.YRL+7W>ABN+B*1"OU(7$)D?3G[AIQ>A([UM(!]XCY_R#?SA
MW;HF47N#N6MS28%ICH 3LZC=8$:M'-V6_8K*+C.%-4(5AF'R;U%= UQ)U+G[
M#,]]9GC&9X9LO3_/_-E)' >A:UD%R= DAM)B570K9PSN=/+/+D,/G/#&TO+7
M?PK$9T(#0M./.\7SL[FL:I:H]O?![T!C$)(=O7;;0% [\@K!*!@+NW*N33V
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M]F>3G[-H^3 ?0[*2A&L4GFS[$Q0>W07L6D_6:.'HD) P6$Z5:2I!)%S$ V6
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M&S]K1,.H03D5#5SSCE!]M3HW%%P6A=/XLD#KO\2/)/)#^2MHA%[4U75[J31
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M"N^Z1KOM6 QD+9\?W'F=S_QEO(DET09F'H-!W(WT_T= 0IBVAJ#[:(CT8T
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M_9]P#43E;JZRO%"9');0XLJLJ[4$UM(T]4?,8,*$"VX4D26L-:OL'?$;<]V
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MLI0H-6A\%):$)*1D<45WZ347:B6-<B[-AH/D+>>>99W?#,?<PXON""]Z_&7
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M3=VV4^JT+*F!:(C&,*?4]VY6H_?FFWV%Z_.@,8[W):[]6?5)SJH(IGCRX"B
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M=Z<4MX2,)[\\;^;=N"G_G6B526@N+1%10G?FJ.=@V=4EBV8T52$:(]E<=3)
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MI5_-JL7&_[_+=E7\^?\#4$L#!!0    ( (* :5&*O7@$.PX  /2'   1
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M(;L:$%%!F]_X"\S=HC>$Y?68 &]OP8"T$*P=&EV@.\@]Q5I<T)O??B-4F?=
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M[,?%=/,2A?2&9(2_O/LO4$L#!!0    ( (* :5%L6@L?3AP  &0> 0 5
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MSK<0$586V9!@2_ZJX8)XE# 1-AATYAP(T\1WO@EE3)'XKGJ_3N4]!=XH?KI
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M-"HI:. 4)&OB-*Z',U+K68,@%>3?+(BX ),I2\P+( &$)S(F@1,[8N/<!)'
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M],9<1&],4,FU,5[+-HRZ%=&85G?'RJLZZCP NX341DA$DFPLB9X@B'/<E)(
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M35P+?V+Z:D0?.O\\P=,ZTG[!=^/I]"TY?^<[CC]]O+@=M_O98)5Q+EPQV?H
M6HM"3JQ0F;JH +2Y>%S/^-80JC$NS7$V3K<0G56W<'PUCYU!Q+/%=P?S*3L!
M^#RX>AW9#]_2E].!Y2$4&J]9#,4RS4&1NQT"PTQ<%IZ<A;AV%ES,@ 6F<3$-
M+M_P0Q7 #W@VFUY^9R$)1B[ZA6?YOS=#N6!Z]\;]AE]P-,?IJSB=32#-!B'K
M: )*QK,UU+0LF!=9,YJ%'-=0,B^V1=-6@=QNV+6(7TTNF[CT1W9T6&J4U2O/
MLW&/EKV@CQKP_7?C2<;)W[[G/3']AMI-G6D!Z1\4=+Z>3V?41R8__YG.YC5>
M?36=(OV7/\&? Z7(,1'>,\L-I[!2*.:-BLP9DX,1Z(15#<6P#=;#ZV4_@M>K
MI1D[=P4E]A74<N@=G?S\Y^<Z1E\;@B)\;R1/3.BD"9@T+$+P+"09!3FZ6JG2
M0C8;$3WYP:0?6S<0P>OQ=/:^_'T\SG4"_HB3+\.$TX_CLSP@0,(%*TF> IF6
MR!E%.8*:[[1+/'D=H(4*-D,ZO QZXFW<Q.@-Y/ ;3I$>>$JP?J(1[6S\N?:!
M9>.O!['TW_/A!//;T0=R.FD\JPT:Z%S("X;,LDHT? JG65!DFV!YCL4:EWDC
MSV-GS,]%4(>B[:[B9!O%U6ER=HGW/06$DT^G,/IT.AG/3TY_G$]I4*[PS^-P
MM(@>_C$9SB@R>5_*P%F;.8W%#)VF634$FE4Y+TQ[@]16F22ZP\EP]X8\;VT>
MB."[@E7["O8CGM&/3OZ.([+6&;7J53XG:JJE9A2V+FTW<,H("320EY(B82.\
M$<ED$@1*:PMR+YJ$F)W@/1=Q-2#CKF1T'TY6G>DOFS[@)40+"<C53X)I6X=;
M#9ZX=#)KK1#T^E7X'ERKFT">BPSV,O!=PDUOH=7% E9=RAIDA2Z9DIGWLD9[
M1; 0N651B*2T3XH:V32HNL;R?,*I'>W;P(_Y=3P:WT:U%..5P%W*"3(%^13N
M)P+H./-@)),E9J6#\.2%M1# @\B>O!SZM7T#G^'M:(83G%YZY -/6, 5SF+T
M-!\E2 RBT:Q8GB0HD47F+:2P@N/PQ/?,U+@_,S<(IG\F[W;V]2.F.3FO0YR^
M^?+K\/?1!.%L^#^8_T[V6@Q<R!.YK[[.4"XS3?,6\\XHAEYS%Z/(4N468N@&
M[[EII $I/<XF=3^19/R%1%R'QXOFDV.SB)!^Q=D@%8,0BF)&!9(TR,1B$M3T
M' PJ$9-;#2ON;E$^])+G0GFOQFPP*VQL]2 :=%Y3&Z6J\8K(-"T*79@%S""=
MB<8=UE5X+I+HU_0-0L5KA_9R*VDXFA/(ZWWR'[&,)WCQN4_P)TY__I/L0>\?
MCF#R=>%,4>M2W80:+X+CRUEQ8" %(6QB!;*I<M?,RX#,&"-1Y!Q]2FV\CF9M
M>O*NZV/ANYF4"?*R:_V((^)G-E 99=)>,0KIR5PR!1:1>Z:]4$(Z3!H:RO .
MGF<BH?WLW& -A";8&]%Y@J!0E,@45T@0%&>A>,>2M3EK)7GA35:\;J%X\E3O
M;M.[!-N]%[FJ&W4K9>L:VZLO,*1?.<,WX\E'.,-K?_M5_J_YA3]&C7E?:AZ$
M(28TIW$*9*BG&F1F(69DL0@5B%8*X9H$0'TUX,G+ZBA,WE6DVW^=_4X3KJ"Y
M8JU#X1F7DOPZ$RSS109F/,1 HZ&WH<E^S#V8GKQN^K+W72GXO==>8#(B7VCZ
M 2<?3V&"/\)TF 8J!)<T>J:BIL86ARP@11 R1O+YA8]"-=D;7HOFR=._OXWO
M$A_Z)OZGX=E\AGE0?+8:T5%<1Z.2-BJQ( -GPG#GI3%.8IM5MO5XGAWYN]AY
MS9KKWFFR_\!ZS!+SJR\40)W@K_-JE?=E@7'Z?CZK9Q!K,LQ2K)9[[P0PI6TA
M']DHY@5JFK^X4S:#QMQD4VXKE$]>*^TX6:.@O9?M-Z!="OP.Z(%426OI/0US
MD13/C63!H61)IL1]$@)DDR3K+7$^5Q7UPLL:'>V](WS5_$_5?1YP8;EU7M/
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M?6S]$@O!AKV&FDTO_B:F_OGI\>C\ NOJ9#D IRR/NC!E,H%Q(;!8 DV89(X
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MWHZ[_6VQPC3-ORADHL&I.&UCB$+0 )8%S\%JE])ZIG>"L6?0>I5SL[BOCN:
M=T.(P[/ET'L!XOWUFR^N7)G< G*]:N!I[$@B6&92O8^.9TX3@16,6^-YMDH!
M-+D L-=6]%=#9#K@V0LG?:R%!,D3,[ X!.B8,Y 0><Q>-CGV=@/#$>Y#/)JF
M-E<3V8Z*%K5Q%[:X,LU/PVE=FR)+#'0,7-!(P6C \$P'LP#&&7(?E,H6=0XM
M-+(1T4M63#\T-8AE^C#1Q2J:,+4X8'%DCUR83F0HD$&S8@)$83+(V*1:16\M
M.-2*^>-1Y7'(?RP+Z_<<LJ<XL'#G(@N\EKKTM> ,>&#H8\K: :;2Y,3PXZN\
M<B2)=*_,L@U5CZT>1A?LWRJSM!!"GX4Q=F'QL2G16)>4C(1<*<UTD9K%@H5)
MY[+#S(%#DR2@QZ? W2NS'$V VY#7]^V!2V"_C$?X]1>8_!-G;^;TSV7IO)"*
M@!"8%#30:XN!@?.!92M*L5):<"NJVE"D[KZW/+&J*UN1-6YAZ091Z/JF2A53
MPDQ0@JL%P[5E!#-1:*/ )I^YL4TBT.:CQ2.527]LM-@TP\EL6(:I7JGXOOR$
MGVLNQA*: I4,!2P7#J$.VK$8A&%)H0!# Z?Q3=;W[L'TDN32$S,])N\O!KS;
M!ED"2LFX#*&PG S2)"L(4%S<1!"#42YJ\*'3E++NZ2^ ]'XLVR!W?7U%,9*>
M<RIR5FQ-J =28E#6,TF#&,80 O@F?NESJ.^VUYBP-QL-LLTWY:5(+P3-;(5Q
M6RLT>ZR#5. U'9Y'!<Y(V40DCRP3\G$LU?1!4H-C8+VFHW1IR[>$R%T2(K=2
M2<L4LUTH?O0)D8HGKJ*@^%"*>CI-UMO %#,R>"N4+6G5=WHI<MTQ(?+1J'4;
M9@^>$*DP8H)%\:9:44Q:Q0(/R KHX+. 5'*C&KW/."%R&\*W2HC<AJW'4O_-
M).'0"<M23(FBU$S^BBV*.=3&%^JD%-:T4-@+K/^VC_":<]M@:+LZ4%3&D^FM
M0VV7-Y+$X(1;7(M=:I$Z"K7($A1%2T76H9A:^]0DS>8!8"]89[URUB 6J:'Z
M[.L=5,#1:>4U0Q?K1304?P59-$N!PNM"H5AJ4_9G/9P7K)\>^.EQ@6RQ8O=I
M/(.S#;@$&.ET4(P\3HK6M8_,Z^192N"+S-IPLW*Q_88ET7M>\@+5T*O=6ZR&
M72[W_/CUZLM_'^*$7G+Z]1U^P;-%C)*#B9A59,8):GIRGOPY@RS$XE%!R(A-
M@KYN\%[X6EG_%#98F5][IN NWF57ZP*VY=K85FB/M/C5@/9-RFK&6<M<Y$Z@
MDS'>*P?,9V_J?K:OTW%BP?  P@3A8YM;78XOL(>6JQZ;OK:AJJ6NWHX^SV?3
MA07$958$BDQ-C_4^6<XT&,X\E, RV!B\$EJ')J=U[\%TQ',2_;.Y23=[4M'B
M]J@UT.3EWK@H,A15RQ=RPL<EN7H9# .C;<X A*Y):'8/II>FDEVH.-!8HJXR
M* (&0E=S/S7]0:WU8!-S.<9L05N1FA2<N ?32U/)+E0T6.&Y,0/?,,.;"?[W
M'$?IZV+Z-=JE4*)CSFK)=/".(&K-9(C:6&D\K-[@W'M@M@G;MZBL3_):QO[K
M "Z[5A>(AP[$5C >/?SJA]\.OG$?Y!PHXEJ%&KAPF(1F-M=;>#RW+$KOF9.1
M.R<!16J3774L_72/KHXFGVTX.52@?C4J7V[<.15<RIHA1%EWDQT#:X%B3*[1
M)"%<:G+;8!=PC\,MVHO5+@'Y/I0<M=@1 1^/$DW\BXNAQN7]?')=<V$XNDZ+
MO;LTOZ:^R?^;PV2&D[.O"P?A]RD9Y./P9+3(>1_-?A^-XQ0G7ZK?<-.3[+DT
MS2-J4KN"-X^HD;=X6RFCHZ)5(*7 ;$!SZT.JF5H9C8X>'>:-O>FQ-.[X-1_>
M714@X%I97X)G40.YVJ$8%CV-S*B=3S3$"-[F"H1'59QGE?(W7WX=7@MBH'BT
M7J%A%D$PS8-D(;K(:NTF ]8HA4W6JN^']=0+LFRCO(?V^/<@K,%:Y ?X>K&S
M/7Z5".@$KZ'=K#U41($(*C(?DZW5M NCB3VRI)70"74RJ<FU9]W@O61Y-2"P
M@1^_KA-<5\S^.YE\4<:?)DZ(7@.3-$]29_"6@;:%J60P2<<YM"F"WPW>2Y99
M P(/D.^V,M8:$K^HA1( ZBT1NMX-53 P+8PLQ7B*F9LLA&XS.1['R;I8RPQ6
M.9#<,9,5UI1%"MA,<BQQGS2Z$)/^5ECK<?7+XY#_: IKC<_J'3 3N,@SX$%D
M$W1B:I&!%R S4)QZ>O1D1@FU"'";\Q\W83S]/8VMI'#GS,?.E#0Y+W2)9KGR
MU05/R[V*54!'*FZU!TD;^=[#PH=@7D0=<@;+"KK$="%N@H^&95F4$CZ4HMO4
MB#D(XP\5DVI(^#:&/4!HL5R!MHXK]-DRJ6D^U=("\XG";%322F>X%MP\YS,.
M^]'4[9S"-C9NF4=U?_9AQ&B53<A<J1<O0"&O7SI!=E N.E=L5$U.A;Z4O/1]
MO(4&%+9,LNF4:=0%[+>\]-YIWRMO>!?.CIZ7KH2%A%RSF!QUO&(2"W6 M\FY
MR#5'H]M>5O#4\](/IZ]MJ#IP+JG5T@4CD1DA"M/&%N:M2$P8Y%9)25B;.$I/
M.)=T*S:WR"7=AHJV_M3&?",,OG!/WIZL5P=H9Y%</FH_*)D0A1<EME7+<\XE
M[<F3ZH6\ QWO6\U,Z@+Q6RYI'_SND RX"SE'RB75V<<@:$R.Z.H1GZ"H*P7J
M5(%Z49#!%-$VZ'N"N:2MY;,-)\?*)<U.))N*9."QGOR)@@4$SISE26E)XW+C
M^>W)Y9)NQ>HNN:3;4'+47-)7.2\>7>M"E/'D?)&]UW-RYWWO:)=MV;EEJ_=%
M>EMJ(K!.Q6J-/H+T(I*+[*,N2O'U KCO;<??*K_>MT6T02G(##DGY:L22/E1
M,I%%L,5H<#$W'2L>:S[B#3(74<[ 9",D\, $"D.!C18,G 06<R2EIH+0YH:X
M+N">>E;/-BKLDM6S%WDMH](]K%5_?S&*?,)T.AK2_+6,N**UU Q(3,6Z@Q%
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M.FHNR*,N@ELTRKC!%BW8^E3D>/0%)[,A>70?<30<3WX=SW8\G;K^2?V<.>R
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M96JXDPP$U@M*#?VDZILWB2G6HCF\+)IPUT4?6QF^02RZ"FK9X$&066J;@:5
M8+0LB45C/7,A"V>\\1[-(?2PQ/,R%+&+\1LX--=CY/O)Q2FF7W!V.LYOR0.;
MSA!OC)P_?KW[X<N/7>1\(<V$F5QG9GFHYWT5,J^"8L5RR#9GGWSC38;]&W&H
M),N&D]/1.'TL29JO1C-JTD5,<1T[_/QG.IMGS!=UK<\_4_0Q6X08=[K_U_4/
M6*0PB60"=?S (KE_9(^4*#3V@7%R!464,5K91.,-VW2LM-'CZ73\./728,Y?
MC^Q&LE87?"T36!\">)Q$UD>CB$Y*W9/.8\A.9N5L3)JH( =*I\@INHX4OSNE
M0S&!*VB2-'\<N3V0*?MDU;8-BRT"FO//9^.O-%'4*>+]HBS-,E$4=$$?3&#.
MU5;;6I0Y!DM_J!1C1."JS5K()D2'#VKZ)6\UFNG%\@V21'XCEV R3'4=KT*[
MO%FS>*DS!5DQ:W(.P&@&]58 U*!<XEB<:W(0>2V:9R:%_2W>_&3&8B $<@ZU
MEL@0Z\WM(FH6(HV&G$)X"+R6ZSU /9YO_O;^[#2_6.A&S^B"ZT6?[]J*N*Y'
M>G:Q^D%/_4D/OG#->*PG7&+V+'I;R( :Z[7?4/0!2A(^OO-=3<2PC;'[SDCX
M],?XPYA,1'^_H<ES6>[@XFC)C;,F%Z=,YD@?^W0ZGM?C)9_^H ]^?3.>3RX=
M(Q$3@I?,!QHF-?>.Q>+J'0$&%8\IQ["R<+0A&:$_3(_HS-A6)(^/S]"A3I>M
M/4O0\S6_6[^CW<F,72_Y):]#EQ12\=;7W110QEOA<W':>G(XUY_):'?'[\?3
M\611%*P*_GI5'X+5M>0I$](D&A\M.4V&_@A!&T"C+1>-RANO@W/D9?;E_;1!
M9E-,\O48 <T9GF?FK0I,>8C6<JZ<;#*7]H+^"$D-^RNKY^7O'7AL=,_P%L7O
M==".<TPL@:UY9(XB56L40Q"E6&=D4,VJW3WF>PD:R*LA,PU\_LMS>O5 P0U3
M7 2]*=1=?C2,YA?"MKCF3<:Z;))U NFM4[;)^'T/J(-M6/>OC-YL_5@VGM>$
M1*487TQVS('*3+L<&0!92BBNBL])H6BR7_R(EIUZ8_GA9:1MK'W(!8,NN%[T
M,M)6Q'5=.=C%ZH=41:+/&@B%1DP@?$HDYE-TC()-;S1X3Y'GTU?#]LM(3<2P
MC;$/7B8(K8X 4A*D1,,@T 0*X"Q#+8*03M"0^& 8_]3*!&U%R%9E@K:Q9H-0
MI.5VOM4<BZ5>0<W 6C=K<:&Y8"9Z':0.PL0F)_&>8_I9*[_DL?#?8)_LP9WD
M+OB^I9,=31';)OCL0N<QTLEB5 A*U+MWDV":T]@?069F%4TQW&1T7CX?N1TQ
MG:RIVK9AL6\7[48FTW0EI>5WXFSZ:I3O]3D*.(Y2&<:Y3DP;[5A(UC.;H]1)
M T?H=M9X3R"/,+MH*UK'1^)DVPV]Y;?K'Q&F^&__\O\!4$L#!!0    ( (*
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MMG=#8Y_Z'>_NX03^]4GK7"PW@GZA0LY(P%2( @KC#)&Z1STD*=,VI:0LS'!
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M0<.ZJLA>=YJ]1X -#NYE('V]!7;L_$IS.S!M6S1DNSHY95?MF6_">L$@=ND
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M:_7!1G]@!G"U:7,Z5%LW>_"&:_1FH<,KMGZS1ZB[&9S#<WI5F>--KO%VR_9
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M28(Y";( QE&JC2BD]Z(,B1!2SH) \"#-F%/7Q2&5G1H#MJ+A#]9I55M-VY&
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M^#Q+4T6_WB#?+*JF/]AZ3!X/<4<"WNNI[] ZCWM,/-(,')PKCR7WPC(=3:6
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M_FFA)T0VI<2NE5X'[_.R6MXL'A]ER7,Z_T+U!R$.) ]C*B$3,=4&,4XA0W$
MPSA0/&&!_II:K<\^PJ>VC%OJF] P4PVD:;5S!:@9 JCK$B_4^H\.#0-<9Z6;
M!8;&>F"R:,/<J+XI2%@K#VKMP4Y]8/0?$&R'/@L#@CY2QP2_X+OU.^B)7F?G
M M=GCM>#H.=H7W03Z/L,'R7D:G,D% RK2'\W)94A1&:;Q1@1D$11EE&12A:Z
M^4L.1$SM(^"Q?)R%0><'EZ%=)_NEXSQ9=><'/US9N/'LOO.C["X9YZ'VZ\M0
MXVUCTAG+LI1R(B$ADD$4HQ@R93J&BC!,5$AHP%#_)("MG,DM\5.9 &K;??B2
M?( =OG9KWP-J Q/ 06; P%V&SR R7+[ 3M0K)@T<C+<[<^#P\GXD<:=1E:6F
MGB_+!?][4TSG0U6MI)AE21JIA$60:TK0FT260!9S#B,3=ASQE+!8N/#$:5%3
MHXJMIJ RJEYMRJGEM;;]"WAU@&U'&GX@')@W=NA]:=!;%^-J%/7'%^?!\$D9
M'=)&98WSH]XG#HL[^G'')[F\H=7#7;GXE@LIWCS_6DGQH7BO]RX%SXO[:[[,
MO]5]7F<AYD)04WV"Q;'FDB"!E#.EMQ5"R10G.)6)2RE >]%.W#)"%4"3#LVU
MZN!IK3M@ST!M] 9TJ[@;M3C,A1W5#(/PP-1CP#5:@[L6N#\8S4%>_ BVRH/K
M\S [\Y$[8C[YR4'ZJ'SECLH^?_5X0@\7^J:LX(<RKQZ^K%B5BYR69KU$1$2$
MHP#&::*YB[$ 8M,0,5,HY)G (DZMZCATBYF:#;2KI?G[PV(^?P:+WPN]C&J]
M0=52W,%'>QIC"]>W%^2&YI\&M%NUQNF+;YP<O-9>\!K)/]T+-S<W]%DX.AW.
MI^\>S[5\=@0OG,CGK^X;7+=UHY@=J4F#6FGCLEC.1)!F*D$*XB1!IAHJ@B3.
M) RS.&68)0E!F8N-=U+2-$VZLGRN#;A'4\C1->[N%*:6?F0?2 WM3FZYWXR2
M5V"GIL]HO#-(^ W+.R5LY/B\,V,^#-0[=T,/^^DZBI+6@[_4'M9/QL&Z+IN)
M Y9A3 (8,44ABC&#C";"_)2@3,0\LRN'925M:M94]%.4_)_MAAB@41G4.M=]
MY_5+AAQLA+-X6YA4/E$<F#[. 'BV>FD/ !UL+9] CF1R=0/ZDR>KRQ:83N/K
M[$/&L\%LQ_/"%+.^R3WD<B_I:OWFAI1ADB$&1492O6,52.]8]?^D$691DF2Q
M2*T;R1Z5,#5ZW4\QM(_!/ Y@-W=Z@65@OCQ(NO17W_GL\"\-T3S^\-'"-3O'
MU@[=[+ZP;];#@O^]\<Z_795Z0]'$_M1'?>\>G^:+9RGK:^[TF_) *WFGIWV6
MI$R0B-0EOSA$441-23\%XS3&VJP(8R:=ZOKUTF)JI&#TIWJVC0]KTQ;)Z R4
M_LK)]2C6OWI:CP,\Z4>XYEKTF3&[C=W@\S P"]6ZK0_^0#."=>#A51-(< 4V
MPV@."\%F(."N:R)ZY'E< *3?=) ^BHR<-7(!5H?))9<\K!^'OEE5>2&KZF;Q
MR-9QE-6VP(OD*& $49@(E4&$0M,(6R'(&",I"U029TY1#5W"IL:(&UU!6]G>
M%70Z8;;C-U_@#4QCO7%SYBD;0'S24:>\45G'9N3[Y&)U3U\WMS$8:F9JHOHH
M23@/T@RJ3+,%HF$&69($4#%3DU&&F;!+:3LE8&I<<=.RF*[ GX*?@B $3W0=
M*?E7$$7Z5YO *+I:/BQ*T\GHKYL@*5./K]5^<G/E[[*4@,0_(4"7X(M^+VJC
M^9_^&*;!7^/@RGC!@OI>$OT4FVO>2MZ^)#27A,35O[XWF;9N]?Y3-+@WO9Z=
M=8#5VI3R'6!U:OQ^?>A[,D9VG1\?X:''_,1U[C6;WZ[=>^_SBM/Y?TI:OM>_
MJ6:(1*%(X@2&*C3-N22'E*$,DB0+4Z6MDYA8;>$Z9$R-8C9J@D9/8!0%M:;V
ME9Q/P=F]PCV!-/ B[X&/4WWG,PA<4.;YU)-'J_9\9FCMHL_G+NU;EOW+(YW/
M-Q;*+%-81)D0,(T2O>TP9:I(EDJ8\5C%RF3<9IE;9?87SY_:TEZ7)*]U!!LE
M7>NSOT3P_(J^$)>!5[,;)#T*M1\=^,6UVE\^=>1R[4>'=%BQ_?AE_0W_)K?R
MCC[)<G,6F$8I-H9_)$.FEV^ (&$X@BG-J))QBF/L5$GSJ)2I+>)6/O"3T=+=
MZ#X$TM[RO@B>$<SO-3*U@@-TS^R$P+<%?BAH=#/\Y%B/V>*G+^ZYZ&GU<%T(
M\Y]W_UCE>HM;5_DVF;R!8$D4* *)1"E$7"B(A;;0N:"*QCA)@MCJPWU>U.26
MOPFD-UOQ^H>6LHX\<!I;2S+P@MC0C' *+/]YTV?A\,H.IZ6-2Q%G1WW $^?O
MZ&O:WS3A<I_ED^G?7=R;0DAZSTE"A+,XI9 %/(0(BUC;^!&%0:KM Y50%*16
MB=7G!$V-*-:6[5I9L-46-.JZFOTGT+6U_R_';)R-@#-</;8$W5A<O#<X\?B1
M-PG=@SS<+9RYOD_L:QAE.'@WOZ&/>;'X+.E\;>TF,@FPBA*]Z^=ZVR!( AF.
M4YA)(22A,@Q"JW9-G5*F1@>UFN#='#2* J.I2USF*3"["< ;1 .O_F/H] I?
M/0632]BJ![A&"E<]!MM/X%8I4\O*V%WSIA//HGP&JJFADLL*/)BBOR;>YZE<
MB!6O&T"M*NDMO/4,@-UAK:=N'C&<]8S^+\-8SUWLH[O15_E]^4;K]_=9&B!$
M588A0V&FN1/IGY) ?X@XITPA4Y\JZ=_>:"MG:NQY*B+[DNY&.U#M=EP>H!KZ
M:&2_OY%1$M1:#M;AZ "'X5H<[42]8H^C@_%V-SDZO+P?'VPKV[1*RE;;7_Y[
M+DO]R(?G=87Z(,Z$X(+"" L.$<LRB%420B$HIP*1%+EUM':2/C7N:!5HVFI:
M?QP_7?^'&W^X38(=JPP&[<!<TX7J  T%>L'DDXK<%!B5H'IALT];_1[2C\RN
MO]%\;LJJ:QNTHB;WAZ_*VC1=6^L\R%C $P8E$7J'* .]0V1!!C.>**6WB2J.
MG3H7G1,X-<KZ:O*S@3"?\VJK*J";44 ]#%A95P*VAMV.L7R".3!)71\@!G;:
M#G \90N-3V(Z*W-4+K)%8)]^K._S4?7S0Z$7L:R6G^E2MN/O9THJ$F0IAA+%
M"428,LA2H7\*8TJC0,9A9)6-[29V:NQSHB8HH%6EQR$ 6Y3EXG?CFRWU2"XI
M#WIR(NQW9'[A'6.#UBX>NM$9&*5?Y@(-54+T'$S#510]*?D5"XR>0Z.[WNC9
MNWNXS7_)Y_J)BT+>T6<C8Z9XFH6,4Y@D4:B-(95"$M 0<HEDE(8*86+E\CGZ
M]*EQSU8_\-0HZ.#\/4#.PC=^"1X#D\4.BKO+H7#P?U\"R4A^[[5F%7BD0M:>
M[,>-TA58%7JE 0I:C>@7!:#WI:PW-;Z\W*=@ZO1N']PTGE?[E+XOO-DG+[J@
MYV0S!=_D=5F:KC[FL>O]!I.<<*9"2"+CIE)20$HR"5/!8\+CF,F(.W>@/"EN
M:E3W0EO04K='>\K3&-M94OZ0&Y@43X(V2+"A#2C>6UJ>ECA^@\NSHS_:[O+\
M77W+LB^XE*)ZKY7=U#&X5:TTI)EFDXSQ--:V4II"A(((,J$"*#"->("P0G;Y
M0M82IT8JI\H[N)9D/P>T':UXA6]@9MGH"LQ2 &T<VVF%/@NU6V+CMU[[.:$C
MEVVWQ."P>KOMC9<SC>DF=5V(7^C2>*2>;]765_5^47YYX:N:D42DBF<Q%'6+
MST ;,UB:[A 2981D::0"IQY1/?68&BL9[:KZ=.BQT=ZX7_7*\NWA[CMM[FPV
MT&2,RG%&S7I2-J,P4U*[J';*7X%#'_HP'-@#T:&8T4655^/+'GAUL6B?Q[E'
MBE]K6U#4>:5S>C_CG&0D)9F>DT!"%%$!,<:FHUZ(,0I8RA)B&QK^XLE3X[^M
M<L!H9Q_Z_1*N;I:Z"(2!><=R_$ZQW$?'>D'P]LOGC1:M?708[?#LXQ?TK*/'
M'Z18S;6I](Z615[<5W>RK'O?O*%5SO7Z?YO/5TLIZJ;GNP YA2.99EQ EF"]
M4+,D@)29M@]<*DI-60:2.E72ZZ?'U);U9ACFNVG*G7\H])9+@A\^+JKJ1W.,
MTS1Y<JR<UW..[&R8$9 ?F$O:H&_&L,/Z"M3CJ,V:]4C ;_58P"#!D!?BZ;6(
M7D]5QBVC=QE>!X7T+GQ<S]WA^OCAZ^*:_V.5E_*TK63,Z9D2B$2QS" FD=*[
MPEA!%C,.N1"II&$<((1GA;RG6E'+?:&;!E;+ES3+MZW'@#N1=6'#8;:!CO-C
MN?T; /.1MGV;X[+E JQU'WF?UP\ZK_L[1Q7&W=?UP^=@/]?S,5Z+,C>M%#<<
M+,7-XO%)%E5S\$PQ"G&0(1A+I0W)@!*(>4"@DC0004 CPIP"K'KH,#4CLK,@
M\S=9&0O&Q)B4.5]N>J^"59'KY=R[Y6J?J;.T+X>=D*%MRW9/UDV+UO5_(3.*
M;V(QVD>/5X J_:8 O<B4S)=>VS]?@.<(!9H[U9A">68;G"R+,UL]JA^3[I7,
MWS0I:R3>[LJ%;NL(<\K#$*7:H#2=J%$:4,A4J&":H2P*4T1BM[*KK@I,C4,W
M^D.Z[NNP(=)F/;<JKO[%C2B=9\:.)8?$>V"*/&BAL6N)N6;/EOY7NSWX &6A
M^Z+HDQB==1B5%?LBM$^)O9_C(UJ_WKK/XB2BIB,V5$AHRL.<04HYA3%*<<P$
M2U)R06A^+6-JK-;V='U<%/=0"WT$>S'DU=J]Y5BF_AC$=MQU(7 C>@<OP.S"
M&/L7J P74-^(><7H^1?C[ Z5?WEISR3H7&][Y,?\F^ETK2GGWJ2H7%>57%:_
MT/]:E#=S6E6?]-NQSL E-&$91Q0&020@HB*!1&HK 4=$\$CQ..-.72T<Y4^-
M3QKU8:T_V T -".X O480#T(8$;AF!SM.#EV;#,@Y ,SD2O:0R1-]P//:]JT
MHPKC)D[WP^<@=;KG8_J1X(?BFZ;31?F\*S*QW7W@"+$PD@BFBF*(XD1SG8E!
M0XP)G(@LC%CD0G@=LJ9&;EM57Q1 Z=G$IPMC.][RA-S '-47-&<FLH##)^MT
MB1N582S&O<\F-K=<6$-FS4U-H0=Q6WPVQP+&TV4.3:M=2 $E(0U0D$).L8(H
MU=LM(C2=T( +RK(0*^Z4G^.JP!0YIEHV.XB-\J8;3ZL6RJ( V\'4H0B.):J<
MY\C2C!H0^:'MJ"VX5VO;:8?](=J#!GOT17&0.C2V.KQ.*1I'A$Y6HW%]CM\\
MQ6/%XJ@( \[B&$8)X1!AED"64 (S*H1^E], 2<>F!]:RI\:'7_+[(E<YI\42
MW+S,MBT$^)AS651F95YO<F]=BZ0[3(L=#PX$]L 4>#KI<?!B?ST &R,A\M6+
M O; Q395TG_QP$]R:0J^WY6+;[F0XLWSKY79JC;FC'';FQ*P=5C(=I?#,H45
MT3M))K($HB! $"<Q@F&6)"&.TI0@IT0F=Q6F1G9U"X/W\\7OFPS!C>I@I[OC
MZ6*/>;&CN6'1'ICM3"1U#?9&?<">P0]F!" O?CR*^R![UOX@^F3 'EJ,2H3]
M4=KGPPN>='$WV^8DLPGZF(58A(RH!!*6ZFUODID@-4XT]Y%(J@!QA:TZ5IR1
M,SF">]';=ATZL>Y;VSO2[!3&MN;:Q<@-;IJU6\YN L8&[#E[#(>!6L^^$/5:
M'6B/C;>C$>W1R[VVO](D59;/FH^:ILE*FT.)R)BQC#!$J1"0QB&'*<(RBQ,6
M".ED*%E)G1QU;/H\<?.#]-P4:P]Q2^KPC>/01'*J5=:5\3!NM&X<88.WS3J.
MT@@=M/8$3Z&9UG$L+/MJG;BY5UG 9;5B>?60?Z6%_O.=)KI'>K,HG]8^EW6]
MIXAGD0QI!*G>IFGC)5"08I)!DDJ6931AC%JE:KH(G1H=[=0&C=Y.E?/L<.YF
MH:'0&YB$#H #C<Z@I72?MCRVH#I5*?0.[DC%"S\4:J%5K;$LY=PDVYG$K.6#
M!#;X^ZM?Z 3@F;*&=L\:L]JAT^CVBB"ZW=L_R/5N,<_Y\\Z)'1**0D85#!7&
MYFP!0Z9X#",:HHRF,N"ITX'K$1E3X^J]/$3W*-9]#.W,PPN1&9B'C797H-$/
M_+;^[V#-?$[@X#MN=5_,Z'&K)\9Y+&[UU*7]EOKMDS3$4=Q_E%0OJ)PRTXGM
M>::(C&04AY!EDD,D40:QT 8;CR(29SQ!$<6SI>D%8;?<3\AQ6O);:<.]W4UW
MB\5&63 WVH+Y6EUG$CB%KAT1>,!L8#+8:@AJ%:_ 5DE_-' &!9]4<$K4J'1P
M9KS[E'#N<J_'<EMA.X?WC"6IE*8T%L)*F'[K&&+$4A@D$4<LS"A'L0M3V(N>
M&GF8TZ':R_34.AW:<0G=*N[E*.[87%QT!'<APJ][]+9CHNOS,/LZ;^M ;(1S
MMF/2IW"^UH&*Y;E:UQ-Z%H18L2H7.2V?;TOC!%L^_R*7#PO1G.!):2I0W*K:
M3?_F^?#BS65-,IK@*,0L$IKB$@I1%&G;*$PIC G+D"24\< IE-VG<E/;0^W4
MU?,%&H5!,SRP4?RJ*?=ITG3K"A)Z81^];7-]O[1"KZ^ '=&^UL0.3,6O,J?N
MY2D& -]KW0J?^HU;T&( 9 \J70PAH\?9QMUB*8ME3N?[[4>JF<))0EB40J(R
M9%J$A)"()((\D$*&$0^$L/*(G9$S-4;?:KIK;+-IB&1IV)X#UN+\P@]< _/D
M#JF#?DF>D'(XE/"#V$CG$%\?)*"/BU6Q-%^0IXXWSAQ/,///7&R[*\WKZ&[I
MOZ_2>0P[CR(Z;A_O].'\&%X<.%A<[EYJ^YU^XO+Y1C^EI/,/>M:^_U_R>9:@
M "=A2&&61A%$A#/(B&*:7@45.(H1HK%MR>VC$J;&I(V28*TEJ-4$6D_[(MS'
M@>SF3R_P#,R<SL@XE>?N'/T%9;J//W>T<MV=PVJ7[>Z^L(^11 U)?)7EXRP.
M4H7"6$ 5T$P;1?HGABB"G,9!E#!,D70PBK;/G=K2;30#IH*+RY=\AY.-C=-K
M]$/;-)<.W,5DZ07 6":**=ZCC1,3&_%4*WH%\@+\^:[XS^*7XNW7XM_U?[[\
M&30!%5=UR4SYG3X^S?7>^,]WX7\FOX3QVS^#4CYIM1I31C]*_W-1FK +17EM
M_!ACYUG24C_!9%@]+HKE@PF\*X2^/M>7R@((^EQYLW$.0.^V:7:7CVC#'.CX
MTF8Y_',_K^'G)@3FCI;+YW5I&!I'"B.901HAS6\\8Y JDL)([P45Q5DB0Z<
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M M[I%#Y_]W@^XHL:[+F,+U_=S\3]_;68+PWCMX*];$J8$/94P2S@PVHQ%[8
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M.&L!19(E+"$DR]T2=+HFF=I+VPIGFQ,53Z7U^H,MRK+"=AN]TZ#\W*,B\SF
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MZ\WL8;V2KV)SO_ZFUC_F0I6))2G.$F:]"4);0R;)8TBY1##C.DDQP9'63H$
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MB)7U=%_J 1EJ)=S8:UA\!V8RIUJ-._SO2OR#1S'WAW#$(()34DPI9* #)<\
M@:Z1>I2$Z-PVUC9Z\>%5W6I#)O^IV/J3^7K/,I+EJ=W1(80-#3(60QK3%%))
M8TR(RK/4:8/77X2IT:#-55?,2NA1)*$?^-W,-PZD$SC(:M2X 4814&H"K"K
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M$(E3.H3SC%/CC]W66VR%/K'S[G.:T86[SX%0(#1'.Q/:R7M\/!0<R#XG0X$
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M?OH?_ZWYB_F?K3[S/_[;_P902P,$%     @ @H!I4>SRFL:X8   _T<$ !4
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M (ZWZT^XO".2B2G)A^ "R[QV1Y'"LE@BLA@+6)&U$[BER.9XB#PD99RF(^V
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MLI+^(\J6).9!@P1[HFCP1+06KM/1LNX ,!?T3T1,W 7O6,@NU5*?P'QRAFD
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M"+Z>T[/(D%?::VZA29('HI-,=^VX*NAH&U7->,W)&.F3BKE)T.H>'2,G,)T
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M1A%K<UA>[^$\,\9$H[(4NGPSL?2)Y_<8W3D.%$,)LP/3LBVI^I*C>A"=N*)
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MI$R"L@("QPAH-'U2UQ)K$G\=I&9<B;N]Z+T+MDY2PBB.2/?9V(IHXD46RN0
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MQFKA9;-Y5SW/GF\7[/0/S89::M].;OM!_1'#$O_CW_X/4$L#!!0    ( (*
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MFY%[#NX'U[GR1G^XZ#*Z[TYA,!Y"(3L?C0=C9S2XJ&2/'M/EU71V-1A[X$W
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M:7@M,C R,# Y,S N>'-D4$L! A0#%     @ @H!I46Q:"Q].'   9!X! !4
M             ( !-!4" &YB:7@M,C R,# Y,S!?8V%L+GAM;%!+ 0(4 Q0
M   ( (* :5'%F0X[IS\  !.H @ 5              "  ;4Q @!N8FEX+3(P
M,C P.3,P7V1E9BYX;6Q02P$"% ,4    " ""@&E1F%;*0DJN    \08 %0
M            @ &/<0( ;F)I>"TR,#(P,#DS,%]L86(N>&UL4$L! A0#%
M  @ @H!I4>SRFL:X8   _T<$ !4              ( !#" # &YB:7@M,C R
M,# Y,S!?<')E+GAM;%!+ 0(4 Q0    ( (* :5%B&1+L&@@  +XG   ;
M          "  ?>  P!N8FEX+3(P,C P.3,P97AH:6)I=#,Q,2YH=&U02P$"
M% ,4    " ""@&E1UV8-91L(  #-)P  &P              @ %*B0, ;F)I
M>"TR,#(P,#DS,&5X:&EB:70S,3(N:'1M4$L! A0#%     @ @H!I4<T46^@^
M!0  $28  !H              ( !GI$# &YB:7@M,C R,# Y,S!E>&AI8FET
<,S(N:'1M4$L%!@     )  D 9 (  !27 P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
